<SEC-DOCUMENT>0001628280-22-021047.txt : 20220804
<SEC-HEADER>0001628280-22-021047.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804160345
ACCESSION NUMBER:		0001628280-22-021047
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		221136420

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ardx-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:547e7867-d9ac-4b70-ab52-436421bc76c6,g:9e9ed2bd-0902-4fdf-8b0e-0a522fb1fe1f,d:3a1430f6bb744768868435e28c329915--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ardx="http://www.ardelyx.com/20220630" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8wLTEtMS0xLTM0NDkx_41582069-c71c-4105-863e-0f2c501b29e4">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8xLTEtMS0xLTM0NDkx_f915e08a-a3e4-4c7d-9e29-c6212949e7e1">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8yLTEtMS0xLTM0NDkx_313bfc3a-2d01-4568-882c-f3601e81cacc">2022</ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8zLTEtMS0xLTM0NDkx_48c1b208-0f3b-4800-a23f-a9dd0a306e75">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF80LTEtMS0xLTM0NDkx_2dc4a8d3-d7b6-46d2-9b1b-6ac228daffed">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42c961ec51b4da7be28511c4f3d2bf8_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i925bda1ddc9b4f2ca467776b876445bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6c30f784a20e41f48388f279f3478ef5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ad1002e42841d9bab8e33e821c520d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6d660504cb4967842be9bac1eb88e4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6cf208bb934fc49b584ea377c5e697_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75815f35266949a29b3779fbb6a155e2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1348d1b675c4c8fbd7e09f627729c65_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62030e5413144b8da56fee20836acd17_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife16787b966e4f1ba8c452d2912d6b30_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c16a53c2ab74e3c9596e3f257e27abc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df73e23a8cd48398fd1fd77c2ae2509_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc595528aca44fe8a51c84f136bb9823_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac43667a5f074d89b417e46787302ea0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5a8885f6cc40b48afbb753f9d28972_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25246860a01e4ce8a406bd0535351adb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2331fd10761b45e8ab1788d9ee7c5ba7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic11b54c731dd476a84fa52d445b2970d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc6178b87a754bb0aac958078486483a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000a94b69f67402186a7b726e453f414_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e8875e4fffd4e17af63c26d11313c23_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d3cb0dd153487c96f8b541818106a3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5affa987ee348868a5c35901b6e126d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4b48a67d777408085c1b46cc926756a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddd7db5c29bf4b818592913bccc1a693_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2404930cb5c4c28b0452e3a33a5c82b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78670b3ace5c4eafbbf72ad5cef50839_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18818a41172419da6aa45c9edf9817e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f57530b34948d4b13553903ed1228a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f7c7622a396409e8e8df165f90e798e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ea209d52b54b31a2dbc3d0c55488d5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77ff45716224c199ae858f37147e3e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i218e21332806486fa073f409c125d1f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b0d3d8ab19b4d71a852ccd289222b57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab00f1a29e0a43e7b11d43bd6cc9c687_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d56614ba724a608da48861a3cf60c9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6e08a98a1064d38b01236bc993f4f9b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0e0592cff724331842e40befa20fd69_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c6d8d5f1a34f37a1f54a5a716efd5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd458ec42704888b7569b9c391b5347_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164a573f629b464f8fdb0ab0b4582249_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93085e99e934f89baf533a6a0eceafc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f167f86b3554775a6ecae909a898b9e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib501b2d7888048ad8bab2aff0a7e49bf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e60d959ef04f538e57678fb48d39de_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0108f558055448982ef3a107a546127_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4f3c74aea044471bfd38a37ede1fd57_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id537ef3aea1f4e00b37077b727741777_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i642f45e96f164e29bc7beb0165e50cab_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50bec065c1f4bf58f6a04567d2d85b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568c1373e0354d5aa5dd964481012f03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9078c496b28549dc88394c6f9e3f5bd9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e77cc73f998468495a6a26b87a2a968_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a43b3062ca24536868bd6a62ace2205_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibddc548b6b7a4ae280b837265a88e015_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6799c6e5bbe8426c90e26a689637fe8f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ardx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i1555902d2ec1463bacd6e8d3c0cd1ff1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace48da582da4c0683e6c1b47d0ac054_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCommercialCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb917478e7cc4cb19f960aafa0ebf6d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic932086e94cd487a952b91e6f8c04bd1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i243ea0b71955409b86d20ba33c39c16d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2766bdc22382498f96100a7aaec65cb8_I20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df8422a3ac54491960b7f51d8d389ad_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6025aec2272144e0acf8d042ed697ddb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8486993cdcaf4e069d76b8adb41b13a6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia817be3797974733b6dc7b26f51132c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbb22f9725c44ee892344744a4cbbd26_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b66c164e8e4390a1b10b9ea951aaff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9919698f07db4a6a92578760f1c69457_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691c6773fe6c4ffbace66f4223e64445_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c949bca14b4efd8274b5184e05d85f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e98e012f3343f0badc90e26699bbb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ardx:investment</xbrli:measure></xbrli:unit><xbrli:context id="ifc0b0709ef024116a0c9265abca56e5f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7fb0f7426e14cbb8e220839ea644f53_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b3eccd186b4b239771cea14a00e33d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546a6d3ca15649b1b31ac1990141ee51_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08942428c1e14accb811599d6f9c1077_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb85da03916f4959ae20e2dc28f6455c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98257b0990d4eec907be89dfe165197_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93c9bcdad9ec4c5ba892fa935c841839_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9d10adba4d4aeab9e207d99f3aeebe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aaefa25584840cb807733401729c67a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f37d12d66ab426fa73fe7b3c5d57eb4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7372862571244bdca7df10a1706f5b15_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12201884779347479d4fe912a0be5b1f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03a03012ab5410792f139ec7007eb3a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie63c1e4cfb6a4516a7f8967b8e88ef31_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b2c3f0a67c94a8c83f4cce268ad23a1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc5a1fc9b954a588a196da771f45701_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id68a85c2475545a7946d12b3a69a9c7f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if576c80f93ba477a8bd7f301242eb30a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa3bc355b5244eb0b37758f0981ed405_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ffac70a8f02419f80d424ef9aec9556_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7954cbfa4ce4ea4ab4c3f6181db0e2e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b85e98bea364f768c6d835cd20e21da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5cf155031c64016a5a4d37007dc9ab7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i620c4cac0fc54742b917d01906a295b1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07691efdc6d54495bf7cb279afdb630c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8d14510168b435db23351f3042e2fcd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0cb3f52dc7040e1865d853122c39d38_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cad74c2b72746a98815ab0bf53fe597_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i995be0cb8d874d6c9ba41b0dc05d971e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b854a7ada5344f09ef5775e5cba8f93_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b547ba90a040d0b2ad45d6df149223_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie912ea9191f3410a856fb7a0596383a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c82683331d441bb4bb22c1a6fee81b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26ec7fb6b30a44a384e58a556b1d2cf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i964174c2047d42ea872fe68df856aaf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3d98d34e324383930817612f98d9b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a59bd234854baab3810f3de2b8b58a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8051dc6644dd49ddb271e164ef97c689_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67e3e3a40f3c49c083b2d38b581d7312_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e633e223e04648a650081651dfab52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4b58e6d555145f0bdc3410179ee3f96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d88606f5f10482f94f0ee9f6cf00522_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ad9ee3c9d74b2db9e200ae3966bdea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cf5489a8dfe42c2b6bbf447a6a435a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bca70cbb1754fb0bb05cb61bb3092c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65da5e485ec14c3284891b7e6b8296a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id077c7e922dd4a4482ae82df90440e4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d869a99367f4854a7b935212b14932c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd39e9f5df1041638177826f6d98c2c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae239e1a1fb44ff689e8fe9e2e2b5049_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86f2f199f92428483fdae875ebaf628_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ec18a7958d427e9d6cbc9e707fe8c3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8db22a3a4424d38be4990606ba05153_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i030bed782c004d8dba6df6de0d87f2b1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff93d49e06345b38b9bdf4a97525d38_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4db73df4aa148be8f8d748314b92bc9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8bf0daa5741459ebc9bbfb5ddfba604_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd33242ba7c449e8338b810a873ad59_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c98f044f4c64f13aed0711c37e6a610_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c496b3e28c4d63ab0345238346321c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie399179e3b854e06a2b3d719ffa81575_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f73fe9f5f3e400faaf0dbba30e2b6c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if76af73ff9024e19aceae555eb94a4ca_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdac1bc1d6634022aa3677dde7c770f1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1bab5938a824507be1fe347458f5a16_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f92aef188e44c9ba3e6c4cf63228e7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2352e72adbd040919db7f1c7395453a2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib616618f955a41fb961d25698786e446_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i074ffa4e105544b6beba06ccf79db768_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="item"><xbrli:measure>ardx:item</xbrli:measure></xbrli:unit><xbrli:context id="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i061c308d6b1a43f0968b363555e92226_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb105e15b8b47d9b8839aab9ebd811a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f5bff24d8fb4ded926a6a65685e29e5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3db2f9f0408b4c3b8bc1d23c42421c54_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b83b1385d64bb0b4fcdd8478229082_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c9f146a507443cbf42d1ec3614ba5a_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014594d7c2e34a5ba34aa3612a1cf0fe_D20171101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b05c8d90cf241fe9da5a7dfc1eabd4c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i1d511f2c209a4a5aaff9671b49116eb3_I20220411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment_tranche"><xbrli:measure>ardx:payment_tranche</xbrli:measure></xbrli:unit><xbrli:context id="i241a969a3e094d03b3d8dd8e7e25cf1e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f5715e2fbb4db4a6cd85a32f3fc2f6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b1212609cc42c18f655b93c0a406eb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2edefef1531b4386b1099d09c2a70ee0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f7b4102a4754a8cbae7529a244bf3f5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4597c87af79d4327bdff63f69b57b1ae_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109c5f1c267e4db584222bf588b29f9b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7671d7833f84b738c08011e9527d6a6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc59163e21d45b0a82ec6a938f3e4fb_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfae235b525451e977ec2988b5262e7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3965d572ee4aceaf968a9429112520_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifad96d6d72d2427c850a8f4187189002_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17162477fe2411892bc4d952ca4b3c7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c1eb48ebc84ec3b3bdd61a6ce8578c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1177146d35a4e4da142927eaed0ecc9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52011fdfd0334a89bcd53e3d6de2b37f_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b2a409542f4bc1a83f80b78e672650_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i17126d287de74e979cfde5127eb1da69_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4411ff34351946ec9efc6813633c673b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97f3b674467b417ab75287cabe20b889_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de17a790f144efcb20e85eca270e9b7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2354099a5be4c5f9e83fee570934ba6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2325fcd766374f64b728734271bdcb7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc77e1d71d74d1a9a74f5ec6a36efde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f865d48364e43feb2428abb54224a8d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie657c8dfb1514308ada6df2d9ee8bf1e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c552aa84944403c8a3fb465c4b3bc03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee60570c43f40948f1db4079104e9e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i531d15c78ece4f9a9905d6f96710a74c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c7c1add2584109ba82c720ff846b37_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865d6c576ab546bcbf3614308dda7939_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87b20fa0c635463cae3c68920d3544be_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2776e4b43d244212bb36a96e1f7f6bf0_D20220628-20220628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-28</xbrli:startDate><xbrli:endDate>2022-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5599d31da844dc09d6e245bda588015_I20220628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6b9c3554974336b19c0254e81adba0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe07abdbf5b343909ddaf5fb16e06caf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332a0792bd1f4c0e92d7f1b5cbe65a8e_I20180516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45fff355f00f45b192078e143fe5bd5a_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb409ddee548471bb71a3d72714cd69d_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b0db6f01a842ee9808c8aadcd299ed_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca4f47844fc4780baff69e8911b29c0_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d431115a854c79807d5f03cee9dc62_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc61d7b192f49609b11da252ff3673e_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63aef503641b4c29a348a0255e9218d2_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf01893ad4c84865891f7430b162cae9_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0099257ff746c4ba0bf0a5c60285a1_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62823de538114437863d701d8f2af1f0_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445b8ba0bc314f23b2c6d8f35b42ac79_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic904ee852e2546278f6d6a2a871ab36c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb141ea05dc14bd488bc51b17742bb1b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edf9296a4894494938a6948e6255770_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6999cc41a5f44cf0a5b525b6303dd7ea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628699ac92bb4cc4aec87c7221cb6c0e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef0d267ad3d436b9af9981688d023fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if76ea5067c204fabaac4ade032cb88b0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f7c79b7bcf4056b7704b95788cba3b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3004be0bc24d40129c1b7ba07661f272_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02ce57c9f03945a8810129f2967308c3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016dc6bfae9845e092f75be5637f0b18_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd618c73d00048398fb1fc314aaf0e8a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65431a25e35a45e890530a699eb3a862_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a970c46b2e64b9a887463a2644c5079_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9eadd78ecf4cbaa95a089d4e6dde72_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37f41791c3a4469a79f174900a9480a_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3134b5534dfe4e7488897f77ce075b19_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7723c20c25bd40d6a71d48a503fa8f2f_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94e0bb25c3c34a6a85f20fb41dddf6e0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib634f3437de24f219bf6e52991431efe_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic965a8cbb9a44f0fae1e69681ba94b33_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f8bd2473da4add99b5d428ef128fec_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ab1c8385364a98838fa5f372f40780_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7bcb071485841a8932ec94f8a5df8bf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i376a6465db724ab699369fb13e61e824_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc375ebed1e748e3906510f688eb4df4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51d0832aa5449abae8f15be39293d79_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a90b663e53f4f6cb5da4185a20aab45_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7d4677dbca464bb097b04e809bdcfc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69584cc6d6d54ac49447a7432d983409_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3ca526cfc424a98962ab7e989aefbac_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7e1558c9254a6f8b2556d7cf1b84b3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc07daee1204d6c8c91b07672cc6eb4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id703e5f35ca0467cbd70c6dc2f683e5e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44792157aa014c89a7a354b1be5cd930_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca1e42204a84d5baa052102db6344f5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i587c8cafb989442c848613b09b327f6e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3791c5deb445cbbe81a4916add381d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64cb03795f754f9e866d8829eb6f1a18_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477ce922c8374f6e9d0c3d4093c4654b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25fb22c28764b7fa0ee953c024cf888_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217bb17f2bb2437bb698a25f2f589406_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3a1430f6bb744768868435e28c329915_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTIy_c4e3ef31-730a-42cf-a5b1-7d48190a4d53">10-Q</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZTAxM2QwZWYxMWFjNGRhZmIyMmMyMjM3NjNmNmJkMjkvdGFibGVyYW5nZTplMDEzZDBlZjExYWM0ZGFmYjIyYzIyMzc2M2Y2YmQyOV8wLTAtMS0xLTM0NDkx_2fbd49a5-eafb-49e4-8ff7-fc8bcade5071">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8xMzg_3b12cd4a-3cb7-4490-b3cd-9d5b93796ee4">June&#160;30, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6OGI0YmJjMTRjMmYxNGUxYzllMDFiYjJiMjA0NTNhYjUvdGFibGVyYW5nZTo4YjRiYmMxNGMyZjE0ZTFjOWUwMWJiMmIyMDQ1M2FiNV8wLTAtMS0xLTM0NDkx_f85a2c52-4a2f-4ca0-b7c3-ec182ea609d3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTA4_02456b81-b142-49c4-886c-f48e19356f3d">001-36485</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ardx-20220630_g1.jpg" alt="ardx-20220630_g1.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTE2_7e4efcca-e81f-4bed-8e70-c4763a900f82">ARDELYX,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6NDFhYWM1NzIwOGQwNDYzMzlmZWIxZGY0Y2Y0OTYzNDkvdGFibGVyYW5nZTo0MWFhYzU3MjA4ZDA0NjMzOWZlYjFkZjRjZjQ5NjM0OV8wLTAtMS0xLTM0NDkx_b5a168b4-2635-4320-9877-c248e1234e22">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6NDFhYWM1NzIwOGQwNDYzMzlmZWIxZGY0Y2Y0OTYzNDkvdGFibGVyYW5nZTo0MWFhYzU3MjA4ZDA0NjMzOWZlYjFkZjRjZjQ5NjM0OV8wLTEtMS0xLTM0NDkx_5e01ca68-d25b-4cd7-be2f-b2d2fcf802df">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTE4_e7f239f2-9cd6-4d3f-affb-0cf4c76cfc70">400 Fifth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTE0_788e0996-c7c5-4f28-8f8d-f7edf00f06c0">Suite 210</ix:nonNumeric>, <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTEw_fd520245-2a15-4b89-8a03-305b69594739">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTEx_dcca2749-5657-4b26-815e-1943b9251994">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTEy_1f958c37-e99e-457c-8a4c-870901fed4b6">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTI2_f4fe7f1d-e403-4ee4-9833-807e8ef72952">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTI3_58f37f4a-bf08-404a-9346-a7d4e3be539f">745-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6MWY4M2JiMzk1MzhhNDNiYjlmM2Y4NjM3ZjdkZDg5NTEvdGFibGVyYW5nZToxZjgzYmIzOTUzOGE0M2JiOWYzZjg2MzdmN2RkODk1MV8xLTAtMS0xLTM0NDkx_e772c3c8-423a-48cb-af1f-bfdd8be0462c">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6MWY4M2JiMzk1MzhhNDNiYjlmM2Y4NjM3ZjdkZDg5NTEvdGFibGVyYW5nZToxZjgzYmIzOTUzOGE0M2JiOWYzZjg2MzdmN2RkODk1MV8xLTItMS0xLTM0NDkx_134b5605-90b2-4d9c-a5a9-fbdcfa7882a6">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6MWY4M2JiMzk1MzhhNDNiYjlmM2Y4NjM3ZjdkZDg5NTEvdGFibGVyYW5nZToxZjgzYmIzOTUzOGE0M2JiOWYzZjg2MzdmN2RkODk1MV8xLTQtMS0xLTM0NDkx_16379ff4-2915-458a-a3c8-0bbf75d79135">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTA2_789f6d26-9bcc-4202-a473-c81a1a5635ff">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTA3_d0bc1fbe-3732-4c7a-98f7-ad840a297a59">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZmM1OWMzMDJlNjg0NGRlMGE1ZGFiODI4MzUyOTVjNWEvdGFibGVyYW5nZTpmYzU5YzMwMmU2ODQ0ZGUwYTVkYWI4MjgzNTI5NWM1YV8wLTEtMS0xLTM0NDkx_1981d330-4be7-4bbd-8681-c7e1cff0c068">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZmM1OWMzMDJlNjg0NGRlMGE1ZGFiODI4MzUyOTVjNWEvdGFibGVyYW5nZTpmYzU5YzMwMmU2ODQ0ZGUwYTVkYWI4MjgzNTI5NWM1YV8yLTUtMS0xLTM0NDkx_a3844163-48b0-4303-a09e-1431f7a8d2aa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZmM1OWMzMDJlNjg0NGRlMGE1ZGFiODI4MzUyOTVjNWEvdGFibGVyYW5nZTpmYzU5YzMwMmU2ODQ0ZGUwYTVkYWI4MjgzNTI5NWM1YV80LTUtMS0xLTM0NDkx_eef4dfbe-9471-414a-9c7c-ef873fbf087f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8xNTk0MjkxODYwNDg4MQ_cdc37160-4d4f-47cd-8a30-496f73da03c0">&#9746;</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of issued and outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value per share, as of July&#160;31, 2022, was <ix:nonFraction unitRef="shares" contextRef="ic42c961ec51b4da7be28511c4f3d2bf8_I20220731" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTAx_5c67716c-0e37-4954-a412-ae288cdc8933">154,635,575</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, in this Quarterly Report on Form 10-Q the terms &#8220;Ardelyx&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;the Company&#8221; refer to Ardelyx, Inc.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our participation in a Cardiovascular and Renal Drugs Advisory Committee (&#8220;Advisory Committee&#8221;) meeting in connection with the formal dispute resolution (&#8220;FDR&#8221;) process commenced in response to the Complete Response Letter (&#8220;CRL&#8221;) received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) relating to our new drug application (&#8220;NDA&#8221;) for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis (&#8220;CKD&#8221;) (the &#8220;Hyperphosphatemia Indication&#8221;);  </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to address our operating cash flow requirements with our current cash and investments, cash generated from the sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our potential receipt of anticipated milestones from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement; our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans with respect to RDX013 and RDX020; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that could cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described in the &#8220;ITEM 1A. RISK FACTORS&#8221; section and elsewhere in this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update any forward-looking statement publicly, or to revise any forward-looking statement to reflect events or developments occurring after the date of this Quarterly Report on Form 10-Q, even if new information becomes available in the future. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in any such forward-looking statement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF PRINCIPAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and will incur losses in the future, which makes it difficult for us to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash and investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We will require substantial additional financing for the foreseeable future as we invest in the commercialization of IBSRELA and prepare for and participate in a Cardiovascular and Renal Drugs Advisory Committee (&#8220;Advisory Committee&#8221;) meeting. The Advisory Committee meeting has been convened in connection with the formal dispute resolution (&#8220;FDR&#8221;) process we commenced in response to the Complete Response Letter (&#8220;CRL&#8221;) received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) relating to our new drug application (&#8220;NDA&#8221;) for XPHOZAH (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis (&#8220;Hyperphosphatemia Indication&#8221;) and the inability to access necessary capital when needed on acceptable terms, or at all, could force us to limit, reduce or terminate our efforts to commercialize IBSRELA or to seek and obtain approval for XPHOZAH for the Hyperphosphatemia Indication. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to meet the continued listing requirements of The Nasdaq Global Market ("Nasdaq") could result in a de-listing of our common stock. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have generated limited revenue from product sales and may never be profitable. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the successful launch and commercialization of IBSRELA for IBS-C, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA; secure adequate coverage and reimbursement for IBSRELA; or generate sufficient revenue from product sales of IBSRELA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are pursuing regulatory approval for tenapanor for the Hyperphosphatemia Indication. There can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we are successful in obtaining regulatory approval for tenapanor for the Hyperphosphatemia Indication, the expense and time required to do so could adversely impact our ability to successfully commercialize XPHOZAH for the Hyperphosphatemia Indication. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IBSRELA, and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a company, we have limited experience in the marketing, sale and distribution of pharmaceutical products; and there are significant risks in building and managing a commercial organization.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party payor coverage and reimbursement status of newly-commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, for XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA, and, if approved and commercialized of XPHOZAH, and our future development efforts for tenapanor may be materially harmed. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARDELYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are trademarks of Ardelyx. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_16">Item 1. Financial Statements:</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_19">Condensed Balance Sheets (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_22">Condensed Statements of Operations and Comprehensive Loss (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_25">Condensed Statements of Changes in Stockholders' Equity (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_28">Condensed Statements of Cash Flows (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_31">Notes to Condensed Financial Statements (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_82">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3a1430f6bb744768868435e28c329915_118">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3a1430f6bb744768868435e28c329915_121">Item 4. Controls and Procedures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_124">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_127">Item 1. Legal Proceedings</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_130">Item 1A. Risk Factors</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_133">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_136">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_139">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_142">Item 5. Other Information</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_145">Item 6. Exhibits</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_148">Signatures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i3a1430f6bb744768868435e28c329915_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i3a1430f6bb744768868435e28c329915_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNC0xLTEtMS0zNDQ5MQ_9f0840d4-ce3b-403e-80de-9647ef8bd4c6">53,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNC0zLTEtMS0zNDQ5MQ_bb3429b9-437e-4b20-973e-364db749215e">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNS0xLTEtMS0zNDQ5MQ_dbf06ebb-c0d7-4b93-b30f-5a72492f6453">27,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNS0zLTEtMS0zNDQ5MQ_a2b1f50d-bde1-41d8-a618-4fd939405ac2">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNi0xLTEtMS0zNDQ5MQ_b51b4e93-7877-4c57-91f2-15a85c28dac0">5,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNi0zLTEtMS0zNDQ5MQ_920486ca-6625-4ee2-afc0-b6a1118bed9c">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNy0xLTEtMS0zNDQ5MQ_b605d2b5-f74c-4878-9b46-2891b45e53e3">4,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNy0zLTEtMS0zNDQ5MQ_0d84837a-c0d6-4cbe-90e6-76f3e5957a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0xLTEtMS0zODUzNg_df543407-b13c-438c-85e5-4a82b70910b3">17,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0zLTEtMS0zODUzNg_57440293-8188-4b6a-b784-31656fd74eb2">9,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0xLTEtMS0zNDQ5MQ_800a62c8-184e-40fc-8430-5c488c2cc371">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0zLTEtMS0zNDQ5MQ_764ab58d-93d3-45ec-8c9a-71edb1e29aef">7,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOS0xLTEtMS0zNDQ5MQ_372b6752-ed40-4a9e-92dd-81e26a244021">114,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOS0zLTEtMS0zNDQ5MQ_72309ac1-701f-4a1c-971a-04b350705bd1">133,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTAtMS0xLTEtMzQ0OTE_97f9732e-f014-4d5f-8b2a-e7735f8b7c0a">11,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTAtMy0xLTEtMzQ0OTE_5e99a41f-33e5-47b8-91da-dd4ea1cbca88">12,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTEtMS0xLTEtMzQ0OTE_f389d41a-db6c-4c9b-848c-370ad680404f">1,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTEtMy0xLTEtMzQ0OTE_77ba357e-61fa-4bd2-ba16-ee85567a30c7">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTMtMS0xLTEtMzQ0OTE_1e6dfc1e-c21c-4499-a72b-89a693bdd424">4,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTMtMy0xLTEtMzQ0OTE_45871ea9-ea00-4eba-92ec-d782412a984b">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTQtMS0xLTEtMzQ0OTE_dad28d8b-d2b3-46ea-9b77-25f9d9a465d8">131,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTQtMy0xLTEtMzQ0OTE_fced2891-e16b-4696-bdc9-3190d1ebcda3">149,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTctMS0xLTEtMzQ0OTE_36d9a904-7633-4ea0-943d-e9395618f909">4,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTctMy0xLTEtMzQ0OTE_3f1e775e-1d0f-4266-81d0-40c5802266e9">4,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTgtMS0xLTEtMzQ0OTE_43a5404c-93e5-4a9e-b29a-ea4c6b3fcc46">6,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTgtMy0xLTEtMzQ0OTE_778cb081-f59a-4b14-bc80-7216da312857">5,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTktMS0xLTEtMzQ0OTE_3d0bb846-4248-4d91-a35c-36b69da3cb23">26,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTktMy0xLTEtMzQ0OTE_56428996-a975-4046-8b8f-f837511a6ce0">32,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjAtMS0xLTEtMzQ0OTE_e181313e-de54-4b05-b56a-9e3c5784948d">3,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjAtMy0xLTEtMzQ0OTE_12059b39-00de-4b1d-bfbd-7dc93a4e58c2">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjItMS0xLTEtMzQ0OTE_a914b1ce-ca42-46aa-9025-e1e6e052d694">7,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjItMy0xLTEtMzQ0OTE_67cece8d-ad97-43c1-acc4-b9000e2b6108">7,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjMtMS0xLTEtMzQ0OTE_6f2afefc-4cef-4f64-9c6f-2cef64ba16a1">48,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjMtMy0xLTEtMzQ0OTE_d967b7f9-9dbe-4974-abcd-6cd02df70413">52,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjQtMS0xLTEtMzQ0OTE_5d613b07-c6a5-447e-bcd4-cb916646be03">7,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjQtMy0xLTEtMzQ0OTE_a5966eab-1822-495b-a140-932639e57a9e">9,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjYtMS0xLTEtMzQ0OTE_be16afe7-616d-4e2b-97f0-7d1ba0ce688e">12,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjYtMy0xLTEtMzQ0OTE_ea16eb31-9b90-4d45-8a93-87a2952a56df">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:DeferredRoyaltyObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMS0xLTEtMzcwOTI_34f7e468-2002-4f0e-8cd4-12a693ae005c">9,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:DeferredRoyaltyObligationNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMy0xLTEtMzcwOTI_e9cdd6e7-f9b4-406c-a371-d178f19f13bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMS0xLTEtMzQ0OTE_15807e7e-4e3d-45e9-b9c4-0b39c155c5b7">78,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMy0xLTEtMzQ0OTE_6b7d4fa0-e5f9-4ac6-a78d-84d7daba8bc9">67,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjgtMS0xLTEtMzQ0OTE_8c52f106-e7cd-40d4-b42d-0a0c93f78774"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjgtMy0xLTEtMzQ0OTE_27d8bc99-0baf-4177-a637-f3c276d79b22"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8yMQ_05f813cc-ddce-48ea-bdc9-46c3256755d3"><ix:nonFraction unitRef="usdPerShare" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8yMQ_e18b76cc-cba6-4fa3-8c8c-cb82c7459ddc">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8zNQ_5a8b1fe8-bcb5-485a-b8a3-ac16f7c24daa"><ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8zNQ_a7f066d6-00d6-485b-bde1-9bce0f1efbe0">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_0d752b80-1e5f-4c04-9030-225392fac411"><ix:nonFraction unitRef="shares" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_15452dfa-8af3-481c-8de4-5d69b33f164f"><ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_ab793585-3d5b-4dab-b09c-8c7f014407be"><ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_dca2bf34-8d66-4adf-a23e-f22c3035353c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMS0xLTEtMzQ0OTE_56107cc2-b91f-41c8-bd06-e1297ee4698c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMy0xLTEtMzQ0OTE_56eb7c6a-76c3-4dc7-a634-19423873ed6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8xOA_37b9837e-d777-4f81-a729-e3e2af1b805f"><ix:nonFraction unitRef="usdPerShare" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8xOA_b83bda73-3341-484a-8004-5f2110ca9754">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8zMg_3e4d2152-9fe9-4362-a2cd-1281d88dbef2"><ix:nonFraction unitRef="shares" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8zMg_40b9e5e4-6790-459b-8cad-760606fab5c9">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV81NA_c5c688b7-4619-4e51-84e7-ba5fb76a398d"><ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV81NA_dac16394-e47d-4a16-a0ce-7d75613fc975">153,797,834</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV82MQ_483e4090-e116-48f0-9a92-4e35b97d2fdc"><ix:nonFraction unitRef="shares" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV82MQ_e1638a59-efea-4df0-8d6b-5201ac31a891">130,182,535</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMS0xLTEtMzQ0OTE_96fdb94f-a797-42df-80de-d46bf53d6e85">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMy0xLTEtMzQ0OTE_48738efb-10d3-4742-9876-14bcd04ac0cb">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzItMS0xLTEtMzQ0OTE_02e0212f-c15a-4431-917b-da002731b641">821,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzItMy0xLTEtMzQ0OTE_700c0f87-02cc-4385-bd63-6067661b78fa">795,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzMtMS0xLTEtMzQ0OTE_e33d85a0-b106-4268-a0c5-16cabbe01382">767,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzMtMy0xLTEtMzQ0OTE_9e626715-5a98-405f-aa46-3e1ede41baf0">712,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzQtMS0xLTEtMzQ0OTE_7cf2aaf8-b983-475d-b740-2787cd0842d4">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzQtMy0xLTEtMzQ0OTE_760a349e-fda5-4fec-b331-e17487ebfee9">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzUtMS0xLTEtMzQ0OTE_568f98b3-0ba0-412a-84ef-cb3c30808485">53,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzUtMy0xLTEtMzQ0OTE_9be5dd3f-2592-4c8f-820a-5cfadb3ed134">82,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzYtMS0xLTEtMzQ0OTE_3f012277-43c2-4fb5-8c5c-e06b780fb7e7">131,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzYtMy0xLTEtMzQ0OTE_6d1a82da-aac8-4e4a-af7a-4b301851e197">149,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c30f784a20e41f48388f279f3478ef5_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy0xLTEtMS0zNDQ5MQ_240c7e9f-9e09-45cf-9333-9bc4053cc88b">1,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ad1002e42841d9bab8e33e821c520d_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy0zLTEtMS0zNDQ5MQ_779b449b-6684-4fee-b068-9ea74b197aaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6d660504cb4967842be9bac1eb88e4_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy01LTEtMS0zNDk0OQ_609a38e4-4f53-4979-b797-2417cada3a8e">2,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6cf208bb934fc49b584ea377c5e697_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy03LTEtMS0zNDk1Ng_960754ce-ba3e-46b1-bd51-335c9996f07c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75815f35266949a29b3779fbb6a155e2_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS0xLTEtMS0zNDQ5MQ_02e78205-c8f3-43c2-aab5-d79f00c641cf">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1348d1b675c4c8fbd7e09f627729c65_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS0zLTEtMS0zNDQ5MQ_b8f7bd41-f128-4466-960f-4d40e78d38c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62030e5413144b8da56fee20836acd17_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS01LTEtMS0zNDk0OQ_e7943d53-0a51-4d82-a328-62f509c0f823">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife16787b966e4f1ba8c452d2912d6b30_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS03LTEtMS0zNDk1Ng_e216d5c4-5fea-4a11-bbde-fbe0ca8bd525">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c16a53c2ab74e3c9596e3f257e27abc_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi0xLTEtMS0zNDQ5MQ_95e3082a-8126-433e-9109-f451b66123d9">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df73e23a8cd48398fd1fd77c2ae2509_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi0zLTEtMS0zNDQ5MQ_4685d461-cb2e-4f8d-8cb6-5bd250a6d736">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc595528aca44fe8a51c84f136bb9823_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi01LTEtMS0zNDk0OQ_4898cb55-acb5-41c0-b297-fab8d5345fd4">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac43667a5f074d89b417e46787302ea0_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi03LTEtMS0zNDk1Ng_8acae107-2241-4d75-935e-00a759c174aa">5,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5a8885f6cc40b48afbb753f9d28972_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0xLTEtMS0zNjk3Mg_dc4a55b0-0eb5-4458-b259-7c2ca364a440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25246860a01e4ce8a406bd0535351adb_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0zLTEtMS0zNjk3Mg_2b7b0b98-765a-40af-86b8-c2506338a579">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2331fd10761b45e8ab1788d9ee7c5ba7_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy01LTEtMS0zNjk3Mg_26712d15-fd71-4545-bf46-98cb82c701ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11b54c731dd476a84fa52d445b2970d_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy03LTEtMS0zNjk3Mg_a7a05fca-e28f-4c89-9d6e-901ab15cb23c">2,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0xLTEtMS0zNDQ5MQ_6c6b7e85-9774-4362-88ad-eeb04ccfe4a0">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0zLTEtMS0zNDQ5MQ_98205615-5a09-4612-bd6f-c9738460d13a">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy01LTEtMS0zNDk0OQ_e1bc8ba4-92b0-45c3-84b2-76b413f7775f">2,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy03LTEtMS0zNDk1Ng_213a7026-1714-4514-a8d3-e3a3d3d6237e">7,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS0xLTEtMS0zNDQ5MQ_9228e1bd-1ddd-482f-8e79-4da6910402ad">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS0zLTEtMS0zNDQ5MQ_a708698c-6a74-42b2-b655-37ac5604b835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS01LTEtMS0zNDk0OQ_9ea0af40-f7a7-4e99-812f-55b4adbca0b8">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS03LTEtMS0zNDk1Ng_e8191292-f3cf-4eb0-965c-297a89407f53">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtMS0xLTEtMzQ0OTE_0e075f89-27e5-485b-9604-bb87ef6ac6f6">9,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtMy0xLTEtMzQ0OTE_4a3db4be-2e73-4fa9-9d3e-fecf5a554511">26,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtNS0xLTEtMzQ5NDk_2c6fa47b-b44a-47f3-ac7d-b08173480821">18,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtNy0xLTEtMzQ5NTY_05f729c4-3364-4c04-9d79-e7f6772a5aeb">46,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtMS0xLTEtMzQ0OTE_e20ab77c-b267-4d53-b596-ae4438a93653">18,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtMy0xLTEtMzQ0OTE_5b782854-515f-4720-bf57-ef41c232618a">20,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtNS0xLTEtMzQ5NDk_70cbf4d4-c5cd-4369-8e36-015c45b949b1">38,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtNy0xLTEtMzQ5NTY_760df076-a61d-4a2a-b9b4-a73d62e6747c">37,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItMS0xLTEtMzQ0OTE_8b75722b-20b8-4a2a-9ce2-d4e9d7c01f93">28,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItMy0xLTEtMzQ0OTE_5372efb5-e48d-4b46-80be-fc82bec5eddd">46,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItNS0xLTEtMzQ5NDk_853f0f42-be33-4c0a-a468-8ab493d1408a">57,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItNy0xLTEtMzQ5NTY_f167fdc1-fd5a-4e5a-a75b-7c8ab2014128">84,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtMS0xLTEtMzQ0OTE_cff03338-56c8-43cb-8aef-19a54d8e7e59">26,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtMy0xLTEtMzQ0OTE_50b2f110-9fc5-467c-a8c3-2ef0a56c7a95">44,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtNS0xLTEtMzQ5NDk_60160b1c-60ac-49df-b9c3-bc7c1dfb60c2">54,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtNy0xLTEtMzQ5NTY_34746de1-60ee-4233-a12a-50289d7cceb8">76,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtMS0xLTEtMzQ0OTE_0acacaa5-48fc-43be-b5fa-7332224d31c3">787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtMy0xLTEtMzQ0OTE_e54f4e38-e112-44fc-b0e6-24ddffae08ae">1,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtNS0xLTEtMzQ5NDk_5cfa50cf-2730-48b2-a656-5f95a002b252">1,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtNy0xLTEtMzQ5NTY_f207e211-78d8-44d6-bf89-81309e55f66c">2,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtMS0xLTEtMzQ0OTE_8ab53a34-85ae-4c46-a842-c57c7739b45f">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtMy0xLTEtMzQ0OTE_2ea16195-32a8-47bc-bfad-64b97b270cde">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtNS0xLTEtMzQ5NDk_5b6d28e5-4c33-4816-985c-2548589d4487">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtNy0xLTEtMzQ5NTY_69b918cb-f5c2-4333-9b51-4a9de84968c7">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtMS0xLTEtMzQ0OTE_3347d077-e6e5-43ce-ba88-2476ddfde88d">26,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtMy0xLTEtMzQ0OTE_a8e96f33-afff-46ae-8dc8-c30f38140ff0">45,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtNS0xLTEtMzQ5NDk_a7f0c31a-73a3-4ad7-86bb-5cf0f5b395bf">55,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtNy0xLTEtMzQ5NTY_7baaa5a4-a0f3-4231-b5fa-6b155ece47da">78,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctMS0xLTEtMzQ0OTE_d00c5bb1-16e1-4a79-ae14-b6639cb4bae1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctMy0xLTEtMzQ0OTE_e7094ba9-6b98-4356-b920-e2d191ea9f53">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctNS0xLTEtMzQ5NDk_285cab84-897a-4ec1-8bca-11cd549e6367">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctNy0xLTEtMzQ5NTY_d84b59a3-61ad-4e73-8d0c-4cc85ba535f6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtMS0xLTEtMzQ0OTE_a5507ae7-1ff4-4bd5-b73b-c046f62f62a8">26,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtMy0xLTEtMzQ0OTE_b2f040cb-a547-4e34-b731-03ffa310aee2">45,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtNS0xLTEtMzQ5NDk_a22ed643-2d9d-4df0-a376-23f67e91eb0b">55,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtNy0xLTEtMzQ5NTY_a8c47182-4d98-44be-a27f-3bccb03d62d1">78,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMS0xLTEtMzQ0OTE_34f42e4c-771a-49fd-b885-107a73909437"><ix:nonFraction unitRef="usdPerShare" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMS0xLTEtMzQ0OTE_bc34697c-d2a8-4719-a582-7d72cfc6c817">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMy0xLTEtMzQ0OTE_06614748-e63c-4bd5-9583-f104ced31505"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMy0xLTEtMzQ0OTE_a0e5729b-70d9-4b84-a1b0-0ce9b5ede6d4">0.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNS0xLTEtMzQ5NDk_3a4c7bb8-b47b-4d2e-9b20-7a6943fa4596"><ix:nonFraction unitRef="usdPerShare" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNS0xLTEtMzQ5NDk_76916180-3191-4e28-a1a1-c3f41f644fd0">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNy0xLTEtMzQ5NTY_2ec8220e-c881-4180-9aaa-22229778acbf"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNy0xLTEtMzQ5NTY_769ac6b5-647a-4351-94db-9eae19078ef5">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMS0xLTEtMzQ0OTE_0ba2abb7-bdf3-4c65-8dd9-dfc24fe754ad"><ix:nonFraction unitRef="shares" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMS0xLTEtMzQ0OTE_65d4a0bf-22c3-4c1c-b82d-2d13d2bf5a37">145,544,372</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMy0xLTEtMzQ0OTE_3efc2eb0-5f2d-4a64-beab-7de15f77575f"><ix:nonFraction unitRef="shares" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMy0xLTEtMzQ0OTE_5e569a4e-3a23-491e-b662-0eda4553cc9a">100,040,083</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNS0xLTEtMzQ5NDk_7dacb971-f4a0-43d6-bc01-222439a6b5ff"><ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNS0xLTEtMzQ5NDk_ba51b3db-f879-4900-9e26-ccb9adfcd226">138,279,945</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNy0xLTEtMzQ5NTY_c2c3df68-271f-4bd2-b69c-aeff48b10b92"><ix:nonFraction unitRef="shares" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNy0xLTEtMzQ5NTY_dfa420b8-e531-4309-a55c-2e4e02d08665">98,617,564</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItMS0xLTEtMzQ0OTE_4bb3e792-345e-4570-9346-3c905c503a09">26,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItMy0xLTEtMzQ0OTE_6007e2fe-1247-4f49-9302-a912af97818d">45,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItNS0xLTEtMzQ5NDk_a47b9f65-1f21-4a36-bc2e-813d17b46ff9">55,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItNy0xLTEtMzQ5NTY_a2ea05e6-b52e-406c-af70-d6459ac51c33">78,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtMS0xLTEtMzQ0OTE_3de25bfd-d4fc-4e57-bfe0-abb677de4797">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtMy0xLTEtMzQ0OTE_e769a157-7fc7-419b-a6d6-ecaeb4343082">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtNS0xLTEtMzQ5NDk_2ba1c50e-1eb0-4e13-9214-9b720826361a">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtNy0xLTEtMzQ5NTY_7b2494c6-1eb3-4f6c-9f33-e25b3e4eb8b4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtMS0xLTEtMzQ0OTE_97b937f3-d20e-439d-85e8-71da7a8e31ff">26,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtMy0xLTEtMzQ0OTE_cd79f43e-f81e-40ce-9c69-eb733dbb42d1">45,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtNS0xLTEtMzQ5NDk_63fc7b7a-5536-4fa0-a2b7-083114a7f8f7">55,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtNy0xLTEtMzQ5NTY_2d1a658d-d24b-4726-a61e-18c14e0e5ba7">78,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Three and Six Months ended June&#160;30, 2022 and 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc6178b87a754bb0aac958078486483a_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy0xLTEtMS0zNDQ5MQ_afa8c6e9-1b10-482d-8452-6caf65ae3a23">136,330,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6178b87a754bb0aac958078486483a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy0zLTEtMS0zNDQ5MQ_00d7a5e9-e85c-4e90-a820-03e459cc5d1d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000a94b69f67402186a7b726e453f414_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy01LTEtMS0zNDQ5MQ_f013d141-794c-4f1b-b89e-16ba6c10a5e5">805,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e8875e4fffd4e17af63c26d11313c23_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy03LTEtMS0zNDQ5MQ_4e7b69c3-c7ab-40fa-8c61-de89c9c33063">741,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8d3cb0dd153487c96f8b541818106a3_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy05LTEtMS0zNDQ5MQ_8e9630f9-9f76-4359-82ae-2a96069aeecb">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5affa987ee348868a5c35901b6e126d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy0xMS0xLTEtMzQ0OTE_b93b9538-32f7-402f-8304-2ac856fe8584">64,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4b48a67d777408085c1b46cc926756a_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfNy0xLTEtMS0zNDQ5MQ_df146825-ac0f-4e2c-bbf7-daada94f9b5e">2,882,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4b48a67d777408085c1b46cc926756a_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS0xLTEtMS0zNDQ5MQ_ea25bfc4-130b-4123-bae0-3c11c33f9417">14,584,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4b48a67d777408085c1b46cc926756a_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS0zLTEtMS0zNDQ5MQ_73598ce3-8004-4c4e-b4ab-269d7813ed32">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd7db5c29bf4b818592913bccc1a693_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS01LTEtMS0zNDQ5MQ_7c9d28a5-af60-4b63-b6fd-dc60ef81cd40">12,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS0xMS0xLTEtMzQ0OTE_3b4f40ea-933e-4d9b-8366-27a34b8eee1c">12,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddd7db5c29bf4b818592913bccc1a693_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTAtNS0xLTEtMzQ0OTE_bb750e0b-3f11-40fa-8cbc-8ea0e9cb5c93">3,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTAtMTEtMS0xLTM0NDkx_a50fe046-dc23-4977-8fab-0326d836107d">3,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2404930cb5c4c28b0452e3a33a5c82b_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTEtOS0xLTEtMzQ0OTE_571a144d-2e56-4288-a520-9acf4dddfe62">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTEtMTEtMS0xLTM0NDkx_2b1fb6e6-f54e-481d-834a-116db5581116">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78670b3ace5c4eafbbf72ad5cef50839_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTItNy0xLTEtMzQ0OTE_36863159-ea9d-45ad-a188-0e7853ba078d">26,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTItMTEtMS0xLTM0NDkx_4871e876-fc55-463e-b3f6-7b6280f26a4f">26,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtMS0xLTEtMzQ0OTE_a5b22e5f-c05d-4031-8144-af49a1a341f8">153,797,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtMy0xLTEtMzQ0OTE_3c585ced-61f6-4dc0-86d4-80fb72cc3152">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f57530b34948d4b13553903ed1228a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtNS0xLTEtMzQ0OTE_dfe941a5-9f06-4633-b7fa-eb8db0af2752">821,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f7c7622a396409e8e8df165f90e798e_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtNy0xLTEtMzQ0OTE_5e2d8c4d-cd8f-40e7-b898-b7a68d9079a3">767,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0ea209d52b54b31a2dbc3d0c55488d5_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtOS0xLTEtMzQ0OTE_78fac055-fbb5-4fa6-a6c2-bd8124390cc4">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtMTEtMS0xLTM0NDkx_58e5b77e-3cb3-43b4-a4ab-d0d1c5d05645">53,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id77ff45716224c199ae858f37147e3e6_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy0xLTEtMS0zNDk4NQ_3143acca-97cb-4b9c-94dd-d6af8eac4cc8">130,182,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77ff45716224c199ae858f37147e3e6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy0zLTEtMS0zNDk4NQ_096f0737-8358-45aa-ac8f-901a5e1e9c14">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218e21332806486fa073f409c125d1f3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy01LTEtMS0zNDk4NQ_5f40589c-d91a-4864-bef2-efcc5dd6939b">795,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b0d3d8ab19b4d71a852ccd289222b57_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy03LTEtMS0zNDk4NQ_43ca8a86-7083-40f5-8ef2-e55e15e9bdd9">712,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab00f1a29e0a43e7b11d43bd6cc9c687_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy05LTEtMS0zNDk4NQ_bf37b221-6c0e-42c7-808a-bbc2cf38b8f3">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy0xMS0xLTEtMzQ5ODU_ad353276-fce7-4d3f-bfbd-4d6ebb650350">82,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNC0xLTEtMS0zNDk4NQ_bb84b861-12fb-4ff9-87e4-f7d337f6ce3a">127,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNC01LTEtMS0zNDk4NQ_22fa3c14-e6cf-4ee5-8ea4-d92a2f40294a">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNC0xMS0xLTEtMzQ5ODU_e67d08f3-1717-4c0d-bdeb-47070a7f2c87">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNy0xLTEtMS0zNDk4NQ_161bd314-5465-412a-a880-cfaddce17b57">2,996,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS0xLTEtMS0zNDk4NQ_f030517c-4c1a-4d26-8fe8-4a00a60ffec4">20,492,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS0zLTEtMS0zNDk4NQ_5f2d65f2-dd02-446a-9ca5-109efe3bf7ab">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS01LTEtMS0zNDk4NQ_b9d4d0d4-d9a2-43a4-bf42-6551fe68253a">18,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS0xMS0xLTEtMzQ5ODU_4dbac830-d37f-4e1f-a45a-514f0d200a9e">18,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTAtNS0xLTEtMzQ5ODU_d0357333-0264-4cc5-90b8-4e734cdbd3c9">6,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTAtMTEtMS0xLTM0OTg1_a421081c-007d-4b75-80a8-ae5dc0b69f14">6,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73d56614ba724a608da48861a3cf60c9_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTEtOS0xLTEtMzQ5ODU_fea41417-1f3e-4e72-9c47-eaae627b544d">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTEtMTEtMS0xLTM0OTg1_9642f5df-7274-4a63-84ce-0e5241bdd6c4">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6e08a98a1064d38b01236bc993f4f9b_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTItNy0xLTEtMzQ5ODU_e8024b44-0f38-471b-8fff-d3d1146316b2">55,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTItMTEtMS0xLTM0OTg1_76b9489f-4b66-44af-bb29-cbcf2accafa5">55,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtMS0xLTEtMzQ5ODU_d03ef4e0-931a-4902-8082-fa01c4375dd7">153,797,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtMy0xLTEtMzQ5ODU_7a4e2655-e131-43e3-9ea0-69150684b4f1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f57530b34948d4b13553903ed1228a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtNS0xLTEtMzQ5ODU_62fe4198-410a-4044-8d6a-758638c027be">821,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f7c7622a396409e8e8df165f90e798e_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtNy0xLTEtMzQ5ODU_4f1ac15b-a767-480c-9f4d-584d872d25dc">767,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0ea209d52b54b31a2dbc3d0c55488d5_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtOS0xLTEtMzQ5ODU_e90b28b2-8b1f-473e-a5d7-bbfb459ccc54">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtMTEtMS0xLTM0OTg1_58f1f182-c571-46b0-a7d7-045bdf8f0fb8">53,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0e0592cff724331842e40befa20fd69_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy0xLTEtMS0zNDQ5MQ_98c1c996-dc6d-4610-aafb-49c4b5ea9ab8">98,688,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e0592cff724331842e40befa20fd69_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy0zLTEtMS0zNDQ5MQ_9517c72e-45b1-45f8-91ef-059893039384">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6d8d5f1a34f37a1f54a5a716efd5a_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy01LTEtMS0zNDQ5MQ_64d1a34f-105a-4dc7-8aeb-b9d94e427815">718,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd458ec42704888b7569b9c391b5347_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy03LTEtMS0zNDQ5MQ_3b2e7b06-5c4e-4e7d-9bcc-8e3beb9b94e7">587,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i164a573f629b464f8fdb0ab0b4582249_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy05LTEtMS0zNDQ5MQ_5728a5b3-c7f5-4bc9-a6d7-ef2d8476b3b7">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93085e99e934f89baf533a6a0eceafc_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy0xMS0xLTEtMzQ0OTE_3719d1b9-ad6c-4730-b79a-a6a62b6ddae2">130,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNi0xLTEtMS0zNDQ5MQ_26b1ebd7-44b3-4fdd-a40c-94cc9f0acbc8">194,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNi01LTEtMS0zNDQ5MQ_741ab92a-db35-46fd-92c3-ba1b0b03fd62">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNi0xMS0xLTEtMzQ0OTE_1041c39c-758e-4c59-b314-9e948f65b03d">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNy0xLTEtMS0zNDQ5MQ_4bb3164a-cc17-4cc7-a90d-6601fc9de49d">44,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOC0xLTEtMS0zNDQ5MQ_c6feb876-f00d-4428-9572-4496b51dd5ee">4,038,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOC01LTEtMS0zNDQ5MQ_b98d8c4a-d8d2-4220-b530-6c651e4bc2d2">28,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOC0xMS0xLTEtMzQ0OTE_37838ae5-1fff-4c0c-9328-de62bac0b078">28,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOS01LTEtMS0zNDQ5MQ_4c3cd2e9-8a0e-442e-b1b5-465bab246b13">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOS0xMS0xLTEtMzQ0OTE_695c9433-8a82-46ea-9a4c-3fb3a9e16005">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f167f86b3554775a6ecae909a898b9e_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTAtOS0xLTEtMzQ0OTE_0b70f723-57a4-4cff-ad70-904957a33944">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTAtMTEtMS0xLTM0NDkx_0ee9bc7e-6dac-42f5-8db9-ba5a9e862289">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib501b2d7888048ad8bab2aff0a7e49bf_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTEtNy0xLTEtMzQ0OTE_16339ecf-a8ca-4880-9315-d4c051374a1c">45,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTEtMTEtMS0xLTM0NDkx_2efb21e7-ecba-4aae-8fb9-2800b2b9d5db">45,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItMS0xLTEtMzQ0OTE_4cfb543a-7fbf-4e97-9874-426de9ccf665">102,967,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItMy0xLTEtMzQ0OTE_f2b73afa-ddc6-44d3-80d7-1e85cda58849">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0108f558055448982ef3a107a546127_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItNS0xLTEtMzQ0OTE_3ed6af48-0003-44f0-bd54-4d68d2ba1857">750,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4f3c74aea044471bfd38a37ede1fd57_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItNy0xLTEtMzQ0OTE_296253f4-e70e-4c62-a605-18a0f8a3b70f">633,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id537ef3aea1f4e00b37077b727741777_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItOS0xLTEtMzQ0OTE_010acd79-e90c-4324-9eeb-caab6ba418ce">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItMTEtMS0xLTM0NDkx_85a25e92-1f93-40b4-8751-dcaa766a511b">117,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if50bec065c1f4bf58f6a04567d2d85b9_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy0xLTEtMS0zNDQ5MQ_f807b6e1-48d3-4600-b8ef-3adc4536de9f">93,599,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50bec065c1f4bf58f6a04567d2d85b9_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy0zLTEtMS0zNDQ5MQ_372b30fd-06f0-4e22-bef1-8812a57ac677">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568c1373e0354d5aa5dd964481012f03_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy01LTEtMS0zNDQ5MQ_14bf56af-2f53-458b-91a7-d61beb25e580">680,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9078c496b28549dc88394c6f9e3f5bd9_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy03LTEtMS0zNDQ5MQ_075a90aa-28a4-4bc9-bab0-b1ae63d06c0c">554,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e77cc73f998468495a6a26b87a2a968_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy05LTEtMS0zNDQ5MQ_b6c644d2-5316-495d-a9e4-4587331ac58a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43b3062ca24536868bd6a62ace2205_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy0xMS0xLTEtMzQ0OTE_4c153032-745b-41fe-8e14-30cfac3a0204">126,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNC0xLTEtMS0zNDQ5MQ_8d272ccc-9951-4062-bc2d-3fabc767641e">102,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNC01LTEtMS0zNDQ5MQ_632e0fe8-3379-4dcd-b8f6-ade97d9bb28f">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNC0xMS0xLTEtMzQ0OTE_b25045dc-49ba-4aa2-8329-dcd8f7d7e15c">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNi0xLTEtMS0zNDQ5MQ_6a2b00aa-18c3-4454-888b-065b66165f48">205,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNi01LTEtMS0zNDQ5MQ_8f5b419f-2f7a-4cb4-b30e-62b875c966dc">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNi0xMS0xLTEtMzQ0OTE_8bed0cbc-c841-4932-a87d-e2746aa39e18">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNy0xLTEtMS0zNDQ5MQ_c801c495-a678-4a4d-a78d-fb394382662a">79,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS0xLTEtMS0zNDQ5MQ_b37989cc-8d5c-4d62-a5b2-717ac8a357c0">8,979,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS0zLTEtMS0zNDQ5MQ_27f48369-7d35-4801-afdb-18dcbcfa714e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS01LTEtMS0zNDQ5MQ_cfa3f6bb-aee4-401d-966d-843a18f8dce6">62,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS0xMS0xLTEtMzQ0OTE_d793894c-dc88-466f-8417-1de629c9515f">62,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTAtNS0xLTEtMzQ0OTE_5b116b01-8afa-484e-b34b-861ad83cdeff">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTAtMTEtMS0xLTM0NDkx_623c53be-d2b3-44d4-8afc-07e7dacf929c">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibddc548b6b7a4ae280b837265a88e015_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTEtOS0xLTEtMzQ0OTE_0b1177ba-4af4-455d-944c-a9f24b107601">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTEtMTEtMS0xLTM0NDkx_fb344c5d-a5d2-4883-bdf2-e83e48f16635">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6799c6e5bbe8426c90e26a689637fe8f_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTItNy0xLTEtMzQ0OTE_1c814d7e-127d-4685-9cef-826d45c38e63">78,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTItMTEtMS0xLTM0NDkx_64a7418b-20a7-4f25-a5b2-9f9fb230f487">78,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtMS0xLTEtMzQ0OTE_c2594f7f-3680-47a4-95af-474186866973">102,967,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtMy0xLTEtMzQ0OTE_38608e18-8141-48c1-bc4f-aee266178e65">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0108f558055448982ef3a107a546127_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtNS0xLTEtMzQ0OTE_64d8ab3a-1d96-4608-a996-c7ae1f131576">750,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4f3c74aea044471bfd38a37ede1fd57_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtNy0xLTEtMzQ0OTE_e744da73-c5bd-4dbc-a9bd-18f5b646feb3">633,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id537ef3aea1f4e00b37077b727741777_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtOS0xLTEtMzQ0OTE_1be83060-bf90-4c80-abc4-4bcfaae4f0af">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtMTEtMS0xLTM0NDkx_40ef3602-4c90-4b8a-9948-0198c8c7dca8">117,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMy0xLTEtMS0zNDQ5MQ_a2fc610f-c21f-47b7-bbb8-98332c902584">55,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMy0zLTEtMS0zNDQ5MQ_6bad27c0-1d7c-467c-8942-218ff2b35da9">78,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNS0xLTEtMS0zNDQ5MQ_91bf1232-707c-4a77-8afe-23de9c2ae957">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNS0zLTEtMS0zNDQ5MQ_70e5062d-bc83-4afb-8446-dd3dc6b62257">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNi0xLTEtMS0zNDQ5MQ_762d9fd9-6f30-4921-8af3-7a9510519684">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNi0zLTEtMS0zNDQ5MQ_ef4d93ea-1216-4de8-a0bd-19273271b033">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred compensation for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNy0xLTEtMS0zNDQ5MQ_87f6117f-391e-4d56-be00-7526841af9d0">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDeferredCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNy0zLTEtMS0zNDQ5MQ_0587e277-cd11-411a-afda-38f3abd97f48">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOC0xLTEtMS0zNDQ5MQ_9835f9a1-dc84-4a2d-9b5d-ae3d376e6cf7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOC0zLTEtMS0zNDQ5MQ_a7b75237-cd36-4ab1-94c2-9a1c94e16246">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOS0xLTEtMS0zNDQ5MQ_ee38783f-cdfb-429a-8915-25a1ab8248af">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOS0zLTEtMS0zNDQ5MQ_bad3bf59-b2a3-4fc5-bef4-33977d9144ee">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTAtMS0xLTEtMzQ0OTE_5df1bc5d-93aa-420a-b433-fec989267413">6,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTAtMy0xLTEtMzQ0OTE_e2340a90-d523-4bae-afcf-c0f2f480834b">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTEtMS0xLTEtMzQ0OTE_8e6fc522-57f1-472c-b3e2-6fd223230820">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTEtMy0xLTEtMzQ0OTE_142870cf-4c98-43d9-b14a-fbf35c679509">713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt refinancing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTItMS0xLTEtMzQ0OTE_c097acc7-23bb-4d59-8607-1cad65568358">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTItMy0xLTEtMzQ0OTE_d9124942-d276-4b69-b9df-7c2ece7a16f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTMtMS0xLTEtMzQ0OTE_bda01c9a-9cd7-4b3b-b677-09c60ac37d0c">853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTMtMy0xLTEtMzQ0OTE_5311bd2b-e242-4269-9108-d42d1a2db227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest associated with debt discount accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTQtMS0xLTEtMzQ0OTE_eebae906-327c-4d82-97ee-bbc50fabee77">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTQtMy0xLTEtMzQ0OTE_14838bbe-58df-4892-9e16-cc4e941d055e">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTctMS0xLTEtMzQ0OTE_1e8707b1-83e8-4e8b-a1d1-50bf4883564c">5,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTctMy0xLTEtMzQ0OTE_c98531a6-afeb-454d-837d-63f2037937c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTgtMS0xLTEtMzQ0OTE_83ed3355-9b5a-4663-9914-44a957aa8026">4,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTgtMy0xLTEtMzQ0OTE_63c055dd-602f-4589-b812-988e47851ae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMS0xLTEtMzkxMjE_1dbbe47f-ca02-4bdf-bbc4-58acf692665a">12,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMy0xLTEtMzkxMTQ_6f21224d-9963-43a2-9774-19165a27a0ff">8,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMS0xLTEtMzQ0OTE_7f07e6ae-3060-4b33-8f1d-d54e77211f0d">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMy0xLTEtMzQ0OTE_3949ebb6-ec62-41a9-9193-8066a03f2e2b">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjAtMS0xLTEtMzQ0OTE_9405a4f6-cc71-45e9-8dc4-a4761d48ad26">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjAtMy0xLTEtMzQ0OTE_4bd309de-9a85-4597-bbe1-bee7c343e0ca">3,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjEtMS0xLTEtMzQ0OTE_1f15fe73-92c2-4b48-b5db-d579762493d8">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjEtMy0xLTEtMzQ0OTE_1d8c1609-c1d3-40bc-b8b8-c3d6fdb171f7">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjItMS0xLTEtMzQ0OTE_dd880763-397e-4e82-bd62-a4df40ea4890">1,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjItMy0xLTEtMzQ0OTE_ebff7449-9155-47b2-9d4f-b33fdc6c12c0">1,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjMtMS0xLTEtMzQ0OTE_c05af8cc-1968-45e4-9788-258a79bac5cd">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjMtMy0xLTEtMzQ0OTE_3010f6d3-65c1-4299-97b9-b7c6ba1ffcbe">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjQtMS0xLTEtMzQ0OTE_362a8062-adb5-4c34-b048-b37f9c1a9f95">7,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjQtMy0xLTEtMzQ0OTE_f306e457-f5aa-49cf-a301-6088f08cd815">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjUtMS0xLTEtMzQ0OTE_bfa53a74-d9e1-4316-a5f0-11330dfb46ff">58,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjUtMy0xLTEtMzQ0OTE_fae90220-8d78-4251-a9d0-a1caf74aef9f">78,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and redemptions of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjctMS0xLTEtMzQ0OTE_6d797247-0dcc-4baf-800a-790db1c5728a">42,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjctMy0xLTEtMzQ0OTE_d74dd4ba-7997-4dcc-ad73-3dae68ea5b04">60,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjgtMS0xLTEtMzQ0OTE_7acfc9a0-60eb-4236-b634-8b5824d6ac8e">25,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjgtMy0xLTEtMzQ0OTE_5bd57337-ec6c-4974-b7a5-9cdce535598c">48,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjktMS0xLTEtMzQ0OTE_97bfa8c2-6580-424f-a2f7-8357eb1aa15b">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjktMy0xLTEtMzQ0OTE_6de875e6-073a-4f23-8c88-30c61f83899d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzAtMS0xLTEtMzQ0OTE_38188d72-ce66-4ddc-9914-e7ed60515aa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzAtMy0xLTEtMzQ0OTE_bb66d654-1e85-460b-b8c9-f9b4657f4b8b">1,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzEtMS0xLTEtMzQ0OTE_ceeb46fe-0095-473a-9ae9-38e8646b255e">17,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzEtMy0xLTEtMzQ0OTE_21982805-3dc2-4ef7-97fa-088a0e67268b">10,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from 2022 Loan, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzMtMS0xLTEtMzQ0OTE_b814f898-88d9-44c4-ad32-e06320056d19">26,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzMtMy0xLTEtMzQ0OTE_8955fd95-1115-4a58-984b-abe8738a9025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of 2018 Loan, net of settlement costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzQtMS0xLTEtMzQ0OTE_2cb6e2c9-7eb6-498e-8898-6709417904a5">33,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzQtMy0xLTEtMzQ0OTE_7eb54dba-c2d4-408b-b2d1-b27bb44dc655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of future royalties, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzUtMS0xLTEtMzc4NTE_254bf74a-1bb7-4d83-9893-312a3e2c5405">9,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzUtMy0xLTEtMzc5MjI_c399ba61-2ae3-42d9-9873-bef61c9edae9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in at the market offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzgtMS0xLTEtMzQ0OTE_5cbba1c3-654f-4377-99b7-bfa5da438743">18,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzgtMy0xLTEtMzQ0OTE_c7df11b2-0766-490c-b373-fe76f16ce0e1">62,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzktMS0xLTEtMzQ0OTE_40fbc71f-e009-4f53-96cb-ce4bc0bfc3ea">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzktMy0xLTEtMzQ0OTE_4cc79f43-373d-4db6-9e1d-1e5d8df07488">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDItMS0xLTEtMzQ0OTE_7beb598f-3528-41db-a654-bf8d5b00f295">22,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDItMy0xLTEtMzQ0OTE_66febbb4-af65-402d-870b-6fe8654204af">63,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDMtMS0xLTEtMzQ0OTE_4ce498c8-03f6-4db3-970c-68a15dc32916">19,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDMtMy0xLTEtMzQ0OTE_72122f37-ae2a-4a67-aff1-7eba48783792">4,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDQtMS0xLTEtMzQ0OTE_3ac91770-d2a1-4115-b0ca-1dbda01bd847">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a43b3062ca24536868bd6a62ace2205_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDQtMy0xLTEtMzQ0OTE_aa0c3f58-4a19-4a40-9d9d-1a20ccd9b02a">91,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDUtMS0xLTEtMzQ0OTE_8f7c9499-5e91-4f85-9976-6e8f847c36f4">53,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDUtMy0xLTEtMzQ0OTE_29fc5835-d02c-47a7-84d0-cb3aa24cd14e">86,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDctMS0xLTEtMzQ0OTE_dcf6fd85-c43f-4c38-8a7b-d9e60b2b88e7">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDctMy0xLTEtMzQ0OTE_f74ab9ac-5b2d-4cce-9b7b-5131658f03bd">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDgtMS0xLTEtMzQ0OTE_a3c803c7-abc3-452d-a307-f7cbb189bc6d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDgtMy0xLTEtMzQ0OTE_560620de-cb03-4cda-a6c7-e79227cf43da">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTAtMS0xLTEtMzQ0OTE_11e60778-f7d2-4e20-bf72-a6babb39fb83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTAtMy0xLTEtMzQ0OTE_e808cef1-3fdc-4e8c-a813-d27d4d48222d">14,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of derivative in connection with issuance of loan payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="ardx:DerivativeIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTItMS0xLTEtMzQ0OTE_10ddfd48-cc85-452f-85bc-9f16743f2213">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="ardx:DerivativeIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTItMy0xLTEtMzQ0OTE_623c8732-4d3c-47b1-a50c-a076e8d61dc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amounts in thousands, except per share amounts and where otherwise noted)</span></div><div id="i3a1430f6bb744768868435e28c329915_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDU_4802acca-0414-4821-9183-2fbde573f3e7" continuedAt="i1e24b6bce59e44c4bbbe01f67c1a551a" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i1e24b6bce59e44c4bbbe01f67c1a551a" continuedAt="i89015627575c4239bb80a9c4b953a1b0"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMjg5_83d0b56a-459a-488d-8bfc-61a23655c86f">one</ix:nonFraction> business segment, which is the development and commercialization of biopharmaceutical products.</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM4OTk_b47acf4f-caeb-409c-a471-8343ac00eb5b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDA_7cc068b5-77d8-48df-95d3-c9c36725f6e3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash and investments of approximately $<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-5" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMjQ0OA_f67c3eb8-978a-4ab2-a0d8-39f5157a9e2a">81.0</ix:nonFraction>&#160;million. We have incurred operating losses since inception and our accumulated deficit as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMjU0Mg_4181f6b4-380d-46d2-a591-0ddee2a22f57">767.9</ix:nonFraction>&#160;million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from sales of IBSRELA, our potential receipt of anticipated milestones from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i89015627575c4239bb80a9c4b953a1b0" continuedAt="i288063d5a87e41cb8c05e4af5b4242b8"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 1 to our audited financial statements for the fiscal year ended December&#160;31, 2021, included in our Annual Report on Form 10-K. Our significant accounting policies for the three and six months ended June&#160;30, 2022 also included the policies discussed below related to accounts receivable, inventory, revenue and cost of revenue for commercial product sales. With the exception of those noted below, there have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM4OTg_dcee3ea5-4e9a-4e7f-afb7-360927305868" continuedAt="i8f948aa4eea047c3a61a59117d9ad095" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8f948aa4eea047c3a61a59117d9ad095">Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required.</ix:continuation> As of June&#160;30, 2022 our accounts receivable balance is comprised of $<ix:nonFraction unitRef="usd" contextRef="i1555902d2ec1463bacd6e8d3c0cd1ff1_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNTExNQ_86164dcb-40fa-4123-bf88-3aad2942e1f1">4.1</ix:nonFraction>&#160;million from our collaborators and $<ix:nonFraction unitRef="usd" contextRef="iace48da582da4c0683e6c1b47d0ac054_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNTE0NQ_0bb89c6e-b5a4-4160-9e41-2b22ad12893d">1.5</ix:nonFraction>&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $<ix:nonFraction unitRef="usd" contextRef="icb917478e7cc4cb19f960aafa0ebf6d2_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNTIzMw_9ec70efb-abf8-456d-bec7-5628a89bd0a1">0.5</ix:nonFraction>&#160;million from our collaborators.</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDE_c9584dc7-6429-4682-9af3-50e245badd92" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDI_9af629d1-6a31-4f42-ae30-44bb45ea7d29" continuedAt="ic1aa36fcc2bd4352b1cb89815edc3819" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through a limited number of wholesalers and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i288063d5a87e41cb8c05e4af5b4242b8" continuedAt="i18d5b1c63f7c448b81492d4fea1f3e66"><ix:continuation id="ic1aa36fcc2bd4352b1cb89815edc3819"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally <ix:nonNumeric contextRef="ic932086e94cd487a952b91e6f8c04bd1_D20220101-20220630" name="ardx:RevenueGeneralPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTA5OTE_b96d46a1-34f8-4bb1-ab6e-fb5c7a856baa">30</ix:nonNumeric> to <ix:nonNumeric contextRef="i243ea0b71955409b86d20ba33c39c16d_D20220101-20220630" name="ardx:RevenueGeneralPaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTA5OTc_73e62e12-7421-4098-aa22-3be9557b14a6">60</ix:nonNumeric> days. Wholesalers and specialty pharmacies are offered various forms of consideration, including service fees. Wholesalers may also receive prompt pay discounts for payment within a specified period. We expect prompt pay discounts to be earned when offered and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the condensed balance sheets.</span></div></ix:continuation><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDM_36690042-c9c1-48c9-beae-a8e3e613ac4f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three and six months ended June&#160;30, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of <ix:nonFraction unitRef="number" contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTI4Nzc_65c02c32-51f0-41fb-8c66-1d39a68e8daa">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTI5NjI_396b92d0-6711-461c-85b2-03dbfe12e4c6">20</ix:nonFraction>% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i2766bdc22382498f96100a7aaec65cb8_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTMxODI_479d9d34-948e-4dd2-b07f-c75bf04b38dc">75.0</ix:nonFraction> million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i9df8422a3ac54491960b7f51d8d389ad_I20220630" decimals="-5" name="ardx:CostOfRevenueAggregateAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM0MDM_59f0d461-2e2e-4e6c-82f6-8544e73df52a">11.9</ix:nonFraction> million as cost of revenue under the AZ Termination Agreement.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i18d5b1c63f7c448b81492d4fea1f3e66"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="ardx:NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNzE0NjgyNTYwMzQ3OA_fef533fc-1730-4b19-aa60-e94240171982" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-cash Interest Expense on Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds we receive from the sale of certain future royalties are amortized to non-cash interest expense over the estimated life of the associated agreement using the effective interest method. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDQ_68bcf7d6-0cae-4163-994b-abdc49dc8b52" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i3a1430f6bb744768868435e28c329915_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMjMyOA_98f39bc0-bd61-4557-bf72-d6d4b802c7d9" continuedAt="i0965ca727b454740ba57eb5bd850dc96" escape="true">CASH, CASH EQUIVALENTS AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i0965ca727b454740ba57eb5bd850dc96" continuedAt="i1a7bd86ae2924f5ea1c24d3845991063"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMjMyOQ_6fddc062-946b-4aa2-887d-064122700fcd" continuedAt="i1bc3fd0ba8414dbab45fc3fc27f4b7fe" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of June&#160;30, 2022 and December&#160;31, 2021 are summarized below (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC0xLTEtMS0zNDQ5MQ_df783112-93ae-4e2f-bbec-13d6ae5c1645">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC0zLTEtMS0zNDQ5MQ_018e9e8b-61fb-408c-9bf7-062c57945f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC01LTEtMS0zNDQ5MQ_ac003500-0f01-4996-b962-bb1215614574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC03LTEtMS0zNDQ5MQ_a989d815-a626-4471-a71e-de8ad6fbf10d">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS0xLTEtMS0zNDQ5MQ_111073f7-e285-4368-bbeb-0aae98d0bbf1">50,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS0zLTEtMS0zNDQ5MQ_1679637a-e88a-438e-a315-83d8f7166f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS01LTEtMS0zNDQ5MQ_0b48e82e-4dde-419b-b9a3-6ee5b62db724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS03LTEtMS0zNDQ5MQ_098da2b0-4f43-42d4-a40e-40db65e5b646">50,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC0xLTEtMS0zNDQ5MQ_a88c7ff4-cc32-4988-a8a6-bebf5f665044">53,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC0zLTEtMS0zNDQ5MQ_abbec24d-acf1-4006-a8b4-b8285365b2e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC01LTEtMS0zNDQ5MQ_203bf806-9613-43f3-b10f-49e100309e6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC03LTEtMS0zNDQ5MQ_5b8192ce-fc26-40f4-ae9d-e2dcb82d9910">53,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtMS0xLTEtMzQ0OTE_a5a6c418-0f35-4ac1-83bc-78e4820fadc0">16,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtMy0xLTEtMzQ0OTE_cc87485d-72e6-4f1d-aacd-9f7030572050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtNS0xLTEtMzQ0OTE_beb4e920-8c80-4476-bc58-385f773f722e">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtNy0xLTEtMzQ0OTE_34b2b911-7cab-4eda-abc8-7a49af45766a">16,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtMS0xLTEtMzQ0OTE_2a217b3f-9ab0-4a9e-857a-803f11d424b8">8,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtMy0xLTEtMzQ0OTE_dd2b99e9-7bcc-47b4-a52e-af9e14f54c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtNS0xLTEtMzQ0OTE_fb8364b8-6940-45c6-a6dd-cf186e91e78e">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtNy0xLTEtMzQ0OTE_2ef52f61-8118-413c-a61e-e5ed8f1ca7a0">8,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItMS0xLTEtMzQ0OTE_3b0d80e0-3e7b-40e8-8574-7c78d1ba22fc">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItMy0xLTEtMzQ0OTE_67daa6dc-7dd9-4b98-953e-827c1409398b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItNS0xLTEtMzQ0OTE_07728c3e-4ad7-40f3-8bec-dd8f8a3c1980">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItNy0xLTEtMzQ0OTE_5d07f1a5-5283-4d0d-a26c-e03bbb09341a">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtMS0xLTEtMzQ0OTE_faa230c1-5c49-47ba-9c08-050ff5aa203c">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtMy0xLTEtMzQ0OTE_3c8e4b61-3255-4444-b04d-5895041b9b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtNS0xLTEtMzQ0OTE_9684bb60-5d4b-4beb-bdd7-a4e3e209d56e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtNy0xLTEtMzQ0OTE_a0a5feff-5220-4bcc-94c4-b063b2ca8c98">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtMS0xLTEtMzQ0OTE_6f3bf8bb-07e3-4c95-b0d1-5b8bdbe5a15d">27,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtMy0xLTEtMzQ0OTE_db709b3f-009a-4b95-9ba5-ba096e9df713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtNS0xLTEtMzQ0OTE_7157e6e7-5996-41fa-9f8b-31a8b5be1a3f">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtNy0xLTEtMzQ0OTE_487b434e-8bf5-497e-99c6-fb2a8ff9c42b">27,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtMS0xLTEtMzQ0OTE_4cf1cf90-6eb4-4a30-8372-74f71c31a9e6">81,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtMy0xLTEtMzQ0OTE_7a924f60-c036-4af7-9a3c-a425d52af487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtNS0xLTEtMzQ0OTE_feeb4ba5-698d-4e85-a2f3-8a05ad249c19">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtNy0xLTEtMzQ0OTE_b64388b9-9f4a-428e-ae1b-dc8506e48c2e">81,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i1a7bd86ae2924f5ea1c24d3845991063"><div style="text-align:justify"><ix:continuation id="i1bc3fd0ba8414dbab45fc3fc27f4b7fe"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9919698f07db4a6a92578760f1c69457_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC0xLTEtMS0zNDQ5MQ_ea9b2c34-a786-4a0c-98b2-8658561e08f0">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9919698f07db4a6a92578760f1c69457_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC0zLTEtMS0zNDQ5MQ_41bc099f-332a-4af2-ab38-e630f76cab9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9919698f07db4a6a92578760f1c69457_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC01LTEtMS0zNDQ5MQ_a03f3acd-3306-42a0-8eac-a3358c7e18cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9919698f07db4a6a92578760f1c69457_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC03LTEtMS0zNDQ5MQ_e9c4c8ee-f4a4-40e4-b893-8a3113d623f0">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS0xLTEtMS0zNDQ5MQ_2ca22a08-d440-4d4e-836c-c817a714b828">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS0zLTEtMS0zNDQ5MQ_be41a0a1-b9f5-497e-885a-1b410bd2406b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS01LTEtMS0zNDQ5MQ_7138b056-c105-4ca4-902a-5ae24c7cb8ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS03LTEtMS0zNDQ5MQ_15be2ec7-2cd9-45f5-9dcb-2f85b3d6040b">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC0xLTEtMS0zNDQ5MQ_58136f34-8d0a-42eb-accd-cee3dd100000">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedGains" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC0zLTEtMS0zNDQ5MQ_0140dd66-4d6b-4fd1-ac22-a62811bec584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:CashAndCashEquivalentsGrossUnrealizedLosses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC01LTEtMS0zNDQ5MQ_79e29b3a-374f-4827-bd34-8d05c5c2c53c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC03LTEtMS0zNDQ5MQ_d878cb46-42f7-4d9f-ac2a-03b5465d60ee">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtMS0xLTEtMzQ0OTE_cf421704-be93-408f-a55f-8e21fbb6e61b">31,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtMy0xLTEtMzQ0OTE_af69ea8e-38ae-49c7-b8d2-0fb28f5d68eb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtNS0xLTEtMzQ0OTE_bed88418-8887-4bcb-9e52-a0b685da9db3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtNy0xLTEtMzQ0OTE_eb2187ac-5614-43cf-9111-bfe0ad658645">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtMS0xLTEtMzQ0OTE_b4ee98a0-ba22-483b-a845-9d1e8ea738d7">7,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtMy0xLTEtMzQ0OTE_6fc962b8-1494-41e5-a753-fe84e93cf1ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtNS0xLTEtMzQ0OTE_9d755132-34fe-4025-ba1c-8c7600870cfc">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtNy0xLTEtMzQ0OTE_2796b8cf-8d9d-4d88-ae0f-6f445d9720c9">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtMS0xLTEtMzQ0OTE_57eb7066-ee35-4bb6-a41b-931fe66f1754">5,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtMy0xLTEtMzQ0OTE_e495343b-dd5e-40aa-9b5c-ae4a704d31ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtNS0xLTEtMzQ0OTE_3e689f2e-0d18-4fc5-ba51-cd85a6a42922">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtNy0xLTEtMzQ0OTE_94ae8c7c-e25e-4e20-94f0-e142bcf375ae">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtMS0xLTEtMzQ0OTE_ce27a590-fecc-48f4-a4a7-b3a58de0b488">44,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtMy0xLTEtMzQ0OTE_df533192-21e2-49ff-a908-d13fb0c4b7d4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtNS0xLTEtMzQ0OTE_6b6a9df6-f546-4ea3-a398-d6101244e9b9">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtNy0xLTEtMzQ0OTE_39756726-c43e-4576-a3bf-09dd86481214">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctMS0xLTEtMzQ0OTE_160aa67b-fb9a-4a90-9abf-f18b403b24b9">116,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctMy0xLTEtMzQ0OTE_50d6166c-113d-4d91-a828-e32a039bf3e2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctNS0xLTEtMzQ0OTE_b3d2e0d8-6723-420d-ad18-9580ea6caa31">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctNy0xLTEtMzQ0OTE_16f5e30a-3c5c-484a-86e7-9ae76749fdde">116,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds and other debt securities with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive income (loss) within stockholders&#8217; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income (expense), net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All short-term available-for-sale securities held as of June&#160;30, 2022 had contractual maturities of less than <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMTEwMw_c8d3693d-4288-49a5-88ac-2751436bebb7">one year</ix:nonNumeric>. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write it down through the statement of operations and comprehensive loss to its fair value and establishes that value as a new cost basis for the investment. We did not identify any of our available-for-sale securities as other-than-temporarily impaired in any of the periods presented. As of June&#160;30, 2022, <ix:nonFraction unitRef="investment" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMjExNw_f8ffacc2-8f8c-48fe-a89b-9ef01e2373f3">no</ix:nonFraction> investment was in a continuous unrealized loss position for more than one year and we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3a1430f6bb744768868435e28c329915_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RleHRyZWdpb246NzMwOTBkMDc5NTRlNDI1NGJlYzNkYTRlYmYwYTQ5NjdfMTk2Mw_56814414-e7cc-4ae2-a6b3-b2b536479f34" continuedAt="i1096069f4c954562838702348d213a6e" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1096069f4c954562838702348d213a6e" continuedAt="i70181cf4e498477e8037afb2e007f77d"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RleHRyZWdpb246NzMwOTBkMDc5NTRlNDI1NGJlYzNkYTRlYmYwYTQ5NjdfMTk2NA_daa09129-f16c-4c5b-9323-7ffe17554500" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i70181cf4e498477e8037afb2e007f77d"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RleHRyZWdpb246NzMwOTBkMDc5NTRlNDI1NGJlYzNkYTRlYmYwYTQ5NjdfMTk2NQ_8425c48e-096d-44ff-8af5-0a8b333692f4" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0b0709ef024116a0c9265abca56e5f_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy0xLTEtMS0zNDQ5MQ_c4e974bc-b522-40e1-b901-8231965cad75">50,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fb0f7426e14cbb8e220839ea644f53_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy0zLTEtMS0zNDQ5MQ_a6d22419-1606-461a-8373-57102a422497">50,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b3eccd186b4b239771cea14a00e33d_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy01LTEtMS0zNDQ5MQ_4989e570-a5ab-454b-9184-68c44571d651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546a6d3ca15649b1b31ac1990141ee51_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy03LTEtMS0zNDQ5MQ_dca5d0b1-e88a-4198-b3c3-a9be8feb6ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08942428c1e14accb811599d6f9c1077_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC0xLTEtMS0zNDQ5MQ_77762c73-2613-488e-8032-7d3ea00a237a">16,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb85da03916f4959ae20e2dc28f6455c_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC0zLTEtMS0zNDQ5MQ_ab5970f7-f00c-4797-bc2a-1126b0641bb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98257b0990d4eec907be89dfe165197_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC01LTEtMS0zNDQ5MQ_04c76763-7a12-48f8-9b2e-c86af9cfd914">16,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93c9bcdad9ec4c5ba892fa935c841839_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC03LTEtMS0zNDQ5MQ_d5789b7f-96c3-4045-b294-6d904e60ff1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9d10adba4d4aeab9e207d99f3aeebe_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS0xLTEtMS0zNDQ5MQ_e5572caa-d4e4-4e58-bfa5-26df5f12ae5c">8,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaefa25584840cb807733401729c67a_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS0zLTEtMS0zNDQ5MQ_6bb8dee2-7660-42ec-81d1-4300cd4cf940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f37d12d66ab426fa73fe7b3c5d57eb4_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS01LTEtMS0zNDQ5MQ_cde92e30-e03c-49e2-ae1f-896bfbb9819d">8,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7372862571244bdca7df10a1706f5b15_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS03LTEtMS0zNDQ5MQ_7ec668be-e6a1-42c7-9884-a6f8f485e614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12201884779347479d4fe912a0be5b1f_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi0xLTEtMS0zNDQ5MQ_51a09232-5b59-4d60-82c0-f26ef31c21cf">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03a03012ab5410792f139ec7007eb3a_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi0zLTEtMS0zNDQ5MQ_733052d7-928b-4bf5-a382-5c99985aa5ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63c1e4cfb6a4516a7f8967b8e88ef31_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi01LTEtMS0zNDQ5MQ_db7f0136-2c1e-4584-a200-97ba08d90ab0">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2c3f0a67c94a8c83f4cce268ad23a1_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi03LTEtMS0zNDQ5MQ_2cde2985-6780-49f0-a75b-54b1c0375d05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc5a1fc9b954a588a196da771f45701_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy0xLTEtMS0zNDQ5MQ_964fe13e-01e3-4ca0-911b-f4c3dda56372">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id68a85c2475545a7946d12b3a69a9c7f_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy0zLTEtMS0zNDQ5MQ_bb6ad4ef-ac4a-45fd-87df-52099942a504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if576c80f93ba477a8bd7f301242eb30a_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy01LTEtMS0zNDQ5MQ_cb20d3d1-4ef1-4ec4-b575-c3ce818d30c0">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa3bc355b5244eb0b37758f0981ed405_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy03LTEtMS0zNDQ5MQ_350596a0-116c-42b1-9883-8dbfc9d8587d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ffac70a8f02419f80d424ef9aec9556_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS0xLTEtMS0zNDQ5MQ_03ed43fd-91d1-4c82-8907-94c0efcf9e78">78,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7954cbfa4ce4ea4ab4c3f6181db0e2e_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS0zLTEtMS0zNDQ5MQ_fdf6c156-173c-4a5d-8c5a-78b7e50d0139">50,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b85e98bea364f768c6d835cd20e21da_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS01LTEtMS0zNDQ5MQ_6ef9c3b3-5d8c-4d74-9053-9c5a0c311d02">27,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf155031c64016a5a4d37007dc9ab7_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS03LTEtMS0zNDQ5MQ_add95c1e-b09b-4c59-b9b5-37c45c31c846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620c4cac0fc54742b917d01906a295b1_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItMS0xLTEtMzQ0OTE_f9af0518-8ae2-4eb2-96f9-d4091ccf46c2">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07691efdc6d54495bf7cb279afdb630c_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItMy0xLTEtMzQ0OTE_3b27f592-894e-49aa-bb91-147d80e1e50e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d14510168b435db23351f3042e2fcd_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItNS0xLTEtMzQ0OTE_680ebbf3-de2d-4c7c-bc9e-2c7c9146c22f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0cb3f52dc7040e1865d853122c39d38_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItNy0xLTEtMzQ0OTE_f5e4c484-402f-4e63-a9b1-aecd6afe748a">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ffac70a8f02419f80d424ef9aec9556_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtMS0xLTEtMzQ0OTE_79bc456c-051e-4ea1-9117-e2071963407f">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7954cbfa4ce4ea4ab4c3f6181db0e2e_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtMy0xLTEtMzQ0OTE_aa4a0bd7-09da-42f3-9798-3e92101541f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b85e98bea364f768c6d835cd20e21da_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtNS0xLTEtMzQ0OTE_65d60abe-0105-43f0-8fc7-ffde38b360d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5cf155031c64016a5a4d37007dc9ab7_I20220630" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtNy0xLTEtMzQ0OTE_176f90ad-e6f0-4c3b-aec3-ee0b179325c0">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cad74c2b72746a98815ab0bf53fe597_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy0xLTEtMS0zNDQ5MQ_9c641e1c-0c84-4461-9b72-28c21629f594">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995be0cb8d874d6c9ba41b0dc05d971e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy0zLTEtMS0zNDQ5MQ_810c4b61-67df-4899-922d-196164bfcd0f">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b854a7ada5344f09ef5775e5cba8f93_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy01LTEtMS0zNDQ5MQ_9f5d9b1f-a525-4b62-8b46-84ff1ecbccf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b547ba90a040d0b2ad45d6df149223_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy03LTEtMS0zNDQ5MQ_364c3929-93fa-4000-a847-b728aa3946aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie912ea9191f3410a856fb7a0596383a4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC0xLTEtMS0zNDQ5MQ_14b4eb2d-8b54-4555-8e15-80ea68ed964a">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c82683331d441bb4bb22c1a6fee81b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC0zLTEtMS0zNDQ5MQ_bcff2f8f-ae9a-494c-81fd-8c6a0bd3895c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ec7fb6b30a44a384e58a556b1d2cf6_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC01LTEtMS0zNDQ5MQ_a8392052-a6fd-4505-b58c-0b8e20815b94">31,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964174c2047d42ea872fe68df856aaf0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC03LTEtMS0zNDQ5MQ_31af8db4-b565-48f2-95d1-8d5a974ec958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3d98d34e324383930817612f98d9b0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS0xLTEtMS0zNDQ5MQ_00be7b8b-4289-4648-a272-b2d88417250d">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a59bd234854baab3810f3de2b8b58a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS0zLTEtMS0zNDQ5MQ_614398ea-e957-4927-a5f1-b1b9bb171e9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8051dc6644dd49ddb271e164ef97c689_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS01LTEtMS0zNDQ5MQ_be27809a-d158-4c6b-96f3-e84581c4c99b">7,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e3e3a40f3c49c083b2d38b581d7312_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS03LTEtMS0zNDQ5MQ_b7aec4d0-2e27-47a1-abac-cfbd0950f9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e633e223e04648a650081651dfab52_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy0xLTEtMS0zNDQ5MQ_1402b93e-0d09-489b-a17f-cecff6aa54ac">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b58e6d555145f0bdc3410179ee3f96_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy0zLTEtMS0zNDQ5MQ_faf11c7e-1a84-4617-9945-30842938f560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d88606f5f10482f94f0ee9f6cf00522_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy01LTEtMS0zNDQ5MQ_a6e1f559-f3ca-41cb-a1b2-2d57d5f62d90">5,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ad9ee3c9d74b2db9e200ae3966bdea_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy03LTEtMS0zNDQ5MQ_f68f267f-b764-491f-b2ec-3c48ce808094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf5489a8dfe42c2b6bbf447a6a435a2_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS0xLTEtMS0zNDQ5MQ_50356a7a-29ef-487d-828e-ffbcf9c91f50">115,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca70cbb1754fb0bb05cb61bb3092c5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS0zLTEtMS0zNDQ5MQ_0721f0ed-3307-4dc1-b8a9-50da9a56d341">71,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65da5e485ec14c3284891b7e6b8296a6_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS01LTEtMS0zNDQ5MQ_ab3d6650-f07f-4848-ae73-f42bee13f64b">44,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id077c7e922dd4a4482ae82df90440e4a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS03LTEtMS0zNDQ5MQ_ce824730-f12b-4acd-8f19-2fdb4736ce20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d869a99367f4854a7b935212b14932c_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItMS0xLTEtMzQ0OTE_88e788eb-227d-4b86-82a2-888ea39564bc">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd39e9f5df1041638177826f6d98c2c5_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItMy0xLTEtMzQ0OTE_8b58cf03-7b48-40a1-b743-21637772ac27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae239e1a1fb44ff689e8fe9e2e2b5049_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItNS0xLTEtMzQ0OTE_23a5edbb-a1d3-4b28-ba31-b6e72e17843a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86f2f199f92428483fdae875ebaf628_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItNy0xLTEtMzQ0OTE_d01f08a2-3f21-4da2-99d9-a3db2ab8d5d0">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf5489a8dfe42c2b6bbf447a6a435a2_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtMS0xLTEtMzQ0OTE_d5db5cbd-71da-43d3-a03d-48eedbbe3d44">698</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca70cbb1754fb0bb05cb61bb3092c5_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtMy0xLTEtMzQ0OTE_4958a12c-8c81-4220-a4a1-747c84cdb301">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65da5e485ec14c3284891b7e6b8296a6_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtNS0xLTEtMzQ0OTE_d0f80eb0-618d-4f49-8c68-2839680f7b92">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id077c7e922dd4a4482ae82df90440e4a_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtNy0xLTEtMzQ0OTE_557f911a-a04c-4853-970c-8f634f979681">698</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and 2022 Exit Fee, as defined and discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are classified as Level 3.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both June&#160;30, 2022 and December&#160;31, 2021, due to their short-term nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rates of our deferred royalty obligation and term loan facility approximate the rate at which we could obtain alternative financing. Therefore, the carrying amount of the deferred royalty obligation and the term loan facility approximated their fair values at June&#160;30, 2022 and December&#160;31, 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation and Note 8. Borrowing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 3 inputs used to estimate the fair value of each respective liability.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMjc4_734ae970-94b3-4857-a904-d644a3eee324" continuedAt="i9f0bdd45cece46af919bc61187b8a826" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i9f0bdd45cece46af919bc61187b8a826"><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMjc5_2e604996-669c-4157-a11f-4bd1cac6aa3c" continuedAt="ib6c0f42022fc4eb3bc63c1785c442102" escape="true">Inventory consisted of the following (in thousands):</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><ix:continuation id="ib6c0f42022fc4eb3bc63c1785c442102"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfMS0yLTEtMS0zNDQ5MQ_c9f073c7-5db0-46cb-a235-dd20428641a2">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfMi0yLTEtMS0zNDQ5MQ_4888f3b5-0b8c-4cc5-b884-d73e1e14cf98">3,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfMy0yLTEtMS0zNDQ5MQ_64e3d1bb-c6ad-499b-85e1-3756262984e6">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfNC0yLTEtMS0zNDQ5MQ_362402d5-f58f-47dc-8ce7-12c816feb343">4,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid commercial manufacturing of $<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-5" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMTA5OTUxMTYzMDA4Mw_a4a989dd-511e-4378-93d9-f12ed8569d25">17.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-5" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMTY0OTI2NzQ0MjkyNA_88167b85-925f-41ef-a933-699158e0164e">9.4</ix:nonFraction>&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, consist of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months. Prepayments for commercial manufacturing of $<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:PrepaidCommercialManufacturingExpenseNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMTA5OTUxMTYzMDU3OA_a8cbd08f-b11c-4592-8e7e-ec517c63d67d">3.8</ix:nonFraction>&#160;million as of June&#160;30, 2022 that are expected to be converted into inventory after 12 months are included in other assets on our Condensed Balance Sheets.</span></div></ix:continuation><div><span><br/></span></div><div id="i3a1430f6bb744768868435e28c329915_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNzYw_b55dc1a3-1f7e-49db-8afd-e7be129b6031" continuedAt="i744f1dce76d24cab99a6242ef6b27db8" escape="true">PRODUCT REVENUE, NET</ix:nonNumeric></span></div><ix:continuation id="i744f1dce76d24cab99a6242ef6b27db8"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA, the first and only NHE3 inhibitor for the treatment of IBS-C in adults, in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $<ix:nonFraction unitRef="usd" contextRef="i59ec18a7958d427e9d6cbc9e707fe8c3_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMzU5_5c2d9ace-1f6f-4f41-93cf-5f3b949cf88f">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if8db22a3a4424d38be4990606ba05153_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODY0NQ_f7c82f36-a88d-4e95-b534-6fcf3385a715">2.0</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation made up <ix:nonFraction unitRef="number" contextRef="i030bed782c004d8dba6df6de0d87f2b1_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTY0OTI2NzQ0MjYxOA_e75d7a6e-55c6-449c-a3df-e0e0cf18d3b6">40.2</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="icff93d49e06345b38b9bdf4a97525d38_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNDI1_bc308992-5ed0-4979-9b8e-e42642cd44b1">22.7</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="id4db73df4aa148be8f8d748314b92bc9_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNDM3_c53da9bc-67a7-4bd0-91b8-694afb1cd157">24.6</ix:nonFraction>% of our gross product revenue during the three months ended June&#160;30, 2022 and <ix:nonFraction unitRef="number" contextRef="ic8bf0daa5741459ebc9bbfb5ddfba604_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODY5Mg_351a0621-eda2-4c25-8460-1a978f374d50">35.1</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="icfd33242ba7c449e8338b810a873ad59_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODY5Nw_6283898a-08a1-427d-a5e0-c7679a9cd72e">21.7</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i9c98f044f4c64f13aed0711c37e6a610_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODcwNg_82fbdfa0-4c21-43b0-83b9-729e31464052">22.5</ix:nonFraction>% during the six months ended June&#160;30, 2022.</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNzU5_fcd8cd60-6e84-4653-911c-36c722329a53" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Fees, Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c496b3e28c4d63ab0345238346321c_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS0xLTEtMS0zNDQ5MQ_f8158f2f-69e1-4a26-a6f7-6e189e1bf2a9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie399179e3b854e06a2b3d719ffa81575_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS0zLTEtMS0zNDQ5MQ_42a97fa8-64fe-498f-8010-cec31591c4c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f73fe9f5f3e400faaf0dbba30e2b6c3_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS01LTEtMS0zNDQ5MQ_b87ccc63-48d6-45cf-a61a-a38a208f6f8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS03LTEtMS0zNDQ5MQ_d836d6e5-a727-4afb-8bd3-1f53117b2191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if76af73ff9024e19aceae555eb94a4ca_D20220101-20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi0xLTEtMS0zNDQ5MQ_abee6988-6da9-4191-80f8-69952d2c907f">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdac1bc1d6634022aa3677dde7c770f1_D20220101-20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi0zLTEtMS0zNDQ5MQ_a1e40895-e276-4d9a-bd65-b7181301eee6">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bab5938a824507be1fe347458f5a16_D20220101-20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi01LTEtMS0zNDQ5MQ_57a9aa19-6619-4433-b0e6-1a7ef369a24a">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi03LTEtMS0zNDQ5MQ_f292348e-e787-484e-9c07-e4e24db5a85c">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/deductions issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if76af73ff9024e19aceae555eb94a4ca_D20220101-20220630" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy0xLTEtMS0zNDQ5MQ_c5c2c3ab-e1e3-45b6-8da8-2bf0b2bb8902">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdac1bc1d6634022aa3677dde7c770f1_D20220101-20220630" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy0zLTEtMS0zNDQ5MQ_bb17d2f5-ac1d-44b4-b117-ded871c133f0">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1bab5938a824507be1fe347458f5a16_D20220101-20220630" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy01LTEtMS0zNDQ5MQ_298fac97-0d92-4ec8-8d99-ccc667e47e85">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy03LTEtMS0zNDQ5MQ_6adb4ea8-586e-4ab3-8b9c-1cc116d140db">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f92aef188e44c9ba3e6c4cf63228e7_I20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC0xLTEtMS0zNDQ5MQ_11cb3cd8-0299-49d6-8feb-0cbfa1457fe7">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2352e72adbd040919db7f1c7395453a2_I20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC0zLTEtMS0zNDQ5MQ_bf0c63bc-a932-4a17-adac-3b347f01e007">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib616618f955a41fb961d25698786e446_I20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC01LTEtMS0zNDQ5MQ_2047b171-c7a1-442b-b5e0-71239c8e6f1e">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC03LTEtMS0zNDQ5MQ_f0101ef6-5d60-4b4b-8b45-86dd3d28959c">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="iee6cf208bb934fc49b584ea377c5e697_D20210101-20210630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_509656b1-9165-4b43-b868-420adc71b1b3"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="INF" name="ardx:ContractWithCustomerProductSalesGrossToNetAccruals" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_7b4f2ebf-fa57-4632-ba1c-f76c41f71c87"><ix:nonFraction unitRef="usd" contextRef="i17ad1002e42841d9bab8e33e821c520d_D20210401-20210630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_83a20da2-5614-4625-909a-9e4d19dc5bfe"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="INF" name="ardx:ContractWithCustomerProductSalesGrossToNetAccruals" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_d47efc00-1c76-4da3-b063-1fe0006f2371">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> product sales or gross-to-net accruals during the three and six months ended June&#160;30, 2021.</span></div></ix:continuation><div id="i3a1430f6bb744768868435e28c329915_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzE0NjgyNTU5MTU4Mg_f974e78c-ee3d-47df-b0b5-0800be92d330" continuedAt="ib840b6a67a4d42b1a1ee8074b3f95a10" escape="true">COLLABORATION AND LICENSING AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ib840b6a67a4d42b1a1ee8074b3f95a10" continuedAt="i67137f1dc2a64028804326d9ed803640"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC (the &#8220;2019 KKC Agreement&#8221;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#8220;DCs&#8221;), with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;), and a second inhibiting the second undisclosed target (&#8220;Program 2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute <ix:nonFraction unitRef="item" contextRef="i074ffa4e105544b6beba06ccf79db768_D20191101-20191130" decimals="INF" name="ardx:NumberOfSeparateCollaborativeAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNjYw_f696305e-36c6-4c73-a45a-663a7d2ad647">one</ix:nonFraction> or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i67137f1dc2a64028804326d9ed803640" continuedAt="if42160c289564d04bc176d41c318f7a7"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTEx_520f04d7-7fd9-44d1-afbb-9fa36605dfb4">10.0</ix:nonFraction>&#160;million in two installments as follows: the first installment of $<ix:nonFraction unitRef="usd" contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTcx_c06eb2f7-f90c-4592-a1f0-7a7846b0e34f">5.0</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130" name="ardx:TermOfPaymentOfLicenseFeeFirstInstallment" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTgx_e1556b52-518b-41b2-8f9c-c9448e7d6406">30</ix:nonNumeric> days of November 11, 2019 (the &#8220;Effective Date&#8221;), and the second installment of $<ix:nonFraction unitRef="usd" contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA1OQ_a102a389-3b9b-4c27-bce5-50aab553dc88">5.0</ix:nonFraction>&#160;million on the first anniversary of the Effective Date. The original term of the 2019 KKC Agreement commenced on the Effective Date and was to end on the earliest of: (i) <ix:nonNumeric contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130" name="ardx:TermOfAgreement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTIxMA_1a3a81df-ec6d-4f08-a291-c0e0f5effbfc">2</ix:nonNumeric> years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. We entered into <ix:nonFraction unitRef="segment" contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130" decimals="INF" name="ardx:CollaborationAndLicensingAgreementsNumberOfAmendments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMjc0ODc3OTA4ODEwMA_d5dc4f41-0f07-4ab5-9aa9-f6d9f4a5f5ea">three</ix:nonFraction> amendments to the 2019 KKC Agreement, which have resulted in the extension of the original term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the third amendment to the 2019 KKC Agreement entered into on June 28, 2022, the current term will end on February 28, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no material future obligations under the 2019 KKC Agreement and recorded <ix:nonFraction unitRef="usd" contextRef="i061c308d6b1a43f0968b363555e92226_D20220101-20220630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTU2NQ_c68cf941-35db-4d93-a824-b9f1a0e548ad"><ix:nonFraction unitRef="usd" contextRef="i3fb105e15b8b47d9b8839aab9ebd811a_D20220401-20220630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTU2NQ_e6d9fb46-f8db-4aa8-88fc-c0bbfa47b8eb">no</ix:nonFraction></ix:nonFraction> revenue under the 2019 KKC Agreement during the three and six months ended June&#160;30, 2022. During the three and six months ended June&#160;30, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i1f5bff24d8fb4ded926a6a65685e29e5_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY4MQ_96f0b135-24e7-4216-a0a4-1efb9a0be097">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3db2f9f0408b4c3b8bc1d23c42421c54_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODU5MQ_c333b033-88bf-40fd-85eb-5d6d64428bd4">2.8</ix:nonFraction>&#160;million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (the &#8220;2017 KKC Agreement&#8221;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i41b83b1385d64bb0b4fcdd8478229082_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzE2NQ_a60cb498-2826-4fdf-9953-a9e57656cc53">30.0</ix:nonFraction>&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2017 KKC Agreement, KKC paid us an up-front license fee of $<ix:nonFraction unitRef="usd" contextRef="i41b83b1385d64bb0b4fcdd8478229082_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzU2MQ_a60cb498-2826-4fdf-9953-a9e57656cc53">30.0</ix:nonFraction>&#160;million. We may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i08c9f146a507443cbf42d1ec3614ba5a_I20171130" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzYwMQ_07814917-cb4e-4ae9-ba5b-1d541db251ec">55.0</ix:nonFraction>&#160;million in total development and regulatory milestones, of which $<ix:nonFraction unitRef="usd" contextRef="i014594d7c2e34a5ba34aa3612a1cf0fe_D20171101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzY0Ng_7b09af32-e6eb-4279-8dca-1808809366ff">10.0</ix:nonFraction>&#160;million has been received and recognized as revenue as of June&#160;30, 2022. We may also be eligible to receive approximately &#165;<ix:nonFraction unitRef="jpy" contextRef="i9b05c8d90cf241fe9da5a7dfc1eabd4c_I20220630" decimals="-8" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTY0MDA4Mw_ac8322b2-52cd-4835-a040-2ad6b46b4a2f">8.5</ix:nonFraction>&#160;billion for commercialization milestones, or approximately $<ix:nonFraction unitRef="usd" contextRef="i9b05c8d90cf241fe9da5a7dfc1eabd4c_I20220630" decimals="-5" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTY0MDA5MA_e0c6c251-d5d4-4e3b-a038-a704dc42348f">62.3</ix:nonFraction>&#160;million at the currency exchange rate on June&#160;30, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, we and KKC have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future commercial milestones and royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional $<ix:nonFraction unitRef="usd" contextRef="i1d511f2c209a4a5aaff9671b49116eb3_I20220411" decimals="-5" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODU1MQ_9ee346f1-4a37-4b24-afc8-a0a1a02b80c7">40.0</ix:nonFraction>&#160;million payable in <ix:nonFraction unitRef="payment_tranche" contextRef="i1d511f2c209a4a5aaff9671b49116eb3_I20220411" decimals="INF" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNDc3MQ_4a07a5ab-b217-41c4-8961-6d8fc9bd553e">two</ix:nonFraction> tranches, with the first payment due following KKC's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. The variable consideration related to the reduction in the royalty rate has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="if42160c289564d04bc176d41c318f7a7" continuedAt="i0b4ca3edbfc64a81bfc45031586240d1"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 we recognized <ix:nonFraction unitRef="usd" contextRef="i241a969a3e094d03b3d8dd8e7e25cf1e_D20220101-20220630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTEyMg_69211798-2195-4d4e-a8c4-bb610e4284c9"><ix:nonFraction unitRef="usd" contextRef="i82f5715e2fbb4db4a6cd85a32f3fc2f6_D20220401-20220630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTEyMg_f85bb2b9-cf1b-44e8-9ea3-c748ce7f3f03">no</ix:nonFraction></ix:nonFraction> licensing revenue upon the achievement of development milestones. During the three and six months ended June&#160;30, 2021, we recognized <ix:nonFraction unitRef="usd" contextRef="if8b1212609cc42c18f655b93c0a406eb_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTIzNg_cd7ce893-bec2-420a-a447-e61505753512">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2edefef1531b4386b1099d09c2a70ee0_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODYxNA_6896b028-923a-4b80-b13c-9e4b8a649e45">5.0</ix:nonFraction>&#160;million respectively, as licensing revenue upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia. During the three and six months ended June&#160;30, 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="i8f7b4102a4754a8cbae7529a244bf3f5_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTQxMQ_edc3b628-729f-415f-abc6-80ad91421357">952</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i4597c87af79d4327bdff63f69b57b1ae_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODY0Mg_d5f91051-8325-414e-a764-6e08d38a28bb">966</ix:nonFraction>&#160;thousand, respectively, as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three and six months ended June&#160;30, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized <ix:nonFraction unitRef="usd" contextRef="i109c5f1c267e4db584222bf588b29f9b_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTU5Nw_ffaadb40-1edf-4c0f-bb54-05b9e91ab33d">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia7671d7833f84b738c08011e9527d6a6_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODcwMw_e339e873-1f67-471b-bf14-d695d43d7de6">126</ix:nonFraction>&#160;thousand, respectively, as product supply revenue pursuant to the 2017 KKC Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed below under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue - non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have received prepayments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Fosun Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBS-C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Fosun Agreement, Fosun paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i0bc59163e21d45b0a82ec6a938f3e4fb_D20171201-20171231" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNjc1OA_5cef2042-3843-40c5-95b2-de9b4ef5c2c5">12.0</ix:nonFraction> million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fee. We may be entitled to receive development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9bfae235b525451e977ec2988b5262e7_D20220101-20220630" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ1Nzk2NQ_7d8a45d1-cf02-4734-952b-3aedf3d6d195">113.0</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i0e3965d572ee4aceaf968a9429112520_I20220630" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ1Nzk5Mw_7e2ce9d1-1f74-418c-b10f-b96fbf3fe055">3.0</ix:nonFraction> million has been received and recognized as revenue as of June&#160;30, 2022, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9bfae235b525451e977ec2988b5262e7_D20220101-20220630" decimals="INF" name="ardx:ThresholdPercentageOfSalesForTieredRoyalties" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ1ODIxMA_e74f097d-b1cc-4dc4-8b14-6ac992674936">20</ix:nonFraction>%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded <ix:nonFraction unitRef="usd" contextRef="ifad96d6d72d2427c850a8f4187189002_D20220401-20220630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_0d7c4472-8de8-4bb6-a767-f5e995bd1f1e"><ix:nonFraction unitRef="usd" contextRef="ie17162477fe2411892bc4d952ca4b3c7_D20210101-20210630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_45d8ac7f-7290-4c8f-bf17-7bc151fdcff5"><ix:nonFraction unitRef="usd" contextRef="i39c1eb48ebc84ec3b3bdd61a6ce8578c_D20210401-20210630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_4f7c427b-0623-402f-9528-2a8d700cb872"><ix:nonFraction unitRef="usd" contextRef="if1177146d35a4e4da142927eaed0ecc9_D20220101-20220630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_d8635df6-6960-46da-9cf7-e32be47faa15">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue during the three and six months ended June&#160;30, 2022 or 2021 related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (the &#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. Under the terms of the Knight Agreement, Knight paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i52011fdfd0334a89bcd53e3d6de2b37f_D20180301-20180331" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfODI4Mw_16ead127-30a2-4e57-a288-ba0a2467b0d7">2.3</ix:nonFraction> million upfront payment. We may also be eligible to receive approximately CAD<ix:nonFraction unitRef="cad" contextRef="if3b2a409542f4bc1a83f80b78e672650_D20220101-20220630" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ2MDIwNw_75e816c7-f50e-44da-b341-038780bf741b">22.2</ix:nonFraction>&#160;million for development and commercialization milestones, or approximately $<ix:nonFraction unitRef="usd" contextRef="if3b2a409542f4bc1a83f80b78e672650_D20220101-20220630" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ2MDIzMQ_e713366b-d2be-4651-99c8-0d918391a0eb">17.2</ix:nonFraction> million at the currency exchange rate on June&#160;30, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="i17126d287de74e979cfde5127eb1da69_I20220630" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ2MDA1NQ_414b29be-201c-43f0-8946-8e05906dff2c">0.7</ix:nonFraction> million has been received and recognized as revenue as of June&#160;30, 2022. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of <ix:nonFraction unitRef="number" contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfODk4Mw_65c02c32-51f0-41fb-8c66-1d39a68e8daa">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTA2OA_396b92d0-6711-461c-85b2-03dbfe12e4c6">20</ix:nonFraction>% of non-royalty revenue received from a licensee of tenapanor or another NHE3 inhibitor, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i2766bdc22382498f96100a7aaec65cb8_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTE3OA_479d9d34-948e-4dd2-b07f-c75bf04b38dc">75.0</ix:nonFraction> million in aggregate for (i) and (ii). As of June&#160;30, 2022, to date in aggregate, we have recognized $<ix:nonFraction unitRef="usd" contextRef="i9df8422a3ac54491960b7f51d8d389ad_I20220630" decimals="-5" name="ardx:CostOfRevenueAggregateAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTI2Mw_756f0715-7559-4b6c-a29d-d85fd17477b2">11.9</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="i2766bdc22382498f96100a7aaec65cb8_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTI3Mw_479d9d34-948e-4dd2-b07f-c75bf04b38dc">75.0</ix:nonFraction> million, which has been recorded as cost of revenue, and have paid AstraZeneca $<ix:nonFraction unitRef="usd" contextRef="i9df8422a3ac54491960b7f51d8d389ad_I20220630" decimals="-5" name="ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTM0Nw_059b0805-f65a-45cb-9296-156b23680406">11.6</ix:nonFraction> million. During the three and six months ended June&#160;30, 2022 we recognized and recorded as cost of revenue $<ix:nonFraction unitRef="usd" contextRef="i4411ff34351946ec9efc6813633c673b_D20220401-20220630" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc1Mw_82e0218a-5c28-418d-9756-ec1ae5e6ab68">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i97f3b674467b417ab75287cabe20b889_D20220101-20220630" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc2Ng_ee0dedff-fd48-4419-a928-42bad9a2e514">0.3</ix:nonFraction> million, respectively, related to the AstraZeneca Termination Agreement. During the three and six months ended June&#160;30, 2021 we recognized <ix:nonFraction unitRef="usd" contextRef="i2de17a790f144efcb20e85eca270e9b7_D20210401-20210630" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc4MQ_769b79ae-95b3-4c1e-877a-16071f91c4ab">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if2354099a5be4c5f9e83fee570934ba6_D20210101-20210630" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc5NA_74f5b344-46d9-4894-9cef-ee30200535cd">1.0</ix:nonFraction> million, respectively, as cost of revenue related to the AstraZeneca Termination Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i0b4ca3edbfc64a81bfc45031586240d1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTk1Ng_8cc9279c-6e17-40ae-90f9-f99277bf3b81" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The June&#160;30, 2022 and 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances are attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2325fcd766374f64b728734271bdcb7f_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfMS0xLTEtMS0zNDQ5MQ_21341a94-049a-4fd2-896b-79f18ce41571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc77e1d71d74d1a9a74f5ec6a36efde_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfMS0zLTEtMS0zNDQ5MQ_27817b38-6d3f-4b95-8057-bd5bd96dceb2">4,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i061c308d6b1a43f0968b363555e92226_D20220101-20220630" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNC0xLTEtMS0zNDQ5MQ_6de04b5a-bb17-47d2-81f9-acab3d4571c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3db2f9f0408b4c3b8bc1d23c42421c54_D20210101-20210630" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNC0zLTEtMS0zNDQ5MQ_c6930833-3c54-4f79-a348-c1337c12687f">2,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f865d48364e43feb2428abb54224a8d_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNi0xLTEtMS0zNDQ5MQ_452a90f5-0c6f-41b4-b77a-9deae2d7f6c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie657c8dfb1514308ada6df2d9ee8bf1e_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNi0zLTEtMS0zNDQ5MQ_156e9165-75e4-40b2-87ba-c0d7b5744cdc">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c552aa84944403c8a3fb465c4b3bc03_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMS0xLTEtMS0zNDQ5MQ_e0974372-bfb4-4a63-80c2-9e53db51b8d2">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee60570c43f40948f1db4079104e9e0_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMS0zLTEtMS0zNDQ5MQ_904718a5-881c-4a95-a032-25e5e828ffc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531d15c78ece4f9a9905d6f96710a74c_D20220101-20220630" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForCashReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMi0xLTEtMS0zNDQ5MQ_f77ae66f-5a15-499e-b1e4-f43f1564de90">3,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c7c1add2584109ba82c720ff846b37_D20210101-20210630" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForCashReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMi0zLTEtMS0zNDQ5MQ_e9173eb0-7087-4038-9528-a6197b986717">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531d15c78ece4f9a9905d6f96710a74c_D20220101-20220630" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMy0xLTEtMS0zNDQ5MQ_f27b62b8-99ce-41eb-a7c6-36cd195f457c">3,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c7c1add2584109ba82c720ff846b37_D20210101-20210630" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMy0zLTEtMS0zNDQ5MQ_d7d3e1dd-c8aa-4ff5-874e-ce0e35c763ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865d6c576ab546bcbf3614308dda7939_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfNi0xLTEtMS0zNDQ5MQ_d46b886c-87c1-4b26-9698-292aa110f41d">12,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87b20fa0c635463cae3c68920d3544be_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfNi0zLTEtMS0zNDQ5MQ_7ade92b9-8e2c-4228-b605-2876e72181ae">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i3a1430f6bb744768868435e28c329915_1164"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:AssetRetirementObligationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF83MTQ2ODI1NTg4NzU5_e96847ac-5884-4c51-a409-23e4bddf1927" continuedAt="i9f2de6775e4949f984dbb78abfb870a8" escape="true">DEFERRED ROYALTY OBLIGATION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9f2de6775e4949f984dbb78abfb870a8" continuedAt="id5bece95be174c9599631fd1a8e66f00"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (the &#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $<ix:nonFraction unitRef="usd" contextRef="i2776e4b43d244212bb36a96e1f7f6bf0_D20220628-20220628" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MTAw_23400831-122f-4198-9c37-bbac842d0d29">20.0</ix:nonFraction> million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with KKC based upon KKC's net sales of tenapanor in Japan. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $<ix:nonFraction unitRef="usd" contextRef="ic5599d31da844dc09d6e245bda588015_I20220628" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MDA4_2828db50-19f9-4165-9739-6890f5045a81">10.0</ix:nonFraction> million upfront payment, and we are eligible to receive a $<ix:nonFraction unitRef="usd" contextRef="ic5599d31da844dc09d6e245bda588015_I20220628" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MDI2_7c56c88a-ec20-4720-9e05-e284cd11187f">5.0</ix:nonFraction> million payment following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $<ix:nonFraction unitRef="usd" contextRef="ic5599d31da844dc09d6e245bda588015_I20220628" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MTA4_6f4b29d2-4b6a-4d64-b431-3a7f1aafd554">5.0</ix:nonFraction> million payment in the event net sales by KKC in Japan exceed a certain annual target level by the end of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 KKC Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 KKC Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 KKC Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 KKC Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 KKC Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id5bece95be174c9599631fd1a8e66f00">We received the $<ix:nonFraction unitRef="usd" contextRef="ide6b9c3554974336b19c0254e81adba0_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8yNzQ4Nzc5MDc4MjQ5_f7b5771f-02ce-4d56-a3e0-d169bbdf24d0">10.0</ix:nonFraction>&#160;million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation on our condensed balance sheet. As part of the sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ide6b9c3554974336b19c0254e81adba0_I20220630" decimals="-5" name="ardx:ContractWithCustomerLiabilityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MDY4_6b30411d-d17c-4722-8bf1-f55c1d37a1a1">0.4</ix:nonFraction> million in transaction costs, which, along with the deferred royalty obligation, will be amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by KKC, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. To determine the amortization of the deferred royalty obligation, we are required to estimate the total amount of future royalty payments to be received from KKC for sales of tenapanor in Japan. There are a number of factors that could materially affect the amount and timing of royalty payments from KKC, most of which are not within our control. We will periodically assess the estimated royalty payments from KKC and, to the extent that the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation. As of June&#160;30, 2022, our effective interest rate used to amortize the liability is <ix:nonFraction unitRef="number" contextRef="ibe07abdbf5b343909ddaf5fb16e06caf_D20220101-20220630" decimals="3" name="ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xMDk5NTExNjM2MjAz_1fc29994-4386-4704-a078-b5865b551605">34.4</ix:nonFraction>%. During the three and six months ended June&#160;30, 2022, we did not recognize a material amount of non-cash interest expense for the amortization of the deferred royalty obligation.</ix:continuation></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3a1430f6bb744768868435e28c329915_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNzE4MA_8698ce73-40ee-4b55-9a33-ad66843a6db7" continuedAt="id58ed19e06274d8790e7b1d30d3badef" escape="true">BORROWING </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id58ed19e06274d8790e7b1d30d3badef" continuedAt="ib9f37ba2a08c42659ecc1a44a1442a70"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;2018 Lenders&#8221;). The 2018 Loan Agreement provided for a $<ix:nonFraction unitRef="usd" contextRef="i332a0792bd1f4c0e92d7f1b5cbe65a8e_I20180516" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzc3_652912d8-16f9-4040-8263-0e977956cd3f">50.0</ix:nonFraction> million loan facility with a maturity date of November&#160;1, 2022 (the &#8220;2018 Loan&#8221;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $<ix:nonFraction unitRef="usd" contextRef="i332a0792bd1f4c0e92d7f1b5cbe65a8e_I20180516" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNjA0NzMxMzk1OTk2NA_332d9e08-f422-4366-8ec1-2d7619e7f488">25.0</ix:nonFraction>&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i45fff355f00f45b192078e143fe5bd5a_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNzc3_22be1f59-7c06-4c5a-9112-06da625be773">1.5</ix:nonFraction> million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investment Corp. Loan Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (the &#8220;Closing Date&#8221;), we entered into a loan and security agreement (the &#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (the &#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement provides for a senior secured loan facility, with $<ix:nonFraction unitRef="usd" contextRef="ibb409ddee548471bb71a3d72714cd69d_D20220223-20220223" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMTM0NQ_834f2467-e7f4-4e49-8327-5b790b602b8c">27.5</ix:nonFraction> million (the &#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $<ix:nonFraction unitRef="usd" contextRef="id7b0db6f01a842ee9808c8aadcd299ed_I20220223" decimals="-5" name="ardx:RemainingFundingBasedOnConditionalMilestoneAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMTQxMw_01e7ca67-ada7-4c67-9d8d-c1bd1cd70047">22.5</ix:nonFraction> million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (the &#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). On August 1, 2022, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis in order to borrow the additional $<ix:nonFraction unitRef="usd" contextRef="id7b0db6f01a842ee9808c8aadcd299ed_I20220223" decimals="-5" name="ardx:RemainingFundingBasedOnConditionalMilestoneAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMTA5OTUxMTYzNTM3Mg_01e7ca67-ada7-4c67-9d8d-c1bd1cd70047">22.5</ix:nonFraction> million from December 31, 2022 to March 31, 2023. The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="ib9f37ba2a08c42659ecc1a44a1442a70"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to <ix:nonFraction unitRef="number" contextRef="i5ca4f47844fc4780baff69e8911b29c0_D20220223-20220223" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjA1NA_05df2df4-72db-422b-a0a2-1bb58ba5cf2c">7.95</ix:nonFraction>% plus the greater of (i) one tenth percent (<ix:nonFraction unitRef="number" contextRef="i5ca4f47844fc4780baff69e8911b29c0_D20220223-20220223" decimals="INF" name="ardx:DebtInstrumentVariableRateBaseOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjEwMA_0a685888-9501-4e48-b3af-ec218eacba37">0.10</ix:nonFraction>%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024. Accordingly, beginning on April 1, 2024, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal over <ix:nonNumeric contextRef="ibb409ddee548471bb71a3d72714cd69d_D20220223-20220223" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjc0ODc3OTA3NzA1NQ_c9dc2232-5214-4d2f-a50e-d1c37aaba1b6">36</ix:nonNumeric> months. We were obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i53d431115a854c79807d5f03cee9dc62_I20220223" decimals="-5" name="ardx:DebtInstrumentClosingFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjUxNQ_640798b8-23d0-4a9d-9eb8-a81535b01953">0.2</ix:nonFraction> million, upon the closing of the Term A Loan, and we are obligated to pay $<ix:nonFraction unitRef="usd" contextRef="id7b0db6f01a842ee9808c8aadcd299ed_I20220223" decimals="-5" name="ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjU4NA_8be6a5bd-d957-4c69-827d-696401c5bd89">0.1</ix:nonFraction> million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to <ix:nonFraction unitRef="number" contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223" decimals="INF" name="ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjgyOQ_1040532c-b795-4cbb-88e1-8c0d768437e7">4.95</ix:nonFraction>% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) <ix:nonFraction unitRef="number" contextRef="i63aef503641b4c29a348a0255e9218d2_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzE2Mw_1c15a7e6-5777-4b5a-bea4-c16eea301947">3</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) <ix:nonFraction unitRef="number" contextRef="idf01893ad4c84865891f7430b162cae9_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzI5Mw_9c5c35c5-30ce-4d26-ada4-e8ada37db053">2</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) <ix:nonFraction unitRef="number" contextRef="i5e0099257ff746c4ba0bf0a5c60285a1_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzQ4Mw_85744885-f679-4df6-9e7e-53f85c873658">1</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of <ix:nonFraction unitRef="number" contextRef="i62823de538114437863d701d8f2af1f0_I20220223" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzg5OA_6d32f082-4a97-455c-b797-25f3399206a5">2</ix:nonFraction>% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNDA4NA_c2e0c691-7a5a-4902-9572-906981dc6270">100.0</ix:nonFraction>&#160;million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire <ix:nonNumeric contextRef="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223" name="ardx:LoanAgreementExitFeeTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNDI1OQ_eca47477-ade4-42f6-a0da-b2b8661b2b9c">10</ix:nonNumeric> years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (<ix:nonFraction unitRef="number" contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNTEwMw_93e200f0-7e38-47a0-ad21-23cecbbf204e">80</ix:nonFraction>%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (<ix:nonNumeric contextRef="i445b8ba0bc314f23b2c6d8f35b42ac79_D20220101-20220630" name="ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNTI1MA_0c98da53-c75f-4519-9bed-f78cdc3b480c">6</ix:nonNumeric>) month basis and tested monthly, is less than sixty percent (<ix:nonFraction unitRef="number" contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNTMxNA_f490374f-e414-4f43-8386-211eecc10a30">60</ix:nonFraction>%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to <ix:nonFraction unitRef="number" contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223" decimals="INF" name="ardx:DebtInstrumentInterestRateOnDefaultPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNjQ0Mg_8b565812-6967-4fd7-a907-60b56a5a9be4">4</ix:nonFraction>% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of June&#160;30, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization and Basis of Presentation: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNzE3OQ_874e9aa1-cf7e-41f3-8abc-96effcd25b51" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMC0xLTEtMS0zNDQ5MQ_037884e4-1a01-476c-873b-28098afc9dda">28,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMS0xLTEtMS0zNDQ5MQ_83967937-9abd-4bf4-aa9c-ec3e438a863b">1,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMi0xLTEtMS0zNDQ5MQ_7aab12ea-da28-4e63-af2d-f0eeb09bb098">1,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMy0xLTEtMS0zNDQ5MQ_23cfde7b-f6e4-4c57-b3b9-3f9689e30beb">26,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfNC0xLTEtMS0zNDQ5MQ_8365688b-eb52-47ae-95c9-37b834813743">26,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfNS0xLTEtMS0zNDQ5MQ_f0218d4a-2cb7-4785-99d2-8afb316e73dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;<ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfNDM3Nw_7c262c21-fb6e-4cc4-b56c-1df788203518" continuedAt="i9c71b0a9c5d5479b83bb516360d9ee9d" escape="true">DERIVATIVE LIABILITY</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="i9c71b0a9c5d5479b83bb516360d9ee9d"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i45fff355f00f45b192078e143fe5bd5a_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTg1_22be1f59-7c06-4c5a-9112-06da625be773">1.5</ix:nonFraction> million in cash (the &#8220;2018 Exit Fee&#8221;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with IBS-C, which was obtained on September 12, 2019 when the FDA approved IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of both June&#160;30, 2022 and December&#160;31, 2021, the estimated fair value of the 2018 Exit Fee was $<ix:nonFraction unitRef="usd" contextRef="ic904ee852e2546278f6d6a2a871ab36c_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTA5OTUxMTYzMjI0Ng_7e26980b-9f1a-46fc-a30d-42aaade052e1"><ix:nonFraction unitRef="usd" contextRef="idb141ea05dc14bd488bc51b17742bb1b_I20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTA5OTUxMTYzMjI0Ng_a9136754-8e7e-48fd-b219-e5475fa97aeb">0.7</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2018 derivative liability include: (i) our estimates of both the probability and timing of a potential $<ix:nonFraction unitRef="usd" contextRef="i45fff355f00f45b192078e143fe5bd5a_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTU2Nw_22be1f59-7c06-4c5a-9112-06da625be773">1.5</ix:nonFraction> million payment to the 2018 Lenders as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a <ix:nonFraction unitRef="number" contextRef="i9edf9296a4894494938a6948e6255770_I20220630" decimals="3" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTk5NA_20942b27-af9d-4969-a504-6d653111dee7">10.0</ix:nonFraction>% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $<ix:nonFraction unitRef="usd" contextRef="i9edf9296a4894494938a6948e6255770_I20220630" decimals="-5" name="ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMjEyOA_11870450-85a7-48da-aef1-626d2a3b201d">0.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  <ix:nonFraction unitRef="number" contextRef="i62823de538114437863d701d8f2af1f0_I20220223" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMjMxMQ_4ffa2813-ab0a-440f-93df-bc90f6158f47">2</ix:nonFraction>% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMjQ5Nw_8ca61a5d-83c1-4cc8-a483-50e8697ffab8">100.0</ix:nonFraction> million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of June&#160;30, 2022, the estimated fair value of the 2022 Exit Fee is $<ix:nonFraction unitRef="usd" contextRef="i6999cc41a5f44cf0a5b525b6303dd7ea_I20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTA5OTUxMTYzMjMzOA_d4cd58e2-32c0-4af5-bf78-45589a9b9f43">0.4</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a <ix:nonFraction unitRef="number" contextRef="i628699ac92bb4cc4aec87c7221cb6c0e_I20220630" decimals="3" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMzk5Mg_5d633696-2f93-42b7-8979-cbb31d1649f9">10.0</ix:nonFraction>% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfNDM3OA_2d21b4f8-f000-46e3-af48-9aa54fce4eae" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef0d267ad3d436b9af9981688d023fa_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMi0xLTEtMS0zNDQ5MQ_75a4e003-f723-44e3-b3c8-e2adf51f2614">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if76ea5067c204fabaac4ade032cb88b0_I20210331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMi0zLTEtMS0zNDQ5MQ_3840295f-5a6d-415f-bdb3-b75402062829">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f7c79b7bcf4056b7704b95788cba3b_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMy0xLTEtMS0zNDQ5MQ_af155d71-9d20-435d-ab28-5f8c8e826349">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3004be0bc24d40129c1b7ba07661f272_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMy0zLTEtMS0zNDQ5MQ_5729befb-3b2f-441a-9dd5-0af9f3411375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02ce57c9f03945a8810129f2967308c3_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0xLTEtMS0zNjE3MA_5fa80f47-bf71-4a77-a1c4-79c8d2ac7e8a">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016dc6bfae9845e092f75be5637f0b18_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0zLTEtMS0zNjE3MA_58eaf5fc-688d-474e-8596-03ecaa1c6475">713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd618c73d00048398fb1fc314aaf0e8a_D20220401-20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNi0xLTEtMS0zNjE3MA_83dd38c5-4eed-4284-9ae1-79ef2fd862f7">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65431a25e35a45e890530a699eb3a862_D20210401-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNi0zLTEtMS0zNjE3MA_5021ca0d-b331-4532-9044-ed9c6afa61b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a970c46b2e64b9a887463a2644c5079_I20220630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0xLTEtMS0zNDQ5MQ_3fdb731f-c2b6-4c8f-b2b6-4a3300a5b3c3">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9eadd78ecf4cbaa95a089d4e6dde72_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0zLTEtMS0zNDQ5MQ_c31e9543-f1e6-42bc-91b4-6eac4ddce917">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzgx_f17521e3-288b-4ce6-afac-95a9a380244f" continuedAt="i018d4f99accb4d40ac9b8e43a9259555" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i018d4f99accb4d40ac9b8e43a9259555"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzgy_4993259c-6d9e-43b9-9da0-cf41369eef0f" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMS0xLTEtMS0zNDQ5MQ_65cbe5f9-485a-44a0-b41b-82ac1cf2e0a2">11,054</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMS0zLTEtMS0zNDQ5MQ_e17c056b-22fb-4198-8f31-c00d3e60a861">12,752</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMy0xLTEtMS0zNDQ5MQ_6a1d6c0b-ba8f-45f8-b0bf-d14a06a116f3">3,691</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMy0zLTEtMS0zNDQ5MQ_3bd78acb-4575-4b13-b8a7-fc85fcb4e0f5">3,492</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNC0xLTEtMS0zNDQ5MQ_83ee9a81-a145-4023-a602-247bd03866ce">7,857</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNC0zLTEtMS0zNDQ5MQ_5bf54bb2-a5de-4dbb-a603-109a4051586f">9,748</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNS0xLTEtMS0zNDQ5MQ_b4d7ff0b-1bf7-4d34-8ac2-409c2c1cb09e">11,548</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNS0zLTEtMS0zNDQ5MQ_97b0885b-2be3-43c1-9803-0cb1d3bf873b">13,240</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNy0xLTEtMS0zNDQ5MQ_6dd69424-204b-4819-907c-57166b471ef1">2.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNy0zLTEtMS0zNDQ5MQ_29a9d930-74c5-4a26-b0fa-0b7b59d38e19">3.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfOC0xLTEtMS0zNDQ5MQ_973a5877-3a57-41a4-b172-e8f153d8d86e">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfOC0zLTEtMS0zNDQ5MQ_3e39c003-a30a-4e36-acb8-452b0a9590ca">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzgz_5d3b7243-522c-41e1-a77c-59eb472158ee" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi0xLTEtMS0zNDQ5MQ_273db59d-59fa-4470-bdd0-dbe22919b267">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi0zLTEtMS0zNDQ5MQ_3aee965e-05e6-478b-af9b-f7bb90bab4a2">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi01LTEtMS0zNDQ5MQ_329820ef-509c-48dc-b0db-bf3212293717">2,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi03LTEtMS0zNDQ5MQ_c37347c6-d8d2-46fc-bdbb-d8115021abb5">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy0xLTEtMS0zNDQ5MQ_fcd38801-1823-490d-b8fb-ef90abbc4a9e">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy0zLTEtMS0zNDQ5MQ_e331849c-e6c1-4b9b-a4d7-fea0183e65bc">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy01LTEtMS0zNDQ5MQ_798d90e6-2fcf-414d-ac49-29f5d9d9ea30">2,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy03LTEtMS0zNDQ5MQ_e103e958-c144-4892-9001-d0b3d6abc03b">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzg0_de2de67f-41df-4d81-98e5-6d9a615f0ba9" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMC0xLTEtMS0zNDQ5MQ_d35dd614-c8b0-4c18-af99-008b838b1888">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMS0xLTEtMS0zNDQ5MQ_aea5b90d-732a-4a15-9bb0-4c728ce0b470">4,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMi0xLTEtMS0zNDQ5MQ_512b4a0b-213d-4d09-9195-2fadf236d8e7">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMy0xLTEtMS0zNDQ5MQ_17872a95-358e-400f-afe4-694f04bc27a4">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfNC0xLTEtMS0zNDQ5MQ_f57fe767-8e78-485c-8935-daa7be14be53">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfNi0xLTEtMS0zNDQ5MQ_659be724-1181-4c9e-9a8a-b0eb0d3066af">12,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfNy0xLTEtMS0zNDQ5MQ_e3566ab8-a472-440d-8fa0-1104a2b981c3">1,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfOC0xLTEtMS0zNDQ5MQ_79400488-c840-47ae-be57-c7e0fd8230b9">11,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfOS0xLTEtMS0zNDQ5MQ_64493c55-eaee-45d9-9215-7e57d6086a26">3,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMTAtMS0xLTEtMzQ0OTE_ca5b0941-19b1-40e2-8c62-822f586b4cdf">7,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMjM5Nw_96e2ae9a-6161-48fd-b1f5-270a15a8417d" continuedAt="ic20aaecd7a914d53b3b63dd71b7522bc" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ic20aaecd7a914d53b3b63dd71b7522bc" continuedAt="i527d126b63534af78a618285473856db"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offerings Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="id37f41791c3a4469a79f174900a9480a_I20200731" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMzE1_0c236f96-7169-4f39-89b2-50cbf06e8437">250.0</ix:nonFraction> million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i3134b5534dfe4e7488897f77ce075b19_I20200731" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfNTYy_c77362da-da24-415b-9545-569a11c3501d">100.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at the market offerings&#8221; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the six months ended June&#160;30, 2021 we sold <ix:nonFraction unitRef="shares" contextRef="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfODkx_fbda8abb-6b25-49e7-8d4c-47100a4ddf31">9.0</ix:nonFraction> million shares and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfOTMy_2c809821-e1a5-4842-8526-ed7959ce4ad0">63.8</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfOTg2_ac6339b0-0c53-433c-908c-e910bc2e4a2a">7.10</ix:nonFraction> per share under the 2020 Open Market Sales Agreement.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i527d126b63534af78a618285473856db">In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i7723c20c25bd40d6a71d48a503fa8f2f_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTIyNg_c8b3f561-1813-446c-89f9-5b1516a03ef2">150.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="i7723c20c25bd40d6a71d48a503fa8f2f_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTQ2Mg_c8b3f561-1813-446c-89f9-5b1516a03ef2">150.0</ix:nonFraction> million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to <ix:nonFraction unitRef="number" contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTcwNQ_5ed60d78-2b80-44c7-902b-d686e3a64a20">3</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the six months ended June&#160;30, 2022 we sold <ix:nonFraction unitRef="shares" contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTg0Nw_e66d3080-e7cd-4214-87d7-32eb2e2eda53">20.5</ix:nonFraction> million shares and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTg4OA_615143f9-89b4-4f58-b881-c95c7d5bdb58">18.9</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTk0Mg_5c515e83-06b8-41db-85ef-611c4601c25c">0.92</ix:nonFraction> per share under the 2021 Open Market Sales Agreement.</ix:continuation> </span></div><div id="i3a1430f6bb744768868435e28c329915_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5NA_2c2e3bab-f082-4428-b95b-80e9c923f5a1" continuedAt="if9a02b114067447db74323835680c1f4" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><ix:continuation id="if9a02b114067447db74323835680c1f4" continuedAt="i1fb7c5cc73ea467784b06bb8f9e15dcd"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5NQ_c6524160-cf47-472a-88e5-0acbdf729311" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e0bb25c3c34a6a85f20fb41dddf6e0_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy0xLTEtMS0zNDQ5MQ_34bc3cc0-5953-4f8c-aab9-43a924e1fec5">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib634f3437de24f219bf6e52991431efe_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy0zLTEtMS0zNDQ5MQ_7e18315c-a4b6-45e6-bef4-6bc834b20bce">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic965a8cbb9a44f0fae1e69681ba94b33_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy01LTEtMS0zNDQ5MQ_77333ee2-8551-433d-9a08-68ec8e281232">4,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f8bd2473da4add99b5d428ef128fec_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy03LTEtMS0zNDQ5MQ_117f8b26-5eb3-4d0a-bb19-5327e10237ec">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ab1c8385364a98838fa5f372f40780_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0xLTEtMS0zODc4OQ_d7bd6ea6-d7bf-4d34-928b-1fe46049bfc9">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7bcb071485841a8932ec94f8a5df8bf_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0zLTEtMS0zODc4OQ_2465b76b-7b9a-4b9d-81e8-4d0e16097a61">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376a6465db724ab699369fb13e61e824_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC01LTEtMS0zODc4OQ_ec9a5e7e-5ccd-4908-9d8d-82f8d54092a8">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc375ebed1e748e3906510f688eb4df4_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC03LTEtMS0zODc4OQ_3361badb-a173-4100-91b3-b0be7d248a59">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0xLTEtMS0zNDQ5MQ_d4dda598-ef16-4470-917a-d3e0ef8c9547">3,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0zLTEtMS0zNDQ5MQ_70be32af-47c3-4fe2-a983-1e8122d76bb0">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC01LTEtMS0zNDQ5MQ_fbb0deee-4dce-410e-ae3a-94e1ff2d6394">6,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC03LTEtMS0zNDQ5MQ_0ad98574-471a-4fba-be62-95d1915667a1">6,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the balance of inventory included in our condensed balance sheet includes $<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-5" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTA5OTUxMTYyOTUyNw_1726d3a7-4dee-46d6-be1f-b0f43e46870d">0.2</ix:nonFraction> million stock-based compensation. During the three and six months ending June&#160;30, 2022, the amount of stock-based compensation released from inventory into cost of revenue was not material. </span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5Ng_0a7dfb19-5c96-4736-b94d-98f55ed2660a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51d0832aa5449abae8f15be39293d79_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMS0xLTEtMS0zNDQ5MQ_5ce10b7d-d4aa-4515-9c5e-a1c8ce3b405c">13,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a90b663e53f4f6cb5da4185a20aab45_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMS0zLTEtMS0zNDQ5MQ_c9781161-6dcc-4783-bd36-982cfa830909">2.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e7d4677dbca464bb097b04e809bdcfc_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMi0xLTEtMS0zNDQ5MQ_2ffbceb0-adcd-4823-90db-755a58d8cdbe">3,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMi0zLTEtMS0zNDQ5MQ_fd39db99-c376-40e4-b0b6-c9951a7b5e70">2.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69584cc6d6d54ac49447a7432d983409_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMy0xLTEtMS0zNDQ5MQ_673f1b0f-b1f7-4615-baee-9a46daf3b98e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3ca526cfc424a98962ab7e989aefbac_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMy0zLTEtMS0zNDQ5MQ_a56ea81d-6004-40b4-9862-044dea8e431d">0.2</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><ix:continuation id="i1fb7c5cc73ea467784b06bb8f9e15dcd" continuedAt="ic0c8c910d40247bba20670bafbfa92c9"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5Nw_0ae29372-454c-4b2a-a697-8f11816adc72" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:58.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMS0xLTEtMS0zNDQ5MQ_aa4465c0-7f3d-4d7b-8568-6151c684c66b">10,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMS0zLTEtMS0zNDQ5MQ_7375e786-8f5b-4a7a-82e6-fa183f5b1891">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMi0xLTEtMS0zNDQ5MQ_f6f36b53-4418-4c22-8e79-f7fd46e3baab">4,773</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMi0zLTEtMS0zNDQ5MQ_cd09c15b-7e96-48bb-8efb-4f709ac0e969">0.88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMy0xLTEtMS0zNDQ5MQ_3a729423-33f9-4595-839d-f32180e1ded7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMy0zLTEtMS0zNDQ5MQ_33595250-5c50-4b45-9f88-738b4f727bc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNC0xLTEtMS0zNDQ5MQ_b4313133-6d93-493e-bea2-3efbcdad9c73">1,190</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNC0zLTEtMS0zNDQ5MQ_67874e3d-420e-41e3-b65e-32678ae9929b">7.04</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNS0xLTEtMS0zNDQ5MQ_0fbcfa8f-6462-4302-a7a9-f74598b596d0">14,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNS0zLTEtMS0zNDQ5MQ_6ee021d1-e231-4e15-85da-bac6897a2ac6">4.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNi0xLTEtMS0zNDQ5MQ_e84cc4f1-8352-40b4-906c-b0055ab4c06a">7,085</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNi0zLTEtMS0zNDQ5MQ_1c276839-d08b-408b-8169-647c1199cea3">6.91</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5OA_6577af74-948f-487c-90d0-c05fd4ccbf41" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMS0xLTEtMS0zNDQ5MQ_7f02e6c2-80b0-4441-9676-7b1a830ea272">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMS0zLTEtMS0zNDQ5MQ_2a6d68c1-3698-4e53-84a0-a25730db356f">2.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMi0xLTEtMS0zNDQ5MQ_960a3854-ccd2-4737-8410-8a55b2a76c5a">1,980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMi0zLTEtMS0zNDQ5MQ_fd7ae230-ce39-47e1-9539-c3eae5252a30">0.81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMy0xLTEtMS0zNDQ5MQ_2dcbea63-588a-45b6-9e33-c5cbc831bd4b">3,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMy0zLTEtMS0zNDQ5MQ_b3ec6a24-9187-435f-b01a-762d1a0a56aa">1.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNC0xLTEtMS0zNDQ5MQ_d9901184-f848-4e33-9a54-bacfb3c6165e">121</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNC0zLTEtMS0zNDQ5MQ_c9ae105d-f5da-4d15-8f14-b3c5df50969d">2.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e7d4677dbca464bb097b04e809bdcfc_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNS0xLTEtMS0zNDQ5MQ_e9e3b847-4bd6-4391-a7c9-68f2b60c40ee">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e7d4677dbca464bb097b04e809bdcfc_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNS0zLTEtMS0zNDQ5MQ_d9fa2ae2-75bb-45d0-afca-941994fe58ec">2.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we sold approximately <ix:nonFraction unitRef="shares" contextRef="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfOTY5_f914c7b2-f2d2-4633-88fb-f14f4aefe4e2">0.1</ix:nonFraction> million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228" decimals="2" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTA3Nw_97d2382c-cda8-48c4-93ff-b8a53127385c">0.65</ix:nonFraction> per share resulting in proceeds to us of approximately $<ix:nonFraction unitRef="usd" contextRef="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTEzNQ_1997335e-3129-4ad7-8930-5edab9209c37">0.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic0c8c910d40247bba20670bafbfa92c9">Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the six months ended June&#160;30, 2022, we issued <ix:nonFraction unitRef="shares" contextRef="i8a7e1558c9254a6f8b2556d7cf1b84b3_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTM5Ng_d9044a34-4b76-4478-8297-720270dafcea">no</ix:nonFraction> shares of our common stock to members of the board of directors in accordance with the program.</ix:continuation> </span></div><div id="i3a1430f6bb744768868435e28c329915_70"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RleHRyZWdpb246ODMwNDAxNTg0YzRkNGU4N2EwZjc3ZTVjMTc5MjRmMWFfMTI1NA_fa9e2f7c-b28f-4227-8bf3-c255aa36f153" continuedAt="i61534b76640241439b4fd33d7b81dd12" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i61534b76640241439b4fd33d7b81dd12" continuedAt="id80afd8ad76e4f57b8d375c306cdae22">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the six months ended June&#160;30, 2022 and 2021, all potential common shares were determined to be anti-dilutive. </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="id80afd8ad76e4f57b8d375c306cdae22"><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RleHRyZWdpb246ODMwNDAxNTg0YzRkNGU4N2EwZjc3ZTVjMTc5MjRmMWFfMTI1Ng_d7484624-f8d8-42ec-bdf0-286f835e9307" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi0xLTEtMS0zNDQ5MQ_3d0e22ad-85ca-4c26-96ec-8b8a227b510e">26,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi0zLTEtMS0zNDQ5MQ_d1352238-99c1-41e8-b39b-aae8105df0ea">45,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi01LTEtMS0zNDQ5MQ_4e3b3493-e94f-4152-a685-4d743ff70325">55,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi03LTEtMS0zNDQ5MQ_169bd6b3-9d8f-473c-b6fa-dd49c1359405">78,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0xLTEtMS0zNDQ5MQ_0d99dd72-6d62-4348-a07c-6a075229bdd8"><ix:nonFraction unitRef="shares" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0xLTEtMS0zNDQ5MQ_40e5a1e1-c28d-43c5-a4e2-fb03743e8b2a">145,544</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0zLTEtMS0zNDQ5MQ_4c6fa988-6cc3-4b1e-b6d8-5a991d835975"><ix:nonFraction unitRef="shares" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0zLTEtMS0zNDQ5MQ_ef2f6ea4-e9e3-40c8-8484-9a1295d458da">100,040</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC01LTEtMS0zNDQ5MQ_80b67e29-8264-429f-b626-c286c90b74ed"><ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC01LTEtMS0zNDQ5MQ_8ce142bf-f2e1-49f5-9d0b-81def61b8b18">138,280</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC03LTEtMS0zNDQ5MQ_63cc04fe-0685-4baf-8534-c6166ad7d342"><ix:nonFraction unitRef="shares" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC03LTEtMS0zNDQ5MQ_ff6dc99a-e3b1-4a57-a333-2879f29a0762">98,618</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0xLTEtMS0zNDQ5MQ_8f54097e-2e64-4f3d-8fce-765f0dee5c15"><ix:nonFraction unitRef="usdPerShare" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0xLTEtMS0zNDQ5MQ_9fbd2188-7a48-4408-8c7a-405c053194b9">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0zLTEtMS0zNDQ5MQ_2aea7436-174b-4d92-a9b0-e0a7c2c920f3"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0zLTEtMS0zNDQ5MQ_9a888292-5c71-44fe-9057-7fc0c0f7913f">0.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS01LTEtMS0zNDQ5MQ_03403fe8-d13d-477e-9a74-33f97cd2cf18"><ix:nonFraction unitRef="usdPerShare" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS01LTEtMS0zNDQ5MQ_140b50a3-3233-4aff-8c72-854ccecf7a3d">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS03LTEtMS0zNDQ5MQ_76d206b6-9f9d-41e4-b0f5-1debbd191d32"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS03LTEtMS0zNDQ5MQ_dc4eebed-767b-4eb4-b910-c50fe204518c">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RleHRyZWdpb246ODMwNDAxNTg0YzRkNGU4N2EwZjc3ZTVjMTc5MjRmMWFfMTA5OTUxMTYyNzk3NTc_89cbedfc-c8e4-4c99-a8f3-36dbe2161f32" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, all common stock equivalents are excluded from the computation of diluted loss per share, as the result would be anti-dilutive, including the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dc07daee1204d6c8c91b07672cc6eb4_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMi0xLTEtMS0zNjkyMw_a90488a9-1618-4a26-989c-e540da94d941">13,099</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id703e5f35ca0467cbd70c6dc2f683e5e_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMi0zLTEtMS0zNjkyMw_7ec3882f-fb92-482d-9196-d1d845f05d38">12,447</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a90b663e53f4f6cb5da4185a20aab45_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMS0xLTEtMS0zNTEyNw_c44b023b-c8bb-4d89-ae56-6ddd82fe090f">13,182</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44792157aa014c89a7a354b1be5cd930_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMS0zLTEtMS0zNTEyNw_1e157f27-8117-4cc1-a8aa-d1b9ddff4553">12,211</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idca1e42204a84d5baa052102db6344f5_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNC0xLTEtMS0zNjkyMw_53c8887e-a518-4efb-808b-64be687c4b83">3,520</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i587c8cafb989442c848613b09b327f6e_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNC0zLTEtMS0zNjkyMw_3603bc95-c072-4e04-81d5-22c3365b105b">1,125</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMy0xLTEtMS0zNTEyNw_755a12a9-048e-4e17-8008-4f8d456ef7a1">3,963</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a3791c5deb445cbbe81a4916add381d_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMy0zLTEtMS0zNTEyNw_92f263e1-1902-44d1-83cb-32fa13b5d545">1,006</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64cb03795f754f9e866d8829eb6f1a18_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0xLTEtMS0zNjkyMw_af98e432-c2a3-455c-bb1b-88a89d60dfe7">200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i477ce922c8374f6e9d0c3d4093c4654b_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0zLTEtMS0zNjkyMw_dba84975-bb5f-426c-a75a-661b3baa611a">230</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib25fb22c28764b7fa0ee953c024cf888_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNS0xLTEtMS0zNTEyNw_aa311bb6-092c-4733-b606-332444c36a64">176</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i217bb17f2bb2437bb698a25f2f589406_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNS0zLTEtMS0zNTEyNw_b5a5884e-ce2b-44b5-bad2-c295d72b02c4">188</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNy0xLTEtMS0zNjkyMw_a50a4c45-1c0c-45c4-9bea-023dfd7d8f3c">16,819</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNy0zLTEtMS0zNjkyMw_986aad68-b794-40b8-a548-f2d87ea71573">13,802</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0xLTEtMS0zNTEyNw_f2693972-d517-42ed-b0b4-55c2a1c35305">17,321</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0zLTEtMS0zNTEyNw_72901e82-6490-43b2-9263-770c2fde018e">13,406</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i3a1430f6bb744768868435e28c329915_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. <ix:nonNumeric contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83Ni9mcmFnOmYyYjU2ZTIzMDFkNDRhNjI5ZmYzM2YzYzdkNmI4MzQ1L3RleHRyZWdpb246ZjJiNTZlMjMwMWQ0NGE2MjlmZjMzZjNjN2Q2YjgzNDVfNDA1_2897cfee-d892-424b-af59-38cf15a933ed" continuedAt="ia173cf178c1640c398e0f5dfa32481b5" escape="true">CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia173cf178c1640c398e0f5dfa32481b5">From time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us will not be material to our financial condition or cash flows, and <ix:nonFraction unitRef="usd" contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83Ni9mcmFnOmYyYjU2ZTIzMDFkNDRhNjI5ZmYzM2YzYzdkNmI4MzQ1L3RleHRyZWdpb246ZjJiNTZlMjMwMWQ0NGE2MjlmZjMzZjNjN2Q2YjgzNDVfMzUy_513d57bc-c4b0-4b54-9b6b-08eacefa5105"><ix:nonFraction unitRef="usd" contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83Ni9mcmFnOmYyYjU2ZTIzMDFkNDRhNjI5ZmYzM2YzYzdkNmI4MzQ1L3RleHRyZWdpb246ZjJiNTZlMjMwMWQ0NGE2MjlmZjMzZjNjN2Q2YjgzNDVfMzUy_8ab81fba-861f-432c-8543-16abd1312301">no</ix:nonFraction></ix:nonFraction> contingent liabilities were accrued as of June&#160;30, 2022 or 2021.</ix:continuation></span></div><div id="i3a1430f6bb744768868435e28c329915_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed financial statements and notes thereto included elsewhere in this report and with the audited financial statements and related notes thereto included as part of our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021. This discussion and analysis and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason. Unless the context requires otherwise, the terms &#8220;Ardelyx&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221; refer to Ardelyx,&#160;Inc.</span></div><div id="i3a1430f6bb744768868435e28c329915_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since commencing operations in October 2007, substantially all our efforts have been dedicated to our research and development (&#8220;R&amp;D&#8221;) activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We realized our first product sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tenapanor) in March 2022. As of June&#160;30, 2022, we had an accumulated deficit of $767.9 million.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we commercialize IBSRELA, seek to gain approval for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the control of serum phosphorus in adult patients with CKD on dialysis; prepare for the potential commercialization of XPHOZAH, if approved; and incur manufacturing and development cost for, tenapanor. To date, we have funded our operations from the sale and issuance of common stock and convertible preferred stock, funds from our collaboration partnerships, which includes license fees, milestones and product supply revenue, as well as funds from our loan agreements with our lenders.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Product</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA for IBS-C</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our unique discovery platform and deep understanding of the primary mechanism of sodium transport in the intestine resulted in our discovery and development of IBSRELA, a first-in-class, U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved, sodium hydrogen exchanger 3 ("NHE3") inhibitor for the treatment of irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;) in adults. IBSRELA acts locally in the gut and is minimally absorbed. IBS-C is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 11 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our commercial launch of IBSRELA, we built a commercial organization highly experienced in launching novel therapies into specialty areas. We recognized our first sales of IBSRELA in the U.S. in March 2022. The established nature of the market, limited number of players, concentration of prescribers, recognized unmet need, and favorable response to the novel mechanism IBSRELA product profile enable a targeted promotional effort centered on the 9,000 health care providers that account for 50% of IBS-C prescriptions. Central to the go to market strategy for IBSRELA is a highly experienced specialty sales force, many with existing relationships across their GI target base, full company engagement, and innovative peer-to-peer and digital initiatives leveraging the rapidly evolving market dynamics in how HCPs receive information and interact with industry. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Candidate XPHOZAH for The Control of Serum Phosphorus in Adult Patients with CKD on Dialysis</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XPHOZAH is a first-in-class medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis. XPHOZAH has a unique mechanism of action and acts locally in the gut to inhibit NHE3. This results in the tightening of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate, the primary pathway of phosphate absorption. If approved, XPHOZAH would be the first therapy for phosphate management that blocks phosphorus absorption at the primary site of uptake. It is not a phosphate binder. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we submitted a new drug application ("NDA") to the FDA for XPHOZAH for the control of serum phosphorus in adult patients with CKD on dialysis. The NDA was supported by three Phase 3 trials involving over 1,000 adult patients that evaluated the use of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, with two trials evaluating tenapanor as monotherapy and one trial evaluating tenapanor as part of a dual mechanism approach with phosphate binders. All three Phase 3 trials met their primary and key secondary endpoints. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2021, we received a Complete Response Letter ("CRL") from the FDA regarding our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, while the FDA agrees &#8220;that the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in adult patients with CKD on dialysis,&#8221; the FDA characterizes the magnitude of the treatment effect as &#8220;small and of unclear clinical significance.&#8221;  In December 2021, we submitted a Formal Dispute Resolution Request (&#8220;FDRR&#8221;). The FDRR was focused on demonstrating that the data submitted in the NDA supported the clinical significance of the treatment effect of tenapanor. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2022, we received an Appeal Denied Letter (&#8220;ADL&#8221;) from the FDA&#8217;s Office of Cardiology, Hematology, Endocrinology and Nephrology (&#8220;OCHEN&#8221;). On February 18, 2022, we submitted an appeal of the ADL to the FDA&#8217;s Center for Drug Evaluation and Research, Office of New Drugs (&#8220;OND&#8221;). </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, we announced that OND had provided an interim response to our second level of appeal of the CRL. The OND noted that additional input from the Cardiovascular and Renal Drug Advisory Committee (&#8220;Advisory Committee&#8221;) in general, and specifically, from experts, including expert clinicians, would be valuable in further considering the clinical meaningfulness of the phosphate lowering effect observed in our phase 3 clinical program for XPHOZAH. Accordingly, the OND directed the Division of Cardiology and Nephrology to convene the Advisory Committee, and indicated that a response to our appeal could be expected within thirty calendar days after the conclusion of the Advisory Committee meeting. On June 21, 2022 we announced that the FDA has informed us that a meeting of the Advisory Committee is tentatively scheduled for November 16, 2022. There can be no assurances that the response from the Advisory Committee will be positive, or if the outcome of the Advisory Committee is positive, that approval of our NDA will ultimately be granted by the FDA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RDX013 Program: Small Molecule for Treating Hyperkalemia</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule potassium secretagogue program, RDX013, is focused on the development of a potential treatment for hyperkalemia. Hyperkalemia is a common problem in patients with heart and kidney disease, particularly in patients taking customary blood pressure medications known as renin-angiotensin-aldosterone system (&#8220;RAAS&#8221;) inhibitors. RDX013 is a novel mechanism agent designed to target the underlying biological mechanisms of potassium secretion to lower elevated potassium. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, we reported that we have completed our data analyses of the Phase 2 dose ranging clinical trial for RDX013 evaluating the safety and efficacy of our potassium secretagogue for the treatment of hyperkalemia, or elevated potassium, in chronic kidney disease patients who are not on dialysis. While the results of the study demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. We currently expect that the next steps for the program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study at such time as we have determined our available resources support conducting such an additional clinical study after prioritization of the commercialization  of IBSRELA and preparations for the Advisory Committee meeting for XPHOZAH.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RDX020 Program: Small molecule for Treating Metabolic Acidosis </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an ongoing discovery program targeting the inhibition of bicarbonate exchange for the treatment of metabolic acidosis, a highly prevalent comorbidity in CKD patients that is strongly correlated with disease progression and adverse outcomes. We have identified lead compounds that are potent, selective and proprietary inhibitors of bicarbonate secretion. Our research organization was eliminated as part of our October 2021 restructuring, and therefore, we currently expect to continue to advance this discovery program utilizing third-party resources managed by internal non-clinical expertise. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Partners</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to tenapanor in the U.S. and we have established agreements with Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;) in Japan, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;) in China and Knight Therapeutics, Inc. (&#8220;Knight&#8220;) in Canada for the development and commercialization of tenapanor for certain indications in their respective territories. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Knight has exclusive rights for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. In March 2021, Knight announced the commercial availability of IBSRELA in Canada, following its approval by Health Canada in April 2020. Under the terms of the Knight Agreement, Knight paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million upfront payment. We may also be eligible to receive approximately CAD22.2&#160;million for development and commercialization milestones, or approximately $17.2 million at the currency exchange rate on June&#160;30, 2022, of which $0.7 million has been received and recognized as revenue as of June&#160;30, 2022. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at June&#160;30, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KKC has exclusive rights for the development, commercialization and distribution of tenapanor in Japan for cardiorenal indications. Under the terms of the agreement with KKC, we received a $30.0 million upfront payment from KKC, and we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0 million in total development and regulatory milestones, of which $10.0 million has been received and recognized as revenue as of June&#160;30, 2022. We may also be eligible to receive approximately &#165;8.5&#160;billion for commercialization milestones, or approximately $62.3&#160;million at the currency exchange rate on June&#160;30, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, we and KKC have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional $40.0&#160;million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fosun Pharma has exclusive rights for the development and commercialization of tenapanor in China for both hyperphosphatemia and IBS-C. Under the terms of the Fosun Agreement, Fosun paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fee. We may be entitled to receive development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$113.0 million, of which $3.0 million has been received and recognized as revenue as of June&#160;30, 2022, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%. </span></div><div id="i3a1430f6bb744768868435e28c329915_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has impacted the operational decisions of companies worldwide. It also has created and may continue to create significant uncertainty in the global economy. We have undertaken measures to protect our employees, partners, collaborators, and vendors, some of which impact our normal operations. To date, we have been able to continue our operations with our workforce, most of whom are working remotely, and our pre-existing infrastructure that supports secure access to our internal systems. If, however, the COVID-19 pandemic has a substantial impact on the productivity of our employees, the results of our operations and overall financial performance may be adversely impacted. The extent of the impact from the COVID-19 pandemic on our business will depend largely on future developments that are highly uncertain and cannot be predicted. For a discussion of risks of COVID-19 relating to our business, see &#8220;Part II: Other Information-Item 1A.- Risk Factors- Risks Related to Our Business-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; As of the date of issuance of this financial report, we are not aware of any specific event or circumstance that would require updates to our estimates and judgments or revisions to the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained.</span></div><div id="i3a1430f6bb744768868435e28c329915_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those that require significant judgment and/or estimates by management at the time that financial statements are prepared such that materially different results might have been reported if other assumptions had been made. These estimates form the basis for making judgments about the carrying values of assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our condensed financial statements presented in this report are described in Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our Annual Report on Form 10-K filed with the SEC on February 28, 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;six months ended June&#160;30, 2022, we adopted the following critical accounting policies and significant judgements and estimates:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the FDA in September 2019 to market IBSRELA, the first and only NHE3 inhibitor for the treatment of IBS-C in adults, in the United States (the "U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute our products principally through a limited number of distributors and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell our products to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch. Rebates are generally invoiced and paid quarterly in arrears.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers and specialty pharmacies are offered various forms of consideration, including service fees. Wholesalers may also receive prompt pay discounts for payment within a specified period. We expect prompt pay discounts to be earned when offered and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the condensed balance sheets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-cash Interest Expense on Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds we receive from the sale of certain future royalties are amortized to non-cash interest expense over the estimated life of the associated agreement using the effective interest method. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.</span></div><div id="i3a1430f6bb744768868435e28c329915_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of recent accounting pronouncements that we have adopted or may expect to adopt is included in Note 1 &#8211; Organization and Basis of Presentation to our condensed financial statements (see Part I, Item 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Quarterly Report on Form 10-Q).</span></div><div id="i3a1430f6bb744768868435e28c329915_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue to date has been generated primarily through license, research and development collaborative agreements with various collaboration partners. We realized our first commercial product sales of IBSRELA in March 2022. In the future, we may generate revenue from a combination of our own product sales and payments in connection with our current or future collaborative partnerships, including license fees, other upfront payments, milestone payments, royalties and payments for drug product and/or drug substance. We expect that any revenue we generate will fluctuate in future periods as a result of, among other factors: whether and the extent to which we are successful in our commercialization of IBSRELA, whether we are able to gain approval from the FDA for our NDA for XPHOZAH; the timing and progress of goods and services provided pursuant to our current or future collaborative partnerships; our or our collaborators&#8217; achievement of clinical, regulatory or commercialization milestones, to the extent achieved; the timing and amount of any payments to us relating to the aforementioned milestones; and the extent to which tenapanor is approved and successfully commercialized by a collaboration partner. If our current collaboration partners or any future collaboration partners fail to obtain regulatory approval for tenapanor, our ability to generate future revenue from our collaborative arrangements, and our results of operations and financial position, would be materially and adversely affected. Our past revenue performance is not necessarily indicative of results to be expected in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to Customers, collaboration partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three and six months ended June&#160;30, 2022 were expensed prior to the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. We believe our cost of goods sold for the three and six months ended June&#160;30, 2022 would have been $140&#160;thousand and $149&#160;thousand higher, respectively, if we had not previously expensed certain material and production costs with respect to the units sold. As of June&#160;30, 2022, we had approximately $31.2&#160;million of inventory on hand that was previously expensed as research and development expense and will not be reported as cost of goods sold in future periods when sales of IBSRELA are recognized as revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners in connection with the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.9 million as cost of revenue under the AZ Termination Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the October 2021 restructuring plan, we eliminated our internal research organization and expect to continue our discovery efforts with respect to RDX020 through the use of third-parties managed internally by non-clinical expertise. We recognize all research and development expenses as they are incurred to support the discovery, research, development and manufacturing of our product candidates. Research and development expenses include, but are not limited to, the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under agreements with consultants, third-party contract research organizations (&#8220;CROs&#8221;) and investigative sites where a substantial portion of our clinical studies are conducted, and with contract manufacturing organizations where our clinical supplies are produced;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with supplies and materials consumed in connection with our research operations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with producing tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis prior to FDA approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with research, clinical development and regulatory activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, bonuses, benefits, travel and stock-based compensation; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense, information technology expense and other supplies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, for certain of our executives, our board members, and our finance, legal, business development, market development, commercial and support staff. Other selling, general and administrative expenses include facility related costs and professional fees for legal, accounting and audit, investor relations, other consulting services and allocated facility related costs not otherwise included in research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense represents the interest paid on our loan payable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists of interest income earned on our cash and cash equivalents and available-for-sale investments, the periodic revaluation of the exit fee related to our loan, gains on sales of property and equipment, and currency exchange gains and losses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022, for any other interim period, or for any other future year.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">three and six months ended June&#160;30, 2022 and 2021</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our total revenue (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:22.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,901)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Percent change is not meaningful.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase to total revenues during the three months ended June&#160;30, 2022 is primarily attributable to $1.6&#160;million of net product sales for IBSRELA to our Customers in connection with the commercial launch of IBSRELA, as well as $1.0&#160;million product supply revenue for which there was no comparable revenue during the three months ended June 30, 2021. Partially offsetting these increases was the full recognition of upfront payments associated with the 2019 KKC Agreement through the end of 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease to total revenues during the six months ended June&#160;30, 2022 is primarily attributable to a $5.0&#160;million development milestone that was earned during the prior year that did not recur during the current year, as well as the full recognition of upfront payments associated with the 2019 KKC Agreement through the end of 2021, for which there was no comparable revenue during the six months ended June&#160;30, 2022. Partially offsetting these decreases is recognition of $2.0&#160;million of net product sales for sales of IBSRELA to our Customers in connection with the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our operating expenses (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:24.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,280)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,404)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,716)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) Percent change is not meaningful.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fluctuations in cost of revenue for the three and six months ended June&#160;30, 2022 are primarily attributable to payments due to AstraZeneca under the AZ Termination Agreement related to the commercial sales of IBSRELA during the three and six months ended June&#160;30, 2022 and a development milestone we earned during the six months ended June&#160;30, 2021. In addition, during the three and six months ended June&#160;30, 2022, we incurred cost of revenue from sales of IBSRELA to our Customers in connection with the commercial launch of IBSRELA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our research and development expenses (dollars in thousands): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:24.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,892)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,460)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,980)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, equipment and depreciation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,021&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,280)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,477&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,885)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our external R&amp;D expenses for the three months ended June&#160;30, 2022 is primarily the result of lower clinical study costs from the OPTIMIZE study, lower tenapanor manufacturing expense as we have begun to capitalize costs associated with the production of IBSRELA to inventory, and lower expenses for research following the elimination of our research function in the fourth quarter of 2021. The decrease in our employee-related expenses for the three and six months ended June&#160;30, 2022 is due to lower compensation and benefits expenses for our research and development workforce following restructuring actions in 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fluctuations in general and administrative expenses for the three and six months ended June&#160;30, 2022 is primarily due to the timing of costs associated with building and staffing our commercial infrastructure and teams as we prepared for the U.S. launch of IBSRELA. The changes consisted of headcount and related personnel costs and external spending for disease awareness initiatives, commercial infrastructure and strategy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our interest expense (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,302)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense for the three and six months ended June&#160;30, 2022 was primarily due to lower principal outstanding on our loan payable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other&#160;Income, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our other income, net (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.663%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other income, net for the three and months ended June 30, 2022 is primarily due to revaluation of our 2018 Exit Fee during the three months ended June 30, 2021 following the receipt of the CRL from the FDA. Partially offsetting this decrease are sales of certain lab equipment and supplies for a net gain of $1.1 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our cash, cash equivalents and investments (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liquid funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,677)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash, cash equivalents and investments totaling $81.0 million compared to $116.7 million as of December&#160;31, 2021. We have incurred operating losses since inception and our accumulated deficit as of June&#160;30, 2022 is $767.9 million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the filing of these financial statements on August&#160;4, 2022. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from the product launch of IBSRELA, our potential receipt of anticipated milestone payments from our collaboration partners, our potential receipt of anticipated payments from KKC under the Amendment, our ability to access the capital markets, and execute asset monetization strategies, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at the market offerings&#8221; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the six months ended June&#160;30, 2021 we sold 9.0 million shares and received gross proceeds of $63.8 million at a weighted average sales price of approximately $7.10 per share under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the six months ended June&#160;30, 2022 we sold 20.5 million shares and received gross proceeds of $18.9 million at a weighted average sales price of approximately $0.92 per share under the 2021 Open Market Sales Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into a loan and security agreement (the &#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. The 2022 Loan Agreement provides for a senior secured term loan facility, with $27.5 million funded at closing and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for tenapanor for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement. The initial funding of $27.5 million is being used to repay the 2018 Loan and to fund our ongoing operations. On August 1, 2022, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis in order to borrow the additional $22.5 million from December 31, 2022 to March 31, 2023. We had $25.0 million principal from the 2018 Loan outstanding as of the closing date. In connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  2% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of cash have been from the sale and issuance of common stock (in both public offerings and private placements) and private placements of convertible preferred stock, funds from our collaboration partnerships and funds from our 2018 Loan Agreement and 2022 Loan Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash have been to fund operating expenses, primarily research and development expenditures, pre-commercial and commercial expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">whether we are successful in our efforts under the FDR process, including the Advisory Committee meeting to be convened as part of the FDR process, to secure approval for our NDA for XPHOZAH, or to reach resolution with the FDA regarding a path to address the deficiencies in the NDA noted in the CRL and ADL, and the time and cost associated with such path;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the manufacturing costs of IBSRELA and XPHOZAH; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the timing, receipt and amount of revenue, if any, that may be received from KKC in connection with the 2022 KKC Amendment;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the timing, receipt, and amount of sales of, or royalties on, tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the cash requirements of any future acquisitions or discovery of product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any clinical trials we are required to or decide to pursue for tenapanor or RDX013;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the payment of interest and principal related to the 2022 Loan Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the risk factors set forth in Part II, Item 1A, Risk Factors, in this Quarterly Report on Form 10-Q for additional risks associated with our capital requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOW ACTIVITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,901)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,020)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,287)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,733)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="i3a1430f6bb744768868435e28c329915_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the six months ended June&#160;30, 2022 decreased by $19.6 million primarily as a result of our net loss which was $23.3 million less than during the six months ended June&#160;30, 2021. Partially offsetting the net loss improvement were changes to our operating assets and liabilities related to expenditures for commercial manufacturing and inventory for the production of IBSRELA. </span></div><div id="i3a1430f6bb744768868435e28c329915_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities increased by $7.1 million due to the timing of our investment maturities and purchases, as well as $1.3 million proceeds from sale of laboratory equipment and supplies during the six months ended June&#160;30, 2022.</span></div><div id="i3a1430f6bb744768868435e28c329915_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities decreased by $41.4 million primarily due to net proceeds from issuance of our common stock pursuant to the at the market offerings of $62.4 million during the six months ended June&#160;30, 2021 compared to $18.5 million during the six months ended June&#160;30, 2022. In addition, during the six months ended June&#160;30, 2022, we received net proceeds of $27.0 million pursuant to the 2022 Loan Agreement, $9.6 million in proceeds for the sale of certain future royalties, and repaid $33.0 million, net of settlement costs, to repay the 2018 Loan.</span></div><div id="i3a1430f6bb744768868435e28c329915_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and 2021, respectively, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K as promulgated by the SEC.</span></div><div id="i3a1430f6bb744768868435e28c329915_118"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are subject to market risks, including interest rate fluctuation exposure through our investments, in the ordinary course of our business. However, the goals of our investment policy are the preservation of capital, fulfillment of liquidity needs and fiduciary control of cash. To achieve our goal of maximizing income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and short-term debt securities. Because of the short-term maturities of our cash equivalents, we do not believe that an increase in interest rates would have any material negative impact on the fair value of our cash equivalents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash, cash equivalents and investments of $81.0&#160;million, which consist of bank deposits and money market funds, as well as high quality fixed income instruments including corporate bonds, commercial paper, and asset-backed securities collateralized by non-mortgage consumer receivables. The credit rating of our investments must be rated A-1/P-1, or better by Standard and Poor&#8217;s and Moody&#8217;s Investors Service. Asset-backed securities must be rated AAA/Aaa. Money Market funds must be rated AAA/Aaa. Such interest-earning instruments carry a degree of interest rate risk. However, because our investments are high quality and short-term in duration, we believe that our exposure to interest rate risk is not significant and that a 10% movement in market interest rates would not have a significant impact on the total value of our portfolio, as noted above. We do not enter into investments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate fluctuation exposure through our borrowings under the Loan Agreement and our investment in money market accounts which bear a variable interest rate. Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd ("ICE") or its successor. A hypothetical increase in one-month ICE of 100 basis points above the current one-month ICE rates would have increased our interest expense by approximately $0.1&#160;million for the three and six months ended June&#160;30, 2022. As of June&#160;30, 2022, we had an aggregate principal amount of $27.5&#160;million outstanding pursuant to our 2022 Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The majority of our transactions are denominated in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily Swiss francs and the euro, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities associated with a limited number of manufacturing activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the earnings effects of changes in foreign currency exchange rates. The counterparties to our forward foreign currency exchange contracts are creditworthy commercial banks, which minimizes the risk of counterparty nonperformance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had no open forward foreign currency exchange contracts.</span></div><div id="i3a1430f6bb744768868435e28c329915_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule&#160;13a-15(b)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of June&#160;30, 2022. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of June&#160;30, 2022, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, we implemented certain internal controls in connection with our product launch. There were no other changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div id="i3a1430f6bb744768868435e28c329915_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Siegel v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between August 6, 2020, and July 19, 2021. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#8217; fees. On September 28, 2021, several shareholders filed motions to consolidate the two putative class actions and to be appointed lead plaintiff and have their selection of counsel be appointed lead counsel, and on July 19, 2022, the court issued an order to consolidate the two putative class actions and appointed the lead plaintiff and lead counsel. The parties have agreed upon a proposed schedule for the lead plaintiff to file a consolidated amended complaint and for defendants to file a motion to dismiss. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Go v. Raab, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-09455-HSG, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Morris v. Raab, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:22-cv-01988-JSC. The complaints allege violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste, and seek contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Go </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Morris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions, and the cases remain stayed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of June&#160;30, 2022, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of June&#160;30, 2022.</span></div><div id="i3a1430f6bb744768868435e28c329915_130"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Our business involves significant risks, some of which are described below. You should carefully consider these risks, as well as other information in this Quarterly Report on Form 10-Q, including our financial statements and the notes thereto and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows, the trading price of our common stock and our growth prospects. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to our Financial Condition and Capital Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We have incurred significant losses since our inception and we will incur losses in the future, which makes it difficult to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash and investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We recently commenced the commercialization of our first product, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(tenapanor) for the treatment of irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;), and have generated limited revenue from product sales to date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are not profitable and have incurred losses in each year since our inception in October 2007, and we do not know whether or when we will become profitable. We continue to incur significant commercialization, development and other expenses related to our ongoing operations. As of June&#160;30, 2022, we had an accumulated deficit of $767.9&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We expect to continue to incur substantial operating losses for the foreseeable future as we commercialize IBSRELA, seek to gain approval for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis (the &#8220;Hyperphosphatemia Indication&#8221;); prepare for the potential commercialization of XPHOZAH, if approved; and incur manufacturing and development cost for, tenapanor. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Ernst &amp; Young LLP, our independent registered public accounting firm for the fiscal year ended December 31, 2021, has included an explanatory paragraph in their opinion that accompanies our audited financial statements as of the year ended December 31, 2021, indicating our current liquidity position raises substantial doubt about our ability to continue as a going concern. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from the product launch of IBSRELA, our potential receipt of anticipated milestone payments from our collaboration partners, our potential receipt of anticipated payments from our collaboration partner, Kyowa Kirin, Co., Ltd. (&#8220;KKC&#8221;) in connection with the transaction entered into with KKC in March 2022 which amended our License Agreement entered into with KKC in 2017 (the &#8220;2022 KKC Amendment&#8221;); our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months, our liquidity, financial condition and business prospects will be materially affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have substantial net operating loss and tax credit carryforwards for Federal and California income tax purposes. Such net operating losses and tax credits carryforwards may be reduced as a result of certain intercompany restructuring transactions. In addition, the future utilization of such net operating loss and tax credit carryforwards and credits will be subject to limitations, pursuant to Internal Revenue Code Sections 382 and 383, as a result of ownership changes that have occurred previously and additional limitations may be applicable as a result of ownership changes that could occur in the future. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We will require substantial additional financing for the foreseeable future as we invest in the commercialization of IBSRELA and prepare for and participate in a Cardiovascular and Renal Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Advisory Committee (&#8220;Advisory Committee&#8221;) meeting in connection with the formal dispute resolution ("FDR") process commenced in response to the Complete Response Letter (&#8220;CRL&#8221;) received from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) relating to our New Drug Application (&#8220;NDA&#8221;) for tenapanor for the Hyperphosphatemia Indication and the inability to access necessary capital when needed on acceptable terms, or at all, could force us to limit, reduce or terminate our efforts to commercialize IBSRELA or to seek and obtain approval for tenapanor for the Hyperphosphatemia Indication. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Since our inception, most of our resources have been dedicated to our research and development activities, including developing tenapanor. Following the receipt of the CRL, we implemented two restructuring plans in order to reduce operating costs and to better align our workforce with the needs of our business. Notwithstanding the restructurings, we believe that we will continue to expend substantial resources for the foreseeable future, including, costs associated with our efforts to commercialize IBSRELA, which we began selling in the U.S. in March 2022, cost associated with our efforts to pursue approval for our NDA for tenapanor for the Hyperphosphatemia Indication through the FDR process, and Advisory Committee meeting; conducting pediatric clinical trials for IBSRELA and XPHOZAH, if approved, and manufacturing for IBSRELA and, if approved, XPHOZAH. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">whether we are successful in our efforts under the FDR process, including the Advisory Committee meeting to be convened as part of the FDR process, to secure approval for our NDA for tenapanor for the Hyperphosphatemia Indication, or to reach resolution with the FDA regarding a path to address the deficiencies in the NDA noted in the CRL and ADL, and the time and cost associated with such path;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the manufacturing costs of IBSRELA and XPHOZAH; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.5pt">the selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the timing, receipt and amount of revenue, if any, that may be received from KKC in connection with the 2022 KKC Amendment;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the timing, receipt, and amount of sales of, or royalties on, tenapanor, if any;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the cash requirements of any future acquisitions or discovery of product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any clinical trials we are required to or decide to pursue for tenapanor or RDX013;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with SLR Investment Corp. in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to limit, reduce or terminate our commercialization of IBSRELA, delay, limit, reduce or terminate our efforts to secure approval for XPHOZAH for the Hyperphosphatemia Indication, or clinical trials for tenapanor. Additionally, our inability to access capital on a timely basis and on terms that are acceptable to us may force us to restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA or the development and commercialization of XPHOZAH, if approved, through the use of alternative structures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our failure to meet the continued listing requirements of The Nasdaq Global Market could result in a de-listing of our common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we fail to satisfy the continued listing requirements of The Nasdaq Global Market ("Nasdaq") such as the minimum stockholders&#8217; equity requirement or the minimum closing bid price requirement, Nasdaq may take steps to de-list our common stock. For example, on each of February 28, 2022 and May 23, 2022, we received a letter from Nasdaq indicating that Nasdaq had determined that we had failed to comply with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Global Market maintain a minimum closing bid price of at least $1.00 per share (the &#8220;Listing Requirement&#8221;). We received a letter from Nasdaq dated March 31, 2022, indicating that we had regained compliance with the Listing Requirement after the closing bid price for its common stock listed on Nasdaq equaled or exceeded $1.00 per share for ten (10) consecutive business days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">However, we have not yet regained compliance with the Listing Requirement following the second letter we received on May 23, 2022 letter, and there can be no assurances that we will regain compliance with the Listing Requirement during the 180 day grace period afforded us by Nasdaq. On April 29, 2022, we filed our definitive Proxy Statement with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) indicating our intention to seek approval from our stockholders during our Annual Meeting of Stockholders to be held on June 15, 2022, for a proposal to grant our Board of Directors authority to effect a reverse stock split of our authorized common stock and issued and outstanding common stock by amending our Amended and Restated Certificate of Incorporation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">by September 15, 2022 and within a range of not less than 1-for-2 and not more than 1-for-10, if our Board of Directors deems it within our best interests. This proposal failed to receive a sufficient number of votes for approval from our stockholders during our Annual Meeting of Stockholders and the adjournment thereof. We are monitoring the bid price of our common stock and will consider options available to us to regain compliance with the Listing Requirement. There can be no assurances that we will have other options available to regain compliance with the Listing Requirement. If we fail to regain compliance with this requirement, or any other of the continued listing requirements of The Nasdaq Global Market, Nasdaq may take steps to de-list our common stock. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If Nasdaq de-lists our securities for trading on the Nasdaq or takes other actions with respect to our Nasdaq listing, we could face significant adverse consequences, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;      a limited availability of market quotations for our common stock;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;      reduced liquidity with respect to our common stock;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;      reduced trading volume in and market price of our common stock;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;      a limited amount of news and analyst coverage for our company; and</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;      a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Such a de-listing would likely have an adverse effect on the price of our common stock and would impair the ability of our stockholders to sell or purchase our common stock. We may take actions to avoid such a de-listing or in the event of a de-listing, we may take actions to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to remain listed or to become listed again, stabilize the market price or improve the liquidity or trading volume of our common stock, prevent our common capitalization and stockholder&#8217;s equity from dropping below the Nasdaq minimum requirements, or prevent other future non-compliance with Nasdaq&#8217;s continued listing requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We have generated limited revenue from product sales and may never be profitable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We began selling IBSRELA in the U.S. in March 2022, and have generated limited revenue from product sales to date. We have no other products approved for sale and have received a CRL from the FDA for our NDA for the Hyperphosphatemia Indication and an Appeal Denied Letter (&#8220;ADL&#8221;) in response to our first level of appeal of the CRL to the FDA Office of Cardiology, Hematology, Endocrinology and Nephrology (&#8220;OCHEN&#8221;). Additionally, we have received an Interim Response (the &#8220;Interim Response&#8221;) to our second level of appeal to the Office of New Drugs (&#8220;OND&#8221;), Center for Drug Evaluation and Research (CDER), in which OND indicated that additional input from the Advisory Committee, in general, and specifically from experts, including clinicians would be valuable in further considering the clinical meaningfulness of the phosphate lowering effect observed in our phase 3 clinical program for XPHOZAH.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">OND has directed the Division of Cardiology and Nephrology of OCHEN (the &#8220;Division&#8221;) to convene the Advisory Committee, and a tentative date for the Advisory Committee meeting has been set for November 16, 2022. There can be no assurances that the response from the Advisory Committee will be positive, or thatthat approval of our NDA will ultimately be granted by the FDA. To date, we have generated limited product revenue from product sales of IBSRELA. There can be no assurances that we will be successful in increasing the amount of product revenue from sales of IBSRELA. There can be no assurances that we will generate sufficient product revenue from sales of IBSRELA and, if approved, XPHOZAH, to cover our expenses. Our ability to generate product revenue from sales or pursuant to milestone payments depends heavily on many factors, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to successfully commercialize IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">obtaining market acceptance of IBSRELA as a viable treatment option for IBS-C;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">whether we are successful in our efforts during the Advisory Committee meeting and under the FDR process to secure approval for our NDA for tenapanor for the Hyperphosphatemia Indication, or whether we are otherwise able during the FDR to reach resolution with the FDA regarding a path to addressing the deficiencies in our NDA noted in the CRL, ADL and Interim Response that is achievable in terms of clinical study design, time and cost;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate (in amount and quality) supply of product to support the market demand for IBSRELA, and, if approved, XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">addressing any competing technological and market developments;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">With respect to our commercialization of IBSRELA, and if we are successful in obtaining regulatory approval to market XPHOZAH, our revenue will be dependent, in part, upon the size of the markets in the U.S. and the label for which approval is or was granted, acceptance of the price for the product, and the ability to get reimbursement at any price. While there is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in general in the United States, there is additional uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. If we are successful in obtaining regulatory approval to market XPHOZAH for such indication, our ability to generate and sustain future revenues from sales of tenapanor for such indication, may be dependent upon whether and when XPHOZAH, along with other oral ESRD related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur. See &#8220;Third-party payor coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA or, if approved, XPHOZAH, could limit our ability to market those products and decrease our ability to generate revenue&#8221; below. Additionally, if the number of adult patients for IBSRELA or, if approved, XPHOZAH is not as significant as we estimate, the indication approved by regulatory authorities for XPHOZAH is narrower than we expect, coverage and reimbursement for either IBSRELA or, if approved, XPHOZAH are not available in the manner and to the extent we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from the sale of IBSRELA or, if approved, XPHOZAH. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to generate adequate revenue from product sales would likely depress our market value and could impair our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations. A decline in the value of our common stock could cause our stockholders to lose all or part of their investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Principal Risks Related to Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We are substantially dependent on the successful launch and commercialization of IBSRELA for IBS-C, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA; secure adequate coverage and reimbursement for IBSRELA; or generate sufficient revenue from product sales of IBSRELA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We began selling IBSRELA, our approved treatment for IBS-C in adults in the U.S. in March 2022. The overall commercial success of IBSRELA will depend on a number of factors, including the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the launch and market demand for IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the effectiveness of IBSRELA as a treatment for adult patients with IBS-C;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the size of the treatable patient population; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the effectiveness of our sales, market access and marketing efforts; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">whether physicians view IBSRELA as a safe and effective treatment for adult patients with IBS-C, which will impact the adoption of IBSRELA by physicians for the treatment of IBS-C;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of IBSRELA compared to alternative and competing treatments; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the prevalence and severity of adverse side effects of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights directed to IBSRELA, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of IBSRELA following approval.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The amount of potential revenue we may achieve from the commercialization of IBSRELA is subject to these and other factors, and may be unpredictable from quarter-to-quarter. If the number of patients in the market for IBSRELA or the price that the market can bear is not as significant as we estimate, or if we are not able to secure adequate physician and patient acceptance of IBSRELA or adequate coverage and reimbursement for IBSRELA, we may not generate sufficient revenue from sales of IBSRELA. Any failure of IBSRELA to achieve market acceptance, sufficient third-party coverage or reimbursement, or commercial success for would adversely affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We are pursuing regulatory approval for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, and there can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are pursuing regulatory approval for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. To date, we have invested a significant amount of our efforts and financial resources in the research and development of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. On July 28, 2021, we received a CRL from the Division regarding our NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis. According to the CRL, the FDA has determined that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and of unclear of clinical significance. Following an End-of-Review Type A meeting (&#8220;End of Review Meeting&#8221;) in October 2021, with the Division, we submitted a Formal Dispute Resolution Request (&#8220;FDRR&#8221;) in December 2021. The FDRR was focused on demonstrating that the data submitted in the NDA supported the clinical significance of the treatment effect of tenapanor. On February 4, 2022, we received an ADL from OCHEN. On February 18, 2022, we submitted an appeal of the ADL to the FDA&#8217;s Center for Drug Evaluation and Research, Office of New Drugs (&#8220;OND&#8221;), and on April 15, 2022, we received an Interim Response from OND. The Interim Response indicated that OND would direct the Division to convene the Advisory Committee to provide additional input for consideration by OND, and the Advisory Committee meeting has been tentatively scheduled for November 16, 2022. OND expects to provide a response to the FDR within thirty (30) days after the conclusion of the Advisory Committee meeting. There can be no assurances that the response from the Advisory Committee will be positive, or that approval of the NDA will ultimately be granted by the FDA.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Even if we are successful in obtaining regulatory approval for tenapanor for control of serum phosphorus in adult patients with CKD on dialysis, the expense and time required to do so could adversely impact our ability to successfully commercialize XPHOZAH for the Hyperphosphatemia Indication. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may not be successful in obtaining approval for tenapanor for the Hyperphosphatemia Indication, and if we are able to obtain approval, the expense and time to do so could adversely impact our ability to successfully commercialize XPHOZAH for the Hyperphosphatemia Indication, our business and our results of operations. If we are successful in obtaining approval for XPHOZAH for the Hyperphosphatemia Indication, the commercial success of XPHOZAH will depend on a number of factors, including the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the market demand for both IBSRELA and XPHOZAH;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">whether or not the content and breadth of the label approved by the FDA for XPHOZAH may materially and adversely impact our ability to commercialize the product for the approved indication;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">whether or when XPHOZAH, along with other oral end-stage renal disease (&#8220;ESRD&#8221;) related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the prevalence and severity of adverse side effects of XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">acceptance of XPHOZAH as safe, effective and well-tolerated by patients and the medical community, and, the extent to which the issuance of a CRL by the FDA has impacted the potential acceptance of XPHOZAH as safe, effective and well-tolerated;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our ability to manage the commercialization of IBSRELA and XPHOZAH and the complex pricing and reimbursement negotiations that may arise with marketing the same product at different doses for separate indications;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of XPHOZAH compared to alternative and competing treatments;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">obtaining and sustaining an adequate level of coverage and reimbursement for XPHOZAH by third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to XPHOZAH;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of XPHOZAH following approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">IBSRELA, and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Undesirable side effects caused by IBSRELA, and/or, if approved, XPHOZAH, could cause us or regulatory authorities to interrupt, delay or halt the commercialization of the product. Despite our receipt of marketing approval for IBSRELA and the completion of our Phase 3 clinical program for XPHOZAH, the prevalence and/or severity of side effects caused by IBSRELA, and/or if approved, XPHOZAH, could result in a number of potentially significant negative consequences could occur, including:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we or a collaboration partner may be required to recall the product;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof, including the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) which could require creation of a Medication Guide or patient package insert outlining the risks of such side effects for distribution to patients, a communication plan to educate healthcare providers of the drugs&#8217; risks, as well as other elements to assure safe use of the product, such as a patient registry and training and certification of prescribers;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we or a collaboration partner may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">regulatory authorities may require the addition of new labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Any of the foregoing events could prevent us, or a collaboration partner, from achieving or maintaining market acceptance of IBSRELA, and/or, if approved, XPHOZAH, and could result in the loss of significant revenue to us, which would materially and adversely affect our results of operations and business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">As a company, we have limited experience in the marketing, sale and distribution of pharmaceutical products; and there are significant risks in building and managing a commercial organization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a company, we have limited experience in building and managing a commercial organization, or in the marketing, sale and distribution of pharmaceutical products. There can be no assurances that we will be successful in our efforts to retain, and incentivize qualified individuals, generate sufficient sales leads, comply with regulatory requirements applicable to the marketing and sale of drug products and effectively manage a geographically dispersed sales and marketing team.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we fail or are delayed in the development of our internal sales, marketing and distribution capabilities, the commercialization of IBSRELA could be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On February 23, 2022, we entered into a loan and security agreement with SLR Investment Corp. (the &#8220;Lender&#8221;) pursuant to which the Lender agreed to provide us a $50.0 million term loan facility with a maturity date of March 1, 2027. The loan was funded in the amount of $27.5 million on February 23, 2022 and the remaining $22.5 million may be funded upon the satisfaction of both (i) receipt from the FDA of approval of the NDA for tenapanor for the Hyperphosphatemia Indication on or prior to December 31, 2022 and (ii) our achievement of certain product revenue milestone targets described in the 2022 Loan Agreement. On August 1, 2022, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the Hyperphosphatemia Indication in order to borrow the additional $22.5 million from December 31, 2022 to March 31, 2023. Until we have repaid all funded indebtedness, the loan and security agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into licensing agreements, to engage in transactions with affiliates, and to encumber our intellectual property. Our business may be adversely affected by these restrictions on our ability to operate our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are permitted to make interest only payments on the loan facility through March 2024, with principal repayments commencing on April 1, 2024, however, we may be required to repay the outstanding indebtedness under the loan facility if an event of default occurs under the loan and security agreement. An event of default will occur if, among other things, we fail to make payments under the loan and security agreement; we breach any of our covenants under the loan and security agreement, subject to specified cure periods with respect to certain breaches; the Lender determines that a material adverse change has occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit the Lender to accelerate the maturity of such indebtedness or that could have a material adverse change on us. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to delay, limit, reduce or terminate our activities necessary to commercialize IBSRELA, and/or if approved, XPHOZAH, or clinical trials for tenapanor. The Lender could also exercise its rights as collateral agent to take possession of and to dispose of the collateral securing the term loans, which collateral includes substantially all of our property (excluding intellectual property, which is subject to a negative pledge). Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Third-party payor coverage and reimbursement status of newly commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, XPHOZAH, could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The pricing, coverage and reimbursement of IBSRELA and, if approved, XPHOZAH, must be adequate to support a commercial infrastructure. The availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford treatments. Sales of IBSRELA, and, if approved and commercialized, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">XPHOZAH, will depend substantially, both domestically and abroad, on the extent to which the costs of the product will be paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, we, or our collaboration partners, may not be able to successfully commercialize IBSRELA, or, if approved, XPHOZAH. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the United States Department of Health and Human Services responsible for administering the Medicare program, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There is increased uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH for the Hyperphosphatemia Indication, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis or for another other related indication. In January 2011, CMS implemented a new prospective payment system for dialysis treatment. Under the ESRD prospective payment system, CMS generally makes a single bundled payment to the dialysis facility for each dialysis treatment that covers all items and services routinely required for dialysis treatments furnished to Medicare beneficiaries in Medicare-certified ESRD facilities or at their home, including the cost of certain routine drugs. The inclusion of oral medications without injectable or intravenous equivalents in the bundled payment was initially delayed until January 1, 2014, and through several subsequent legislative actions was delayed until January 1, 2025. As a result, absent further legislation or regulation on this matter, beginning in 2025, oral ESRD-related drugs without injectable or intravenous equivalents may be included in the ESRD bundle and separate Medicare payment for these drugs will no longer be available, as is the case today under Medicare Part D. While it is too early to project the full impact that bundling may have on sales of XPHOZAH, if approved and commercialized, and on our business should XPHOZAH be brought into the bundle in 2025, or at any time, we may be unable to sell XPHOZAH for the Hyperphosphatemia Indication, if approved, to dialysis providers on a profitable basis if third-party payors reduce their current levels of payment, or if our costs of production are higher than levels necessary for an appropriate gross margin after payment of all discounts, rebates and chargebacks. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, Japan, China and other countries has and will continue to put pressure on the pricing and usage of IBSRELA and XPHOZAH, even if regulatory approval is received in such countries. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, these caps may not cover or provide adequate payment for IBSRELA, and if approved and commercialized, XPHOZAH. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA, and, if approved and commercialized, XPHOZAH, and our future development efforts for tenapanor may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture IBSRELA, or any of other our product candidates on a commercial scale, or to manufacture our drug supplies for use in the conduct of our nonclinical and clinical studies. The facilities used by our contract manufacturers to manufacture our drug supply are subject to inspection by the FDA. Our ability to control the manufacturing process of our product candidates is limited to the contractual requirements and obligations we impose on our contract manufacturer. Although they are contractually required to so do, we are completely dependent on our contract manufacturing partners for compliance with the regulatory requirements, known as current Good Manufacturing Practice requirements (&#8220;cGMPs&#8221;), for manufacture of both active drug substances and finished drug products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The manufacture of pharmaceutical products requires significant expertise and capital investment. Manufacturers of pharmaceutical products often encounter difficulties in commercial production. These problems may include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, and shortages of qualified personnel, as well as compliance with federal, state and foreign regulations and the challenges associated with complex supply chain management. Even if our contract manufacturers do not experience problems and commercial manufacturing is achieved, their maximum or available manufacturing capacities may be insufficient to meet commercial demand. Finding alternative manufacturers or adding additional manufacturers requires a significant amount of time and involves significant expense. New manufacturers would need to develop and implement the necessary production techniques and processes, which along with their facilities, would need to be inspected and approved by the regulatory authorities in each applicable territory. In addition, the raw materials necessary to make API for our products are acquired from a limited number of sources. Any delay or disruption in the availability of these raw materials could result in production disruptions, delays or higher costs with consequent adverse effects on us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If our contract manufacturers fail to adhere to applicable GMP or other regulatory requirements, experience delays or disruptions in the availability of raw materials or experience manufacturing or distribution problems, we may suffer significant consequences, including the inability to meet our product requirements for our clinical development programs, and if tenapanor is commercialized for any indication, such events could result in product seizures or recalls, loss of product approval, fines and sanctions, reputational damage, shipment delays, inventory shortages, inventory write-offs and other product-related charges and increased manufacturing costs. As a result, or if maximum or available manufacturing capacities are insufficient to meet demand, our development or our commercialization efforts for IBSRELA, and/or, if approved, XPHOZAH, may be materially harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Additional Risks Related to Our Business and Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. For example, while the results of our Phase 2 clinical trial evaluating RDX013 for the treatment of hyperkalemia demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. We currently expect that the next step for the program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study at such time as we have determined that our available resources support conducting such an additional clinical study. There can be no assurances that any additional clinical study that we determine to conduct with RDX013 will be successful. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, if we conduct additional clinical trials with RDX013, we could encounter delays in our future development if any clinical trials are suspended or terminated by us, by the IRBs of the institutions in which the trial is being conducted, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, identifying and qualifying patients to participate in any clinical trials is critical to the success of the clinical trials. The timing of any future clinical trials, including any additional RDX013 clinical trial that we may determine to conduct, will depend, in part, on the speed at which we can recruit patients to participate in testing our product candidates. Patients may be unwilling to participate in our clinical studies because of concerns about adverse events observed with the current standard of care, competitor products and/or other investigational agents, in each case for the same indications and/or similar patient populations. In addition, patients currently receiving treatment with the current standard of care or a competitor product may be reluctant to participate in a clinical trial with an investigational drug, or our inclusion and exclusion criteria for our clinical trials may present challenges in identifying acceptable patients. As a result, the timeline for recruiting patients and conducting clinical trials may be delayed. These delays could result in increased costs, delays in advancing our development the program, or termination of the clinical studies altogether. Any of these occurrences may significantly harm our business, financial condition and prospects. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We will rely on third parties to conduct all of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for additional products or commercialize our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We do not have the ability to independently conduct nonclinical studies or clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs, to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of the clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we control only certain aspects of their activities and have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely, and will continue to rely, on these third parties to conduct our nonclinical studies and our clinical trials, we remain responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We, and these third parties are required to comply with current GLPs for nonclinical studies, and good clinical practices (&#8220;GCPs&#8221;) for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(&#8220;EEA&#8221;) and comparable foreign regulatory authorities for all of our products in nonclinical and clinical development, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable regulatory requirements, including GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We face substantial competition, and our competitors may discover, develop or commercialize products faster or more successfully than us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The biotechnology and pharmaceutical industries are highly competitive, and we face significant competition from companies in the biotechnology, pharmaceutical and other related markets that are researching and marketing products designed to address diseases that we are currently developing products to treat. If approved for marketing by the FDA or other regulatory agencies, tenapanor, as well as our other product candidates, would compete against existing treatments. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">For example, numerous treatments exist for constipation and the constipation component of IBS-C, many of which are over-the-counter. These include psyllium husk (such as Metamucil), methylcellulose (such as Citrucel), calcium polycarbophil (such as FiberCon), lactulose (such as Cephulac), polyethylene glycol (such as MiraLax), sennosides (such as Exlax), bisacodyl (such as Ducolax), docusate sodium (such as Colace), magnesium hydroxide (such as Milk of Magnesia), saline enemas (such as Fleet), and sorbitol. These agents are generally inexpensive and work well to temporarily relieve constipation. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are aware of four prescription products marketed for certain patients with IBS-C, including Linzess (linaclotide), Amitiza (lubiprostone), Trulance (plecanatide) and Zelnorm (tegaserod maleate).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, XPHOZAH, if approved for the Hyperphosphatemia Indication will compete with phosphate binders used for the same or similar indication`. If approved, our label for XPHOZAH may include data comparing the effectiveness of tenapanor to phosphate binders used for the same indication. The various types of phosphate binders commercialized in the United States include the following: Calcium carbonate (many over-the-counter brands including Tums and Caltrate); Calcium acetate (several prescription brands including PhosLo and Phoslyra); Lanthanum carbonate (Fosrenol); Sevelamer hydrochloride (Renagel); Sevelamer carbonate (Renvela); Sucroferric oxyhydroxide (Velphoro); and Ferric citrate (Auryxia). </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">All of the phosphate binders listed above are available as generics in the U.S., with the exception of Velphoro and Auryxia. In addition to the currently available phosphate binders, we are aware of at least two other binders in development, including fermagate (Alpharen), an iron-based binder in Phase 3 being developed by Opko Health, Inc., and PT20, an iron-based binder in Phase 3 being developed by Shield Therapeutics. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">It is possible that our competitors' drugs may be less expensive and more effective than our product candidates, or that will render our product candidates obsolete. It is also possible that our competitors will commercialize competing drugs or treatments before we or our collaboration partners can launch any products developed from our product candidates. We also anticipate that we will face increased competition in the future as new companies enter into our target markets. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaboration partnerships or licensing relationships with our competitors. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may experience difficulties in managing our current activities and growth given our level of managerial, operational, financial and other resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">While we have continued to work to optimize our management composition, personnel and systems to support our current activities for future growth, these resources may not be adequate for this purpose. Our need to effectively execute our business strategy requires that we:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">manage any commercialization activities in which we may engage effectively;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">manage our clinical trials effectively;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">manage our internal development efforts effectively while carrying out our contractual obligations to licensors, contractors, collaborators, government agencies and other third parties;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">continue to improve our operational, financial and management controls, reporting systems and procedures; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">retain and motivate our remaining employees and potentially identify, recruit, and integrate additional employees. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we are unable to maintain or expand our managerial, operational, financial and other resources to the extent required to manage our development and commercialization activities, our business will be materially adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of IBSRELA, and/or, if approved, XPHOZAH. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and our commercial launch of IBSRELA. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">decreased demand for the product;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the inability to commercialize or co-promote IBSRELA, and/or, if approved, XPHOZAH. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. Although we maintain product liability insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we fail to attract, retain and motivate our executives, senior management and key personnel, our business will suffer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Recruiting and retaining qualified scientific, clinical, medical, manufacturing, and sales and marketing personnel is critical to our success. We are highly dependent on our executives, senior management and certain other key employees. The loss of the services of our executives, senior management or other key employee could impede the achievement of our development and commercial objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executives, senior management and other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. We may be unable to hire, train or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel, particularly in our geographic regions. If we are unable to continue to attract and retain high quality personnel, our ability to grow and pursue our business strategy will be limited. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act ("CCPA") went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act (CPRA) recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Furthermore, the Federal Trade Commission (FTC) and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, in Europe, the European Union General Data Protection Regulation (GDPR) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (EEA). Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States; in July 2020, the Court of Justice of the EU (CJEU) limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Relatedly, following the United Kingdom&#8217;s withdrawal from the European Economic Area and the European Union, and the expiry of the transition period, companies have to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which may expose us to further compliance risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We and our collaborators, CROs and other contractors and consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We and our collaborators, CROs, and other contractors and consultants collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we and our collaborators, CROs and other contractors and consultants collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we and our collaborators, CROs and other contractors and consultants do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, CROs, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The risk of a security breach or disruption or data loss, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date. If such an event were to occur and cause interruptions in our operations, it could result in material disruption to our business. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable. Moreover, if a computer security breach affects our systems or those of our collaborators, CROs or other contractors, or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We have previously identified a material weakness in our internal control over financial reporting. If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors&#8217; views of us and could have a material adverse effect on the price of our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In 2019, management and our independent registered public accounting firm identified a control deficiency that constituted a material weakness in our internal control over financial reporting. The material weakness was due to a failure in the design and implementation of controls over the evaluation of the terms of our clinical trial contracts for inclusion into our clinical financial model which estimates clinical trial expenses. Specifically, we had failed to properly interpret an expense in our clinical trial contracts which resulted in the over accrual of our clinical trial expenses during 2018 and the first quarter of 2019. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We developed and implemented a remediation plan for this material weakness which included modifications to the design and implementation of certain internal controls, and the material weakness was remediated as of December 31, 2019. Although we have remediated this material weakness, as attested by our independent registered public accounting firm, we can give no assurance that an additional material weakness or significant deficiency in our internal controls over financial reporting will not be identified in the future. Our failure to implement and maintain effective internal controls over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. If we cannot in the future favorably assess the effectiveness of our internal controls over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on the trading price of our common stock. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We have formed in the past, and may form in the future, collaboration partnerships, joint ventures and/or licensing arrangements, and we may not realize the benefits of such collaborations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have current collaboration partnerships for the commercialization of tenapanor in certain foreign countries, and we may form additional collaboration partnerships, create joint ventures or enter into additional licensing arrangements with third parties in the United States and abroad that we believe will complement or augment our existing business. In particular, we have formed collaboration partnerships with KKC for commercialization of tenapanor for hyperphosphatemia in Japan; with Fosun Pharma for commercialization of tenapanor for hyperphosphatemia and IBS-C in China and related territories; and in Canada with Knight for commercialization of tenapanor for IBS-C and hyperphosphatemia. We face significant competition in seeking appropriate collaboration partners, and the process to identify an appropriate partner and negotiate appropriate terms is time-consuming and complex. Any delays in identifying suitable additional collaboration partners and entering into agreements to develop our product candidates could also delay the commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. There is no guarantee that our current collaboration partnerships or any such arrangements we enter into in the future will be successful, or that any collaboration partner will commit sufficient resources to the development, regulatory approval, and commercialization effort for such products, or that such alliances will result in us achieving revenues that justify such transactions. We have received a CRL from the FDA regarding our NDA for the Hyperphosphatemia Indication. While we are pursuing an appeal through the FDR process, and an Advisory Committee has been tentatively scheduled for November 16, 2022, there can be no assurances that the outcome of the Advisory Committee will be positive, or that approval of the NDA for the Hyperphosphatemia Indication will ultimately be granted by the FDA. Even if we are successful in obtaining approval for the NDA, the delay in obtaining such approval may result in delay in the regulatory process for our partners, which could have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Outbreaks of epidemic, pandemic, or contagious diseases, such as the current novel coronavirus (&#8220;COVID-19&#8221;) pandemic or, historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome or the H1N1 virus, could disrupt our business. Economic and health conditions related to the COVID-19 pandemic in the United States and across most of the globe remain uncertain and continue to evolve. The continuing effects of the coronavirus outbreak may result in delays in the manufacture of tenapanor, or in the delivery of key intermediates or raw materials required to manufacture tenapanor or delays in clinical development activities by us, or our collaboration partners. Such effects could also materially and negatively impact our ability to successfully commercialize IBSRELA, and/or, if approved, XPHOZAH, or the ability of our collaboration partners to successfully commercialize such products, if approved for marketing and sale by the foreign regulatory authorities, including our ability, and that of our collaboration partners to educate physicians and patients about the benefits, administration and use of the product. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Although we have reopened our offices and invited our personnel to return to the office, we continue to permit our personnel to work remotely, which could negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber-security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and important agencies and contractors. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The FDA and comparable foreign regulatory agencies may continue to experience operational interruptions or delays, which may impact timelines for regulatory submission, trial initiation and regulatory approval. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The full effects of the COVID-19 remain unknown. The extent to which the outbreak may continue to impact our business, including, our commercialization and manufacturing will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as access to physician offices for our commercial and medical teams, business closures or business disruptions. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may consider strategic transactions, such as acquisitions of companies, asset purchases, and/or in-licensing of products, product candidates or technologies. In addition, if we are unable to access capital on a timely basis and on terms that are acceptable to us, we may be forced to further restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA, our continued efforts to seek approval for our NDA for tenapanor for the Hyperphosphatemia Indication and/or the development of RDX013 through the use of alternative structures. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, spin outs, collaboration partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">up-front, milestone and royalty payments, equity investments and financial support of new research and development candidates including increase of personnel, all of which may be substantial;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates or technologies;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of equity securities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">higher-than-expected acquisition and integration costs;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">write-downs of assets or goodwill or impairment charges;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our CMOs manufacture tenapanor API outside of the United States, and we may seek and obtain approval to commercialize IBSRELA or XPHOZAH outside of the United States, and as a result, a variety of risks associated with international operations could materially adversely affect our business. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We or our collaboration partners may decide to seek marketing approval for IBSRELA or XPHOZAH outside the United States. Additionally we have contractual arrangements with CMOs involving the manufacture of tenapanor API outside of the United States, and we may otherwise engage in business outside the United States, including entering into additional contractual agreements with third-parties. We are subject to additional risks related to entering these international business markets and relationships, including:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">differing United States and foreign drug import and export rules;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">reduced protection for intellectual property rights in foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">different reimbursement systems, and different competitive drugs;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">potential liability resulting from development work conducted by these distributors; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials, including the components of our tenapanor and our product candidates. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We currently occupy a leased facility located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our California facility, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Government Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Despite having received regulatory approval for IBSRELA, and even if we receive regulatory approval for XPHOZAH, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, IBSRELA, and, if approved, XPHOZAH, could be subject to other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Even if a drug is approved by the FDA or foreign regulatory authorities, the manufacturing processes, labeling, packaging, distribution, pharmacovigilance, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP regulations for any clinical trials that we conduct post-approval. As such, we and our third-party contract manufacturers will be subject to continual review and periodic inspections to assess compliance with regulatory requirements. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. Regulatory authorities may also impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure compliance. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">warning or untitled letters, or fines;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">suspension or revocation of existing regulatory approvals;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">suspension of any of our ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">restrictions on our or our contract manufacturers&#8217; operations; or</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize IBSRELA and, if approved, XPHOZAH. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, the FDA&#8217;s policies may change, and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise review and process regulatory submissions in a timely manner, which could negatively impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The ability of the FDA to review and process regulatory submissions can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We and our contract manufacturers are subject to significant regulation with respect to manufacturing of IBSRELA and XPHOZAH. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">All entities involved in the preparation of product for commercial sale, or product candidates for clinical trials, including our existing contract manufacturers are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our products or product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of an NDA or comparable regulatory filing on a timely basis and must adhere to cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection programs. The facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the manufacture of our product or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the contract manufacturers, we cannot control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent suspension of production or closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA, a supplemental NDA or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we fail to comply or are found to have failed to comply with FDA and other regulations related to the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other government agencies. With respect to the commercialization of IBSRELA and/or, if approved, XPHOZAH, we will be restricted from marketing the product outside of its approved labeling, also referred to as off-label promotion. However, physicians may nevertheless prescribe an approved product to their patients in a manner that is inconsistent with the approved label, which is an off-label use. We have implemented compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations regarding off-label promotion. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our product candidates for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Over the past several years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the FFDCA, the False Claims Act, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;qui tam&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim, or caused a false claim to be submitted, to the government for payment. The person bringing a qui tam suit is entitled to a share of any recovery or settlement. Qui tam suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a qui tam suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a qui tam suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">IBSRELA and/or, if approved, XPHOZAH, may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Some participants in clinical studies of tenapanor have reported adverse effects after being treated with tenapanor, including diarrhea, abdominal distension, flatulence and dizziness. We are required to report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate any of the following: FDA regulations, including those laws that require the reporting of true, complete and accurate financial and other information to the FDA; manufacturing standards; or federal and state healthcare fraud and abuse laws and regulations. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Failure to obtain regulatory approvals in foreign jurisdictions would prevent us from marketing our products internationally. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In order to market any product in the EEA (which is composed of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein), and many other foreign jurisdictions, separate regulatory approvals are required. In the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). Before the MA is granted, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in any market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We and our collaboration partners may be subject to healthcare laws, regulation and enforcement; our failure or the failure of any such collaboration partners to comply with these laws could have a material adverse effect on our results of operations and financial conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We and our collaboration partners may be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate as a commercial organization include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the federal physician sunshine requirements under the ACA, which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, and ownership and investment interests held by physicians (as defined by the statute) and their immediate family members;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or pricing information and marketing expenditures; and </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to market our products and adversely impact our financial results. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">additional clinical trials to be conducted prior to obtaining approval;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes to manufacturing methods;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">recall, replacement, or discontinuance of one or more of our products; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">additional record keeping. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, the full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model. In the United States, the ACA was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These new laws, among other things, included aggregate reductions of Medicare payments of 2% per fiscal year to providers that will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a 1% reduction from April 1, 2022 through June 30, 2022, unless additional action is taken by Congress, additional specific reductions in Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024. Recently, there has also been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. By way of example, the Build Back Better Act, if enacted, would introduce substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated &#8220;maximum fair price&#8221; for certain selected drugs or pay an excise tax for noncompliance, and the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D. If the Build Back Better Act is not enacted, similar or other drug pricing proposals could appear in future legislation. Additionally, individual states have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and to encourage importation from other countries and bulk purchasing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">With the commercial launch of IBSRELA, we participate in the Medicaid Drug Rebate Program ("MDRP") and other federal and state government pricing programs in the United States, and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries of these programs. Medicaid drug rebates are based on pricing data that we are obligated to report on a monthly and quarterly basis to the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price (&#8220;AMP&#8221;) and the best price (&#8220;BP&#8221;) for each drug. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. In addition, there is increased focus by the Office of Inspector General within the U.S. Department of Health and Human Services on the methodologies used by manufacturers to calculate AMP, and BP to assess manufacturer compliance with MDRP reporting requirements. If we fail to provide information timely or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for our covered drugs under Medicaid. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the Federal False Claims Act and other laws and regulations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program (the &#8220;340B program&#8221;) in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid. We participate in the 340B program, which is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;), and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We will be obligated to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B-eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs. In addition, legislation may be introduced that, if passed, would further expand the 340B program, such as adding further covered entities or requiring participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, we also participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, we are obligated to report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We are also required to pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for IBSRELA, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate our Medicaid rebate agreement, no federal payments would be available under Medicaid or Medicare for IBSRELA. We cannot assure you that our submissions will not be found to be incomplete or incorrect.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our success and ability to compete depend in part on our ability to obtain, maintain and enforce issued patents, trademarks and other intellectual property rights and proprietary technology in the United States and elsewhere. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We rely on a combination of contractual provisions, confidentiality procedures and patent, trademark, copyright, trade secret and other intellectual property laws to protect the proprietary aspects of our products, product candidates, brands, technologies, trade secrets, know-how and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property rights and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining, maintaining and enforcing other intellectual property rights. We may not be able to obtain, maintain and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights and products by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated by others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We rely in part on our portfolio of issued and pending patent applications in the United States and other countries to protect our intellectual property and competitive position. However, it is also possible that we may fail to identify patentable aspects of inventions made in the course of our development, manufacture and commercialization activities before it is too late to obtain patent protection on them. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee of a third party&#8217;s patents or patent applications, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained and/or enforced in a manner consistent with the best interests of our business. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing, manufacturing and commercializing a product or technologies in a non-infringing manner that would be competitive with one or more of our products or technologies, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for our commercial success. Further, there can be no assurance that we will have adequate resources to enforce our patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Patents have a limited lifespan. In the United States, the natural expiration of a utility patent is generally 20 years from the earliest effective non-provisional filing date. Though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products or services. Patents, if issued, may be challenged, deemed unenforceable, invalidated, narrowed or circumvented. Proceedings challenging our patents or patent applications could result in either loss of the patent, or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. Any successful challenge to our patents and patent applications could deprive us of exclusive rights necessary for our commercial success. In addition, defending such challenges in such proceedings may be costly. Thus, any patents that we may own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an adverse decision may result in a third party receiving a patent right sought by us, which in turn could affect our ability to develop, manufacture or commercialize our products or technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products or product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Any of our pending patent applications will issue as patents;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We were the first to make the inventions covered by each of our patents and pending patent applications;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We were the first to file patent applications for these inventions;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Others will not develop, manufacture and/or commercialize similar or alternative products or technologies that do not infringe our patents;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Any of our challenged patents will be found to ultimately be valid and enforceable;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Any patents issued to us will provide a basis for an exclusive market for our commercially viable products or technologies will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We will develop additional proprietary technologies or products that are separately patentable; or</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">Our commercial activities or products will not infringe upon the patents of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may become subject to third party claims alleging infringement, misappropriation or violation of such third parties&#8217; patents or other intellectual property rights and/or third party claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development, manufacture or commercialization of our products or product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our commercial success depends, in part, on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There have been many lawsuits and other proceedings asserting infringement or misappropriation of patents and other intellectual property rights in the pharmaceutical and biotechnology industries, and companies in the industry have used intellectual property litigation to gain a competitive advantage. While we take steps to ensure that we do not infringe upon, misappropriate or otherwise violate the intellectual property rights of others, there can be no assurances that we will not be subject to claims alleging that the manufacture, use or sale of IBSRELA or XPHOZAH or of any other product candidates infringes existing or future third-party patents, or that such claims, if any, will not be successful. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of IBSRELA or XPHOZAH or other product candidates. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of IBSRELA or XPHOZAH or our other product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights. These proceedings could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents. We may be required to indemnify future collaboration partners against such claims. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If a patent infringement suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, we may be unable to maintain such licenses and the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to redesign it if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, or unable to maintain such licenses when granted. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We also could be ordered to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents or other intellectual property right. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies. If we were to challenge the validity of any such third party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third party claim of patent infringement. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition to infringement claims against us, third parties may also raise similar claims before administrative bodies in the United States or abroad. Such mechanisms include reexamination, post grant review, inter parties review, derivation or opposition proceedings before the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. If third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Such administrative proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or product candidates. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If our intellectual property related to IBSRELA, XPHOZAH, RDX013 or any future product candidates is not adequate or if we are not able to successfully enforce our intellectual property rights, the commercial value of IBSRELA, or our product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or license may fail to result in issued patents in the United States or in foreign countries. Additionally, our research and development efforts may result in product candidates for which patent protection is limited or not available. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any person before the new USPTO Patent Trial and Appeals Board at any time before one year after that person is served an infringement complaint based on the patents. Patents granted by the European Patent Office may be similarly opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in the United States, Europe and other jurisdictions third parties can raise questions of validity with a patent office even before a patent has granted. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. For example, a third party may develop a competitive product that provides therapeutic benefits similar to one or more of our product candidates but has a sufficiently different composition to fall outside the scope of our patent protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to IBSRELA, XPHOZAH, RDX013 or any future product candidates is successfully challenged, then our ability to commercialize such product could be negatively affected, and we may face unexpected competition that could have a material adverse impact on our business. Further, we have reported that we have completed the data analysis from our Phase 2 clinical trial evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia, and that we currently expect that the next steps for the RDX013 program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study. We currently expect to delay further development of RDX013 until such time as we have determined that our available resources support conducting such additional formulation work and an additional clinical study. As a result of this delay in our development program for RDX013, the period of time during which we or our collaboration partners could market RDX013 under patent protection would be reduced. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering a product or product candidate, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability against our intellectual property related to a product or a product candidate, we would lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain and/or enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology, to assign their inventions to us, and endeavor to execute confidentiality agreements with all such parties, we cannot be certain that we have executed such agreements with all parties who may have helped to develop our intellectual property or who had access to our proprietary information, nor can we be certain that our agreements will not be breached by such consultants, advisors or third parties, or by our former employees. The breach of such agreements by individuals or entities who were actively involved in the discovery and design of our products or potential drug candidates, or in the development of our discovery and design platform, including APECCS, could require us to pursue legal action to protect our trade secrets and confidential information, which would be expensive, and the outcome of which would be unpredictable. If we are not successful in prohibiting the continued breach of such agreements, our business could be negatively impacted. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for IBSRELA or our product candidates, our business may be materially harmed. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Following the approval by the FDA for our NDA to market tenapanor for IBS-C, we became eligible to seek and sought patent term restoration under the Hatch-Waxman Act for one of the U.S. patents covering our approved product or the use thereof. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Despite seeking patent term extension for tenapanor or other product candidates, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may not be able to enforce our intellectual property rights throughout the world. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third party, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property and other proprietary information or know-how or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or these employees, consultants and contractors have used or disclosed such intellectual property, including know-how, trade secrets or other proprietary information. In addition, an employee, advisor or consultant who performs work for us may have obligations to a third party that are in conflict with their obligations to us, and as a result such third party may claim an ownership interest in the intellectual property arising out of work performed for us. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Our stock price may be volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the success or lack of success with regards to our commercialization of IBSRELA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the success or lack of success with regards to the Advisory Committee meeting convened as a part of our FDR related to  our NDA seeking marketing approval for tenapanor for the Hyperphosphatemia Indication, and announcements of regulatory decisions regarding our NDA;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">announcements regarding any potential receipt from Nasdaq of notice regarding lack of compliance with the listing requirements of Nasdaq or a de-listing of our common stock; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">results of regulatory inspections of our facilities or those of our contract manufacturing organizations, or specific label restrictions or patient populations for XPHOZAH&#8217;s use, if approved, or changes or delays in the regulatory review process;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">announcements regarding whether XPHOZAH, if approved, alone or with other oral only medications, will be included in the bundled prospective payment system for the treatment of ESRD patients, and the time and manner in which such transition is achieved;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">announcements relating to our current or future collaboration partnerships;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">announcements of therapeutic innovations or new products by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">adverse actions taken by regulatory agencies with respect to our product label, our clinical trials, manufacturing supply chain or sales and marketing activities;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes or developments in laws or regulations applicable to our approved products or our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the success of our testing and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">failure to meet any of our projected timelines or goals with regard to the commercial launch of IBSRELA, or the clinical development and commercialization of any of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the success of our efforts to acquire or license or discover additional product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any intellectual property infringement actions in which we may become involved;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the success of our efforts to obtain adequate intellectual property protection for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">announcements concerning our competitors or the pharmaceutical industry in general;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">achievement of expected product sales and profitability;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">manufacture, supply or distribution shortages;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">actual or anticipated fluctuations in our operating results;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the United States;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">changes in financial estimates or recommendations by securities analysts;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">sales of our common stock by us, our executive officers and directors or our stockholders in the future;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">sales of debt securities and sales or licensing of assets;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">general economic and market conditions and overall fluctuations in the United States equity markets; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the loss of any of our key scientific or management personnel. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;) and the related rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) which require, among other things, our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">During the course of our review and testing of our internal controls, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We may be adversely affected by the global economic environment. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our ability to attract and retain collaboration partners or customers, invest in and grow our business and meet our financial obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, presidential elections, other political influences and inflationary pressures. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including the current inflationary environment and rising interest rates. For example, the 2008 global financial crisis caused extreme volatility and disruptions in the capital and credit markets. We cannot anticipate all the ways in which the global economic climate and global financial market conditions could adversely impact our business in the future. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are exposed to risks associated with reduced profitability and the potential financial instability of our collaboration partners or customers, many of which may be adversely affected by volatile conditions in the financial markets. For example, unemployment and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, our collaboration partners or customers may experience reductions in revenues, profitability and/or cash flow that could lead them to reduce their support of our programs or financing activities. If collaboration partners or customers are not successful in generating sufficient revenue or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. In addition, volatility in the financial markets could cause significant fluctuations in the interest rate and currency markets. We currently do not hedge for these risks. The foregoing events, in turn, could adversely affect our financial condition and liquidity. In addition, if economic challenges in the United States result in widespread and prolonged unemployment, either regionally or on a national basis, or if certain provisions of the Patient Protection and ACA, as amended by the Health Care and Education Reconciliation Act, collectively known as the ACA, are repealed, a substantial number of people may become uninsured or underinsured. To the extent economic challenges result in fewer individuals pursuing or being able to afford our product candidates once commercialized, our business, results of operations, financial condition and cash flows could be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquirer or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnities, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of our common stock. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Additionally, the terms of our loan and security agreements could restrict our ability to pay dividends. Therefore, our stockholders are not likely to receive any dividends on our common stock for the foreseeable future. Since we do not intend to pay dividends, our stockholders&#8217; ability to receive a return on their investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">The United Kingdom&#8217;s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Following a national referendum and enactment of legislation by the government of the United Kingdom, the United Kingdom formally withdrew from the European Union and ratified a trade and cooperation agreement governing its future relationship with the European Union. The agreement, which is being applied provisionally from January 1, 2021, until it is ratified by the European Parliament and the Council of the European Union, addresses trade, economic arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute resolution, among other things. Because the agreement merely sets forth a framework in many respects and will require complex additional bilateral negotiations between the United Kingdom and the European Union as both parties continue to work on the rules for implementation, significant political and economic uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">These developments, or the perception that any related developments could occur, have had and may continue to have a material adverse effect on global economic conditions and financial markets, and may significantly reduce global market liquidity, restrict the ability of key market participants to operate in certain financial markets or restrict our access to capital. Any of these factors could have a material adverse effect on our business, financial condition and results of operations and reduce the price of our common stock.</span></div><div id="i3a1430f6bb744768868435e28c329915_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 23, 2022, we entered into a loan and security agreement pursuant to which the Lenders agreed to provide us a loan facility for up to $50.0 million. Covenants in the loan and security agreement limit our ability to pay dividends or make other distributions. For additional information refer to &#8220;NOTE 8. BORROWING&#8221; in the notes to our condensed financial statements in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Quarterly Report on Form 10-Q.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i3a1430f6bb744768868435e28c329915_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3a1430f6bb744768868435e28c329915_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3a1430f6bb744768868435e28c329915_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement with SLR Investment Corp. provides us the right to borrow an additional $22.5 million on or prior to July 25, 2023; provided that (i) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement and (ii) that we have received approval by the FDA for our NDA for the Hyperphosphatemia Indication by a particular date. On August 1, 2022, we entered into an amendment to the 2022 Loan Agreement to extend the date for approval of our NDA for the Hyperphosphatemia Indication from December 31, 2022 to March 31, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits </span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hcr-ardelyxxroyaltyandmile.htm">Royalty and Sales Milestone Interest Acquisition Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hcr-ardelyxxroyaltyandmile.htm">dated June 29, 2022, by and between Ardelyx, Inc. and Healthcare Royalty Partners IV, L.P.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="slr-ardelyxxfirstamendment.htm">First Amendment to the Loan and Security Agreement dated August 1, 2022, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="secondamendedandrestatedno.htm">Second Amended and Restated Non-Employee Director Compensation Program</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20220630xex311.htm">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20220630xex312.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20220630xex321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL): (i) Condensed Balance Sheets as of June&#160;30, 2022 and December&#160;31, 2021, (ii) Condensed Statements of Operations and Comprehensive Loss for the three and six months ended June&#160;30, 2022 and 2021, (iii) Condensed Statements of Cash Flows for the three and six months ended June&#160;30, 2022 and 2021, and (iv) Notes to Unaudited Condensed Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8224;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicates management contract or management or non-employee director compensatory plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i3a1430f6bb744768868435e28c329915_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3a1430f6bb744768868435e28c329915_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:47.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ardelyx, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Accounting Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>hcr-ardelyxxroyaltyandmile.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ied0ffebe45d64ece94d69869904f651a_1"></div><div style="min-height:87.12pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div><div style="margin-bottom:36pt"><font><br></font></div><div style="margin-bottom:36pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTION COPY</font></div><div style="margin-bottom:36pt;text-align:center"><font><br></font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROYALTY AND SALES MILESTONE INTEREST ACQUISITION AGREEMENT</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dated as of June 29, 2022</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">between</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ardelyx, Inc.</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:126%">HealthCare Royalty Partners IV, L.P.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ied0ffebe45d64ece94d69869904f651a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE I DEFINITIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 1.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Definitions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE II ASSIGNMENT OF THE PURCHASED ASSETS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 2.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Assignment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 2.02.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Royalty Interest Payments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 2.03.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Payments to Seller</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 2.04.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Assumption</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">18</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Organization</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">18</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.02.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Authorizations&#59; Enforceability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.03.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Litigation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.04.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance with Laws</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.05.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conflicts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.06.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Ownership</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.07.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Subordination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.08.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">License Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.09.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Production Agreements.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">23</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.10.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Net Sales&#59; Milestones</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.11.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Broker&#8217;s Fees</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">25</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.12.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.13.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Insolvency Event&#59; Material Adverse Effect</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.14.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Indebtedness and Liens</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.15.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Intellectual Property Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.16.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.17.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exploitation&#59; Material Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 3.18.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Taxes</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 4.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Organization</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 4.02.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Authorization</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 4.03.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Broker&#8217;s Fees</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 4.04.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conflicts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE V COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Consents and Waivers</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.02.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Compliance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">31</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.03.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Confidentiality&#59; Public Announcement&#59; SEC Filings</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">32</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.04.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Further Assurances</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">35</a></font></div></td></tr></table></div><div style="height:115.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;i</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.05.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notice by Seller</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.07.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Negative Covenants</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.08.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Future Agreements</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.09.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Records&#59; Access</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.10.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Regulatory Approvals</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.11.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Misdirected Payments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.12.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Licensee Instruction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.13.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Seller&#8217;s Commercially Reasonable Efforts and Judgment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.14.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Royalty Reports&#59; Notices and Communications from Licensee.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.15.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Maintenance of License Agreement.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.16.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Enforcement of License Agreement and the Production Agreements (excluding the Back-up Manufacturing Agreements).</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.17.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Audits</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 5.18.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Post-Closing Obligations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VI THE CLOSING&#59; CONDITIONS TO CLOSING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 6.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Closing</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 6.02.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Conditions Applicable to Buyer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VII TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 7.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Termination.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 7.02.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Effects of Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VIII MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.01.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Survival</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.02.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Notices</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.03.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Successors and Assigns</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.04.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Indemnification</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.05.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Independent Nature of Relationship&#59; Taxes</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">51</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.06.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Entire Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.07.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendments&#59; No Waivers</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.08.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.09.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Headings and Captions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.10.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Counterparts&#59; Effectiveness&#59; Electronic Signatures</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.11.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.12.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Expenses</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.13.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law&#59; Jurisdiction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 8.14.</a></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a></font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Waiver of Jury Trial</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ied0ffebe45d64ece94d69869904f651a_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">54</a></font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBITS</font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit A&#160;&#160;&#160;&#160;&#8211;&#160;&#160;&#160;&#160;License Agreement</font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit B&#160;&#160;&#160;&#160;&#8211;&#160;&#160;&#160;&#160;Form of Assignment</font></div><div style="height:115.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;ii</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit C&#160;&#160;&#160;&#160;&#8211;&#160;&#160;&#160;&#160;Form of Licensee Instruction</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULES</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.01(a)&#8211;&#160;&#160;&#160;&#160;Permitted Liens</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.01 &#8211;&#160;&#160;&#160;&#160;Subsidiaries</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.03&#160;&#160;&#160;&#160;&#8211;&#160;&#160;&#160;&#160;Litigation</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.08(g) &#8211;&#160;&#160;&#160;&#160;Sublicenses</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.08(n) &#8211;&#160;&#160;&#160;&#160;Agreements</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.09(a) &#8211; &#160;&#160;&#160;&#160;Production Agreements</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.09(i) &#8211;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.10(a) &#8211;&#160;&#160;&#160;&#160;Net Sales through end of period immediately preceding Closing Date</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.10(b) &#8211;&#160;&#160;&#160;&#160;Milestone payments through end of period immediately preceding Closing Date</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.14(a) &#8211;&#160;&#160;&#160;&#160;Indebtedness</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.14(b) &#8211;&#160;&#160;&#160;&#160;Liens</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(a) &#8211;&#160;&#160;&#160;&#160;Ardelyx Controlled Patents</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(c) &#8211; &#160;&#160;&#160;&#160;Disputes</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(e) &#8211; &#160;&#160;&#160;&#160;Ardelyx Controlled Patent Claims</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(f) &#8211;&#160;&#160;&#160;&#160;Dispute Regarding Ardelyx Controlled Patents</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(k)&#8211;&#160;&#160;&#160;&#160;Lapse, Expiration or Termination of Ardelyx Controlled Patents</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule  3.15(p) &#8211; &#160;&#160;&#160;&#160;Third Party Patent Rights</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(q) &#8211; &#160;&#160;&#160;&#160;Patent Applications</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(r) &#8211; &#160;&#160;&#160;&#160;Third Party Infringement</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(s) &#8211;&#160;&#160;&#160;&#160;&#91;Reserved&#93;</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(t) &#8211;&#160;&#160;&#160;&#160;Third Party Exploitation Disputes</font></div><div style="padding-left:144pt;text-align:justify;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.15(v)&#160;&#160;&#160;&#160;Validity and Prior Art</font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.03(f) &#8211; &#160;&#160;&#160;&#160;Publication Format</font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 5.16 &#8211;&#160;&#160;&#160;&#160;Enforcement of License Agreement and Production Agreements (excluding the Back-up Manufacturing Agreements</font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 8.03 &#8211;&#160;&#160;&#160;&#160;Competitor</font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 8.12&#160;&#160;&#160;&#160;&#8211;&#160;&#160;&#160;&#160;Expenses</font></div><div><font><br></font></div><div style="height:115.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;iii</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><div id="ied0ffebe45d64ece94d69869904f651a_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ROYALTY AND SALES MILESTONE INTEREST ACQUISITION AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is made and entered into as of June 29, 2022 by and between Ardelyx, Inc., a corporation organized under the laws of the State of Delaware, and HealthCare Royalty Partners IV, L.P., a limited partnership organized under the laws of the State of Delaware (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Seller (this and other capitalized terms used in these Recitals shall have the meanings provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below) and Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.), a company organized under the laws of Japan, have entered into that certain License Agreement, dated as of November 27, 2017, with respect to the Product, a true, correct and complete copy of which, together with all amendments, supplements, restatements or other modifications thereto, is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, pursuant to the License Agreement, subject to the terms and conditions set forth therein, Seller has been and remains entitled to receive the Royalty Interest&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Seller wishes to sell, assign, convey and transfer to Buyer, and Buyer wishes to accept the sale, assignment, conveyance, and transfer from Seller of, the right to receive all payments in respect of the Royalty Interest, upon and subject to the terms and conditions hereinafter set forth&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in consideration of the mutual covenants, agreements representations and warranties set forth herein, the Parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9.7pt"><br><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Definitions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following terms, as used herein, shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to Seller, the acquisition by any Person, in a single transaction or in a series of related transactions, of (a)&#160;assets of Seller which constitute all or substantially all of the assets of Seller, (b)&#160;at least a majority of the Voting Stock of Seller or (c) all of Seller&#8217;s assets, rights and obligations regarding the Product or the Lead Licensed Compound, in each case whether or not involving a merger or consolidation with such other Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Patents listed in Exhibit C to the License Agreement, and any Patents issuing after the Effective Date in the Territory claiming priority to any such Patents listed on Exhibit C to the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any Person that controls, is controlled by, or is under common control with another Person.  For purposes of this definition, &#8220;control&#8221; shall mean (a) in the case of corporate entities, direct or indirect ownership of at least &#91;***&#93; of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or indirect ownership of at least &#91;***&#93; of the equity interest with the power to direct the management and policies of such non-corporate entities. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning given in the preamble hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment Number 2 of the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Amendment Number 2 of the License Agreement, dated as of April 11, 2022, by and between Seller and the Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means active pharmaceutical ingredient, which is also commonly referred to as drug substance.  For the avoidance of doubt, API shall include any prodrug form.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ardelyx &#91;***&#93; Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Patents that &#91;***&#93; (i) inventions that &#91;***&#93; of a Licensed Compound or a Licensed Product, (ii) &#91;***&#93; for a Licensed Product or Licensed Compound, or (iii) &#91;***&#93; a Licensed Product in the Field.  Ardelyx &#91;***&#93; Patents specifically excludes Excluded Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ardelyx Controlled Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, Licensed Patents, Ardelyx &#91;***&#93; Patents and Joint Patents, in each case, to the extent such Patents are subject to the License Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ardelyx Sole Invention Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Patent claiming Sole Program Know-How owned solely by Seller or its Affiliates, in each case, to the extent such Patents are subject to the License Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Bill of Sale pursuant to which Seller shall assign, convey and transfer to Buyer, Seller&#8217;s rights and interests in and to the Purchased Assets, which Bill of Sale shall be substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Back-up Manufacturing Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any separate manufacturing and supply agreement, between Seller and a contract manufacturing organization under which Seller acquires or intends to acquire API for delivery to Licensee under the Manufacturing and Supply Agreement for Development&#59; Interim Commercial Supply Letter or Supply Agreement for Commercial, as may be amended, supplemented, restated or otherwise modified or replaced from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Backup Licensed Compounds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) any compound, other than the Lead Licensed Compound, that is claimed by the Compound Patent(s) and (ii) any &#91;***&#93; of any such compound described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Seller or its Affiliates may Develop during the term of the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Title 11 of the United States Code entitled &#8220;Bankruptcy&#8221; and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions (domestic or foreign) from time to time in effect affecting the rights of creditors generally.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of the State of New York or in Japan, or any day on which banking institutions located in the State of New York or in Japan are required by law or other governmental action to close.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean HealthCare Royalty Partners IV, L.P., a limited partnership organized under the laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Buyer Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each of Buyer and its Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of any Person shall mean any and all shares, interests, ownership interest units, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) equity of such Person, including any preferred stock, but excluding any debt securities convertible into such equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any claim, demand, action or proceeding (including any investigation by any Governmental Authority).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any clinical study of a pharmaceutical product on human subjects to assess the dosing, safety and&#47;or efficacy of such pharmaceutical product, including but not limited to phase 1 clinical trials, phase 2 clinical trials and phase 3 clinical trials and, if imposed by the Regulatory Authorities as a condition to Regulatory Approval, phase 4 clinical trials.  For the avoidance of doubt, post-marketing surveillance clinical studies are not Clinical Trials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.01(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean $10,000,000.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the date of this Agreement, which is the date all of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are fulfilled or waived in writing by the applicable Party, as set forth in such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any prescription pharmaceutical product which comprises two (2) or more APIs, at least one (1) of which is the Lead Licensed Compound, that is sold either as a fixed dose or as separate doses in a single package.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product or a Combination Product, any and all activities directed to the marketing, promotion, distribution, offering for sale, and sale of such Product or Combination Product in the Territory, and interacting with Regulatory Authorities regarding the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to the efforts to be expended, or considerations to be undertaken, by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitive Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning provide in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compound Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Patents listed in Exhibit B to the License Agreement, and any Patents issuing after the Effective Date in the Territory claiming priority to any such Patents listed on Exhibit B to the License Agreement.  </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all information, whether communicated orally or in any physical form, including without limitation, financial and all other information which Disclosing Party or its authorized Representatives provide to the Receiving Party, together with such portions of analyses, compilations, studies, or other documents, prepared by or for the Receiving Party and its Representatives, which contain or are derived from information provided by Disclosing Party, and shall include the terms of the Transaction Documents.  Without limiting the foregoing, information shall be deemed to be provided by Disclosing Party to the extent it is learned or derived by Receiving Party or Receiving Party&#8217;s Representatives (a) from any inspection, examination or other review of books, records, contracts, other documentation or operations of Disclosing Party, (b) from communications with authorized Representatives of Disclosing Party or (c) created, developed, gathered, prepared or otherwise derived by Receiving Party while in discussions with Disclosing Party.  However, Confidential Information does not include any information which Receiving Party can demonstrate (i) is or becomes part of the public domain through no fault of Receiving Party or its Representatives, (ii) was known by Receiving Party on a non-confidential basis prior to disclosure, or (iii) was independently developed by Persons who were not given access to the Confidential Information disclosed to Receiving Party by Disclosing Party.  For the avoidance of doubt, Confidential Information shall include all Evaluation Material (as defined in the Confidentiality Agreement) previously disclosed by Seller to Buyer under the Confidentiality Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Confidentiality Agreement by and between HealthCare Royalty Management, LLC and Seller, dated as of December 7, 2020. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any agreement, contract, obligation, or undertaking.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to an item of Know-How, Patent or other Intellectual Property Rights, the ability and authority of a Party or its Affiliates, whether arising by ownership, possession, or pursuant to a license or sublicense, to grant licenses, sublicenses, or other rights to the other Party under or to such item of Know-How, Patent or Intellectual Property Rights as provided for in the License Agreement without breaching the terms of any agreement between such Party and any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Deposit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the deposit account control agreement entered into by the Depositary Bank, Buyer and the Seller, which shall be in form and substance reasonably acceptable to Buyer and Seller, as amended, supplemented or otherwise modified from time to time and any replacements thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Depositary Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means such bank or other financial institution approved by Buyer and Seller, including any successor Depositary Bank appointed pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all internal and external research, development and regulatory activities regarding a Lead Licensed Compound and Product, as the case may be.  This includes (a) research, preclinical testing, toxicology, route of synthesis, non-clinical activities, formulation and clinical studies of a Lead Licensed Compound and a Product&#59; and (b) preparation, submission, review, and development of data or information for the purpose of submission to a governmental authority to obtain authorization to conduct Clinical Trials and Regulatory Approval of a Product.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall include development and regulatory activities for additional forms, formulations, or indications for a Product after Regulatory Approval of such Product, including clinical trials initiated following receipt of Regulatory Approval or any Clinical Trial to be conducted after a Regulatory Approval which was mandated by the </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved indication.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be construed accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Quality Assurance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain Quality Agreement, dated as of June 10, 2020, by and between the Seller and Licensee, as may be amended, supplemented, restated or otherwise modified or replaced from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Confidential Information, the Party disclosing the Confidential Information to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any opposition, interference proceeding, reexamination proceeding, cancellation proceeding, re-issue proceeding, invalidation proceeding, inter parties review proceeding, injunction, claim, lawsuit, proceeding, hearing, investigation, complaint, arbitration, mediation, demand, decree, dispute or disagreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Dispute shall not include any exchanges between Seller and&#47;or Licensee and the Japan Patent Office relating to the examination of patent applications included in the Ardelyx Controlled Patents or the Licensee Controlled Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means November 27, 2017.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence of one or more of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">any &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Seller fails to &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Seller fails to&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Seller shall be in breach of or in default under &#91;***&#93;, and such breach or default would reasonably be likely to cause a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the occurrence of a &#91;***&#93;&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">the occurrence of &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934 and the regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Liabilities and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each liability or obligation of Seller or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether known or unknown, and whether under the License Agreement, any Production Agreement, any Transaction Document or otherwise.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Patents claiming aspects of Seller&#8217;s proprietary platform technology known as Ardelyx Primary Enterocyte and Colonocyte Culture System.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.05(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to a product such as the Product, the manufacture, use, sale, offer for sale (including marketing and promotion), importation, distribution or other commercialization&#59; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exploitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the correlative meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the treatment of any cardiorenal diseases and conditions, but excluding cancer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any government, court, regulatory or administrative agency or commission, or other governmental authority, agency or instrumentality, whether foreign, federal, state or local, including any applicable Patent Office or any other government authority in any country.  For the avoidance of doubt, Governmental Authorities include Regulatory Authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of any Person means any indebtedness for borrowed money, obligation evidenced by a note, bond, debenture or similar instrument, or guarantee of any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.05(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnity Threshold Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Insolvency Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the following with respect to Seller&#58;</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">(i) an involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of competent jurisdiction seeking (x)&#160;relief in respect of Seller or any material Subsidiary, or of a material part of the property of Seller or any material Subsidiary, under any Bankruptcy Law now or hereafter in effect, (y)&#160;the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for Seller or any material Subsidiary or for a material part of the property of Seller or any material Subsidiary or (z)&#160;the winding-up or liquidation of Seller or any Subsidiary, which proceeding or petition shall continue undismissed for 60&#160;calendar days or (ii) an order of a court of competent jurisdiction approving or ordering any of the foregoing shall be entered&#59;</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Seller or any material Subsidiary shall (i)&#160;voluntarily commence any proceeding or file any petition seeking relief under any Bankruptcy Law now or hereafter in effect, (ii)&#160;apply for the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for Seller or any material Subsidiary or for a material part of the property of Seller or any material Subsidiary, (iii)&#160;fail to contest in a timely and appropriate manner any proceeding or the filing of any petition described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause&#160;(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this definition, (iv)&#160;file an answer admitting the material allegations of a petition filed against it in any proceeding described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this definition, (v)&#160;make a general assignment for the benefit of creditors or (vi)&#160;wind up or liquidate (except as permitted under this Agreement)&#59;</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.69pt">Seller or any material Subsidiary shall take any action in furtherance of or for the purpose of effecting, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this definition&#59; or</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.01pt">Seller or any material Subsidiary shall become unable, admit in writing its inability, or fail generally, to pay its debts as they become due.<br></font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Instruction to Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Patents, Trademarks, service marks, Know-How, trade names, registered designs, design rights, copyrights (including rights in computer software), domain names, database rights and any rights or property similar to any of the foregoing in any part of the world, whether registered or not, together with the right to apply for the registration of any such rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interim Commercial Supply Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that separate letter agreement entered into between Seller and Licensee as of March 4, 2021, as may be amended, supplemented, restated or otherwise modified or replaced from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Payment Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) Buyer has received notice in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> evidencing the achievement specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to the related Investment Payment, (b) Seller shall have complied in all material respects with its material covenants and obligations hereunder and under the Transaction Documents, (c) no Material Adverse Effect has occurred, (d) with respect to the Investment Payment described in Section 2.03(b)(i)(A) only, the representations and warranties made by Seller in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will be true as of the date of such Investment Payment, unless any of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedules 3.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.08(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.08(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.14(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.15(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.15(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.15(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.15(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.15(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.15(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have been amended or supplemented since the Closing Date, and such amendment or supplement to such Schedule could reasonably be expected to have a Material Adverse Effect, and (e) there is no event or circumstance that, upon notice or the passage of time, or both, would constitute or give rise to any breach or default in the performance of the Seller under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Return Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any inventions and Know-How that are invented jointly by employees or independent contractors of Seller or Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Patent claiming any invention within the Joint Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all inventions, discoveries, data, information (including scientific, technical or regulatory information), trade secrets, processes, means, methods, practices, formulae, instructions, procedures, techniques, materials, technology, results, analyses, designs, drawings, computer programs, apparatuses, specifications, technical assistance, laboratory, nonclinical and clinical data (including laboratory notes and notebooks), and other material or know-how, in written, electronic or any other form, whether or not confidential, proprietary or patentable, including without limitation&#58; development technology&#59; biology, chemistry, pharmacology, toxicology, drug stability, Manufacturing and formulation, test procedures, synthesis, purification and isolation techniques, quality control data and information, methodologies and techniques&#59; information regarding clinical and nonclinical safety and efficacy studies, including study designs and protocols, marketing studies, absorption, distribution, metabolism and excretion studies&#59; assays and biological methodology.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Knowledge of Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to Seller, as applicable, the knowledge of &#91;***&#93; and any successors to such persons with similar responsibilities, regardless of title, relating to a particular matter without any obligation to inquire or otherwise investigate relating to a </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">particular matter&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that such persons shall be deemed to have knowledge, if, in the prudent exercise of his or her duties and responsibilities in the ordinary course of business, such person should have known of such matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, collectively, all U.S. or non-U.S. federal, state, provincial, territorial, municipal or local statute, treaty, rule, regulation, ordinance, code or administrative or judicial precedent or authority, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority (including any Regulatory Authority), or any similar provision having the force or effect of law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lead Licensed Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the compound tenapanor, as further described on Exhibit A to the License Agreement, and any &#91;***&#93; of such compound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean that certain License Agreement, dated as of November 27, 2017, by and between Seller, as licensor, and Licensee, as licensee, with respect to the Product, as amended by Amendment Number 1 of the License Agreement dated June 23, 2020, and Amendment Number 2 of the License Agreement, and as may be amended, supplemented, restated or otherwise modified from time to time, subject to Buyer&#8217;s rights under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.07(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the termination </font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the License Agreement under Section 11.02, Section 11.03 or Section 11.04 of the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Compounds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Lead Licensed Compound and any and all Backup Licensed Compounds</font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Patents</font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) the Compound Patents, (b) the Additional Patents, and (c) all Ardelyx Sole Invention Patents&#59; </font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in the case of (b) and (c) above, such Patents claim any inventions necessary or useful for the Exploitation of the Licensed Compounds and&#47;or Licensed Products pursuant to the terms and conditions of the License Agreement.  Licensed Patents exclude Ardelyx &#91;***&#93; Patents and the Excluded Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all pharmaceutical preparations, compositions and formulations in forms suitable for human applications containing a Licensed Compound as an active ingredient.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Kyowa Kirin Co., Ltd. (formerly known as Kyowa Hakko Kirin Co., Ltd.), a company organized under the laws of Japan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee &#91;***&#93; Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Patents (a) that &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such Patents claim (i) inventions that &#91;***&#93; a Licensed Compound or a Licensed Product, (ii) &#91;***&#93; for a Licensed Product or Licensed Compound, or (iii) is &#91;***&#93; a Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee Controlled Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, collectively, Licensee Sole Invention Patents and Licensee &#91;***&#93; Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee Instruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the written instruction from Seller to Licensee, substantially in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensee Sole Invention Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Patent claiming Sole Program Know-How owned solely by Licensee to the extent such Patents are subject to the License Agreement.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any lien, hypothecation, charge, security agreement, security interest, mortgage, pledge or any other encumbrance, right or claim of any Person of any kind whatsoever whether choate or inchoate, filed or unfiled, noticed or unnoticed, recorded or unrecorded, contingent or non-contingent, material or non-material, known or unknown.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lockbox Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the &#8220;deposit account&#8221; (as defined in Article 9 of the UCC), investment account or other account in which funds are held or invested to or for the credit or account of any Party, established and maintained at any Depositary Bank solely for the purpose of receiving remittance of Royalty Interest Payments and disbursement thereof as provided herein, and any successor Lockbox Account entered into in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all direct or indirect liabilities, claims, actions, damages, losses or expenses, including interest, penalties, and reasonable lawyers&#8217; fees and disbursements.  In calculating Losses, the legal duty to mitigate on the part of the Party suffering the Loss shall be taken into account.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means activities in connection with the synthesis, manufacture, processing, formulating, testing (including, without limitation quality control, quality assurance, lot release testing, and development of any relevant analytical methods), bulk packaging or storage and delivery of Licensed Compound or Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing and Supply Agreement for Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that separate manufacturing and supply agreement effective as of April 9, 2018 between Seller and Licensee, as amended, supplemented, restated or otherwise modified from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any amounts due, paid or payable for achievement of the Milestones, including any interest payable pursuant to Section 6.03 of the License Agreement, without any deduction or set-off of any kind, including any deduction or set-off under the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the sales related milestones captioned as &#8220;Milestone Payment&#91;s&#93;&#8221; pursuant to Section 6.03(a) of the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in the License Agreement (whether or not the License Agreement remains in effect).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Seller or Buyer as the context indicates and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Seller and Buyer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the respective patent office in any jurisdiction, including the United States Patent and Trademark Office, the European Patent Organisation, the Japan Patent Office and any comparable foreign patent office, for any Ardelyx Controlled Patents or Licensee Controlled Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) all national, regional and international patents and patent applications, including provisional patent applications, (b) all patent applications filed either </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from such patents, patent applications or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b) and (c)), and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Liens described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any individual, sole proprietorship, corporation, partnership, association, joint-stock company, trust, unincorporated organization, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PMDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Pharmaceuticals and Medical Devices Agency in Japan or any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any pharmaceutical product, drug product, preparation, formulation or dosage form that has the Lead Licensed Compound as at least one API.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Production Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each of the Back-Up Manufacturing Agreement, the Manufacturing and Supply Development Agreement, the Interim Commercial Supply Letter and the Development Quality Assurance Agreement as may be amended, supplemented, restated or otherwise modified or replaced from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchased Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) the Royalty Interest and (b) all proceeds (as defined under the UCC) of any of the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Confidential Information disclosed by a Party hereto, the other Party which is receiving such Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all approvals (including without limitation pricing and reimbursement approvals), product or establishment licenses, registrations, or authorizations of any regional, federal, state, or local Regulatory Health Authority, department, bureau, or other governmental entity, necessary to commercially distribute, sell or market a Licensed Product in a regulatory jurisdiction, including, where applicable, (a) pricing or reimbursement approval in such jurisdiction, (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto), (c) labeling approval and (d) technical, medical and scientific licenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any court or government body, whether national, supra-national, federal, state, local, foreign or provincial, including any political subdivision thereof, including any department, commission, board, bureau, agency, or other regulatory or administrative governmental authority or instrumentality, and further including any quasi-governmental Person or entity exercising the functions of any of these.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Health Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any applicable national (for example the PMDA), supra-national, regional, state, provincial or local regulatory health authority, department, bureau, commission, council, or other government entity regulating or otherwise exercising authority with respect to the Exploitation of Licensed Compounds or Licensed Products in the Territory pursuant to the terms and conditions of the License Agreement, including any such entity involved in the granting of Regulatory Approval for pharmaceutical products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, directors, officers, employees, agents, co-investors, advisors, potential investors, underwriters, rating agencies, permitted assignees, transferees or successors-in-interest, sources of financing and trustees of such Person (other than competitors of Buyer and its Affiliates).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) any amounts due, paid or payable to Seller pursuant to Section 6.04 of the License Agreement on and after the Closing Date and (b) any amounts payable to Seller as a result of Net Sales of the Licensed Product in the Field and in the Territory pursuant to any New Arrangement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the amount due to Buyer under any New Arrangement shall not exceed the amount that would have been due Buyer under Section 6.04 and 6.03(a) of the License Agreement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in each case of clauses (a) and (b), without any deduction or set-off of any kind, other than as set forth in clause (b).  Without limiting the foregoing, if the License Agreement is terminated and Seller or its Affiliates Commercialize the Product in the Territory pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any amounts received by or on behalf of Seller or its Affiliates (or its or their licensees) for such Commercialization less any such amounts that are allocated to the cost of manufacturing and supplying the Product, or which are intended to reimburse Seller, its Affiliates or licensees for expenses incurred outside of the scope of the calculation of Net Sales, which are itemized by Seller in each royalty report to the extent such expenses are being taken as a deduction from net sales for which royalties are payable, shall be treated as &#8220;Net Sales&#8221; subject to the same royalty rate set forth in Section 6.04 of the License Agreement, and the product of such net sales times such royalty rate shall be Royalties hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean (a) the Royalties</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (b) the Milestone Payments arising after the Closing Date, (c) any payments made in lieu of the Royalties or the Milestone Payments or in satisfaction of the obligation to pay the Royalties or the Milestone Payments, including any amounts payable to Buyer pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in satisfaction of the obligation to pay Royalties or the Milestone Payments&#59; provided, that (i) such amounts payable under this subsection (c) as a result of enforcement of the License Agreement pursuant to  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall include any damages, penalties, fees or expenses payable in connection with the enforcement of the License Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the extent such damages, penalties, fees or expenses relate to amounts otherwise due under Sections 6.03 or 6.04 of the License Agreement, and (ii) the amounts due under this subsection (c) shall not include duplication of any corresponding Royalty Interest Payments or Milestone Payments, and (d) all amounts payable by Licensee (or other licensee pursuant to a New Arrangement) pursuant to Section 365(n) of the Bankruptcy Law in the event of rejection of the License Agreement (or other licensee agreement pursuant to a New Arrangement).  For the avoidance of doubt, the Royalty Interest shall not include the Excluded Liabilities and Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Interest Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the payment of the Royalty Interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to each calendar quarter, the report (including any certifications in respect thereof) required to be prepared and delivered pursuant to Section 6.07 of the License Agreement.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Ardelyx, Inc., a corporation organized under the laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Seller Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each of Seller, its Affiliates and any of their respective partners, directors, managers, officers, employees and agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Set-Off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any right of set-off, counterclaim, credit, reduction or deduction by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sole Program Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all inventions and other Know-How invented by employees or independent contractors of Seller or Licensee in such Party&#8217;s performance of the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person that is not a distributor or an Affiliate of the Licensee who is granted a sublicense under the License Agreement by the Licensee or its Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, at any time, any entity of which more than fifty percent (50%) of the outstanding Voting Stock or other equity interest entitled ordinarily to vote in the election of the directors or other governing body (however designated) is at the time beneficially owned or controlled directly or indirectly by such Person, by one or more such entities or by such Person and one or more such entities.  Unless otherwise indicated herein, &#8220;Subsidiary&#8221; shall refer a &#8220;Subsidiary&#8221; of Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Supply Agreement for Commercial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that separate manufacturing and supply agreement, between Seller and the Licensee to be entered into pursuant to Section 5.01(c) of the License Agreement, providing for the manufacture of the Lead Licensed Compound and Product, as may be amended, supplemented, restated or otherwise modified or replaced from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Japan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any Person other than Seller or Buyer or their respective Affiliates. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to any Third Party, any and all issued patents and pending patent applications as of the date of this Agreement, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms (including regulatory extensions), and all supplementary protection certificates, together with any foreign counterparts thereof anywhere in the world, of such Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any registered trademark, application for registration thereof, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, collectively, this Agreement, the Assignment, the Deposit Agreement and the Instruction to Payor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall include the use, manufacture, marketing, sale, offer for sale, importation, distribution or commercialization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean Capital Stock issued by a company, or equivalent interests in any other Person, the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such Person, even if the right so to vote has been suspended by the happening of such contingency.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:5.04pt"><br><br>ASSIGNMENT OF THE PURCHASED ASSETS</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Assignment.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, Seller shall assign, transfer and convey to Buyer, free and clear of all Liens (other than any Permitted Liens or Liens in favor of Buyer) and subject to the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the other provisions of this Agreement, the Purchased Assets, and Buyer shall accept such assignment, transfer and conveyance from Seller.  Such assignment, transfer and conveyance shall be evidenced by the execution and delivery of the Assignment by Seller in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">It is the intention of the Parties hereto that the assignment, transfer and conveyance contemplated by this Agreement be, and is, a true, complete, absolute and irrevocable assignment, transfer and conveyance by Seller to Buyer of all of Seller&#8217;s right, title and interest in and to the Purchased Assets, free and clear of all Liens (other than any Liens in favor of Buyer).  Neither Seller nor Buyer intends the transactions contemplated by this Agreement to be, for any purpose (other than financial accounting purposes), characterized as a loan from Buyer to Seller or a pledge, a security interest, a financing transaction or a borrowing.  Each of Seller and Buyer hereby waives, to the maximum extent permitted by applicable Law, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any right to contest or otherwise assert that this Agreement does not constitute a true, complete, absolute and irrevocable assignment, transfer and conveyance by Seller to Buyer of all of Seller&#8217;s right, title and interest in and to the Purchased Assets under applicable Law, which waiver shall, to the maximum extent permitted by applicable Law, be enforceable against Seller in any bankruptcy or insolvency proceeding relating to Seller.  Not in derogation of the foregoing statement of the intent of the Parties hereto in this regard and for the purposes of providing additional assurance to Buyer (i) Seller does hereby grant to Buyer as security for the payment of amounts to Buyer equal to the Royalty Interests as they become due and payable, a security interest in and to (x) all right, title and interest of Seller, in, to and under the Royalty Interests&#59; and (y) any &#8220;proceeds&#8221; (as such term is defined in the UCC) of the items set forth </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Seller does hereby authorize Buyer, from and after the Closing, to file such financing statements (and continuation statements with respect to such financing statements when applicable) in such manner and such jurisdictions as are necessary or appropriate to perfect such security interest and (ii) upon the occurrence of the Termination Date, Buyer shall, at the sole cost and expense of Seller, release its Liens in the Collateral (and execute and deliver any termination or release documents reasonably requested by Seller in connection therewith) and all rights, title and interests, in, to and under the Collateral shall revert to Seller.  Notwithstanding the foregoing, the Collateral does not include rights held under a license or other agreement that are not assignable by their terms without the consent of the licensor or counterparty thereof (but only to the extent such restriction on assignment is effective under Section 9-406, 9-407, 9-408 or 9-409 of the UCC (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code) or principles of equity).  </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Royalty Interest Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Effective as of the execution and delivery of the Assignment at the Closing and subject to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Seller and Buyer agree that Buyer shall have all right, title, interest in and to the Purchased Assets, and is entitled to receive all Royalty Interest Payments payable to Seller under the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#91;reserved&#93; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Buyer shall be entitled to receive 100% of the Royalty Interest Payments from the Closing Date through the Termination Date. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Payments to Seller.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Subject to the terms and conditions set forth herein, Buyer shall pay Seller the Closing Amount by wire transfer of immediately available funds as directed by Seller promptly at the Closing, but in any event, within one&#160;(1) Business Day of the Closing Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Investment Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Following the Closing, Buyer shall, subject to the conditions set forth below and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, make the following one-time payments (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Investment Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to Seller&#58; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">upon approval of a new drug application for the Lead Licensed Compound for application in the Field by the PMDA, Buyer shall make a payment to Seller of $5,000,000&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">a payment to Seller of $5,000,000 if Licensee&#8217;s Net Sales exceed &#91;***&#93; for the calendar year 2025.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">The Investment Payment provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)(i)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be due and payable promptly, but in any event within ten&#160;(10) Business Days after the date that the Investment Payment Conditions for such Investment Payment have been met, by wire transfer of immediately available funds as directed by Seller.  Buyer agrees to retain in the Lockbox Account any Royalty Interest Payments paid to Seller from Licensee in the first quarter of 2026 relating to Licensee achieving the Net Sales milestone set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon deposit of such amounts, Buyer shall direct the Depository Bank to pay to Seller the Investment Payment then due Seller pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)(i)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> within five (5) Business Days of the date on which the related Investment Payment Condition has been met. In the event amounts deposited into the Lockbox Account are insufficient to pay the full amount of such Investment Payment, Buyer shall direct the Depository Bank to pay any subsequent deposits into the Lockbox Account to Seller, to be applied towards such Investment Payment Amount, until the aggregate amounts so paid to Seller equal $5,000,000.  If such Investment Payment is not earned by Seller for the calendar year 2025, Buyer may direct the Depository Bank to pay Royalty Interests Payments on deposit in the Lockbox Account to Buyer.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Buyer shall have the right to deduct from any Investment Payment the amount of any Losses resulting from Seller&#8217;s breach of any representation or warranty set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as of the date on which such representation or warranty is made or any covenant set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that Buyer makes a good faith determination that it is entitled to Set-Off (and of the amount thereof) from any Investment Payment, Buyer shall notify Seller, in reasonable detail, of the basis of Buyer&#8217;s claim to a right of Set-Off (and the amount thereof) within thirty (30) days after the date that the Investment Payment Conditions for such Investment Payment have been met.  In the event that Seller disagrees, either with respect to the basis of the claim or the amount in controversy, then such dispute shall be escalated to the senior leadership of the Parties for resolution in good faith (which senior leadership shall be the Chief Executive Officer of Seller and the Chief Executive Officer of Buyer), within thirty (30) days of the date on which such dispute is referred to them If the senior leadership, notwithstanding their good faith efforts, is unable to resolve such dispute within such thirty (30) day period, then Buyer may make such Set-Off.  For the avoidance of doubt, (a) Buyer&#8217;s exercise of the foregoing right of Set-Off will not limit Buyer&#8217;s right to pursue any other available remedies in law or equity, including as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and (b) Seller retains its right to challenge such Set-Off and does not waive its right, nor shall its right be limited by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to pursue any remedy in law or equity.  The prevailing party in the final resolution of any dispute regarding such Set-Off will be entitled to recover from the other party all of its reasonable and documented out-of-pocket costs and expenses arising from such proceedings (including attorneys&#8217; fees incurred both before and through the completion of such proceedings).</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">No Assumption.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision in this Agreement or any other Transaction Document or writing to the contrary, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Buyer is accepting the purchase and assignment of only the Purchased Assets and is not assuming any Excluded Liabilities and Obligations.  All Excluded Liabilities and Obligations shall be retained by and remain obligations and liabilities solely of Seller or its Affiliates</font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Lockbox Account </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Seller shall, on or prior to the date that is sixty (60) days following the Closing, enter into a Deposit Agreement with the Depositary Bank with respect to the Lockbox Account.  Seller shall deliver instructions to Licensee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Instruction to Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with respect to any Royalty Interest Payments (which instruction shall be in form and substance reasonably satisfactory to Buyer) to remit such Royalty Interest Payments to the Lockbox Account.  To the extent any such Royalty Interest Payments are paid directly to Seller, Seller shall remit to Buyer all such amounts within fifteen (15) Business Days of Knowledge of Seller of such receipt of any such funds.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Buyer shall have the right to exercise all of its rights and remedies under this Agreement including, without limitation, directing the Depositary Bank to transfer all of the funds in the Lockbox Account to Buyer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Seller shall have no right to terminate the Lockbox Account without Buyer&#8217;s prior written consent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, without Buyer&#8217;s consent to the change of location of such accounts (provided such location is in the United States), Seller shall have the right from time to time to establish a replacement Lockbox Account with a replacement Depositary Bank, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> such replacement Depositary Bank entered into a Deposit Agreement with respect to such replacement accounts effective no later than the date of replacement.  For purposes of this Agreement, any reference to the &#8220;Lockbox Account&#8221;, &#8220;Depositary Bank&#8221; and &#8220;Deposit Agreement&#8221; shall refer to such replacement Lockbox Account, Depositary Bank, or Deposit Agreement, as the context requires.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:0.38pt"><br><br>REPRESENTATIONS AND WARRANTIES OF SELLER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller hereby represents and warrants to Buyer that the following representations are true and complete as of the Closing Date and with respect to those representations and warranties that reference a Schedule, subject to such Schedule as amended and updated by Seller (with a copy of such amendment or update to Buyer) as of the date such representation and warranty is being made as of&#58;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each of Seller and its Subsidiaries are duly organized and validly existing and in good standing under the laws of its and their respective jurisdictions of formation.  Each of Seller and its Subsidiaries have all corporate powers and all licenses, authorizations, consents and approvals </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">required to carry on its and their business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents and the License Agreement, except where the failure to be so licensed, authorized or qualified has not and would not reasonably be expected to have a Material Adverse Effect.  Each of Seller and its Subsidiaries is duly qualified to do business and is in good standing in every jurisdiction in which the failure to so qualify or be in good standing would result in a Material Adverse Effect.  Seller has no Subsidiaries, other than those listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with the jurisdiction of formation listed after the name of each such Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.03.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Authorizations&#59; Enforceability.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Seller has all necessary corporate power and authority to enter into, execute and deliver this Agreement and the other Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder.  </font><font style="color:#010202;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">None of the execution and delivery by Seller of the Transaction Documents, the performance by Seller of any of the obligations to be performed by it hereunder or thereunder, or the consummation by Seller of any of the transactions contemplated hereby or thereby, will require any notice to, action, approval or consent by, or in respect of, or filing or registration with, any Governmental Authority or other Person, except those that have already been obtained and copies of which have been provided to Buyer, and filings necessary to perfect Liens created by the Transaction Documents.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Once signed, the Transaction Documents will have been duly authorized, executed and delivered by Seller and each Transaction Document will then constitute the valid and binding obligation of Seller, enforceable against Seller in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally or general equitable principles.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.03.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Litigation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> sets forth each (i) Dispute pending or, to the Knowledge of Seller, threatened against Seller or its Subsidiaries, (ii) inquiry of any Governmental Authority pending or, to the Knowledge of Seller, threatened against Seller or its Subsidiaries, or (iii) to the Knowledge of Seller with respect to the following clauses (x) and (y), (x) Dispute pending or threatened against Licensee, or (y) inquiry of any Governmental Authority pending or threatened against Licensee which, in each instance of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if adversely determined, whether individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.04.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Compliance with Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller and its Subsidiaries are not in material violation of, and have not materially violated any, applicable Law, judgment, order, writ, decree, permit or license entered by any Governmental Authority and, to the Knowledge of Seller, are not under investigation with respect to any applicable Law, and have not been threatened in writing to be charged with, or been given written notice of any, material violation of any applicable Law relating to the Product or the License Agreement.  Except as would not, whether individually or in the aggregate, </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reasonably be expected to have a Material Adverse Effect, Seller and its Subsidiaries are not in violation of, and have not violated any, applicable Law, judgment, order, writ, decree, permit or license entered by any Governmental Authority and</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Knowledge of Seller, are not under investigation with respect to any applicable Law, and have not been threatened in writing to be charged with, or been given written notice of any, violation of any applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.05.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Conflicts.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Neither the execution and delivery by Seller of any of the Transaction Documents nor the performance or consummation of the transactions contemplated thereby (including, without limitation, the assignment to Buyer of the Royalty Interest) to be performed or consummated by Seller will&#58;  (i) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of&#58; (A) any Law, or any judgment, order, writ, decree, permit or license of any Governmental Authority, in any case, applicable to the Royalty Interest&#59; or (B) any material contract, agreement, commitment or instrument to which Seller is a party&#59; (ii) except for the filing of the UCC-1 financing statements required hereunder (or pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), require any notification to, filing with, or consent of, any Person or Governmental Authority that has not already been obtained, a copy of which has been provided to Buyer&#59; (iii) give rise to any right of termination, cancellation or acceleration of any right or obligation of Seller or any other Person as such right or obligation relates to the Royalty Interest or the Royalty Interest Payments&#59; or (iv) result in the creation or imposition of any Lien on the Royalty Interest or the Royalty Interest Payments (other than Liens in favor of Buyer).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Seller has not granted, nor agreed to grant to any Person other than Buyer, nor does there exist, any Lien granted by Seller on the Royalty Interest.  No Subsidiary has granted, nor agreed to grant to any Person other than Buyer, nor does there exist, any Lien on any such Subsidiary&#8217;s rights to receive Royalty Interest Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">None of Seller, any Subsidiary nor any of their respective property is subject to any judgment, order, writ or decree of any Governmental Authority which could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Neither Seller nor its Subsidiaries are party to any contract, agreement, commitment or instrument for which Seller or any of its Subsidiaries are in breach which could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Ownership.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other than the rights of Buyer upon the consummation of the transactions contemplated in the Transaction Documents including delivery of the Assignment, Seller is the sole holder of, the License Agreement and of all of the Purchased Assets, free and clear of any and all Liens (other than any Liens in favor of Buyer).  Seller has full right and power to assign and convey the Purchased Assets as contemplated by this Agreement.  Seller has not transferred, sold, conveyed, assigned, or otherwise disposed of, or agreed to transfer, sell, convey, assign, or otherwise dispose of any portion of the License Agreement or the Purchased Assets other than as contemplated by this Agreement.  Upon delivery to Buyer of the executed Assignment, no </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Person other than Buyer shall have any right to receive the Royalty Interest payable under the License Agreement.  Upon delivery to Buyer of the executed Assignment, Seller shall have sold, transferred, conveyed and assigned to Buyer, and Seller shall have done everything which is required to be done by Seller to cause Buyer to acquire all of Seller&#8217;s rights, interests and obligations arising on or after the Closing Date under the License Agreement and the Purchased Assets, free and clear of any Liens (other than any Liens in favor of Buyer), but subject to the further provisions of this Agreement.  Seller is legally competent to execute this Agreement and the other Transaction Documents and upon such execution by Seller, the obligations of Seller hereunder and thereunder shall constitute the legally binding and enforceable obligations of Seller, subject to bankruptcy, insolvency, reorganization, moratorium, ad hoc representative appointment, conciliation, safeguard proceedings, judicial receivership, or other laws affecting creditors&#8217; rights generally or general equitable principles.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Subordination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller has not caused, by any means, Seller&#8217;s Royalty Interest to be subordinated to the rights of any creditor of Licensee or any other Person.  In addition, Seller has not caused, and to the Knowledge of Seller no other Person has caused, the claims and rights of Buyer created by any Transaction Document in and to the Purchased Assets to be subordinated to any creditor of Licensee or any other Person&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Seller makes no representation as to whether Buyer (or any Person acting on behalf of Buyer) has caused any such subordination.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.03.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto contains a true and complete copy of the License Agreement (including, without limitation, all amendments, supplements and other modifications or restatements thereto) as of the Closing Date.  To the Knowledge of Seller, other than the Royalty Interest for the calendar quarter (or portion thereof) ended immediately preceding the Closing Date, if any, there are no unpaid Royalty Interests that have become due or are overdue, and none are expected to become overdue as of the Closing Date, in each case subject to the terms of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Seller is not in breach of the License Agreement which could have a Material Adverse Effect.  To the Knowledge of Seller, no circumstances or grounds exist that would give rise (i) to a claim by Licensee of a breach of the License Agreement or any other agreement, in each case, which could have a Material Adverse Effect, or (ii) to a right of rescission, termination, revision, setoff, or any other rights, in, to or under the Purchased Assets.  Seller has no unfulfilled obligations in respect of the License Agreement or the Purchased Assets that were required to be fulfilled on or prior to the Closing Date, the lack of completion of which would have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">To the Knowledge of Seller, Licensee is not in breach of or in default under the License Agreement which could have a Material Adverse Effect.  To the Knowledge of Seller, Licensee has no obligations unfulfilled in respect of the License Agreement that were required to be fulfilled that could reasonably be expected to have a Material Adverse Effect.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Seller has the full right, power and authority to grant all rights and interests granted to Buyer in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the Knowledge of Seller, no circumstance or grounds exist, that would invalidate, reduce or eliminate, in whole or in part, the enforceability or scope of the Purchased Assets, including, without limitation, Seller&#8217;s right to payments made in respect of Royalty Interests.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">To the Knowledge of Seller (i) no Person is in breach of the License Agreement, (ii) nothing has occurred and no condition exists that would permit either party thereto to terminate the License Agreement for cause and (iii) Seller has not received any notice of termination for convenience from the Licensee under Section 11.02(b) of the License Agreement. To the Knowledge of Seller, the License Agreement is valid and binding on each other party thereto in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium, ad hoc representative appointment, conciliation, safeguard proceedings, judicial receivership, or other laws affecting creditors&#8217; rights generally or general equitable principles, and is in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.08(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) to the Knowledge of Seller, Licensee has not entered into any sublicense under the License Agreement, and (ii) Seller has not consented to Licensee entering into any sublicense under the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the Knowledge of the Seller, Licensee has not exercised any right of rescission, offset, counterclaim or defense, with respect to the License Agreement or provided notice to Seller that it planned to do any of the foregoing.  To the Knowledge of Seller, nothing has occurred and no condition exists that would permit Licensee to exercise any right of rescission, offset, counterclaim or defense, with respect to the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Licensee has not provided Seller with notice of termination of the License Agreement nor any notice that it plans to terminate the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All payments due and payable by Seller or, to the Knowledge of Seller, the Licensee, under the License Agreement have been timely paid.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">There have been no claims for indemnification made under Article XII of the License Agreement by any Indemnified Party (as defined in the License Agreement).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">The Seller has not&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">forgiven, released, delayed, postponed or compromised any payment in respect of the Royalty Interest&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">waived, amended, cancelled or terminated, exercised or to the Knowledge of Seller failed to exercise, any material rights constituting or relating to the Purchased Assets&#59;</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, amended, modified, restated, cancelled, supplemented, terminated or waived any provision of the License Agreement, or granted any consent thereunder, or agreed to do any of the foregoing&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">exercised any right of rescission, offset, counterclaim or defense, upon or with respect to the Purchased Assets, or agreed to do or suffer to exist any of the foregoing&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">sold, leased, pledged, licensed, transferred or assigned (or attempted to do any of the foregoing) all or any portion of the Purchased Assets, except in favor of Buyer pursuant to the Transaction Documents&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">received any advance payments on the Royalty Interest&#59; it being understood that the transaction contemplated by Amendment Number 2 to the License Agreement does not constitute advance payments on the Royalty Interests.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt">No credit is owed to or claimed by Licensee with respect to Royalty Interest Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.08(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the License Agreement constitutes the only agreement (i) to which Seller is a party relating to the Royalty Interests, (ii) which relate to Seller&#8217;s entitlement to the Purchased Assets or (iii) which relate to the Development or Commercialization of the Product in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.06.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Production Agreements.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.09(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the License Agreement and the Production Agreements constitute the only agreements to which the Seller is a party (i) relating to the Royalty Interests, (ii) which relate to Seller&#8217;s entitlement to the Purchased Assets, or (iii) which relate to the right to Develop and Commercialize the Product in the Field in the Territory. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Seller is not in breach of any Production Agreement which could have a Material Adverse Effect.  No circumstances or grounds exist that would give rise to a claim by Licensee of a breach of the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement.  Seller has no unfulfilled obligations in respect of any Production Agreement, the lack of which would be reasonably likely to have a Material Adverse Effect or could give rise to a right of set-off against the Royalty Interest Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">To the Knowledge of Seller, Licensee is not in breach of or in default under the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement, in any case, which could have a Material Adverse Effect.  To the Knowledge of Seller, Licensee has no unfulfilled obligations in respect of the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement that were required to be fulfilled.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">To the Knowledge of Seller, no Person is in breach of any Production Agreement which could have a Material Adverse Effect and nothing has occurred and no condition exists that would permit any other party thereto to terminate any Production Agreement.  To the Knowledge of Seller, each of the Production Agreements is valid and binding on each other party thereto in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium, ad hoc representative appointment, conciliation, safeguard proceedings, judicial receivership, or other laws affecting creditors&#8217; rights generally or general equitable principles, and is in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Licensee has not exercised any right of rescission, offset, counterclaim or defense, with respect to the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement or provided notice to Seller that it planned to do any of the foregoing.  To the Knowledge of Seller, nothing has occurred and no condition exists that would permit Licensee to exercise any right of rescission, offset, counterclaim or defense, with respect to the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Licensee has not provided Seller with notice of termination of the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement nor any notice that it plans to terminate the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">All payments due and payable by the Seller or the Licensee under any Production Agreement to which they are a party have been timely paid.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">There have been no claims for indemnification made under Article XII of the License Agreement by Seller or Licensee under the Manufacturing and Supply Agreement for Development, the Interim Commercial Supply Letter or the Development Quality Assurance Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ac)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">The &#91;***&#93; set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.09(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;&#91;***&#93;), is &#91;***&#93;, as applicable, and to the Knowledge of Seller, is accurate and complete in all material respects&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Seller does not represent or warrant that any &#91;***&#93; is accurate.  To the Knowledge of Seller, Seller will be able to &#91;***&#93; as set forth therein. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ad)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Seller has not&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">forgiven, released, delayed, postponed or compromised any payment in respect of any Production Agreement which could have a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">waived, amended, cancelled or terminated, exercised or to the Knowledge of Seller failed to exercise, any material rights constituting or relating to any Production Agreement which could have a Material Adverse Effect&#59;</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">amended, modified, restated, cancelled, supplemented, terminated or waived any provision of any Production Agreement, or granted any consent thereunder, or agreed to do any of the foregoing which could have a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">exercised any right of rescission, offset, counterclaim or defense, upon or with respect to any Production Agreement, or agreed to do or suffer to exist any of the foregoing which could have a Material Adverse Effect&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">sold, leased, pledged, licensed, transferred or assigned (or attempted to do any of the foregoing) all or any portion of any Production Agreement.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Net Sales&#59; Milestones.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ae)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt;text-decoration:underline">Schedule 3.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto sets forth a true and complete list of all Net Sales of the Product provided by Licensee pursuant to Section 6.07 of the License Agreement and, to the Knowledge of Seller, payable by Licensee to Seller, through but excluding the Closing Date.  Seller has provided to Buyer a copy of the Royalty Reports delivered to Seller as of the Closing.  Buyer is aware that payments may differ in the future and that past payments made are no guarantee for future payments to be made.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(af)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.71pt;text-decoration:underline">Schedule 3.10(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto sets forth a true and complete list of all milestone payments provided by Licensee pursuant to Section 6.03 of the License Agreement and, to the Knowledge of Seller, payable by Licensee to Seller, through but excluding the Closing Date. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Broker&#8217;s Fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither Seller nor its Affiliates have taken any action that would entitle any Person to any commission or broker&#8217;s fee in connection with the transactions contemplated by the Transaction Documents. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All Seller&#8217;s written information heretofore or herein supplied by or on behalf of Seller to Buyer is accurate and complete in all material respects, and none of such information, when taken together with all other information furnished and information available through Seller&#8217;s SEC filings, contains any untrue statement of a material fact or omits to state any material fact necessary to make such information not materially misleading in light of the circumstances under which made.  To the Knowledge of Seller, there is no fact or circumstance that could reasonably be expected to have a Material Adverse Effect that has not been expressly disclosed in this Agreement, in the other Transaction Documents, in any of Seller&#8217;s SEC filings, or in any other documents, certificates and statements furnished to Buyer for use in connection with the transactions contemplated hereby.  Notwithstanding the above, Seller makes no representation or warranty with respect to the &#91;***&#93; or any other &#91;***&#93;.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Insolvency Event&#59; Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Insolvency Event has occurred regarding Seller.  To the Knowledge of Seller, no event has occurred and no condition exists that could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Indebtedness and Liens.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ag)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.14(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is a complete and correct list of all Indebtedness of Seller and each of its Subsidiaries outstanding.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ah)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.14(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is a complete and correct list of all Liens granted by Seller and each of its Subsidiaries with respect to their respective property.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Intellectual Property Rights. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ai)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt;text-decoration:underline">Schedule 3.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> sets forth under the caption, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ardelyx Controlled Patents,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; the following for each Ardelyx Controlled Patent&#58; (i) the application number&#59; (ii) the title of the application or patent, if any, (iii) the patent or registration number, if any&#59; and (iv) the scheduled initial expiration date of such Ardelyx Controlled Patents, including a notation if such scheduled expiration date includes a term extension.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt;text-decoration:underline">Schedule 3.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> includes a complete and accurate list of all Patents Controlled by Seller in the Territory that are necessary or useful to Exploit the Licensed Product in accordance with the terms of the License Agreement. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ak)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(c), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Knowledge of Seller, there have not been, nor are there, any Disputes relating to Seller&#8217;s or its Subsidiaries&#8217; rights in the Ardelyx Controlled Patents or related Intellectual Property Rights.  To the Knowledge of Seller, there have not been, nor are there, any Disputes relating to Licensee&#8217;s rights in the Ardelyx Controlled Patents or related Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(al)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt">To the Knowledge of Seller, neither Seller nor its Subsidiaries has received, and to the Knowledge of Seller, Licensee has not received, any opinion of counsel that any of the Ardelyx Controlled Patents are invalid or unenforceable.  To the Knowledge of Seller, neither Seller nor its Subsidiaries has received, and to the Knowledge of Seller, Licensee has not received, any notice of any claim by any Third Party challenging the validity, inventorship, ownership or enforceability of any of the Ardelyx Controlled Patents.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(am)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.37pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(e), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Knowledge of Seller, there is at least one valid claim in each of the Ardelyx Controlled Patents that would be infringed by Licensee&#8217;s Exploitation of the Product in the Territory but for Licensee&#8217;s license under the License Agreement to such Ardelyx Controlled Patents. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(an)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, there are no pending, decided or settled Disputes, and to the Knowledge of Seller, no such Dispute has been threatened </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that could (i) impact the validity, enforceability, scope, inventorship or ownership of any of the claims of the Ardelyx Controlled Patents, or (ii) otherwise impact whether any claim within the Ardelyx Controlled Patents or Licensee Controlled Patents is a valid claim.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ao)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">The term for which consideration is to be paid pursuant to the License Agreement as is set forth in Section 6.04(d) on Exhibit A of Amendment Number 2 of the License Agreement has not been amended or revised since the date thereof.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ap)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">To the Knowledge of Seller, each of the Ardelyx Controlled Patents correctly identifies each and every inventor of the claims thereof as determined in accordance with the laws of Japan.  To the Knowledge of Seller, there is not any Person who is or claims to be an inventor of any of the Ardelyx Controlled Patents who is not a named inventor thereof.  Seller and its Subsidiaries have not, and to the Knowledge of Seller, Licensee has not, received any notice from any Person who is or claims to be an inventor of any of the Ardelyx Controlled Patents who is not a named inventor thereof.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">To the Knowledge of Seller, each Person who has or has had any rights in or to the Ardelyx Controlled Patents, including each inventor named on the Ardelyx Controlled Patents, has executed a Contract assigning his, her or its entire right, title and interest in and to such Ardelyx Controlled Patents and the inventions embodied, described or claimed therein, to Seller and each such Contract has been, duly recorded at the Japan Patent Office where such recordation has been required as of the Closing Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ar)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.71pt">To the Knowledge of Seller, maintenance fees, annuities or other like payments with respect to any Ardelyx Controlled Patents required to be paid as of the Closing Date have been paid.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.04pt">To the Knowledge of Seller, no issued Ardelyx Controlled Patent has lapsed, expired or otherwise been terminated.  Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">t</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">o the Knowledge of Seller, no Ardelyx Controlled Patent applications have lapsed, expired, been abandoned or otherwise been terminated, other than by operation of law.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(at)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt">To the Knowledge of Seller, none of the conception, development and reduction to practice of the inventions claimed in the Ardelyx Controlled Patents has constituted or involved the misappropriation of trade secrets or other rights or property of any Third Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(au)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">To the Knowledge of Seller, Seller and its Subsidiaries have not, and to the Knowledge of Seller, Licensee has not, filed any disclaimer, other than a terminal disclaimer, or made or permitted any other voluntary reduction in the scope of any Ardelyx Controlled Patents.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(av)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">To the Knowledge of Seller, Seller and its Subsidiaries have not, and to the Knowledge of Seller, no other Person has, undertaken or omitted to undertake any acts, and to the Knowledge of Seller no circumstances or grounds exist, that would void, invalidate, reduce or eliminate, in whole or in part, the enforceability </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of claims specifically covering the Lead Licensed Compound within any issued Ardelyx Controlled Patent. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aw)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.04pt">&#91;Reserved&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ax)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(p), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Knowledge of Seller, no Third Party Patent Right has been, or is, or will be, infringed by Licensee&#8217;s Exploitation of the Product in accordance with the terms of the License Agreement.  To the Knowledge of Seller, there are no patent rights that Licensee does not have the right to use that would limit or prohibit in any material respect Licensee&#8217;s Exploitation of the Product in accordance with the terms of the License Agreement.  To the Knowledge of Seller, neither Seller nor Licensee has received any notice of any claim by any Third Party asserting that Licensee&#8217;s Exploitation of the Product infringes such Third Party&#8217;s Patent Rights.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ay)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(q), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Knowledge of Seller, there are no pending, published patent applications owned by any Third Party, which Licensee does not have the right to use, which if issued, would limit or prohibit in any material respect Licensee&#8217;s Exploitation of the Product in accordance with the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(az)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(r), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Knowledge of Seller, no Third Party is infringing any of the issued Ardelyx Controlled Patents.  Seller has not, and to the Knowledge of Seller, Licensee has not, put any Third Party on notice of any of the issued Ardelyx Controlled Patents.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ba)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">&#91;Reserved&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(bb)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.15(t), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the Knowledge of Seller, there are no Disputes between Licensee and a Third Party relating to Licensee&#8217;s Exploitation of the Product in accordance with the terms of the License Agreement.  Seller has not received notice of any such Dispute, and to the Knowledge of Seller, there exists no circumstances or grounds upon which any such claims could be reasonably asserted.  To the Knowledge of Seller, the Ardelyx Controlled Patents are not subject to any outstanding injunction, judgment or other decree, ruling, charge settlement or other disposition of any Dispute which could reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(bc)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">To the Knowledge of Seller, no individual associated with the filing and prosecution of the Ardelyx Controlled Patents failed to comply in all material respects with all applicable duties of candor and good faith in dealing with any Patent Office, including the duty to disclose to the Japanese Patent Office all information known to be material to patentability where such duty to disclose is required.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(bd)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule Section 3.15(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, to the Knowledge of Seller, no validity concerns, or prior art have been raised in connection with any Patents outside of the Territory which specifically claim the compound tenapanor which, if raised in connection with the Ardelyx Controlled Patents, could reasonably be </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;26</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expected to impact the validity of any claims in the issued Ardelyx Controlled Patents which specifically claim the compound tenapanor.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Compliance.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the Knowledge of Seller, all applications, submissions, information and data related to the Product submitted or utilized as the basis for any request to any Regulatory Authority by or on behalf of Licensee relating to the Product were true and correct in all material respects as of the date of such submission or request, and any material updates, changes, corrections or modifications to such applications, submissions, information or data required under applicable Law were submitted to the necessary Regulatory Authorities, or were corrected by subsequent submission to the applicable Regulatory Authority.  To the Knowledge of Seller, Licensee has not committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis for any Governmental Authority to invoke its policy with respect to &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#8221; or similar policies set forth in any applicable Laws. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Exploitation&#59; Material Information.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(be)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">To the Knowledge of Seller, Licensee is neither (i) considering terminating the Exploitation of the Product, nor (ii) considering manufacturing, selling, offering for sale (including marketing and promotion), importation, distribution or other commercialization of a Competitive Product that would compete with the Product during the term of this Agreement in the Territory.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(bf)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#91;Reserved&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(bg)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt">To the Knowledge of Seller, Licensee is neither contemplating nor planning to commence any case, proceeding or other action relating to Licensee&#8217;s bankruptcy, insolvency, liquidation or dissolution or reorganization by any of the foregoing means.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No deduction or withholding for or on account of any tax has been made, or was required to have been made, from any payment to Seller under the License Agreement and, other than with respect to Japanese tax withholding, Seller was not required to claim any treaty benefits in order to avoid such withholding.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br><br>REPRESENTATIONS AND WARRANTIES OF BUYER</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer hereby represents and warrants to Seller that the following representations are true and complete as of the Closing Date, except as otherwise indicated&#58; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.07.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer is a limited partnership formed and validly existing under the laws of the State of Delaware, and has all limited partnership powers and all licenses, authorizations, consents and </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">approvals required to carry on its business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.08.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Authorization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Buyer has all necessary limited partnership power and authority to enter into, execute and deliver this Agreement and the other Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder.  Once signed, the Transaction Documents will have been duly authorized, executed and delivered by Buyer and each Transaction Document will then constitute the valid and binding obligation of Buyer, enforceable against Buyer in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#8217; rights generally or general equitable principles.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.09.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Broker&#8217;s Fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">None of Buyer or its Affiliates has taken any action that would entitle any Person to any commission or broker&#8217;s fee in connection with the transactions contemplated by the Transaction Documents.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.010.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.7pt">Conflicts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Neither the execution and delivery of this Agreement or any other Transaction Document nor the performance or consummation of the transactions contemplated hereby or thereby will&#58;  (i) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects, any provisions of&#58; (A) any Law, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which Buyer or any of its assets or properties may be subject or bound&#59; or (B) any contract, agreement, commitment or instrument to which Buyer is a party or by which Buyer or any of its assets or properties is bound or committed&#59; (ii) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the organizational or constitutional documents of Buyer&#59; or (iii) require any notification to, filing with, or consent of, any Person or Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:5.7pt"><br><br>COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the term of this Agreement, the following covenants shall apply&#58; </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.04.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Consents and Waivers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller and Buyer shall use commercially reasonable efforts to obtain and maintain any required consents, acknowledgements, certificates or waivers so that the transactions contemplated by this Agreement or any other Transaction Document may be consummated and shall not result in any default or breach or termination of the License Agreement.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;28</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.05.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Compliance.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Seller shall comply with and fulfill, in all material respects, all of Seller&#8217;s obligations under the License Agreement and each Production Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event the License Agreement is terminated for any reason whatsoever prior to its expiration pursuant to Section 11.01 of the License Agreement, Seller shall use Commercially Reasonable Efforts, at its sole cost and expense, to locate and secure a replacement licensee to Develop and Commercialize the Product in the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Seller agrees to use Commercially Reasonable Efforts to negotiate substantially similar obligations and liabilities as it currently has under the License Agreement (such New Arrangement shall, for purposes of the assignment of the Purchased Assets hereunder, be deemed to constitute the &#8220;License Agreement&#8221; hereunder and shall be subject to the terms and conditions hereof and of the other Transaction Documents) and Seller shall &#91;***&#93;.   If Seller is not able to enter into a New Arrangement pursuant to the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, despite using Commercially Reasonable Efforts, then &#91;***&#93; Seller or its Affiliates shall, &#91;***&#93;.  The Parties will work together in good faith, if necessary, to amend this Agreement and the Transaction Documents, as appropriate, in order to address any alternative or differing provisions in a New Arrangement entered into pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.02(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or to address Seller or its Affiliates performing the obligations of Licensee under the License Agreement, as applicable.  Without limiting the foregoing, if the License Agreement is terminated and Seller or its Affiliates &#91;***&#93;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall be treated as &#8220;Net Sales&#8221; subject to the specified royalty rates set forth in the applicable provision of Section 6.04 of Amendment Number 2 of the License Agreement, and the product of such net sales times such royalty rate for the corresponding royalty periods for which such royalty rates apply shall be Royalties hereunder, and Seller shall pay Purchaser an amount equal to any milestone payments that would otherwise have been payable under Section 6.03 of the License Agreement related to the Commercialize the Product in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.011.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.7pt">Confidentiality&#59; Public Announcement&#59; SEC Filings.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Except as expressly authorized in this Agreement or the other Transaction Documents or except with the prior written consent of the Disclosing Party, the Receiving Party hereby agrees that (i) it will use the Confidential Information of the Disclosing Party solely for the purpose of the transactions contemplated by this Agreement and the other Transaction Documents and exercising its rights and remedies and performing its obligations hereunder and thereunder&#59; (ii) it will keep confidential the Confidential Information of the Disclosing Party&#59; and (iii) it will not furnish or disclose to any Person any Confidential Information of the Disclosing Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding anything to the contrary set forth in this Agreement or any other Transaction Document, the Receiving Party may, without the consent of the Disclosing Party, but with prior written notice to the Disclosing Party, furnish or disclose Confidential Information of the Disclosing Party to (i) the Receiving </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;29</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Party&#8217;s Affiliates and their respective Representatives, actual or potential financing sources, investors or co-investors and permitted assignees, transferees or successors-in-interest under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in each such case, who need to know such information in order to provide or evaluate the provision of financing to the Receiving Party or any of its Affiliates or to assist the Receiving Party in evaluating the transactions contemplated by this Agreement and the other Transaction Documents or in exercising its rights and remedies and performing its obligations hereunder and thereunder and who are, prior to such furnishing or disclosure, informed of the confidentiality and non-use obligations contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and who are bound by written or professional confidentiality and non-use obligations no less stringent than those contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; and (ii)&#160;permitted assignees, transferees or successors-in-interest under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in each such case, who need to know such information in connection with such actual or potential assignment, sale or transfer, including, following any such assignment, sale or transfer, in order to exercise their rights and remedies and perform their obligations under this Agreement and the other Transaction Documents and who are, prior to such furnishing or disclosure, informed of the confidentiality and non-use obligations contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and who are bound by written or professional confidentiality and non-use obligations no less stringent than those contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party hereby acknowledges that the United States federal and state securities laws prohibit any Person that has material, non-public information about a company from purchasing or selling securities of such a company or from communicating such information to any other Person under circumstances in which it is reasonably foreseeable that such Person is likely to purchase or sell such securities.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the event that the Receiving Party, its Affiliates or any of their respective Representatives is required by applicable Law, applicable stock exchange rules or legal or judicial process (including by deposition, interrogatory, request for documents, subpoena, civil investigative demand or similar process) to furnish or disclose any portion of the Confidential Information of the Disclosing Party, the Receiving Party shall, to the extent legally permitted, provide the Disclosing Party, as promptly as practicable, with written notice of the existence of, and terms and circumstances relating to, such requirement, so that the Disclosing Party may seek, at its expense, a protective order or other appropriate remedy (and, if the Disclosing Party seeks such an order, the Receiving Party, such Affiliates or such Representatives, as the case may be, shall provide, at their expense, such cooperation as such Disclosing Party shall reasonably require).  Subject to the foregoing, the Receiving Party, such Affiliates or such Representatives, as the case may be, may disclose that portion (and only that portion) of the Confidential Information of the Disclosing Party that is legally required to be disclosed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that the Receiving Party, such Affiliates or such Representatives, as the case may be, shall exercise reasonable efforts (at their expense) to preserve the confidentiality of the Confidential Information of the Disclosing Party, including by obtaining reliable assurance that confidential treatment will be accorded any such Confidential Information disclosed.  Notwithstanding anything to the contrary contained in this Agreement or any of the other Transaction Documents, in the event that the Receiving Party or any of its Affiliates receives a request from an authorized representative of a U.S. or foreign tax authority for a copy of this Agreement or any of the other </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;30</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transaction Documents, the Receiving Party or such Affiliate, as the case may be, may provide a copy hereof or thereof to such tax authority representative without advance notice to, or the consent of, the Disclosing Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that the Receiving Party shall, to the extent legally permitted, provide the Disclosing Party with written notice of such disclosure as soon as practicable.  Notwithstanding the above, the Parties acknowledge and agree that this Agreement is a material contract of Seller that will be required to be disclosed to the Securities and Exchange Commission pursuant to the Exchange Act.  Seller will be permitted to file this Agreement with the Securities and Exchange Commission in its entirety or with confidential treatment of certain terms and conditions of this Agreement, as determined by Seller in its sole discretion. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Notwithstanding anything to the contrary contained in this Agreement or any of the other Transaction Documents, the Receiving Party may disclose the Confidential Information of the Disclosing Party, including this Agreement, the other Transaction Documents and the terms and conditions hereof and thereof, to the extent necessary in connection with the enforcement of its rights and remedies hereunder or thereunder or as required to perfect the Receiving Party&#8217;s rights hereunder or thereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Receiving Party shall only disclose that portion of the Confidential Information that its counsel advises that it is legally required to disclose and will exercise commercially reasonable efforts to ensure that confidential treatment will be accorded to that portion of the Confidential Information that is being disclosed, including requesting confidential treatment of information in the Transaction Documents.  In any event, Receiving Party will not oppose action by Disclosing Party to obtain an appropriate protective order or other reliable assurance, at its own expense, that confidential treatment will be accorded the Confidential Information in the event that confidential treatment cannot be obtained by the Receiving Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each Party shall have the right to issue a press release with respect to the transactions contemplated by this Agreement or any other Transaction Document, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the form of such press release is substantially similar to that set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Following the initial press release, the Parties shall be permitted to make additional public disclosures regarding the transactions contemplated by this Agreement or any other Transaction Document, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> such additional public disclosures are consistent with such initial disclosure or as may be necessary to correct any facts or circumstances that have changed since the initial disclosure.  In addition, each Party shall be permitted to provide any public disclosure regarding the transactions contemplated by this Agreement or any other Transaction Document if and to the extent that any such release or disclosure is required by applicable Law, by the rules and regulations of any applicable stock exchange or by any Governmental Authority of competent jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Except with respect to Buyer&#8217;s internal communications or private communications with its Representatives, Buyer shall not, and shall cause its Representatives, its Affiliates and its Affiliates&#8217; Representatives not to make use of the name, nickname, trademark, logo, service mark, trade dress or other name, term, mark or symbol identifying or associated with Seller without Seller&#8217;s prior written consent to the specific use in question&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the consent of Seller </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;31</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall not be required with respect to publication of Seller&#8217;s name and logos in Buyer&#8217;s promotional materials, including without limitation the websites for Buyer and its Affiliates, if such publication is made in accordance with the format set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.03(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and Buyer does not make any such publication until after Seller files this Agreement in compliance with United States securities laws.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Each of Seller and Buyer hereby (i) agree that, notwithstanding the terms thereof, the Confidentiality Agreement is hereby terminated and (ii) acknowledge that this Agreement shall supersede such Confidentiality Agreement with respect to the treatment of Confidential Information by the Parties (including, without limitation, with regard to Confidential Information previously provided pursuant to such Confidentiality Agreement).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Buyer further agrees to (a) comply with the terms of Article VII of the License Agreement with respect to any Confidential Information (as defined in the License Agreement) of Licensee and (b) to keep confidential and not publish or otherwise disclose or use for any purpose other than to conduct its activities under this Agreement any Confidential Information of Licensee, unless such disclosure falls within the exceptions set forth in Section 7.02 or 7.04 of the License Agreement, in which case Buyer agrees to make any such limited permitted disclosure in strict compliance with the requirements set forth in Article VII of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.04.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Further Assurances.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to the terms and conditions of this Agreement, each of Buyer and Seller will use commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable Laws to consummate the transactions contemplated by this Agreement and any other Transaction Document.  Buyer and Seller agree to execute and deliver such other documents, certificates, agreements and other writings (including any financing statement filings, other documents, certificates or agreements requested by Buyer) and to take such other actions as may be reasonably necessary to carry out and effectuate all of the provisions of this Agreement and any other Transaction Document, to consummate the transactions contemplated by this Agreement and any other Transaction Document and to vest in Buyer all of Seller&#8217;s rights and obligations (whether joint, several or joint and several) to the Purchased Assets, free and clear of all Liens except any Permitted Liens or Liens created in favor of Buyer.  Seller shall take all actions and do, all things necessary to pay off, satisfy and release any Permitted Liens.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Except for Disputes between the Parties, each of Buyer and Seller shall cooperate and provide assistance as reasonably requested by the other Party (and at no expense to the requesting Party unless the requesting Party is obligated to indemnify the other Party pursuant to the requesting Party&#8217;s indemnification obligations provided for in this Agreement) in connection with any litigation, arbitration or other proceeding (whether threatened, existing, initiated, or contemplated prior to, on or after the date hereof) to which any Party or any of its officers, directors, shareholders, agents or employees is or may become a party or is or may become otherwise directly or indirectly affected or as to which any such </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;32</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Persons have a direct or indirect interests, in each case relating to this Agreement or any other Transaction Document, and the Purchased Assets, the License Agreement, or the transactions described herein or therein, and, without limiting the generality of the preceding provision, shall provide promptly to the other Party copies of all correspondence, reports, notices or other information sent by or on behalf of such Party to, or received by or on behalf of such Party from, Licensee, in any case relating to the License Agreement&#59; it being understood that a Party&#8217;s failure to provide such information shall not limit any otherwise applicable indemnification obligations under this Agreement of the other Party other than to the extent of any final non-appealable order of a court of competent jurisdiction finding that a Loss was incurred by such other Party as a result of such failure to provide such information.  In particular, with respect to the immediately preceding sentence, Seller shall, upon request of Buyer, be available and fully cooperate with and support Buyer in connection with the License Agreement and its performance, at reasonable times and, unless otherwise set forth in this Agreement.  Notwithstanding anything in this Section 5.04(b) to the contrary, at no time shall either Buyer or Seller be required to provide any attorney-client privileged information.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Seller and its Subsidiaries shall obtain Buyer&#8217;s prior written consent prior to delivering any notice or correspondence to Licensee alleging any material breach or material default of any representation, warranty or covenant (or otherwise) by Licensee or its Subsidiaries under the License Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.012.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.7pt">Notice by Seller.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller shall provide Buyer with written notice as promptly as practicable (and in any event within five (5) Business Days) after obtaining actual knowledge of any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any Event of Default&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the occurrence of an Insolvency Event with respect to Seller or the occurrence of any equivalent event with respect to Licensee&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any material breach or material default, or alleged material breach or material default, of any representation, warranty or covenant by Licensee or its Subsidiaries or Seller or its Subsidiaries under the License Agreement or any Production Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">that Seller shall be unable to provide the supply of API set forth in the Manufacturing and Supply Agreement for Development or the Interim Commercial Supply Letter in any material respect&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">any written notice, report or other communication, together with copies of the same, received from or on behalf of the Licensee with respect to the License Agreement, any Production Agreement, the Royalty Interest, the Patent rights, or any of the Purchased Assets, in each case, to the extent regarding matters affecting the Purchased Assets that would, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect&#59;  </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;33</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt">any written notice, report or other communication, together with copies of the same, sent to the Licensee by or on behalf of Seller with respect to the License Agreement, any Production Agreement, the Royalty Interest, the Patent rights, or any of the Purchased Assets, in each case, to the extent regarding matters affecting the Purchased Assets that would, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">any change in, or amendment or alteration of, Seller&#8217;s (a) legal name, (b) form or type of organization, or (c) jurisdiction of organization.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.06.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Patent Rights.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Seller shall, at its sole expense, take any and all commercially reasonable actions and prepare, execute, deliver and file any and all agreements, documents or instruments which are necessary or desirable to diligently prosecute and maintain the Licensed Patents, to the extent required to prevent a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Seller shall, or shall permit Licensee to, at its sole expense, defend or assert the Licensed Patents against infringement by any other Persons, and against any claims of invalidity or unenforceability, in the Territory (including, without limitation, by bringing any legal action for infringement or defending any counterclaim of invalidity or action of a Third Party for declaratory judgment of non-infringement), to the extent required to prevent a Material Adverse Effect.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">Seller shall not disclaim or abandon, or fail to take any action necessary or desirable to prevent the disclaimer or abandonment of, any Licensed Patents, to the extent the disclaimer or abandonment of such Licensed Patent could reasonably be likely to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without limiting Seller&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.06(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Seller shall keep Buyer reasonably informed and shall promptly provide to Buyer any information of which Seller becomes aware that could reasonably be expected to have an effect on the prosecution, maintenance, defense or enforcement of any Licensed Patents, in a manner that could reasonably be expected to have a Material Adverse Effect.  To the extent that Seller receives any material correspondence regarding the prosecution, maintenance, defense or enforcement of any such Licensed Patents, that could reasonably be expected to have a Material Adverse Effect, Seller will provide such correspondence to Buyer. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In furtherance of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.06(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the event of defense or enforcement of any Licensed Patent, Seller shall provide regular updates regarding the status of and strategy for such defense or enforcement activities, including with respect to infringement, validity, enforceability, any counterclaim or settlement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, notwithstanding anything to the contrary contained herein, this provision is not deemed to grant Buyer any rights to (i) dictate or control any enforceability with respect to any Licensed Patent or (ii) information protected by attorney-client privilege or that would otherwise cause a conflict of interest. </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In the event that Seller becomes aware of any Third Party Claim, whether actual or threatened in writing, alleging that the manufacture, Commercialization or </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;34</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other Exploitation of the Product may infringe or misappropriate intellectual property of a Third Party, Seller will notify Buyer, and will provide such information as Buyer may reasonably request.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">In the event Seller becomes aware that any Third Party has filed a marketing authorization request for a generic version of the Lead Licensed Compound in the Territory or has otherwise initiated a Dispute alleging that a Generic does not infringe the Ardelyx Controlled Patents or Licensee Controlled Patents, in the Territory, or that the Ardelyx Controlled Patents or Licensee Controlled Patents (or any claims thereof) are invalid or unenforceable, in the Territory, Seller will notify Buyer, and will provide such information as Buyer may reasonably request.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.013.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.7pt">Negative Covenants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller shall not, nor shall it permit any of its Subsidiaries to, without the prior written consent of Buyer&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">forgive, release or reduce any amount, or delay or postpone any amount, owed to Seller or its Affiliates and relating to the Royalty Interest or the Royalty Interest Payments&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ac)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">create, incur, assume or suffer to exist any Lien, upon or with respect to the Royalty Interest, the Licensee Agreement, the Ardelyx Controlled Patents (excluding any Ardelyx Controlled Patents that are Ardelyx Sole Invention Patents or Ardelyx &#91;***&#93; Patents, in each case, in jurisdictions outside of the Territory), the right to receive Royalty Interest Payments, or agree to do or suffer to exist any of the foregoing, except for any Permitted Liens and any Lien or agreements in favor of Buyer granted under or pursuant to this Agreement and the other Transaction Documents&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ad)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">waive, amend, cancel or terminate, exercise or fail to exercise, any material rights constituting or relating to the Royalty Interest or other Purchased Assets&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ae)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt">grant or withhold any consent, exercise or waive any right or option or fail to exercise any right or option in respect of, affecting or relating to the Royalty Interest or other Purchased Assets in any manner that would (i) reasonably be expected to have a Material Adverse Effect or (ii) conflict with, or that would reasonably be expected to give rise to a material breach, material violation, termination or material default under the License Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(af)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.71pt">amend, modify, restate, cancel, supplement, terminate or waive any provision of the License Agreement or grant any consent thereunder, or agree to do any of the foregoing, in each case, in a manner that could adversely affect Buyer&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ag)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">assign, in whole or in part, the License Agreement or any provision thereof or right thereunder other than pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ah)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">sell, lease, license, transfer or assign (or attempt to do any of the foregoing) all or any material portion of any of the Ardelyx Controlled Patents (excluding any Ardelyx Controlled Patents that are Ardelyx Sole Invention Patents or Ardelyx </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;35</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; Patents, in each case, in jurisdictions outside of the Territory) other than pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or pursuant to a license outside of the Territory and&#47;or Field&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ai)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt">directly or indirectly, launch, license, sell, commercialize, distribute, assign or sell rights to any Competitive Product or intellectual property related to any Competitive Product which, in either case, would compete with the Product during the term of this Agreement in the Territory.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Future Agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller shall not enter into, nor shall it permit any of its Subsidiaries to enter into, any agreement that would reasonably be expected to result in a Material Adverse Effect without Buyer&#8217;s prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned by Buyer.  For clarity, nothing in this Section 5.08, or otherwise in this Agreement shall restrict Seller from entering into an agreement for the development and commercialization of the Product in the Territory for irritable bowel syndrome with constipation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> any such agreement does not result in a breach of Seller&#8217;s obligations under the License Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Records&#59; Access.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aj)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt">During the term of this Agreement and for a period of two (2) years thereafter, Seller shall keep and maintain proper books of record and account in which full, true and correct entries in conformity with GAAP and all requirements of applicable Law are made of all dealings and transactions as are adequate to correctly calculate and verify the accuracy of all reports and all Royalty Interest Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ak)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">During the term of this Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">Buyer and its representatives shall have the right, from time to time during normal business hours and upon at least twenty (20) Business Days&#8217; prior written notice to Seller, but no more frequently than one (1) time per calendar year to visit the offices and properties of Seller and the Subsidiaries where books and records relating or pertaining to the Royalty Interest Payments, the Royalty Interest and the Purchased Assets are kept and maintained, to inspect and make extracts from and copies of such books and records, to discuss, with officers of Seller and the Subsidiaries, the business, operations, properties and financial and other condition of Seller and the Subsidiaries and to verifying the accuracy of the reports and the Royalty Interest Payments.  In the event any inspection of such books and records reveals any underpayment of any Royalty Interest Payment in respect of any calendar quarter, Seller shall pay promptly (but in any event within five (5) Business Days thereafter) to Buyer (x) the amount of such underpayment&#59; and (y) if such underpayment exceeds &#91;***&#93; of the Royalty Interest Payment that was required to be made in respect of such calendar quarter, the reasonable and documented out-of-pocket fees and expenses incurred by Buyer and its Affiliates in connection with such inspection (in all other cases, such fees and expenses will be borne by Buyer and its Affiliates).</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;36</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.03pt">All information furnished or disclosed to Buyer or any of its representatives in connection with any inspection shall constitute Confidential Information of Seller and shall be subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xiv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.69pt">Subject to Section 5.03(h), Seller shall deliver to Buyer such information and data relating or pertaining to the Royalty Interest Payments, the Royalty Interest or the Purchased Assets as Buyer shall reasonably request, promptly upon such request.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(al)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt">Seller shall on, on at least a quarterly basis, or more frequently if requested in writing by Buyer (such notice to be given at least ten (10) Business Days&#8217; in advance), cause such of the executive officers and employees of Seller as shall be reasonably identified by Buyer in such notice to meet (virtually or in person), or, at Buyer&#8217;s option, to participate in a conference call with, Buyer for the purpose of discussing the Product and the Purchased Assets.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Regulatory Approvals.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller shall, to the extent permitted under the License Agreement, take any and all commercially reasonable actions and prepare, execute, deliver and file any and all agreements, documents or instruments that are necessary to secure and maintain all Regulatory Approvals for the Product in the Territory, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.  To the extent permitted under the License Agreement, Seller shall not withdraw or abandon, or fail to take any action necessary to prevent the withdrawal or abandonment of, any such Regulatory Approval in the Territory once obtained, except where such withdrawal or abandonment would not reasonably be expected to result in a Material Adverse Effect.  Notwithstanding the foregoing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Seller shall not consent to the withdrawal or abandonment of any Regulatory Approval for the Product in the Territory by Licensee unless Seller obtains Buyer&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Misdirected Payments.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(am)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.37pt">Notwithstanding the terms of the Licensee Instruction, commencing on the Closing Date and at all times thereafter, if any portion of the Royalty Interest is paid to Seller (after giving effect to the adjustments set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), including any payments remitted by Buyer to Seller plus any of Buyer&#8217;s reasonable and documented out-of-pocket costs and expenses (including reasonable and documented attorneys&#8217; fees and expenses) incurred in enforcing Buyer&#8217;s rights under this Agreement, any Transaction Document or the License Agreement, which are not otherwise reimbursed hereunder then (i) Seller shall hold such amount in trust for the benefit of Buyer in a segregated account, (ii)&#160;Seller shall have no right, title or interest whatsoever in such amount and shall not create or suffer to exist any Lien thereon and (iii)&#160;Seller promptly, and in any event no later than five (5) Business Days following the receipt by Seller of such amount, shall remit such amount to Buyer.  The Seller shall notify Buyer of such wire transfer and provide reasonable details regarding the Royalty Interest Payment so received by Seller.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;37</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(an)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">If the Licensee exercises any set-off or deduction against any payment of the Royalty Interests, then Seller shall promptly (and in any event no later than five (5) Business Days) following payment of the Royalty Interest reduced by such set-off or deduction, make a true-up payment to Buyer such that Buyer receives the full amount of such Royalty Interest Payment that would have been payable to Buyer had such set-off or deduction not been exercised.  After Seller makes the payment referred to in the first sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Seller shall be entitled to, and Buyer shall not be entitled to, any amounts recovered from the Licensee in respect of such set-off or deduction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ao)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">All remittances pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be made (i) without set-off or deduction of any kind (except as required by applicable Law) and (ii) by wire transfer of immediately available funds to such account as Buyer designates in writing.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ap)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Any amounts payable by Seller under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall bear interest, to the extent not paid within thirty (30) days of demand therefore by Buyer at a per annum rate equal to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Licensee Instruction.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the term of this Agreement, other than the Licensee Instruction, Seller shall not, without Buyer&#8217;s prior written consent (which consent may be withheld or granted in Buyer&#8217;s sole discretion), deliver any written instructions to Licensee redirecting the payment of the Royalty Interests. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Seller&#8217;s Commercially Reasonable Efforts and Judgment.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is understood and agreed that, in determining whether Seller&#8217;s efforts or judgments are &#8220;commercially reasonable&#8221; with respect to any covenant that specifically references such term in this Agreement, Seller shall be deemed to be acting or making a judgment in a commercially reasonable manner if Seller would reasonably be expected to act in the same manner if Seller had the sole right, title and interest in and to the Purchased Assets.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Royalty Reports&#59; Notices and Communications from Licensee.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aq)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">Seller shall promptly (and in any event no later than five (5) Business Days) following the receipt by Seller from the Licensee of a Royalty Report furnish a copy of the same to Buyer.  Except for the Licensee Instruction and notices and correspondence required to be given or made by Seller (i) under the License Agreement or (ii) by applicable Law, Seller shall not send any notice or correspondence to the Licensee relating to, affecting or involving, the Purchased Assets that would reasonably be expected to result in a Material Adverse Effect, except with the prior written consent of Buyer.  Without limiting the foregoing, Seller shall, promptly (and in any event no later than five (5) Business Days) following the delivery thereof by Seller to the Licensee, furnish a copy of a written notice sent by Seller to the Licensee relating to, affecting or involving the Purchased Assets or that would reasonably be expected to result in a Material </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;38</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Adverse Effect.  Without limiting the foregoing, Seller shall, promptly (and in any event no later than five (5) Business Days) following the delivery thereof by Seller to the Licensee, furnish a copy of correspondence sent by Seller to the Licensee that would reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ar)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.71pt">Seller shall promptly deliver (i) notices received by Seller from Licensee&#59; and (ii) invoices provided by Seller to Licensee, in each case regarding the achievement of Milestones.  </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Maintenance of License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within five (5) Business Days after becoming aware, by written notice, of Licensee&#8217;s (A) intent to&#160;terminate the License Agreement, in whole or in part or (B) allegation of a breach or violation of or default, in each case in any material respect, under the License Agreement by Seller, Seller shall give written notice thereof to Buyer.  Such notice shall (x) describe in reasonable detail such breach, default or termination event, (y) include a copy of any written notice received from Licensee with respect thereto, and (z) in the case of any breach or default or alleged breach or default by Seller, in each case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in any material respect, describe in reasonable detail any corrective action Seller proposes to take in respect of such breach or default.  In consultation with Buyer, Seller shall use Commercially Reasonable Efforts to cure any breach or default by it under the License Agreement, as applicable, and, in any case, shall give written notice to Buyer upon curing such breach or default.  Seller shall pay the costs and expenses associated with all of the foregoing actions, including in connection with any Disputes related to any alleged breach or alleged default under the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Enforcement of License Agreement and the Production Agreements (excluding the Back-up Manufacturing Agreements).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Seller will comply with the enforcement provisions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 5.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Audits.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(as)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.04pt">The Seller and Buyer shall consult with each other regarding the timing, manner and conduct of any review or audit of the Licensee&#8217;s books and records pursuant to Section 8.06 of the License Agreement.  For the avoidance of doubt, Seller shall not request an examination of the Licensee&#8217;s records and books of account without the prior written consent of Buyer, such consent not to be unreasonably withheld, conditioned or delayed.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(at)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.37pt">Following consultation in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.17(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, if requested in writing by Buyer, Seller shall to the extent permitted by Section 10.01 of the License Agreement, provide written notice to the Licensee to cause an inspection or audit to determine the correctness of any Royalty Interest Payments made under the License Agreement.  Seller will promptly furnish to Buyer a true, correct and complete copy of any inspection or audit report prepared in connection with such an inspection or audit.  If, following the completion of such inspection or audit, Seller is required to reimburse Licensee for overpayment of the Royalty Interests, then Buyer shall promptly upon request reimburse Seller, or, at Seller&#8217;s request, Licensee on behalf of Seller, for the portion of such overpaid amount that was </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;39</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">actually paid to Buyer, and shall promptly (and in any event within two (2) Business Days) after making such payment provide documentation satisfactory to Seller evidencing that such payment was made.  If, following the completion of such inspection or audit, Licensee is required to pay amounts representing an underpayment of the Royalty Interests during the applicable period of time, Buyer shall be paid from such amounts a portion equal to the amount by which the Royalty Interest was underpaid during the applicable period of time.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(au)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">All of the expenses of any inspection or audit requested by Buyer pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, including such fees and expenses of any public accounting firm engaged by Seller (and reasonably acceptable to Buyer) in connection with such an inspection or audit shall be paid by Buyer unless the amount of the overpayment or underpayment payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.17(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is greater than &#91;***&#93; of the total amount actually owed for the period audited, in which case Seller shall pay such fees and expenses. </font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Post-Closing Obligations.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(av)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt">&#91;Reserved&#93;.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aw)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.04pt">Notwithstanding any provision herein or in any other Transaction Document, as soon as practicable, Seller shall deliver to Licensee a duly executed copy of the Licensee Instruction.  Within three (3) Business Days thereafter, Seller shall deliver to Buyer evidence reasonably satisfactory to Buyer confirming the delivery to and receipt by Licensee of the Licensee Instruction.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:1.04pt"><br><br>THE CLOSING&#59; CONDITIONS TO CLOSING</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Closing. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Subject to the closing conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and unless otherwise mutually agreed by the Parties, the closing of the transactions contemplated under this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall take place remotely via electronic delivery of the executed Transaction Documents and other deliverables, on the Closing Date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">As soon as practicable (but in any event no later than one (1) Business Day after the Closing Date) Seller shall deliver to Buyer a receipt (which may be confirmation by electronic mail) for payment of the amount set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Conditions Applicable to Buyer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The obligations of Buyer to effect the Closing and pay the Closing Amount pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, shall be subject to the satisfaction of the following conditions, as of the Closing Date, any of which may be waived in writing by Buyer in its sole discretion&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">All notices to, consents, approvals, authorizations and waivers from Third Parties and Governmental Authorities that are required for the consummation of the </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;40</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transactions contemplated by this Agreement or any of the Transaction Documents shall have been obtained or provided for and shall remain in effect, in form and substance reasonably acceptable to Buyer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All of the Transaction Documents (including without limitation, the Assignment) shall have been executed and delivered by Seller to Buyer, and Buyer shall have received the same.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Buyer shall have received an opinion of Latham &#38; Watkins, LLP, counsel to Seller, in form and substance reasonably acceptable to Buyer. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Buyer shall have received a certificate of an executive officer of Seller (the statements made in which shall be true and correct on and as of the Closing Date)&#58; (i) attaching copies, certified by such officer as true and complete, of (x) the organizational documents of Seller and (y) resolutions of the governing body of Seller authorizing and approving the execution, delivery and performance by Seller of the Transaction Documents and the transactions contemplated herein and therein&#59; (ii) setting forth the incumbency of the officer or officers of Seller who have executed and delivered the Transaction Documents, including therein a signature specimen of each such officer or officers&#59; and (iii) attaching a copy, certified by such officer as true and complete, of a good standing certificate of the appropriate Governmental Authority of Seller&#8217;s jurisdiction of organization issued as of a recent date, stating that Seller is in good standing under the Applicable Laws of such jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Buyer shall have received a certificate of an executive officer of Seller (the statements made in which shall be true and correct on and as of the date of such certificate) attesting that (i) the representations made by Seller in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> will be true as of the Closing Date, and (ii) there is no event or circumstance that, upon notice or the passage of time, or both, would constitute or give rise to any breach or default in the performance of Seller under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Searches of Uniform Commercial Code filings in the jurisdictions where a filing would need to be made in order to perfect Purchaser's ownership of or security interest in the Purchased Assets, copies of the financing statements on file in such jurisdictions and evidence that no Liens exist on the Purchased Assets (apart from Liens created pursuant to this Agreement) have been completed, and copies of such search results provided to Buyer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">UCC financing statements for each appropriate jurisdiction as is necessary, in Purchaser's sole discretion, to perfect Purchaser's ownership of and security interest in the Purchased Assets have been provided to Buyer. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Payment of the amounts obligated to be paid by Seller to Purchaser under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have been made&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the condition set forth in this clause (g) will be satisfied by Purchaser's deduction of such amount from the Closing Payment.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;41</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:32.38pt"><br><br>TERMINATION</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.07.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Termination.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement shall survive the expiration of any Licensed Patents and shall continue in full force and effect unless terminated on a date (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) mutually agreed upon in writing by the Parties.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.08.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Effects of Termination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The termination of this Agreement shall not release either Party of any obligation or liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding anything herein to the contrary, the termination of this Agreement shall be without prejudice to other remedies such Party may have at Law or in equity (including any enforcement of its rights under any of the Transaction Documents).  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Definitions) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (No Assumption), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Confidentiality&#59; Public Announcement), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.04(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Further Assurance) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.09(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Records), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Audits), this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Effects of Termination) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Miscellaneous) shall survive the termination of this Agreement.  Except as otherwise provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (Effects of Termination), all rights and obligations of the Parties under this Agreement shall terminate upon termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.72pt"><br><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.01.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Survival.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each representation and warranty of the Parties contained in the Transaction Documents will survive the Closing and continue in full force and effect, in each case, only as of the date such representation and warranty is made, until the Termination Date. Notwithstanding anything in this Agreement or implied by Law to the contrary, each covenant and obligation in the Transaction Documents or in any certificate delivered pursuant to the Transaction Documents will survive the Closing and continue in full force and effect until the Termination Date, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7.02(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless expressly waived pursuant to any Transaction Document, no representation, warranty, covenant, right or remedy available to any Person out of or in connection with any Transaction Document will be deemed waived by any action or inaction of that Person (including consummation of the Closing, any inspection or investigation, or the awareness of any fact or matter) at any time, whether before, on or after the Closing.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;42</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.02.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Notices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All notices, consents, waivers and communications hereunder given by any Party to the other shall be in writing (including electronic mail) and delivered personally, by electronic mail, by a recognized overnight courier, or by dispatching the same by certified or registered mail, return receipt requested, with postage prepaid, in each case addressed&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Buyer to&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCare Royalty Partners IV, L.P.</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Atlantic Street, 6th Floor</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stamford, CT 06901</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  &#91;***&#93;<br>Email&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a courtesy copy to (which shall not constitute notice)&#58;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCare Royalty Partners IV, L.P.</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">300 Atlantic Street, 6th Floor</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stamford, CT 06901</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58;  &#91;***&#93;<br>Email&#58;&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cadwalader, Wickersham &#38; Taft LLP</font></div><div style="padding-left:72pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">200 Liberty Street<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, NY 10281</font></div><div style="padding-left:72pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;<br>Email&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Seller to&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ardelyx, Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34175 Ardenwood Blvd.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fremont, CA 94555</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Telephone&#58; &#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a courtesy copy to (which shall not constitute notice)&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Ardelyx, Inc.<br>400 Fifth Avenue<br>Suite 210<br>Waltham, MA 02451<br>Attention&#58;  &#91;***&#93;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font></div><div style="padding-left:72pt;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Latham &#38; Watkins LLP</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;43</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">140 Scott Drive</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Menlo Park, CA 94025-1008</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; &#91;***&#93;.</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Telephone&#58; &#91;***&#93;</font></div><div style="padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to such other address or addresses as Buyer or Seller may from time to time designate by notice as provided herein, except that notices of changes of address shall be effective only upon receipt.  All such notices, consents, waivers and communications shall&#58;  (a)&#160;when posted by certified or registered mail, postage prepaid, return receipt requested, be effective five (5) Business Days after dispatch, (b) when sent by electronic mail, be effective upon receipt by the transmitting party of confirmation of complete transmission or return email or &#8220;read&#8221; receipt from the recipient, (c) when delivered by an internationally recognized overnight courier, be effective upon delivery (such date being evidenced by the courier&#8217;s service records), or (d) when delivered in person, be effective upon delivery.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.03.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Successors and Assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The provisions of this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.  Seller shall not be entitled to assign any of its obligations or rights under the Transaction Documents without the prior written consent of Buyer&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, such consent shall not be required in connection with an Acquisition, so long as the acquirer has delivered evidence, in form and substance reasonably satisfactory to Buyer, to Buyer that such Person has assumed all of Seller&#8217;s rights and obligations under the Transaction Documents.  Buyer may assign without the consent of Seller any of its rights or obligations under the Transaction Documents without restriction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, so long as no Event of Default shall have occurred and be continuing, Buyer may not assign any of its rights and obligations under the Transaction Documents to any Competitor without the prior written consent of Seller.  Any purported assignment in violation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be null and void.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.04.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Indemnification.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Seller hereby indemnifies and holds each Buyer Indemnified Party harmless from and against any and all Losses incurred or suffered by any Buyer Indemnified Party arising out of (i) any breach of any representation or warranty made by Seller in any of the Transaction Documents or in any certificate delivered pursuant to the Transaction Documents, (ii) any breach of or default under any covenant or agreement by Seller pursuant to any Transaction Document, the License Agreement or any Production Agreement, including any failure by Seller to satisfy any of the Excluded Liabilities and Obligations, (iii) any product liability claims or claims of infringement or misappropriation of any intellectual property rights of any Third Parties in respect of the Product, (iv) any Event of Default, (v) any Excluded Liabilities and Obligations, or (vi) any Losses suffered or incurred by any Buyer Indemnified Party as a result of the existence of any Permitted Liens.  Notwithstanding the foregoing, such indemnification by Seller shall not apply with respect to any Losses to the extent resulting from the gross negligence, willful misconduct or bad faith of any Buyer Indemnified Party.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;44</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Buyer hereby indemnifies and holds each Seller Indemnified Party harmless from and against any and all Losses incurred or suffered by a Seller Indemnified Party arising out of (i) any breach of any representation or warranty made by Buyer in any of the Transaction Documents or in any certificate delivered pursuant to the Transaction Documents or (ii) any breach of or default under any covenant or agreement by Buyer pursuant to any Transaction Document.  Notwithstanding the foregoing, such indemnification by Buyer shall not apply with respect to any Losses to the extent resulting from the gross negligence, willful misconduct or bad faith of any Seller Indemnified Party. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If any a Claim shall be brought or alleged against an indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to the preceding paragraphs, the indemnified party shall, promptly after receipt of notice of the commencement of any such Claim, notify the indemnifying party in writing of the commencement of such Claim, enclosing a copy of all papers served, if any&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> unless, and only to the extent that, such omission results in the forfeiture of, or has a material adverse effect on the exercise or prosecution of, substantive rights or defenses by the indemnifying party.  In case any such Claim is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation.  In any such proceeding, an indemnified party shall have the right to retain its own counsel, but the reasonable and documented fees and expenses of such counsel shall be at the expense of such indemnified party unless (i)&#160;the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii)&#160;the indemnifying party has assumed the defense of such proceeding and has failed within a reasonable time to retain counsel reasonably satisfactory to such indemnified party or has failed to diligently conduct the defense of such Claim, (iii)&#160;the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of such counsel&#59; or (iv) the Claim relates to taxes or any criminal or regulatory enforcement Claim.  The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;45</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement (i) includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding&#59; (ii) provides for the payment by the indemnifying party of money as sole relief for the claimant&#59; and (iii) involves no finding or admission of any violation of Law or the rights of any Person and has no effect on any other claims that have been made against the indemnified person.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">The only legal action that may be asserted by or on behalf of any Buyer Indemnified Party or Seller Indemnified Party with respect to any matter arising out of the transactions contemplated by this Agreement or the Transaction Documents shall be an action to enforce or to recover Losses as an indemnification claim pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting the generality of the foregoing, no legal action based upon predecessor or successor liability, contribution, tort, strict liability or any statute, regulation or ordinance may be maintained by or on behalf of Buyer or any Buyer Indemnified Party or Seller or any Seller Indemnified Party, as applicable, with respect to any matter that is the subject of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Losses shall be (i) calculated net of actual recoveries received by or on behalf of an indemnified party under insurance policies, risk sharing pools or similar arrangements (net of any actual collection costs and recoveries and deductibles) and (ii) reduced by any proceeds received from third parties, through indemnification, counterclaim or otherwise in compensation for the subject matter of an indemnification claim made hereunder.  Notwithstanding the foregoing, any indemnified party may take any action against an indemnifying party to enforce or recover Losses pursuant to the indemnification obligations of the indemnifying party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> without any requirement to take any action or exhaust any right or remedy against any other Person, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the indemnified party agrees that the indemnifying party shall then be subrogated to any and all other rights of the indemnified party to recovery to the extent of such indemnification paid by the indemnifying party (but excluding interest amounts and gross-up or other payments in respect of taxes).  If any proceeds, benefits or recoveries are received by or on behalf an indemnified party with respect to Losses after an indemnifying party has made an indemnification payment to an indemnified party with respect thereto and receipt of such proceeds, benefits or recoveries prior to such payment would have reduced the amount of such indemnification payment if received prior to such payment, then such indemnified party shall hold such amounts in trust for the benefit of the indemnifying party and, within three (3) Business Days after receipt thereof, deliver such amounts (net of any applicable withholding tax) to the indemnifying party by wire transfer of immediately available funds as directed by the indemnifying party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Neither Party shall be obligated to indemnify Seller Indemnified Parties or Buyer Indemnified Parties, as applicable, with respect to any Losses as to which such Party is otherwise entitled to assert any claim for indemnification, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as applicable, unless and until the aggregate amount of the Losses of Seller Indemnified Parties or Buyer Indemnified Parties in respect of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, as applicable, exceed the Indemnity Threshold Amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, however, that </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;46</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">thereafter the indemnifying party shall indemnify Buyer Indemnified Parties or Seller Indemnified Parties, as applicable, for all amounts including, for the avoidance of doubt, the Indemnity Threshold Amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, further, that such foregoing limitation shall not apply to any Losses suffered by any indemnified party in connection with a Third Party Claim.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Notwithstanding anything in this Agreement to the contrary, Seller shall not have any liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in excess of the sum of (i) the Closing Amount, (ii) all Investment Payments made by Buyer to Seller, and (iii) the applicable Investment Return Amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> such foregoing limitation shall not apply to any Losses suffered by any Buyer Indemnified Party in connection with a Third Party Claim (other than any Losses to the extent resulting from the gross negligence, willful misconduct or bad faith of any Buyer Indemnified Party).  Notwithstanding anything in this Agreement to the contrary, Buyer shall not have any liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in excess of the amount of Royalty Interest Payments received by Buyer pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.05.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Independent Nature of Relationship&#59; Taxes. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The relationship between Seller, on the one hand, and Buyer, on the other hand, is solely that of assignor and assignee, and neither Buyer, on the one hand, nor Seller, on the other hand, has any fiduciary or other special relationship with the other or any of their respective Affiliates.  For the avoidance of doubt, nothing in this Agreement shall be read to create any agency, partnership, association or joint venture of Seller (or any of its Affiliates) and Buyer (or any of its Affiliates) and each Party agrees not to refer to the other as a &#8220;partner&#8221; or the relationship as a &#8220;partnership&#8221; or &#8220;joint venture&#8221; or other kind of entity or legal form.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Except as otherwise contemplated herein, no Party shall at any time obligate the other Party, or impose on such other Party any obligation, in any manner or respect to any Third Party.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Seller and Buyer shall treat the transactions contemplated by the Transaction Documents as a sale of the Purchased Assets for all purposes (other than financial accounting purposes)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> including United States federal, state and local tax purposes. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Parties hereto agree not to take any position that is inconsistent with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on any tax return or in any audit or other administrative or judicial proceeding unless (i) the other Party to this Agreement has consented to such actions, or (ii) such inconsistent position is required by applicable Law.  If a Governmental Authority conducts an inquiry of Seller or Buyer related to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties hereto shall cooperate with each other in responding to such inquiry in a reasonable manner consistent with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Parties shall use commercially reasonable efforts to ensure all payments to Buyer under this Agreement are made without any deduction or withholding for or on account of any tax, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> if deduction or withholding is required from any payment under this Agreement, other than any deduction or withholding </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;47</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in respect of (i) any tax that would not have been imposed (or would have been imposed but at a lower rate) but for any connection of Buyer with the jurisdiction of the applicable taxing authority (other than a connection arising solely from this Agreement or any transaction contemplated hereby)&#59; (ii) any tax that would not have been imposed (or would have been imposed but at a lower rate) but for any failure of Buyer to provide any applicable documentation permitting such payments to be made without (or at a reduced rate of) withholding that is reasonably requested by Seller and that Buyer is legally eligible to provide and (iii) any U.S. federal withholding tax (such taxes described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and all such taxes other than Excluded Taxes, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the sum payable shall be increased and paid by Seller or any of its Affiliates as necessary so that after all such deductions and withholdings have been made, Buyer receives an amount equal to the amount it would have received had no such deductions or withholding been made.  Seller shall promptly notify Buyer in writing in the event that any deduction or withholding is effected or proposed by Seller or, to the Knowledge of Seller, any Governmental Authority, with respect to any such payments hereunder.  On or prior to the Closing Date, Buyer shall deliver to Seller a duly executed Internal Revenue Service Form W-9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">The Parties shall treat any Investment Payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2.03(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and any indemnification payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (except to the extent treated as imputed interest pursuant to Sections 483 or 1274 of the Internal Revenue Code of 1986, as amended or otherwise) as adjustments to the purchase price of the Purchased Assets for all tax purposes to the extent permitted by applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without limitation of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.05(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, this Agreement is not intended to create a deemed partnership, association or joint venture between Buyer and any counterparty.  Each Party agrees not to refer to the other as a &#8220;partner,&#8221; or the relationship as a &#8220;partnership&#8221; or &#8220;joint venture.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.06.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Entire Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement, together with the Exhibits and Schedules hereto (which are incorporated herein by reference), and the other Transaction Documents constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior agreements (including the Confidentiality Agreement), understandings and negotiations, both written and oral, between the Parties with respect to the subject matter of this Agreement.  Neither this Agreement nor any provision hereof (other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), is intended to confer upon any Person other than the Parties any rights or remedies hereunder.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.07.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Amendments&#59; No Waivers.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This Agreement or any term or provision hereof may not be amended, changed or modified except with the written consent of both Parties.  No waiver of any right hereunder shall be effective unless such waiver is signed in writing by the Party against whom such waiver is sought to be enforced.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;48</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">No failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">No waiver or approval hereunder shall, except as may otherwise be stated in such waiver or approval, be applicable to subsequent transactions.  No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder.  The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by applicable Law.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.08.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Interpretation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">When a reference is made in this Agreement to Articles, Sections, Schedules or Exhibits, such reference shall be to an Article, Section, Schedule or Exhibit to this Agreement unless otherwise indicated.  The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation&#8221;.  Neither Party shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one Party or the other.  The word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;or.&#8221; References to an agreement or instrument mean such agreement or instrument as from time to time amended, supplemented, restated or otherwise modified in compliance with the terms thereunder.  References to a Person are also to its permitted successors and assigns.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.09.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Headings and Captions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The headings and captions in this Agreement are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Counterparts&#59; Effectiveness&#59; Electronic Signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument.  This Agreement shall become effective when each Party shall have received a counterpart hereof signed by the other Party.  Any counterpart may be executed by facsimile, .pdf signature or other electronic signature and any such signature shall be deemed an original.  The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Buyer, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;49</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Severability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect.  Any provision of this Agreement held invalid or unenforceable only in part or degree by a court of competent jurisdiction shall remain in full force and effect to the extent not held invalid or unenforceable.  Upon such determination that a provision is invalid or unenforceable, the Parties shall negotiate in good faith to modify this Agreement as to effect the original intent of the Parties as closely as possible to the fullest extent permitted by applicable Law to the end that the transactions contemplated hereby are fulfilled to the extent possible.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each party will pay all of its own fees and expenses in connection with entering into and consummating the transactions contemplated by this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:25.7pt">Governing Law&#59; Jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the State of New York, USA without giving effect to the principles of conflicts of law thereof (other than Section 5-1401 of the General Obligations Law of the State of New York).  Each Party unconditionally and irrevocably consents to the exclusive jurisdiction of the courts of the State of New York, USA located in the County of New York and the Federal district court for the Southern District of New York located in the County of New York with respect to any suit, action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.  Each Party hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">forum non conveniens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, which it may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of any Transaction Document.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each Party hereby irrevocably consents to the service of process out of any of the courts referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8.13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this Agreement.  Each Party hereby irrevocably waives any objection to such service of process and further irrevocably waives and agrees not to plead or claim in any suit, action or proceeding commenced hereunder or under any other Transaction Document that service of process was in any way invalid or ineffective.  Nothing herein shall affect the right of a Party to serve process on the other Party in any other manner permitted by law.</font></div><div style="margin-bottom:12pt;padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:31.7pt">Waiver of Jury Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM ARISING OUT OF OR RELATING TO ANY TRANSACTION DOCUMENT OR THE TRANSACTIONS CONTEMPLATED UNDER ANY TRANSACTION DOCUMENT.  THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR </font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;50</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MODIFICATIONS TO ANY TRANSACTION DOCUMENT (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO ANY TRANSACTION DOCUMENT.  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE OTHER PARTY HERETO WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.14.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div style="height:110.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;51</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Certain confidential information contained in this document, marked by &#91;***&#93;, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></div><div><font><br></font></div></div></div><div id="ied0ffebe45d64ece94d69869904f651a_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the Parties have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SELLER&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:24pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ardelyx, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Michael Raab</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  Michael Raab<br>Title&#58;  CEO<br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BUYER&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCare Royalty Partners IV, L.P.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Clarke Futch</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  Clarke B. Futch&#160;&#160;&#160;&#160;<br>Title&#58;  Chairman &#38; CEO</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ied0ffebe45d64ece94d69869904f651a_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">License Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.35 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and Exhibit 10.1  of the Company&#8217;s  report on Form 8-K  filed in April 11, 2022 filed with the Securities and Exchange Commission. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>slr-ardelyxxfirstamendment.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib34e3f82dd8e46238949a770e066ff80_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is entered into as of August 1, 2022, by and among SLR INVESTMENT CORP., a Maryland corporation with an office located at 500 Park Avenue, 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Floor, New York, NY 10022 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SLR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as collateral agent (in such capacity, together with its successors and assigns, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Lenders listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> thereto or otherwise a party thereto from time to time including SLR in its capacity as a Lender (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and ARDELYX, INC., a Delaware corporation with offices located at 400 Fifth Avenue, Suite 210, Waltham, MA 02451 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement dated as of February 23, 2022 (as amended, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;Borrower, Collateral Agent and the Required Lenders have agreed to amend the defined term &#8220;Term B Milestone&#8221;, subject to, and in accordance with, the terms and conditions set forth herein, and in reliance upon the representations and warranties set forth herein.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, the Required Lenders and Collateral Agent hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Amendment to Loan Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The defined term &#8220;Term B Milestone&#8221; in Section 1.4 of the Loan Agreement is hereby amended by replacing the reference to December 31, 2022 with March 31, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Limitation of Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The amendment set forth in Section 2 above is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Representations and Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  To induce Collateral Agent and the Required Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and the Required Lenders as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date) and (b) no Event of Default has occurred and is continuing&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect&#59;  </font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Loan Document.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower, Lenders and Collateral Agent agree that this Amendment shall be a Loan Document.  Except as expressly set forth herein, the Loan Agreement and the other Loan Documents shall continue in full force and effect without alteration or amendment.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Amendment shall be deemed effective as of the date hereof upon the due execution of this Amendment by the parties thereto. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.  Delivery by electronic transmission (e.g. &#8220;.pdf&#8221;) of an executed counterpart of this Amendment shall be effective as a manually executed counterpart signature thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Electronic Execution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The words &#8220;execution,&#8221; &#8220;execute&#8221;, &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt">Governing Law.   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAW OF SUCH STATE), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, REGARDLESS OF THE LOCATION OF THE COLLATERAL, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL CONTINUE TO APPLY TO THAT EXTENT.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:105.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="ib34e3f82dd8e46238949a770e066ff80_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the parties hereto have caused this First Amendment to Loan and Security Agreement to be executed as of the date first set forth above.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARDELYX, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By &#47;s&#47; Justin Renz</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Justin Renz</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COLLATERAL AGENT AND LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR INVESTMENT CORP.</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By &#47;s&#47; Anthony J. Storino</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Anthony J. Storino</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LENDERS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR SENIOR INVESTMENT CORP.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME FUND SPV, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CREDIT INCOME BDC SPV LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP PRIVATE CORPORATE LENDING FUND SPV LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCP SF DEBT FUND L.P.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR HC FUND SPV, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SLR HC BDC LLC</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By &#47;s&#47; Anthony J. Storino</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Anthony J. Storino</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Authorized Signatory </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signature Page to First Amendment to Loan and Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>secondamendedandrestatedno.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i170a106ea87d4024ac9b09a1ac5c1a0c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARDELYX, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECOND AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Ardelyx, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which was  adopted pursuant to the Board&#8217;s resolutions on May 23, 2014, and amended pursuant to the Board&#8217;s resolutions on March 3, 2017, March 14, 2019, March 11, 2021 and June 15, 2022.  The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time in its sole discretion.  The terms and conditions of this Program shall supersede any prior cash and&#47;or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors.  This Program shall become effective on the date of the closing of the initial public offering of Company common stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Non-Employee Director shall be eligible to receive an annual retainer of $45,000 for service on the Board.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition, a Non-Employee Director shall receive the following annual retainers&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Chairman of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairman of the Board shall receive an additional annual retainer of $30,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $20,000 for such service.  A Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $10,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $15,000 for such service.  A Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $7,500 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $10,000 for such service.  A Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The annual retainers described in Sections 1(a) and 1(b) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be paid by the Company in a single cash lump sum immediately following the Effective Date and on the date of each annual meeting of the Company&#8217;s stockholders after the Effective Date.  In the event a Non-Employee Director is initially elected or appointed to the Board or a committee thereunder on a date other than the date of an annual meeting of the Company&#8217;s stockholders, the Annual Retainers paid to such Non-Employee Director shall be paid on the date of election or appointment, prorated to reflect the number of months (rounded up to the next whole month) remaining until the next annual meeting of the Company&#8217;s stockholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Election to Receive Stock in Lieu of Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. After the first payment of Annual Retainers following the Effective Date, Non-Employee Directors shall have the ability to elect to receive the Annual Retainers in an award of stock in lieu of cash pursuant to an election form provided by the Company for such purpose. Non-Employee Directors must complete and deliver the election form to the Company no later than 15 days prior to the next annual meeting of the Company&#8217;s stockholders.  In the event that a Non-Employee Director makes an election to receive the Annual Retainers in an award of stock in lieu of cash, on the annual meeting of the Company&#8217;s stockholders, he or she will automatically be granted that number of shares of fully vested Company common stock calculated by dividing the aggregate amount of the Annual Retainers by the Fair Market Value (as defined in the Equity Plan (as defined below)) of a share of Company common stock on the date of grant, rounded down to the nearest whole share.  The stock awards shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2014 Equity Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In the event of any inconsistency between the Equity Plan and this Program, the terms of this Program shall control.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Non-Employee Directors shall be granted the equity awards described below.  The awards described below shall be granted under and shall be subject to the terms and provisions of the Equity Plan and shall be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms previously approved by the Board.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan.  In the event of any inconsistency between the Equity Plan and this Program, the terms of this Program shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall be eligible to receive, on the date of such initial election or appointment, an option to purchase </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shares of the Company&#8217;s common stock with a grant date fair value of $300,000, but with a maximum number of shares of 200,000 shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Company&#8217;s common stock.  The awards described in this Section 2(a) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;  No Non-Employee Director shall be granted more than one Initial Award.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director who (i) has been serving on the Board for at least six months as of the date of any annual meeting of the Company&#8217;s stockholders after the Effective Date and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted, on the date of such annual meeting, an option to purchase </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shares of the Company&#8217;s common stock with a grant date fair value of $150,000, but with a maximum number of shares of 100,000 shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the Company&#8217;s common stock.   The awards described in this Section 2(b) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;  For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an annual meeting of the Company&#8217;s stockholders shall only receive an Initial Award in connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their service with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from service with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Initial Award shall vest and become exercisable with respect to 1&#47;36th of the shares subject to the Initial Award on each monthly anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through each such vesting </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">date.  Each Subsequent Award shall vest and become exercisable with respect to 1&#47;12th of the shares subject to the Subsequent Award on each monthly anniversary of the date of grant, which vesting will accelerate in full immediately prior to the next annual meeting of the Company&#8217;s stockholders after the date of grant to the extent unvested as of such date, subject to the Non-Employee Director continuing in service on the Board through each such vesting date.  Unless as otherwise specified herein, no portion of an Initial Award or Subsequent Award which is unvested or unexercisable at the time of a Non-Employee Director&#8217;s termination of service on the Board shall become vested and exercisable thereafter.  All of a Non-Employee Director&#8217;s Initial Awards and Subsequent Awards, and any other stock options or other equity-based awards outstanding and held by the Non-Employee Director, shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term of each stock option granted to a Non-Employee Director shall be ten (10) years from the date the option is granted. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall reimburse each Non-Employee Director for all reasonable, documented, out-of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties to the Company in accordance with the Company&#8217;s applicable expense reimbursement policies and procedures as in effect from time to time. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">* * * * *</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ardx-20220630xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i832ba616219c465faa781ce1830402fe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Raab, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ardx-20220630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie1769abd07ac494db607eee18dbcb0a8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Justin Renz, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ardx-20220630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia18e3dbaf52c4924a48ef400ea340dce_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quartlery Report of Ardelyx, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June&#160;30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Michael Raab, President and Chief Executive Officer of the Company, and Justin Renz, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ardx-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:547e7867-d9ac-4b70-ab52-436421bc76c6,g:9e9ed2bd-0902-4fdf-8b0e-0a522fb1fe1f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestments" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments">
        <link:definition>2104102 - Disclosure - Cash, Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsTables" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables">
        <link:definition>2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
        <link:definition>2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails">
        <link:definition>2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.ardelyx.com/role/FairValueMeasurements">
        <link:definition>2108103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables">
        <link:definition>2309302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails">
        <link:definition>2410404 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.ardelyx.com/role/Inventory">
        <link:definition>2111104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.ardelyx.com/role/InventoryTables">
        <link:definition>2312303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleDetails" roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails">
        <link:definition>2413405 - Disclosure - Inventory - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.ardelyx.com/role/InventoryNarrativeDetails">
        <link:definition>2414406 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNet" roleURI="http://www.ardelyx.com/role/ProductRevenueNet">
        <link:definition>2115105 - Disclosure - Product Revenue, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetTables" roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables">
        <link:definition>2316304 - Disclosure - Product Revenue, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetNarrativeDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails">
        <link:definition>2417407 - Disclosure - Product Revenue, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetGrosstoNetSalesAccrualsDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails">
        <link:definition>2418408 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreements" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements">
        <link:definition>2119106 - Disclosure - Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsTables" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables">
        <link:definition>2320305 - Disclosure - Collaboration and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails">
        <link:definition>2421409 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsDeferredRevenueDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails">
        <link:definition>2422410 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRoyaltyObligation" roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligation">
        <link:definition>2123107 - Disclosure - Deferred Royalty Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRoyaltyObligationDetails" roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails">
        <link:definition>2424411 - Disclosure - Deferred Royalty Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowing" roleURI="http://www.ardelyx.com/role/Borrowing">
        <link:definition>2125108 - Disclosure - Borrowing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingTables" roleURI="http://www.ardelyx.com/role/BorrowingTables">
        <link:definition>2326306 - Disclosure - Borrowing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingNarrativeDetails" roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails">
        <link:definition>2427412 - Disclosure - Borrowing - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails">
        <link:definition>2428413 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1">
        <link:definition>2428413 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiability" roleURI="http://www.ardelyx.com/role/DerivativeLiability">
        <link:definition>2129109 - Disclosure - Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityTables" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityTables">
        <link:definition>2330307 - Disclosure - Derivative Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityNarrativeDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails">
        <link:definition>2431414 - Disclosure - Derivative Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilityChangesinFairValueDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails">
        <link:definition>2432415 - Disclosure - Derivative Liability - Changes in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ardelyx.com/role/Leases">
        <link:definition>2133110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ardelyx.com/role/LeasesTables">
        <link:definition>2334308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalDetailsofFacilityLeasesDetails" roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails">
        <link:definition>2435416 - Disclosure - Leases - Additional Details of Facility Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails">
        <link:definition>2436417 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails">
        <link:definition>2437418 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1">
        <link:definition>2437418 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ardelyx.com/role/StockholdersEquity">
        <link:definition>2138111 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails">
        <link:definition>2439419 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.ardelyx.com/role/EquityIncentivePlans">
        <link:definition>2140112 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables">
        <link:definition>2341309 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails">
        <link:definition>2442420 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>2443421 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
        <link:definition>2444422 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockOptionsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails">
        <link:definition>2445423 - Disclosure - Equity Incentive Plans - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansRestrictedStockUnitsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails">
        <link:definition>2446424 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.ardelyx.com/role/NetLossPerShare">
        <link:definition>2147113 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.ardelyx.com/role/NetLossPerShareTables">
        <link:definition>2348310 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationofNetLossPerCommonShareDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails">
        <link:definition>2449425 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails">
        <link:definition>2450426 - Disclosure - Net Loss Per Share - Summary of Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.ardelyx.com/role/Contingencies">
        <link:definition>2151114 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.ardelyx.com/role/ContingenciesDetails">
        <link:definition>2452427 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" abstract="false" name="ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermLoan2022AMember" abstract="true" name="TermLoan2022AMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" abstract="false" name="RemainingFundingBasedOnConditionalMilestoneAchievement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermLoan2022BMember" abstract="true" name="TermLoan2022BMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" abstract="false" name="ContractWithCustomerLiabilityIncreaseForCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ExitFee2022Member" abstract="true" name="ExitFee2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" abstract="false" name="ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AmerisourceBergenDrugCorporationMember" abstract="true" name="AmerisourceBergenDrugCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PrepaidCommercialManufacturingCurrent" abstract="false" name="PrepaidCommercialManufacturingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ProductSupplyRevenueMember" abstract="true" name="ProductSupplyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PercentageOfNonRoyaltyRevenue" abstract="false" name="PercentageOfNonRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" abstract="false" name="LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialCommercializationMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ExitFee2018Member" abstract="true" name="ExitFee2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" abstract="false" name="PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermOfPaymentOfLicenseFeeFirstInstallment" abstract="false" name="TermOfPaymentOfLicenseFeeFirstInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" abstract="false" name="ScheduleOfGrossToNetSalesAccrualsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_ContractWithCustomerProductSalesGrossToNetAccruals" abstract="false" name="ContractWithCustomerProductSalesGrossToNetAccruals" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2021AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityTransactionCosts" abstract="false" name="ContractWithCustomerLiabilityTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" abstract="false" name="NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" abstract="false" name="IncreaseDecreaseInPrepaidCommercialManufacturingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ThresholdPercentageOfSalesForTieredRoyalties" abstract="false" name="ThresholdPercentageOfSalesForTieredRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_TermLoan2022Member" abstract="true" name="TermLoan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" abstract="false" name="CollaborationAndLicensingAgreementsNumberOfAmendments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_ExitFeePercentage" abstract="false" name="ExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2020AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AstrazenecaMember" abstract="true" name="AstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" abstract="false" name="CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsAbstract" abstract="true" name="CollaborationAndLicensingAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_StockIssuanceCostCommissionPercent" abstract="false" name="StockIssuanceCostCommissionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_RevenueGeneralPaymentTerms" abstract="false" name="RevenueGeneralPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" abstract="false" name="ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AccountsReceivableCommercialCustomerMember" abstract="true" name="AccountsReceivableCommercialCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_HealthCareRoyaltyPartnersIVLPMember" abstract="true" name="HealthCareRoyaltyPartnersIVLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" abstract="true" name="ContractWithCustomerGrossToNetSalesAccrualRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ContractWithCustomerDiscountsAndChargebacksMember" abstract="true" name="ContractWithCustomerDiscountsAndChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CashAndCashEquivalentsGrossUnrealizedGains" abstract="false" name="CashAndCashEquivalentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CardinalHealthMember" abstract="true" name="CardinalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CostOfRevenueAggregateAmountRecognized" abstract="false" name="CostOfRevenueAggregateAmountRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AccountsReceivableCollaboratorMember" abstract="true" name="AccountsReceivableCollaboratorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" abstract="false" name="LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_DerivativeIssued" abstract="false" name="DerivativeIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CashAndCashEquivalentsAmortizedCost" abstract="false" name="CashAndCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" abstract="false" name="FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_PercentageOfRoyaltyRevenue" abstract="false" name="PercentageOfRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" abstract="false" name="ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" abstract="false" name="LoanAgreementFutureObligationUponFundingOrOtherEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeTerm" abstract="false" name="LoanAgreementExitFeeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_DebtInstrumentClosingFeeAmount" abstract="false" name="DebtInstrumentClosingFeeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PrepaidCommercialManufacturingExpenseNoncurrent" abstract="false" name="PrepaidCommercialManufacturingExpenseNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_DebtInstrumentVariableRateBaseOption" abstract="false" name="DebtInstrumentVariableRateBaseOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_KnightTherapeuticsIncMember" abstract="true" name="KnightTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_MaximumAggregateOfferingPrice" abstract="false" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_KyowaKirinCo.LtdMember" abstract="true" name="KyowaKirinCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CashAndCashEquivalentsGrossUnrealizedLosses" abstract="false" name="CashAndCashEquivalentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" abstract="true" name="ContractWithCustomerOtherFeesCopayAndReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" abstract="false" name="ContractWithCustomerGrossToCreditsOrDeductionsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeDevelopmentMember" abstract="true" name="CollaborativeDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" abstract="false" name="DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ResearchCollaborationAndOptionAgreementMember" abstract="true" name="ResearchCollaborationAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" abstract="true" name="ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ProductIBSRELAMember" abstract="true" name="ProductIBSRELAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccruals" abstract="false" name="ContractWithCustomerGrossToNetSalesAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AstraZenecaTerminationAgreementMember" abstract="true" name="AstraZenecaTerminationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_NumberOfSeparateCollaborativeAgreements" abstract="false" name="NumberOfSeparateCollaborativeAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentInterestRateOnDefaultPercentage" abstract="false" name="DebtInstrumentInterestRateOnDefaultPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_TermLoan2018Member" abstract="true" name="TermLoan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DeferredRoyaltyObligationNoncurrent" abstract="false" name="DeferredRoyaltyObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" abstract="false" name="AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_DebtInstrumentPrepaymentFeePercentage" abstract="false" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ContractWithCustomerRebatesMember" abstract="true" name="ContractWithCustomerRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" abstract="false" name="FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" abstract="false" name="ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ardx-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:547e7867-d9ac-4b70-ab52-436421bc76c6,g:9e9ed2bd-0902-4fdf-8b0e-0a522fb1fe1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c9768766-0703-4e69-ab68-2ecbe7eb823c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_989f690e-28f0-40ce-a2b7-066a5d7a1763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9768766-0703-4e69-ab68-2ecbe7eb823c" xlink:to="loc_us-gaap_AssetsCurrent_989f690e-28f0-40ce-a2b7-066a5d7a1763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e26b3354-878d-405d-9255-9cb2fc94c26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9768766-0703-4e69-ab68-2ecbe7eb823c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e26b3354-878d-405d-9255-9cb2fc94c26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ab46c02-3fd6-4272-bb53-78365d43ff47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9768766-0703-4e69-ab68-2ecbe7eb823c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3ab46c02-3fd6-4272-bb53-78365d43ff47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8a358644-a285-456c-a814-02cf3fd79c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c9768766-0703-4e69-ab68-2ecbe7eb823c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8a358644-a285-456c-a814-02cf3fd79c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3c21e5ee-fbb2-43a6-93be-d7371fd9ad9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0547cf7f-ef1b-4a89-8840-29d394106f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3c21e5ee-fbb2-43a6-93be-d7371fd9ad9b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_0547cf7f-ef1b-4a89-8840-29d394106f31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c67972e6-b8ea-4c2a-94a8-66e44d18fe2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3c21e5ee-fbb2-43a6-93be-d7371fd9ad9b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c67972e6-b8ea-4c2a-94a8-66e44d18fe2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent_58cfc0d5-f706-4784-841b-04146fb56dc2" xlink:href="ardx-20220630.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3c21e5ee-fbb2-43a6-93be-d7371fd9ad9b" xlink:to="loc_ardx_DeferredRoyaltyObligationNoncurrent_58cfc0d5-f706-4784-841b-04146fb56dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f081d749-8767-4fed-b559-5ad1967102c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3c21e5ee-fbb2-43a6-93be-d7371fd9ad9b" xlink:to="loc_us-gaap_LiabilitiesCurrent_f081d749-8767-4fed-b559-5ad1967102c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_06f3c30f-7a26-45ac-9241-a2ba51211f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f19ccd07-4b64-4db2-a471-3c1e559e5068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_06f3c30f-7a26-45ac-9241-a2ba51211f13" xlink:to="loc_us-gaap_LongTermDebtCurrent_f19ccd07-4b64-4db2-a471-3c1e559e5068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d956822e-1c60-476f-9631-9235f92ab80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_06f3c30f-7a26-45ac-9241-a2ba51211f13" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_d956822e-1c60-476f-9631-9235f92ab80e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50fedb58-791c-4249-ba50-8ca0b1af83a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_06f3c30f-7a26-45ac-9241-a2ba51211f13" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50fedb58-791c-4249-ba50-8ca0b1af83a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_046a08ff-03df-4896-b75e-44bfe99aa23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_06f3c30f-7a26-45ac-9241-a2ba51211f13" xlink:to="loc_us-gaap_AccountsPayableCurrent_046a08ff-03df-4896-b75e-44bfe99aa23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc20c9e7-2f2f-4ff7-9b60-fc53ab6ba7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_06f3c30f-7a26-45ac-9241-a2ba51211f13" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc20c9e7-2f2f-4ff7-9b60-fc53ab6ba7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e200494c-89d6-471c-9e24-f627bcb4d438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_69c38f33-a032-4c2f-9f38-ba753b087cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e200494c-89d6-471c-9e24-f627bcb4d438" xlink:to="loc_us-gaap_PreferredStockValue_69c38f33-a032-4c2f-9f38-ba753b087cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_907d39b0-1511-4672-8421-08563f26b605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e200494c-89d6-471c-9e24-f627bcb4d438" xlink:to="loc_us-gaap_CommonStockValue_907d39b0-1511-4672-8421-08563f26b605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5d0342e3-22c3-4da5-911c-70494cc0cb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e200494c-89d6-471c-9e24-f627bcb4d438" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5d0342e3-22c3-4da5-911c-70494cc0cb8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5f8a6ea-c44a-445f-9f41-2cc07f6d633f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e200494c-89d6-471c-9e24-f627bcb4d438" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5f8a6ea-c44a-445f-9f41-2cc07f6d633f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_60a1ed42-2616-41fc-9141-91a9b47efece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e200494c-89d6-471c-9e24-f627bcb4d438" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_60a1ed42-2616-41fc-9141-91a9b47efece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2c94d3da-acca-4c2c-bdd7-e8eefd61e7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_056ba6cd-9210-4dee-a363-454fc6bcc976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c94d3da-acca-4c2c-bdd7-e8eefd61e7c6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_056ba6cd-9210-4dee-a363-454fc6bcc976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_40f4e4df-ad0e-4231-8140-59c415b10b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c94d3da-acca-4c2c-bdd7-e8eefd61e7c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_40f4e4df-ad0e-4231-8140-59c415b10b38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dffb3201-bbe1-45dd-8175-6e335fad0ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c94d3da-acca-4c2c-bdd7-e8eefd61e7c6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dffb3201-bbe1-45dd-8175-6e335fad0ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_03f7a8cb-a17c-4e06-8e42-723e452d9b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c94d3da-acca-4c2c-bdd7-e8eefd61e7c6" xlink:to="loc_us-gaap_InventoryNet_03f7a8cb-a17c-4e06-8e42-723e452d9b2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_28ea0d3b-c355-4336-b63c-776fe93812b5" xlink:href="ardx-20220630.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c94d3da-acca-4c2c-bdd7-e8eefd61e7c6" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_28ea0d3b-c355-4336-b63c-776fe93812b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_793cb12b-84d9-4b71-9eaf-a2399eab25c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c94d3da-acca-4c2c-bdd7-e8eefd61e7c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_793cb12b-84d9-4b71-9eaf-a2399eab25c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_acc6346b-9319-49d1-9da2-f0f55c895694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f522fa8a-8c9a-4e7b-9cc1-f75361f48837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_acc6346b-9319-49d1-9da2-f0f55c895694" xlink:to="loc_us-gaap_Liabilities_f522fa8a-8c9a-4e7b-9cc1-f75361f48837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f2acbfb8-e46b-4701-ad17-7392d4cce798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_acc6346b-9319-49d1-9da2-f0f55c895694" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f2acbfb8-e46b-4701-ad17-7392d4cce798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc814408-70d3-4eed-9a0f-fec37d19168b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_acc6346b-9319-49d1-9da2-f0f55c895694" xlink:to="loc_us-gaap_StockholdersEquity_cc814408-70d3-4eed-9a0f-fec37d19168b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b840de91-362b-448a-91ef-16a2a0e1aace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5b19c8eb-2a44-4767-bd4a-20a457ecf79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b840de91-362b-448a-91ef-16a2a0e1aace" xlink:to="loc_us-gaap_OperatingIncomeLoss_5b19c8eb-2a44-4767-bd4a-20a457ecf79a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b0c166fa-18bc-429a-8bfc-444f84cbf69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b840de91-362b-448a-91ef-16a2a0e1aace" xlink:to="loc_us-gaap_InterestExpense_b0c166fa-18bc-429a-8bfc-444f84cbf69d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2a47ab58-11f1-4fd8-899c-22a7c3aeb877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b840de91-362b-448a-91ef-16a2a0e1aace" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2a47ab58-11f1-4fd8-899c-22a7c3aeb877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_56e3fec4-431d-435b-8037-9e6083691480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_beaf4f61-0fbc-418f-ab75-6b905928e950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_56e3fec4-431d-435b-8037-9e6083691480" xlink:to="loc_us-gaap_CostOfRevenue_beaf4f61-0fbc-418f-ab75-6b905928e950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9caae222-a1b3-4e97-9750-f7002698f27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_56e3fec4-431d-435b-8037-9e6083691480" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9caae222-a1b3-4e97-9750-f7002698f27b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78130144-42e9-459c-b47d-0fb0d48af199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_56e3fec4-431d-435b-8037-9e6083691480" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78130144-42e9-459c-b47d-0fb0d48af199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fbf9e708-2dcf-44dc-86ce-fb26a595af5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bffaf972-de7e-4c9a-ada2-b18a655a4f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fbf9e708-2dcf-44dc-86ce-fb26a595af5e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bffaf972-de7e-4c9a-ada2-b18a655a4f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d3c586c0-bac1-43c6-9d82-b26be38c2940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fbf9e708-2dcf-44dc-86ce-fb26a595af5e" xlink:to="loc_us-gaap_CostsAndExpenses_d3c586c0-bac1-43c6-9d82-b26be38c2940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b8a57af4-43f9-4b56-806b-499c6ec49d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e82e884-6878-4dd9-9c24-7d01f9e681f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b8a57af4-43f9-4b56-806b-499c6ec49d28" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e82e884-6878-4dd9-9c24-7d01f9e681f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_66a7cd47-cc69-4015-8902-cd1a94558428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_b8a57af4-43f9-4b56-806b-499c6ec49d28" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_66a7cd47-cc69-4015-8902-cd1a94558428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f93b742c-109a-4fc8-91e9-6f03f08350b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6db35640-17d3-468e-b49b-590a044a0344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f93b742c-109a-4fc8-91e9-6f03f08350b4" xlink:to="loc_us-gaap_NetIncomeLoss_6db35640-17d3-468e-b49b-590a044a0344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7a117b84-fabe-47e3-ad4e-9a891bf3225f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f93b742c-109a-4fc8-91e9-6f03f08350b4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7a117b84-fabe-47e3-ad4e-9a891bf3225f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79148dda-73b6-493e-85ef-3263e813fe1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b763b242-d138-4c14-bac1-5d7a2ef9a9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79148dda-73b6-493e-85ef-3263e813fe1d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b763b242-d138-4c14-bac1-5d7a2ef9a9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_37006a76-e9f1-46ac-ac36-11e7148a2799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79148dda-73b6-493e-85ef-3263e813fe1d" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_37006a76-e9f1-46ac-ac36-11e7148a2799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f5b41d26-70a5-4e6c-acf8-2988c64f2818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79148dda-73b6-493e-85ef-3263e813fe1d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f5b41d26-70a5-4e6c-acf8-2988c64f2818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_80b0663b-fa3e-418d-8797-d8a936bc0161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79148dda-73b6-493e-85ef-3263e813fe1d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_80b0663b-fa3e-418d-8797-d8a936bc0161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_f3ecb1a3-082a-46bb-9a98-903699c271c3" xlink:href="ardx-20220630.xsd#ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79148dda-73b6-493e-85ef-3263e813fe1d" xlink:to="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_f3ecb1a3-082a-46bb-9a98-903699c271c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_43bc3688-b913-4513-aca4-8005d47798bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_43bc3688-b913-4513-aca4-8005d47798bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_54bbfee0-0076-4017-abd5-7c003878a818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_54bbfee0-0076-4017-abd5-7c003878a818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d7652f27-2e3e-4932-8b63-f0d22d2dd1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d7652f27-2e3e-4932-8b63-f0d22d2dd1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_73784d21-a172-46c7-8448-2a2ec57a56e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_73784d21-a172-46c7-8448-2a2ec57a56e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_805e8476-899f-491b-a064-4aa283be1333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_805e8476-899f-491b-a064-4aa283be1333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d27ab68b-dadc-4914-bba4-e7ec6aac8361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_NetIncomeLoss_d27ab68b-dadc-4914-bba4-e7ec6aac8361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_457e75da-a8da-4b10-b51b-9b6f9c90af8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_457e75da-a8da-4b10-b51b-9b6f9c90af8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7f90ba03-4e18-4f92-b7af-f5616666c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_Depreciation_7f90ba03-4e18-4f92-b7af-f5616666c106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges_22c17872-b331-4d86-bf05-924690d782aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_AmortizationOfDeferredCharges_22c17872-b331-4d86-bf05-924690d782aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1ea607e1-81fb-488f-b581-ddc1f39add8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1ea607e1-81fb-488f-b581-ddc1f39add8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd96a043-d5b4-422f-82e0-0dedf8a7ff98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd96a043-d5b4-422f-82e0-0dedf8a7ff98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4b7394e0-1c59-4092-8ab1-0d404de96890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4b7394e0-1c59-4092-8ab1-0d404de96890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bfd86ecb-ce7b-4c50-b171-a090091d4810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bfd86ecb-ce7b-4c50-b171-a090091d4810" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_cae65bd6-2660-4fe8-8a3a-a7db34d07511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_cae65bd6-2660-4fe8-8a3a-a7db34d07511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e7d1570b-792c-4554-830d-2214cc6b9174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e7d1570b-792c-4554-830d-2214cc6b9174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_67834020-7ff2-4108-a337-b7ba95b1819f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_67834020-7ff2-4108-a337-b7ba95b1819f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7f257227-2b39-4f34-8a47-bc3040ac6ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_ShareBasedCompensation_7f257227-2b39-4f34-8a47-bc3040ac6ea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_26af215d-4131-4cbf-959d-05295afd0607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_26af215d-4131-4cbf-959d-05295afd0607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_58d832e3-a57e-4241-8385-f6a1ba96efbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_58d832e3-a57e-4241-8385-f6a1ba96efbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_fc1b3e27-de0f-4fc4-b5a6-01637e141def" xlink:href="ardx-20220630.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb64b69d-42d5-4b84-8cab-26fb39bc2d90" xlink:to="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_fc1b3e27-de0f-4fc4-b5a6-01637e141def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_94a1ceac-1668-461d-9303-ea263b133b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67245720-0ef0-4c51-b02c-e3406fa8cb79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_94a1ceac-1668-461d-9303-ea263b133b0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67245720-0ef0-4c51-b02c-e3406fa8cb79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f8da895-62f7-42aa-8bcf-30aafd2e4849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_94a1ceac-1668-461d-9303-ea263b133b0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5f8da895-62f7-42aa-8bcf-30aafd2e4849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_98cfdff6-e631-41fd-9b16-e77176f9b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_94a1ceac-1668-461d-9303-ea263b133b0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_98cfdff6-e631-41fd-9b16-e77176f9b68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5360013-a049-4345-9d12-2884c70a5f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c5f709f-01bf-434e-a6b2-bb1fcd6496aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5360013-a049-4345-9d12-2884c70a5f2a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c5f709f-01bf-434e-a6b2-bb1fcd6496aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9a6a0815-2fd1-4c1a-b44d-52fcf2e7f378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5360013-a049-4345-9d12-2884c70a5f2a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9a6a0815-2fd1-4c1a-b44d-52fcf2e7f378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a4ac80e3-9578-420d-97d2-8f73ebfbd71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5360013-a049-4345-9d12-2884c70a5f2a" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a4ac80e3-9578-420d-97d2-8f73ebfbd71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e94c7c33-ca63-4b6d-9e3b-ac4c959c2b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c5360013-a049-4345-9d12-2884c70a5f2a" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e94c7c33-ca63-4b6d-9e3b-ac4c959c2b7e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost_94b2ee38-4d0c-44c7-a906-caae3480f9d3" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_bd0265be-6abc-4705-8192-2684c39b5b0b" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost_94b2ee38-4d0c-44c7-a906-caae3480f9d3" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_bd0265be-6abc-4705-8192-2684c39b5b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_a74d1990-cbca-4482-bd21-4e317f7e5284" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost_94b2ee38-4d0c-44c7-a906-caae3480f9d3" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_a74d1990-cbca-4482-bd21-4e317f7e5284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32b82a72-75d3-4eaf-8cbd-8e71174b2771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost_94b2ee38-4d0c-44c7-a906-caae3480f9d3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32b82a72-75d3-4eaf-8cbd-8e71174b2771" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_398ea7bb-7998-4118-ae2f-952c3263575a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_847ea560-7ae2-496c-aeab-d4cc4e96f869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_398ea7bb-7998-4118-ae2f-952c3263575a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_847ea560-7ae2-496c-aeab-d4cc4e96f869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db3fa153-a5cf-4fd1-837e-8c23bd77ac32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_398ea7bb-7998-4118-ae2f-952c3263575a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_db3fa153-a5cf-4fd1-837e-8c23bd77ac32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_09b94b60-d239-4be9-9045-80e4cd3a23dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_398ea7bb-7998-4118-ae2f-952c3263575a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_09b94b60-d239-4be9-9045-80e4cd3a23dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_0ae992de-9c5b-484a-b7d4-334cf22437e1" xlink:href="ardx-20220630.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_af2e2dff-fdd2-4bf2-be2f-a6c612d15acb" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_0ae992de-9c5b-484a-b7d4-334cf22437e1" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_af2e2dff-fdd2-4bf2-be2f-a6c612d15acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_6cd76847-87c8-438a-9e39-23ba09874dac" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_0ae992de-9c5b-484a-b7d4-334cf22437e1" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_6cd76847-87c8-438a-9e39-23ba09874dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_40e3d672-4d8e-436d-b708-f086278f8cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_0ae992de-9c5b-484a-b7d4-334cf22437e1" xlink:to="loc_us-gaap_InvestmentsAndCash_40e3d672-4d8e-436d-b708-f086278f8cd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#InventoryScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d6574283-b9d2-4469-ab77-20ac2e075a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ffe53452-e300-43f6-a505-c123e48353d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d6574283-b9d2-4469-ab77-20ac2e075a77" xlink:to="loc_us-gaap_InventoryRawMaterials_ffe53452-e300-43f6-a505-c123e48353d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_3c916608-c62b-4a5e-a477-b87119c77520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d6574283-b9d2-4469-ab77-20ac2e075a77" xlink:to="loc_us-gaap_InventoryWorkInProcess_3c916608-c62b-4a5e-a477-b87119c77520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_0ea59695-0e2d-4ba0-a248-d94848ab4814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d6574283-b9d2-4469-ab77-20ac2e075a77" xlink:to="loc_us-gaap_InventoryFinishedGoods_0ea59695-0e2d-4ba0-a248-d94848ab4814" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_80df9e92-9120-477c-8933-66202df50e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_afaa3320-51e6-4fc9-8e18-11c39acfade8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80df9e92-9120-477c-8933-66202df50e0d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_afaa3320-51e6-4fc9-8e18-11c39acfade8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e7822dda-e799-4057-923e-4b4255dc0a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80df9e92-9120-477c-8933-66202df50e0d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e7822dda-e799-4057-923e-4b4255dc0a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_75ad8281-adce-4cfd-ae49-d66c9c6dd257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80df9e92-9120-477c-8933-66202df50e0d" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_75ad8281-adce-4cfd-ae49-d66c9c6dd257" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220630.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a019516-ecd0-41d1-b2df-33ea8166f554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1647004b-2b91-4121-b5e0-95f576ef2f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1a019516-ecd0-41d1-b2df-33ea8166f554" xlink:to="loc_us-gaap_LongTermDebtCurrent_1647004b-2b91-4121-b5e0-95f576ef2f31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dfa85edf-982d-4618-96e3-b2a753fdda6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_1a019516-ecd0-41d1-b2df-33ea8166f554" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dfa85edf-982d-4618-96e3-b2a753fdda6e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesAdditionalDetailsofFacilityLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_084c84dd-9a85-4436-80df-ad368f86946a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_029a4e7b-f17d-43ad-a749-09b167153335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_084c84dd-9a85-4436-80df-ad368f86946a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_029a4e7b-f17d-43ad-a749-09b167153335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_99b4e754-63ca-44c0-b64f-6d7a2a533357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_084c84dd-9a85-4436-80df-ad368f86946a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_99b4e754-63ca-44c0-b64f-6d7a2a533357" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cb6d737-03ce-425c-85de-6a30db351597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d8581be4-3cf8-4308-af83-d8186fb0c018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cb6d737-03ce-425c-85de-6a30db351597" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d8581be4-3cf8-4308-af83-d8186fb0c018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bea13265-71ca-4f66-9dc8-1d705d9f1fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cb6d737-03ce-425c-85de-6a30db351597" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bea13265-71ca-4f66-9dc8-1d705d9f1fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_61cdb5b8-0497-4aaf-a2b2-f53e06156faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cb6d737-03ce-425c-85de-6a30db351597" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_61cdb5b8-0497-4aaf-a2b2-f53e06156faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50fb771f-f781-401f-8867-10b020f10cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cb6d737-03ce-425c-85de-6a30db351597" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50fb771f-f781-401f-8867-10b020f10cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d29fa40-6469-4c97-982e-b488bffdf66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9cb6d737-03ce-425c-85de-6a30db351597" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8d29fa40-6469-4c97-982e-b488bffdf66c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_72997095-70a7-4535-8a68-c2378f1f4754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_05bade4f-2454-4efb-a109-33e7fe5097e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_72997095-70a7-4535-8a68-c2378f1f4754" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_05bade4f-2454-4efb-a109-33e7fe5097e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3b913520-34f6-4fcc-aea2-8026ec641c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_72997095-70a7-4535-8a68-c2378f1f4754" xlink:to="loc_us-gaap_OperatingLeaseLiability_3b913520-34f6-4fcc-aea2-8026ec641c0c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ardx-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:547e7867-d9ac-4b70-ab52-436421bc76c6,g:9e9ed2bd-0902-4fdf-8b0e-0a522fb1fe1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="if9a3bcfa49f54a93957275e64b7eddfe_CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_18c11927-cc15-4248-8aee-5fd7d59915ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_RevenuesAbstract_18c11927-cc15-4248-8aee-5fd7d59915ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a66a943-e22d-444b-af69-4eb110dca97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_18c11927-cc15-4248-8aee-5fd7d59915ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a66a943-e22d-444b-af69-4eb110dca97c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_8daa2d39-21df-4a58-aa3b-6dfd0a5d5d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_CostOfRevenue_8daa2d39-21df-4a58-aa3b-6dfd0a5d5d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_82f1c39d-8b94-481f-820d-35c62d80d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_82f1c39d-8b94-481f-820d-35c62d80d8ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78ce63eb-589e-402e-bcf3-669e0782c2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78ce63eb-589e-402e-bcf3-669e0782c2f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_defc8aaf-27ed-430c-ac6e-ebfc8ddbed22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_CostsAndExpenses_defc8aaf-27ed-430c-ac6e-ebfc8ddbed22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a6a9a551-3d10-4c12-9eb4-6d71367828d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_OperatingIncomeLoss_a6a9a551-3d10-4c12-9eb4-6d71367828d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fadffbd7-9bc2-475c-961a-6e6d32ea1ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_InterestExpense_fadffbd7-9bc2-475c-961a-6e6d32ea1ba7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a7edbbd9-1d93-45dc-8009-9554ac5f1461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a7edbbd9-1d93-45dc-8009-9554ac5f1461" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a7d67f6c-04ad-4916-af01-47a3eb77f53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a7d67f6c-04ad-4916-af01-47a3eb77f53d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60a80ddd-9df6-4264-9919-f3a589fc7108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_60a80ddd-9df6-4264-9919-f3a589fc7108" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4781444a-cd13-452d-85fd-15314aef5706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_NetIncomeLoss_4781444a-cd13-452d-85fd-15314aef5706" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_33d35b35-33f1-4b0a-86d0-0df8b242e26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_EarningsPerShareBasic_33d35b35-33f1-4b0a-86d0-0df8b242e26d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1bca5267-93fe-4e65-9457-fafc321e7f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1bca5267-93fe-4e65-9457-fafc321e7f06" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c75bf77-bb84-4e57-8171-68cc47328c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c75bf77-bb84-4e57-8171-68cc47328c09" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7fbbb0d-1b15-42b0-8948-478638fbb7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7fbbb0d-1b15-42b0-8948-478638fbb7ad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c57d75c8-fde9-4ca1-9dab-4bbbdb7df50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27ee999f-6857-4fae-a08e-8dd1b23c5663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27ee999f-6857-4fae-a08e-8dd1b23c5663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7301b9f-1a18-43f9-bc9c-cf350f5186ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7301b9f-1a18-43f9-bc9c-cf350f5186ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48dc97a7-67db-4de6-861f-2241d2258f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_StatementTable_48dc97a7-67db-4de6-861f-2241d2258f70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_26dbae53-d127-4a28-a840-9f5e193e3ecb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_48dc97a7-67db-4de6-861f-2241d2258f70" xlink:to="loc_srt_ProductOrServiceAxis_26dbae53-d127-4a28-a840-9f5e193e3ecb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_26dbae53-d127-4a28-a840-9f5e193e3ecb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_26dbae53-d127-4a28-a840-9f5e193e3ecb" xlink:to="loc_srt_ProductsAndServicesDomain_26dbae53-d127-4a28-a840-9f5e193e3ecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_26dbae53-d127-4a28-a840-9f5e193e3ecb" xlink:to="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6049c138-dea6-4eef-a0f3-83b8a17b35a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_us-gaap_ProductMember_6049c138-dea6-4eef-a0f3-83b8a17b35a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_4009bb91-8e59-441d-b2d5-2903a13a61c0" xlink:href="ardx-20220630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_ardx_ProductSupplyRevenueMember_4009bb91-8e59-441d-b2d5-2903a13a61c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_00d39e2d-6bda-42f6-8446-96999bf45ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_us-gaap_LicenseMember_00d39e2d-6bda-42f6-8446-96999bf45ba7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_18b26c1b-5876-4644-ae95-73768f69025e" xlink:href="ardx-20220630.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_ardx_CollaborativeDevelopmentMember_18b26c1b-5876-4644-ae95-73768f69025e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i4248e17c0b684251a56d9dbf7f26a374_CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_38e49f71-dd07-40a9-875d-06a4eff3eeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_38e49f71-dd07-40a9-875d-06a4eff3eeaa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e43cf23d-4232-42f3-ac99-937d21d6e9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_SharesOutstanding_e43cf23d-4232-42f3-ac99-937d21d6e9ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a4e3d687-f661-4c91-9e13-b9d90079b3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockholdersEquity_a4e3d687-f661-4c91-9e13-b9d90079b3e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2af4c7f5-9d0b-42ee-9662-11b95cfc3012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2af4c7f5-9d0b-42ee-9662-11b95cfc3012" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4b6e85e-7400-46b5-a7f0-d0938957cc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4b6e85e-7400-46b5-a7f0-d0938957cc4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5946ff1f-0a77-41b0-aa41-5f6ca7c35c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5946ff1f-0a77-41b0-aa41-5f6ca7c35c53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_747fd357-944c-4130-ba67-ad08046de85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_747fd357-944c-4130-ba67-ad08046de85b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f2057bca-6486-48ce-a5fd-a64c05ad2063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f2057bca-6486-48ce-a5fd-a64c05ad2063" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346ec900-33f5-4414-8976-74c5187df3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346ec900-33f5-4414-8976-74c5187df3cc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0473d13b-2bd2-4d68-9b13-b1133d67d6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0473d13b-2bd2-4d68-9b13-b1133d67d6c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a5d0a3-a027-43b3-8637-9cd943456212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a5d0a3-a027-43b3-8637-9cd943456212" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e4b567f0-8a8b-4b80-beae-ddfd9dddf0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e4b567f0-8a8b-4b80-beae-ddfd9dddf0c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_522f22d0-7470-4cdf-bc19-c6c428c87d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_NetIncomeLoss_522f22d0-7470-4cdf-bc19-c6c428c87d1e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e79b2b7c-1133-405b-a45e-da9f8c965469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d879b7c-d008-4b40-ad05-0fbbe0e2a4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_987c8e05-6b2c-4bfb-93a1-cdafda3a712c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_38e49f71-dd07-40a9-875d-06a4eff3eeaa" xlink:to="loc_us-gaap_StatementTable_987c8e05-6b2c-4bfb-93a1-cdafda3a712c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9a0bd92a-f807-4cee-b45c-c78d061e288e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_987c8e05-6b2c-4bfb-93a1-cdafda3a712c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9a0bd92a-f807-4cee-b45c-c78d061e288e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9a0bd92a-f807-4cee-b45c-c78d061e288e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9a0bd92a-f807-4cee-b45c-c78d061e288e" xlink:to="loc_us-gaap_EquityComponentDomain_9a0bd92a-f807-4cee-b45c-c78d061e288e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9a0bd92a-f807-4cee-b45c-c78d061e288e" xlink:to="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b490e8f1-6189-4310-963f-1086951554af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_CommonStockMember_b490e8f1-6189-4310-963f-1086951554af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2567b7e9-b3b2-41c7-bf10-385769a5a629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2567b7e9-b3b2-41c7-bf10-385769a5a629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_314b1c4c-a765-4e6f-81df-ec10d351e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_RetainedEarningsMember_314b1c4c-a765-4e6f-81df-ec10d351e0ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77e3e834-7966-44e4-abb5-44c8ecd8d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77e3e834-7966-44e4-abb5-44c8ecd8d4b4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="if0f57be63c134fec8ea40fb398dfbba0_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_db9b5520-2a0d-4d5c-a4a8-60ecc5b9cc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_db9b5520-2a0d-4d5c-a4a8-60ecc5b9cc61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms_f199fa5e-8a7d-48a4-856f-f4b1c28de15d" xlink:href="ardx-20220630.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_RevenueGeneralPaymentTerms_f199fa5e-8a7d-48a4-856f-f4b1c28de15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_bd971927-e05a-4a23-93b9-65660698148a" xlink:href="ardx-20220630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_bd971927-e05a-4a23-93b9-65660698148a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_04e05064-3f8f-4ced-a3e8-43a74555a5d9" xlink:href="ardx-20220630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_04e05064-3f8f-4ced-a3e8-43a74555a5d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_91349112-64a4-4b88-96d7-0e401bd54116" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_91349112-64a4-4b88-96d7-0e401bd54116" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_fcf55bf3-89f4-4619-aff3-2a04fdf5e0b8" xlink:href="ardx-20220630.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_fcf55bf3-89f4-4619-aff3-2a04fdf5e0b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86a0528f-e9a4-4b02-9df0-9b8a4032b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86a0528f-e9a4-4b02-9df0-9b8a4032b89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_86a0528f-e9a4-4b02-9df0-9b8a4032b89d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86a0528f-e9a4-4b02-9df0-9b8a4032b89d" xlink:to="loc_us-gaap_ReceivableTypeDomain_86a0528f-e9a4-4b02-9df0-9b8a4032b89d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86a0528f-e9a4-4b02-9df0-9b8a4032b89d" xlink:to="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember_ded8ef25-9df4-46e2-afdf-784b8688d9a3" xlink:href="ardx-20220630.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:to="loc_ardx_AccountsReceivableCollaboratorMember_ded8ef25-9df4-46e2-afdf-784b8688d9a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember_8192bb30-cf40-4713-b090-90a50a8a8cc0" xlink:href="ardx-20220630.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:to="loc_ardx_AccountsReceivableCommercialCustomerMember_8192bb30-cf40-4713-b090-90a50a8a8cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_srt_RangeAxis_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3" xlink:to="loc_srt_RangeMember_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3" xlink:to="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea739470-6ea4-4588-9b2d-78d9ed5c7066" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:to="loc_srt_MinimumMember_ea739470-6ea4-4588-9b2d-78d9ed5c7066" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10bd2bd4-e9b0-417c-8622-621ec758ff82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:to="loc_srt_MaximumMember_10bd2bd4-e9b0-417c-8622-621ec758ff82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8b85ef5-9687-4c7a-9737-86daff9d4749" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_srt_CounterpartyNameAxis_c8b85ef5-9687-4c7a-9737-86daff9d4749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8b85ef5-9687-4c7a-9737-86daff9d4749_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c8b85ef5-9687-4c7a-9737-86daff9d4749" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c8b85ef5-9687-4c7a-9737-86daff9d4749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82e80a33-7412-41be-bc23-d6cf7e01183c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c8b85ef5-9687-4c7a-9737-86daff9d4749" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82e80a33-7412-41be-bc23-d6cf7e01183c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_46b2ac74-287b-4fdb-8dd6-87ade7912402" xlink:href="ardx-20220630.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82e80a33-7412-41be-bc23-d6cf7e01183c" xlink:to="loc_ardx_AstrazenecaMember_46b2ac74-287b-4fdb-8dd6-87ade7912402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_034de5fb-1930-4d28-87f1-1cce14161e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_us-gaap_TypeOfArrangementAxis_034de5fb-1930-4d28-87f1-1cce14161e06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_034de5fb-1930-4d28-87f1-1cce14161e06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_034de5fb-1930-4d28-87f1-1cce14161e06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_034de5fb-1930-4d28-87f1-1cce14161e06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057fe0e2-ea06-4cbb-8176-d528a9a21c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_034de5fb-1930-4d28-87f1-1cce14161e06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057fe0e2-ea06-4cbb-8176-d528a9a21c87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_449109ca-2fc0-4db0-9848-a07fbe8500e0" xlink:href="ardx-20220630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057fe0e2-ea06-4cbb-8176-d528a9a21c87" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_449109ca-2fc0-4db0-9848-a07fbe8500e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="i81fc7762d2af4dbba1dc7b8e0d659735_CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost_03f9ef8e-6b16-4b31-b9ab-af864444bf3b" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_ardx_CashAndCashEquivalentsAmortizedCost_03f9ef8e-6b16-4b31-b9ab-af864444bf3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_a570f402-9bdb-4c4b-8023-06c654f63985" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_a570f402-9bdb-4c4b-8023-06c654f63985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_1961eb4d-fed0-412b-bf60-5384d3cc3d5c" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_1961eb4d-fed0-412b-bf60-5384d3cc3d5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1ce1dc8-eaf3-45b0-9f08-42b9f2582f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1ce1dc8-eaf3-45b0-9f08-42b9f2582f02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0ccc719-b82d-49bb-a133-802002a54ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0ccc719-b82d-49bb-a133-802002a54ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8a7dc625-78b2-4027-b905-46b29d44f93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8a7dc625-78b2-4027-b905-46b29d44f93a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61c50a1d-8292-4040-85f4-98e5cf819481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61c50a1d-8292-4040-85f4-98e5cf819481" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5c2a8ae-a2ac-446b-841d-15c4f034a89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5c2a8ae-a2ac-446b-841d-15c4f034a89b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_6633907b-8192-4fb2-b936-48f0773bc273" xlink:href="ardx-20220630.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_6633907b-8192-4fb2-b936-48f0773bc273" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_c7285e45-e5ac-4ccb-92ff-288c5d5ce0f9" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_c7285e45-e5ac-4ccb-92ff-288c5d5ce0f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_53823f2b-f5dc-4f00-844c-e01d0cf6718b" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_53823f2b-f5dc-4f00-844c-e01d0cf6718b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_9b0abd5c-149f-43df-9d1f-b50c061fb6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_us-gaap_InvestmentsAndCash_9b0abd5c-149f-43df-9d1f-b50c061fb6bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_33e16a62-4d61-4fdb-a51d-94ae24356fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_33e16a62-4d61-4fdb-a51d-94ae24356fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33e16a62-4d61-4fdb-a51d-94ae24356fd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_33e16a62-4d61-4fdb-a51d-94ae24356fd2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_33e16a62-4d61-4fdb-a51d-94ae24356fd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_33e16a62-4d61-4fdb-a51d-94ae24356fd2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_c26e369c-ee81-4c52-b59a-8ea100ca1af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:to="loc_us-gaap_CashMember_c26e369c-ee81-4c52-b59a-8ea100ca1af7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84413349-cd01-4e2f-8a28-907270073922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84413349-cd01-4e2f-8a28-907270073922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_597b29be-1608-4b7c-88d1-6cfa22d09570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_597b29be-1608-4b7c-88d1-6cfa22d09570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_597b29be-1608-4b7c-88d1-6cfa22d09570_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_597b29be-1608-4b7c-88d1-6cfa22d09570" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_597b29be-1608-4b7c-88d1-6cfa22d09570_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_597b29be-1608-4b7c-88d1-6cfa22d09570" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_931fc15b-8661-40c7-8578-9820cfe750c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_931fc15b-8661-40c7-8578-9820cfe750c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_463b5a49-235b-4f95-be2d-e7e239e9203a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_463b5a49-235b-4f95-be2d-e7e239e9203a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b87974e3-cd2e-4abe-8b5a-6b2e99a82b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b87974e3-cd2e-4abe-8b5a-6b2e99a82b92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a16957ca-c98d-45dc-a06a-b5c15ca46d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a16957ca-c98d-45dc-a06a-b5c15ca46d53" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ic8dcef64bfd74f50bad893e2870e224e_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_57bc9637-589f-4615-a1d2-8e01038e6ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_57bc9637-589f-4615-a1d2-8e01038e6ea2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bc822902-dc24-4441-9675-1b270ab644fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_57bc9637-589f-4615-a1d2-8e01038e6ea2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bc822902-dc24-4441-9675-1b270ab644fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e5e006a-693e-4487-bc60-d033ee7b7cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e5e006a-693e-4487-bc60-d033ee7b7cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b1f102b-947c-42b7-b9ae-c001385a4d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e5e006a-693e-4487-bc60-d033ee7b7cb8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b1f102b-947c-42b7-b9ae-c001385a4d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5180f892-5071-48c5-b11c-031902e94d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5180f892-5071-48c5-b11c-031902e94d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5180f892-5071-48c5-b11c-031902e94d26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5180f892-5071-48c5-b11c-031902e94d26" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5180f892-5071-48c5-b11c-031902e94d26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ed1f863-a6f6-4387-97e6-f868606635d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5180f892-5071-48c5-b11c-031902e94d26" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ed1f863-a6f6-4387-97e6-f868606635d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5a8df26c-8507-49f1-b229-cce8beef25c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ed1f863-a6f6-4387-97e6-f868606635d5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5a8df26c-8507-49f1-b229-cce8beef25c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f57007e0-20d5-4800-a0c2-03f9e64b5e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f57007e0-20d5-4800-a0c2-03f9e64b5e15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f57007e0-20d5-4800-a0c2-03f9e64b5e15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f57007e0-20d5-4800-a0c2-03f9e64b5e15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f57007e0-20d5-4800-a0c2-03f9e64b5e15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f57007e0-20d5-4800-a0c2-03f9e64b5e15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0baecc4d-230f-4872-8c25-7701b3869408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0baecc4d-230f-4872-8c25-7701b3869408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b92d432c-bdc7-4779-a8ac-86f9258b5344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b92d432c-bdc7-4779-a8ac-86f9258b5344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fa3d3c19-9cd6-42ba-8c9b-58b249c01e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fa3d3c19-9cd6-42ba-8c9b-58b249c01e9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c32b0846-4856-4444-89a2-757f5ed54de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c32b0846-4856-4444-89a2-757f5ed54de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_814e8671-9de4-40e6-8621-1cd59cf19691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c32b0846-4856-4444-89a2-757f5ed54de8" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_814e8671-9de4-40e6-8621-1cd59cf19691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0f215447-c170-4eaf-8361-517bac28bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0f215447-c170-4eaf-8361-517bac28bc70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0f215447-c170-4eaf-8361-517bac28bc70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0f215447-c170-4eaf-8361-517bac28bc70" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0f215447-c170-4eaf-8361-517bac28bc70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0f215447-c170-4eaf-8361-517bac28bc70" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7d27426d-161f-47b9-ab60-da7c819e1328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7d27426d-161f-47b9-ab60-da7c819e1328" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_022e62ff-759b-41cc-b0b5-d9aa26bcab42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_CommercialPaperMember_022e62ff-759b-41cc-b0b5-d9aa26bcab42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1f10cd3c-d02a-48da-b62d-adf940d0b595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1f10cd3c-d02a-48da-b62d-adf940d0b595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cb01accf-b5f4-48df-a9f6-72517afebca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cb01accf-b5f4-48df-a9f6-72517afebca6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a6e858b6-ab05-4c53-97ff-0bc4c417efef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a6e858b6-ab05-4c53-97ff-0bc4c417efef" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended" id="i7b2e80c872d64ac7bb700eb97b0011e0_ProductRevenueNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6ef94df-1341-42c3-9065-050796846d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6ef94df-1341-42c3-9065-050796846d5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_923a68f6-017d-43e2-a144-206acf6f9925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_923a68f6-017d-43e2-a144-206acf6f9925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_2dcfba4b-3a36-493a-9e2b-61ed9add9842" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerProductSalesGrossToNetAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:to="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_2dcfba4b-3a36-493a-9e2b-61ed9add9842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_srt_ProductOrServiceAxis_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04" xlink:to="loc_srt_ProductsAndServicesDomain_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04" xlink:to="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_25090740-1b82-4819-b9af-07c8ff0b3bb9" xlink:href="ardx-20220630.xsd#ardx_ProductIBSRELAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:to="loc_ardx_ProductIBSRELAMember_25090740-1b82-4819-b9af-07c8ff0b3bb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1e673b18-b1d5-4e04-bf07-a852876d0460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:to="loc_us-gaap_ProductMember_1e673b18-b1d5-4e04-bf07-a852876d0460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1eb24b7d-4698-4267-8787-1e6aa246d3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1eb24b7d-4698-4267-8787-1e6aa246d3a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eb24b7d-4698-4267-8787-1e6aa246d3a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1eb24b7d-4698-4267-8787-1e6aa246d3a6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1eb24b7d-4698-4267-8787-1e6aa246d3a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19098973-3df8-4422-94cc-f715631a7ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1eb24b7d-4698-4267-8787-1e6aa246d3a6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19098973-3df8-4422-94cc-f715631a7ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_8bf06048-63e9-48d5-ba2e-d6ba7976220f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19098973-3df8-4422-94cc-f715631a7ef6" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_8bf06048-63e9-48d5-ba2e-d6ba7976220f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_90eaf5bc-a82b-416a-b575-d5da972cea79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_90eaf5bc-a82b-416a-b575-d5da972cea79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_90eaf5bc-a82b-416a-b575-d5da972cea79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_90eaf5bc-a82b-416a-b575-d5da972cea79" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_90eaf5bc-a82b-416a-b575-d5da972cea79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a2401929-3fb4-4ec7-bbb0-8f88d9decf20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_90eaf5bc-a82b-416a-b575-d5da972cea79" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a2401929-3fb4-4ec7-bbb0-8f88d9decf20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e4581347-d318-465a-8ba7-72f71546d261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a2401929-3fb4-4ec7-bbb0-8f88d9decf20" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e4581347-d318-465a-8ba7-72f71546d261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9cb5a75f-efd1-4064-8d91-0a376b8f4956" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_srt_MajorCustomersAxis_9cb5a75f-efd1-4064-8d91-0a376b8f4956" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9cb5a75f-efd1-4064-8d91-0a376b8f4956_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9cb5a75f-efd1-4064-8d91-0a376b8f4956" xlink:to="loc_srt_NameOfMajorCustomerDomain_9cb5a75f-efd1-4064-8d91-0a376b8f4956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9cb5a75f-efd1-4064-8d91-0a376b8f4956" xlink:to="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_d5282b6f-26df-4c00-8623-6d0f10035333" xlink:href="ardx-20220630.xsd#ardx_CardinalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:to="loc_ardx_CardinalHealthMember_d5282b6f-26df-4c00-8623-6d0f10035333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_a4a049d3-ef01-43c5-a70c-da664f1ee0a5" xlink:href="ardx-20220630.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_a4a049d3-ef01-43c5-a70c-da664f1ee0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_dfcebb21-ad2a-4c59-bd84-89b14e1329a2" xlink:href="ardx-20220630.xsd#ardx_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:to="loc_ardx_McKessonCorporationMember_dfcebb21-ad2a-4c59-bd84-89b14e1329a2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended" id="ic12cb6b1d1df4591a51404ac8ea98445_ProductRevenueNetGrosstoNetSalesAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0d729b62-45ec-4add-a727-a09d48f98062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d729b62-45ec-4add-a727-a09d48f98062" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_10fc7c14-ff72-4af6-8d57-b98cfc0bda18" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_10fc7c14-ff72-4af6-8d57-b98cfc0bda18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_51827145-6f49-4def-a5b8-c8970cbbc659" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_51827145-6f49-4def-a5b8-c8970cbbc659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_668d4460-3315-4003-aba7-5d4731acccd4" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:to="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_668d4460-3315-4003-aba7-5d4731acccd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_e739bd45-1681-480c-aac4-956a5132f7aa" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a197d4f6-86d2-483e-88a3-67511852b0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d729b62-45ec-4add-a727-a09d48f98062" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a197d4f6-86d2-483e-88a3-67511852b0f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6" xlink:href="ardx-20220630.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a197d4f6-86d2-483e-88a3-67511852b0f3" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6_default" xlink:href="ardx-20220630.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:href="ardx-20220630.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_4cbd59da-2e32-481b-8eca-c96027cb1c9e" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_4cbd59da-2e32-481b-8eca-c96027cb1c9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember_2b1dfa42-f915-4a1a-8792-48f2d268ee3e" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:to="loc_ardx_ContractWithCustomerRebatesMember_2b1dfa42-f915-4a1a-8792-48f2d268ee3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5f020311-2df5-4b96-8ad6-d7b30f1862a8" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:to="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5f020311-2df5-4b96-8ad6-d7b30f1862a8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended" id="i71ec84febe6c4bfc9a6b648356cd8386_CollaborationandLicensingAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_e184e568-4d62-499b-8a02-ad834422d392" xlink:href="ardx-20220630.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_e184e568-4d62-499b-8a02-ad834422d392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_617c8972-60e1-4545-8f28-15d64f455451" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_617c8972-60e1-4545-8f28-15d64f455451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_421b3643-e71e-4497-896d-909033e29874" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_421b3643-e71e-4497-896d-909033e29874" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_225f0fad-cd3b-48fa-a9c8-5ae8c051ee80" xlink:href="ardx-20220630.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_225f0fad-cd3b-48fa-a9c8-5ae8c051ee80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_b56c9fa2-c9c4-4dfa-aeb7-4b8ccf1bdac9" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_b56c9fa2-c9c4-4dfa-aeb7-4b8ccf1bdac9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_e5d46c12-2b0c-481f-ab7a-74ce30db44d5" xlink:href="ardx-20220630.xsd#ardx_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_TermOfAgreement_e5d46c12-2b0c-481f-ab7a-74ce30db44d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_5bc5a5fb-a841-4ecf-9009-4d99a249ca22" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsNumberOfAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_5bc5a5fb-a841-4ecf-9009-4d99a249ca22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60e7a07b-66a4-4532-bd3a-b72eb162473f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60e7a07b-66a4-4532-bd3a-b72eb162473f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_f9a180fe-47b1-4fe2-918d-800fa10eac5e" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_f9a180fe-47b1-4fe2-918d-800fa10eac5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_2ee51539-d020-4d8e-87a2-dbaa249fc940" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_2ee51539-d020-4d8e-87a2-dbaa249fc940" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_0d7ead8a-69ce-4cda-aff2-1a098dad6926" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_0d7ead8a-69ce-4cda-aff2-1a098dad6926" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_1a0bc424-14f3-4bd8-ac81-7c85eec7de4b" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_1a0bc424-14f3-4bd8-ac81-7c85eec7de4b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_af82d230-9a2e-4b68-8c8b-7f8d06b1866b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_af82d230-9a2e-4b68-8c8b-7f8d06b1866b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_ed577d7f-d0fe-471b-86cd-c73d7adaf13d" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_ed577d7f-d0fe-471b-86cd-c73d7adaf13d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_5f8e45da-18f0-4b55-a3a4-9119df292a05" xlink:href="ardx-20220630.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_5f8e45da-18f0-4b55-a3a4-9119df292a05" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_9d161a0e-cd67-4cd0-a37a-8ee277b12862" xlink:href="ardx-20220630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_9d161a0e-cd67-4cd0-a37a-8ee277b12862" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_51bf9f32-4fb9-4a5d-9891-28ea05465d96" xlink:href="ardx-20220630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_51bf9f32-4fb9-4a5d-9891-28ea05465d96" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_da4007f1-2861-440d-acae-4bf240161eeb" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_da4007f1-2861-440d-acae-4bf240161eeb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_82aaba72-fd17-462f-8bc4-1cc24b00519b" xlink:href="ardx-20220630.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_82aaba72-fd17-462f-8bc4-1cc24b00519b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_744a908c-a473-4525-8ad6-e499a3f3e4fd" xlink:href="ardx-20220630.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_744a908c-a473-4525-8ad6-e499a3f3e4fd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_aa9749fd-f4b3-4cd7-824b-d623a4063374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_us-gaap_CostOfRevenue_aa9749fd-f4b3-4cd7-824b-d623a4063374" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_153de88f-efdd-45ff-9d49-ab09fcd26719" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_srt_RangeAxis_153de88f-efdd-45ff-9d49-ab09fcd26719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_153de88f-efdd-45ff-9d49-ab09fcd26719_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_153de88f-efdd-45ff-9d49-ab09fcd26719" xlink:to="loc_srt_RangeMember_153de88f-efdd-45ff-9d49-ab09fcd26719_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae37f547-75c5-481f-ae70-da68dae0b6cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_153de88f-efdd-45ff-9d49-ab09fcd26719" xlink:to="loc_srt_RangeMember_ae37f547-75c5-481f-ae70-da68dae0b6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ba2e876e-2851-4a43-8897-772600737a85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae37f547-75c5-481f-ae70-da68dae0b6cf" xlink:to="loc_srt_MinimumMember_ba2e876e-2851-4a43-8897-772600737a85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a22bdaed-67d9-4265-8de2-1e60dfb14a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a22bdaed-67d9-4265-8de2-1e60dfb14a2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a22bdaed-67d9-4265-8de2-1e60dfb14a2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a22bdaed-67d9-4265-8de2-1e60dfb14a2d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a22bdaed-67d9-4265-8de2-1e60dfb14a2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a22bdaed-67d9-4265-8de2-1e60dfb14a2d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_19131730-9eac-474e-a9b8-afc960290eb9" xlink:href="ardx-20220630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_19131730-9eac-474e-a9b8-afc960290eb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5f07f03e-847d-432b-8bca-d64a25e08b4f" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5f07f03e-847d-432b-8bca-d64a25e08b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_9d316ca8-02e8-40d2-afbc-df7fd98b84c7" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_9d316ca8-02e8-40d2-afbc-df7fd98b84c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_edd2ecb4-94a0-4019-9dc0-10fd7f39ce8b" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_edd2ecb4-94a0-4019-9dc0-10fd7f39ce8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_df98481e-39da-487a-9a48-da0f0c316874" xlink:href="ardx-20220630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_df98481e-39da-487a-9a48-da0f0c316874" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_733aada8-8f3f-4473-a9ba-7938deb05583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_srt_CounterpartyNameAxis_733aada8-8f3f-4473-a9ba-7938deb05583" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_733aada8-8f3f-4473-a9ba-7938deb05583_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_733aada8-8f3f-4473-a9ba-7938deb05583" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_733aada8-8f3f-4473-a9ba-7938deb05583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_733aada8-8f3f-4473-a9ba-7938deb05583" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_e65ebf9f-b1c0-4606-8138-a613fb8c21d7" xlink:href="ardx-20220630.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_e65ebf9f-b1c0-4606-8138-a613fb8c21d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_071d4aba-0bcc-4ca6-a265-eff7bb00646f" xlink:href="ardx-20220630.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_071d4aba-0bcc-4ca6-a265-eff7bb00646f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_acdebac7-634e-445a-ad8a-959fa47d04d1" xlink:href="ardx-20220630.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_KnightTherapeuticsIncMember_acdebac7-634e-445a-ad8a-959fa47d04d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_d080ba56-38bd-4cd9-b906-019c75fc323e" xlink:href="ardx-20220630.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_AstrazenecaMember_d080ba56-38bd-4cd9-b906-019c75fc323e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d97a3549-78af-4e2c-92fc-6c05417ccdb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_srt_ProductOrServiceAxis_d97a3549-78af-4e2c-92fc-6c05417ccdb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d97a3549-78af-4e2c-92fc-6c05417ccdb0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d97a3549-78af-4e2c-92fc-6c05417ccdb0" xlink:to="loc_srt_ProductsAndServicesDomain_d97a3549-78af-4e2c-92fc-6c05417ccdb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d97a3549-78af-4e2c-92fc-6c05417ccdb0" xlink:to="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7604dbaa-0aea-439d-b3f8-d6501359b504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:to="loc_us-gaap_LicenseMember_7604dbaa-0aea-439d-b3f8-d6501359b504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_802a6377-a2b6-49c5-b54b-51f702a88b69" xlink:href="ardx-20220630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:to="loc_ardx_ProductSupplyRevenueMember_802a6377-a2b6-49c5-b54b-51f702a88b69" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended" id="if0f9839873d24bb7beb5b449cd5e9c65_CollaborationandLicensingAgreementsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:href="ardx-20220630.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b3ddd65e-71d2-439c-bab6-2833460cc675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b3ddd65e-71d2-439c-bab6-2833460cc675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_e13ecbdc-85ba-4f6b-bf97-4a9a6a6630e5" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_e13ecbdc-85ba-4f6b-bf97-4a9a6a6630e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8da4c3e9-204b-49da-b912-20b860921a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:href="ardx-20220630.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ed891719-5369-4e6b-8a9e-ed580629ac72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ed891719-5369-4e6b-8a9e-ed580629ac72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_58afeb7b-29ac-47d4-b75e-8e40cb6d42cf" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_58afeb7b-29ac-47d4-b75e-8e40cb6d42cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_d97bacf0-69d5-4f56-8bfa-99701d8ccab1" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_d97bacf0-69d5-4f56-8bfa-99701d8ccab1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46a1db8a-c694-4cc2-b19b-9034870e9d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d86be1a9-2af8-418e-a40a-29adb07758e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d86be1a9-2af8-418e-a40a-29adb07758e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c428076-79ab-42a4-a57d-b661f2f75d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d86be1a9-2af8-418e-a40a-29adb07758e5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c428076-79ab-42a4-a57d-b661f2f75d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c428076-79ab-42a4-a57d-b661f2f75d05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c428076-79ab-42a4-a57d-b661f2f75d05" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1c428076-79ab-42a4-a57d-b661f2f75d05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c428076-79ab-42a4-a57d-b661f2f75d05" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_be409f32-9ca0-496d-ad9b-5496b8493601" xlink:href="ardx-20220630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_be409f32-9ca0-496d-ad9b-5496b8493601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_285907af-ca1f-49f6-9854-f5062988f507" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_285907af-ca1f-49f6-9854-f5062988f507" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#DeferredRoyaltyObligationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails" xlink:type="extended" id="ide9af794aff740a4bdad04d0dcef50b2_DeferredRoyaltyObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_395ee4bc-198d-4f20-83b4-3d69725bccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_395ee4bc-198d-4f20-83b4-3d69725bccb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1577b59f-649d-4ae8-8389-4242388e4eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1577b59f-649d-4ae8-8389-4242388e4eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c1981fdd-7f54-40f4-a3f0-16b8983f15ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c1981fdd-7f54-40f4-a3f0-16b8983f15ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_ad6221ab-2688-4260-aace-2dc2c625ddf9" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_ad6221ab-2688-4260-aace-2dc2c625ddf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_ad47cc5e-2611-43be-8bee-c63028512e7f" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_ad47cc5e-2611-43be-8bee-c63028512e7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_49b4058e-9646-4250-a0eb-1166acd8cad6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:to="loc_srt_CounterpartyNameAxis_49b4058e-9646-4250-a0eb-1166acd8cad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49b4058e-9646-4250-a0eb-1166acd8cad6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_49b4058e-9646-4250-a0eb-1166acd8cad6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49b4058e-9646-4250-a0eb-1166acd8cad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2daf1bac-b96d-4ebc-b0b7-c14250fcacae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_49b4058e-9646-4250-a0eb-1166acd8cad6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2daf1bac-b96d-4ebc-b0b7-c14250fcacae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_d1252f5d-ca5b-4303-b69d-b671222613e9" xlink:href="ardx-20220630.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2daf1bac-b96d-4ebc-b0b7-c14250fcacae" xlink:to="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_d1252f5d-ca5b-4303-b69d-b671222613e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6384be0-84a7-48fe-80fa-268c011d1311" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:to="loc_srt_ProductOrServiceAxis_f6384be0-84a7-48fe-80fa-268c011d1311" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f6384be0-84a7-48fe-80fa-268c011d1311_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f6384be0-84a7-48fe-80fa-268c011d1311" xlink:to="loc_srt_ProductsAndServicesDomain_f6384be0-84a7-48fe-80fa-268c011d1311_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49feacdc-3b67-4184-a292-b2101d160e54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f6384be0-84a7-48fe-80fa-268c011d1311" xlink:to="loc_srt_ProductsAndServicesDomain_49feacdc-3b67-4184-a292-b2101d160e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_9fa43c39-b538-4db8-8d25-d06c52bec7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49feacdc-3b67-4184-a292-b2101d160e54" xlink:to="loc_us-gaap_LicenseMember_9fa43c39-b538-4db8-8d25-d06c52bec7c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#BorrowingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended" id="i8268d27521084802b7df9aaace6724a5_BorrowingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0bbdae7f-7ec5-4934-aeaf-e2c18d026e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0bbdae7f-7ec5-4934-aeaf-e2c18d026e21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b079eee-20d8-4bf6-b048-5bb771a99f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b079eee-20d8-4bf6-b048-5bb771a99f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_e1e229b1-c479-4849-9cb7-d44fe5b55596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_e1e229b1-c479-4849-9cb7-d44fe5b55596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_13146bca-12a0-4e12-90b9-84c1cc5609eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_13146bca-12a0-4e12-90b9-84c1cc5609eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_7e5e03c7-909c-4904-8def-814974e3f5b1" xlink:href="ardx-20220630.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_7e5e03c7-909c-4904-8def-814974e3f5b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6ad556e8-c800-4a5b-acdf-36f46833a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6ad556e8-c800-4a5b-acdf-36f46833a2d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_8c796c78-ab50-411f-8bf7-62de2076639b" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_8c796c78-ab50-411f-8bf7-62de2076639b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_dbe1f0aa-3380-481e-9bc2-0392f87d32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentTerm_dbe1f0aa-3380-481e-9bc2-0392f87d32bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_33016a71-7dbf-44d7-ba64-92b2fc46436f" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_33016a71-7dbf-44d7-ba64-92b2fc46436f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_2afc10d1-2d33-4b7b-8095-51d0083e23b4" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_2afc10d1-2d33-4b7b-8095-51d0083e23b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_ae7ed6fd-9d8a-4468-9bd1-e248a058ab73" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_ae7ed6fd-9d8a-4468-9bd1-e248a058ab73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_1bd54de3-2678-45e5-9013-789b2206ecf1" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_1bd54de3-2678-45e5-9013-789b2206ecf1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_b9cd4244-81d0-4e1c-9e64-8a07d7796dc9" xlink:href="ardx-20220630.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_ExitFeePercentage_b9cd4244-81d0-4e1c-9e64-8a07d7796dc9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_89e917ea-7b75-4589-8ec8-112b755c298f" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_89e917ea-7b75-4589-8ec8-112b755c298f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_3f3d90e8-82ba-45f2-b6ea-ffa3fc30c25e" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_3f3d90e8-82ba-45f2-b6ea-ffa3fc30c25e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3e7e924b-ae20-4df6-9b29-33e67b412cad" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3e7e924b-ae20-4df6-9b29-33e67b412cad" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_5825e6bc-4127-4166-8bb4-8652c00d0e24" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_5825e6bc-4127-4166-8bb4-8652c00d0e24" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_2e8e93e4-72d3-439b-bef2-00e3ac961265" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_2e8e93e4-72d3-439b-bef2-00e3ac961265" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_efb04d3f-47e8-4871-801b-cc571ab79020" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_efb04d3f-47e8-4871-801b-cc571ab79020" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_87880dc3-dd68-432c-bb9b-ab7b4063d77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_87880dc3-dd68-432c-bb9b-ab7b4063d77f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_87880dc3-dd68-432c-bb9b-ab7b4063d77f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_87880dc3-dd68-432c-bb9b-ab7b4063d77f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_87880dc3-dd68-432c-bb9b-ab7b4063d77f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_87880dc3-dd68-432c-bb9b-ab7b4063d77f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_7d332960-73db-42db-8bd6-8ddff9cea532" xlink:href="ardx-20220630.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:to="loc_ardx_ExitFee2018Member_7d332960-73db-42db-8bd6-8ddff9cea532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_0618ab55-ce58-499e-b4c7-53781bc2a484" xlink:href="ardx-20220630.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:to="loc_ardx_ExitFee2022Member_0618ab55-ce58-499e-b4c7-53781bc2a484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_df5924cc-5001-4059-9272-860f03967e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_DebtInstrumentAxis_df5924cc-5001-4059-9272-860f03967e42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df5924cc-5001-4059-9272-860f03967e42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_df5924cc-5001-4059-9272-860f03967e42" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df5924cc-5001-4059-9272-860f03967e42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_df5924cc-5001-4059-9272-860f03967e42" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_30595820-f473-4882-9419-87466a6e3942" xlink:href="ardx-20220630.xsd#ardx_TermLoan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:to="loc_ardx_TermLoan2018Member_30595820-f473-4882-9419-87466a6e3942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:to="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_e65af892-1bbf-4f66-8e5a-e50bd9e6ee15" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:to="loc_ardx_TermLoan2022AMember_e65af892-1bbf-4f66-8e5a-e50bd9e6ee15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_0c08fe53-637a-4cae-833a-ac50ebdaaab7" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:to="loc_ardx_TermLoan2022BMember_0c08fe53-637a-4cae-833a-ac50ebdaaab7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe0aba63-b530-44a9-af60-15f1289e1a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe0aba63-b530-44a9-af60-15f1289e1a7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fe0aba63-b530-44a9-af60-15f1289e1a7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe0aba63-b530-44a9-af60-15f1289e1a7c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fe0aba63-b530-44a9-af60-15f1289e1a7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0b1cdea1-5f35-44d8-9131-7c50f77ac9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe0aba63-b530-44a9-af60-15f1289e1a7c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0b1cdea1-5f35-44d8-9131-7c50f77ac9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_687b83ea-cc0d-4afc-8f1b-90eea9aa893d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0b1cdea1-5f35-44d8-9131-7c50f77ac9b3" xlink:to="loc_us-gaap_LoansPayableMember_687b83ea-cc0d-4afc-8f1b-90eea9aa893d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d52ed155-4382-4df9-8db0-87dcf9f4ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_VariableRateAxis_d52ed155-4382-4df9-8db0-87dcf9f4ca31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d52ed155-4382-4df9-8db0-87dcf9f4ca31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d52ed155-4382-4df9-8db0-87dcf9f4ca31" xlink:to="loc_us-gaap_VariableRateDomain_d52ed155-4382-4df9-8db0-87dcf9f4ca31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_02871f18-66bd-45ca-a5b5-b346b3bbd108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d52ed155-4382-4df9-8db0-87dcf9f4ca31" xlink:to="loc_us-gaap_VariableRateDomain_02871f18-66bd-45ca-a5b5-b346b3bbd108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_04ec5658-8c3f-42ea-b73c-2092b081f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_02871f18-66bd-45ca-a5b5-b346b3bbd108" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_04ec5658-8c3f-42ea-b73c-2092b081f8b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_fd760fed-916a-465e-9a5d-741e2e5f6b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_fd760fed-916a-465e-9a5d-741e2e5f6b73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_51c68e53-f818-4059-a9d9-1a45ab767c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_51c68e53-f818-4059-a9d9-1a45ab767c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f24d2a83-844d-4e85-86f9-20710020b06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f24d2a83-844d-4e85-86f9-20710020b06d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#DerivativeLiabilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="extended" id="i2b432c4a9ba04dea8d111129febac570_DerivativeLiabilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_222263b6-58ff-4c1e-8600-92258329fe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_222263b6-58ff-4c1e-8600-92258329fe0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5b6a8281-4154-4b56-bb32-3863814937e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5b6a8281-4154-4b56-bb32-3863814937e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_b9cc7ace-8ce3-4ae7-9386-bc5111d887cd" xlink:href="ardx-20220630.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_b9cc7ace-8ce3-4ae7-9386-bc5111d887cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_fc1022b0-8822-4c7e-aa4c-d2a06f89b8de" xlink:href="ardx-20220630.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_fc1022b0-8822-4c7e-aa4c-d2a06f89b8de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_6ff2d2d6-7cc6-4de6-8e35-009fa567e395" xlink:href="ardx-20220630.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_ExitFeePercentage_6ff2d2d6-7cc6-4de6-8e35-009fa567e395" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_4cbc8087-0a00-48c4-842f-11e7415fb58d" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_4cbc8087-0a00-48c4-842f-11e7415fb58d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_394f6aa7-0043-4438-a3b5-ef87d340d785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_394f6aa7-0043-4438-a3b5-ef87d340d785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_394f6aa7-0043-4438-a3b5-ef87d340d785_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_394f6aa7-0043-4438-a3b5-ef87d340d785" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_394f6aa7-0043-4438-a3b5-ef87d340d785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_394f6aa7-0043-4438-a3b5-ef87d340d785" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_cafd76fa-3b35-4055-9ef1-54a62f26e229" xlink:href="ardx-20220630.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:to="loc_ardx_ExitFee2018Member_cafd76fa-3b35-4055-9ef1-54a62f26e229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_589c030c-3f74-4179-a07b-2931f2238d95" xlink:href="ardx-20220630.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:to="loc_ardx_ExitFee2022Member_589c030c-3f74-4179-a07b-2931f2238d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fb8ced9-62c3-4725-bf09-4ded0994cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fb8ced9-62c3-4725-bf09-4ded0994cfe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb8ced9-62c3-4725-bf09-4ded0994cfe1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fb8ced9-62c3-4725-bf09-4ded0994cfe1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fb8ced9-62c3-4725-bf09-4ded0994cfe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2e9f1b6-4417-4ed4-8f9a-941ec83476c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fb8ced9-62c3-4725-bf09-4ded0994cfe1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2e9f1b6-4417-4ed4-8f9a-941ec83476c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_79191b6b-2837-416b-bb74-d67cf2e577ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2e9f1b6-4417-4ed4-8f9a-941ec83476c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_79191b6b-2837-416b-bb74-d67cf2e577ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#DerivativeLiabilityChangesinFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="extended" id="ie027d0dfc5924cdd935629c1d44e75fc_DerivativeLiabilityChangesinFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4205de6b-4858-4597-b5a5-8f2afe6aeaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4205de6b-4858-4597-b5a5-8f2afe6aeaa0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9450dbda-764d-469d-a4c9-5f9cb88e8375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9450dbda-764d-469d-a4c9-5f9cb88e8375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_837de7ed-510a-4177-b186-0f70219d44e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_837de7ed-510a-4177-b186-0f70219d44e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c412a29f-9249-4168-9c38-afcf250073ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c412a29f-9249-4168-9c38-afcf250073ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_50c25072-a446-4e95-a6d8-670fecd31d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4205de6b-4858-4597-b5a5-8f2afe6aeaa0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_805a9b46-93c3-4e75-93e6-0b355fbbd0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_805a9b46-93c3-4e75-93e6-0b355fbbd0ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b263ddb2-6116-466b-8e78-304429c76a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_805a9b46-93c3-4e75-93e6-0b355fbbd0ba" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b263ddb2-6116-466b-8e78-304429c76a45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_81553fe4-a291-413e-b9c1-2a667b97c0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_81553fe4-a291-413e-b9c1-2a667b97c0b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_81553fe4-a291-413e-b9c1-2a667b97c0b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_81553fe4-a291-413e-b9c1-2a667b97c0b7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_81553fe4-a291-413e-b9c1-2a667b97c0b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_81553fe4-a291-413e-b9c1-2a667b97c0b7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_178276ea-4e6f-46b3-ac46-79bd7dacd53d" xlink:href="ardx-20220630.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:to="loc_ardx_ExitFee2018Member_178276ea-4e6f-46b3-ac46-79bd7dacd53d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_31f99ec9-0b21-4905-a87d-e5f61aa6a92e" xlink:href="ardx-20220630.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:to="loc_ardx_ExitFee2022Member_31f99ec9-0b21-4905-a87d-e5f61aa6a92e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended" id="ic5180b01373e415a963b1241dbc36080_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_b0f992c9-672c-4a02-b57c-ab4873297624" xlink:href="ardx-20220630.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_b0f992c9-672c-4a02-b57c-ab4873297624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d57202cc-f68b-47b5-ab39-f4c9e2b0f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d57202cc-f68b-47b5-ab39-f4c9e2b0f0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1697276-17d1-44a3-839c-6f00cbeaa86c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1697276-17d1-44a3-839c-6f00cbeaa86c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_17d1546f-152e-4668-8a4b-5c21986b209c" xlink:href="ardx-20220630.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_17d1546f-152e-4668-8a4b-5c21986b209c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_66b3019b-bdfa-4151-98a4-b0d02843c4f0" xlink:href="ardx-20220630.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_66b3019b-bdfa-4151-98a4-b0d02843c4f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_57a4edb9-219c-4730-b0e8-19aa7932fab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_57a4edb9-219c-4730-b0e8-19aa7932fab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57a4edb9-219c-4730-b0e8-19aa7932fab1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57a4edb9-219c-4730-b0e8-19aa7932fab1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57a4edb9-219c-4730-b0e8-19aa7932fab1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57a4edb9-219c-4730-b0e8-19aa7932fab1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_c5b29a74-8fe3-43f9-8afc-db61f70bb30a" xlink:href="ardx-20220630.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:to="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_c5b29a74-8fe3-43f9-8afc-db61f70bb30a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_045a81b2-17e7-45b3-842b-d32775928133" xlink:href="ardx-20220630.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_045a81b2-17e7-45b3-842b-d32775928133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c472a156-7e03-48d6-8533-e3429b328db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c472a156-7e03-48d6-8533-e3429b328db9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c472a156-7e03-48d6-8533-e3429b328db9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c472a156-7e03-48d6-8533-e3429b328db9" xlink:to="loc_us-gaap_ClassOfStockDomain_c472a156-7e03-48d6-8533-e3429b328db9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cb0b9acf-0d4e-4e75-92a1-11fa942c83b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c472a156-7e03-48d6-8533-e3429b328db9" xlink:to="loc_us-gaap_ClassOfStockDomain_cb0b9acf-0d4e-4e75-92a1-11fa942c83b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c8f1676b-ad54-4455-b198-f1a9ecd81b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cb0b9acf-0d4e-4e75-92a1-11fa942c83b0" xlink:to="loc_us-gaap_CommonClassAMember_c8f1676b-ad54-4455-b198-f1a9ecd81b7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended" id="ib2672a274e7b4475bab51d3c3e38d6f6_EquityIncentivePlansStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25cd1f3e-6ada-4558-af72-b600eb2c4cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c38678f7-fbb2-4623-b6dd-97185a1fcd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25cd1f3e-6ada-4558-af72-b600eb2c4cdf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c38678f7-fbb2-4623-b6dd-97185a1fcd77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb6c0b0-97f7-4fee-8ea6-613ec84c836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25cd1f3e-6ada-4558-af72-b600eb2c4cdf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb6c0b0-97f7-4fee-8ea6-613ec84c836d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97e91250-291e-46ea-b732-be58e92b3716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb6c0b0-97f7-4fee-8ea6-613ec84c836d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97e91250-291e-46ea-b732-be58e92b3716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97e91250-291e-46ea-b732-be58e92b3716_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97e91250-291e-46ea-b732-be58e92b3716" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97e91250-291e-46ea-b732-be58e92b3716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97e91250-291e-46ea-b732-be58e92b3716" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f68251e5-4857-44fb-b1e8-57ee0c1c6401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f68251e5-4857-44fb-b1e8-57ee0c1c6401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3f8cc53-4aeb-494d-ae3c-e550706a2130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3f8cc53-4aeb-494d-ae3c-e550706a2130" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" id="i02c90789aa1845b1a9ac39334725327d_EquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_cabf29f2-643a-4f23-800b-765537aca50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_cabf29f2-643a-4f23-800b-765537aca50e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0a421429-9d01-4a04-bf79-4dfb9e1ec9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0a421429-9d01-4a04-bf79-4dfb9e1ec9df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_e12b7524-87da-4536-bcc1-b99370803e0f" xlink:href="ardx-20220630.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_e12b7524-87da-4536-bcc1-b99370803e0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_692cae19-1fff-4f1e-91d4-082de349175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_ProceedsFromStockPlans_692cae19-1fff-4f1e-91d4-082de349175b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d8c3da4c-2ee3-4666-b8e2-fda91420e444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d8c3da4c-2ee3-4666-b8e2-fda91420e444" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_26c0da94-9b2a-4192-b3e5-f041eb888bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:to="loc_us-gaap_PlanNameAxis_26c0da94-9b2a-4192-b3e5-f041eb888bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_26c0da94-9b2a-4192-b3e5-f041eb888bc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_26c0da94-9b2a-4192-b3e5-f041eb888bc7" xlink:to="loc_us-gaap_PlanNameDomain_26c0da94-9b2a-4192-b3e5-f041eb888bc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7957f3bd-ad45-403d-8643-b0cc1627c298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_26c0da94-9b2a-4192-b3e5-f041eb888bc7" xlink:to="loc_us-gaap_PlanNameDomain_7957f3bd-ad45-403d-8643-b0cc1627c298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_0607d911-8193-4e9f-9857-7bf2634a7e5c" xlink:href="ardx-20220630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7957f3bd-ad45-403d-8643-b0cc1627c298" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_0607d911-8193-4e9f-9857-7bf2634a7e5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a23dc2ff-6fd0-400b-b4f2-3a82719dae00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:to="loc_srt_TitleOfIndividualAxis_a23dc2ff-6fd0-400b-b4f2-3a82719dae00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a23dc2ff-6fd0-400b-b4f2-3a82719dae00_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a23dc2ff-6fd0-400b-b4f2-3a82719dae00" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a23dc2ff-6fd0-400b-b4f2-3a82719dae00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4eca56c-da49-4fd9-b47e-d90f88f37647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a23dc2ff-6fd0-400b-b4f2-3a82719dae00" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4eca56c-da49-4fd9-b47e-d90f88f37647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_14fb1bd2-f7bb-4acf-b90d-9a043d28ee30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4eca56c-da49-4fd9-b47e-d90f88f37647" xlink:to="loc_srt_DirectorMember_14fb1bd2-f7bb-4acf-b90d-9a043d28ee30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended" id="ie4768b23372544bdb80731247777af4c_EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f322b5f2-1e61-479b-89e7-817abd31e3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f322b5f2-1e61-479b-89e7-817abd31e3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56d0f984-5e87-4f3b-a511-2e544de0c34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56d0f984-5e87-4f3b-a511-2e544de0c34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3175f341-15d8-41cd-abc7-3661e9305567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:to="loc_us-gaap_PlanNameAxis_3175f341-15d8-41cd-abc7-3661e9305567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3175f341-15d8-41cd-abc7-3661e9305567_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3175f341-15d8-41cd-abc7-3661e9305567" xlink:to="loc_us-gaap_PlanNameDomain_3175f341-15d8-41cd-abc7-3661e9305567_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e0f99426-b4ef-436c-baab-87ffe5455913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3175f341-15d8-41cd-abc7-3661e9305567" xlink:to="loc_us-gaap_PlanNameDomain_e0f99426-b4ef-436c-baab-87ffe5455913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_9643d35c-f9bd-45e0-929d-d6d2b80276ff" xlink:href="ardx-20220630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e0f99426-b4ef-436c-baab-87ffe5455913" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_9643d35c-f9bd-45e0-929d-d6d2b80276ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06ea23bf-28ac-433f-ac12-105eeb9c3e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:to="loc_us-gaap_AwardTypeAxis_06ea23bf-28ac-433f-ac12-105eeb9c3e23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06ea23bf-28ac-433f-ac12-105eeb9c3e23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_06ea23bf-28ac-433f-ac12-105eeb9c3e23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06ea23bf-28ac-433f-ac12-105eeb9c3e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_06ea23bf-28ac-433f-ac12-105eeb9c3e23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f8ea1f8a-2656-4eb2-8aa0-058834d1f30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f8ea1f8a-2656-4eb2-8aa0-058834d1f30c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f939b6-abb0-4ddc-9145-df147fcea504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f939b6-abb0-4ddc-9145-df147fcea504" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended" id="i2c3aca633e9c4947ad6aba2e95b7358f_EquityIncentivePlansRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04609cdd-6f0e-421b-93ee-010246c74e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04609cdd-6f0e-421b-93ee-010246c74e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4de4066d-a837-4d45-b913-bca0f504012e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4de4066d-a837-4d45-b913-bca0f504012e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_412c73d8-2910-433f-9349-8321d1ee97de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_412c73d8-2910-433f-9349-8321d1ee97de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_169a9ed8-9821-4977-86e9-7c89ee8810da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_169a9ed8-9821-4977-86e9-7c89ee8810da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e5fcb72-8fd0-479e-b107-c3cbb821a734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82daedf0-d85c-4de0-a98b-131b291a6dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82daedf0-d85c-4de0-a98b-131b291a6dd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a43e79da-f8a8-455d-b3d0-ca7c6f1c63d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a43e79da-f8a8-455d-b3d0-ca7c6f1c63d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_df34c005-5e5d-4463-bc24-eed3397325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_df34c005-5e5d-4463-bc24-eed3397325a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6fbe8fb-c4dd-4be0-91b7-72f94934022b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6fbe8fb-c4dd-4be0-91b7-72f94934022b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_766ccfb1-49fb-4ff0-9b1b-8af6ffc9b121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_794a93dd-8432-4b0f-9d66-863be1260d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_794a93dd-8432-4b0f-9d66-863be1260d03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b607fd92-df64-4ecd-8e0a-3819e8832d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_794a93dd-8432-4b0f-9d66-863be1260d03" xlink:to="loc_us-gaap_AwardTypeAxis_b607fd92-df64-4ecd-8e0a-3819e8832d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b607fd92-df64-4ecd-8e0a-3819e8832d7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b607fd92-df64-4ecd-8e0a-3819e8832d7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b607fd92-df64-4ecd-8e0a-3819e8832d7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd7eb1c-0fc9-4c2e-808c-f1d0d398ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b607fd92-df64-4ecd-8e0a-3819e8832d7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd7eb1c-0fc9-4c2e-808c-f1d0d398ce29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3c3bb467-40b4-43af-be90-42c081d4bbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd7eb1c-0fc9-4c2e-808c-f1d0d398ce29" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3c3bb467-40b4-43af-be90-42c081d4bbf6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i821cba97cc524e0cb7691073080fa706_NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_017572aa-bd5e-47c6-8cca-43db34c73017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407c86d1-8d21-453b-9413-77680496dc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_017572aa-bd5e-47c6-8cca-43db34c73017" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407c86d1-8d21-453b-9413-77680496dc2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62c3c6cf-fb86-4c18-857a-83c9b2b345cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_017572aa-bd5e-47c6-8cca-43db34c73017" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62c3c6cf-fb86-4c18-857a-83c9b2b345cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9b8f91c-dc77-416b-9d47-baa820653e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62c3c6cf-fb86-4c18-857a-83c9b2b345cc" xlink:to="loc_us-gaap_AwardTypeAxis_e9b8f91c-dc77-416b-9d47-baa820653e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9b8f91c-dc77-416b-9d47-baa820653e26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e9b8f91c-dc77-416b-9d47-baa820653e26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9b8f91c-dc77-416b-9d47-baa820653e26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e9b8f91c-dc77-416b-9d47-baa820653e26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_382196dd-0cb9-4d0b-8f6b-1d0eb4257b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_382196dd-0cb9-4d0b-8f6b-1d0eb4257b07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d007ae08-56a2-4ccb-959f-40dba89108e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d007ae08-56a2-4ccb-959f-40dba89108e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_aaa23bf8-1ff2-48c2-a291-00a3d79a394b" xlink:href="ardx-20220630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_aaa23bf8-1ff2-48c2-a291-00a3d79a394b" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ardx-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:547e7867-d9ac-4b70-ab52-436421bc76c6,g:9e9ed2bd-0902-4fdf-8b0e-0a522fb1fe1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d4e1739e-cc1a-485b-9396-52e8290e656f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3289e021-99ee-40ea-9fea-fa2ead8ae413_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6c209dd9-c58f-4633-9103-da557152ba88_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b702145f-16bb-4e65-ac58-4e0330db514d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total repayment obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a308d2bd-db4d-4689-bc93-1d1ef115a2f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_f730358f-bdd1-41ed-9eb5-3efad05c38e0_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional default interest rate</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate On Default, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional default interest rate on the event of default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:to="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8893b9b0-0eda-4d5e-9204-ca9d4da2e987_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2b472206-9e63-4fd8-af5a-7316e763c93a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_90f3711a-1a8f-4a86-819c-2763f3ca2d29_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_d5e06cdf-83ee-40c4-b5ea-cc98f2bee08a_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Additional Details of Leases</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Additional Details Of Leases [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of additional details of the leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:href="ardx-20220630.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:to="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_ab7fe341-abc2-4309-a726-bd92891e6742_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_8128b96b-fd3b-417f-a298-d58fcfd57068_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2876db5e-12a1-4e57-a95b-b05e10817e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_4412a244-10db-45ec-a5c5-dd8b910981b5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1826220a-80ad-4571-89d1-c60625c5eb5d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_74a7d384-4974-43f1-a576-acf081813ced_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating per annum rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_869a0bf3-5cfe-4251-a8ef-1c7f1fcbeff6_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_8c38ab4d-461d-440a-860b-172edfd052d9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6fed0fba-62dc-4c07-8fee-dcd49d8c409c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0aba6f30-dc6a-48ec-b060-e7d891cc9d50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_b697e757-1f46-42cf-a357-de29f3e9b609_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7ab564b8-8bf1-4cfc-ab94-18338ee10567_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_095e5928-4131-4efe-a0f9-be203b13e999_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9b0ca6a3-7cd9-481c-a970-4e4ae45f6fc5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_403fc5d3-4d75-41d4-934d-82b472e0d58c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After second anniversary to maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3aebc6fc-a1d2-4559-b026-ab04b795eb45_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c1892d7d-baad-4ab5-a775-5436953b2d78_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f0550f11-af8c-4a4e-a58a-9949cdb0bcfa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28e6fde0-a0bb-4cd8-ab18-c2b035942fa8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d635e51e-79c4-4a31-bed0-737516091ca8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Debt Payment Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_97d3332c-d6d7-427e-b840-be29d4594a9e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted cash payment obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9e0f9e63-c27b-40d4-b850-c7604b02916a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_649db3b9-b554-46fe-a9c2-3c0a76ce77be_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of amendments</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Number Of Amendments</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Number Of Amendments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsNumberOfAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b0ca698a-9f2d-44c8-8b18-09c934e6b100_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_eabc672f-cf2a-407a-84b7-ea52c7c85d2d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0ca18531-a2d7-422b-a070-03a8623c5304_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_cbb900ef-5c7a-4fcf-bd3c-9aa90369bc67_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_8bd7421f-b05b-405a-8dd0-b1d7b02816ec_periodStartLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_29056663-4498-42e4-8852-fd1ee028fd2d_periodEndLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_676f1d5b-5fea-4a05-a460-9d70654de63d_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_30ac4514-5211-49d6-afc0-e1f8583f60cd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_04215116-28d9-45dd-b359-36d1e44b9d4c_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Fees, Copay and Returns</link:label>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Other Fees, Copay And Returns [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Other Fees, Copay And Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:to="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_ab535b13-821e-4210-9100-4eedf486ac6d_terseLabel_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKC</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_label_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd [Member]</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_documentation_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Kyowa Kirin Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember" xlink:href="ardx-20220630.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KyowaKirinCo.LtdMember" xlink:to="lab_ardx_KyowaKirinCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fc95f988-b2ec-4d7b-b309-ff61d3cb9f94_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_515799e2-e62e-4e9e-afcf-3f8038cd3507_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_3810034b-2350-4d37-a0df-0c66a6209a48_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_ace9aee0-eddd-400c-a4fe-bd985a3cf4e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e466bc5f-0609-4db1-b629-257906946e50_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f4d2fddd-999d-4b18-8ef8-7820ceed0b62_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_610f632f-5b58-406d-87b6-a1282e2df273_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1923d0e1-ab80-4ad8-b4d1-27f021087dc6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_f4e7a618-dd34-4c4d-8bb2-58be91ac555d_terseLabel_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining funding based on milestone achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_label_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_documentation_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:href="ardx-20220630.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:to="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f21f662e-ac71-4345-9270-5b30dc42ae7e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_03196722-6e2a-4ca7-abb1-7c5514fff536_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_34cc8fd4-c3da-482f-982c-8ebe8f3cfcdb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7e5f459c-4959-4237-ac99-b8317ee1fbe5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff258453-1656-4205-a868-d2934f5d5383_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e816a0ce-ee66-4e90-8b29-c05516c78f09_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f2a1c67e-e7e7-4e25-9a7e-3d1c4cc3884a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_3cb2c232-e411-4b8f-8b89-a51e38aa864c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_17ae2cbe-0ede-43fb-9fc5-244d9cea09fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_2483b211-2d3e-43c5-99a9-da7edd18b894_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:to="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_90be8679-4462-4e1e-95a3-77db54f11e91_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1dcfe5b9-cbb1-4250-aa01-d0987b756a21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39d1ff13-e7dd-4365-b3b1-b96be1c0a5ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited or canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_a01f8557-4485-422c-a30a-2639a0eca467_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing fee</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_label_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:to="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_c601be59-d411-470e-b1a8-1d0a5ee04857_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_00c70776-e081-4af7-93e5-1aecf64b65d6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_a39f474c-acef-472d-b997-ea1c69afb9ea_negatedTerseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6b21bfd0-7dd6-4adb-92ae-4d7f5f703ba8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_306132d7-3f2a-4553-89a4-16e7d130daef_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining life (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d4d6750-87ce-44bf-b7bb-308642db5e6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b71978e4-3b35-45f4-b73e-bc12ccb96f57_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_d90dfca2-f689-46e7-8044-06fde36e4f6a_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue" xlink:href="ardx-20220630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_63733af3-026c-4c94-b4e9-cc0224bcdff3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_32c43ce6-86ac-400b-bb24-98c7ab8e5cb5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_35bc5635-afbb-4a6b-83ab-41263550dc11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fb75163e-fb3a-4e10-acd7-c985b8f763bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales, Net and Reserves for Variable Consideration</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_32527d88-6bc8-48e2-a2ec-2fba1ac52da7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b12325e7-7ef6-4dbf-acf7-393a96e2922a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_75810b80-300d-4b0a-a1d7-0dc93196a4db_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9b552ed6-49f8-4e9e-9e62-1f5f8da5e450_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise&#160;Price&#160;per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7c35d56-8316-42ce-8643-82baf93e8889_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ce712f59-ee89-492b-9984-e99f02e427ff_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CardinalHealthMember_312e67aa-bb3a-4381-8c31-db4432a9bb3f_terseLabel_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_label_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health [Member]</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_documentation_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember" xlink:href="ardx-20220630.xsd#ardx_CardinalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CardinalHealthMember" xlink:to="lab_ardx_CardinalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7f782005-ccef-478d-8176-4f49955ef109_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_7262e5f9-9796-4481-9da2-51b5546263c1_terseLabel_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial customers</link:label>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_label_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Commercial Customer [Member]</link:label>
    <link:label id="lab_ardx_AccountsReceivableCommercialCustomerMember_documentation_en-US" xlink:label="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Commercial Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember" xlink:href="ardx-20220630.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccountsReceivableCommercialCustomerMember" xlink:to="lab_ardx_AccountsReceivableCommercialCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d0febf4c-cd96-4a0c-94ee-203c512b0e08_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_17e5e44f-643e-4efe-9882-abbd82e46578_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_19af7dad-7111-4937-ae45-81e03081a7c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9deee075-ebef-42fe-acac-557d7542b5e8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f40ad7ee-5fba-499f-a3ee-f09d7bc96571_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_366503e8-9c5d-4783-bab5-320270be2cb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_15e528fc-51ce-47c7-9c32-958e749255f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_33f8eee6-1b81-4921-a98c-ac0e264374cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_bfdb639b-a93c-4dcf-81be-bad882af62cb_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases due to cash received during the period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Cash Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_2e40a8b7-ad82-4fe1-89dc-1c44f3b2609b_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Transaction Costs</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:to="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_afcb8c7a-976c-4f60-80e3-4ccb0b3ad93a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_9115be04-c383-4cee-8710-a34393bf2b39_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:href="ardx-20220630.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductIBSRELAMember_e84a5192-960e-4ede-94ad-e12f436c24e2_terseLabel_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IBSRELA</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_label_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA [Member]</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_documentation_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember" xlink:href="ardx-20220630.xsd#ardx_ProductIBSRELAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductIBSRELAMember" xlink:to="lab_ardx_ProductIBSRELAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c9b06bdc-2680-4610-bb4e-ef79e0dbfc62_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a641fc25-de4a-446e-8cba-60eeeabb93a6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_e1e1d836-e578-4757-a965-44ddd77bf3c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_476942cf-83f9-4e47-85c4-1993e971b7b4_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the purchase price per share of shares issued to employees under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:href="ardx-20220630.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_05d01873-44dd-4cc9-8ab9-6582985f50d5_terseLabel_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_label_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation [Member]</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_documentation_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:href="ardx-20220630.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:to="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1ddaf430-2755-48f9-92e0-c999f05c37b3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_753242bb-0298-4e42-bab8-220a29bd1000_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development And Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of future development and commercialization milestone under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8584255e-5d27-463a-8c23-0ce8838c3e7f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c60c82e3-c143-4ebf-9a1d-be3e48ecdec4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_943674d5-0488-41ad-bdb0-6d9b4af36b44_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d8574e3c-f816-4e43-b8de-09edad9cbe83_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_08d14f67-ab05-4c65-b166-68e8f6c5556c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_d7450b0e-7e7b-4b6a-ab36-cffb505de832_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4fde0bea-e551-49eb-8bb9-7074a7f99792_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b75408d0-956e-4e20-888e-4451261b07de_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_4f7609ed-f2cc-4cf3-9111-b6c4d902c31c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f91dcb42-47e3-44e1-a670-0a0d112ae825_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_ecf1d451-0b58-4f4f-befe-19e3810b7f06_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8fc0e6b0-4a1d-44d9-a898-d7169fc37252_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b92ea657-884b-43d5-9180-a89690376b56_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_212edbe8-2c8d-44a5-9b39-25715b46b749_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_ec3ff8dd-f9eb-4508-9462-6fe18ee8b0c7_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:href="ardx-20220630.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_be48e036-db77-4391-9ec8-e900c49f36f1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_14bb67e8-7391-4a8d-a534-6e0696dd0a6c_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_511c5978-e3d8-45d6-90c0-e2642ca73bb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9fa507c-f50a-4a41-846c-aaa00b12f512_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d0aa93bc-9cc9-43a3-9f46-7a00858f0145_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Vesting Period (Years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_76a6a8b0-5a47-4a79-b02d-ef50051420f2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022Member_c96a24b5-8258-4f2e-8129-4071f16d5d5b_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_label_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022Member" xlink:to="lab_ardx_TermLoan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_637dfbb3-d203-4ba2-989c-62d4ae2b9434_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_1636ed78-e3ed-4caa-8d11-1791808b7748_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9ac8ce5d-41f8-4109-b00e-6e03e650bd3e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7b500b4b-dfb4-482f-994f-1a5eaa86897a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_96bfeb26-6297-4db0-a9f5-ac07d9efa6a3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5901a500-bf60-4199-8f4d-bdd39237a307_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_23d2f550-7c77-4d50-83c8-176f858c9004_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7d61079a-57b0-4306-b6fa-afc0c50d1581_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b235fd93-9712-4cd4-b3d3-f729e138c1ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_ea430e88-8925-42a0-97e5-36bedab54756_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d55863cf-c07b-40c3-a81e-1ef7cac94bbe_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b96c7233-3469-415b-80c8-2420a2a44482_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2bea6772-8f2f-42b4-a493-fa94da3a5c2f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_e31e08c2-d906-4b96-b55b-3bd246362dd8_terseLabel_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid commercial manufacturing</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_label_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing, Current</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_documentation_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent" xlink:href="ardx-20220630.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PrepaidCommercialManufacturingCurrent" xlink:to="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_354f1259-32c1-4565-a807-777450d72595_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_6614869c-72b7-420d-b3bf-c5086f60525a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from 2022 Loan, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f9d73ef8-eb58-417b-b67a-49d75a4edb99_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fc3c50d2-3c44-4b97-b93d-31294c54af6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bf9aa837-7e6a-486f-8e25-f29f97cd566e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e6bdec2d-17e8-45bd-a781-7c8d1ce303ea_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfAgreement_57c61d31-c9ff-4752-8838-b54b0ec95188_terseLabel_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_label_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_ardx_TermOfAgreement_documentation_en-US" xlink:label="lab_ardx_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement" xlink:href="ardx-20220630.xsd#ardx_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfAgreement" xlink:to="lab_ardx_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_ace0b736-6320-4834-9484-3cc0559b4ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_130ecebf-2d54-458d-a3bd-4e878b8def16_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_056f342a-1d96-4ac4-a3bd-5bbc908d1e52_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a7f01cf4-90ce-45b7-a940-194c675ff39a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_1b6714fa-335c-4d30-a703-7abec8d8c9cd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cef9bd80-2ab4-43fa-a3e4-39038e54c950_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_70107f71-503b-43ed-94ce-88378cb426eb_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_954d4c9b-c097-46a0-827d-4586b7d14b5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_48bc0daf-b6d5-4ac2-9dbe-b33c2e22d7a3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_6049aaf0-6468-43f7-902c-f918f4ce838e_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium (as a percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of fee payable on prepayment of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:to="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e73fbe79-b235-4ec7-8527-fe16a677157a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_7e72e15b-c2d2-49b7-911e-c23853eed2ad_terseLabel_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term available-for-sale securities contractual maturities, maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_label_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_documentation_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:href="ardx-20220630.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:to="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_826ef37f-1991-47c2-9aa6-a94d93487409_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_e9c50f41-9d3c-411c-96e8-6e31d92b731e_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon occurrence of certain conditions</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_eb5af7b3-4529-42fd-ab07-1da8266a76bf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon change of control or regulatory approval</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_43d9f656-f57a-4305-be7b-7d6dc3c30d0d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_da0bc07e-c385-43b8-bf21-808553c55b2f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_2f62e8d5-241c-40f3-a88f-b07eb4fdef40_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_8ab469b2-4e46-498c-bde0-23a3129f3893_terseLabel_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of net sales for tiered royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_label_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Percentage of Sales For Tiered Royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_documentation_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the threshold percentage of net sales for tiered royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:href="ardx-20220630.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:to="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_da09073a-bdaf-4d68-99d2-2cdbe3ed13f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f8f25291-7bc5-43b8-a00d-93ee101a632e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9ca3f4ba-072f-4c80-a11f-9e0d360d8534_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d954afa5-5cc1-4166-a6bf-dc4d986f5f83_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_52771b55-c5ca-47e8-93c1-01bc273d009a_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2020, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2020, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:href="ardx-20220630.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_1681a371-b999-4f67-8f5f-72e9e06021a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unaccreted value of final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b726c15e-f924-44f3-83f1-07a098412407_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_84d684b3-085f-4e71-9e4e-dce4974564f9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_aec42bf8-1f19-46db-91de-1b1808b2b63a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_baf54c26-767b-4a13-9ebc-bd423c40fb7b_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, term (in years)</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeTerm" xlink:to="lab_ardx_LoanAgreementExitFeeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_943e9927-65f7-4838-a17d-e977b6e8a0e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_bb9f2516-5e49-402f-8e9a-ebcf6deebedf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_14f6920e-8faa-4bf3-8085-cf6153f12155_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashAndCashEquivalentsAmortizedCost_4f7fbba2-5880-40b1-8bf4-0fca6731a0fd_totalLabel_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashAndCashEquivalentsAmortizedCost" xlink:to="lab_ardx_CashAndCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_6e5a57a4-f088-413f-8356-8e6c8f359092_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9c305eb7-aac8-4642-a09d-f8d1287a5971_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1974bac9-da68-4f30-b383-2e430969e644_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c6b3d2b6-f07f-4373-9072-00aa53314c58_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1929250d-b884-4d16-9ab9-28dd660b9c45_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_3ed6ed76-4080-483f-92f3-f7c54385b21a_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_fa84f134-c127-40ab-8da9-f31f75b50480_terseLabel_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Pharma</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_label_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development [Member]</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Shanghai Fosun Pharmaceutical Industrial Development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:href="ardx-20220630.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:to="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ea337bf9-e66a-4981-a3d9-21ade7a24f63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3d2127c6-7edb-4ec3-bf30-50d1df6919ef_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_656255bf-54c1-4e54-903e-593c5f35e00d_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Canada [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_49988a04-af58-4186-914c-0ef6a89ef2a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_528a2b74-750a-405c-babc-ee303bd51014_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9d3bf05b-34d2-4017-b4ec-ad54b12feea5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_38649e60-4d54-48ae-ba19-11922e22d89a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a9947a72-449e-44bf-b424-6132e82a3467_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_30a9f81b-ffcf-4f33-bd05-8a5d9c897059_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4f54123e-243c-4c96-bbe9-7c1c6aa930ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8716d4e6-0310-4296-812e-a81df3c47d0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_9f538ca8-ca3b-450c-8f00-ce5d5874c05a_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7e02b13b-fd5c-45c1-aa51-20ce55203d02_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9c46ee3f-0f3a-4c33-8877-f3f275b70f18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5d536838-34e2-409d-95c3-1108cb386038_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_bd1c2aaf-7b33-4520-b922-b6816fed625d_terseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP shares issuable</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember" xlink:href="ardx-20220630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EmployeeStockPurchasePlanMember" xlink:to="lab_ardx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cda6023c-aabe-4047-b753-0296de3031e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_88bbcdb8-2d97-43a2-8fdc-da0c9420f734_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_12e63d6d-20bb-4f17-945c-3c78b14ff0c2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2ab7af06-8161-434e-a0f7-f623463c3517_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0d59ba87-15c1-4753-88eb-064ae7fb39a5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_aea0a70c-7105-496d-8ba4-da1162310021_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_b0f39a1b-1c21-4239-a146-2523f2e8ac09_terseLabel_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average sales price per share (in dollars per share)</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:href="ardx-20220630.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_447fab38-b94d-41e9-93c4-decab52918eb_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_8d45eb93-2a97-4cc5-b331-7f0292bb40d4_terseLabel_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate cost of revenue recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_label_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Revenue, Aggregate Amount Recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_documentation_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue, aggregate amount recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:href="ardx-20220630.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:to="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_2e532113-d408-473a-b854-f0287e17cd3c_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity related to 2022 sales</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_2152cec4-e609-4a75-8107-d522afcc9ba5_terseLabel_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AZ Termination Agreement</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_label_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement [Member]</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_documentation_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:href="ardx-20220630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:to="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_278dbbd8-9747-427c-b23a-54ef0dadecdd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_01d13a1e-8626-44bc-992b-cd4a584f6a8d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0b387680-967c-4dd7-a3dd-07ffcfad110d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_14f48743-fe97-4827-bc78-dde8c36a6377_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3f014e8f-4296-46f2-a2c7-12c8bfcce9af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_e84a895f-dad9-458c-bfd5-cc18d2e454e6_terseLabel_en-US" xlink:label="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Interest Expense on Deferred Royalty Obligation</link:label>
    <link:label id="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_label_en-US" xlink:label="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense On Deferred Royalty Obligation [Policy Text Block]</link:label>
    <link:label id="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_documentation_en-US" xlink:label="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense On Deferred Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:href="ardx-20220630.xsd#ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:to="lab_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9481a84d-f25c-4e7b-9913-aaf556c1e277_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fc0967fb-ede9-4271-a771-62011fc89644_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b03b2234-72b1-4062-92d9-f8d865a0f9cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_566fb9ec-4463-43a0-ae38-36739f3882b5_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities for exit fees</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_3f031d93-66e1-4b63-94b5-df800a3f85f8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8af5b5bd-e796-4268-969e-0df7d114888c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc139ed5-25dc-4540-bde4-d9f4c76c0e3d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9180218a-a3aa-4d02-a602-fa74d63675cf_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ca211797-8555-41b8-a4a3-a37e649033da_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d7565bcf-905f-4b5b-9776-d17a7d96b283_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_df1ea3f9-648c-4d05-978e-b20ccc3bd888_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_4d8f7b5a-a030-4e70-9c1a-c6e80280a076_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non-Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of non-royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:href="ardx-20220630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_70b99bd6-eb0b-4aea-b8af-0a8664696361_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_7b4fed87-c126-4619-ab36-6ae88d27d01b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_be48edb4-db77-463d-b935-bf16a320c406_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_47797337-904f-4b1a-8c15-d22f8891627e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_407ced88-2003-4688-8900-4574acacda08_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_aa726073-3620-4f36-87e1-ed1875e25e52_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits and Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0c06da1f-2302-4982-aaa1-746041c4d618_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_101c37d4-3339-4df4-950f-da1fc5faf570_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dd428638-7b6d-4717-a0a1-f8ba8d5cdac6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3c6802e7-ba2d-4d67-ab97-8783d1785d45_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4233ddb4-f0d8-4e56-8dc9-3600361354d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a03f1b96-68f3-446f-884b-a5f2b09f7d7a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_d450b657-a9a3-426d-89f0-a7e9e4af5934_terseLabel_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_label_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue [Member]</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_documentation_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember" xlink:href="ardx-20220630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductSupplyRevenueMember" xlink:to="lab_ardx_ProductSupplyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFeePercentage_6d96ab28-6a3e-4bb3-8c40-78a438222716_terseLabel_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee (percent)</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_label_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_documentation_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage" xlink:href="ardx-20220630.xsd#ardx_ExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFeePercentage" xlink:to="lab_ardx_ExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e269c4f1-ea43-4f50-bec9-c21aaca55134_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_68d545f1-bf7e-4d08-9a6a-74e197674327_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_23b73bfe-f6ff-44e7-b232-f50281d7c423_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_823abd34-7797-4ac4-a4ad-5e6b5be114c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_e1efcfa2-bf4d-40d5-9a72-d891d1a5fad8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_8410a7f5-91dc-4f0a-8835-31a3f7e60c30_terseLabel_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission on sale of stock per agreement (percent)</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_label_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_documentation_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent" xlink:href="ardx-20220630.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StockIssuanceCostCommissionPercent" xlink:to="lab_ardx_StockIssuanceCostCommissionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_65993c9a-3791-472d-9191-be665dbd3dff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3c0cadd1-f1fa-45eb-a1f7-2f1cba6b4f79_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_76e93d41-170e-4027-94b0-3f4c27c2bf24_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_643e3e52-a9bf-40e0-a46d-63f2a7937a48_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76ed2b12-a901-46ab-9125-8c69c7eef181_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_18cf5a5c-3bc8-4554-a0a7-c22d70043e9f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4be28675-636e-4a30-b032-81269c8ec3d7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_829840ad-ee57-46c4-9400-e4311a0d9b30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f4312c79-3af2-471d-93f9-1f6c05ff29ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_eeeb6b69-5966-4608-9631-69ce68d1f0ea_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_5cef85a7-fc99-4743-968e-60065a8b0dfd_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative development revenue</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_label_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:label id="lab_ardx_CollaborativeDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_CollaborativeDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember" xlink:href="ardx-20220630.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeDevelopmentMember" xlink:to="lab_ardx_CollaborativeDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_202b68d8-12f1-4eef-93ab-eaa64b6ce881_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_51b6a471-11b4-4115-a0c3-dc051aa175fc_terseLabel_en-US" xlink:label="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties, net of issuance costs</link:label>
    <link:label id="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_label_en-US" xlink:label="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Future Royalties, Net Of Issuance Costs</link:label>
    <link:label id="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Future Royalties, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:href="ardx-20220630.xsd#ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:to="lab_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_5f259fbd-0ad5-4ca7-ab40-08d3ec8c6291_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d283a71-ffc2-4634-8ae2-59a4560f27b7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d9b720b-b1ac-49e9-b330-656a18dd0689_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_f89413d3-faf1-44d6-aa3b-6caf3011d9ef_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:to="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d016ae1b-f47d-410a-af75-9c4824dfd8c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstrazenecaMember_6fab4b1f-de5d-491b-8684-4ee62d3ded00_terseLabel_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_label_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astrazeneca [Member]</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_documentation_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to AstraZeneca.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember" xlink:href="ardx-20220630.xsd#ardx_AstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstrazenecaMember" xlink:to="lab_ardx_AstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_19642e0e-2c52-4f63-928f-16ed38037375_terseLabel_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of license fee, first installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_label_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Payment Of License Fee, First Installment</link:label>
    <link:label id="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_documentation_en-US" xlink:label="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment of first installment fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:href="ardx-20220630.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:to="lab_ardx_TermOfPaymentOfLicenseFeeFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_a2702215-dd08-4f3a-9625-436cfe8168f8_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, percentage change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:href="ardx-20220630.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:to="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa25e052-bce1-4e3d-8124-e11af1b91fd0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_59b706f8-9235-475e-9ce1-ff1cc46dfb36_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payment tranches for fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_db306ed7-7bc9-4075-b36b-ac269ba94368_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_95c6b545-8580-4ac0-98f2-91dbfa31bb07_terseLabel_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_label_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Separate Collaborative Agreements</link:label>
    <link:label id="lab_ardx_NumberOfSeparateCollaborativeAgreements_documentation_en-US" xlink:label="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of separate collaborative agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:href="ardx-20220630.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_NumberOfSeparateCollaborativeAgreements" xlink:to="lab_ardx_NumberOfSeparateCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_66b11b60-aecb-4139-9ebb-39d580546562_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 shares authorized; 153,797,834 and 130,182,535 shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_61ab742c-f6b9-47aa-8198-875e5e1b6625_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains_3dea7860-d3a2-4d3b-bea2-f5458eb115eb_terseLabel_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains_label_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:to="lab_ardx_CashAndCashEquivalentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_44f2a367-db77-4eaa-a54a-547acb09d533_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9108ec60-9a5a-4d28-b0e5-ad9d4cdadb91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2018Member_7b785ec0-26c1-4377-9b43-13d2efd15282_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_label_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member" xlink:href="ardx-20220630.xsd#ardx_TermLoan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2018Member" xlink:to="lab_ardx_TermLoan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5bedd8d5-792a-4cef-8bd3-b49e1b73d6a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_63246b1c-d181-4096-bbe2-a3fab8b47060_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer product sales gross to net accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_label_en-US" xlink:label="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Product Sales Gross To Net Accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Product Sales Gross To Net Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerProductSalesGrossToNetAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:to="lab_ardx_ContractWithCustomerProductSalesGrossToNetAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0f58edda-4d54-4cb5-910c-5738f801e451_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9492ecb0-4bc0-4d52-9209-55cc4540ab0a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f0af2228-6553-4a0b-95c0-7eff2e721382_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_9a085462-9b92-4523-a52c-bb5927afe580_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In China [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DerivativeIssued_74600722-6d78-4cbd-a453-c57485a3cb3d_terseLabel_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of derivative in connection with issuance of loan payable</link:label>
    <link:label id="lab_ardx_DerivativeIssued_label_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Issued</link:label>
    <link:label id="lab_ardx_DerivativeIssued_documentation_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued" xlink:href="ardx-20220630.xsd#ardx_DerivativeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DerivativeIssued" xlink:to="lab_ardx_DerivativeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40b389a6-fccb-4123-bccd-b4df42cdf0dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25f6c9b7-b2a1-47ec-bccd-d4abc6cacf61_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_e24092b5-15a8-4fc1-a352-9350a2b72830_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - non-current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:href="ardx-20220630.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_061007ef-8983-4e1f-88f1-49693ebc7c6b_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Chargebacks, Discounts and Reserve Balances</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:href="ardx-20220630.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:to="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_a66804c9-727b-40f2-9854-34857fd76de9_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5081b49c-b708-46b9-b364-b1e537de93e9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_bffb5398-8e7c-47bc-88f3-ed333846b564_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022AMember_1bb2c578-99fd-4fb5-a05c-acf2616ec2a2_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_label_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022AMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022AMember" xlink:to="lab_ardx_TermLoan2022AMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_ee507617-9fd3-428e-a1fa-858daacb6ed7_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, net product revenue threshold</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:to="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fdc3a338-0bad-4602-b68a-8272bd9816cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5ba084d6-3f38-4e38-961c-01de33c92286_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee addition at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ec10914c-4a03-4491-bed8-be3afa11875d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_89830f36-9fd2-4e07-95cc-8e1f8e25322c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_2910f9ae-0337-4dac-94a0-d1a54703f6de_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 KKC Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Japan [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a7d21d03-d218-49f4-b5c6-1cbdf756986d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fa2daafc-3e71-46a7-89d6-9cd63e52b843_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_fede45b3-5815-40b4-a417-9bff722d0ad2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9f153bbd-37d2-47be-9cb4-1454dd8e85f2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b4a3281-2b3d-4c6c-8fcc-5183922bd5c0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_3d5b4214-d7b0-42fa-90e0-38c5613cd85e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in derivative liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f7f10d53-8745-4e9d-813e-9701d5a504dc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f620d098-c7f0-45a9-975f-8b427029a8e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_b5df75fa-1fec-426f-95b8-8dc3a1ec28de_terseLabel_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount paid</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_label_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Uncharged License Fees, Aggregate Amount Paid</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_documentation_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of uncharged license fees, aggregate amount paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:href="ardx-20220630.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:to="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9039bf25-5c7e-42fe-aa13-5e48473896b5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_845d43fe-19f6-4402-98d5-c88ae0b690f9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fb659fed-188d-4201-93cc-b370f6e40390_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_99a14073-479d-40c0-b77d-43f14c22f6f2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a1cf80b8-2b69-431a-be6b-28b8b18619ec_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_03d2b5b5-c1d2-45ff-b521-f6e34cd672e9_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:href="ardx-20220630.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_91ad219e-6c4a-4be3-941c-28da1fd8316e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_0375fc2e-9970-49d9-99ad-2adb837cee05_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4d1ec504-b3d5-405d-8e37-ba8e88b38bdd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_fa4f1eaf-2d11-4002-a956-f91627616670_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_143d08ab-fb56-48a0-94f6-0912da57cfba_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to amounts invoiced, for which cash has not yet been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_5bfd944e-880d-4525-9d60-9fb5717dece5_terseLabel_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 KKC Agreement</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_label_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Option Agreement [Member]</link:label>
    <link:label id="lab_ardx_ResearchCollaborationAndOptionAgreementMember_documentation_en-US" xlink:label="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:href="ardx-20220630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:to="lab_ardx_ResearchCollaborationAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_573504c2-e5d5-4dbb-b89d-f5676d736ddf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_56ea16c3-8b39-42ec-b7c9-29d618f1bb5b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_46d4de31-8718-4eeb-a9ca-4cf95d43b7c9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_0aeea40d-5375-485f-9efb-0ecb80da8ccc_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c379d9b-f481-42bf-9ac7-c6df7dcabd61_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_358fe9ea-beac-4eb2-8d79-8aaced639388_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3905537a-207e-444a-9306-107480165648_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_845d7723-7a8f-4403-a1b2-345f04d9923d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c9e54b90-218d-4675-8f9a-e0ff96024298_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e047c8d-8487-48fe-8ef5-fe3cc500d4c4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6f1ef8d8-1249-4bc1-83c3-3214218c0062_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cab5cc1c-6aff-48ef-86ae-cc52e1cced45_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_0f55bd79-7f4e-4f5b-b1f4-d7febfe8c00b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_163c48c9-260c-4722-bc5d-aeb8be280104_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_0703c011-4042-4c2a-ab6e-dd41342df9c4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_720219ce-2f63-4b37-ba66-cbb169291e32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3dcb44b8-cf90-470f-b8be-6aed70820c44_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_71d6875b-9698-4a36-8adf-de90314630cd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_e5fdf173-0c29-46ef-b90b-9cb7b09319d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c25d4f83-a048-4123-8ae0-2dc06768db83_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_04cef5df-4bca-47d7-97d9-14f067acf00b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_0f209a76-a5b5-4b43-bb23-2cf82fea566b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0dc553ec-1028-4fb7-9bc8-c135b738183d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ab24317e-9846-4c9e-97ef-125e1df44d4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_e73a12eb-9b8f-4dcb-a91e-f9a8c5049e38_terseLabel_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare royalty partners IV, L.P</link:label>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_label_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthCare Royalty Partners IV, L.P [Member]</link:label>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_documentation_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthCare Royalty Partners IV, L.P</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:href="ardx-20220630.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:to="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2db513bc-f337-48ea-9009-22cdf5366f96_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e00e4c8c-a0da-4f20-9e1b-f199d5dedf17_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_9c172481-418d-4bd9-80b7-7abae86506a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b346ffb9-fc7f-45ff-8a59-646ebf25255d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6babe31d-99fa-49f2-8057-dafbf3838f96_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_49428724-a7d9-4249-9d23-e74f07db9a46_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a1d63d7f-7af7-4176-923f-ce99dfa9feaa_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock_ca8e06d9-1d12-4725-a2b7-0282d0190b90_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:to="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_47885c52-9a9b-44e2-aa15-9805d14f6648_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_77382b44-4362-4d1f-9d9b-c3d8b1837608_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_2d912ca3-b467-43f8-8e36-2995e804dabd_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d2d69e66-27ec-4662-853a-8b0352d33fc8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_009870a7-4527-428f-8eef-e0ccac93011a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_efc5bd44-5791-4c91-8a8b-b9b35484c6b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_99cb99b0-0fbc-4191-bce3-f4a25531f49f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_bc0bfcd7-e852-45a9-a3b0-c94d8d055989_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_c84b12c3-a6bf-4aee-a184-aa12ba3dd86e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_a624ce2f-44bb-4cc9-bbc2-89ca31b3ad36_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_29ef8030-df7d-4932-89ee-5c7032a4f39a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of&#160;Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_ebc311ca-96de-4b00-83e5-ac4dcebb69c5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest associated with debt discount accretion</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_e1a32cc6-991c-48c5-9412-2bcb9d90630f_terseLabel_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_label_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Therapeutics Inc [Member]</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Knight Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember" xlink:href="ardx-20220630.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KnightTherapeuticsIncMember" xlink:to="lab_ardx_KnightTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f9040863-2fb6-4b54-8d08-a774294f4339_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_409f27c4-65e7-4f58-a06b-4d1ea875ef86_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_5255a68e-af51-4183-841b-d7318a9184c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional details</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_d85d0e84-e84c-45db-a308-262e9b123045_negatedTerseLabel_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents, Gross Unrealized Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:to="lab_ardx_CashAndCashEquivalentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_504a5c69-cbf8-47be-9eb6-213e143983f2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_f4395565-18e3-4e00-bc1c-5768985c38a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3920210a-3cc4-4e59-bac6-b2199d3dfc86_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_81c434c8-446a-4046-94b9-456eb5bac622_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on investment securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e198283f-e083-403a-838a-f6b96aebd2f7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingExpenseNoncurrent_0841b8ac-d880-4922-a62e-31c21005f630_terseLabel_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid commercial manufacturing, noncurrent</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingExpenseNoncurrent_label_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing Expense, Noncurrent</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingExpenseNoncurrent_documentation_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingExpenseNoncurrent" xlink:href="ardx-20220630.xsd#ardx_PrepaidCommercialManufacturingExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PrepaidCommercialManufacturingExpenseNoncurrent" xlink:to="lab_ardx_PrepaidCommercialManufacturingExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_932b2195-3b02-4bda-9070-fc592e835af1_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0f4dc295-9a79-4a89-ae04-a3de76c08495_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c93d2200-0ab2-46bc-aa79-80abfa859392_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4b51b15-c20d-4df0-beed-ef3fecf869c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_10285a2b-d9be-49f4-903a-acbce5511631_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_fd6229ad-b032-4c6b-bbd9-ca7a9e3efb7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_874201cb-cef3-4012-af26-20a8287e2605_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_71a02e19-a845-448e-987a-9ee9999f9ad0_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a2daf1a2-15c9-4a05-a537-7b3457c5a3c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_71219ad1-a1c3-4a5f-a8e7-38cfdd45a14d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_2f390342-8035-4fc0-983d-40c9ddd9457e_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:href="ardx-20220630.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_08550daf-1855-4a5a-a709-efa7fadbe992_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_c0bf4a39-28e4-4806-82a6-e058f8506f58_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_3ef31c6a-2777-415a-b392-709360c5970e_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_de48cf81-d47e-47a1-99ba-beb73d77c20c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_041969fd-a426-4ad7-beed-0022827cf3c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in at the market offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_41e25ae1-5b33-4577-96d7-5b8b8dd25305_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ca02373b-e662-4797-b255-6926d8051136_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_184bd5b5-2e5e-4d32-9b90-fc4b1e1f3757_terseLabel_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborators</link:label>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_label_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Collaborator [Member]</link:label>
    <link:label id="lab_ardx_AccountsReceivableCollaboratorMember_documentation_en-US" xlink:label="lab_ardx_AccountsReceivableCollaboratorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember" xlink:href="ardx-20220630.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AccountsReceivableCollaboratorMember" xlink:to="lab_ardx_AccountsReceivableCollaboratorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_feace441-1bcc-4072-bb8e-0c664a557ae6_terseLabel_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred royalty obligation</link:label>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_label_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_documentation_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent" xlink:href="ardx-20220630.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DeferredRoyaltyObligationNoncurrent" xlink:to="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_1d953cc3-3f3a-4170-8293-a36687515375_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_0445413d-a257-4bfe-85b7-8225b36169e8_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:href="ardx-20220630.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:to="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_fd06993d-9b6f-4bbd-b33a-3e494d99caa5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_014d7b7a-b090-4f3d-8601-5d3b2d8822c4_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Chargebacks</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:to="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ffede19a-2322-412a-8136-fe5ec72cb8d1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e4cb2f6a-cd18-408d-a057-a655f62fcb2f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0920699a-455e-497c-9335-6cafe8798fa2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_be42843e-5ab5-4875-ad40-294a6f6a9c34_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12ed9235-5cdb-43f6-a4a9-13566ebd47b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2b91baaa-52dc-474b-9da6-461e1ff8f7b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_6d60bf10-4666-4cfd-9f45-cbd6d5aaac2a_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_b919835e-5972-40cf-a7b7-3c98c58bcea7_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_ac874be6-830e-4953-8db3-3c91e0341d77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt refinancing costs</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_dca076d3-856f-4c52-90e7-c4e7c5d06fc9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDeferredCharges_4212fe84-7f02-4231-afd3-70a9d6b72571_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred compensation for services</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDeferredCharges_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDeferredCharges" xlink:to="lab_us-gaap_AmortizationOfDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_5fa0a087-48da-4970-9459-38dd8f8cf6ec_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_68e7dbe6-bfec-4233-9c00-fd5200ab51e7_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_fd993af5-fc65-4ecc-8682-196d6bfd4088_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential payment per agreement</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:to="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b05ab1d2-fc6e-4289-bcaf-a905dd0b1842_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21fe3796-56d4-4dfb-a1a4-a088183f5b6f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_a318ac68-3516-492f-b07e-1309b4118829_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerRebatesMember" xlink:to="lab_ardx_ContractWithCustomerRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7153dd2a-3fe5-4eea-82a6-e64ecd3c83ad_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d411fd93-75a8-4961-9b1c-804b8c84d25e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_30b28777-4a8f-49e6-85b9-27b144e75376_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4d414ec9-4195-41b1-a411-ab131feedf5a_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_aeece2d3-b03b-4bf3-bc02-cddbc0efa533_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_56685f77-e9d7-4a5b-bda3-262f85de452c_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future obligation upon loan funding or other events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_label_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_documentation_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:to="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b6a4e635-3092-454d-afbe-bb93c5c355b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After first anniversary through second anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d9824868-714c-480c-a4b7-c1fa83833ffe_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_f4979114-1d92-411d-a265-299d96c14f1a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_a4e893e1-77b0-48ca-9fe8-1c4a93bd543a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments and commercial milestone payments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Royalties Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e85d584b-7eee-4c3c-9aa4-4bf0500de85b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_affa59fa-075b-4265-a616-ac6de9ea477d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f647263a-e67d-46c6-a59a-4f783f518eee_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0345360-546d-4b9c-8c88-09ba78435fc5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_18926223-b02a-437a-8c57-a2b141cd6deb_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits/deductions issued</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Credits Or Deductions Issued</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Credits Or Deductions Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:to="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_acf996d1-e790-415f-b826-78ea8f12d97f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_44ee05cd-9ada-450d-9263-7df2637609a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ec4550da-ca48-4d5e-9a41-caac5265fa29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to first anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3e849a52-c965-43ae-83f4-2cc84008ce2c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_18f55324-1ac6-486f-8cf3-ecb48914ce30_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expenses</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_0c403581-08b6-43d8-8931-66eba4b86f0a_terseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_53ac8baf-f3d8-496f-8de2-502506db19b7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6f9814d5-cb39-4220-b5a9-06ad5ce7a260_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_6005bc97-7da6-41f5-8de3-1a4881fb9151_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvanceRoyaltiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Royalties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:to="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_684811ff-1675-4db5-8b23-93445046b04f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_8f31ec67-bea1-4072-a775-60f2c16fe8b7_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization, effective interest rate, percent</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:to="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd7bdd6e-b8bf-4c8c-8382-6324c1fd8e29_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_cfa41085-3736-4681-899c-75e351c04533_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_937a72b0-eef0-4916-8126-5f65232dfe13_negatedTerseLabel_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid commercial manufacturing</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_label_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Commercial Manufacturing Expense</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_documentation_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Commercial Manufacturing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:href="ardx-20220630.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:to="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_24caf308-4dec-4dd6-919c-5732de353a27_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_21922d42-28ec-4a97-b000-6d92e2ab65fc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d72df2fa-3c45-4ac2-bc2f-55121415e111_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_793a1f98-244a-4a1b-a7ec-25265db2d168_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022BMember_a4f1e867-3252-458b-b7f1-01d844a963aa_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_label_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022BMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022BMember" xlink:to="lab_ardx_TermLoan2022BMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_b6ea3301-71da-4a85-bb35-b0beb6d2a66a_terseLabel_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_label_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, General Payment Terms</link:label>
    <link:label id="lab_ardx_RevenueGeneralPaymentTerms_documentation_en-US" xlink:label="lab_ardx_RevenueGeneralPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, General Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms" xlink:href="ardx-20220630.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RevenueGeneralPaymentTerms" xlink:to="lab_ardx_RevenueGeneralPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0407fe5a-9c73-446e-8aec-fd6c5796f143_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_91801849-51f3-442b-9eef-557cf1a35c4d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to be received</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a96b413e-1088-433a-8375-31042e565863_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_af4a7665-f3ce-46c0-b09f-3334c813f999_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_2574a1d9-90c3-48ea-800d-793985054767_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_08d02d01-3f1d-4064-8cfd-b4fac5670e5b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_80d821ef-941a-47bc-a5bf-700784fb09cf_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_31ca96b0-9b5a-41a8-9f9a-d5718be4c5c4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_bc80f5f4-ed11-4d34-927c-5b36a02fe83e_totalLabel_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:href="ardx-20220630.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:to="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c04a9a75-90a4-4850-befe-8d53e4b72124_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_30745eb5-f2e6-4342-9b34-b5864b8bb171_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b48f086f-1416-4f3f-bd63-043c10376f14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_McKessonCorporationMember_c5b2f76e-591d-444f-aa03-6eb46d47c1be_terseLabel_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_label_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_documentation_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember" xlink:href="ardx-20220630.xsd#ardx_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_McKessonCorporationMember" xlink:to="lab_ardx_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_27e1a4f2-d76f-487c-9291-4bdfa778649e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_95e7171d-f633-4ace-b6cd-f26f09aa05f6_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_82ca4ce8-3993-49c0-9cc8-4ef4b1bb632e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6048934e-a0a6-417d-9e68-be93bff034c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and redemptions of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_59e9467e-d50f-450a-b9ee-94d060e7f1da_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_23627af7-b9f0-4484-886b-f5c03a954244_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9efb2dd6-e892-450d-829d-29161ba08e74_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ba3e49d-1261-43a8-a1e2-eeceb35bcfb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_54723848-a532-4e3f-9d97-010cf1275ad5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_530cb3a2-0938-4135-b1c5-54a5bb373c90_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-to-net sales accruals and reserves</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual [Roll Forward]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_6d7a8e18-5529-4a02-85c6-6a1ed88de494_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_fe024eb5-40b3-4f2a-b776-5ada20bfbb41_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2b2eca7c-6812-4c12-81d1-21aebc5c70a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e5ff8252-0a48-4c86-960f-2ab67cc70a06_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d619e741-417d-4a4e-a1d1-2cd017662900_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_009f55ec-79dd-4943-bec9-e44312236d66_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_64497522-9811-4228-8a44-f3b623d6e068_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of 2018 Loan, net of settlement costs</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c9cc96f6-2a75-47d7-9220-58c386c5774e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_926a83e1-44bd-4bec-90f9-22f151f3fdea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_782889d6-d959-4bae-a94d-8a1326ad3367_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d0c26a6a-b2f7-4967-af7b-f87e52b852c2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_0b1e22f7-547b-422e-b90e-fe1369b63503_negatedTerseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases due to revenue recognized in the period for which cash has been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue Recognized Cash Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2018Member_03e0bba7-c9ac-4ae5-b202-dac868e8237b_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_label_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member" xlink:href="ardx-20220630.xsd#ardx_ExitFee2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2018Member" xlink:to="lab_ardx_ExitFee2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7aae4633-76b9-493d-ba0b-4f45c98a6c3e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c0ee8729-95d9-4bac-9a3e-ebd45ffaf08f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e31a15df-8965-4ed4-af18-1b5bf4d7483e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_73358371-2cf3-42a4-a1a0-a379d52a33f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6ec45b30-d522-49fd-bff0-645a673193f7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_f65225d3-2e54-4ea7-8e1f-728a2f0ea97b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eecfab54-19b8-4ce5-9b85-ad88b3a9e6fb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_a7e6599f-22d5-4e1d-9091-2376dfc0696a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2022Member_0ac94eb7-033b-4009-af76-b93efb629abb_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_label_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member" xlink:href="ardx-20220630.xsd#ardx_ExitFee2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2022Member" xlink:to="lab_ardx_ExitFee2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_6880d2c8-2acc-408b-9fd7-a9886f2df4a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0a03ccde-cea2-4091-a3bb-7fe3e39aad40_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b2775f38-8051-4579-a008-91a10b7a8400_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_e981d338-1448-4e6c-a843-af898c40d624_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_5180e3e6-aaa4-4bbb-9304-85d5be7b7087_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition to floating per annum rate (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_label_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:to="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87855131-5cc6-42fa-b149-20418774039c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f0a2d252-f7f9-43b0-9503-7efd35451d2a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4ba9c57a-5f64-4afe-bfcf-75e68ede1380_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6c1df907-60d2-4ae6-b331-745cc22374d2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_79fee9a6-0283-463a-8a07-855f26328e64_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_3ffbfc4e-c50e-4085-9f34-82590ffd414e_terseLabel_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of maximum aggregate offering price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice" xlink:href="ardx-20220630.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_MaximumAggregateOfferingPrice" xlink:to="lab_ardx_MaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_a49cbed5-12aa-46ea-8c43-a743a71d632e_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First installment of upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees, First Installment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_735f1a06-1866-496b-bb64-549ed6e010e7_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ardx-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:547e7867-d9ac-4b70-ab52-436421bc76c6,g:9e9ed2bd-0902-4fdf-8b0e-0a522fb1fe1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_14b06908-c623-4adb-ad13-eb5ba8862abe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_DocumentType_14b06908-c623-4adb-ad13-eb5ba8862abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b3b94495-55cd-4657-b9ec-c7f9c1e6ca59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_DocumentQuarterlyReport_b3b94495-55cd-4657-b9ec-c7f9c1e6ca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f5cd1343-f2cd-4aa4-bb16-5bfbc3375a62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_DocumentPeriodEndDate_f5cd1343-f2cd-4aa4-bb16-5bfbc3375a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d7de034a-4cd5-4712-957a-b0eb9c5f4da6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_DocumentTransitionReport_d7de034a-4cd5-4712-957a-b0eb9c5f4da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a5a9da0e-b65e-43a8-9c0e-433485152bc2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityFileNumber_a5a9da0e-b65e-43a8-9c0e-433485152bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0c8c3f83-dbe9-4f91-934a-157556393954" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityRegistrantName_0c8c3f83-dbe9-4f91-934a-157556393954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_46083ef0-707c-4f63-bb5d-593ce62e957a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityIncorporationStateCountryCode_46083ef0-707c-4f63-bb5d-593ce62e957a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_28018e7b-37b6-4404-889b-d15c56f24ca0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityTaxIdentificationNumber_28018e7b-37b6-4404-889b-d15c56f24ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8d9b15e8-a411-416b-9393-6b5c6deed006" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityAddressAddressLine1_8d9b15e8-a411-416b-9393-6b5c6deed006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e1cc2389-a05e-4423-ad91-c7c38d0f6fbd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityAddressAddressLine2_e1cc2389-a05e-4423-ad91-c7c38d0f6fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_33baeb46-146f-4a2a-9bf2-fc4270b48a25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityAddressCityOrTown_33baeb46-146f-4a2a-9bf2-fc4270b48a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3ae2a21a-2feb-4805-9658-92ef58431b4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityAddressStateOrProvince_3ae2a21a-2feb-4805-9658-92ef58431b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_51f20d3a-cd3e-4322-a17f-ac867befdab3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityAddressPostalZipCode_51f20d3a-cd3e-4322-a17f-ac867befdab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c8e3ffbe-1967-47ee-ba59-de34cc7c4242" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_CityAreaCode_c8e3ffbe-1967-47ee-ba59-de34cc7c4242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aca1733f-9fa6-4d0e-bb88-24f55b9b8a35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_LocalPhoneNumber_aca1733f-9fa6-4d0e-bb88-24f55b9b8a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c1aaa663-2456-4df0-ad25-d29306d2c0e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_Security12bTitle_c1aaa663-2456-4df0-ad25-d29306d2c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_59a0b509-943f-4a73-9243-fb3cad4afeaf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_TradingSymbol_59a0b509-943f-4a73-9243-fb3cad4afeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4bb46726-c5a3-44f8-9b64-0e2081f8bbf4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_SecurityExchangeName_4bb46726-c5a3-44f8-9b64-0e2081f8bbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_566f8142-68a9-457d-b809-3a542040aeab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityCurrentReportingStatus_566f8142-68a9-457d-b809-3a542040aeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ece0db34-ef9d-477f-ad7e-7f7b786e29bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityInteractiveDataCurrent_ece0db34-ef9d-477f-ad7e-7f7b786e29bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_07497329-8604-4355-abea-03d4b436722b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityFilerCategory_07497329-8604-4355-abea-03d4b436722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_683757f2-2c4d-4848-8a1a-86b8c810d733" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntitySmallBusiness_683757f2-2c4d-4848-8a1a-86b8c810d733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f214c0c9-fc6b-4a90-a31e-5f25fbe7303a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityEmergingGrowthCompany_f214c0c9-fc6b-4a90-a31e-5f25fbe7303a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_750de484-5d66-4f4c-903b-e01ec6619c93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityShellCompany_750de484-5d66-4f4c-903b-e01ec6619c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3c4b10ee-0e61-4665-8b54-437421ce8723" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3c4b10ee-0e61-4665-8b54-437421ce8723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dccf9f70-20be-4626-958e-e8aa4d7b9c4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_EntityCentralIndexKey_dccf9f70-20be-4626-958e-e8aa4d7b9c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_12fac308-d490-470f-8ff7-7d02ff4512fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_CurrentFiscalYearEndDate_12fac308-d490-470f-8ff7-7d02ff4512fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_485cd1f9-3a7c-4824-95e3-76d1a013b3c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_DocumentFiscalYearFocus_485cd1f9-3a7c-4824-95e3-76d1a013b3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1813b4d8-ac50-43cb-a3c3-0c1f4af0967c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1813b4d8-ac50-43cb-a3c3-0c1f4af0967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_be01bc9d-8bb3-4e68-9550-b60bfec6d7cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_498e7d6a-723f-4b88-b12e-a68b17099364" xlink:to="loc_dei_AmendmentFlag_be01bc9d-8bb3-4e68-9550-b60bfec6d7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b0c88166-2895-40c1-9573-c60ebd015f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f6d1318d-d176-478b-a840-d81beab81399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0c88166-2895-40c1-9573-c60ebd015f71" xlink:to="loc_us-gaap_AssetsAbstract_f6d1318d-d176-478b-a840-d81beab81399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f6d1318d-d176-478b-a840-d81beab81399" xlink:to="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8bfaad2-9429-4aa9-a593-2e2118c4d98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8bfaad2-9429-4aa9-a593-2e2118c4d98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2231363b-ab1c-4738-b0db-0a54d6cafd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2231363b-ab1c-4738-b0db-0a54d6cafd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6f92e049-3e15-4524-bca9-b68700b4c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6f92e049-3e15-4524-bca9-b68700b4c05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2667600c-a319-4958-82b0-4ea382b300fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:to="loc_us-gaap_InventoryNet_2667600c-a319-4958-82b0-4ea382b300fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_521a9a4c-4c3b-4cd4-8930-e2d701c0f296" xlink:href="ardx-20220630.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_521a9a4c-4c3b-4cd4-8930-e2d701c0f296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6e0cabd-2467-48a7-ae7a-a542a29eef28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d6e0cabd-2467-48a7-ae7a-a542a29eef28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_824bf043-aa6a-46c8-a261-8bf242870c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_260c2add-d88a-48cd-9564-71841df1b400" xlink:to="loc_us-gaap_AssetsCurrent_824bf043-aa6a-46c8-a261-8bf242870c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_878505aa-ad53-4d6b-b165-19308c220d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f6d1318d-d176-478b-a840-d81beab81399" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_878505aa-ad53-4d6b-b165-19308c220d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8ec814e9-2c13-4d3f-b4d4-dcb1eda9211a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f6d1318d-d176-478b-a840-d81beab81399" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8ec814e9-2c13-4d3f-b4d4-dcb1eda9211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2c4503ed-cd53-4814-b3e1-770d1fdbb0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f6d1318d-d176-478b-a840-d81beab81399" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2c4503ed-cd53-4814-b3e1-770d1fdbb0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9917e7ea-ad51-4de7-ae8b-3f149a493def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f6d1318d-d176-478b-a840-d81beab81399" xlink:to="loc_us-gaap_Assets_9917e7ea-ad51-4de7-ae8b-3f149a493def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b0c88166-2895-40c1-9573-c60ebd015f71" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f48e183c-7b9e-4864-a0d0-155ddcf33f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:to="loc_us-gaap_AccountsPayableCurrent_f48e183c-7b9e-4864-a0d0-155ddcf33f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a92a438-89d7-47d2-879b-91d0f573f880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a92a438-89d7-47d2-879b-91d0f573f880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e87b1d0e-067d-4e42-8b9e-57c2f56e88bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:to="loc_us-gaap_LongTermDebtCurrent_e87b1d0e-067d-4e42-8b9e-57c2f56e88bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3f62aeda-10c8-4c4b-a1c1-98526a5047d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3f62aeda-10c8-4c4b-a1c1-98526a5047d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a09ae9fd-007c-4c66-bd2b-030d61f16cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a09ae9fd-007c-4c66-bd2b-030d61f16cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_487c4681-ff3e-40bf-9865-6e6fed330700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9115c089-552e-47ea-98ae-3da64d80e497" xlink:to="loc_us-gaap_LiabilitiesCurrent_487c4681-ff3e-40bf-9865-6e6fed330700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_86e832a4-4b6d-48bb-ac62-0451c92d8d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_86e832a4-4b6d-48bb-ac62-0451c92d8d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ec5b0614-5777-496c-a491-33a0995db015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ec5b0614-5777-496c-a491-33a0995db015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent_7f48d503-9386-4d5a-b406-c2f669cbac08" xlink:href="ardx-20220630.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_ardx_DeferredRoyaltyObligationNoncurrent_7f48d503-9386-4d5a-b406-c2f669cbac08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b3bcf0ad-d27e-45a7-886a-37bcb1fc2448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_us-gaap_Liabilities_b3bcf0ad-d27e-45a7-886a-37bcb1fc2448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_46f3b762-b174-4c2c-aed4-2cd4d9894e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_us-gaap_CommitmentsAndContingencies_46f3b762-b174-4c2c-aed4-2cd4d9894e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c7f3b199-8a13-4775-8f5a-1a00a863cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:to="loc_us-gaap_PreferredStockValue_c7f3b199-8a13-4775-8f5a-1a00a863cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_72429c7f-b3d2-4df4-9370-4efed220c948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:to="loc_us-gaap_CommonStockValue_72429c7f-b3d2-4df4-9370-4efed220c948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cd624eb6-a62d-49d9-ad8f-4217a9874b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cd624eb6-a62d-49d9-ad8f-4217a9874b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_696815bb-c9a9-4a35-9003-2b2a553ac151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_696815bb-c9a9-4a35-9003-2b2a553ac151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_827f4d0f-aee3-4d67-8232-17ba69de1261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_827f4d0f-aee3-4d67-8232-17ba69de1261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aa063a81-639e-498d-8d22-23f5efab7811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_99ad4876-ea37-437b-a070-8b2d3acec381" xlink:to="loc_us-gaap_StockholdersEquity_aa063a81-639e-498d-8d22-23f5efab7811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e36e6d7d-780e-49fa-a447-cfaf12cf9896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a176db1c-1555-4cf9-a347-28f4d2b85b82" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e36e6d7d-780e-49fa-a447-cfaf12cf9896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_17b59fd9-d60d-4c2c-b8db-49893f39ae68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_17b59fd9-d60d-4c2c-b8db-49893f39ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d38f6404-bfa1-49ff-9e2f-484df5b3bd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d38f6404-bfa1-49ff-9e2f-484df5b3bd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_35a44b99-8ab0-48b6-8b7e-815ea3192937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_PreferredStockSharesIssued_35a44b99-8ab0-48b6-8b7e-815ea3192937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_48e587ea-d615-4fbb-b0d3-9c985eee3502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_48e587ea-d615-4fbb-b0d3-9c985eee3502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2e27d6aa-9457-43ec-9dfc-1786e8b480a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2e27d6aa-9457-43ec-9dfc-1786e8b480a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d9964c14-0a25-4670-9836-5d554964d772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d9964c14-0a25-4670-9836-5d554964d772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4a5cf44e-bce8-4529-ae63-f4af70a87e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_CommonStockSharesIssued_4a5cf44e-bce8-4529-ae63-f4af70a87e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54f7589f-ee5c-48a6-b9db-b47d90acabb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6c12121-f9f3-4d73-9852-83888840dece" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_54f7589f-ee5c-48a6-b9db-b47d90acabb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_27c50042-8919-4ca8-9d85-a6667988b367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_48dc97a7-67db-4de6-861f-2241d2258f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_27c50042-8919-4ca8-9d85-a6667988b367" xlink:to="loc_us-gaap_StatementTable_48dc97a7-67db-4de6-861f-2241d2258f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_26dbae53-d127-4a28-a840-9f5e193e3ecb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48dc97a7-67db-4de6-861f-2241d2258f70" xlink:to="loc_srt_ProductOrServiceAxis_26dbae53-d127-4a28-a840-9f5e193e3ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_26dbae53-d127-4a28-a840-9f5e193e3ecb" xlink:to="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6049c138-dea6-4eef-a0f3-83b8a17b35a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_us-gaap_ProductMember_6049c138-dea6-4eef-a0f3-83b8a17b35a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_4009bb91-8e59-441d-b2d5-2903a13a61c0" xlink:href="ardx-20220630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_ardx_ProductSupplyRevenueMember_4009bb91-8e59-441d-b2d5-2903a13a61c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_00d39e2d-6bda-42f6-8446-96999bf45ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_us-gaap_LicenseMember_00d39e2d-6bda-42f6-8446-96999bf45ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeDevelopmentMember_18b26c1b-5876-4644-ae95-73768f69025e" xlink:href="ardx-20220630.xsd#ardx_CollaborativeDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e245dbc0-894b-420e-a7c3-06a2e77a4bbf" xlink:to="loc_ardx_CollaborativeDevelopmentMember_18b26c1b-5876-4644-ae95-73768f69025e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_48dc97a7-67db-4de6-861f-2241d2258f70" xlink:to="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_18c11927-cc15-4248-8aee-5fd7d59915ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_RevenuesAbstract_18c11927-cc15-4248-8aee-5fd7d59915ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a66a943-e22d-444b-af69-4eb110dca97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_18c11927-cc15-4248-8aee-5fd7d59915ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a66a943-e22d-444b-af69-4eb110dca97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_8daa2d39-21df-4a58-aa3b-6dfd0a5d5d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_CostOfRevenue_8daa2d39-21df-4a58-aa3b-6dfd0a5d5d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_82f1c39d-8b94-481f-820d-35c62d80d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_82f1c39d-8b94-481f-820d-35c62d80d8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78ce63eb-589e-402e-bcf3-669e0782c2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_78ce63eb-589e-402e-bcf3-669e0782c2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_defc8aaf-27ed-430c-ac6e-ebfc8ddbed22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4057ef0f-7274-4f52-ab6e-6c31eed32427" xlink:to="loc_us-gaap_CostsAndExpenses_defc8aaf-27ed-430c-ac6e-ebfc8ddbed22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a6a9a551-3d10-4c12-9eb4-6d71367828d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_OperatingIncomeLoss_a6a9a551-3d10-4c12-9eb4-6d71367828d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fadffbd7-9bc2-475c-961a-6e6d32ea1ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_InterestExpense_fadffbd7-9bc2-475c-961a-6e6d32ea1ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a7edbbd9-1d93-45dc-8009-9554ac5f1461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a7edbbd9-1d93-45dc-8009-9554ac5f1461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a7d67f6c-04ad-4916-af01-47a3eb77f53d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a7d67f6c-04ad-4916-af01-47a3eb77f53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60a80ddd-9df6-4264-9919-f3a589fc7108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_60a80ddd-9df6-4264-9919-f3a589fc7108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4781444a-cd13-452d-85fd-15314aef5706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_NetIncomeLoss_4781444a-cd13-452d-85fd-15314aef5706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_33d35b35-33f1-4b0a-86d0-0df8b242e26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_EarningsPerShareBasic_33d35b35-33f1-4b0a-86d0-0df8b242e26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1bca5267-93fe-4e65-9457-fafc321e7f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1bca5267-93fe-4e65-9457-fafc321e7f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c75bf77-bb84-4e57-8171-68cc47328c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c75bf77-bb84-4e57-8171-68cc47328c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7fbbb0d-1b15-42b0-8948-478638fbb7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7fbbb0d-1b15-42b0-8948-478638fbb7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_35deac24-2a12-44f2-a7ea-79a429ed71c3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c57d75c8-fde9-4ca1-9dab-4bbbdb7df50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:to="loc_us-gaap_NetIncomeLoss_c57d75c8-fde9-4ca1-9dab-4bbbdb7df50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27ee999f-6857-4fae-a08e-8dd1b23c5663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_27ee999f-6857-4fae-a08e-8dd1b23c5663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7301b9f-1a18-43f9-bc9c-cf350f5186ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_13b2da58-41df-419e-9f6b-59db099581f0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e7301b9f-1a18-43f9-bc9c-cf350f5186ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_532793ac-907f-428a-9cd4-f9173581ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_987c8e05-6b2c-4bfb-93a1-cdafda3a712c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_532793ac-907f-428a-9cd4-f9173581ca31" xlink:to="loc_us-gaap_StatementTable_987c8e05-6b2c-4bfb-93a1-cdafda3a712c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9a0bd92a-f807-4cee-b45c-c78d061e288e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_987c8e05-6b2c-4bfb-93a1-cdafda3a712c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9a0bd92a-f807-4cee-b45c-c78d061e288e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9a0bd92a-f807-4cee-b45c-c78d061e288e" xlink:to="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b490e8f1-6189-4310-963f-1086951554af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_CommonStockMember_b490e8f1-6189-4310-963f-1086951554af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2567b7e9-b3b2-41c7-bf10-385769a5a629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2567b7e9-b3b2-41c7-bf10-385769a5a629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_314b1c4c-a765-4e6f-81df-ec10d351e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_RetainedEarningsMember_314b1c4c-a765-4e6f-81df-ec10d351e0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77e3e834-7966-44e4-abb5-44c8ecd8d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_83e5358c-50c7-46c2-a0f4-1ae8689965f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77e3e834-7966-44e4-abb5-44c8ecd8d4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_38e49f71-dd07-40a9-875d-06a4eff3eeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_987c8e05-6b2c-4bfb-93a1-cdafda3a712c" xlink:to="loc_us-gaap_StatementLineItems_38e49f71-dd07-40a9-875d-06a4eff3eeaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_38e49f71-dd07-40a9-875d-06a4eff3eeaa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e43cf23d-4232-42f3-ac99-937d21d6e9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_SharesOutstanding_e43cf23d-4232-42f3-ac99-937d21d6e9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a4e3d687-f661-4c91-9e13-b9d90079b3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockholdersEquity_a4e3d687-f661-4c91-9e13-b9d90079b3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2af4c7f5-9d0b-42ee-9662-11b95cfc3012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2af4c7f5-9d0b-42ee-9662-11b95cfc3012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4b6e85e-7400-46b5-a7f0-d0938957cc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4b6e85e-7400-46b5-a7f0-d0938957cc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5946ff1f-0a77-41b0-aa41-5f6ca7c35c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5946ff1f-0a77-41b0-aa41-5f6ca7c35c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_747fd357-944c-4130-ba67-ad08046de85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_747fd357-944c-4130-ba67-ad08046de85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f2057bca-6486-48ce-a5fd-a64c05ad2063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f2057bca-6486-48ce-a5fd-a64c05ad2063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346ec900-33f5-4414-8976-74c5187df3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346ec900-33f5-4414-8976-74c5187df3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0473d13b-2bd2-4d68-9b13-b1133d67d6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0473d13b-2bd2-4d68-9b13-b1133d67d6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a5d0a3-a027-43b3-8637-9cd943456212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d8a5d0a3-a027-43b3-8637-9cd943456212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e4b567f0-8a8b-4b80-beae-ddfd9dddf0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e4b567f0-8a8b-4b80-beae-ddfd9dddf0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_522f22d0-7470-4cdf-bc19-c6c428c87d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_NetIncomeLoss_522f22d0-7470-4cdf-bc19-c6c428c87d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e79b2b7c-1133-405b-a45e-da9f8c965469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_SharesOutstanding_e79b2b7c-1133-405b-a45e-da9f8c965469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d879b7c-d008-4b40-ad05-0fbbe0e2a4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_35707c57-69ba-48aa-8adc-08477b8d4b9e" xlink:to="loc_us-gaap_StockholdersEquity_5d879b7c-d008-4b40-ad05-0fbbe0e2a4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20220630.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8e92457-ab0b-4d0d-a52f-7f99b378c712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8e92457-ab0b-4d0d-a52f-7f99b378c712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1413e59f-a14e-4cd4-980a-4b8460eafd98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8e92457-ab0b-4d0d-a52f-7f99b378c712" xlink:to="loc_us-gaap_NetIncomeLoss_1413e59f-a14e-4cd4-980a-4b8460eafd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8e92457-ab0b-4d0d-a52f-7f99b378c712" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0591f20e-e74b-4d7f-b39d-98857c4eaa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_Depreciation_0591f20e-e74b-4d7f-b39d-98857c4eaa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8e14460b-fe32-4810-9c5d-b42c2a569f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8e14460b-fe32-4810-9c5d-b42c2a569f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDeferredCharges_1ea8ecab-73e4-4df1-a974-3d40b65a80be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_AmortizationOfDeferredCharges_1ea8ecab-73e4-4df1-a974-3d40b65a80be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_08181004-7cfc-4399-aea2-c35f8b9ac5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_08181004-7cfc-4399-aea2-c35f8b9ac5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1cfd925c-27e0-4b88-a367-e1e062eaf87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1cfd925c-27e0-4b88-a367-e1e062eaf87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_014a716a-64c9-4ab7-ad98-0abda0605738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_ShareBasedCompensation_014a716a-64c9-4ab7-ad98-0abda0605738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_254f815c-721d-4b01-85e7-8f90f3ec8d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_254f815c-721d-4b01-85e7-8f90f3ec8d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_c4aebbd5-da50-48c9-aced-449d8ef7912e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_c4aebbd5-da50-48c9-aced-449d8ef7912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_7af11d4d-3299-435b-bd1c-57d24dda1e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_7af11d4d-3299-435b-bd1c-57d24dda1e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_1f79a9e1-9a70-416d-9bc8-2f62d6ef603c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6b7dc513-694c-43e9-9f5e-6094a43874ab" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_1f79a9e1-9a70-416d-9bc8-2f62d6ef603c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8e92457-ab0b-4d0d-a52f-7f99b378c712" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_294fa884-f9d8-42f2-a2dc-486114d6f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_294fa884-f9d8-42f2-a2dc-486114d6f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_40786d3c-6380-4ca8-bd1f-d2aea4d2da0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_40786d3c-6380-4ca8-bd1f-d2aea4d2da0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_e9b1cc64-62d6-4c62-893c-c09ddfa5826e" xlink:href="ardx-20220630.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_e9b1cc64-62d6-4c62-893c-c09ddfa5826e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c549ac23-008c-452f-9231-09e99adf2bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c549ac23-008c-452f-9231-09e99adf2bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_744215e4-7cb1-4f61-b9fa-353d6c50ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_744215e4-7cb1-4f61-b9fa-353d6c50ab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e3e5b0af-60a5-469d-bc4d-df1ff22552d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e3e5b0af-60a5-469d-bc4d-df1ff22552d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9f42011d-d308-4dc0-9e73-920e0eeddc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9f42011d-d308-4dc0-9e73-920e0eeddc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2534d46f-f388-4aef-bf34-2add48ad94a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2534d46f-f388-4aef-bf34-2add48ad94a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_12fcd73e-32dd-47f9-9cb0-6350b16202fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7e1a8469-c00c-4d9a-afb3-fef9817cbf99" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_12fcd73e-32dd-47f9-9cb0-6350b16202fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bdda30c-eb58-4001-82fa-4b6303c05fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8e92457-ab0b-4d0d-a52f-7f99b378c712" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bdda30c-eb58-4001-82fa-4b6303c05fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65ed1a54-93c4-47d2-8c79-0dd44d49f548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65ed1a54-93c4-47d2-8c79-0dd44d49f548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_16fac35f-ae20-4f06-bef5-4d95a13b6757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65ed1a54-93c4-47d2-8c79-0dd44d49f548" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_16fac35f-ae20-4f06-bef5-4d95a13b6757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a11e92ee-e746-46b1-9d34-99719cd90176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65ed1a54-93c4-47d2-8c79-0dd44d49f548" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a11e92ee-e746-46b1-9d34-99719cd90176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5a045559-d3dd-4936-b85a-53fa50f9ce46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65ed1a54-93c4-47d2-8c79-0dd44d49f548" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_5a045559-d3dd-4936-b85a-53fa50f9ce46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_854aca27-aa4c-4ceb-b197-26c82e40c548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65ed1a54-93c4-47d2-8c79-0dd44d49f548" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_854aca27-aa4c-4ceb-b197-26c82e40c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb91b8d1-6f12-4022-8a7d-ab3c54743619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65ed1a54-93c4-47d2-8c79-0dd44d49f548" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb91b8d1-6f12-4022-8a7d-ab3c54743619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_3089b518-2e2b-4b45-983c-4b2c320356a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_3089b518-2e2b-4b45-983c-4b2c320356a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_7ac6a55c-b20a-4c13-a7be-a7ec41745dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_7ac6a55c-b20a-4c13-a7be-a7ec41745dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_1fbc9aae-2498-4582-a791-fbfcaf96d50b" xlink:href="ardx-20220630.xsd#ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:to="loc_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts_1fbc9aae-2498-4582-a791-fbfcaf96d50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0ab8eebc-7e55-445f-9557-8aabe7c3724c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0ab8eebc-7e55-445f-9557-8aabe7c3724c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_91802385-59fa-49ce-b07e-ee3f98996740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_91802385-59fa-49ce-b07e-ee3f98996740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e92977c0-70f8-45ac-ac1f-8e0d55db3e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fe828e5c-390d-4b49-b8f8-fb678148678b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e92977c0-70f8-45ac-ac1f-8e0d55db3e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f0403f03-9fb2-4391-a93d-1ad44605e09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f0403f03-9fb2-4391-a93d-1ad44605e09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67dd7419-1191-425f-9641-ed1e61e64036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67dd7419-1191-425f-9641-ed1e61e64036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b16de912-38fe-4dbf-8ec7-5a5f572420aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b16de912-38fe-4dbf-8ec7-5a5f572420aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_832e42d7-2371-4385-9916-737c75225ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_832e42d7-2371-4385-9916-737c75225ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_da0262e2-64f5-490f-9921-392823f2c764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_832e42d7-2371-4385-9916-737c75225ddf" xlink:to="loc_us-gaap_InterestPaidNet_da0262e2-64f5-490f-9921-392823f2c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_84f53725-50dd-4abe-9827-8ddb37806c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_832e42d7-2371-4385-9916-737c75225ddf" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_84f53725-50dd-4abe-9827-8ddb37806c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1932e243-118a-44bc-93b2-3f3d2c4d32ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_17f79902-45b9-4cb2-982d-4da44d28fd24" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1932e243-118a-44bc-93b2-3f3d2c4d32ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_677f2cc2-24ee-415e-b749-f478c2f67bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1932e243-118a-44bc-93b2-3f3d2c4d32ce" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_677f2cc2-24ee-415e-b749-f478c2f67bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued_452be435-2f0c-434c-b232-c78071b78df9" xlink:href="ardx-20220630.xsd#ardx_DerivativeIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1932e243-118a-44bc-93b2-3f3d2c4d32ce" xlink:to="loc_ardx_DerivativeIssued_452be435-2f0c-434c-b232-c78071b78df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="ardx-20220630.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b8b2791-2738-4bc7-b904-fd61c7421959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_3e421a81-71a1-45cd-85a0-7e0851be632a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b8b2791-2738-4bc7-b904-fd61c7421959" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_3e421a81-71a1-45cd-85a0-7e0851be632a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="ardx-20220630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_57414951-ca20-4009-9266-d4ab2974330a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_57414951-ca20-4009-9266-d4ab2974330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c0a8431e-ff3b-4ea0-bbfe-af07fa71a945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_UseOfEstimates_c0a8431e-ff3b-4ea0-bbfe-af07fa71a945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7ed7053f-b5b9-4d1d-966d-7a03d50df574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7ed7053f-b5b9-4d1d-966d-7a03d50df574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_72d9923a-0eb8-4a27-af29-f559e3e42cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_72d9923a-0eb8-4a27-af29-f559e3e42cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6aabde0d-919f-42b6-aaa7-36c72732001d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6aabde0d-919f-42b6-aaa7-36c72732001d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_ade1d53a-43f7-4128-9519-29c0854e9b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_ade1d53a-43f7-4128-9519-29c0854e9b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_02217e1f-bd28-410b-99b2-512671230fd1" xlink:href="ardx-20220630.xsd#ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock_02217e1f-bd28-410b-99b2-512671230fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e76275ba-2b13-4770-8fe8-99d33e97c364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e76275ba-2b13-4770-8fe8-99d33e97c364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_481b1d77-c87a-4314-8bff-db3809f1180f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8dd7021f-99d8-4c34-817d-6dcae7484887" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_481b1d77-c87a-4314-8bff-db3809f1180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf2d74c5-308c-4cde-8ac6-acd4fdda1ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a6b3fe8f-25e4-45fa-8676-9d908aeb3aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf2d74c5-308c-4cde-8ac6-acd4fdda1ebd" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a6b3fe8f-25e4-45fa-8676-9d908aeb3aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_a97a6615-da72-494a-ac29-9001a466bcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf2d74c5-308c-4cde-8ac6-acd4fdda1ebd" xlink:to="loc_us-gaap_InvestmentsAndCash_a97a6615-da72-494a-ac29-9001a466bcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_462f598f-bac9-4497-9c66-890a5b0426ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf2d74c5-308c-4cde-8ac6-acd4fdda1ebd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_462f598f-bac9-4497-9c66-890a5b0426ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf2d74c5-308c-4cde-8ac6-acd4fdda1ebd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86a0528f-e9a4-4b02-9df0-9b8a4032b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86a0528f-e9a4-4b02-9df0-9b8a4032b89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_86a0528f-e9a4-4b02-9df0-9b8a4032b89d" xlink:to="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCollaboratorMember_ded8ef25-9df4-46e2-afdf-784b8688d9a3" xlink:href="ardx-20220630.xsd#ardx_AccountsReceivableCollaboratorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:to="loc_ardx_AccountsReceivableCollaboratorMember_ded8ef25-9df4-46e2-afdf-784b8688d9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AccountsReceivableCommercialCustomerMember_8192bb30-cf40-4713-b090-90a50a8a8cc0" xlink:href="ardx-20220630.xsd#ardx_AccountsReceivableCommercialCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_bd9a7992-096b-4373-ace7-70e93f47d749" xlink:to="loc_ardx_AccountsReceivableCommercialCustomerMember_8192bb30-cf40-4713-b090-90a50a8a8cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_srt_RangeAxis_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aa18c7db-9186-4d62-b5c1-5eeb46bbf8d3" xlink:to="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea739470-6ea4-4588-9b2d-78d9ed5c7066" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:to="loc_srt_MinimumMember_ea739470-6ea4-4588-9b2d-78d9ed5c7066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10bd2bd4-e9b0-417c-8622-621ec758ff82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d2480d04-3865-4158-997f-e9ad3bbf416c" xlink:to="loc_srt_MaximumMember_10bd2bd4-e9b0-417c-8622-621ec758ff82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c8b85ef5-9687-4c7a-9737-86daff9d4749" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_srt_CounterpartyNameAxis_c8b85ef5-9687-4c7a-9737-86daff9d4749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82e80a33-7412-41be-bc23-d6cf7e01183c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c8b85ef5-9687-4c7a-9737-86daff9d4749" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82e80a33-7412-41be-bc23-d6cf7e01183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_46b2ac74-287b-4fdb-8dd6-87ade7912402" xlink:href="ardx-20220630.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82e80a33-7412-41be-bc23-d6cf7e01183c" xlink:to="loc_ardx_AstrazenecaMember_46b2ac74-287b-4fdb-8dd6-87ade7912402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_034de5fb-1930-4d28-87f1-1cce14161e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_us-gaap_TypeOfArrangementAxis_034de5fb-1930-4d28-87f1-1cce14161e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057fe0e2-ea06-4cbb-8176-d528a9a21c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_034de5fb-1930-4d28-87f1-1cce14161e06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057fe0e2-ea06-4cbb-8176-d528a9a21c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_449109ca-2fc0-4db0-9848-a07fbe8500e0" xlink:href="ardx-20220630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_057fe0e2-ea06-4cbb-8176-d528a9a21c87" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_449109ca-2fc0-4db0-9848-a07fbe8500e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fdd1bba4-bb62-4724-b11f-ad81cdcf0078" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_db9b5520-2a0d-4d5c-a4a8-60ecc5b9cc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_db9b5520-2a0d-4d5c-a4a8-60ecc5b9cc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueGeneralPaymentTerms_f199fa5e-8a7d-48a4-856f-f4b1c28de15d" xlink:href="ardx-20220630.xsd#ardx_RevenueGeneralPaymentTerms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_RevenueGeneralPaymentTerms_f199fa5e-8a7d-48a4-856f-f4b1c28de15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_bd971927-e05a-4a23-93b9-65660698148a" xlink:href="ardx-20220630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_bd971927-e05a-4a23-93b9-65660698148a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_04e05064-3f8f-4ced-a3e8-43a74555a5d9" xlink:href="ardx-20220630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_04e05064-3f8f-4ced-a3e8-43a74555a5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_91349112-64a4-4b88-96d7-0e401bd54116" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_91349112-64a4-4b88-96d7-0e401bd54116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_fcf55bf3-89f4-4619-aff3-2a04fdf5e0b8" xlink:href="ardx-20220630.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_462d870f-24ec-46eb-a72c-4cccca08dc26" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_fcf55bf3-89f4-4619-aff3-2a04fdf5e0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="simple" xlink:href="ardx-20220630.xsd#CashCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_ecd238ad-c022-429c-85b4-362990297ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_b3e37553-a7ea-41df-a0b5-9b8a3b8efbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ecd238ad-c022-429c-85b4-362990297ffe" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_b3e37553-a7ea-41df-a0b5-9b8a3b8efbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#CashCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_324b193a-e620-48e3-b4a8-94ad7bb8cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_de6cc637-d1a3-491c-9833-0e0006ba9d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_324b193a-e620-48e3-b4a8-94ad7bb8cf6e" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_de6cc637-d1a3-491c-9833-0e0006ba9d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_9e7d535b-9099-40d7-998e-a65753175658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_9e7d535b-9099-40d7-998e-a65753175658" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_33e16a62-4d61-4fdb-a51d-94ae24356fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_33e16a62-4d61-4fdb-a51d-94ae24356fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_33e16a62-4d61-4fdb-a51d-94ae24356fd2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_c26e369c-ee81-4c52-b59a-8ea100ca1af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:to="loc_us-gaap_CashMember_c26e369c-ee81-4c52-b59a-8ea100ca1af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_84413349-cd01-4e2f-8a28-907270073922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_016efa59-ba65-4aab-b048-ad440efbfea5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_84413349-cd01-4e2f-8a28-907270073922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_597b29be-1608-4b7c-88d1-6cfa22d09570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_597b29be-1608-4b7c-88d1-6cfa22d09570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_597b29be-1608-4b7c-88d1-6cfa22d09570" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_931fc15b-8661-40c7-8578-9820cfe750c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_931fc15b-8661-40c7-8578-9820cfe750c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_463b5a49-235b-4f95-be2d-e7e239e9203a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_463b5a49-235b-4f95-be2d-e7e239e9203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b87974e3-cd2e-4abe-8b5a-6b2e99a82b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b87974e3-cd2e-4abe-8b5a-6b2e99a82b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a16957ca-c98d-45dc-a06a-b5c15ca46d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_33c48b7b-3ec8-4e13-906e-fb17e0d50170" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a16957ca-c98d-45dc-a06a-b5c15ca46d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0c3d1413-8e10-47d5-9db9-6e383d0fccdf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsAmortizedCost_03f9ef8e-6b16-4b31-b9ab-af864444bf3b" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_ardx_CashAndCashEquivalentsAmortizedCost_03f9ef8e-6b16-4b31-b9ab-af864444bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_a570f402-9bdb-4c4b-8023-06c654f63985" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedGains"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedGains_a570f402-9bdb-4c4b-8023-06c654f63985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_1961eb4d-fed0-412b-bf60-5384d3cc3d5c" xlink:href="ardx-20220630.xsd#ardx_CashAndCashEquivalentsGrossUnrealizedLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_ardx_CashAndCashEquivalentsGrossUnrealizedLosses_1961eb4d-fed0-412b-bf60-5384d3cc3d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1ce1dc8-eaf3-45b0-9f08-42b9f2582f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_0de07c1b-16d8-4d99-b59e-d3e086871ee7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a1ce1dc8-eaf3-45b0-9f08-42b9f2582f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0ccc719-b82d-49bb-a133-802002a54ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0ccc719-b82d-49bb-a133-802002a54ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8a7dc625-78b2-4027-b905-46b29d44f93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8a7dc625-78b2-4027-b905-46b29d44f93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61c50a1d-8292-4040-85f4-98e5cf819481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_61c50a1d-8292-4040-85f4-98e5cf819481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5c2a8ae-a2ac-446b-841d-15c4f034a89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_63e1fb25-03f2-4120-95ff-bf8f7ed2a0b3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a5c2a8ae-a2ac-446b-841d-15c4f034a89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_6633907b-8192-4fb2-b936-48f0773bc273" xlink:href="ardx-20220630.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_6633907b-8192-4fb2-b936-48f0773bc273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_c7285e45-e5ac-4ccb-92ff-288c5d5ce0f9" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_c7285e45-e5ac-4ccb-92ff-288c5d5ce0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_53823f2b-f5dc-4f00-844c-e01d0cf6718b" xlink:href="ardx-20220630.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_53823f2b-f5dc-4f00-844c-e01d0cf6718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_9b0abd5c-149f-43df-9d1f-b50c061fb6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_00e87f0c-85d0-40af-bbd0-e625419f10bc" xlink:to="loc_us-gaap_InvestmentsAndCash_9b0abd5c-149f-43df-9d1f-b50c061fb6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CashCashEquivalentsandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_cfa981a1-f256-4b2a-9de2-c4a672696e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_5df0a44b-7cf8-401d-a858-855855532bd0" xlink:href="ardx-20220630.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_cfa981a1-f256-4b2a-9de2-c4a672696e71" xlink:to="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_5df0a44b-7cf8-401d-a858-855855532bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9c168a0c-c976-467a-889d-892c81c0a12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_cfa981a1-f256-4b2a-9de2-c4a672696e71" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9c168a0c-c976-467a-889d-892c81c0a12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ardx-20220630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7811d38e-3476-4eca-b754-884f6941bb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b2e5f123-466e-4082-8269-d9abc4eec906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7811d38e-3476-4eca-b754-884f6941bb88" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b2e5f123-466e-4082-8269-d9abc4eec906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f08b4fbe-55f8-4ffc-86e8-5e733d316b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0371978d-74d4-4723-9d3c-b692b55dd6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f08b4fbe-55f8-4ffc-86e8-5e733d316b97" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0371978d-74d4-4723-9d3c-b692b55dd6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d3ed3f18-9ee1-4076-b3c6-f19fea81d8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d3ed3f18-9ee1-4076-b3c6-f19fea81d8b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5180f892-5071-48c5-b11c-031902e94d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5180f892-5071-48c5-b11c-031902e94d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ed1f863-a6f6-4387-97e6-f868606635d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5180f892-5071-48c5-b11c-031902e94d26" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ed1f863-a6f6-4387-97e6-f868606635d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5a8df26c-8507-49f1-b229-cce8beef25c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6ed1f863-a6f6-4387-97e6-f868606635d5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5a8df26c-8507-49f1-b229-cce8beef25c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f57007e0-20d5-4800-a0c2-03f9e64b5e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f57007e0-20d5-4800-a0c2-03f9e64b5e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f57007e0-20d5-4800-a0c2-03f9e64b5e15" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0baecc4d-230f-4872-8c25-7701b3869408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0baecc4d-230f-4872-8c25-7701b3869408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b92d432c-bdc7-4779-a8ac-86f9258b5344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b92d432c-bdc7-4779-a8ac-86f9258b5344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fa3d3c19-9cd6-42ba-8c9b-58b249c01e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9b4939b6-9fa8-411b-af0a-4825ca958e62" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fa3d3c19-9cd6-42ba-8c9b-58b249c01e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c32b0846-4856-4444-89a2-757f5ed54de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_6bb6a8d3-66c8-450a-baaf-19ad3682a3dd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c32b0846-4856-4444-89a2-757f5ed54de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_814e8671-9de4-40e6-8621-1cd59cf19691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c32b0846-4856-4444-89a2-757f5ed54de8" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_814e8671-9de4-40e6-8621-1cd59cf19691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0f215447-c170-4eaf-8361-517bac28bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0f215447-c170-4eaf-8361-517bac28bc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0f215447-c170-4eaf-8361-517bac28bc70" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7d27426d-161f-47b9-ab60-da7c819e1328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7d27426d-161f-47b9-ab60-da7c819e1328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_022e62ff-759b-41cc-b0b5-d9aa26bcab42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_CommercialPaperMember_022e62ff-759b-41cc-b0b5-d9aa26bcab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1f10cd3c-d02a-48da-b62d-adf940d0b595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_1f10cd3c-d02a-48da-b62d-adf940d0b595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cb01accf-b5f4-48df-a9f6-72517afebca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cb01accf-b5f4-48df-a9f6-72517afebca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a6e858b6-ab05-4c53-97ff-0bc4c417efef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6aebd0fc-a441-4129-998d-87cd6e172ecd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a6e858b6-ab05-4c53-97ff-0bc4c417efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_66b7efdb-5698-417a-b4cf-4589a9acf01a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_57bc9637-589f-4615-a1d2-8e01038e6ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_57bc9637-589f-4615-a1d2-8e01038e6ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bc822902-dc24-4441-9675-1b270ab644fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_57bc9637-589f-4615-a1d2-8e01038e6ea2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_bc822902-dc24-4441-9675-1b270ab644fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e5e006a-693e-4487-bc60-d033ee7b7cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92f3a917-2823-491d-86e0-3f28781ad4c5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e5e006a-693e-4487-bc60-d033ee7b7cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b1f102b-947c-42b7-b9ae-c001385a4d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2e5e006a-693e-4487-bc60-d033ee7b7cb8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b1f102b-947c-42b7-b9ae-c001385a4d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Inventory" xlink:type="simple" xlink:href="ardx-20220630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_11d37bba-27ca-49aa-958d-10fbad2c7d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_dfec7c55-621c-4102-914f-ff126e93f460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_11d37bba-27ca-49aa-958d-10fbad2c7d56" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_dfec7c55-621c-4102-914f-ff126e93f460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ed4072c6-cce6-4711-abd7-8d1a7187016d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_db9750b7-260d-4b47-95c7-d9ca145602fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ed4072c6-cce6-4711-abd7-8d1a7187016d" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_db9750b7-260d-4b47-95c7-d9ca145602fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#InventoryScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_789cde45-0b50-4289-b2f9-fab22e32303d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_404217f8-ce9d-44dd-9a1d-61034fb3f419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_789cde45-0b50-4289-b2f9-fab22e32303d" xlink:to="loc_us-gaap_InventoryNetAbstract_404217f8-ce9d-44dd-9a1d-61034fb3f419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ccf20443-432f-4def-95b7-b51e719f0116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_404217f8-ce9d-44dd-9a1d-61034fb3f419" xlink:to="loc_us-gaap_InventoryRawMaterials_ccf20443-432f-4def-95b7-b51e719f0116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_e44fc69e-55b7-4cab-ad7e-b31b32b4dd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_404217f8-ce9d-44dd-9a1d-61034fb3f419" xlink:to="loc_us-gaap_InventoryWorkInProcess_e44fc69e-55b7-4cab-ad7e-b31b32b4dd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_99cd9691-ca58-4c2f-8b5b-298422afb86b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_404217f8-ce9d-44dd-9a1d-61034fb3f419" xlink:to="loc_us-gaap_InventoryFinishedGoods_99cd9691-ca58-4c2f-8b5b-298422afb86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_39af7c6c-5657-442b-adbc-8b63637d8b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_404217f8-ce9d-44dd-9a1d-61034fb3f419" xlink:to="loc_us-gaap_InventoryNet_39af7c6c-5657-442b-adbc-8b63637d8b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8f83e2d4-f190-478f-bd74-3cb7239bc1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_59e60cb7-577d-42e1-9c99-7e7cd328e75e" xlink:href="ardx-20220630.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8f83e2d4-f190-478f-bd74-3cb7239bc1be" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_59e60cb7-577d-42e1-9c99-7e7cd328e75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingExpenseNoncurrent_52f72d8d-f91d-43bd-ba76-f777ea2d94c1" xlink:href="ardx-20220630.xsd#ardx_PrepaidCommercialManufacturingExpenseNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8f83e2d4-f190-478f-bd74-3cb7239bc1be" xlink:to="loc_ardx_PrepaidCommercialManufacturingExpenseNoncurrent_52f72d8d-f91d-43bd-ba76-f777ea2d94c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="simple" xlink:href="ardx-20220630.xsd#ProductRevenueNet"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56afba06-b2d6-4e49-bf4a-91694fe1baca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5ba174bf-478b-47f7-beb4-b8a48678a190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_56afba06-b2d6-4e49-bf4a-91694fe1baca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5ba174bf-478b-47f7-beb4-b8a48678a190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#ProductRevenueNetTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6b8e413d-dd72-43bf-a40d-6e3dd9f03ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_061463a1-fc8c-4498-bd4e-c805dd676829" xlink:href="ardx-20220630.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6b8e413d-dd72-43bf-a40d-6e3dd9f03ceb" xlink:to="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_061463a1-fc8c-4498-bd4e-c805dd676829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3f293c3-f9ac-47c0-a79e-b41e2246b518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e3f293c3-f9ac-47c0-a79e-b41e2246b518" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_srt_ProductOrServiceAxis_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c6ad1eaa-1a7c-4e9e-af61-15d4552faf04" xlink:to="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_25090740-1b82-4819-b9af-07c8ff0b3bb9" xlink:href="ardx-20220630.xsd#ardx_ProductIBSRELAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:to="loc_ardx_ProductIBSRELAMember_25090740-1b82-4819-b9af-07c8ff0b3bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1e673b18-b1d5-4e04-bf07-a852876d0460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c7a20ef-0f46-43eb-a978-b739687b4a60" xlink:to="loc_us-gaap_ProductMember_1e673b18-b1d5-4e04-bf07-a852876d0460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1eb24b7d-4698-4267-8787-1e6aa246d3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1eb24b7d-4698-4267-8787-1e6aa246d3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19098973-3df8-4422-94cc-f715631a7ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1eb24b7d-4698-4267-8787-1e6aa246d3a6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19098973-3df8-4422-94cc-f715631a7ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_8bf06048-63e9-48d5-ba2e-d6ba7976220f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_19098973-3df8-4422-94cc-f715631a7ef6" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_8bf06048-63e9-48d5-ba2e-d6ba7976220f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_90eaf5bc-a82b-416a-b575-d5da972cea79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_90eaf5bc-a82b-416a-b575-d5da972cea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a2401929-3fb4-4ec7-bbb0-8f88d9decf20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_90eaf5bc-a82b-416a-b575-d5da972cea79" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a2401929-3fb4-4ec7-bbb0-8f88d9decf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e4581347-d318-465a-8ba7-72f71546d261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a2401929-3fb4-4ec7-bbb0-8f88d9decf20" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e4581347-d318-465a-8ba7-72f71546d261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9cb5a75f-efd1-4064-8d91-0a376b8f4956" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_srt_MajorCustomersAxis_9cb5a75f-efd1-4064-8d91-0a376b8f4956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9cb5a75f-efd1-4064-8d91-0a376b8f4956" xlink:to="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_d5282b6f-26df-4c00-8623-6d0f10035333" xlink:href="ardx-20220630.xsd#ardx_CardinalHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:to="loc_ardx_CardinalHealthMember_d5282b6f-26df-4c00-8623-6d0f10035333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_a4a049d3-ef01-43c5-a70c-da664f1ee0a5" xlink:href="ardx-20220630.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_a4a049d3-ef01-43c5-a70c-da664f1ee0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_dfcebb21-ad2a-4c59-bd84-89b14e1329a2" xlink:href="ardx-20220630.xsd#ardx_McKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2d4b8de8-9f1b-47dc-86ad-d16e54432a0a" xlink:to="loc_ardx_McKessonCorporationMember_dfcebb21-ad2a-4c59-bd84-89b14e1329a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_afeff78a-403d-4a79-885b-ca6ccd7fe996" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6ef94df-1341-42c3-9065-050796846d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6ef94df-1341-42c3-9065-050796846d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_923a68f6-017d-43e2-a144-206acf6f9925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_923a68f6-017d-43e2-a144-206acf6f9925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_2dcfba4b-3a36-493a-9e2b-61ed9add9842" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerProductSalesGrossToNetAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e672f09a-e955-4816-8756-4865222cfe49" xlink:to="loc_ardx_ContractWithCustomerProductSalesGrossToNetAccruals_2dcfba4b-3a36-493a-9e2b-61ed9add9842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_432ad3ba-a914-48e3-bc5c-428f426e12d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a197d4f6-86d2-483e-88a3-67511852b0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_432ad3ba-a914-48e3-bc5c-428f426e12d1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a197d4f6-86d2-483e-88a3-67511852b0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6" xlink:href="ardx-20220630.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a197d4f6-86d2-483e-88a3-67511852b0f3" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:href="ardx-20220630.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_7cefc67e-f7c5-4787-ab46-e47e2fe4c1c6" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_4cbd59da-2e32-481b-8eca-c96027cb1c9e" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_4cbd59da-2e32-481b-8eca-c96027cb1c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember_2b1dfa42-f915-4a1a-8792-48f2d268ee3e" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:to="loc_ardx_ContractWithCustomerRebatesMember_2b1dfa42-f915-4a1a-8792-48f2d268ee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5f020311-2df5-4b96-8ad6-d7b30f1862a8" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_0a4cfba7-2eb0-451f-94eb-6b6e4eefa4d6" xlink:to="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5f020311-2df5-4b96-8ad6-d7b30f1862a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0d729b62-45ec-4add-a727-a09d48f98062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a197d4f6-86d2-483e-88a3-67511852b0f3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0d729b62-45ec-4add-a727-a09d48f98062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d729b62-45ec-4add-a727-a09d48f98062" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_10fc7c14-ff72-4af6-8d57-b98cfc0bda18" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_10fc7c14-ff72-4af6-8d57-b98cfc0bda18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_51827145-6f49-4def-a5b8-c8970cbbc659" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod_51827145-6f49-4def-a5b8-c8970cbbc659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_668d4460-3315-4003-aba7-5d4731acccd4" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:to="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_668d4460-3315-4003-aba7-5d4731acccd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_e739bd45-1681-480c-aac4-956a5132f7aa" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_7e0945a6-d52e-448f-afb8-4927fa172540" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_e739bd45-1681-480c-aac4-956a5132f7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="simple" xlink:href="ardx-20220630.xsd#CollaborationandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_35927c05-4203-43ed-8d18-54f213201673" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2c446a91-80e6-49b3-ba68-85f8c959f717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_35927c05-4203-43ed-8d18-54f213201673" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2c446a91-80e6-49b3-ba68-85f8c959f717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#CollaborationandLicensingAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_0a71d2e2-8988-46d1-9059-e277b4d50d57" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c038b9f7-3615-4c05-9404-e022e63b6b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_0a71d2e2-8988-46d1-9059-e277b4d50d57" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_c038b9f7-3615-4c05-9404-e022e63b6b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_08d57624-4bb3-4050-b628-ffe5aa4c7907" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_08d57624-4bb3-4050-b628-ffe5aa4c7907" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_153de88f-efdd-45ff-9d49-ab09fcd26719" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_srt_RangeAxis_153de88f-efdd-45ff-9d49-ab09fcd26719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae37f547-75c5-481f-ae70-da68dae0b6cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_153de88f-efdd-45ff-9d49-ab09fcd26719" xlink:to="loc_srt_RangeMember_ae37f547-75c5-481f-ae70-da68dae0b6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ba2e876e-2851-4a43-8897-772600737a85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae37f547-75c5-481f-ae70-da68dae0b6cf" xlink:to="loc_srt_MinimumMember_ba2e876e-2851-4a43-8897-772600737a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a22bdaed-67d9-4265-8de2-1e60dfb14a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a22bdaed-67d9-4265-8de2-1e60dfb14a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a22bdaed-67d9-4265-8de2-1e60dfb14a2d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_19131730-9eac-474e-a9b8-afc960290eb9" xlink:href="ardx-20220630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_19131730-9eac-474e-a9b8-afc960290eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5f07f03e-847d-432b-8bca-d64a25e08b4f" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_5f07f03e-847d-432b-8bca-d64a25e08b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_9d316ca8-02e8-40d2-afbc-df7fd98b84c7" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_9d316ca8-02e8-40d2-afbc-df7fd98b84c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_edd2ecb4-94a0-4019-9dc0-10fd7f39ce8b" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_edd2ecb4-94a0-4019-9dc0-10fd7f39ce8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_df98481e-39da-487a-9a48-da0f0c316874" xlink:href="ardx-20220630.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6bab818-55af-44da-b4ed-c734e2cc7408" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_df98481e-39da-487a-9a48-da0f0c316874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_733aada8-8f3f-4473-a9ba-7938deb05583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_srt_CounterpartyNameAxis_733aada8-8f3f-4473-a9ba-7938deb05583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_733aada8-8f3f-4473-a9ba-7938deb05583" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_e65ebf9f-b1c0-4606-8138-a613fb8c21d7" xlink:href="ardx-20220630.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_e65ebf9f-b1c0-4606-8138-a613fb8c21d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_071d4aba-0bcc-4ca6-a265-eff7bb00646f" xlink:href="ardx-20220630.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_071d4aba-0bcc-4ca6-a265-eff7bb00646f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_acdebac7-634e-445a-ad8a-959fa47d04d1" xlink:href="ardx-20220630.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_KnightTherapeuticsIncMember_acdebac7-634e-445a-ad8a-959fa47d04d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_d080ba56-38bd-4cd9-b906-019c75fc323e" xlink:href="ardx-20220630.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_467bfd19-8de8-43d0-aa4d-0da80bfdf262" xlink:to="loc_ardx_AstrazenecaMember_d080ba56-38bd-4cd9-b906-019c75fc323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d97a3549-78af-4e2c-92fc-6c05417ccdb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_srt_ProductOrServiceAxis_d97a3549-78af-4e2c-92fc-6c05417ccdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d97a3549-78af-4e2c-92fc-6c05417ccdb0" xlink:to="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_7604dbaa-0aea-439d-b3f8-d6501359b504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:to="loc_us-gaap_LicenseMember_7604dbaa-0aea-439d-b3f8-d6501359b504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_802a6377-a2b6-49c5-b54b-51f702a88b69" xlink:href="ardx-20220630.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c3f2c0c5-1743-4b24-8387-934da25b1c92" xlink:to="loc_ardx_ProductSupplyRevenueMember_802a6377-a2b6-49c5-b54b-51f702a88b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bab01484-5f2e-4547-bc6f-b8fbb4faa82a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_NumberOfSeparateCollaborativeAgreements_e184e568-4d62-499b-8a02-ad834422d392" xlink:href="ardx-20220630.xsd#ardx_NumberOfSeparateCollaborativeAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_NumberOfSeparateCollaborativeAgreements_e184e568-4d62-499b-8a02-ad834422d392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_617c8972-60e1-4545-8f28-15d64f455451" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_617c8972-60e1-4545-8f28-15d64f455451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_421b3643-e71e-4497-896d-909033e29874" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment_421b3643-e71e-4497-896d-909033e29874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_225f0fad-cd3b-48fa-a9c8-5ae8c051ee80" xlink:href="ardx-20220630.xsd#ardx_TermOfPaymentOfLicenseFeeFirstInstallment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_TermOfPaymentOfLicenseFeeFirstInstallment_225f0fad-cd3b-48fa-a9c8-5ae8c051ee80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_b56c9fa2-c9c4-4dfa-aeb7-4b8ccf1bdac9" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment_b56c9fa2-c9c4-4dfa-aeb7-4b8ccf1bdac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermOfAgreement_e5d46c12-2b0c-481f-ab7a-74ce30db44d5" xlink:href="ardx-20220630.xsd#ardx_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_TermOfAgreement_e5d46c12-2b0c-481f-ab7a-74ce30db44d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_5bc5a5fb-a841-4ecf-9009-4d99a249ca22" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsNumberOfAmendments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments_5bc5a5fb-a841-4ecf-9009-4d99a249ca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60e7a07b-66a4-4532-bd3a-b72eb162473f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60e7a07b-66a4-4532-bd3a-b72eb162473f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_f9a180fe-47b1-4fe2-918d-800fa10eac5e" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_f9a180fe-47b1-4fe2-918d-800fa10eac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_2ee51539-d020-4d8e-87a2-dbaa249fc940" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_2ee51539-d020-4d8e-87a2-dbaa249fc940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_0d7ead8a-69ce-4cda-aff2-1a098dad6926" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_0d7ead8a-69ce-4cda-aff2-1a098dad6926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_1a0bc424-14f3-4bd8-ac81-7c85eec7de4b" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_1a0bc424-14f3-4bd8-ac81-7c85eec7de4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_af82d230-9a2e-4b68-8c8b-7f8d06b1866b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_af82d230-9a2e-4b68-8c8b-7f8d06b1866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_ed577d7f-d0fe-471b-86cd-c73d7adaf13d" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_ed577d7f-d0fe-471b-86cd-c73d7adaf13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_5f8e45da-18f0-4b55-a3a4-9119df292a05" xlink:href="ardx-20220630.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_5f8e45da-18f0-4b55-a3a4-9119df292a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_9d161a0e-cd67-4cd0-a37a-8ee277b12862" xlink:href="ardx-20220630.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_9d161a0e-cd67-4cd0-a37a-8ee277b12862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_51bf9f32-4fb9-4a5d-9891-28ea05465d96" xlink:href="ardx-20220630.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_51bf9f32-4fb9-4a5d-9891-28ea05465d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_da4007f1-2861-440d-acae-4bf240161eeb" xlink:href="ardx-20220630.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_da4007f1-2861-440d-acae-4bf240161eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_82aaba72-fd17-462f-8bc4-1cc24b00519b" xlink:href="ardx-20220630.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_82aaba72-fd17-462f-8bc4-1cc24b00519b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_744a908c-a473-4525-8ad6-e499a3f3e4fd" xlink:href="ardx-20220630.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_744a908c-a473-4525-8ad6-e499a3f3e4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_aa9749fd-f4b3-4cd7-824b-d623a4063374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb2a8692-1507-43e0-992e-bc986b902aff" xlink:to="loc_us-gaap_CostOfRevenue_aa9749fd-f4b3-4cd7-824b-d623a4063374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_b553204a-94ed-48a4-b604-5bca9a572513" xlink:href="ardx-20220630.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d86be1a9-2af8-418e-a40a-29adb07758e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_b553204a-94ed-48a4-b604-5bca9a572513" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d86be1a9-2af8-418e-a40a-29adb07758e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1c428076-79ab-42a4-a57d-b661f2f75d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d86be1a9-2af8-418e-a40a-29adb07758e5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1c428076-79ab-42a4-a57d-b661f2f75d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1c428076-79ab-42a4-a57d-b661f2f75d05" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ResearchCollaborationAndOptionAgreementMember_be409f32-9ca0-496d-ad9b-5496b8493601" xlink:href="ardx-20220630.xsd#ardx_ResearchCollaborationAndOptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:to="loc_ardx_ResearchCollaborationAndOptionAgreementMember_be409f32-9ca0-496d-ad9b-5496b8493601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_285907af-ca1f-49f6-9854-f5062988f507" xlink:href="ardx-20220630.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_11a574ee-9c4c-43f8-a074-1dc0767c974e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_285907af-ca1f-49f6-9854-f5062988f507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d86be1a9-2af8-418e-a40a-29adb07758e5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:href="ardx-20220630.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b3ddd65e-71d2-439c-bab6-2833460cc675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b3ddd65e-71d2-439c-bab6-2833460cc675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_e13ecbdc-85ba-4f6b-bf97-4a9a6a6630e5" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived_e13ecbdc-85ba-4f6b-bf97-4a9a6a6630e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8da4c3e9-204b-49da-b912-20b860921a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_4146b71d-b433-4f29-9757-54c565c9b76c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8da4c3e9-204b-49da-b912-20b860921a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:href="ardx-20220630.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa27b4c7-6619-4834-8dcb-a7e6637d0e87" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ed891719-5369-4e6b-8a9e-ed580629ac72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ed891719-5369-4e6b-8a9e-ed580629ac72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_58afeb7b-29ac-47d4-b75e-8e40cb6d42cf" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForCashReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived_58afeb7b-29ac-47d4-b75e-8e40cb6d42cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_d97bacf0-69d5-4f56-8bfa-99701d8ccab1" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_d97bacf0-69d5-4f56-8bfa-99701d8ccab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46a1db8a-c694-4cc2-b19b-9034870e9d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_598b714d-538a-4b8d-a792-4702f6ea46cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_46a1db8a-c694-4cc2-b19b-9034870e9d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligation" xlink:type="simple" xlink:href="ardx-20220630.xsd#DeferredRoyaltyObligation"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_b769bce2-2884-4ba2-b319-903451a7b88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock_e5e687f3-601c-47ed-842a-d0ea8937b7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_b769bce2-2884-4ba2-b319-903451a7b88e" xlink:to="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock_e5e687f3-601c-47ed-842a-d0ea8937b7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#DeferredRoyaltyObligationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_b3e2cc18-8ff0-420b-9c9f-316fc8032ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_b3e2cc18-8ff0-420b-9c9f-316fc8032ced" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_49b4058e-9646-4250-a0eb-1166acd8cad6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:to="loc_srt_CounterpartyNameAxis_49b4058e-9646-4250-a0eb-1166acd8cad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2daf1bac-b96d-4ebc-b0b7-c14250fcacae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_49b4058e-9646-4250-a0eb-1166acd8cad6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2daf1bac-b96d-4ebc-b0b7-c14250fcacae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_d1252f5d-ca5b-4303-b69d-b671222613e9" xlink:href="ardx-20220630.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2daf1bac-b96d-4ebc-b0b7-c14250fcacae" xlink:to="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_d1252f5d-ca5b-4303-b69d-b671222613e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f6384be0-84a7-48fe-80fa-268c011d1311" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:to="loc_srt_ProductOrServiceAxis_f6384be0-84a7-48fe-80fa-268c011d1311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49feacdc-3b67-4184-a292-b2101d160e54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f6384be0-84a7-48fe-80fa-268c011d1311" xlink:to="loc_srt_ProductsAndServicesDomain_49feacdc-3b67-4184-a292-b2101d160e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_9fa43c39-b538-4db8-8d25-d06c52bec7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49feacdc-3b67-4184-a292-b2101d160e54" xlink:to="loc_us-gaap_LicenseMember_9fa43c39-b538-4db8-8d25-d06c52bec7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ab2e8718-b08a-42ea-997d-1d1e3463e510" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_395ee4bc-198d-4f20-83b4-3d69725bccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_395ee4bc-198d-4f20-83b4-3d69725bccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1577b59f-649d-4ae8-8389-4242388e4eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1577b59f-649d-4ae8-8389-4242388e4eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_c1981fdd-7f54-40f4-a3f0-16b8983f15ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_c1981fdd-7f54-40f4-a3f0-16b8983f15ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_ad6221ab-2688-4260-aace-2dc2c625ddf9" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_ad6221ab-2688-4260-aace-2dc2c625ddf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_ad47cc5e-2611-43be-8bee-c63028512e7f" xlink:href="ardx-20220630.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_57c59f9b-96b1-47a6-8abe-d410463c668d" xlink:to="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_ad47cc5e-2611-43be-8bee-c63028512e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Borrowing" xlink:type="simple" xlink:href="ardx-20220630.xsd#Borrowing"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Borrowing" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_91040976-e2cb-4473-8d4a-81c1318fbf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_c7fb103f-c8cc-4cc9-a347-3f584fe70c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_91040976-e2cb-4473-8d4a-81c1318fbf9b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_c7fb103f-c8cc-4cc9-a347-3f584fe70c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#BorrowingTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e7bf7227-7f43-414c-b3eb-c11ce19f0b52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_756ab6a4-92cd-432d-9570-d7c53775bc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e7bf7227-7f43-414c-b3eb-c11ce19f0b52" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_756ab6a4-92cd-432d-9570-d7c53775bc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#BorrowingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_320f0de9-cf40-4056-8d81-f45c97e0f881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_320f0de9-cf40-4056-8d81-f45c97e0f881" xlink:to="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_87880dc3-dd68-432c-bb9b-ab7b4063d77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_87880dc3-dd68-432c-bb9b-ab7b4063d77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_87880dc3-dd68-432c-bb9b-ab7b4063d77f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_7d332960-73db-42db-8bd6-8ddff9cea532" xlink:href="ardx-20220630.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:to="loc_ardx_ExitFee2018Member_7d332960-73db-42db-8bd6-8ddff9cea532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_0618ab55-ce58-499e-b4c7-53781bc2a484" xlink:href="ardx-20220630.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f822e632-dfb0-4573-a4f5-2fa3c1b14f05" xlink:to="loc_ardx_ExitFee2022Member_0618ab55-ce58-499e-b4c7-53781bc2a484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_df5924cc-5001-4059-9272-860f03967e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_DebtInstrumentAxis_df5924cc-5001-4059-9272-860f03967e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_df5924cc-5001-4059-9272-860f03967e42" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_30595820-f473-4882-9419-87466a6e3942" xlink:href="ardx-20220630.xsd#ardx_TermLoan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:to="loc_ardx_TermLoan2018Member_30595820-f473-4882-9419-87466a6e3942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e992a693-c8e1-4ec2-add8-ef5212bdb55e" xlink:to="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_e65af892-1bbf-4f66-8e5a-e50bd9e6ee15" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022AMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:to="loc_ardx_TermLoan2022AMember_e65af892-1bbf-4f66-8e5a-e50bd9e6ee15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_0c08fe53-637a-4cae-833a-ac50ebdaaab7" xlink:href="ardx-20220630.xsd#ardx_TermLoan2022BMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_26e7f5be-5ff7-46e9-889e-4f3bf12bc4ac" xlink:to="loc_ardx_TermLoan2022BMember_0c08fe53-637a-4cae-833a-ac50ebdaaab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fe0aba63-b530-44a9-af60-15f1289e1a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fe0aba63-b530-44a9-af60-15f1289e1a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0b1cdea1-5f35-44d8-9131-7c50f77ac9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fe0aba63-b530-44a9-af60-15f1289e1a7c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0b1cdea1-5f35-44d8-9131-7c50f77ac9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_687b83ea-cc0d-4afc-8f1b-90eea9aa893d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0b1cdea1-5f35-44d8-9131-7c50f77ac9b3" xlink:to="loc_us-gaap_LoansPayableMember_687b83ea-cc0d-4afc-8f1b-90eea9aa893d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d52ed155-4382-4df9-8db0-87dcf9f4ca31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_VariableRateAxis_d52ed155-4382-4df9-8db0-87dcf9f4ca31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_02871f18-66bd-45ca-a5b5-b346b3bbd108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d52ed155-4382-4df9-8db0-87dcf9f4ca31" xlink:to="loc_us-gaap_VariableRateDomain_02871f18-66bd-45ca-a5b5-b346b3bbd108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_04ec5658-8c3f-42ea-b73c-2092b081f8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_02871f18-66bd-45ca-a5b5-b346b3bbd108" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_04ec5658-8c3f-42ea-b73c-2092b081f8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_4e2ec4ee-1a53-4081-89f6-9d82f3f963f0" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_fd760fed-916a-465e-9a5d-741e2e5f6b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_fd760fed-916a-465e-9a5d-741e2e5f6b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_51c68e53-f818-4059-a9d9-1a45ab767c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_51c68e53-f818-4059-a9d9-1a45ab767c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f24d2a83-844d-4e85-86f9-20710020b06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f8c0da1c-75dc-46e5-98a9-199277d4200d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f24d2a83-844d-4e85-86f9-20710020b06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_72d56cdf-82fe-4cfe-843b-e9289dd25893" xlink:to="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0bbdae7f-7ec5-4934-aeaf-e2c18d026e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0bbdae7f-7ec5-4934-aeaf-e2c18d026e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0b079eee-20d8-4bf6-b048-5bb771a99f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0b079eee-20d8-4bf6-b048-5bb771a99f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_e1e229b1-c479-4849-9cb7-d44fe5b55596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_e1e229b1-c479-4849-9cb7-d44fe5b55596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_13146bca-12a0-4e12-90b9-84c1cc5609eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_13146bca-12a0-4e12-90b9-84c1cc5609eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_7e5e03c7-909c-4904-8def-814974e3f5b1" xlink:href="ardx-20220630.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_7e5e03c7-909c-4904-8def-814974e3f5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6ad556e8-c800-4a5b-acdf-36f46833a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6ad556e8-c800-4a5b-acdf-36f46833a2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_8c796c78-ab50-411f-8bf7-62de2076639b" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_8c796c78-ab50-411f-8bf7-62de2076639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_dbe1f0aa-3380-481e-9bc2-0392f87d32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_us-gaap_DebtInstrumentTerm_dbe1f0aa-3380-481e-9bc2-0392f87d32bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_33016a71-7dbf-44d7-ba64-92b2fc46436f" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_33016a71-7dbf-44d7-ba64-92b2fc46436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_2afc10d1-2d33-4b7b-8095-51d0083e23b4" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_2afc10d1-2d33-4b7b-8095-51d0083e23b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_ae7ed6fd-9d8a-4468-9bd1-e248a058ab73" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_ae7ed6fd-9d8a-4468-9bd1-e248a058ab73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_1bd54de3-2678-45e5-9013-789b2206ecf1" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_1bd54de3-2678-45e5-9013-789b2206ecf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_b9cd4244-81d0-4e1c-9e64-8a07d7796dc9" xlink:href="ardx-20220630.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_ExitFeePercentage_b9cd4244-81d0-4e1c-9e64-8a07d7796dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_89e917ea-7b75-4589-8ec8-112b755c298f" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_89e917ea-7b75-4589-8ec8-112b755c298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_3f3d90e8-82ba-45f2-b6ea-ffa3fc30c25e" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_3f3d90e8-82ba-45f2-b6ea-ffa3fc30c25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3e7e924b-ae20-4df6-9b29-33e67b412cad" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_3e7e924b-ae20-4df6-9b29-33e67b412cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_5825e6bc-4127-4166-8bb4-8652c00d0e24" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_5825e6bc-4127-4166-8bb4-8652c00d0e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_2e8e93e4-72d3-439b-bef2-00e3ac961265" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_2e8e93e4-72d3-439b-bef2-00e3ac961265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_efb04d3f-47e8-4871-801b-cc571ab79020" xlink:href="ardx-20220630.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_63552420-dc67-4bc4-ae0c-44710011b1de" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_efb04d3f-47e8-4871-801b-cc571ab79020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_65f367ff-19a4-4cf6-bbe1-2f26d1aa2fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_011eaa27-d872-468b-ac5e-33aa42250420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65f367ff-19a4-4cf6-bbe1-2f26d1aa2fd9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_011eaa27-d872-468b-ac5e-33aa42250420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8bf45767-66ca-4d9e-8bf7-ad63d8f2c1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65f367ff-19a4-4cf6-bbe1-2f26d1aa2fd9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_8bf45767-66ca-4d9e-8bf7-ad63d8f2c1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_cda819b7-8e54-4150-b640-555ab68fadf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65f367ff-19a4-4cf6-bbe1-2f26d1aa2fd9" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_cda819b7-8e54-4150-b640-555ab68fadf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5a862f2a-0ec2-421e-a74a-ed2795a47ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65f367ff-19a4-4cf6-bbe1-2f26d1aa2fd9" xlink:to="loc_us-gaap_LongTermDebt_5a862f2a-0ec2-421e-a74a-ed2795a47ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e8a6c759-c911-4147-b508-321eb3748b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65f367ff-19a4-4cf6-bbe1-2f26d1aa2fd9" xlink:to="loc_us-gaap_LongTermDebtCurrent_e8a6c759-c911-4147-b508-321eb3748b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fe897f56-287e-480f-a1bd-bf898709ac61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_65f367ff-19a4-4cf6-bbe1-2f26d1aa2fd9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fe897f56-287e-480f-a1bd-bf898709ac61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220630.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiability" xlink:type="simple" xlink:href="ardx-20220630.xsd#DerivativeLiability"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_371e8a49-78de-4394-b92e-6e4840390c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5a4fd990-0c2d-4562-b70b-f9c7183803d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_371e8a49-78de-4394-b92e-6e4840390c00" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_5a4fd990-0c2d-4562-b70b-f9c7183803d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#DerivativeLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d325819f-5c72-4878-b79e-dcb0fab1a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e95db27d-d82f-49af-a44b-a0feb2aeded5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d325819f-5c72-4878-b79e-dcb0fab1a4e5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e95db27d-d82f-49af-a44b-a0feb2aeded5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#DerivativeLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eaacb8b8-2b7e-407e-a933-b0ad53568f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eaacb8b8-2b7e-407e-a933-b0ad53568f56" xlink:to="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_394f6aa7-0043-4438-a3b5-ef87d340d785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_394f6aa7-0043-4438-a3b5-ef87d340d785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_394f6aa7-0043-4438-a3b5-ef87d340d785" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_cafd76fa-3b35-4055-9ef1-54a62f26e229" xlink:href="ardx-20220630.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:to="loc_ardx_ExitFee2018Member_cafd76fa-3b35-4055-9ef1-54a62f26e229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_589c030c-3f74-4179-a07b-2931f2238d95" xlink:href="ardx-20220630.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3a489445-dc55-44ea-83e0-ed1d80a63a77" xlink:to="loc_ardx_ExitFee2022Member_589c030c-3f74-4179-a07b-2931f2238d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fb8ced9-62c3-4725-bf09-4ded0994cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fb8ced9-62c3-4725-bf09-4ded0994cfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2e9f1b6-4417-4ed4-8f9a-941ec83476c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fb8ced9-62c3-4725-bf09-4ded0994cfe1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2e9f1b6-4417-4ed4-8f9a-941ec83476c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_79191b6b-2837-416b-bb74-d67cf2e577ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f2e9f1b6-4417-4ed4-8f9a-941ec83476c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_79191b6b-2837-416b-bb74-d67cf2e577ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_350e3666-62c0-4a2a-8cfe-36a8c7e1d752" xlink:to="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_222263b6-58ff-4c1e-8600-92258329fe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_222263b6-58ff-4c1e-8600-92258329fe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5b6a8281-4154-4b56-bb32-3863814937e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5b6a8281-4154-4b56-bb32-3863814937e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_b9cc7ace-8ce3-4ae7-9386-bc5111d887cd" xlink:href="ardx-20220630.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_b9cc7ace-8ce3-4ae7-9386-bc5111d887cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_fc1022b0-8822-4c7e-aa4c-d2a06f89b8de" xlink:href="ardx-20220630.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_fc1022b0-8822-4c7e-aa4c-d2a06f89b8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_6ff2d2d6-7cc6-4de6-8e35-009fa567e395" xlink:href="ardx-20220630.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_ExitFeePercentage_6ff2d2d6-7cc6-4de6-8e35-009fa567e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_4cbc8087-0a00-48c4-842f-11e7415fb58d" xlink:href="ardx-20220630.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9766e19d-23d3-4b5e-82f7-f699dd71be18" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_4cbc8087-0a00-48c4-842f-11e7415fb58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#DerivativeLiabilityChangesinFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_133cf223-ae90-4440-a125-d318366898c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_133cf223-ae90-4440-a125-d318366898c1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_805a9b46-93c3-4e75-93e6-0b355fbbd0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_84769450-db2f-4f2c-b2ea-ee7eaa9ee4f7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_805a9b46-93c3-4e75-93e6-0b355fbbd0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b263ddb2-6116-466b-8e78-304429c76a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_805a9b46-93c3-4e75-93e6-0b355fbbd0ba" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b263ddb2-6116-466b-8e78-304429c76a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_81553fe4-a291-413e-b9c1-2a667b97c0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_81553fe4-a291-413e-b9c1-2a667b97c0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_81553fe4-a291-413e-b9c1-2a667b97c0b7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_178276ea-4e6f-46b3-ac46-79bd7dacd53d" xlink:href="ardx-20220630.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:to="loc_ardx_ExitFee2018Member_178276ea-4e6f-46b3-ac46-79bd7dacd53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_31f99ec9-0b21-4905-a87d-e5f61aa6a92e" xlink:href="ardx-20220630.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a3c96258-3815-4d03-8807-a09dba95221a" xlink:to="loc_ardx_ExitFee2022Member_31f99ec9-0b21-4905-a87d-e5f61aa6a92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4205de6b-4858-4597-b5a5-8f2afe6aeaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_64d7f922-f423-4251-a68e-27132227e62e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4205de6b-4858-4597-b5a5-8f2afe6aeaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4205de6b-4858-4597-b5a5-8f2afe6aeaa0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9450dbda-764d-469d-a4c9-5f9cb88e8375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9450dbda-764d-469d-a4c9-5f9cb88e8375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_837de7ed-510a-4177-b186-0f70219d44e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_837de7ed-510a-4177-b186-0f70219d44e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c412a29f-9249-4168-9c38-afcf250073ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c412a29f-9249-4168-9c38-afcf250073ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_50c25072-a446-4e95-a6d8-670fecd31d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_be540cbe-485e-4f75-b869-2b5b05d40570" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_50c25072-a446-4e95-a6d8-670fecd31d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Leases" xlink:type="simple" xlink:href="ardx-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c24ed285-b83a-4e76-b612-a5791450e8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9a32a357-1605-45e0-a21d-29e20d41862f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c24ed285-b83a-4e76-b612-a5791450e8f2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9a32a357-1605-45e0-a21d-29e20d41862f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2ae3b0f4-cc00-4f2c-a479-ee359720f89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_510fbe21-8b44-45cd-adc5-8d0c79b9f7dc" xlink:href="ardx-20220630.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2ae3b0f4-cc00-4f2c-a479-ee359720f89d" xlink:to="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_510fbe21-8b44-45cd-adc5-8d0c79b9f7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b6a0a6d2-26cd-4fd5-aae0-64a80e6dc875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2ae3b0f4-cc00-4f2c-a479-ee359720f89d" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b6a0a6d2-26cd-4fd5-aae0-64a80e6dc875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_986e9674-42bc-4e25-8728-82b3f1372ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2ae3b0f4-cc00-4f2c-a479-ee359720f89d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_986e9674-42bc-4e25-8728-82b3f1372ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesAdditionalDetailsofFacilityLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d938b06f-2603-4d69-9874-15833e1ce98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_dbda3df9-619b-4611-9b1b-0a988a5290d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d938b06f-2603-4d69-9874-15833e1ce98c" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_dbda3df9-619b-4611-9b1b-0a988a5290d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b52b347b-0199-4189-b2e4-c22872285671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_dbda3df9-619b-4611-9b1b-0a988a5290d7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b52b347b-0199-4189-b2e4-c22872285671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c98b12e0-cfca-48bf-8a46-7ee63d079fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_dbda3df9-619b-4611-9b1b-0a988a5290d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c98b12e0-cfca-48bf-8a46-7ee63d079fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0eb7be2c-b9ab-4727-b18d-4bd925ca9459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_dbda3df9-619b-4611-9b1b-0a988a5290d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0eb7be2c-b9ab-4727-b18d-4bd925ca9459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eb7a7928-2391-4fec-a4e9-b4dedcbfc51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_dbda3df9-619b-4611-9b1b-0a988a5290d7" xlink:to="loc_us-gaap_OperatingLeaseLiability_eb7a7928-2391-4fec-a4e9-b4dedcbfc51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_31fd2218-b5c9-4975-94d3-0c18591c9787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d938b06f-2603-4d69-9874-15833e1ce98c" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_31fd2218-b5c9-4975-94d3-0c18591c9787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_797d3912-c1ef-4c69-b7df-cd006ef71c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_31fd2218-b5c9-4975-94d3-0c18591c9787" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_797d3912-c1ef-4c69-b7df-cd006ef71c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ed23f873-8d2e-409a-a080-94a82fab1d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_31fd2218-b5c9-4975-94d3-0c18591c9787" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ed23f873-8d2e-409a-a080-94a82fab1d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b6a53ad2-8161-43c8-917e-bf3c2af3820f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_3ddebac7-f876-4cc7-b624-b4c30629efe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6a53ad2-8161-43c8-917e-bf3c2af3820f" xlink:to="loc_us-gaap_LeaseCostAbstract_3ddebac7-f876-4cc7-b624-b4c30629efe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_da34c22b-4358-489b-adbf-2b3a00350f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3ddebac7-f876-4cc7-b624-b4c30629efe9" xlink:to="loc_us-gaap_OperatingLeaseCost_da34c22b-4358-489b-adbf-2b3a00350f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3605ca3f-cfcf-40bc-bfad-8049f6dbb1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_3ddebac7-f876-4cc7-b624-b4c30629efe9" xlink:to="loc_us-gaap_OperatingLeasePayments_3605ca3f-cfcf-40bc-bfad-8049f6dbb1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_098911ea-fcdc-4740-af27-f8c1839a4aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_098911ea-fcdc-4740-af27-f8c1839a4aa5" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1e6eaada-b902-4e55-93d7-ad326e260470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1e6eaada-b902-4e55-93d7-ad326e260470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2f9bf058-40c4-4b04-85dd-edf2b5a36aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2f9bf058-40c4-4b04-85dd-edf2b5a36aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5d827ee8-c37d-4d3d-976a-51e6a255314a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5d827ee8-c37d-4d3d-976a-51e6a255314a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_712ef2d3-35c5-40e4-985b-d1795d7782b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_712ef2d3-35c5-40e4-985b-d1795d7782b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd3c39b0-d8de-45a2-ad70-6527e0adddbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd3c39b0-d8de-45a2-ad70-6527e0adddbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86f8091e-fc1b-4bc4-b717-76b1d36d7fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_86f8091e-fc1b-4bc4-b717-76b1d36d7fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c6a8ea9b-72a7-4679-a40c-dbd94fe1c75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c6a8ea9b-72a7-4679-a40c-dbd94fe1c75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1a484633-e82f-4dde-91ac-127f9bd8f61d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_OperatingLeaseLiability_1a484633-e82f-4dde-91ac-127f9bd8f61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b561b19d-8512-455a-9779-7b35f99305cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b561b19d-8512-455a-9779-7b35f99305cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df5fed81-ad60-413a-b552-b5aa160fba67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_85b6dc78-cecf-468d-98bd-436049b2d980" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df5fed81-ad60-413a-b552-b5aa160fba67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20220630.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ardx-20220630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9f2194e0-8d20-4900-bc60-5d0a7b88630e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bad6f91a-f5f5-491f-9d8e-6175958b99ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9f2194e0-8d20-4900-bc60-5d0a7b88630e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bad6f91a-f5f5-491f-9d8e-6175958b99ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cc097e76-bd3c-48dd-8063-005ef8e11132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cc097e76-bd3c-48dd-8063-005ef8e11132" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_57a4edb9-219c-4730-b0e8-19aa7932fab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_57a4edb9-219c-4730-b0e8-19aa7932fab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57a4edb9-219c-4730-b0e8-19aa7932fab1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_c5b29a74-8fe3-43f9-8afc-db61f70bb30a" xlink:href="ardx-20220630.xsd#ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:to="loc_ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember_c5b29a74-8fe3-43f9-8afc-db61f70bb30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_045a81b2-17e7-45b3-842b-d32775928133" xlink:href="ardx-20220630.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5b3fe227-dbcf-4d09-9c73-182736ab39d6" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_045a81b2-17e7-45b3-842b-d32775928133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c472a156-7e03-48d6-8533-e3429b328db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c472a156-7e03-48d6-8533-e3429b328db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cb0b9acf-0d4e-4e75-92a1-11fa942c83b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c472a156-7e03-48d6-8533-e3429b328db9" xlink:to="loc_us-gaap_ClassOfStockDomain_cb0b9acf-0d4e-4e75-92a1-11fa942c83b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c8f1676b-ad54-4455-b198-f1a9ecd81b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cb0b9acf-0d4e-4e75-92a1-11fa942c83b0" xlink:to="loc_us-gaap_CommonClassAMember_c8f1676b-ad54-4455-b198-f1a9ecd81b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_4de381b8-8869-4765-a5ef-7c6aa8daa7b7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_b0f992c9-672c-4a02-b57c-ab4873297624" xlink:href="ardx-20220630.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_b0f992c9-672c-4a02-b57c-ab4873297624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d57202cc-f68b-47b5-ab39-f4c9e2b0f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d57202cc-f68b-47b5-ab39-f4c9e2b0f0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1697276-17d1-44a3-839c-6f00cbeaa86c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1697276-17d1-44a3-839c-6f00cbeaa86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_17d1546f-152e-4668-8a4b-5c21986b209c" xlink:href="ardx-20220630.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_17d1546f-152e-4668-8a4b-5c21986b209c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_66b3019b-bdfa-4151-98a4-b0d02843c4f0" xlink:href="ardx-20220630.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_6281771a-740e-41f4-906b-bac23565c539" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_66b3019b-bdfa-4151-98a4-b0d02843c4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7297b4f9-61c1-4931-8b63-54cdd0bec5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c462e76b-2a58-45fe-bd5c-37834ad37e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7297b4f9-61c1-4931-8b63-54cdd0bec5ad" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c462e76b-2a58-45fe-bd5c-37834ad37e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2130061-1bb0-49cf-a63b-a20f5ab17473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e0c2be06-9942-4321-a306-edefcbedd41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2130061-1bb0-49cf-a63b-a20f5ab17473" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e0c2be06-9942-4321-a306-edefcbedd41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_ee2c14c2-c2b6-410e-8fe6-a85ad2c1d586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2130061-1bb0-49cf-a63b-a20f5ab17473" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_ee2c14c2-c2b6-410e-8fe6-a85ad2c1d586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_25b612ab-dd6a-4d08-9508-7f3bb8d8ebda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2130061-1bb0-49cf-a63b-a20f5ab17473" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_25b612ab-dd6a-4d08-9508-7f3bb8d8ebda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_fcf8fad9-f4f4-4db7-9fde-c720dc11541e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2130061-1bb0-49cf-a63b-a20f5ab17473" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_fcf8fad9-f4f4-4db7-9fde-c720dc11541e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fbd4f70b-c26b-454c-a37b-eb6fb987f9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb6c0b0-97f7-4fee-8ea6-613ec84c836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fbd4f70b-c26b-454c-a37b-eb6fb987f9c5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb6c0b0-97f7-4fee-8ea6-613ec84c836d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97e91250-291e-46ea-b732-be58e92b3716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb6c0b0-97f7-4fee-8ea6-613ec84c836d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97e91250-291e-46ea-b732-be58e92b3716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97e91250-291e-46ea-b732-be58e92b3716" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f68251e5-4857-44fb-b1e8-57ee0c1c6401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f68251e5-4857-44fb-b1e8-57ee0c1c6401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3f8cc53-4aeb-494d-ae3c-e550706a2130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1beb1405-9175-4a3a-b91f-b55d5d611daf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d3f8cc53-4aeb-494d-ae3c-e550706a2130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25cd1f3e-6ada-4558-af72-b600eb2c4cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7eb6c0b0-97f7-4fee-8ea6-613ec84c836d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25cd1f3e-6ada-4558-af72-b600eb2c4cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c38678f7-fbb2-4623-b6dd-97185a1fcd77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_25cd1f3e-6ada-4558-af72-b600eb2c4cdf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c38678f7-fbb2-4623-b6dd-97185a1fcd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f640dba9-3ff0-4a97-af8f-21c4c24270c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f640dba9-3ff0-4a97-af8f-21c4c24270c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_26c0da94-9b2a-4192-b3e5-f041eb888bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:to="loc_us-gaap_PlanNameAxis_26c0da94-9b2a-4192-b3e5-f041eb888bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7957f3bd-ad45-403d-8643-b0cc1627c298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_26c0da94-9b2a-4192-b3e5-f041eb888bc7" xlink:to="loc_us-gaap_PlanNameDomain_7957f3bd-ad45-403d-8643-b0cc1627c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_0607d911-8193-4e9f-9857-7bf2634a7e5c" xlink:href="ardx-20220630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7957f3bd-ad45-403d-8643-b0cc1627c298" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_0607d911-8193-4e9f-9857-7bf2634a7e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a23dc2ff-6fd0-400b-b4f2-3a82719dae00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:to="loc_srt_TitleOfIndividualAxis_a23dc2ff-6fd0-400b-b4f2-3a82719dae00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4eca56c-da49-4fd9-b47e-d90f88f37647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a23dc2ff-6fd0-400b-b4f2-3a82719dae00" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4eca56c-da49-4fd9-b47e-d90f88f37647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_14fb1bd2-f7bb-4acf-b90d-9a043d28ee30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d4eca56c-da49-4fd9-b47e-d90f88f37647" xlink:to="loc_srt_DirectorMember_14fb1bd2-f7bb-4acf-b90d-9a043d28ee30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0cf91abe-7bdf-4a49-b98e-49d17870e501" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_cabf29f2-643a-4f23-800b-765537aca50e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_cabf29f2-643a-4f23-800b-765537aca50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0a421429-9d01-4a04-bf79-4dfb9e1ec9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0a421429-9d01-4a04-bf79-4dfb9e1ec9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_e12b7524-87da-4536-bcc1-b99370803e0f" xlink:href="ardx-20220630.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_e12b7524-87da-4536-bcc1-b99370803e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_692cae19-1fff-4f1e-91d4-082de349175b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_ProceedsFromStockPlans_692cae19-1fff-4f1e-91d4-082de349175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d8c3da4c-2ee3-4666-b8e2-fda91420e444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f141e5dd-7dbe-461a-8764-298947ea3ab2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d8c3da4c-2ee3-4666-b8e2-fda91420e444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e90e442-8b4b-46ca-948f-0546ca322318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e90e442-8b4b-46ca-948f-0546ca322318" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3175f341-15d8-41cd-abc7-3661e9305567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:to="loc_us-gaap_PlanNameAxis_3175f341-15d8-41cd-abc7-3661e9305567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e0f99426-b4ef-436c-baab-87ffe5455913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3175f341-15d8-41cd-abc7-3661e9305567" xlink:to="loc_us-gaap_PlanNameDomain_e0f99426-b4ef-436c-baab-87ffe5455913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_9643d35c-f9bd-45e0-929d-d6d2b80276ff" xlink:href="ardx-20220630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e0f99426-b4ef-436c-baab-87ffe5455913" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_9643d35c-f9bd-45e0-929d-d6d2b80276ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_06ea23bf-28ac-433f-ac12-105eeb9c3e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:to="loc_us-gaap_AwardTypeAxis_06ea23bf-28ac-433f-ac12-105eeb9c3e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_06ea23bf-28ac-433f-ac12-105eeb9c3e23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f8ea1f8a-2656-4eb2-8aa0-058834d1f30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f8ea1f8a-2656-4eb2-8aa0-058834d1f30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f939b6-abb0-4ddc-9145-df147fcea504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1f5e4e47-46d3-43c9-bead-056846ca532a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c7f939b6-abb0-4ddc-9145-df147fcea504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_395c650f-3fc5-43c6-87f6-38be1daab176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f322b5f2-1e61-479b-89e7-817abd31e3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f322b5f2-1e61-479b-89e7-817abd31e3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56d0f984-5e87-4f3b-a511-2e544de0c34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2476cfbb-9cfd-44d6-b799-fb04833fb378" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56d0f984-5e87-4f3b-a511-2e544de0c34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_449e49a1-98cb-4b80-814c-f374bf9de633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_714ff1cb-f576-4da4-9eee-b0e434b2197c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_449e49a1-98cb-4b80-814c-f374bf9de633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_714ff1cb-f576-4da4-9eee-b0e434b2197c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43145d5e-f7cc-4bd4-8259-3634ab52be97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_714ff1cb-f576-4da4-9eee-b0e434b2197c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43145d5e-f7cc-4bd4-8259-3634ab52be97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25f157b6-05b5-4212-956c-5b44a69051da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_714ff1cb-f576-4da4-9eee-b0e434b2197c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_25f157b6-05b5-4212-956c-5b44a69051da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e982591a-37f1-4445-90fb-a5d868765f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_714ff1cb-f576-4da4-9eee-b0e434b2197c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e982591a-37f1-4445-90fb-a5d868765f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1034a997-16e9-4a76-abd7-01c692cf537c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_714ff1cb-f576-4da4-9eee-b0e434b2197c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1034a997-16e9-4a76-abd7-01c692cf537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4896e4ca-96e0-4125-ae1f-c10297db1b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_714ff1cb-f576-4da4-9eee-b0e434b2197c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4896e4ca-96e0-4125-ae1f-c10297db1b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b388873-92bd-4466-8f5d-11370c3c0320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_449e49a1-98cb-4b80-814c-f374bf9de633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7b388873-92bd-4466-8f5d-11370c3c0320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fd5914f8-9704-4d06-86e7-cb653b0da594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_449e49a1-98cb-4b80-814c-f374bf9de633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fd5914f8-9704-4d06-86e7-cb653b0da594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3cfa7219-2a9b-4754-b579-6755476a7110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fd5914f8-9704-4d06-86e7-cb653b0da594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3cfa7219-2a9b-4754-b579-6755476a7110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f2dedbc6-8028-4af0-9644-d18455466d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fd5914f8-9704-4d06-86e7-cb653b0da594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f2dedbc6-8028-4af0-9644-d18455466d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc6b6d6f-a203-4e7c-9aa6-2198fbbebe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fd5914f8-9704-4d06-86e7-cb653b0da594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_cc6b6d6f-a203-4e7c-9aa6-2198fbbebe5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aaf6f115-0011-4d0d-89ff-8162151bce75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fd5914f8-9704-4d06-86e7-cb653b0da594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aaf6f115-0011-4d0d-89ff-8162151bce75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a2a2945e-3958-4c2d-9e84-3dfdfcfe1cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fd5914f8-9704-4d06-86e7-cb653b0da594" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a2a2945e-3958-4c2d-9e84-3dfdfcfe1cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ee3b2ee-1496-4ca8-bc2a-3bfac84a1b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_449e49a1-98cb-4b80-814c-f374bf9de633" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ee3b2ee-1496-4ca8-bc2a-3bfac84a1b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25e0dc56-b0c3-4375-a52d-79d7bac28202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_794a93dd-8432-4b0f-9d66-863be1260d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_25e0dc56-b0c3-4375-a52d-79d7bac28202" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_794a93dd-8432-4b0f-9d66-863be1260d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b607fd92-df64-4ecd-8e0a-3819e8832d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_794a93dd-8432-4b0f-9d66-863be1260d03" xlink:to="loc_us-gaap_AwardTypeAxis_b607fd92-df64-4ecd-8e0a-3819e8832d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd7eb1c-0fc9-4c2e-808c-f1d0d398ce29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b607fd92-df64-4ecd-8e0a-3819e8832d7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd7eb1c-0fc9-4c2e-808c-f1d0d398ce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3c3bb467-40b4-43af-be90-42c081d4bbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2bd7eb1c-0fc9-4c2e-808c-f1d0d398ce29" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3c3bb467-40b4-43af-be90-42c081d4bbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_794a93dd-8432-4b0f-9d66-863be1260d03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04609cdd-6f0e-421b-93ee-010246c74e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_04609cdd-6f0e-421b-93ee-010246c74e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4de4066d-a837-4d45-b913-bca0f504012e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4de4066d-a837-4d45-b913-bca0f504012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_412c73d8-2910-433f-9349-8321d1ee97de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_412c73d8-2910-433f-9349-8321d1ee97de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_169a9ed8-9821-4977-86e9-7c89ee8810da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_169a9ed8-9821-4977-86e9-7c89ee8810da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e5fcb72-8fd0-479e-b107-c3cbb821a734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5b155e6b-ff2c-4e09-b0bb-a7db82524b95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e5fcb72-8fd0-479e-b107-c3cbb821a734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6a42f56b-d82f-44dc-9f2a-83c1b4095b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82daedf0-d85c-4de0-a98b-131b291a6dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82daedf0-d85c-4de0-a98b-131b291a6dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a43e79da-f8a8-455d-b3d0-ca7c6f1c63d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a43e79da-f8a8-455d-b3d0-ca7c6f1c63d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_df34c005-5e5d-4463-bc24-eed3397325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_df34c005-5e5d-4463-bc24-eed3397325a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6fbe8fb-c4dd-4be0-91b7-72f94934022b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e6fbe8fb-c4dd-4be0-91b7-72f94934022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_766ccfb1-49fb-4ff0-9b1b-8af6ffc9b121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3406b959-b19b-4c56-bf7a-a935cfa7c4b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_766ccfb1-49fb-4ff0-9b1b-8af6ffc9b121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ardx-20220630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7eefd91e-e022-4a93-8afc-90171c177dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f0f51673-8ef7-4e96-b9d7-3ce087a495e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7eefd91e-e022-4a93-8afc-90171c177dac" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f0f51673-8ef7-4e96-b9d7-3ce087a495e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ardx-20220630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_63a86503-d6fb-4517-9ec8-bce48728d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_37a5b0d3-7af6-4f8b-b06f-c93fff85232c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_63a86503-d6fb-4517-9ec8-bce48728d59d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_37a5b0d3-7af6-4f8b-b06f-c93fff85232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8201ae16-17fa-4d8b-8a93-08e6f7b98e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_63a86503-d6fb-4517-9ec8-bce48728d59d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8201ae16-17fa-4d8b-8a93-08e6f7b98e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#NetLossPerShareComputationofNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e9e0c099-fde3-46d5-8215-b1be79ee6cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_be0c3ecb-94e4-471b-9665-2771584e25e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e9e0c099-fde3-46d5-8215-b1be79ee6cdf" xlink:to="loc_us-gaap_NetIncomeLossAbstract_be0c3ecb-94e4-471b-9665-2771584e25e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c84492a7-666c-4e17-a440-ecff8e99f0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_be0c3ecb-94e4-471b-9665-2771584e25e9" xlink:to="loc_us-gaap_NetIncomeLoss_c84492a7-666c-4e17-a440-ecff8e99f0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_28bc7445-1a36-4865-bf35-6a5b08e5a58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e9e0c099-fde3-46d5-8215-b1be79ee6cdf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_28bc7445-1a36-4865-bf35-6a5b08e5a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569950a0-a52b-4497-9334-d22639452af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_28bc7445-1a36-4865-bf35-6a5b08e5a58e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569950a0-a52b-4497-9334-d22639452af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe1a07fc-cc73-41e1-8439-7e3eb11b9b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_28bc7445-1a36-4865-bf35-6a5b08e5a58e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fe1a07fc-cc73-41e1-8439-7e3eb11b9b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_81689d14-71b1-4afa-934c-e5878ae5ea8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e9e0c099-fde3-46d5-8215-b1be79ee6cdf" xlink:to="loc_us-gaap_EarningsPerShareBasic_81689d14-71b1-4afa-934c-e5878ae5ea8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_96e14e28-51e8-4076-bb73-ca581d7843a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e9e0c099-fde3-46d5-8215-b1be79ee6cdf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_96e14e28-51e8-4076-bb73-ca581d7843a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f6d4d5b3-bdc9-447b-9d97-cb51623d6cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62c3c6cf-fb86-4c18-857a-83c9b2b345cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f6d4d5b3-bdc9-447b-9d97-cb51623d6cac" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62c3c6cf-fb86-4c18-857a-83c9b2b345cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9b8f91c-dc77-416b-9d47-baa820653e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62c3c6cf-fb86-4c18-857a-83c9b2b345cc" xlink:to="loc_us-gaap_AwardTypeAxis_e9b8f91c-dc77-416b-9d47-baa820653e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e9b8f91c-dc77-416b-9d47-baa820653e26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_382196dd-0cb9-4d0b-8f6b-1d0eb4257b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_382196dd-0cb9-4d0b-8f6b-1d0eb4257b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d007ae08-56a2-4ccb-959f-40dba89108e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d007ae08-56a2-4ccb-959f-40dba89108e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_aaa23bf8-1ff2-48c2-a291-00a3d79a394b" xlink:href="ardx-20220630.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0551d6da-c82f-4d5c-97ad-0e2a7ab571d1" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_aaa23bf8-1ff2-48c2-a291-00a3d79a394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_017572aa-bd5e-47c6-8cca-43db34c73017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_62c3c6cf-fb86-4c18-857a-83c9b2b345cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_017572aa-bd5e-47c6-8cca-43db34c73017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407c86d1-8d21-453b-9413-77680496dc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_017572aa-bd5e-47c6-8cca-43db34c73017" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_407c86d1-8d21-453b-9413-77680496dc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Contingencies" xlink:type="simple" xlink:href="ardx-20220630.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a5c1f115-1088-449e-ad33-c6d541735679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c600663d-c03b-45de-9c23-9615af4c6082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a5c1f115-1088-449e-ad33-c6d541735679" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c600663d-c03b-45de-9c23-9615af4c6082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="ardx-20220630.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c308242-9ae7-4360-b244-59df756c0ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_065ae3c1-d017-494c-a442-3eab0a60a509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c308242-9ae7-4360-b244-59df756c0ae4" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_065ae3c1-d017-494c-a442-3eab0a60a509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ardx-20220630_g1.jpg
<TEXT>
begin 644 ardx-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3B1N/?\ 2L6\_P""N&DHY^S^"M0E7'!DU!(SG\$;\Z\JIXE\,T_BQ<?DI/\
M*+/5I^&G$U3X<)+YN*_.2/L"BOBNZ_X*[S/%^Y\ QQOGJ^M%QCZ" ?SJG<?\
M%<-6:%A#X)T^.3LSZB[*/PV#^=<<O%CA=;8AO_MRI^L4=D?"?BA[X=+_ +?I
M_I(^X**^%?\ A[7XB_Z%'1?_  )EH_X>U^(O^A1T7_P)EK'_ (BYPS_S^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC6HU*4W2JIQDG9IJS371H****T,PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHKF_BM\6M!^"W@ZXUSQ#?+9V4'"C[TD[GHD:]68^@Z<DX )K'$8
MBE0IRK5I*,8J[;=DDNK9MA\/5KU8T:,7*4G9)*[;?1(U?%'BG3O!6@76J:M>
M6^GZ?9(9)[B9]J1J/\X ')/ YK\_/VP/V]=2^-LEQX?\,M<:5X3#%)'SLN-4
M'J_=8SV3OU;^Z.*_:B_:WU_]I77\3M)IOAVUDW6>F))E5/3S)#QODZ\GA<D#
M&23Y-7\O^('BE5S)RR_*FX4-G+:4_P!5'RW?6RT/Z@\/_"VEEJCF&:I3K[J.
M\8?HY>>R>UWJ%%%%?C)^S!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!WW[/_
M .T?XD_9S\5#4-%N/,M9F'VS3YB3;WBC^\.S#LPY'N,@_I%^SY^TAX=_:.\)
M_P!H:+,8KN  7NGS$?:+-SZC^)3@X8<'V(('Y/UN?#KXCZU\*/%MKK>@7TVG
MZA:G*R(>'7C*..C*<<J>#7Z1P+XB8O(:BH5;U,.WK'K'SAV?=;/R>I^;\=>'
M>$SZFZ]*U/$):2Z2\I]_)[KS6A^PE%>+_LF?MDZ+^TEHRV<WE:7XJM8]UU8%
MOEF QF6$G[R^J_>7OD88^T5_6F59MA<RPT<9@IJ<);-?D^S75/5'\EYKE.+R
MW$RP>-@X3CNG^:?5/HUHPHHHKT#SPHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M*\Y_:3_:7T+]FWP8^H:C(MUJ=PI6PTU' FNW]?\ 9C'\3D8'09) /'C\?A\%
MAY8K%34815VWT_KHMV]$=F P&(QN(CA<+!RG)V277^NKV2U9<^/O[07A_P#9
MW\%R:MK4X::0,ME8HP\^^D&/E4>@R,L>%!]< _FG\??V@_$'[1'C235M:G*P
MQEELK*-CY%C&?X5'<G RQY8CT  S?B]\8M>^./C2XUWQ!>&ZNY?EC11MBMH\
MDB.-?X5&?J3DDDDD\O7\D\?>(>)SZJ\/0O##1>D>LK?:E^BV7F]3^MN ?#S#
M9#26(KVGB9+672-_LQ_5[OR6@4445^:GZ4%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 445Z-\(OV3O'OQM\N31-!NA82<_;[O_ $>UQZAV^_\ \ #'VKLP.7XG
M&550PE.4Y/I%-O\  X\=F&&P=)U\74C"*ZR:2_$\YHK[:^&G_!)JT@2.;Q?X
MFFN)."UKI,8C0?\ ;60$D?\  %/O7NG@;]BSX8_#\*UGX1TVZF7!\W4%-ZQ/
MK^]+ '_= K]-RGP;S[%)3Q'+17]YWE]T;_BT?F>:^,F0X5N&'YJS_NJR^^5O
MP3/R]T;P]J'B*X\G3[&\OIN/DMX6E;GIPH)KMM"_9.^)?B/;]F\#^)%#8P;B
MS:W4YQSF3:,<]>E?JOINEVNCVBV]G;P6L"_=CAC$:+] .*GK[G!^!.%BO]JQ
M<I?X8J/YN1\+B_';%-_[+A(Q_P 4G+\E$_,C3?\ @GM\7-1"M_PBHMT8'YIM
M1M5Q]1YF[]*U+3_@FI\5;E"SZ;I=N0<;9-1C)/\ WSFOTCHKV:?@ED,?BJ57
M_P!O1_2!XU3QMSZ7PTZ2_P"W9?K-GYO7'_!-'XJ00LRV&DS,.B)J*;C^>!^M
M9U]_P3L^+EFH9?#,-QP2?*U.U^7'^](/TS7Z944ZG@GD$MIU5Z2C^L&*GXV9
M_'>%)^L9?I-'Y4ZU^QU\4-!5FG\$:])MZ_9H/M/O_P LRU<1XA\%:SX1DV:M
MI.IZ6V<;;NU>$Y_X$!7[&TR>WCNH6CEC22-QAE9=RL/<5X^*\"L%)?[-BI1_
MQ14ORY3V,+X[8V+_ -IPL9?X9./YJ1^,5%?JWXY_9*^&_P 158ZGX/T?S7Y,
MUK%]DE)]2\14D_4FO"OB7_P2?T74$DF\)^(K[39N2+;44%Q"?8.H5E'N0YKX
MC-O!C/,,G/"N-9=D^67W2LONDS[?*?&?(\2U#%*5%]VN:/WQN_OBCX9HKT_X
MP_L>?$#X)))/JVARW.FQ<F_L#]IMP/5B!N0>[JM>85^7X[+<5@JKH8RG*G+M
M)-/\>GF?J.!S+"XVDJ^#J1J1[Q::_#KY!1117$=@4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI]Q;R6EQ)%+&\<L;%'1UVLC#@@CL1Z4ROYEVT9_35[ZH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** )+2[FL+J.>"22&>%Q)')&Q5HV!R"".00><BOT*_85_;13XV:7'X
M8\27"KXNLXSY4I&U=4B4?>';S0/O#C(^8?Q ?GC5C2-7NM U2WOK&XFM+RTD
M66&:)RDD3J<AE(Y!!KZ[@[B_%9!C5B*/O0EI.'22_22Z/IZ-H^1XQX0PO$&"
M>'K>[..L)]8O]4^JZ^J3/V8HKP_]B[]KNU_:.\*?8=2>&V\7:7&/MD( 1;M.
M@GC'ITW ?=8]@5KW"O[,RC-L+F>$AC<'+FA):>7=/LULT?QGF^4XK+,7/!8R
M/+.+U\^S7=/=,****](\T**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBD9@BEF(55&23VH I>)/$ECX/T"\U35+J&RT^PB:
M>XGE.%B11DD_X#DU^9/[7?[4U_\ M+>._,C\ZU\-Z:Q33;-C@X[RR#)'F-^2
MC '<GM_V^OVP6^,OB&3PKX>NL^%=+E_?31GC5)U/WL]XU/W1T)&[GY<?-E?R
MWXI>(']I57E.7R_<1?O-?;DO_;4]N[UV2/ZD\+?#_P#LZDLVS"/[^:]U/[$7
M_P"W-;]EINV%%%%?BY^T!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6-+TRXUO4
MK>SLX);J[NY%AAAC4L\KL<*H ZDD@8K],_V,_P!E:U_9N\!;[J..;Q3JR*^I
M7 (;R1U$"'^ZO<C[S<] H'C?_!,_]ET6UJ/B-KEO^]FW1:)#(OW%Y5[C'ORJ
M^VX]U-?9-?TUX1\#K"T5G>-C^\FOW:?V8O[7K);=H^NG\R^+G'#Q59Y)@I?N
MX/\ >-?:DOL^D7OWEZ:E%%%?N1^&A1110 4444 %%%% !1110 4444 %%%%
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MDTULT]FC^/<1AZE"K*C6BXRBVFGNFMTPHHHK8Q"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7;?LZ_"F3XU_&CP_P"'%5VM[ZY#7;*<;+=/GE.>QV*P'N0.]<37VA_P2?\
MA3QXB\:7$7II5BQ'TDF(_P#(0R/]H5]5P3D?]KYU0P4E>+=Y?X8ZO[[6]6?*
M\;9Y_9&2U\;%VDE:/^*6B^Z]_1,^S;:WCL[>.&&-8XHE"(BC"HHX  ]!3Z**
M_N+;1'\.WOJPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H[JUCOK:2&:-)89E*.CC<KJ1@@CN"*DHH
M>NC!-K5'Y/\ [4/P;D^!'QMUK0 K"Q27[1I[$YWVTGS1\]RO*D^J&O/Z^^?^
M"H_P8_X2KX9V'C"TAW7OAN3R+HJ.7M96 R?79)MQZ"1S7P-7\2\?<._V-G57
M"P5J<O>A_AET^3O'Y']M< \1?VSDM+%3=ZD?=G_BCU^:M+YA1117QI]D%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;,YY;4?NUE=?XXZ_C&_JTCY.HHHK^6S^I HHHH **** "BBB@ HHHH ****
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MZLK ^%G@&W^%OPXT3P[:;6AT>SCMMX&/-91\SX]6;+'W-;]?W5PKDJRG*:&
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M_+T'Q,4LKO<?EAER1#+[88[2>RNQ[5^E=?V?X=\5+/,IC5J/][3]V?JMI?\
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M["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV@N;_MYZ1_5K_"?D_C%GGU+)/JD'[U=\O_;JUE^B?^(]"HHHK^M#^2PHHHH
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MO^V[>/;8>+(?M8P,*MPF$F'X_(Y]Y#7X7XW9#[;!4LUIK6F^67^&6S^4M/\
MMX_=/!'/O8XVKE51Z5%S1_Q1W2]8Z_\ ;I\ZT445_,Y_3 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /3OV._BQ_P *<_:%\/ZI))Y5A<S?
M8+XDX7R)OD+-[(Q5_P#@%?JE7XOU^K7[)OQ3/QB_9^\-ZU+()+W[,+6\.<MY
M\1\MR?=MH?Z.*_HCP-SS2OE,W_T\C^$9?^VO[S^=_'+([.AFT%_T[E^,H_\
MMR^X]&HHHK^A#^>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /*_P!M/XFGX5?LW>)+Z*0QWEY!_9UJ0<,))ODR#ZJI=O\
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MBBB@ HHHH *^SO\ @DW\3\2^)O!LTGW@NKVBG\(IO_:/'L:^,:](_9'^)/\
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ML"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OT-_X)A_"K_A#/@7-X@GBV
M7GBJY,JDC#?9XB4C'KRWF-[AA7P-X'\)77C[QEI6AV*[KO5KN*TBXR SL%!/
ML,Y/L*_7OPAX8M?!/A33='L4\NSTJUCM(%]$10H_' K]O\$<C]OF%7,YK2DN
M6/\ BE_E&Z?^)'XAXW9Y[#+Z660>M5\TO\,=OODTU_A9HT445_3I_,04444
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MUZ+XE_X#=^J1^E>%.??V=GU.G-VA6]Q^K^%_^!67HV?GG1117\>G]A!1110
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M9:4[S?\ VZM/_)G$^9:***_C<_L@**** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %=5\#OAM-\7_BWX?\-Q;L:I>)',R]4A'S2M^"!C^%<K7UY_P2
MB^%/]I>*M?\ &5Q'F+38AIMF3T,LF&D(]U0*/I*:^FX/R5YMG%# M>[*5Y?X
M5K+\$UZM'S7&&=+*<GKXY/WHQM'_ !/2/XM/T3/M^RLH=-LH;>WC6&"W18XT
M485% P /8 5+117]RI)*R/X9;;=V%%%%,04444 %%%% !1110 4444 %%%%
M!7Y4_M>?%,?&#]H7Q)JT4GF6,=Q]CLR#E?)A_=J1[,07_P"!U^B'[67Q3/P=
M_9^\2:U%)Y=[]F-K9G/S>?*?+0CW7<7^B&OREK^>O'+.M,/E,'_T\E^,8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_5+]CSX4_\ "G?V>?#NES1^7?7$'V^]!7#":;YRK>Z
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M/DFBBBOXG/[8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO_ KZ=$T?V-X6Y]_:60TU-WG2]Q_+X7_ . VUZM,****_.3]&"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^W?^"1VK^=X=\<6'_/O<VEP/^!K*O_M.OL.OA;_@DIJ?
ME?$+Q=9\?Z1IT,V,?W)".O\ VTK[IK^Q_"FO[3AC#I_9YU_Y/+]&C^./%:A[
M/B?$/^;D?_DD?U3"BBBOT4_.@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *^=?\ @I_?_8_V8_+X_P!*U:VBZXZ"1_Q^[7T57R[_ ,%8+S9\"-!M]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M])GDV6/BJ V+ GY1.OSPGZDAD'_72OT<K^R?"_//[2R"ESN\Z7[N7_;OP_\
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M?>^&,K<3X1^<O_2)'PO1117\8G]GA1110 4444 %%%% !1110 4444 %%%%
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M117 =X4J(TKJJJ69C@ #))I*]@_86^%7_"U_VD="AFC\RPT=SJMWE<KMA(*
M^S2&-3GL3UZ5Z&59?4Q^,I8*C\522BOF[7^6[//S7,*> P=7&UOAIQ<G\E>W
MJ]D?H1^S=\+E^#7P/\.>'BFRXL[17N^G-Q)^\EY[X=F ]@*[BBBO[SP>%IX7
M#PPU%6C!**]$K(_@S&8NIBL1/$UG>4VY/U;NPHHHKI.8**** "BBB@ HHHH
M**** "BBB@ KY=_X*F_%/_A&?A!IOABWEVW/B2[\R=0>?L\.&((]Y#'CUVM7
MU%7YF?\ !0/XICXF_M*:M'#(9+'PZHTF#GC=&293C_KJSC/<**_,_%C.OJ&0
M5*<'[]9J"]'K+_R5-?-'Z9X3Y+]?S^G4FO<HIS?JM(_^3-/Y,\2HHHK^/S^P
M HHHH **TO"'@_5/'WB*UTG1;&XU+4KQ]D,$";F<_P! .I)P !DD"OJ;X=?\
M$GM;U?3([CQ-XFL]%F<9^R6EM]K9/9G+*H(_V=P]Z^@R/A7-<X;6747-+=Z*
M*\N9M*_E>Y\_GG%659.D\QK*#>RU<GY\J3=O.UCY'HK[J'_!)3P[C_D;M:_\
M!HJ/^'2GAW_H;M:_\!HJ^L_XA'Q-_P ^5_X''_,^3_XBYPS_ ,_G_P" 2_R/
MA6BONK_ATIX=_P"ANUK_ ,!HJ/\ ATIX=_Z&[6O_  &BH_XA'Q-_SY7_ (''
M_,/^(N<,_P#/Y_\ @$O\CX5HK[J_X=*>'?\ H;M:_P# :*C_ (=*>'?^ANUK
M_P !HJ/^(1\3?\^5_P"!Q_S#_B+G#/\ S^?_ (!+_(^%:*^ZO^'2GAW_ *&[
M6O\ P&BH_P"'2GAW_H;M:_\  :*C_B$?$W_/E?\ @<?\P_XBYPS_ ,_G_P"
M2_R/A6BONR'_ ()+>&EE7S/%FN-'GD+!$I/X\_RJW_PZ;\&?]#)XG_.#_P"-
MU4?"'B5[THK_ +?C_F3+Q>X:6U63_P"W)?Y'P117WO\ \.F_!G_0R>)_S@_^
M-UY5^V'^PMX=_9S^$T?B#2]8UJ^N7OXK0QW1B\O:ZN2?E4'/RCO7'F7A?GV
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M_GZT7_P7K_C1_P /,_BE_P _6B_^"]?\:^?:*/\ 7CB#_H,J?^!,/]1^'_\
MH#I_^ H^@O\ AYG\4O\ GZT7_P %Z_XT?\/,_BE_S]:+_P""]?\ &OGVBC_7
MCB#_ *#*G_@3#_4?A_\ Z Z?_@*/H+_AYG\4O^?K1?\ P7K_ (UX%?7LVI7L
MUQ<2--/<.TDDC'+.Q.23[DFHJ*\O,\^S',5%8ZM*IRWMS-NU][7[V1ZF69#E
MV7.3P-&-/FM?E25[;7MVNPHHHKR3U@HHHH _1[_@GK^SQ9_"CX/6?B"ZMT;Q
M#XH@6ZEF9<M!;-\T42GL"NUV]6.#G:,?059_A&VCLO"FEPQ+MCAM(D1?0!
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MK_Z$:^@J^??^"F?_ ":W=?\ 81M?_0C7RO''_)/XS_KW+\CZK@?_ )*#!_\
M7R'YH_.&BBBOX=/[B"BBB@ HHHH **** "BBB@ HHHH ^R_^"3_Q7\J[\1>"
M[B3B4#5K)2>XVQS ?4>4<?[+'UK[5K\E/V=?BBWP9^-?AWQ%N9;>QNU%T!D[
MK=_DE&.YV,V/<"OUIAF6XB62-EDCD 964Y# ]"#7]7^#>>?7,F>"F_>H.W_;
MLM8_CS+T2/Y1\9<C^IYRL;!>[75_^WHV4OPY7ZMCJ***_73\A"BBB@ HHHH
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M .@M7M<-_P#(VPO_ %\A_P"E(\;B+_D4XK_KW/\ ])9^J5%%%?WD?P8%%%%
M!1110 4444 %%%% !1110 5\*_\ !6O_ )*)X1_[!TO_ *-K[JKX5_X*U_\
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M!@[?\_(_F?G+1117\.G]Q!1110 4444 %%%% !1110 4444 %?IU^P5\5?\
MA:G[-FBM-)YE]H0.D7.>N8@/+/J<Q&,D]SFOS%KZB_X)9_%;_A&/B]J/A>XD
MVVOB:U\R!3_S\0 L/IF,R9]=JU^F^$V>?V?GT*4W[E9<C]7K'_R96^;/S/Q9
MR/\ M#(9U8+WZ+YUZ+27_DK;^2/OZBBBOZ_/X_"BBB@ HHHH **** "BBB@
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M$N;]3^'N.L5[?B#&5/\ IY)?^ OE_0****^K/E HHHH **** "BBB@ HHHH
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M,8_[C_'0^P\/X\W$6#7]]'Y]T445_$9_;@4444 %%%% !1110 4444 %%%%
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MGM4BF_)[-?)W7R"BBBO'/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBKWA?0Y/%'B;3M-BXDU&ZBM4^KN%'\ZJ
M$)3DH1W>A,YJ$7.6RU/U?_9T\._\(I\!/!NG[=KV^C6OF#_;,2L__CQ-=G3+
M:W2SMXX8U"1Q*$11_"!P!3Z_T!P>'6'P\*$=HQ2^Y6/\_<9B'B,1.O+>3;^]
MW"BBBNDYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B_\ X*W^
M%CM\%ZVB\?Z38S-_W[>,?^C*^+Z_1W_@IGX1/B3]F"YO%7<V@ZA;WN1U"DF
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MKQ.=82CWJ0OZ<R;_  N?/\68I8;)<77[4YV]>5I?C8_2&BBBO[L/X3"BBB@
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MX@<;UW/$Q]ROF#)[(HK[:K@?VG?A0OQJ^!GB'0%C$EY/;&:R]1<1_/'@]LL
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MYX^DM;?*5U\C^U/#G/?[5R&C6D[S@N27K'2_SC9_,****^&/N HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -+P;X9G\:^+]
M*T>U_P"/C5KR*SBX_BD<(/U-?L-I6F0Z+I=M9VZ^7;VD2PQ+_=50 !^0K\V?
M^"=G@/\ X3?]J'1YGC\RWT&&74Y>. 579&?PD=#^%?I=7]->!N6>SR_$8^2U
MJ245Z05_SD_N/YE\<LS]IF&'P$7I3BY/UF[?E%/YA1117[D?AH4444 %%%%
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MD,WS-8?#2O2HW2:V<G\37=:)+TNM&%%%%?J1^6A1110 4444 %%%% !1110
M4444 !.!7X[_ !"\1?\ "7^/]<U;.[^U-0N+O///F2,_?GOWK]7?CKXJ_P"$
M'^"_BO5MRJ]AI-S+'DXS((VV#\6P/QK\BJ_G;QVQEYX3"+HIR?SY4OR9_17@
M3@[0Q>+?5PBOES-_F@HHHK^?#^@@HHHH **** "BBB@ HHHH **** "BBB@
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M>_\ A1\RT445_,)_3P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #/Z]\(\X^N\/PHR?O46X/TWC^#M\@HHHK\P/T\**** "BBB@ HHHH ****
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MX)KU/F>,LX_LO)<1C4[2C%J/^*7NQ_%I^A]T ;1@4445_<Q_#(4444 %%%%
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MW(6BBBOZ,/YS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>]0E?_MV5D_QY7Z)GV%1117]6'\IA1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!F98"K@<74P=;XJ<G%^J=O\ A@HHHKN.$**** "BBB@ HHHH **** "BBB@
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M445XY[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI+[D[KS2/R/HJ2ZM9+&ZDAF1HYH6*.C#!5@<$'Z&HZ_AMW6C/[D3NKH****
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MPN)I8BC'$4'S0DDTUU3U3"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "O0O@7^T_XP_9ZU'S- U$FQD??/IUR#):3GW7(*M_M(5;@<XXKSVBNK
M X[$8.LL1A9N$X[-.S_K\SEQV!P^,HO#XJ"G"6Z:NOZ_(_2+X"?\%#O!7Q>2
M&SU:9?"FN287R+V0?9IF_P"F<W"\^C[3DX&>M>^JP=0RD,K#(([U^,%>H_!3
M]L3QY\"?)M]*U9KS2HN!IM^#/; >BC(9/^ ,M?NG#/C94@E1SNGS+^>"2?\
MV]'1/UC;_"S\+XF\$Z<VZV25.5_R3;:_[=EJUZ2O_B1^I]%?,?P?_P""H/@[
MQBL=OXHM;KPO?-@&7!N;-C_O*-Z_0K@?WJ^B_"_B_2O&VE)?:/J5CJMG)]V>
MTG6:,_BI(S[5^Y9-Q)EF:PY\OK1GY)VDO6+LU\T?AN<\-YGE4^3,*,H>;5XO
MTDKI_)FC1117N'AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%>:?%K]KSX?\ P8$L>K>(+6:_BR#86)^TW.?[I5>$/^^5
M%?*WQG_X*E^(O$PFL_!NFP^'K1LJ+RYQ<7C#U"_ZN/Z8<\=:^+S_ ,0,DRA.
M.(K*4U]B'O2]';1?]O-'VF0>'^=YNU+#T7&#^W/W8^JOJ_\ MU,^T/B9\8/#
M/P=T3^T/$NL6>E6Y!V"5LR3$=D099S[*#7QE^T)_P4]UCQ8DVF^!+:30;%LJ
MVHW 5KR4=/D7E8OK\S=""IKY@\4>+=4\;:S)J&L:A>ZI?3??N+J9I9&]!EB3
M@=AT%9]?@?%'B]F>8IT,!^XIOL[S?K+I_P!NV?FS]\X7\(<LRYJOC_W]1=U:
M"](]?^WKKR1-J&HW&KWTUU=3S75S<,7EEE<O)(QZEF/))]34-%%?DDI-N[/U
MN,4E9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5SP_KUWX6UZQU.PF:WOM.G2YMY5ZQR(P96'T(!J
MG151E*,E*+LUL3*,91<9*Z>Y^N7P*^+^G_'7X7:7XDT]D47D0%Q"&W&UG7B2
M(]^&Z$XR"#T(KKJ_,7]C?]J^[_9K\:M'=>==>%]4<#4+9>6B/03QC.-X[C^)
M1CJ%(_2CPAXQTOQ]X<M=6T:^M]1TV]020SPMN5Q_,$="#@@\$ U_9O /&E#/
ML"N9I5X)*<?_ &Y+L_P>G:_\9<?<%U\AQSY$W0F[PE_[:WW7XK7O;2HHHK[T
M^""BBB@ HHHH **** "BBB@ HHHH **** /S/_X*#_"?_A6'[1^J3PQ^7I_B
M11JL&!P'<D2CZ^8';'8.*\/K]"O^"G_PH_X3+X'V_B*WCW7GA6Y$CD#DVTI"
M./P?RF]@K5^>M?QAXE9'_9F?UH15H5/?CZ2W^Z5UZ(_L_P -<\_M/(*,Y.\Z
M?N2]8[??&S]6%%%%?!'WH4444 %%%% !1110 4444 %%% &30!ZI^QW\!)/V
M@?C5I^FS1L=%T\B]U1\<>2I'[OZNV%]0"3VK]2H($M8$CC18XXU"HBC"J!P
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M_A?G;JS^CO!GB[GIO(L3+6-Y4[]5O*/R^)>5^B1XO1117X"?OP4444 %%%%
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MU+"8>/,OM/WI?)RNU\K!1117R9]8%%%% !1110 4444 %%%% !1110 4444
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M ?CFJO\ PLCP[_T'M%_\#HO_ (JOQYHJ9>/%;I@U_P"!O_Y J/@/1^UC'_X
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M/!G_ $-WAC_P:0?_ !5?D-12_P"([8O_ *!(_P#@3_R'_P 0)PG_ $%R_P#
M5_F?K1XP^(G@+QOX3U/1K[Q9X9>SU:UDM)P-4@SL=2IQ\W7!K\I/$FBMX;\1
M:AIS36]RVGW,EL9H'#Q2E&*[E8<%3C((Z@U2HKX'C;CB7$;I2JT%3E3OJFW=
M.VCNELUIZL^]X)X'CPXJL:5=U(U+.S25FKZJS>]]?1!1117P9]X%%%% !111
M0 4444 %%%% !7T7_P $Z?V<O^%M_%'_ (2/4H-V@^%I%EPP^6ZN^L<?N%^^
MWT4'AJ\(\$>#-0^(GB[3]#TF!KG4=4G6"",=V/<GLH&23V )K]7O@7\(-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6W\.OA[JWQ5\::?H&BVS76I:E)Y<2=%4=69CV50"2>P!K,T
MO3+C6]2M[.S@ENKN[D6&&&-2SRNQPJ@#J22!BOTH_8I_9+M_V<_!OVW4HXIO
M%FKQ@WLHPPM$X(MT/H."Q'WF'<!:^VX%X-K\08[V2O&C&SG+LNR_O/IVU?0^
M)XYXRH</X'VKM*M*ZA'N^[_NKKWT74[+]G+X :5^SI\.+?0]/VS738FO[PKM
M>\F(Y8^BCHJ]A[DD]]117]F8'!4,'0AA<-%1A!6271+^OGNS^,\;C:^+KSQ6
M)DY3F[MOJW_7RV"BBBNHY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\_\ VC_V>='_ &C_ (?2Z/J6+>\AS+I]\J[I+*7'
M4>JGHR]QZ$ CT"BN7'8&AC,//"XF*E":LT^J_K9[IZHZL#CJ^#Q$,5AI.,XN
MZ:Z/^MULUHS\??B9\-=8^$7C6^\/ZY:FUU&P?:ZYW+(IY5T/\2L,$'^1R*P:
M_43]KC]E33?VE_!>U?+L_$FFHS:=>E>IZ^3(>IC8_BIY'<'\S?&'@_4_ /B:
M\T?6+.;3]2T^0Q3P2C#(?Y$$8((R""",@U_'/'G ^(X?Q=E>5";]R7_MLO[R
M_%:KJE_8W ?'&'X@PEW:->"]^/\ [='^Z_P>CZ-YM%%%?!GW@4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % &317
MVM_P3_\ V)?LGV/QYXPL\3<2Z/ITZ?<[K<R ]^Z*>G#==N/HN%^&<7GF-C@\
M*O.4ND8]6_T75Z'SO%'$V$R/ RQF*?E&/64NB7ZOHM3J/V!OV+_^%6:?#XR\
M46NWQ)>1YLK25?FTN-@02P_YZL#TZJ#CJ6 ^HJ**_M#A_(<)D^"A@<&K1CN^
MLGUD^[?X:):)(_B_B#/L7G&-GCL8[RELND5TBNR7XZMZML****]H\4**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *\/_;(_8[L/VC_  \=0T\0V/B[3XB+6Y/RK=J,GR9?;^ZW52?0D5[A17FY
MME.%S/"SP6-CS0ENOR:?1KHSTLIS;%99BX8W!RY9QV\^Z:ZI]4?C7K^@WOA;
M6KK3=2M9K*^LI##/!,NUXG'!!%4Z_2;]L[]C&R_:'T5M7TA8;+QA91XBE/RI
MJ"#I%*?7LKGIT/'3\Y=?T&]\+:U=:;J5K-97UE(89X)EVO$XX((K^..-."\7
MP_B_95?>I2^"?1KL^TEU7S6A_8_!?&F$X@PGM:7NU8_'#JGW7>+Z/Y/4IT44
M5\8?9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>NWEJ_GGCOPC=Y8_(8^<J7ZP_P#D?_ >D3^AN!/%Q/EP&?2\HU?TG_\ )?\
M@75GP+15[Q+X9U#P;KMSIFJV=QI^H6;^7-;SH4DC/N#^>>A'-4:_GV<)0DX3
M5FM&GNF?T%"I&<5.#NGJFMF@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVV[MA11174<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5Y+^T=^QOX3_:,M)+B[@_LOQ J8BU6U0"0X' E7I(HP.O(' 85ZU17#F6
M687,*#PN-IJ<'NFOQ79]FM5T.[+<TQ>7UUBL%4<)K9K\GW7=/1]3\J/C]^RI
MXN_9UU(KK-E]HTN1]L&IVH+VLWH">J-_LM@\'&1S7FU?LQJNE6NNZ;/9WMO!
M>6ETACFAF021RJ>H93P0?0U\E_M'_P#!,.RUO[1JWP]F33KLY=M(N9#]GE/7
M$3GF,G^ZV5R>JBOYSXN\&\3AN;$Y(W4AOR/XUZ/:2\M)?XF?T9PCXR8;$\N&
MSI*G/;G7P/U7V7YZQ_PH^&Z*UO&W@36?AOXAFTG7M-N]+U"W.'AN$VMCL0>C
M*>S#(/8FLFOQ&K2G3FZ=1-26C35FGV:/VZE5A4@JE-IQ>J:U37=,****S- H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIT4;32*B*S.Q"JJC))/
M84 -K:\!?#S6_BAXDATCP_IMUJFH3=(H$SM&0"S'HJC(RS$ >M>_?LZ?\$VO
M$GQ+\C4_%S3^%]%8AA;LG^GW*^R'B+ZN,_[)'-?</PJ^#?AOX*^'%TOPWI=O
MIUO@>:ZC=-<,/XI'/S,?J>.V!Q7ZSPCX39CFEL1C[T:/FO?DO*+V]9>J3/R7
MB[Q9R[*[X? 6K5O)^Y%^<EOZ1]&T?/O[-'_!-32/ _V?5_'1M]>U5</'IRY:
MRMCU^?\ YZL/0_)UX;@U]3PQ+;Q+'&JQQQ@*JJ,!0.@ IU%?TOD/#N7Y/A_J
M^7TU%=7O*3[R>[_)=$D?S3GW$689QB/K&85')]%M&*[16R_-]6V%%%%>X>&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"KK.B6?B+39+/4+.UOK.8;9(+B)98Y!Z%6!!_&OG_XM_\
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M5I'_ ,!5E\VK^84445](?-A1110 4444 %%%% !1110 4444 %%%% !1110
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MKK:\O_ I7E^)^<YMQ?G.976-Q,I)]+VC_P" QM'\ HHHKZ0^;"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]\J/0?E6S117O4J-.G'EIQ279*QX-2M4J2YJC;?=NX4445H9A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041020223840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Fifth Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,635,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021191584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,408<span></span>
</td>
<td class="nump">$ 72,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">27,604<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,623<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">4,529<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PrepaidCommercialManufacturingCurrent', window );">Prepaid commercial manufacturing</a></td>
<td class="nump">17,793<span></span>
</td>
<td class="nump">9,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,150<span></span>
</td>
<td class="nump">7,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">114,107<span></span>
</td>
<td class="nump">133,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">11,054<span></span>
</td>
<td class="nump">12,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,908<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">131,610<span></span>
</td>
<td class="nump">149,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,294<span></span>
</td>
<td class="nump">4,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">6,405<span></span>
</td>
<td class="nump">5,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">26,373<span></span>
</td>
<td class="nump">32,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">3,691<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,936<span></span>
</td>
<td class="nump">7,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,699<span></span>
</td>
<td class="nump">52,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">12,421<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DeferredRoyaltyObligationNoncurrent', window );">Deferred royalty obligation</a></td>
<td class="nump">9,591<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">78,568<span></span>
</td>
<td class="nump">67,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized; 153,797,834 and 130,182,535 shares issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">821,075<span></span>
</td>
<td class="nump">795,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(767,939)<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">53,042<span></span>
</td>
<td class="nump">82,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 131,610<span></span>
</td>
<td class="nump">$ 149,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DeferredRoyaltyObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DeferredRoyaltyObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PrepaidCommercialManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Commercial Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PrepaidCommercialManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041020115680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">153,797,834<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">153,797,834<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041019734464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 2,526,000<span></span>
</td>
<td class="nump">$ 1,313,000<span></span>
</td>
<td class="nump">$ 2,994,000<span></span>
</td>
<td class="nump">$ 7,895,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,741,000<span></span>
</td>
<td class="nump">26,021,000<span></span>
</td>
<td class="nump">18,592,000<span></span>
</td>
<td class="nump">46,477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">18,862,000<span></span>
</td>
<td class="nump">20,124,000<span></span>
</td>
<td class="nump">38,201,000<span></span>
</td>
<td class="nump">37,255,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,741,000<span></span>
</td>
<td class="nump">46,145,000<span></span>
</td>
<td class="nump">57,016,000<span></span>
</td>
<td class="nump">84,732,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(26,215,000)<span></span>
</td>
<td class="num">(44,832,000)<span></span>
</td>
<td class="num">(54,022,000)<span></span>
</td>
<td class="num">(76,837,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(787,000)<span></span>
</td>
<td class="num">(1,202,000)<span></span>
</td>
<td class="num">(1,533,000)<span></span>
</td>
<td class="num">(2,302,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="nump">554,000<span></span>
</td>
<td class="nump">798,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(26,932,000)<span></span>
</td>
<td class="num">(45,187,000)<span></span>
</td>
<td class="num">(55,001,000)<span></span>
</td>
<td class="num">(78,341,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,938,000)<span></span>
</td>
<td class="num">$ (45,189,000)<span></span>
</td>
<td class="num">$ (55,009,000)<span></span>
</td>
<td class="num">$ (78,344,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share - basic (in shares)</a></td>
<td class="nump">145,544,372<span></span>
</td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">138,279,945<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share - diluted (in shares)</a></td>
<td class="nump">145,544,372<span></span>
</td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">138,279,945<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,938,000)<span></span>
</td>
<td class="num">$ (45,189,000)<span></span>
</td>
<td class="num">$ (55,009,000)<span></span>
</td>
<td class="num">$ (78,344,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="num">(103,000)<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(26,959,000)<span></span>
</td>
<td class="num">(45,178,000)<span></span>
</td>
<td class="num">(55,112,000)<span></span>
</td>
<td class="num">(78,336,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,564,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,014,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product Supply Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">952,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">966,000<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">5,005,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember', window );">Collaborative development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,310,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,764,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_CollaborativeDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041017552192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,599,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 126,112<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 680,872<span></span>
</td>
<td class="num">$ (554,765)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,979,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">62,446<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">62,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (losses) gains on available-for-sale securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(78,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,967,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">117,569<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">750,664<span></span>
</td>
<td class="num">(633,109)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,688,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">130,811<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">718,728<span></span>
</td>
<td class="num">(587,920)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,038,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">28,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (losses) gains on available-for-sale securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,967,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">117,569<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">750,664<span></span>
</td>
<td class="num">(633,109)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">82,617<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">795,540<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,996,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,492,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">$ 18,478<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">18,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (losses) gains on available-for-sale securities</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,797,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">53,042<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">821,075<span></span>
</td>
<td class="num">(767,939)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,330,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">64,190<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">805,265<span></span>
</td>
<td class="num">(741,001)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,882,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,584,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">12,557<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (losses) gains on available-for-sale securities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,797,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 53,042<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 821,075<span></span>
</td>
<td class="num">$ (767,939)<span></span>
</td>
<td class="num">$ (109)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041019033440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,009)<span></span>
</td>
<td class="num">$ (78,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred compensation for services</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on investment securities</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,976<span></span>
</td>
<td class="nump">6,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in derivative liabilities</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Debt refinancing costs</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of equipment</a></td>
<td class="num">(853)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest associated with debt discount accretion</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,121)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(4,529)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense', window );">Prepaid commercial manufacturing</a></td>
<td class="num">(12,197)<span></span>
</td>
<td class="num">(8,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(3,039)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">983<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,692)<span></span>
</td>
<td class="num">(1,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">7,694<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(58,901)<span></span>
</td>
<td class="num">(78,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and redemptions of investments</a></td>
<td class="nump">42,300<span></span>
</td>
<td class="nump">60,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(25,762)<span></span>
</td>
<td class="num">(48,314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">1,268<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">17,806<span></span>
</td>
<td class="nump">10,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from 2022 Loan, net of issuance costs</a></td>
<td class="nump">26,971<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of 2018 Loan, net of settlement costs</a></td>
<td class="num">(33,038)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts', window );">Proceeds from the sale of future royalties, net of issuance costs</a></td>
<td class="nump">9,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="nump">18,478<span></span>
</td>
<td class="nump">62,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">22,075<span></span>
</td>
<td class="nump">63,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(19,020)<span></span>
</td>
<td class="num">(4,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">72,428<span></span>
</td>
<td class="nump">91,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">53,408<span></span>
</td>
<td class="nump">86,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DerivativeIssued', window );">Issuance of derivative in connection with issuance of loan payable</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DerivativeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DerivativeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Prepaid Commercial Manufacturing Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Future Royalties, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of deferred charges applied against earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041020208048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment, which is the development and commercialization of biopharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash and investments of approximately $81.0&#160;million. We have incurred operating losses since inception and our accumulated deficit as of June&#160;30, 2022 is $767.9&#160;million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from sales of IBSRELA, our potential receipt of anticipated milestones from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 1 to our audited financial statements for the fiscal year ended December&#160;31, 2021, included in our Annual Report on Form 10-K. Our significant accounting policies for the three and six months ended June&#160;30, 2022 also included the policies discussed below related to accounts receivable, inventory, revenue and cost of revenue for commercial product sales. With the exception of those noted below, there have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of June&#160;30, 2022 our accounts receivable balance is comprised of $4.1&#160;million from our collaborators and $1.5&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through a limited number of wholesalers and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers and specialty pharmacies are offered various forms of consideration, including service fees. Wholesalers may also receive prompt pay discounts for payment within a specified period. We expect prompt pay discounts to be earned when offered and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the condensed balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three and six months ended June&#160;30, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.9 million as cost of revenue under the AZ Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-cash Interest Expense on Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds we receive from the sale of certain future royalties are amortized to non-cash interest expense over the estimated life of the associated agreement using the effective interest method. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021584000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text">CASH, CASH EQUIVALENTS AND INVESTMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of June&#160;30, 2022 and December&#160;31, 2021 are summarized below (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds and other debt securities with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive income (loss) within stockholders&#8217; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income (expense), net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All short-term available-for-sale securities held as of June&#160;30, 2022 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write it down through the statement of operations and comprehensive loss to its fair value and establishes that value as a new cost basis for the investment. We did not identify any of our available-for-sale securities as other-than-temporarily impaired in any of the periods presented. As of June&#160;30, 2022, no investment was in a continuous unrealized loss position for more than one year and we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026255776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and 2022 Exit Fee, as defined and discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are classified as Level 3.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both June&#160;30, 2022 and December&#160;31, 2021, due to their short-term nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rates of our deferred royalty obligation and term loan facility approximate the rate at which we could obtain alternative financing. Therefore, the carrying amount of the deferred royalty obligation and the term loan facility approximated their fair values at June&#160;30, 2022 and December&#160;31, 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation and Note 8. Borrowing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 3 inputs used to estimate the fair value of each respective liability.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041022282000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">INVENTORY<div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. Inventory consisted of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid commercial manufacturing of $17.8&#160;million and $9.4&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, consist of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months. Prepayments for commercial manufacturing of $3.8&#160;million as of June&#160;30, 2022 that are expected to be converted into inventory after 12 months are included in other assets on our Condensed Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026058032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue, Net</a></td>
<td class="text">PRODUCT REVENUE, NET<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA, the first and only NHE3 inhibitor for the treatment of IBS-C in adults, in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $1.6&#160;million and $2.0&#160;million during the three and six months ended June&#160;30, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation made up 40.2%, 22.7%, and 24.6% of our gross product revenue during the three months ended June&#160;30, 2022 and 35.1%, 21.7%, and 22.5% during the six months ended June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Fees, Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/deductions issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales or gross-to-net accruals during the three and six months ended June&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026255776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and Licensing Agreements</a></td>
<td class="text">COLLABORATION AND LICENSING AGREEMENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;KKC&#8221;)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a research collaboration and option agreement with KKC (the &#8220;2019 KKC Agreement&#8221;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#8220;DCs&#8221;), with one compound inhibiting the first undisclosed target (&#8220;Program 1&#8221;), and a second inhibiting the second undisclosed target (&#8220;Program 2&#8221;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0&#160;million in two installments as follows: the first installment of $5.0&#160;million within 30 days of November 11, 2019 (the &#8220;Effective Date&#8221;), and the second installment of $5.0&#160;million on the first anniversary of the Effective Date. The original term of the 2019 KKC Agreement commenced on the Effective Date and was to end on the earliest of: (i) 2 years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. We entered into three amendments to the 2019 KKC Agreement, which have resulted in the extension of the original term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the third amendment to the 2019 KKC Agreement entered into on June 28, 2022, the current term will end on February 28, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no material future obligations under the 2019 KKC Agreement and recorded no revenue under the 2019 KKC Agreement during the three and six months ended June&#160;30, 2022. During the three and six months ended June&#160;30, 2021, we recognized $1.3&#160;million and $2.8&#160;million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 KKC Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with KKC (the &#8220;2017 KKC Agreement&#8221;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#8217;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2017 KKC Agreement, KKC paid us an up-front license fee of $30.0&#160;million. We may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0&#160;million in total development and regulatory milestones, of which $10.0&#160;million has been received and recognized as revenue as of June&#160;30, 2022. We may also be eligible to receive approximately &#165;8.5&#160;billion for commercialization milestones, or approximately $62.3&#160;million at the currency exchange rate on June&#160;30, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, we and KKC have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future commercial milestones and royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional $40.0&#160;million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. The variable consideration related to the reduction in the royalty rate has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 we recognized no licensing revenue upon the achievement of development milestones. During the three and six months ended June&#160;30, 2021, we recognized zero and $5.0&#160;million respectively, as licensing revenue upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia. During the three and six months ended June&#160;30, 2022, we recognized $952&#160;thousand and $966&#160;thousand, respectively, as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three and six months ended June&#160;30, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recognized zero and $126&#160;thousand, respectively, as product supply revenue pursuant to the 2017 KKC Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed below under the heading </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue - non-current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have received prepayments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Fosun Agreement&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBS-C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Fosun Agreement, Fosun paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fee. We may be entitled to receive development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$113.0 million, of which $3.0 million has been received and recognized as revenue as of June&#160;30, 2022, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue during the three and six months ended June&#160;30, 2022 or 2021 related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Fosun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (the &#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. Under the terms of the Knight Agreement, Knight paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million upfront payment. We may also be eligible to receive approximately CAD22.2&#160;million for development and commercialization milestones, or approximately $17.2 million at the currency exchange rate on June&#160;30, 2022, of which $0.7 million has been received and recognized as revenue as of June&#160;30, 2022. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a licensee of tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of June&#160;30, 2022, to date in aggregate, we have recognized $11.9 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $11.6 million. During the three and six months ended June&#160;30, 2022 we recognized and recorded as cost of revenue $0.2 million and $0.3 million, respectively, related to the AstraZeneca Termination Agreement. During the three and six months ended June&#160;30, 2021 we recognized zero and $1.0 million, respectively, as cost of revenue related to the AstraZeneca Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The June&#160;30, 2022 and 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances are attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041022588912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Royalty Obligation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Advance Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureTextBlock', window );">Deferred Royalty Obligation</a></td>
<td class="text">DEFERRED ROYALTY OBLIGATION<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (the &#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with KKC based upon KKC's net sales of tenapanor in Japan. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $10.0 million upfront payment, and we are eligible to receive a $5.0 million payment following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $5.0 million payment in the event net sales by KKC in Japan exceed a certain annual target level by the end of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 KKC Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 KKC Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 KKC Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 KKC Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 KKC Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.</span></div>We received the $10.0&#160;million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation on our condensed balance sheet. As part of the sale, we incurred approximately $0.4 million in transaction costs, which, along with the deferred royalty obligation, will be amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by KKC, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. To determine the amortization of the deferred royalty obligation, we are required to estimate the total amount of future royalty payments to be received from KKC for sales of tenapanor in Japan. There are a number of factors that could materially affect the amount and timing of royalty payments from KKC, most of which are not within our control. We will periodically assess the estimated royalty payments from KKC and, to the extent that the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation. As of June&#160;30, 2022, our effective interest rate used to amortize the liability is 34.4%. During the three and six months ended June&#160;30, 2022, we did not recognize a material amount of non-cash interest expense for the amortization of the deferred royalty obligation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7569-110849<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2175671<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041024920736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowing</a></td>
<td class="text">BORROWING <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;2018 Lenders&#8221;). The 2018 Loan Agreement provided for a $50.0 million loan facility with a maturity date of November&#160;1, 2022 (the &#8220;2018 Loan&#8221;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investment Corp. Loan Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (the &#8220;Closing Date&#8221;), we entered into a loan and security agreement (the &#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (the &#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement provides for a senior secured loan facility, with $27.5 million (the &#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (the &#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). On August 1, 2022, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis in order to borrow the additional $22.5 million from December 31, 2022 to March 31, 2023. The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024. Accordingly, beginning on April 1, 2024, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal over 36 months. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0&#160;million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of June&#160;30, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization and Basis of Presentation: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041022588912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liability</a></td>
<td class="text">DERIVATIVE LIABILITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash (the &#8220;2018 Exit Fee&#8221;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with IBS-C, which was obtained on September 12, 2019 when the FDA approved IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of both June&#160;30, 2022 and December&#160;31, 2021, the estimated fair value of the 2018 Exit Fee was $0.7 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2018 derivative liability include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to the 2018 Lenders as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  2% of the 2022 Loan funded (the &#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of June&#160;30, 2022, the estimated fair value of the 2022 Exit Fee is $0.4 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026058032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,054</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,240</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041022282000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offerings Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at the market offerings&#8221; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the six months ended June&#160;30, 2021 we sold 9.0 million shares and received gross proceeds of $63.8 million at a weighted average sales price of approximately $7.10 per share under the 2020 Open Market Sales Agreement.</span></div>In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the six months ended June&#160;30, 2022 we sold 20.5 million shares and received gross proceeds of $18.9 million at a weighted average sales price of approximately $0.92 per share under the 2021 Open Market Sales Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041024920736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the balance of inventory included in our condensed balance sheet includes $0.2 million stock-based compensation. During the three and six months ending June&#160;30, 2022, the amount of stock-based compensation released from inventory into cost of revenue was not material. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:58.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,190)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,085&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.91&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we sold approximately 0.1 million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $0.65 per share resulting in proceeds to us of approximately $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div>Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the six months ended June&#160;30, 2022, we issued no shares of our common stock to members of the board of directors in accordance with the program.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041025319968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHAREBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the six months ended June&#160;30, 2022 and 2021, all potential common shares were determined to be anti-dilutive. <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,189)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,009)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,344)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, all common stock equivalents are excluded from the computation of diluted loss per share, as the result would be anti-dilutive, including the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,099</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,447</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,182</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,211</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,819</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,802</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,321</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,406</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021309872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">CONTINGENCIESFrom time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us will not be material to our financial condition or cash flows, and no contingent liabilities were accrued as of June&#160;30, 2022 or 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021141024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableAccounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product Sales, Net and Reserves for Variable Consideration</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our commercial product sales, net in accordance with Topic 606 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We received approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#8220;NHE3&#8221;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through a limited number of wholesalers and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers and specialty pharmacies are offered various forms of consideration, including service fees. Wholesalers may also receive prompt pay discounts for payment within a specified period. We expect prompt pay discounts to be earned when offered and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the condensed balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three and six months ended June&#160;30, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.9 million as cost of revenue under the AZ Termination Agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock', window );">Non-cash Interest Expense on Deferred Royalty Obligation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-cash Interest Expense on Deferred Royalty Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds we receive from the sale of certain future royalties are amortized to non-cash interest expense over the estimated life of the associated agreement using the effective interest method. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Interest Expense On Deferred Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026169280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and investments as of June&#160;30, 2022 and December&#160;31, 2021 are summarized below (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,408&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,695&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021175680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026063552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text">Inventory consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026174000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock', window );">Schedule of Chargebacks, Discounts and Reserve Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Fees, Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/deductions issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021627712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The June&#160;30, 2022 and 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances are attributable entirely to the 2017 KKC Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to revenue recognized in the period for which cash has been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to cash received during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026148672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Debt Payment Obligations</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041026021792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Derivative Liability</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(713)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041018994400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock', window );">Summary of Additional Details of Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,054</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,691</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,240</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,772&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,691)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of additional details of the leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041013859712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,193&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:58.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,190)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,085&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.91&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021093536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss Per Common Share</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,189)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,009)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,344)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, all common stock equivalents are excluded from the computation of diluted loss per share, as the result would be anti-dilutive, including the following (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,099</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,447</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,182</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,211</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,520</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,963</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,819</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,802</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,321</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,406</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041019906528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,012<span></span>
</td>
<td class="nump">$ 116,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(767,939)<span></span>
</td>
<td class="num">(712,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca | AZ Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non-royalty revenue</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CostOfRevenueAggregateAmountRecognized', window );">Aggregate cost of revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RevenueGeneralPaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RevenueGeneralPaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember', window );">Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember', window );">Commercial customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CostOfRevenueAggregateAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue, aggregate amount recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CostOfRevenueAggregateAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RevenueGeneralPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, General Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RevenueGeneralPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCollaboratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=ardx_AccountsReceivableCommercialCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041013561344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 53,408<span></span>
</td>
<td class="nump">$ 72,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Fair Value</a></td>
<td class="nump">53,408<span></span>
</td>
<td class="nump">72,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">27,713<span></span>
</td>
<td class="nump">44,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">27,604<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_InvestmentsAndCashAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">81,121<span></span>
</td>
<td class="nump">116,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Fair Value</a></td>
<td class="nump">81,012<span></span>
</td>
<td class="nump">116,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,931<span></span>
</td>
<td class="nump">31,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">16,882<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">8,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">5,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Fair Value</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">50,433<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Fair Value</a></td>
<td class="nump">$ 50,433<span></span>
</td>
<td class="nump">$ 71,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashAndCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashAndCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashAndCashEquivalentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Gross Unrealized Gains</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashAndCashEquivalentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashAndCashEquivalentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents, Gross Unrealized Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashAndCashEquivalentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041016002448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>investment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum', window );">Short-term available-for-sale securities contractual maturities, maximum</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in unrealized loss position</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041017347536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 78,037<span></span>
</td>
<td class="nump">$ 115,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">50,433<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">16,882<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">8,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">50,433<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">50,433<span></span>
</td>
<td class="nump">71,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">27,604<span></span>
</td>
<td class="nump">44,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">16,882<span></span>
</td>
<td class="nump">31,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">8,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">7,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">5,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">$ 1,091<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041018139888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">3,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 4,529<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021153440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PrepaidCommercialManufacturingCurrent', window );">Prepaid commercial manufacturing</a></td>
<td class="nump">$ 17,793<span></span>
</td>
<td class="nump">$ 9,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PrepaidCommercialManufacturingExpenseNoncurrent', window );">Prepaid commercial manufacturing, noncurrent</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PrepaidCommercialManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Commercial Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PrepaidCommercialManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PrepaidCommercialManufacturingExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Commercial Manufacturing Expense, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PrepaidCommercialManufacturingExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041019795504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,526,000<span></span>
</td>
<td class="nump">$ 1,313,000<span></span>
</td>
<td class="nump">$ 2,994,000<span></span>
</td>
<td class="nump">$ 7,895,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerProductSalesGrossToNetAccruals', window );">Contract with customer product sales gross to net accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | Cardinal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">22.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | AmerisourceBergen Drug Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">40.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">24.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember', window );">IBSRELA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,564,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,014,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerProductSalesGrossToNetAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer Product Sales Gross To Net Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerProductSalesGrossToNetAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041018171920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember', window );">Discounts and Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember', window );">Other Fees, Copay and Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod', window );">Activity related to 2022 sales</a></td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/deductions issued</a></td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Credits Or Deductions Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041012702528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Narrative (Details)<br> $ in Millions, &#165; in Billions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">53 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>item </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 11, 2022 </div>
<div>USD ($) </div>
<div>payment_tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,526,000<span></span>
</td>
<td class="nump">$ 1,313,000<span></span>
</td>
<td class="nump">$ 2,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product Supply Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment', window );">First installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment', window );">Term of payment of license fee, first installment</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment', window );">Second installment of upfront license fees</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments', window );">Number of amendments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Product Supply Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones', window );">Potential commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate', window );">Fee receivable for reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches', window );">Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember', window );">Fosun Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember', window );">Fosun Agreement | Fosun Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties', window );">Threshold percentage of net sales for tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember', window );">Knight Agreement | Knight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200,000<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember', window );">AZ Termination Agreement | AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non-royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_CostOfRevenueAggregateAmountRecognized', window );">Aggregate cost of revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid', window );">Aggregate amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2019 KKC Agreement | KKC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_NumberOfSeparateCollaborativeAgreements', window );">Number of separate collaborative agreements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsNumberOfAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Number Of Amendments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsNumberOfAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, First Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees, Second Installment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Commercialization Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of future development and commercialization milestone under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Development Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CostOfRevenueAggregateAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue, aggregate amount recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CostOfRevenueAggregateAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_NumberOfSeparateCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of separate collaborative agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_NumberOfSeparateCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of uncharged license fees, aggregate amount paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_TermOfPaymentOfLicenseFeeFirstInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of payment of first installment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_TermOfPaymentOfLicenseFeeFirstInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of net sales for tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ThresholdPercentageOfSalesForTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041013544048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">$ 4,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">12,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember', window );">2019 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Deferred revenue - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived', window );">Decreases due to revenue recognized in the period for which cash has been received</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">4,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived', window );">Increases due to cash received during the period</a></td>
<td class="nump">3,829<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="nump">3,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">$ 12,421<span></span>
</td>
<td class="nump">$ 2,947<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Current, Rollforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Noncurrent, Rollforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase For Amounts Invoiced</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseForCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase For Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseForCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021478672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Royalty Obligation (Details) - Healthcare royalty partners IV, L.P - License - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalty payments and commercial milestone payments</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Payment to be received</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent', window );">Amortization, effective interest rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041011467488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>May 16, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member', window );">2018 Term Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage', window );">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod', window );">Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage', window );">Additional default interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | Prior to first anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | After first anniversary through second anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | After second anniversary to maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Term Loan | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating per annum rate (percent)</a></td>
<td class="nump">7.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentVariableRateBaseOption', window );">Addition to floating per annum rate (percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember', window );">Term Loan A | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from the sale of future royalties, net of issuance costs</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Payment term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_DebtInstrumentClosingFeeAmount', window );">Closing fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember', window );">Term Loan B | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement', window );">Remaining funding based on milestone achievement</a></td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents', window );">Future obligation upon loan funding or other events</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon occurrence of certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeTerm', window );">Exit fee, term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentClosingFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentClosingFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional default interest rate on the event of default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentInterestRateOnDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of fee payable on prepayment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentVariableRateBaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Base Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentVariableRateBaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Future Obligation Upon Funding Or Other Events</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining Funding Based On Conditional Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RemainingFundingBasedOnConditionalMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021458096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowing - Future Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total repayment obligations</a></td>
<td class="nump">$ 28,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized discount</a></td>
<td class="num">(1,259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Less: Unaccreted value of final fee</a></td>
<td class="num">(1,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">26,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(26,373)<span></span>
</td>
<td class="num">$ (32,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041019865200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liability - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon change of control or regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation', window );">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041021070352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability - Changes in Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit Fee derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">$ 1,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">2022 Exit Fee addition at fair value</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit Fee derivative liability | 2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in estimated fair value</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit Fee derivative liability | 2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Change in Fair Value of Derivative Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in estimated fair value</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041018257616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Details of Facility Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 11,054<span></span>
</td>
<td class="nump">$ 12,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">3,691<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">7,857<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 11,548<span></span>
</td>
<td class="nump">$ 13,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Additional details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining life (years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041013469600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">$ 2,128<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease</a></td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 2,122<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041018244304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Undiscounted Cash Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Undiscounted cash payment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 2,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">12,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest expenses</a></td>
<td class="num">(1,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">11,548<span></span>
</td>
<td class="nump">$ 13,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(3,691)<span></span>
</td>
<td class="num">(3,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 7,857<span></span>
</td>
<td class="nump">$ 9,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041019812944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="nump">$ 18,478,000<span></span>
</td>
<td class="nump">$ 62,446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember', window );">2020 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average sales price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember', window );">2020 Open Market Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average sales price per share (in dollars per share)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Commission on sale of stock per agreement (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockIssuanceCostCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Cost, Commission, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockIssuanceCostCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041012687344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,193<span></span>
</td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="nump">$ 6,824<span></span>
</td>
<td class="nump">$ 6,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">4,728<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 973<span></span>
</td>
<td class="nump">$ 1,087<span></span>
</td>
<td class="nump">$ 2,096<span></span>
</td>
<td class="nump">$ 2,179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041017264912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price per share of shares issued to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041017248720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 13,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 3,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041018161616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding balance, beginning (in shares) | shares</a></td>
<td class="nump">10,417,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">4,773,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited or canceled (in shares) | shares</a></td>
<td class="num">(1,190,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding balance, ending (in shares) | shares</a></td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">7,085,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise&#160;Price&#160;per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">7.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">4.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041017248128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock Units (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, beginning (in shares) | shares</a></td>
<td class="nump">3,529,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,980,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(3,714,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(121,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, ending (in shares) | shares</a></td>
<td class="nump">1,674,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">1.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">2.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041011597440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,938)<span></span>
</td>
<td class="num">$ (45,189)<span></span>
</td>
<td class="num">$ (55,009)<span></span>
</td>
<td class="num">$ (78,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">145,544,372<span></span>
</td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">138,279,945<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">145,544,372<span></span>
</td>
<td class="nump">100,040,083<span></span>
</td>
<td class="nump">138,279,945<span></span>
</td>
<td class="nump">98,617,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041013477184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">16,819<span></span>
</td>
<td class="nump">13,802<span></span>
</td>
<td class="nump">17,321<span></span>
</td>
<td class="nump">13,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">13,099<span></span>
</td>
<td class="nump">12,447<span></span>
</td>
<td class="nump">13,182<span></span>
</td>
<td class="nump">12,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">3,520<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">3,963<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140041114895008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>ardx-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ardx="http://www.ardelyx.com/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ardx-20220630.xsd" xlink:type="simple"/>
    <context id="i285f507425f845998ab1cc87f33146fa_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic42c961ec51b4da7be28511c4f3d2bf8_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="if62c57c8d0834b5693f69a9e3e0744b3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i925bda1ddc9b4f2ca467776b876445bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c30f784a20e41f48388f279f3478ef5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i17ad1002e42841d9bab8e33e821c520d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d6d660504cb4967842be9bac1eb88e4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iee6cf208bb934fc49b584ea377c5e697_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75815f35266949a29b3779fbb6a155e2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie1348d1b675c4c8fbd7e09f627729c65_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62030e5413144b8da56fee20836acd17_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ife16787b966e4f1ba8c452d2912d6b30_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c16a53c2ab74e3c9596e3f257e27abc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5df73e23a8cd48398fd1fd77c2ae2509_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc595528aca44fe8a51c84f136bb9823_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac43667a5f074d89b417e46787302ea0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iec5a8885f6cc40b48afbb753f9d28972_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i25246860a01e4ce8a406bd0535351adb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2331fd10761b45e8ab1788d9ee7c5ba7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic11b54c731dd476a84fa52d445b2970d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:CollaborativeDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idc6178b87a754bb0aac958078486483a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i000a94b69f67402186a7b726e453f414_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7e8875e4fffd4e17af63c26d11313c23_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id8d3cb0dd153487c96f8b541818106a3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id5affa987ee348868a5c35901b6e126d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if4b48a67d777408085c1b46cc926756a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iddd7db5c29bf4b818592913bccc1a693_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if2404930cb5c4c28b0452e3a33a5c82b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i78670b3ace5c4eafbbf72ad5cef50839_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib18818a41172419da6aa45c9edf9817e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i52f57530b34948d4b13553903ed1228a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9f7c7622a396409e8e8df165f90e798e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0ea209d52b54b31a2dbc3d0c55488d5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id77ff45716224c199ae858f37147e3e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i218e21332806486fa073f409c125d1f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b0d3d8ab19b4d71a852ccd289222b57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab00f1a29e0a43e7b11d43bd6cc9c687_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i73d56614ba724a608da48861a3cf60c9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic6e08a98a1064d38b01236bc993f4f9b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib0e0592cff724331842e40befa20fd69_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i31c6d8d5f1a34f37a1f54a5a716efd5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5fd458ec42704888b7569b9c391b5347_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i164a573f629b464f8fdb0ab0b4582249_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie93085e99e934f89baf533a6a0eceafc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5f167f86b3554775a6ecae909a898b9e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib501b2d7888048ad8bab2aff0a7e49bf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia4e60d959ef04f538e57678fb48d39de_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib0108f558055448982ef3a107a546127_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic4f3c74aea044471bfd38a37ede1fd57_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id537ef3aea1f4e00b37077b727741777_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i642f45e96f164e29bc7beb0165e50cab_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if50bec065c1f4bf58f6a04567d2d85b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i568c1373e0354d5aa5dd964481012f03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9078c496b28549dc88394c6f9e3f5bd9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e77cc73f998468495a6a26b87a2a968_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a43b3062ca24536868bd6a62ace2205_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibddc548b6b7a4ae280b837265a88e015_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6799c6e5bbe8426c90e26a689637fe8f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1555902d2ec1463bacd6e8d3c0cd1ff1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iace48da582da4c0683e6c1b47d0ac054_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCommercialCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb917478e7cc4cb19f960aafa0ebf6d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">ardx:AccountsReceivableCollaboratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic932086e94cd487a952b91e6f8c04bd1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i243ea0b71955409b86d20ba33c39c16d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i2766bdc22382498f96100a7aaec65cb8_I20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="i9df8422a3ac54491960b7f51d8d389ad_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6025aec2272144e0acf8d042ed697ddb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8486993cdcaf4e069d76b8adb41b13a6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia817be3797974733b6dc7b26f51132c5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icbb22f9725c44ee892344744a4cbbd26_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05b66c164e8e4390a1b10b9ea951aaff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9919698f07db4a6a92578760f1c69457_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i691c6773fe6c4ffbace66f4223e64445_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1c949bca14b4efd8274b5184e05d85f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58e98e012f3343f0badc90e26699bbb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc0b0709ef024116a0c9265abca56e5f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id7fb0f7426e14cbb8e220839ea644f53_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i79b3eccd186b4b239771cea14a00e33d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i546a6d3ca15649b1b31ac1990141ee51_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i08942428c1e14accb811599d6f9c1077_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idb85da03916f4959ae20e2dc28f6455c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie98257b0990d4eec907be89dfe165197_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i93c9bcdad9ec4c5ba892fa935c841839_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8b9d10adba4d4aeab9e207d99f3aeebe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8aaefa25584840cb807733401729c67a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6f37d12d66ab426fa73fe7b3c5d57eb4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7372862571244bdca7df10a1706f5b15_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i12201884779347479d4fe912a0be5b1f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if03a03012ab5410792f139ec7007eb3a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie63c1e4cfb6a4516a7f8967b8e88ef31_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9b2c3f0a67c94a8c83f4cce268ad23a1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibfc5a1fc9b954a588a196da771f45701_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id68a85c2475545a7946d12b3a69a9c7f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if576c80f93ba477a8bd7f301242eb30a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaa3bc355b5244eb0b37758f0981ed405_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ffac70a8f02419f80d424ef9aec9556_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia7954cbfa4ce4ea4ab4c3f6181db0e2e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0b85e98bea364f768c6d835cd20e21da_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia5cf155031c64016a5a4d37007dc9ab7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i620c4cac0fc54742b917d01906a295b1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i07691efdc6d54495bf7cb279afdb630c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if8d14510168b435db23351f3042e2fcd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if0cb3f52dc7040e1865d853122c39d38_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4cad74c2b72746a98815ab0bf53fe597_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i995be0cb8d874d6c9ba41b0dc05d971e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b854a7ada5344f09ef5775e5cba8f93_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8b547ba90a040d0b2ad45d6df149223_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie912ea9191f3410a856fb7a0596383a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3c82683331d441bb4bb22c1a6fee81b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26ec7fb6b30a44a384e58a556b1d2cf6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i964174c2047d42ea872fe68df856aaf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a3d98d34e324383930817612f98d9b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8a59bd234854baab3810f3de2b8b58a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8051dc6644dd49ddb271e164ef97c689_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67e3e3a40f3c49c083b2d38b581d7312_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74e633e223e04648a650081651dfab52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4b58e6d555145f0bdc3410179ee3f96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d88606f5f10482f94f0ee9f6cf00522_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80ad9ee3c9d74b2db9e200ae3966bdea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cf5489a8dfe42c2b6bbf447a6a435a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bca70cbb1754fb0bb05cb61bb3092c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65da5e485ec14c3284891b7e6b8296a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id077c7e922dd4a4482ae82df90440e4a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d869a99367f4854a7b935212b14932c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd39e9f5df1041638177826f6d98c2c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iae239e1a1fb44ff689e8fe9e2e2b5049_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib86f2f199f92428483fdae875ebaf628_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59ec18a7958d427e9d6cbc9e707fe8c3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if8db22a3a4424d38be4990606ba05153_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i030bed782c004d8dba6df6de0d87f2b1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icff93d49e06345b38b9bdf4a97525d38_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4db73df4aa148be8f8d748314b92bc9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic8bf0daa5741459ebc9bbfb5ddfba604_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icfd33242ba7c449e8338b810a873ad59_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c98f044f4c64f13aed0711c37e6a610_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i57c496b3e28c4d63ab0345238346321c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie399179e3b854e06a2b3d719ffa81575_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f73fe9f5f3e400faaf0dbba30e2b6c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if76af73ff9024e19aceae555eb94a4ca_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibdac1bc1d6634022aa3677dde7c770f1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1bab5938a824507be1fe347458f5a16_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id3f92aef188e44c9ba3e6c4cf63228e7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2352e72adbd040919db7f1c7395453a2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib616618f955a41fb961d25698786e446_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i074ffa4e105544b6beba06ccf79db768_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i061c308d6b1a43f0968b363555e92226_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3fb105e15b8b47d9b8839aab9ebd811a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f5bff24d8fb4ded926a6a65685e29e5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3db2f9f0408b4c3b8bc1d23c42421c54_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i41b83b1385d64bb0b4fcdd8478229082_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i08c9f146a507443cbf42d1ec3614ba5a_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="i014594d7c2e34a5ba34aa3612a1cf0fe_D20171101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b05c8d90cf241fe9da5a7dfc1eabd4c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1d511f2c209a4a5aaff9671b49116eb3_I20220411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-11</instant>
        </period>
    </context>
    <context id="i241a969a3e094d03b3d8dd8e7e25cf1e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i82f5715e2fbb4db4a6cd85a32f3fc2f6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if8b1212609cc42c18f655b93c0a406eb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2edefef1531b4386b1099d09c2a70ee0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8f7b4102a4754a8cbae7529a244bf3f5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4597c87af79d4327bdff63f69b57b1ae_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i109c5f1c267e4db584222bf588b29f9b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia7671d7833f84b738c08011e9527d6a6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0bc59163e21d45b0a82ec6a938f3e4fb_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9bfae235b525451e977ec2988b5262e7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0e3965d572ee4aceaf968a9429112520_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifad96d6d72d2427c850a8f4187189002_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie17162477fe2411892bc4d952ca4b3c7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i39c1eb48ebc84ec3b3bdd61a6ce8578c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if1177146d35a4e4da142927eaed0ecc9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i52011fdfd0334a89bcd53e3d6de2b37f_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if3b2a409542f4bc1a83f80b78e672650_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i17126d287de74e979cfde5127eb1da69_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4411ff34351946ec9efc6813633c673b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i97f3b674467b417ab75287cabe20b889_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2de17a790f144efcb20e85eca270e9b7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if2354099a5be4c5f9e83fee570934ba6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2325fcd766374f64b728734271bdcb7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cc77e1d71d74d1a9a74f5ec6a36efde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f865d48364e43feb2428abb54224a8d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie657c8dfb1514308ada6df2d9ee8bf1e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6c552aa84944403c8a3fb465c4b3bc03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieee60570c43f40948f1db4079104e9e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i531d15c78ece4f9a9905d6f96710a74c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i84c7c1add2584109ba82c720ff846b37_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i865d6c576ab546bcbf3614308dda7939_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i87b20fa0c635463cae3c68920d3544be_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2776e4b43d244212bb36a96e1f7f6bf0_D20220628-20220628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-28</startDate>
            <endDate>2022-06-28</endDate>
        </period>
    </context>
    <context id="ic5599d31da844dc09d6e245bda588015_I20220628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-28</instant>
        </period>
    </context>
    <context id="ide6b9c3554974336b19c0254e81adba0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibe07abdbf5b343909ddaf5fb16e06caf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i332a0792bd1f4c0e92d7f1b5cbe65a8e_I20180516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-16</instant>
        </period>
    </context>
    <context id="i45fff355f00f45b192078e143fe5bd5a_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="ibb409ddee548471bb71a3d72714cd69d_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="id7b0db6f01a842ee9808c8aadcd299ed_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i5ca4f47844fc4780baff69e8911b29c0_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i53d431115a854c79807d5f03cee9dc62_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i9fc61d7b192f49609b11da252ff3673e_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i63aef503641b4c29a348a0255e9218d2_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="idf01893ad4c84865891f7430b162cae9_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i5e0099257ff746c4ba0bf0a5c60285a1_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i62823de538114437863d701d8f2af1f0_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i445b8ba0bc314f23b2c6d8f35b42ac79_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic904ee852e2546278f6d6a2a871ab36c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb141ea05dc14bd488bc51b17742bb1b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9edf9296a4894494938a6948e6255770_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6999cc41a5f44cf0a5b525b6303dd7ea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i628699ac92bb4cc4aec87c7221cb6c0e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ef0d267ad3d436b9af9981688d023fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if76ea5067c204fabaac4ade032cb88b0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i01f7c79b7bcf4056b7704b95788cba3b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3004be0bc24d40129c1b7ba07661f272_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02ce57c9f03945a8810129f2967308c3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i016dc6bfae9845e092f75be5637f0b18_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd618c73d00048398fb1fc314aaf0e8a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i65431a25e35a45e890530a699eb3a862_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8a970c46b2e64b9a887463a2644c5079_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1b9eadd78ecf4cbaa95a089d4e6dde72_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id37f41791c3a4469a79f174900a9480a_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i3134b5534dfe4e7488897f77ce075b19_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2020AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7723c20c25bd40d6a71d48a503fa8f2f_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94e0bb25c3c34a6a85f20fb41dddf6e0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib634f3437de24f219bf6e52991431efe_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic965a8cbb9a44f0fae1e69681ba94b33_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i40f8bd2473da4add99b5d428ef128fec_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i03ab1c8385364a98838fa5f372f40780_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7bcb071485841a8932ec94f8a5df8bf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i376a6465db724ab699369fb13e61e824_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icc375ebed1e748e3906510f688eb4df4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id51d0832aa5449abae8f15be39293d79_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1a90b663e53f4f6cb5da4185a20aab45_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1e7d4677dbca464bb097b04e809bdcfc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i69584cc6d6d54ac49447a7432d983409_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id3ca526cfc424a98962ab7e989aefbac_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i8a7e1558c9254a6f8b2556d7cf1b84b3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7dc07daee1204d6c8c91b07672cc6eb4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id703e5f35ca0467cbd70c6dc2f683e5e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i44792157aa014c89a7a354b1be5cd930_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idca1e42204a84d5baa052102db6344f5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i587c8cafb989442c848613b09b327f6e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a3791c5deb445cbbe81a4916add381d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64cb03795f754f9e866d8829eb6f1a18_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i477ce922c8374f6e9d0c3d4093c4654b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib25fb22c28764b7fa0ee953c024cf888_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i217bb17f2bb2437bb698a25f2f589406_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ardx:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>ardx:investment</measure>
    </unit>
    <unit id="item">
        <measure>ardx:item</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="payment_tranche">
        <measure>ardx:payment_tranche</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8wLTEtMS0xLTM0NDkx_41582069-c71c-4105-863e-0f2c501b29e4">0001437402</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8xLTEtMS0xLTM0NDkx_f915e08a-a3e4-4c7d-9e29-c6212949e7e1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8yLTEtMS0xLTM0NDkx_313bfc3a-2d01-4568-882c-f3601e81cacc">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF8zLTEtMS0xLTM0NDkx_48c1b208-0f3b-4800-a23f-a9dd0a306e75">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80L2ZyYWc6ZWEyZTM1ZmY3MzJmNDY4Mzg0NjYyM2JlNTVmNzc2NGUvdGFibGU6NWEwNWUyZDBlNTViNDY2OGEzMDBjMjVhODlkMWFlN2QvdGFibGVyYW5nZTo1YTA1ZTJkMGU1NWI0NjY4YTMwMGMyNWE4OWQxYWU3ZF80LTEtMS0xLTM0NDkx_2dc4a8d3-d7b6-46d2-9b1b-6ac228daffed">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTIy_c4e3ef31-730a-42cf-a5b1-7d48190a4d53">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZTAxM2QwZWYxMWFjNGRhZmIyMmMyMjM3NjNmNmJkMjkvdGFibGVyYW5nZTplMDEzZDBlZjExYWM0ZGFmYjIyYzIyMzc2M2Y2YmQyOV8wLTAtMS0xLTM0NDkx_2fbd49a5-eafb-49e4-8ff7-fc8bcade5071">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8xMzg_3b12cd4a-3cb7-4490-b3cd-9d5b93796ee4">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6OGI0YmJjMTRjMmYxNGUxYzllMDFiYjJiMjA0NTNhYjUvdGFibGVyYW5nZTo4YjRiYmMxNGMyZjE0ZTFjOWUwMWJiMmIyMDQ1M2FiNV8wLTAtMS0xLTM0NDkx_f85a2c52-4a2f-4ca0-b7c3-ec182ea609d3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTA4_02456b81-b142-49c4-886c-f48e19356f3d">001-36485</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTE2_7e4efcca-e81f-4bed-8e70-c4763a900f82">ARDELYX,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6NDFhYWM1NzIwOGQwNDYzMzlmZWIxZGY0Y2Y0OTYzNDkvdGFibGVyYW5nZTo0MWFhYzU3MjA4ZDA0NjMzOWZlYjFkZjRjZjQ5NjM0OV8wLTAtMS0xLTM0NDkx_b5a168b4-2635-4320-9877-c248e1234e22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6NDFhYWM1NzIwOGQwNDYzMzlmZWIxZGY0Y2Y0OTYzNDkvdGFibGVyYW5nZTo0MWFhYzU3MjA4ZDA0NjMzOWZlYjFkZjRjZjQ5NjM0OV8wLTEtMS0xLTM0NDkx_5e01ca68-d25b-4cd7-be2f-b2d2fcf802df">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTE4_e7f239f2-9cd6-4d3f-affb-0cf4c76cfc70">400 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTE0_788e0996-c7c5-4f28-8f8d-f7edf00f06c0">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTEw_fd520245-2a15-4b89-8a03-305b69594739">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTEx_dcca2749-5657-4b26-815e-1943b9251994">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTEy_1f958c37-e99e-457c-8a4c-870901fed4b6">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTI2_f4fe7f1d-e403-4ee4-9833-807e8ef72952">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTI3_58f37f4a-bf08-404a-9346-a7d4e3be539f">745-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6MWY4M2JiMzk1MzhhNDNiYjlmM2Y4NjM3ZjdkZDg5NTEvdGFibGVyYW5nZToxZjgzYmIzOTUzOGE0M2JiOWYzZjg2MzdmN2RkODk1MV8xLTAtMS0xLTM0NDkx_e772c3c8-423a-48cb-af1f-bfdd8be0462c">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6MWY4M2JiMzk1MzhhNDNiYjlmM2Y4NjM3ZjdkZDg5NTEvdGFibGVyYW5nZToxZjgzYmIzOTUzOGE0M2JiOWYzZjg2MzdmN2RkODk1MV8xLTItMS0xLTM0NDkx_134b5605-90b2-4d9c-a5a9-fbdcfa7882a6">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6MWY4M2JiMzk1MzhhNDNiYjlmM2Y4NjM3ZjdkZDg5NTEvdGFibGVyYW5nZToxZjgzYmIzOTUzOGE0M2JiOWYzZjg2MzdmN2RkODk1MV8xLTQtMS0xLTM0NDkx_16379ff4-2915-458a-a3c8-0bbf75d79135">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTA2_789f6d26-9bcc-4202-a473-c81a1a5635ff">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTA3_d0bc1fbe-3732-4c7a-98f7-ad840a297a59">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZmM1OWMzMDJlNjg0NGRlMGE1ZGFiODI4MzUyOTVjNWEvdGFibGVyYW5nZTpmYzU5YzMwMmU2ODQ0ZGUwYTVkYWI4MjgzNTI5NWM1YV8wLTEtMS0xLTM0NDkx_1981d330-4be7-4bbd-8681-c7e1cff0c068">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZmM1OWMzMDJlNjg0NGRlMGE1ZGFiODI4MzUyOTVjNWEvdGFibGVyYW5nZTpmYzU5YzMwMmU2ODQ0ZGUwYTVkYWI4MjgzNTI5NWM1YV8yLTUtMS0xLTM0NDkx_a3844163-48b0-4303-a09e-1431f7a8d2aa">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGFibGU6ZmM1OWMzMDJlNjg0NGRlMGE1ZGFiODI4MzUyOTVjNWEvdGFibGVyYW5nZTpmYzU5YzMwMmU2ODQ0ZGUwYTVkYWI4MjgzNTI5NWM1YV80LTUtMS0xLTM0NDkx_eef4dfbe-9471-414a-9c7c-ef873fbf087f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8xNTk0MjkxODYwNDg4MQ_cdc37160-4d4f-47cd-8a30-496f73da03c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic42c961ec51b4da7be28511c4f3d2bf8_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xL2ZyYWc6NjI2ZGU0ZDNhMzc3NGU1N2E5ZjZkN2UwOTRiMjVhOTIvdGV4dHJlZ2lvbjo2MjZkZTRkM2EzNzc0ZTU3YTlmNmQ3ZTA5NGIyNWE5Ml8yMTAx_5c67716c-0e37-4954-a412-ae288cdc8933"
      unitRef="shares">154635575</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNC0xLTEtMS0zNDQ5MQ_9f0840d4-ce3b-403e-80de-9647ef8bd4c6"
      unitRef="usd">53408000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNC0zLTEtMS0zNDQ5MQ_bb3429b9-437e-4b20-973e-364db749215e"
      unitRef="usd">72428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNS0xLTEtMS0zNDQ5MQ_dbf06ebb-c0d7-4b93-b30f-5a72492f6453"
      unitRef="usd">27604000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNS0zLTEtMS0zNDQ5MQ_a2b1f50d-bde1-41d8-a618-4fd939405ac2"
      unitRef="usd">44261000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNi0xLTEtMS0zNDQ5MQ_b51b4e93-7877-4c57-91f2-15a85c28dac0"
      unitRef="usd">5623000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNi0zLTEtMS0zNDQ5MQ_920486ca-6625-4ee2-afc0-b6a1118bed9c"
      unitRef="usd">502000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNy0xLTEtMS0zNDQ5MQ_b605d2b5-f74c-4878-9b46-2891b45e53e3"
      unitRef="usd">4529000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfNy0zLTEtMS0zNDQ5MQ_0d84837a-c0d6-4cbe-90e6-76f3e5957a65"
      unitRef="usd">0</us-gaap:InventoryNet>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0xLTEtMS0zODUzNg_df543407-b13c-438c-85e5-4a82b70910b3"
      unitRef="usd">17793000</ardx:PrepaidCommercialManufacturingCurrent>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0zLTEtMS0zODUzNg_57440293-8188-4b6a-b784-31656fd74eb2"
      unitRef="usd">9406000</ardx:PrepaidCommercialManufacturingCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0xLTEtMS0zNDQ5MQ_800a62c8-184e-40fc-8430-5c488c2cc371"
      unitRef="usd">5150000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOC0zLTEtMS0zNDQ5MQ_764ab58d-93d3-45ec-8c9a-71edb1e29aef"
      unitRef="usd">7052000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOS0xLTEtMS0zNDQ5MQ_372b6752-ed40-4a9e-92dd-81e26a244021"
      unitRef="usd">114107000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfOS0zLTEtMS0zNDQ5MQ_72309ac1-701f-4a1c-971a-04b350705bd1"
      unitRef="usd">133649000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTAtMS0xLTEtMzQ0OTE_97f9732e-f014-4d5f-8b2a-e7735f8b7c0a"
      unitRef="usd">11054000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTAtMy0xLTEtMzQ0OTE_5e99a41f-33e5-47b8-91da-dd4ea1cbca88"
      unitRef="usd">12752000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTEtMS0xLTEtMzQ0OTE_f389d41a-db6c-4c9b-848c-370ad680404f"
      unitRef="usd">1541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTEtMy0xLTEtMzQ0OTE_77ba357e-61fa-4bd2-ba16-ee85567a30c7"
      unitRef="usd">2362000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTMtMS0xLTEtMzQ0OTE_1e6dfc1e-c21c-4499-a72b-89a693bdd424"
      unitRef="usd">4908000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTMtMy0xLTEtMzQ0OTE_45871ea9-ea00-4eba-92ec-d782412a984b"
      unitRef="usd">1150000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTQtMS0xLTEtMzQ0OTE_dad28d8b-d2b3-46ea-9b77-25f9d9a465d8"
      unitRef="usd">131610000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTQtMy0xLTEtMzQ0OTE_fced2891-e16b-4696-bdc9-3190d1ebcda3"
      unitRef="usd">149913000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTctMS0xLTEtMzQ0OTE_36d9a904-7633-4ea0-943d-e9395618f909"
      unitRef="usd">4294000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTctMy0xLTEtMzQ0OTE_3f1e775e-1d0f-4266-81d0-40c5802266e9"
      unitRef="usd">4277000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTgtMS0xLTEtMzQ0OTE_43a5404c-93e5-4a9e-b29a-ea4c6b3fcc46"
      unitRef="usd">6405000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTgtMy0xLTEtMzQ0OTE_778cb081-f59a-4b14-bc80-7216da312857"
      unitRef="usd">5422000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTktMS0xLTEtMzQ0OTE_3d0bb846-4248-4d91-a35c-36b69da3cb23"
      unitRef="usd">26373000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMTktMy0xLTEtMzQ0OTE_56428996-a975-4046-8b8f-f837511a6ce0"
      unitRef="usd">32264000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjAtMS0xLTEtMzQ0OTE_e181313e-de54-4b05-b56a-9e3c5784948d"
      unitRef="usd">3691000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjAtMy0xLTEtMzQ0OTE_12059b39-00de-4b1d-bfbd-7dc93a4e58c2"
      unitRef="usd">3492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjItMS0xLTEtMzQ0OTE_a914b1ce-ca42-46aa-9025-e1e6e052d694"
      unitRef="usd">7936000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjItMy0xLTEtMzQ0OTE_67cece8d-ad97-43c1-acc4-b9000e2b6108"
      unitRef="usd">7366000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjMtMS0xLTEtMzQ0OTE_6f2afefc-4cef-4f64-9c6f-2cef64ba16a1"
      unitRef="usd">48699000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjMtMy0xLTEtMzQ0OTE_d967b7f9-9dbe-4974-abcd-6cd02df70413"
      unitRef="usd">52821000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjQtMS0xLTEtMzQ0OTE_5d613b07-c6a5-447e-bcd4-cb916646be03"
      unitRef="usd">7857000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjQtMy0xLTEtMzQ0OTE_a5966eab-1822-495b-a140-932639e57a9e"
      unitRef="usd">9748000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjYtMS0xLTEtMzQ0OTE_be16afe7-616d-4e2b-97f0-7d1ba0ce688e"
      unitRef="usd">12421000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjYtMy0xLTEtMzQ0OTE_ea16eb31-9b90-4d45-8a93-87a2952a56df"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:DeferredRoyaltyObligationNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMS0xLTEtMzcwOTI_34f7e468-2002-4f0e-8cd4-12a693ae005c"
      unitRef="usd">9591000</ardx:DeferredRoyaltyObligationNoncurrent>
    <ardx:DeferredRoyaltyObligationNoncurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMy0xLTEtMzcwOTI_e9cdd6e7-f9b4-406c-a371-d178f19f13bb"
      unitRef="usd">0</ardx:DeferredRoyaltyObligationNoncurrent>
    <us-gaap:Liabilities
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMS0xLTEtMzQ0OTE_15807e7e-4e3d-45e9-b9c4-0b39c155c5b7"
      unitRef="usd">78568000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjctMy0xLTEtMzQ0OTE_6b7d4fa0-e5f9-4ac6-a78d-84d7daba8bc9"
      unitRef="usd">67296000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjgtMS0xLTEtMzQ0OTE_8c52f106-e7cd-40d4-b42d-0a0c93f78774"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMjgtMy0xLTEtMzQ0OTE_27d8bc99-0baf-4177-a637-f3c276d79b22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8yMQ_05f813cc-ddce-48ea-bdc9-46c3256755d3"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8yMQ_e18b76cc-cba6-4fa3-8c8c-cb82c7459ddc"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8zNQ_5a8b1fe8-bcb5-485a-b8a3-ac16f7c24daa"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF8zNQ_a7f066d6-00d6-485b-bde1-9bce0f1efbe0"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_0d752b80-1e5f-4c04-9030-225392fac411"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_15452dfa-8af3-481c-8de4-5d69b33f164f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_ab793585-3d5b-4dab-b09c-8c7f014407be"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMzE1YjllMTk3Mjc0ZjgzOGI2NDViNGJjNmVkZDhjMF81Nw_dca2bf34-8d66-4adf-a23e-f22c3035353c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMS0xLTEtMzQ0OTE_56107cc2-b91f-41c8-bd06-e1297ee4698c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzAtMy0xLTEtMzQ0OTE_56eb7c6a-76c3-4dc7-a634-19423873ed6b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8xOA_37b9837e-d777-4f81-a729-e3e2af1b805f"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8xOA_b83bda73-3341-484a-8004-5f2110ca9754"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8zMg_3e4d2152-9fe9-4362-a2cd-1281d88dbef2"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV8zMg_40b9e5e4-6790-459b-8cad-760606fab5c9"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV81NA_c5c688b7-4619-4e51-84e7-ba5fb76a398d"
      unitRef="shares">153797834</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV81NA_dac16394-e47d-4a16-a0ce-7d75613fc975"
      unitRef="shares">153797834</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV82MQ_483e4090-e116-48f0-9a92-4e35b97d2fdc"
      unitRef="shares">130182535</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMC0xLTEtMzQ0OTEvdGV4dHJlZ2lvbjpmMGQ4ODBhNWY0Yzg0NTA3YTE3MDNlMjllMTllZDk3YV82MQ_e1638a59-efea-4df0-8d6b-5201ac31a891"
      unitRef="shares">130182535</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMS0xLTEtMzQ0OTE_96fdb94f-a797-42df-80de-d46bf53d6e85"
      unitRef="usd">15000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzEtMy0xLTEtMzQ0OTE_48738efb-10d3-4742-9876-14bcd04ac0cb"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzItMS0xLTEtMzQ0OTE_02e0212f-c15a-4431-917b-da002731b641"
      unitRef="usd">821075000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzItMy0xLTEtMzQ0OTE_700c0f87-02cc-4385-bd63-6067661b78fa"
      unitRef="usd">795540000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzMtMS0xLTEtMzQ0OTE_e33d85a0-b106-4268-a0c5-16cabbe01382"
      unitRef="usd">-767939000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzMtMy0xLTEtMzQ0OTE_9e626715-5a98-405f-aa46-3e1ede41baf0"
      unitRef="usd">-712930000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzQtMS0xLTEtMzQ0OTE_7cf2aaf8-b983-475d-b740-2787cd0842d4"
      unitRef="usd">-109000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzQtMy0xLTEtMzQ0OTE_760a349e-fda5-4fec-b331-e17487ebfee9"
      unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzUtMS0xLTEtMzQ0OTE_568f98b3-0ba0-412a-84ef-cb3c30808485"
      unitRef="usd">53042000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzUtMy0xLTEtMzQ0OTE_9be5dd3f-2592-4c8f-820a-5cfadb3ed134"
      unitRef="usd">82617000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzYtMS0xLTEtMzQ0OTE_3f012277-43c2-4fb5-8c5c-e06b780fb7e7"
      unitRef="usd">131610000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xOS9mcmFnOjdiZTBmYzIwMzFmZjRiN2Y4NjZjMDI1OTNiNTJlNmIyL3RhYmxlOjE5ZWIwMWQyYWZlYTQzNmNiMTY3NjBhZDZjMDk4YTJiL3RhYmxlcmFuZ2U6MTllYjAxZDJhZmVhNDM2Y2IxNjc2MGFkNmMwOThhMmJfMzYtMy0xLTEtMzQ0OTE_6d1a82da-aac8-4e4a-af7a-4b301851e197"
      unitRef="usd">149913000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c30f784a20e41f48388f279f3478ef5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy0xLTEtMS0zNDQ5MQ_240c7e9f-9e09-45cf-9333-9bc4053cc88b"
      unitRef="usd">1564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17ad1002e42841d9bab8e33e821c520d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy0zLTEtMS0zNDQ5MQ_779b449b-6684-4fee-b068-9ea74b197aaf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d6d660504cb4967842be9bac1eb88e4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy01LTEtMS0zNDk0OQ_609a38e4-4f53-4979-b797-2417cada3a8e"
      unitRef="usd">2014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee6cf208bb934fc49b584ea377c5e697_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMy03LTEtMS0zNDk1Ng_960754ce-ba3e-46b1-bd51-335c9996f07c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75815f35266949a29b3779fbb6a155e2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS0xLTEtMS0zNDQ5MQ_02e78205-c8f3-43c2-aab5-d79f00c641cf"
      unitRef="usd">952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1348d1b675c4c8fbd7e09f627729c65_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS0zLTEtMS0zNDQ5MQ_b8f7bd41-f128-4466-960f-4d40e78d38c9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62030e5413144b8da56fee20836acd17_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS01LTEtMS0zNDk0OQ_e7943d53-0a51-4d82-a328-62f509c0f823"
      unitRef="usd">966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife16787b966e4f1ba8c452d2912d6b30_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNS03LTEtMS0zNDk1Ng_e216d5c4-5fea-4a11-bbde-fbe0ca8bd525"
      unitRef="usd">126000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c16a53c2ab74e3c9596e3f257e27abc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi0xLTEtMS0zNDQ5MQ_95e3082a-8126-433e-9109-f451b66123d9"
      unitRef="usd">10000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5df73e23a8cd48398fd1fd77c2ae2509_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi0zLTEtMS0zNDQ5MQ_4685d461-cb2e-4f8d-8cb6-5bd250a6d736"
      unitRef="usd">3000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc595528aca44fe8a51c84f136bb9823_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi01LTEtMS0zNDk0OQ_4898cb55-acb5-41c0-b297-fab8d5345fd4"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac43667a5f074d89b417e46787302ea0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNi03LTEtMS0zNDk1Ng_8acae107-2241-4d75-935e-00a759c174aa"
      unitRef="usd">5005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec5a8885f6cc40b48afbb753f9d28972_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0xLTEtMS0zNjk3Mg_dc4a55b0-0eb5-4458-b259-7c2ca364a440"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25246860a01e4ce8a406bd0535351adb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0zLTEtMS0zNjk3Mg_2b7b0b98-765a-40af-86b8-c2506338a579"
      unitRef="usd">1310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2331fd10761b45e8ab1788d9ee7c5ba7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy01LTEtMS0zNjk3Mg_26712d15-fd71-4545-bf46-98cb82c701ef"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic11b54c731dd476a84fa52d445b2970d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy03LTEtMS0zNjk3Mg_a7a05fca-e28f-4c89-9d6e-901ab15cb23c"
      unitRef="usd">2764000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0xLTEtMS0zNDQ5MQ_6c6b7e85-9774-4362-88ad-eeb04ccfe4a0"
      unitRef="usd">2526000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy0zLTEtMS0zNDQ5MQ_98205615-5a09-4612-bd6f-c9738460d13a"
      unitRef="usd">1313000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy01LTEtMS0zNDk0OQ_e1bc8ba4-92b0-45c3-84b2-76b413f7775f"
      unitRef="usd">2994000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfNy03LTEtMS0zNDk1Ng_213a7026-1714-4514-a8d3-e3a3d3d6237e"
      unitRef="usd">7895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS0xLTEtMS0zNDQ5MQ_9228e1bd-1ddd-482f-8e79-4da6910402ad"
      unitRef="usd">138000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS0zLTEtMS0zNDQ5MQ_a708698c-6a74-42b2-b655-37ac5604b835"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS01LTEtMS0zNDk0OQ_9ea0af40-f7a7-4e99-812f-55b4adbca0b8"
      unitRef="usd">223000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfOS03LTEtMS0zNDk1Ng_e8191292-f3cf-4eb0-965c-297a89407f53"
      unitRef="usd">1000000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtMS0xLTEtMzQ0OTE_0e075f89-27e5-485b-9604-bb87ef6ac6f6"
      unitRef="usd">9741000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtMy0xLTEtMzQ0OTE_4a3db4be-2e73-4fa9-9d3e-fecf5a554511"
      unitRef="usd">26021000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtNS0xLTEtMzQ5NDk_2c6fa47b-b44a-47f3-ac7d-b08173480821"
      unitRef="usd">18592000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTAtNy0xLTEtMzQ5NTY_05f729c4-3364-4c04-9d79-e7f6772a5aeb"
      unitRef="usd">46477000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtMS0xLTEtMzQ0OTE_e20ab77c-b267-4d53-b596-ae4438a93653"
      unitRef="usd">18862000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtMy0xLTEtMzQ0OTE_5b782854-515f-4720-bf57-ef41c232618a"
      unitRef="usd">20124000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtNS0xLTEtMzQ5NDk_70cbf4d4-c5cd-4369-8e36-015c45b949b1"
      unitRef="usd">38201000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTEtNy0xLTEtMzQ5NTY_760df076-a61d-4a2a-b9b4-a73d62e6747c"
      unitRef="usd">37255000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItMS0xLTEtMzQ0OTE_8b75722b-20b8-4a2a-9ce2-d4e9d7c01f93"
      unitRef="usd">28741000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItMy0xLTEtMzQ0OTE_5372efb5-e48d-4b46-80be-fc82bec5eddd"
      unitRef="usd">46145000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItNS0xLTEtMzQ5NDk_853f0f42-be33-4c0a-a468-8ab493d1408a"
      unitRef="usd">57016000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTItNy0xLTEtMzQ5NTY_f167fdc1-fd5a-4e5a-a75b-7c8ab2014128"
      unitRef="usd">84732000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtMS0xLTEtMzQ0OTE_cff03338-56c8-43cb-8aef-19a54d8e7e59"
      unitRef="usd">-26215000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtMy0xLTEtMzQ0OTE_50b2f110-9fc5-467c-a8c3-2ef0a56c7a95"
      unitRef="usd">-44832000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtNS0xLTEtMzQ5NDk_60160b1c-60ac-49df-b9c3-bc7c1dfb60c2"
      unitRef="usd">-54022000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTMtNy0xLTEtMzQ5NTY_34746de1-60ee-4233-a12a-50289d7cceb8"
      unitRef="usd">-76837000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtMS0xLTEtMzQ0OTE_0acacaa5-48fc-43be-b5fa-7332224d31c3"
      unitRef="usd">787000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtMy0xLTEtMzQ0OTE_e54f4e38-e112-44fc-b0e6-24ddffae08ae"
      unitRef="usd">1202000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtNS0xLTEtMzQ5NDk_5cfa50cf-2730-48b2-a656-5f95a002b252"
      unitRef="usd">1533000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTQtNy0xLTEtMzQ5NTY_f207e211-78d8-44d6-bf89-81309e55f66c"
      unitRef="usd">2302000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtMS0xLTEtMzQ0OTE_8ab53a34-85ae-4c46-a842-c57c7739b45f"
      unitRef="usd">70000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtMy0xLTEtMzQ0OTE_2ea16195-32a8-47bc-bfad-64b97b270cde"
      unitRef="usd">847000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtNS0xLTEtMzQ5NDk_5b6d28e5-4c33-4816-985c-2548589d4487"
      unitRef="usd">554000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTUtNy0xLTEtMzQ5NTY_69b918cb-f5c2-4333-9b51-4a9de84968c7"
      unitRef="usd">798000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtMS0xLTEtMzQ0OTE_3347d077-e6e5-43ce-ba88-2476ddfde88d"
      unitRef="usd">-26932000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtMy0xLTEtMzQ0OTE_a8e96f33-afff-46ae-8dc8-c30f38140ff0"
      unitRef="usd">-45187000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtNS0xLTEtMzQ5NDk_a7f0c31a-73a3-4ad7-86bb-5cf0f5b395bf"
      unitRef="usd">-55001000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTYtNy0xLTEtMzQ5NTY_7baaa5a4-a0f3-4231-b5fa-6b155ece47da"
      unitRef="usd">-78341000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctMS0xLTEtMzQ0OTE_d00c5bb1-16e1-4a79-ae14-b6639cb4bae1"
      unitRef="usd">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctMy0xLTEtMzQ0OTE_e7094ba9-6b98-4356-b920-e2d191ea9f53"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctNS0xLTEtMzQ5NDk_285cab84-897a-4ec1-8bca-11cd549e6367"
      unitRef="usd">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTctNy0xLTEtMzQ5NTY_d84b59a3-61ad-4e73-8d0c-4cc85ba535f6"
      unitRef="usd">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtMS0xLTEtMzQ0OTE_a5507ae7-1ff4-4bd5-b73b-c046f62f62a8"
      unitRef="usd">-26938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtMy0xLTEtMzQ0OTE_b2f040cb-a547-4e34-b731-03ffa310aee2"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtNS0xLTEtMzQ5NDk_a22ed643-2d9d-4df0-a376-23f67e91eb0b"
      unitRef="usd">-55009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTgtNy0xLTEtMzQ5NTY_a8c47182-4d98-44be-a27f-3bccb03d62d1"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMS0xLTEtMzQ0OTE_34f42e4c-771a-49fd-b885-107a73909437"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMS0xLTEtMzQ0OTE_bc34697c-d2a8-4719-a582-7d72cfc6c817"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMy0xLTEtMzQ0OTE_06614748-e63c-4bd5-9583-f104ced31505"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktMy0xLTEtMzQ0OTE_a0e5729b-70d9-4b84-a1b0-0ce9b5ede6d4"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNS0xLTEtMzQ5NDk_3a4c7bb8-b47b-4d2e-9b20-7a6943fa4596"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNS0xLTEtMzQ5NDk_76916180-3191-4e28-a1a1-c3f41f644fd0"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNy0xLTEtMzQ5NTY_2ec8220e-c881-4180-9aaa-22229778acbf"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMTktNy0xLTEtMzQ5NTY_769ac6b5-647a-4351-94db-9eae19078ef5"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMS0xLTEtMzQ0OTE_0ba2abb7-bdf3-4c65-8dd9-dfc24fe754ad"
      unitRef="shares">145544372</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMS0xLTEtMzQ0OTE_65d4a0bf-22c3-4c1c-b82d-2d13d2bf5a37"
      unitRef="shares">145544372</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMy0xLTEtMzQ0OTE_3efc2eb0-5f2d-4a64-beab-7de15f77575f"
      unitRef="shares">100040083</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtMy0xLTEtMzQ0OTE_5e569a4e-3a23-491e-b662-0eda4553cc9a"
      unitRef="shares">100040083</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNS0xLTEtMzQ5NDk_7dacb971-f4a0-43d6-bc01-222439a6b5ff"
      unitRef="shares">138279945</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNS0xLTEtMzQ5NDk_ba51b3db-f879-4900-9e26-ccb9adfcd226"
      unitRef="shares">138279945</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNy0xLTEtMzQ5NTY_c2c3df68-271f-4bd2-b69c-aeff48b10b92"
      unitRef="shares">98617564</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjAtNy0xLTEtMzQ5NTY_dfa420b8-e531-4309-a55c-2e4e02d08665"
      unitRef="shares">98617564</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItMS0xLTEtMzQ0OTE_4bb3e792-345e-4570-9346-3c905c503a09"
      unitRef="usd">-26938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItMy0xLTEtMzQ0OTE_6007e2fe-1247-4f49-9302-a912af97818d"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItNS0xLTEtMzQ5NDk_a47b9f65-1f21-4a36-bc2e-813d17b46ff9"
      unitRef="usd">-55009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjItNy0xLTEtMzQ5NTY_a2ea05e6-b52e-406c-af70-d6459ac51c33"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtMS0xLTEtMzQ0OTE_3de25bfd-d4fc-4e57-bfe0-abb677de4797"
      unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtMy0xLTEtMzQ0OTE_e769a157-7fc7-419b-a6d6-ecaeb4343082"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtNS0xLTEtMzQ5NDk_2ba1c50e-1eb0-4e13-9214-9b720826361a"
      unitRef="usd">-103000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjMtNy0xLTEtMzQ5NTY_7b2494c6-1eb3-4f6c-9f33-e25b3e4eb8b4"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtMS0xLTEtMzQ0OTE_97b937f3-d20e-439d-85e8-71da7a8e31ff"
      unitRef="usd">-26959000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtMy0xLTEtMzQ0OTE_cd79f43e-f81e-40ce-9c69-eb733dbb42d1"
      unitRef="usd">-45178000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtNS0xLTEtMzQ5NDk_63fc7b7a-5536-4fa0-a2b7-083114a7f8f7"
      unitRef="usd">-55112000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yMi9mcmFnOjk2YWYzNWQ1MDliZjRiYTZhZGRkNzUzODUxM2E0YTNjL3RhYmxlOmM2YThlOTNmNDYxNjQ0ZTZiMDcwNDRkNGUzYmRkYzQ1L3RhYmxlcmFuZ2U6YzZhOGU5M2Y0NjE2NDRlNmIwNzA0NGQ0ZTNiZGRjNDVfMjQtNy0xLTEtMzQ5NTY_2d1a658d-d24b-4726-a61e-18c14e0e5ba7"
      unitRef="usd">-78336000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="idc6178b87a754bb0aac958078486483a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy0xLTEtMS0zNDQ5MQ_afa8c6e9-1b10-482d-8452-6caf65ae3a23"
      unitRef="shares">136330360</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idc6178b87a754bb0aac958078486483a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy0zLTEtMS0zNDQ5MQ_00d7a5e9-e85c-4e90-a820-03e459cc5d1d"
      unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i000a94b69f67402186a7b726e453f414_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy01LTEtMS0zNDQ5MQ_f013d141-794c-4f1b-b89e-16ba6c10a5e5"
      unitRef="usd">805265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e8875e4fffd4e17af63c26d11313c23_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy03LTEtMS0zNDQ5MQ_4e7b69c3-c7ab-40fa-8c61-de89c9c33063"
      unitRef="usd">-741001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8d3cb0dd153487c96f8b541818106a3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy05LTEtMS0zNDQ5MQ_8e9630f9-9f76-4359-82ae-2a96069aeecb"
      unitRef="usd">-88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5affa987ee348868a5c35901b6e126d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMy0xMS0xLTEtMzQ0OTE_b93b9538-32f7-402f-8304-2ac856fe8584"
      unitRef="usd">64190000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if4b48a67d777408085c1b46cc926756a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfNy0xLTEtMS0zNDQ5MQ_df146825-ac0f-4e2c-bbf7-daada94f9b5e"
      unitRef="shares">2882673</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if4b48a67d777408085c1b46cc926756a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS0xLTEtMS0zNDQ5MQ_ea25bfc4-130b-4123-bae0-3c11c33f9417"
      unitRef="shares">14584801</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if4b48a67d777408085c1b46cc926756a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS0zLTEtMS0zNDQ5MQ_73598ce3-8004-4c4e-b4ab-269d7813ed32"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iddd7db5c29bf4b818592913bccc1a693_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS01LTEtMS0zNDQ5MQ_7c9d28a5-af60-4b63-b6fd-dc60ef81cd40"
      unitRef="usd">12556000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfOS0xMS0xLTEtMzQ0OTE_3b4f40ea-933e-4d9b-8366-27a34b8eee1c"
      unitRef="usd">12557000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iddd7db5c29bf4b818592913bccc1a693_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTAtNS0xLTEtMzQ0OTE_bb750e0b-3f11-40fa-8cbc-8ea0e9cb5c93"
      unitRef="usd">3254000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTAtMTEtMS0xLTM0NDkx_a50fe046-dc23-4977-8fab-0326d836107d"
      unitRef="usd">3254000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if2404930cb5c4c28b0452e3a33a5c82b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTEtOS0xLTEtMzQ0OTE_571a144d-2e56-4288-a520-9acf4dddfe62"
      unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTEtMTEtMS0xLTM0NDkx_2b1fb6e6-f54e-481d-834a-116db5581116"
      unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i78670b3ace5c4eafbbf72ad5cef50839_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTItNy0xLTEtMzQ0OTE_36863159-ea9d-45ad-a188-0e7853ba078d"
      unitRef="usd">-26938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTItMTEtMS0xLTM0NDkx_4871e876-fc55-463e-b3f6-7b6280f26a4f"
      unitRef="usd">-26938000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtMS0xLTEtMzQ0OTE_a5b22e5f-c05d-4031-8144-af49a1a341f8"
      unitRef="shares">153797834</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtMy0xLTEtMzQ0OTE_3c585ced-61f6-4dc0-86d4-80fb72cc3152"
      unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52f57530b34948d4b13553903ed1228a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtNS0xLTEtMzQ0OTE_dfe941a5-9f06-4633-b7fa-eb8db0af2752"
      unitRef="usd">821075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f7c7622a396409e8e8df165f90e798e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtNy0xLTEtMzQ0OTE_5e2d8c4d-cd8f-40e7-b898-b7a68d9079a3"
      unitRef="usd">-767939000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0ea209d52b54b31a2dbc3d0c55488d5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtOS0xLTEtMzQ0OTE_78fac055-fbb5-4fa6-a6c2-bd8124390cc4"
      unitRef="usd">-109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmUwNjc1YWFjMjRjNDQ4ZDg5ODJhM2ZmNTM5ODg0YzdmL3RhYmxlcmFuZ2U6ZTA2NzVhYWMyNGM0NDhkODk4MmEzZmY1Mzk4ODRjN2ZfMTMtMTEtMS0xLTM0NDkx_58e5b77e-3cb3-43b4-a4ab-d0d1c5d05645"
      unitRef="usd">53042000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="id77ff45716224c199ae858f37147e3e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy0xLTEtMS0zNDk4NQ_3143acca-97cb-4b9c-94dd-d6af8eac4cc8"
      unitRef="shares">130182535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id77ff45716224c199ae858f37147e3e6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy0zLTEtMS0zNDk4NQ_096f0737-8358-45aa-ac8f-901a5e1e9c14"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i218e21332806486fa073f409c125d1f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy01LTEtMS0zNDk4NQ_5f40589c-d91a-4864-bef2-efcc5dd6939b"
      unitRef="usd">795540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b0d3d8ab19b4d71a852ccd289222b57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy03LTEtMS0zNDk4NQ_43ca8a86-7083-40f5-8ef2-e55e15e9bdd9"
      unitRef="usd">-712930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab00f1a29e0a43e7b11d43bd6cc9c687_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy05LTEtMS0zNDk4NQ_bf37b221-6c0e-42c7-808a-bbc2cf38b8f3"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMy0xMS0xLTEtMzQ5ODU_ad353276-fce7-4d3f-bfbd-4d6ebb650350"
      unitRef="usd">82617000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNC0xLTEtMS0zNDk4NQ_bb84b861-12fb-4ff9-87e4-f7d337f6ce3a"
      unitRef="shares">127100</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNC01LTEtMS0zNDk4NQ_22fa3c14-e6cf-4ee5-8ea4-d92a2f40294a"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNC0xMS0xLTEtMzQ5ODU_e67d08f3-1717-4c0d-bdeb-47070a7f2c87"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfNy0xLTEtMS0zNDk4NQ_161bd314-5465-412a-a880-cfaddce17b57"
      unitRef="shares">2996142</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS0xLTEtMS0zNDk4NQ_f030517c-4c1a-4d26-8fe8-4a00a60ffec4"
      unitRef="shares">20492057</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i10528fa7ec994c7daa9d565fd723bec2_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS0zLTEtMS0zNDk4NQ_5f2d65f2-dd02-446a-9ca5-109efe3bf7ab"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS01LTEtMS0zNDk4NQ_b9d4d0d4-d9a2-43a4-bf42-6551fe68253a"
      unitRef="usd">18476000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfOS0xMS0xLTEtMzQ5ODU_4dbac830-d37f-4e1f-a45a-514f0d200a9e"
      unitRef="usd">18478000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i42a61bdcb7ed4a239ed8c4fcfc4efb4e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTAtNS0xLTEtMzQ5ODU_d0357333-0264-4cc5-90b8-4e734cdbd3c9"
      unitRef="usd">6976000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTAtMTEtMS0xLTM0OTg1_a421081c-007d-4b75-80a8-ae5dc0b69f14"
      unitRef="usd">6976000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i73d56614ba724a608da48861a3cf60c9_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTEtOS0xLTEtMzQ5ODU_fea41417-1f3e-4e72-9c47-eaae627b544d"
      unitRef="usd">-103000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTEtMTEtMS0xLTM0OTg1_9642f5df-7274-4a63-84ce-0e5241bdd6c4"
      unitRef="usd">-103000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ic6e08a98a1064d38b01236bc993f4f9b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTItNy0xLTEtMzQ5ODU_e8024b44-0f38-471b-8fff-d3d1146316b2"
      unitRef="usd">-55009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTItMTEtMS0xLTM0OTg1_76b9489f-4b66-44af-bb29-cbcf2accafa5"
      unitRef="usd">-55009000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtMS0xLTEtMzQ5ODU_d03ef4e0-931a-4902-8082-fa01c4375dd7"
      unitRef="shares">153797834</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib18818a41172419da6aa45c9edf9817e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtMy0xLTEtMzQ5ODU_7a4e2655-e131-43e3-9ea0-69150684b4f1"
      unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52f57530b34948d4b13553903ed1228a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtNS0xLTEtMzQ5ODU_62fe4198-410a-4044-8d6a-758638c027be"
      unitRef="usd">821075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f7c7622a396409e8e8df165f90e798e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtNy0xLTEtMzQ5ODU_4f1ac15b-a767-480c-9f4d-584d872d25dc"
      unitRef="usd">-767939000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0ea209d52b54b31a2dbc3d0c55488d5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtOS0xLTEtMzQ5ODU_e90b28b2-8b1f-473e-a5d7-bbfb459ccc54"
      unitRef="usd">-109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOmRhZWFhNzFmZDk3MjRhYThhMzgyNWYyOWVkMjNmZThjL3RhYmxlcmFuZ2U6ZGFlYWE3MWZkOTcyNGFhOGEzODI1ZjI5ZWQyM2ZlOGNfMTMtMTEtMS0xLTM0OTg1_58f1f182-c571-46b0-a7d7-045bdf8f0fb8"
      unitRef="usd">53042000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib0e0592cff724331842e40befa20fd69_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy0xLTEtMS0zNDQ5MQ_98c1c996-dc6d-4610-aafb-49c4b5ea9ab8"
      unitRef="shares">98688577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib0e0592cff724331842e40befa20fd69_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy0zLTEtMS0zNDQ5MQ_9517c72e-45b1-45f8-91ef-059893039384"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31c6d8d5f1a34f37a1f54a5a716efd5a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy01LTEtMS0zNDQ5MQ_64d1a34f-105a-4dc7-8aeb-b9d94e427815"
      unitRef="usd">718728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5fd458ec42704888b7569b9c391b5347_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy03LTEtMS0zNDQ5MQ_3b2e7b06-5c4e-4e7d-9bcc-8e3beb9b94e7"
      unitRef="usd">-587920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i164a573f629b464f8fdb0ab0b4582249_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy05LTEtMS0zNDQ5MQ_5728a5b3-c7f5-4bc9-a6d7-ef2d8476b3b7"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie93085e99e934f89baf533a6a0eceafc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMy0xMS0xLTEtMzQ0OTE_3719d1b9-ad6c-4730-b79a-a6a62b6ddae2"
      unitRef="usd">130811000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNi0xLTEtMS0zNDQ5MQ_26b1ebd7-44b3-4fdd-a40c-94cc9f0acbc8"
      unitRef="shares">194799</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNi01LTEtMS0zNDQ5MQ_741ab92a-db35-46fd-92c3-ba1b0b03fd62"
      unitRef="usd">543000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNi0xMS0xLTEtMzQ0OTE_1041c39c-758e-4c59-b314-9e948f65b03d"
      unitRef="usd">543000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfNy0xLTEtMS0zNDQ5MQ_4bb3164a-cc17-4cc7-a90d-6601fc9de49d"
      unitRef="shares">44684</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia7c8bc93ba034666ba5163c5036a3aa2_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOC0xLTEtMS0zNDQ5MQ_c6feb876-f00d-4428-9572-4496b51dd5ee"
      unitRef="shares">4038957</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOC01LTEtMS0zNDQ5MQ_b98d8c4a-d8d2-4220-b530-6c651e4bc2d2"
      unitRef="usd">28174000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOC0xMS0xLTEtMzQ0OTE_37838ae5-1fff-4c0c-9328-de62bac0b078"
      unitRef="usd">28174000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie1e0dbf0ae664475a9056f6fbd09a716_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOS01LTEtMS0zNDQ5MQ_4c3cd2e9-8a0e-442e-b1b5-465bab246b13"
      unitRef="usd">3219000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfOS0xMS0xLTEtMzQ0OTE_695c9433-8a82-46ea-9a4c-3fb3a9e16005"
      unitRef="usd">3219000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5f167f86b3554775a6ecae909a898b9e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTAtOS0xLTEtMzQ0OTE_0b70f723-57a4-4cff-ad70-904957a33944"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTAtMTEtMS0xLTM0NDkx_0ee9bc7e-6dac-42f5-8db9-ba5a9e862289"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ib501b2d7888048ad8bab2aff0a7e49bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTEtNy0xLTEtMzQ0OTE_16339ecf-a8ca-4880-9315-d4c051374a1c"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTEtMTEtMS0xLTM0NDkx_2efb21e7-ecba-4aae-8fb9-2800b2b9d5db"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItMS0xLTEtMzQ0OTE_4cfb543a-7fbf-4e97-9874-426de9ccf665"
      unitRef="shares">102967017</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItMy0xLTEtMzQ0OTE_f2b73afa-ddc6-44d3-80d7-1e85cda58849"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0108f558055448982ef3a107a546127_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItNS0xLTEtMzQ0OTE_3ed6af48-0003-44f0-bd54-4d68d2ba1857"
      unitRef="usd">750664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic4f3c74aea044471bfd38a37ede1fd57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItNy0xLTEtMzQ0OTE_296253f4-e70e-4c62-a605-18a0f8a3b70f"
      unitRef="usd">-633109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id537ef3aea1f4e00b37077b727741777_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItOS0xLTEtMzQ0OTE_010acd79-e90c-4324-9eeb-caab6ba418ce"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjFmNGRiNzI5NWQyODQyNzk5MzRjODU5OWU5NzlhMGJmL3RhYmxlcmFuZ2U6MWY0ZGI3Mjk1ZDI4NDI3OTkzNGM4NTk5ZTk3OWEwYmZfMTItMTEtMS0xLTM0NDkx_85a25e92-1f93-40b4-8751-dcaa766a511b"
      unitRef="usd">117569000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="if50bec065c1f4bf58f6a04567d2d85b9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy0xLTEtMS0zNDQ5MQ_f807b6e1-48d3-4600-b8ef-3adc4536de9f"
      unitRef="shares">93599975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if50bec065c1f4bf58f6a04567d2d85b9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy0zLTEtMS0zNDQ5MQ_372b30fd-06f0-4e22-bef1-8812a57ac677"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i568c1373e0354d5aa5dd964481012f03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy01LTEtMS0zNDQ5MQ_14bf56af-2f53-458b-91a7-d61beb25e580"
      unitRef="usd">680872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9078c496b28549dc88394c6f9e3f5bd9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy03LTEtMS0zNDQ5MQ_075a90aa-28a4-4bc9-bab0-b1ae63d06c0c"
      unitRef="usd">-554765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e77cc73f998468495a6a26b87a2a968_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy05LTEtMS0zNDQ5MQ_b6c644d2-5316-495d-a9e4-4587331ac58a"
      unitRef="usd">-4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a43b3062ca24536868bd6a62ace2205_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMy0xMS0xLTEtMzQ0OTE_4c153032-745b-41fe-8e14-30cfac3a0204"
      unitRef="usd">126112000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNC0xLTEtMS0zNDQ5MQ_8d272ccc-9951-4062-bc2d-3fabc767641e"
      unitRef="shares">102208</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNC01LTEtMS0zNDQ5MQ_632e0fe8-3379-4dcd-b8f6-ade97d9bb28f"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNC0xMS0xLTEtMzQ0OTE_b25045dc-49ba-4aa2-8329-dcd8f7d7e15c"
      unitRef="usd">478000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNi0xLTEtMS0zNDQ5MQ_6a2b00aa-18c3-4454-888b-065b66165f48"
      unitRef="shares">205306</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNi01LTEtMS0zNDQ5MQ_8f5b419f-2f7a-4cb4-b30e-62b875c966dc"
      unitRef="usd">563000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNi0xMS0xLTEtMzQ0OTE_8bed0cbc-c841-4932-a87d-e2746aa39e18"
      unitRef="usd">563000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfNy0xLTEtMS0zNDQ5MQ_c801c495-a678-4a4d-a78d-fb394382662a"
      unitRef="shares">79784</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS0xLTEtMS0zNDQ5MQ_b37989cc-8d5c-4d62-a5b2-717ac8a357c0"
      unitRef="shares">8979744</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6c8a4856b3f848ccaf2fd0e4158efa70_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS0zLTEtMS0zNDQ5MQ_27f48369-7d35-4801-afdb-18dcbcfa714e"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS01LTEtMS0zNDQ5MQ_cfa3f6bb-aee4-401d-966d-843a18f8dce6"
      unitRef="usd">62445000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfOS0xMS0xLTEtMzQ0OTE_d793894c-dc88-466f-8417-1de629c9515f"
      unitRef="usd">62446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8b4bf1e423654f1687603127fe86c743_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTAtNS0xLTEtMzQ0OTE_5b116b01-8afa-484e-b34b-861ad83cdeff"
      unitRef="usd">6306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTAtMTEtMS0xLTM0NDkx_623c53be-d2b3-44d4-8afc-07e7dacf929c"
      unitRef="usd">6306000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibddc548b6b7a4ae280b837265a88e015_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTEtOS0xLTEtMzQ0OTE_0b1177ba-4af4-455d-944c-a9f24b107601"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTEtMTEtMS0xLTM0NDkx_fb344c5d-a5d2-4883-bdf2-e83e48f16635"
      unitRef="usd">8000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i6799c6e5bbe8426c90e26a689637fe8f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTItNy0xLTEtMzQ0OTE_1c814d7e-127d-4685-9cef-826d45c38e63"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTItMTEtMS0xLTM0NDkx_64a7418b-20a7-4f25-a5b2-9f9fb230f487"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtMS0xLTEtMzQ0OTE_c2594f7f-3680-47a4-95af-474186866973"
      unitRef="shares">102967017</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia4e60d959ef04f538e57678fb48d39de_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtMy0xLTEtMzQ0OTE_38608e18-8141-48c1-bc4f-aee266178e65"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0108f558055448982ef3a107a546127_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtNS0xLTEtMzQ0OTE_64d8ab3a-1d96-4608-a996-c7ae1f131576"
      unitRef="usd">750664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic4f3c74aea044471bfd38a37ede1fd57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtNy0xLTEtMzQ0OTE_e744da73-c5bd-4dbc-a9bd-18f5b646feb3"
      unitRef="usd">-633109000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id537ef3aea1f4e00b37077b727741777_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtOS0xLTEtMzQ0OTE_1be83060-bf90-4c80-abc4-4bcfaae4f0af"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yNS9mcmFnOjNhMDg0ZGNlZjhkYzRmOThiOTJkNTg5MzFkODA2ZjUxL3RhYmxlOjg5Y2JlZjZmMzFhYjQ2ZDc4ZTI0NjI3MWNlNTAyNTY1L3RhYmxlcmFuZ2U6ODljYmVmNmYzMWFiNDZkNzhlMjQ2MjcxY2U1MDI1NjVfMTMtMTEtMS0xLTM0NDkx_40ef3602-4c90-4b8a-9948-0198c8c7dca8"
      unitRef="usd">117569000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMy0xLTEtMS0zNDQ5MQ_a2fc610f-c21f-47b7-bbb8-98332c902584"
      unitRef="usd">-55009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMy0zLTEtMS0zNDQ5MQ_6bad27c0-1d7c-467c-8942-218ff2b35da9"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNS0xLTEtMS0zNDQ5MQ_91bf1232-707c-4a77-8afe-23de9c2ae957"
      unitRef="usd">407000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNS0zLTEtMS0zNDQ5MQ_70e5062d-bc83-4afb-8446-dd3dc6b62257"
      unitRef="usd">787000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNi0xLTEtMS0zNDQ5MQ_762d9fd9-6f30-4921-8af3-7a9510519684"
      unitRef="usd">226000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNi0zLTEtMS0zNDQ5MQ_ef4d93ea-1216-4de8-a0bd-19273271b033"
      unitRef="usd">316000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNy0xLTEtMS0zNDQ5MQ_87f6117f-391e-4d56-be00-7526841af9d0"
      unitRef="usd">105000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNy0zLTEtMS0zNDQ5MQ_0587e277-cd11-411a-afda-38f3abd97f48"
      unitRef="usd">145000</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOC0xLTEtMS0zNDQ5MQ_9835f9a1-dc84-4a2d-9b5d-ae3d376e6cf7"
      unitRef="usd">-16000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOC0zLTEtMS0zNDQ5MQ_a7b75237-cd36-4ab1-94c2-9a1c94e16246"
      unitRef="usd">-274000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOS0xLTEtMS0zNDQ5MQ_ee38783f-cdfb-429a-8915-25a1ab8248af"
      unitRef="usd">1698000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfOS0zLTEtMS0zNDQ5MQ_bad3bf59-b2a3-4fc5-bef4-33977d9144ee"
      unitRef="usd">1318000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTAtMS0xLTEtMzQ0OTE_5df1bc5d-93aa-420a-b433-fec989267413"
      unitRef="usd">6976000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTAtMy0xLTEtMzQ0OTE_e2340a90-d523-4bae-afcf-c0f2f480834b"
      unitRef="usd">6306000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTEtMS0xLTEtMzQ0OTE_8e6fc522-57f1-472c-b3e2-6fd223230820"
      unitRef="usd">18000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTEtMy0xLTEtMzQ0OTE_142870cf-4c98-43d9-b14a-fbf35c679509"
      unitRef="usd">-713000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTItMS0xLTEtMzQ0OTE_c097acc7-23bb-4d59-8607-1cad65568358"
      unitRef="usd">-102000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTItMy0xLTEtMzQ0OTE_d9124942-d276-4b69-b9df-7c2ece7a16f6"
      unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTMtMS0xLTEtMzQ0OTE_bda01c9a-9cd7-4b3b-b677-09c60ac37d0c"
      unitRef="usd">853000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTMtMy0xLTEtMzQ0OTE_5311bd2b-e242-4269-9108-d42d1a2db227"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTQtMS0xLTEtMzQ0OTE_eebae906-327c-4d82-97ee-bbc50fabee77"
      unitRef="usd">151000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTQtMy0xLTEtMzQ0OTE_14838bbe-58df-4892-9e16-cc4e941d055e"
      unitRef="usd">141000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTctMS0xLTEtMzQ0OTE_1e8707b1-83e8-4e8b-a1d1-50bf4883564c"
      unitRef="usd">5121000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTctMy0xLTEtMzQ0OTE_c98531a6-afeb-454d-837d-63f2037937c7"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTgtMS0xLTEtMzQ0OTE_83ed3355-9b5a-4663-9914-44a957aa8026"
      unitRef="usd">4529000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTgtMy0xLTEtMzQ0OTE_63c055dd-602f-4589-b812-988e47851ae8"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMS0xLTEtMzkxMjE_1dbbe47f-ca02-4bdf-bbc4-58acf692665a"
      unitRef="usd">12197000</ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense>
    <ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMy0xLTEtMzkxMTQ_6f21224d-9963-43a2-9774-19165a27a0ff"
      unitRef="usd">8481000</ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMS0xLTEtMzQ0OTE_7f07e6ae-3060-4b33-8f1d-d54e77211f0d"
      unitRef="usd">-1848000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMTktMy0xLTEtMzQ0OTE_3949ebb6-ec62-41a9-9193-8066a03f2e2b"
      unitRef="usd">-1102000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjAtMS0xLTEtMzQ0OTE_9405a4f6-cc71-45e9-8dc4-a4761d48ad26"
      unitRef="usd">17000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjAtMy0xLTEtMzQ0OTE_4bd309de-9a85-4597-bbe1-bee7c343e0ca"
      unitRef="usd">-3039000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjEtMS0xLTEtMzQ0OTE_1f15fe73-92c2-4b48-b5db-d579762493d8"
      unitRef="usd">983000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjEtMy0xLTEtMzQ0OTE_1d8c1609-c1d3-40bc-b8b8-c3d6fdb171f7"
      unitRef="usd">267000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjItMS0xLTEtMzQ0OTE_dd880763-397e-4e82-bd62-a4df40ea4890"
      unitRef="usd">-1692000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjItMy0xLTEtMzQ0OTE_ebff7449-9155-47b2-9d4f-b33fdc6c12c0"
      unitRef="usd">-1361000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjMtMS0xLTEtMzQ0OTE_c05af8cc-1968-45e4-9788-258a79bac5cd"
      unitRef="usd">259000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjMtMy0xLTEtMzQ0OTE_3010f6d3-65c1-4299-97b9-b7c6ba1ffcbe"
      unitRef="usd">2607000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjQtMS0xLTEtMzQ0OTE_362a8062-adb5-4c34-b048-b37f9c1a9f95"
      unitRef="usd">7694000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjQtMy0xLTEtMzQ0OTE_f306e457-f5aa-49cf-a301-6088f08cd815"
      unitRef="usd">182000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjUtMS0xLTEtMzQ0OTE_bfa53a74-d9e1-4316-a5f0-11330dfb46ff"
      unitRef="usd">-58901000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjUtMy0xLTEtMzQ0OTE_fae90220-8d78-4251-a9d0-a1caf74aef9f"
      unitRef="usd">-78493000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjctMS0xLTEtMzQ0OTE_6d797247-0dcc-4baf-800a-790db1c5728a"
      unitRef="usd">42300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjctMy0xLTEtMzQ0OTE_d74dd4ba-7997-4dcc-ad73-3dae68ea5b04"
      unitRef="usd">60550000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjgtMS0xLTEtMzQ0OTE_7acfc9a0-60eb-4236-b634-8b5824d6ac8e"
      unitRef="usd">25762000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjgtMy0xLTEtMzQ0OTE_5bd57337-ec6c-4974-b7a5-9cdce535598c"
      unitRef="usd">48314000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjktMS0xLTEtMzQ0OTE_97bfa8c2-6580-424f-a2f7-8357eb1aa15b"
      unitRef="usd">1268000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMjktMy0xLTEtMzQ0OTE_6de875e6-073a-4f23-8c88-30c61f83899d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzAtMS0xLTEtMzQ0OTE_38188d72-ce66-4ddc-9914-e7ed60515aa0"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzAtMy0xLTEtMzQ0OTE_bb66d654-1e85-460b-b8c9-f9b4657f4b8b"
      unitRef="usd">1517000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzEtMS0xLTEtMzQ0OTE_ceeb46fe-0095-473a-9ae9-38e8646b255e"
      unitRef="usd">17806000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzEtMy0xLTEtMzQ0OTE_21982805-3dc2-4ef7-97fa-088a0e67268b"
      unitRef="usd">10719000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzMtMS0xLTEtMzQ0OTE_b814f898-88d9-44c4-ad32-e06320056d19"
      unitRef="usd">26971000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzMtMy0xLTEtMzQ0OTE_8955fd95-1115-4a58-984b-abe8738a9025"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzQtMS0xLTEtMzQ0OTE_2cb6e2c9-7eb6-498e-8898-6709417904a5"
      unitRef="usd">33038000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzQtMy0xLTEtMzQ0OTE_7eb54dba-c2d4-408b-b2d1-b27bb44dc655"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzUtMS0xLTEtMzc4NTE_254bf74a-1bb7-4d83-9893-312a3e2c5405"
      unitRef="usd">9581000</ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts>
    <ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzUtMy0xLTEtMzc5MjI_c399ba61-2ae3-42d9-9873-bef61c9edae9"
      unitRef="usd">0</ardx:ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzgtMS0xLTEtMzQ0OTE_5cbba1c3-654f-4377-99b7-bfa5da438743"
      unitRef="usd">18478000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzgtMy0xLTEtMzQ0OTE_c7df11b2-0766-490c-b373-fe76f16ce0e1"
      unitRef="usd">62446000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzktMS0xLTEtMzQ0OTE_40fbc71f-e009-4f53-96cb-ce4bc0bfc3ea"
      unitRef="usd">83000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfMzktMy0xLTEtMzQ0OTE_4cc79f43-373d-4db6-9e1d-1e5d8df07488"
      unitRef="usd">1041000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDItMS0xLTEtMzQ0OTE_7beb598f-3528-41db-a654-bf8d5b00f295"
      unitRef="usd">22075000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDItMy0xLTEtMzQ0OTE_66febbb4-af65-402d-870b-6fe8654204af"
      unitRef="usd">63487000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDMtMS0xLTEtMzQ0OTE_4ce498c8-03f6-4db3-970c-68a15dc32916"
      unitRef="usd">-19020000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDMtMy0xLTEtMzQ0OTE_72122f37-ae2a-4a67-aff1-7eba48783792"
      unitRef="usd">-4287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDQtMS0xLTEtMzQ0OTE_3ac91770-d2a1-4115-b0ca-1dbda01bd847"
      unitRef="usd">72428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a43b3062ca24536868bd6a62ace2205_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDQtMy0xLTEtMzQ0OTE_aa0c3f58-4a19-4a40-9d9d-1a20ccd9b02a"
      unitRef="usd">91032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDUtMS0xLTEtMzQ0OTE_8f7c9499-5e91-4f85-9976-6e8f847c36f4"
      unitRef="usd">53408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDUtMy0xLTEtMzQ0OTE_29fc5835-d02c-47a7-84d0-cb3aa24cd14e"
      unitRef="usd">86745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDctMS0xLTEtMzQ0OTE_dcf6fd85-c43f-4c38-8a7b-d9e60b2b88e7"
      unitRef="usd">1360000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDctMy0xLTEtMzQ0OTE_f74ab9ac-5b2d-4cce-9b7b-5131658f03bd"
      unitRef="usd">1936000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDgtMS0xLTEtMzQ0OTE_a3c803c7-abc3-452d-a307-f7cbb189bc6d"
      unitRef="usd">6000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNDgtMy0xLTEtMzQ0OTE_560620de-cb03-4cda-a6c7-e79227cf43da"
      unitRef="usd">3000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTAtMS0xLTEtMzQ0OTE_11e60778-f7d2-4e20-bf72-a6babb39fb83"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTAtMy0xLTEtMzQ0OTE_e808cef1-3fdc-4e8c-a813-d27d4d48222d"
      unitRef="usd">14379000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ardx:DerivativeIssued
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTItMS0xLTEtMzQ0OTE_10ddfd48-cc85-452f-85bc-9f16743f2213"
      unitRef="usd">375000</ardx:DerivativeIssued>
    <ardx:DerivativeIssued
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8yOC9mcmFnOjdlMTgzOGZmNjFjZTQyOTU4MzkwODczMDRlMTkwNGI1L3RhYmxlOjJjZjE1ZmMxMzVkMjRjMzU5ZDJhZDZkNDZhYzc5MTVjL3RhYmxlcmFuZ2U6MmNmMTVmYzEzNWQyNGMzNTlkMmFkNmQ0NmFjNzkxNWNfNTItMy0xLTEtMzQ0OTE_623c8732-4d3c-47b1-a50c-a076e8d61dc1"
      unitRef="usd">0</ardx:DerivativeIssued>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDU_4802acca-0414-4821-9183-2fbde573f3e7">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ardelyx, Inc. (the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment, which is the development and commercialization of biopharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, we had cash and investments of approximately $81.0&#160;million. We have incurred operating losses since inception and our accumulated deficit as of June&#160;30, 2022 is $767.9&#160;million. Our current level of cash and investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these financial statements. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these financial statements. We plan to address our operating cash flow requirements with our current cash and investments, cash generated from sales of IBSRELA, our potential receipt of anticipated milestones from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, our ability to access the capital markets, as well as through the implementation of cash preservation activities to reduce or defer discretionary spending.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash and investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant accounting policies are described in Note 1 to our audited financial statements for the fiscal year ended December&#160;31, 2021, included in our Annual Report on Form 10-K. Our significant accounting policies for the three and six months ended June&#160;30, 2022 also included the policies discussed below related to accounts receivable, inventory, revenue and cost of revenue for commercial product sales. With the exception of those noted below, there have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required. As of June&#160;30, 2022 our accounts receivable balance is comprised of $4.1&#160;million from our collaborators and $1.5&#160;million from commercial customers. As of December&#160;31, 2021 our accounts receivable balance was comprised of $0.5&#160;million from our collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our commercial product sales, net in accordance with Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We received approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#x201c;NHE3&#x201d;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through a limited number of wholesalers and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers and specialty pharmacies are offered various forms of consideration, including service fees. Wholesalers may also receive prompt pay discounts for payment within a specified period. We expect prompt pay discounts to be earned when offered and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three and six months ended June&#160;30, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.9 million as cost of revenue under the AZ Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-cash Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds we receive from the sale of certain future royalties are amortized to non-cash interest expense over the estimated life of the associated agreement using the effective interest method. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMjg5_83d0b56a-459a-488d-8bfc-61a23655c86f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM4OTk_b47acf4f-caeb-409c-a471-8343ac00eb5b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2021. The results for the three and six months ended June&#160;30, 2022 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2022, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDA_7cc068b5-77d8-48df-95d3-c9c36725f6e3">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, the fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InvestmentsAndCash
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMjQ0OA_f67c3eb8-978a-4ab2-a0d8-39f5157a9e2a"
      unitRef="usd">81000000</us-gaap:InvestmentsAndCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMjU0Mg_4181f6b4-380d-46d2-a591-0ddee2a22f57"
      unitRef="usd">-767900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM4OTg_dcee3ea5-4e9a-4e7f-afb7-360927305868">Accounts ReceivableAccounts receivable is reported net of allowances for returns, chargebacks and contractual discounts offered to our customers. Our estimate of the allowance for doubtful accounts is based on an evaluation of the aging of our receivables. Trade receivable balances are written off against the allowance when it is probable that the receivable will not be collected. To date, we have determined that an allowance for doubtful accounts is not required.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1555902d2ec1463bacd6e8d3c0cd1ff1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNTExNQ_86164dcb-40fa-4123-bf88-3aad2942e1f1"
      unitRef="usd">4100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iace48da582da4c0683e6c1b47d0ac054_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNTE0NQ_0bb89c6e-b5a4-4160-9e41-2b22ad12893d"
      unitRef="usd">1500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icb917478e7cc4cb19f960aafa0ebf6d2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNTIzMw_9ec70efb-abf8-456d-bec7-5628a89bd0a1"
      unitRef="usd">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDE_c9584dc7-6429-4682-9af3-50e245badd92">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the regulatory approval of drug product candidates, we incurred expenses for the manufacture of drug product that could potentially be available to support the commercial launch of our products. We began to capitalize inventory costs associated with IBSRELA during the fourth quarter of 2021, when our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA, which was when it was determined that the inventory had a probable future economic benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value with cost determined under the first-in first-out method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, labor costs for personnel involved in the manufacturing process, and indirect overhead costs. We primarily use actual costs to determine the cost basis for inventory. The determination of whether inventory costs will be realizable requires management review of the expiration dates of IBSRELA compared to our forecasted sales. If actual market conditions are less favorable than projected by management, write-downs of inventory may be required, which would be recorded as cost of goods sold in the condensed statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDI_9af629d1-6a31-4f42-ae30-44bb45ea7d29">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our commercial product sales, net in accordance with Topic 606 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We received approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in September 2019 to market IBSRELA, the first and only sodium hydrogen exchanger 3 (&#x201c;NHE3&#x201d;) inhibitor for the treatment of irritable bowel syndrome with constipation ("IBS-C") in adults, in the United States ("U.S."). We began selling IBSRELA in the U.S. in March 2022. We distribute IBSRELA principally through a limited number of wholesalers and specialty pharmacy providers (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration, including rebates, discounts, patient copay assistance programs, and estimated product returns. These estimates are based on the amounts earned or to be claimed for related sales and are classified as reductions of gross accounts receivable if the amount is payable to our Customers or a current liability if the amount is payable to a party other than a Customer. Where appropriate, these estimates are based on factors such as industry data and forecasted customer buying and payment patterns, our historical experience, current contractual and statutory requirements, specific known market events and trends. Overall, these reductions to gross sales reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. As we gain more historical experience, estimates will be more heavily based on the expected utilization from historical data we have accumulated since the IBSRELA product launch.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Rebates: Rebates include mandated discounts under the Medicaid Drug Rebate Program ("Medicaid") and the Medicare Coverage Gap Program ("Medicare"). Rebates are amounts owed after the final dispensing of products to a benefit plan participant and are based upon contractual agreements or legal requirements with the public-sector benefit providers. These estimates for rebates are recorded in the same period the related gross revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses on the condensed balance sheets. We estimate our Medicaid and Medicare rebates based upon the estimated payor mix, and statutory discount rates. Our estimates for payor mix are guided by payor information received from specialty pharmacies, expected utilization for wholesaler sales to pharmacies, and available industry payor information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted purchasers purchase directly from our wholesalers at a discounted price. The wholesaler, in turn, charges back the difference between the price initially paid to us by the wholesaler and the discounted price paid to the wholesaler by the contracted purchaser. Amounts for estimated chargebacks are established in the same period that the related gross revenue is recognized, resulting in a reduction of product revenue and accounts receivable. The accrual for wholesaler chargebacks is estimated based on known chargeback rates, known sales to wholesalers, and estimated utilization by types of contracted purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounts and Fees: Our payment terms are generally 30 to 60 days. Wholesalers and specialty pharmacies are offered various forms of consideration, including service fees. Wholesalers may also receive prompt pay discounts for payment within a specified period. We expect prompt pay discounts to be earned when offered and therefore, we deduct the full amount of these discounts and service fees from product sales when revenue is recognized, resulting in a reduction of product revenue and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reserves: Patients who have commercial insurance may receive co-pay assistance when product is dispensed by pharmacies to patients. We estimate the amount of co-pay assistance provided to eligible patients based on the terms of the program and redemption information provided by third-party claims processing organizations and are recorded in accounts payable and accrued expenses and other current liabilities on the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ardx:RevenueGeneralPaymentTerms
      contextRef="ic932086e94cd487a952b91e6f8c04bd1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTA5OTE_b96d46a1-34f8-4bb1-ab6e-fb5c7a856baa">P30D</ardx:RevenueGeneralPaymentTerms>
    <ardx:RevenueGeneralPaymentTerms
      contextRef="i243ea0b71955409b86d20ba33c39c16d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTA5OTc_73e62e12-7421-4098-aa22-3be9557b14a6">P60D</ardx:RevenueGeneralPaymentTerms>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDM_36690042-c9c1-48c9-beae-a8e3e613ac4f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue consists of the cost of commercial goods sold to our Customers, international partners under product supply agreements, and royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#x2019;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three and six months ended June&#160;30, 2022 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes payments due to AstraZeneca, which under the terms of a termination agreement entered into in 2015 (the "AZ Termination Agreement") is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners as a result of the development and commercialization of tenapanor or certain other NHE3 inhibitors.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $11.9 million as cost of revenue under the AZ Termination Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTI4Nzc_65c02c32-51f0-41fb-8c66-1d39a68e8daa"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTI5NjI_396b92d0-6711-461c-85b2-03dbfe12e4c6"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i2766bdc22382498f96100a7aaec65cb8_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTMxODI_479d9d34-948e-4dd2-b07f-c75bf04b38dc"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:CostOfRevenueAggregateAmountRecognized
      contextRef="i9df8422a3ac54491960b7f51d8d389ad_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM0MDM_59f0d461-2e2e-4e6c-82f6-8544e73df52a"
      unitRef="usd">11900000</ardx:CostOfRevenueAggregateAmountRecognized>
    <ardx:NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfNzE0NjgyNTYwMzQ3OA_fef533fc-1730-4b19-aa60-e94240171982">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-cash Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds we receive from the sale of certain future royalties are amortized to non-cash interest expense over the estimated life of the associated agreement using the effective interest method. As we earn royalties and remit those royalties pursuant to the agreement, the balance of the deferred royalty obligation will be effectively repaid over the life of agreement. To determine the amortization of our deferred royalty obligation, we are required to estimate the total amount of future royalty payments we expect to earn. There are a number of factors that could materially affect the amount and timing of royalty payments, most of which are not within our control. We periodically assess the amount of royalty payments we expect to receive which are subject to the agreement and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation.&lt;/span&gt;&lt;/div&gt;</ardx:NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNC9mcmFnOjBlYTMwYTQ4YjY1YTRlODA4ZmUzMWI1ZmFlMzVhN2Y0L3RleHRyZWdpb246MGVhMzBhNDhiNjVhNGU4MDhmZTMxYjVmYWUzNWE3ZjRfMTM5MDQ_68bcf7d6-0cae-4163-994b-abdc49dc8b52">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements other than those disclosed in our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to a have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMjMyOA_98f39bc0-bd61-4557-bf72-d6d4b802c7d9">CASH, CASH EQUIVALENTS AND INVESTMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and investments as of June&#160;30, 2022 and December&#160;31, 2021 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of money market funds and other debt securities with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive income (loss) within stockholders&#x2019; equity on our balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income (expense), net, in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All short-term available-for-sale securities held as of June&#160;30, 2022 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired, we write it down through the statement of operations and comprehensive loss to its fair value and establishes that value as a new cost basis for the investment. We did not identify any of our available-for-sale securities as other-than-temporarily impaired in any of the periods presented. As of June&#160;30, 2022, no investment was in a continuous unrealized loss position for more than one year and we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMjMyOQ_6fddc062-946b-4aa2-887d-064122700fcd">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and investments as of June&#160;30, 2022 and December&#160;31, 2021 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC0xLTEtMS0zNDQ5MQ_df783112-93ae-4e2f-bbec-13d6ae5c1645"
      unitRef="usd">2975000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC0zLTEtMS0zNDQ5MQ_018e9e8b-61fb-408c-9bf7-062c57945f74"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC01LTEtMS0zNDQ5MQ_ac003500-0f01-4996-b962-bb1215614574"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6025aec2272144e0acf8d042ed697ddb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNC03LTEtMS0zNDQ5MQ_a989d815-a626-4471-a71e-de8ad6fbf10d"
      unitRef="usd">2975000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS0xLTEtMS0zNDQ5MQ_111073f7-e285-4368-bbeb-0aae98d0bbf1"
      unitRef="usd">50433000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS0zLTEtMS0zNDQ5MQ_1679637a-e88a-438e-a315-83d8f7166f82"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS01LTEtMS0zNDQ5MQ_0b48e82e-4dde-419b-b9a3-6ee5b62db724"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8486993cdcaf4e069d76b8adb41b13a6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfNS03LTEtMS0zNDQ5MQ_098da2b0-4f43-42d4-a40e-40db65e5b646"
      unitRef="usd">50433000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC0xLTEtMS0zNDQ5MQ_a88c7ff4-cc32-4988-a8a6-bebf5f665044"
      unitRef="usd">53408000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC0zLTEtMS0zNDQ5MQ_abbec24d-acf1-4006-a8b4-b8285365b2e1"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC01LTEtMS0zNDQ5MQ_203bf806-9613-43f3-b10f-49e100309e6d"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfOC03LTEtMS0zNDQ5MQ_5b8192ce-fc26-40f4-ae9d-e2dcb82d9910"
      unitRef="usd">53408000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtMS0xLTEtMzQ0OTE_a5a6c418-0f35-4ac1-83bc-78e4820fadc0"
      unitRef="usd">16931000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtMy0xLTEtMzQ0OTE_cc87485d-72e6-4f1d-aacd-9f7030572050"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtNS0xLTEtMzQ0OTE_beb4e920-8c80-4476-bc58-385f773f722e"
      unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia817be3797974733b6dc7b26f51132c5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTAtNy0xLTEtMzQ0OTE_34b2b911-7cab-4eda-abc8-7a49af45766a"
      unitRef="usd">16882000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtMS0xLTEtMzQ0OTE_2a217b3f-9ab0-4a9e-857a-803f11d424b8"
      unitRef="usd">8768000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtMy0xLTEtMzQ0OTE_dd2b99e9-7bcc-47b4-a52e-af9e14f54c7e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtNS0xLTEtMzQ0OTE_fb8364b8-6940-45c6-a6dd-cf186e91e78e"
      unitRef="usd">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbb22f9725c44ee892344744a4cbbd26_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTEtNy0xLTEtMzQ0OTE_2ef52f61-8118-413c-a61e-e5ed8f1ca7a0"
      unitRef="usd">8723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItMS0xLTEtMzQ0OTE_3b0d80e0-3e7b-40e8-8574-7c78d1ba22fc"
      unitRef="usd">1011000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItMy0xLTEtMzQ0OTE_67daa6dc-7dd9-4b98-953e-827c1409398b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItNS0xLTEtMzQ0OTE_07728c3e-4ad7-40f3-8bec-dd8f8a3c1980"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05b66c164e8e4390a1b10b9ea951aaff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTItNy0xLTEtMzQ0OTE_5d07f1a5-5283-4d0d-a26c-e03bbb09341a"
      unitRef="usd">999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtMS0xLTEtMzQ0OTE_faa230c1-5c49-47ba-9c08-050ff5aa203c"
      unitRef="usd">1003000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtMy0xLTEtMzQ0OTE_3c8e4b61-3255-4444-b04d-5895041b9b99"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtNS0xLTEtMzQ0OTE_9684bb60-5d4b-4beb-bdd7-a4e3e209d56e"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i479f2d9c1c214b7d9cf06eeef84cd90f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTMtNy0xLTEtMzQ0OTE_a0a5feff-5220-4bcc-94c4-b063b2ca8c98"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtMS0xLTEtMzQ0OTE_6f3bf8bb-07e3-4c95-b0d1-5b8bdbe5a15d"
      unitRef="usd">27713000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtMy0xLTEtMzQ0OTE_db709b3f-009a-4b95-9ba5-ba096e9df713"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtNS0xLTEtMzQ0OTE_7157e6e7-5996-41fa-9f8b-31a8b5be1a3f"
      unitRef="usd">109000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTQtNy0xLTEtMzQ0OTE_487b434e-8bf5-497e-99c6-fb2a8ff9c42b"
      unitRef="usd">27604000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtMS0xLTEtMzQ0OTE_4cf1cf90-6eb4-4a30-8372-74f71c31a9e6"
      unitRef="usd">81121000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtMy0xLTEtMzQ0OTE_7a924f60-c036-4af7-9a3c-a425d52af487"
      unitRef="usd">0</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtNS0xLTEtMzQ0OTE_feeb4ba5-698d-4e85-a2f3-8a05ad249c19"
      unitRef="usd">109000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOjc4MzAzZDljNGRiNjQ3MTdiOWYzZGFjYmM1NTA2OWE3L3RhYmxlcmFuZ2U6NzgzMDNkOWM0ZGI2NDcxN2I5ZjNkYWNiYzU1MDY5YTdfMTUtNy0xLTEtMzQ0OTE_b64388b9-9f4a-428e-ae1b-dc8506e48c2e"
      unitRef="usd">81012000</us-gaap:InvestmentsAndCash>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i9919698f07db4a6a92578760f1c69457_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC0xLTEtMS0zNDQ5MQ_ea9b2c34-a786-4a0c-98b2-8658561e08f0"
      unitRef="usd">1253000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i9919698f07db4a6a92578760f1c69457_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC0zLTEtMS0zNDQ5MQ_41bc099f-332a-4af2-ab38-e630f76cab9c"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i9919698f07db4a6a92578760f1c69457_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC01LTEtMS0zNDQ5MQ_a03f3acd-3306-42a0-8eac-a3358c7e18cb"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9919698f07db4a6a92578760f1c69457_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNC03LTEtMS0zNDQ5MQ_e9c4c8ee-f4a4-40e4-b893-8a3113d623f0"
      unitRef="usd">1253000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS0xLTEtMS0zNDQ5MQ_2ca22a08-d440-4d4e-836c-c817a714b828"
      unitRef="usd">71175000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS0zLTEtMS0zNDQ5MQ_be41a0a1-b9f5-497e-885a-1b410bd2406b"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS01LTEtMS0zNDQ5MQ_7138b056-c105-4ca4-902a-5ae24c7cb8ec"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i691c6773fe6c4ffbace66f4223e64445_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfNS03LTEtMS0zNDQ5MQ_15be2ec7-2cd9-45f5-9dcb-2f85b3d6040b"
      unitRef="usd">71175000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <ardx:CashAndCashEquivalentsAmortizedCost
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC0xLTEtMS0zNDQ5MQ_58136f34-8d0a-42eb-accd-cee3dd100000"
      unitRef="usd">72428000</ardx:CashAndCashEquivalentsAmortizedCost>
    <ardx:CashAndCashEquivalentsGrossUnrealizedGains
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC0zLTEtMS0zNDQ5MQ_0140dd66-4d6b-4fd1-ac22-a62811bec584"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedGains>
    <ardx:CashAndCashEquivalentsGrossUnrealizedLosses
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC01LTEtMS0zNDQ5MQ_79e29b3a-374f-4827-bd34-8d05c5c2c53c"
      unitRef="usd">0</ardx:CashAndCashEquivalentsGrossUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfOC03LTEtMS0zNDQ5MQ_d878cb46-42f7-4d9f-ac2a-03b5465d60ee"
      unitRef="usd">72428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtMS0xLTEtMzQ0OTE_cf421704-be93-408f-a55f-8e21fbb6e61b"
      unitRef="usd">31936000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtMy0xLTEtMzQ0OTE_af69ea8e-38ae-49c7-b8d2-0fb28f5d68eb"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtNS0xLTEtMzQ0OTE_bed88418-8887-4bcb-9e52-a0b685da9db3"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ebbc1bc34434f3eb3bd1884cd208416_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTAtNy0xLTEtMzQ0OTE_eb2187ac-5614-43cf-9111-bfe0ad658645"
      unitRef="usd">31935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtMS0xLTEtMzQ0OTE_b4ee98a0-ba22-483b-a845-9d1e8ea738d7"
      unitRef="usd">7025000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtMy0xLTEtMzQ0OTE_6fc962b8-1494-41e5-a753-fe84e93cf1ef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtNS0xLTEtMzQ0OTE_9d755132-34fe-4025-ba1c-8c7600870cfc"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1c949bca14b4efd8274b5184e05d85f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTEtNy0xLTEtMzQ0OTE_2796b8cf-8d9d-4d88-ae0f-6f445d9720c9"
      unitRef="usd">7022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtMS0xLTEtMzQ0OTE_57eb7066-ee35-4bb6-a41b-931fe66f1754"
      unitRef="usd">5306000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtMy0xLTEtMzQ0OTE_e495343b-dd5e-40aa-9b5c-ae4a704d31ef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtNS0xLTEtMzQ0OTE_3e689f2e-0d18-4fc5-ba51-cd85a6a42922"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58e98e012f3343f0badc90e26699bbb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTMtNy0xLTEtMzQ0OTE_94ae8c7c-e25e-4e20-94f0-e142bcf375ae"
      unitRef="usd">5304000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtMS0xLTEtMzQ0OTE_ce27a590-fecc-48f4-a4a7-b3a58de0b488"
      unitRef="usd">44267000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtMy0xLTEtMzQ0OTE_df533192-21e2-49ff-a908-d13fb0c4b7d4"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtNS0xLTEtMzQ0OTE_6b6a9df6-f546-4ea3-a398-d6101244e9b9"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTQtNy0xLTEtMzQ0OTE_39756726-c43e-4576-a3bf-09dd86481214"
      unitRef="usd">44261000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctMS0xLTEtMzQ0OTE_160aa67b-fb9a-4a90-9abf-f18b403b24b9"
      unitRef="usd">116695000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctMy0xLTEtMzQ0OTE_50d6166c-113d-4d91-a828-e32a039bf3e2"
      unitRef="usd">1000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctNS0xLTEtMzQ0OTE_b3d2e0d8-6723-420d-ad18-9580ea6caa31"
      unitRef="usd">7000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RhYmxlOmFlMzYwYjhmMDg3ZTQyZmZhY2Q2NDBjMjI4NjBlZWNhL3RhYmxlcmFuZ2U6YWUzNjBiOGYwODdlNDJmZmFjZDY0MGMyMjg2MGVlY2FfMTctNy0xLTEtMzQ0OTE_16f5e30a-3c5c-484a-86e7-9ae76749fdde"
      unitRef="usd">116689000</us-gaap:InvestmentsAndCash>
    <ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMTEwMw_c8d3693d-4288-49a5-88ac-2751436bebb7">P1Y</ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8zNy9mcmFnOmVhNGFlNGQ2ZjA4NzQzZjA5YTU1MzEyZGI2YTQzNDFmL3RleHRyZWdpb246ZWE0YWU0ZDZmMDg3NDNmMDlhNTUzMTJkYjZhNDM0MWZfMjExNw_f8ffacc2-8f8c-48fe-a89b-9ef01e2373f3"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RleHRyZWdpb246NzMwOTBkMDc5NTRlNDI1NGJlYzNkYTRlYmYwYTQ5NjdfMTk2Mw_56814414-e7cc-4ae2-a6b3-b2b536479f34">FAIR VALUE MEASUREMENTS&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and 2022 Exit Fee, as defined and discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Derivative Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both June&#160;30, 2022 and December&#160;31, 2021, due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rates of our deferred royalty obligation and term loan facility approximate the rate at which we could obtain alternative financing. Therefore, the carrying amount of the deferred royalty obligation and the term loan facility approximated their fair values at June&#160;30, 2022 and December&#160;31, 2021. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Deferred Royalty Obligation and Note 8. Borrowing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Level 3 inputs used to estimate the fair value of each respective liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RleHRyZWdpb246NzMwOTBkMDc5NTRlNDI1NGJlYzNkYTRlYmYwYTQ5NjdfMTk2NA_daa09129-f16c-4c5b-9323-7ffe17554500">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RleHRyZWdpb246NzMwOTBkMDc5NTRlNDI1NGJlYzNkYTRlYmYwYTQ5NjdfMTk2NQ_8425c48e-096d-44ff-8af5-0a8b333692f4">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc0b0709ef024116a0c9265abca56e5f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy0xLTEtMS0zNDQ5MQ_c4e974bc-b522-40e1-b901-8231965cad75"
      unitRef="usd">50433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7fb0f7426e14cbb8e220839ea644f53_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy0zLTEtMS0zNDQ5MQ_a6d22419-1606-461a-8373-57102a422497"
      unitRef="usd">50433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79b3eccd186b4b239771cea14a00e33d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy01LTEtMS0zNDQ5MQ_4989e570-a5ab-454b-9184-68c44571d651"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i546a6d3ca15649b1b31ac1990141ee51_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMy03LTEtMS0zNDQ5MQ_dca5d0b1-e88a-4198-b3c3-a9be8feb6ab0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i08942428c1e14accb811599d6f9c1077_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC0xLTEtMS0zNDQ5MQ_77762c73-2613-488e-8032-7d3ea00a237a"
      unitRef="usd">16882000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idb85da03916f4959ae20e2dc28f6455c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC0zLTEtMS0zNDQ5MQ_ab5970f7-f00c-4797-bc2a-1126b0641bb4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie98257b0990d4eec907be89dfe165197_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC01LTEtMS0zNDQ5MQ_04c76763-7a12-48f8-9b2e-c86af9cfd914"
      unitRef="usd">16882000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i93c9bcdad9ec4c5ba892fa935c841839_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNC03LTEtMS0zNDQ5MQ_d5789b7f-96c3-4045-b294-6d904e60ff1b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b9d10adba4d4aeab9e207d99f3aeebe_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS0xLTEtMS0zNDQ5MQ_e5572caa-d4e4-4e58-bfa5-26df5f12ae5c"
      unitRef="usd">8723000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8aaefa25584840cb807733401729c67a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS0zLTEtMS0zNDQ5MQ_6bb8dee2-7660-42ec-81d1-4300cd4cf940"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f37d12d66ab426fa73fe7b3c5d57eb4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS01LTEtMS0zNDQ5MQ_cde92e30-e03c-49e2-ae1f-896bfbb9819d"
      unitRef="usd">8723000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7372862571244bdca7df10a1706f5b15_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNS03LTEtMS0zNDQ5MQ_7ec668be-e6a1-42c7-9884-a6f8f485e614"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i12201884779347479d4fe912a0be5b1f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi0xLTEtMS0zNDQ5MQ_51a09232-5b59-4d60-82c0-f26ef31c21cf"
      unitRef="usd">999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if03a03012ab5410792f139ec7007eb3a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi0zLTEtMS0zNDQ5MQ_733052d7-928b-4bf5-a382-5c99985aa5ea"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie63c1e4cfb6a4516a7f8967b8e88ef31_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi01LTEtMS0zNDQ5MQ_db7f0136-2c1e-4584-a200-97ba08d90ab0"
      unitRef="usd">999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b2c3f0a67c94a8c83f4cce268ad23a1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNi03LTEtMS0zNDQ5MQ_2cde2985-6780-49f0-a75b-54b1c0375d05"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibfc5a1fc9b954a588a196da771f45701_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy0xLTEtMS0zNDQ5MQ_964fe13e-01e3-4ca0-911b-f4c3dda56372"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id68a85c2475545a7946d12b3a69a9c7f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy0zLTEtMS0zNDQ5MQ_bb6ad4ef-ac4a-45fd-87df-52099942a504"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if576c80f93ba477a8bd7f301242eb30a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy01LTEtMS0zNDQ5MQ_cb20d3d1-4ef1-4ec4-b575-c3ce818d30c0"
      unitRef="usd">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa3bc355b5244eb0b37758f0981ed405_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfNy03LTEtMS0zNDQ5MQ_350596a0-116c-42b1-9883-8dbfc9d8587d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ffac70a8f02419f80d424ef9aec9556_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS0xLTEtMS0zNDQ5MQ_03ed43fd-91d1-4c82-8907-94c0efcf9e78"
      unitRef="usd">78037000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia7954cbfa4ce4ea4ab4c3f6181db0e2e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS0zLTEtMS0zNDQ5MQ_fdf6c156-173c-4a5d-8c5a-78b7e50d0139"
      unitRef="usd">50433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0b85e98bea364f768c6d835cd20e21da_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS01LTEtMS0zNDQ5MQ_6ef9c3b3-5d8c-4d74-9053-9c5a0c311d02"
      unitRef="usd">27604000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia5cf155031c64016a5a4d37007dc9ab7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfOS03LTEtMS0zNDQ5MQ_add95c1e-b09b-4c59-b9b5-37c45c31c846"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i620c4cac0fc54742b917d01906a295b1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItMS0xLTEtMzQ0OTE_f9af0518-8ae2-4eb2-96f9-d4091ccf46c2"
      unitRef="usd">1091000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i07691efdc6d54495bf7cb279afdb630c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItMy0xLTEtMzQ0OTE_3b27f592-894e-49aa-bb91-147d80e1e50e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if8d14510168b435db23351f3042e2fcd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItNS0xLTEtMzQ0OTE_680ebbf3-de2d-4c7c-bc9e-2c7c9146c22f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if0cb3f52dc7040e1865d853122c39d38_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTItNy0xLTEtMzQ0OTE_f5e4c484-402f-4e63-a9b1-aecd6afe748a"
      unitRef="usd">1091000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2ffac70a8f02419f80d424ef9aec9556_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtMS0xLTEtMzQ0OTE_79bc456c-051e-4ea1-9117-e2071963407f"
      unitRef="usd">1091000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia7954cbfa4ce4ea4ab4c3f6181db0e2e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtMy0xLTEtMzQ0OTE_aa4a0bd7-09da-42f3-9798-3e92101541f0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0b85e98bea364f768c6d835cd20e21da_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtNS0xLTEtMzQ0OTE_65d60abe-0105-43f0-8fc7-ffde38b360d2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia5cf155031c64016a5a4d37007dc9ab7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOjdhNGZiODM4YWM5NjQwNDhiOWE2YThmYThjZDA3NDIxL3RhYmxlcmFuZ2U6N2E0ZmI4MzhhYzk2NDA0OGI5YTZhOGZhOGNkMDc0MjFfMTMtNy0xLTEtMzQ0OTE_176f90ad-e6f0-4c3b-aec3-ee0b179325c0"
      unitRef="usd">1091000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4cad74c2b72746a98815ab0bf53fe597_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy0xLTEtMS0zNDQ5MQ_9c641e1c-0c84-4461-9b72-28c21629f594"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i995be0cb8d874d6c9ba41b0dc05d971e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy0zLTEtMS0zNDQ5MQ_810c4b61-67df-4899-922d-196164bfcd0f"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b854a7ada5344f09ef5775e5cba8f93_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy01LTEtMS0zNDQ5MQ_9f5d9b1f-a525-4b62-8b46-84ff1ecbccf0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8b547ba90a040d0b2ad45d6df149223_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMy03LTEtMS0zNDQ5MQ_364c3929-93fa-4000-a847-b728aa3946aa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie912ea9191f3410a856fb7a0596383a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC0xLTEtMS0zNDQ5MQ_14b4eb2d-8b54-4555-8e15-80ea68ed964a"
      unitRef="usd">31935000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if3c82683331d441bb4bb22c1a6fee81b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC0zLTEtMS0zNDQ5MQ_bcff2f8f-ae9a-494c-81fd-8c6a0bd3895c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i26ec7fb6b30a44a384e58a556b1d2cf6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC01LTEtMS0zNDQ5MQ_a8392052-a6fd-4505-b58c-0b8e20815b94"
      unitRef="usd">31935000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i964174c2047d42ea872fe68df856aaf0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNC03LTEtMS0zNDQ5MQ_31af8db4-b565-48f2-95d1-8d5a974ec958"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6a3d98d34e324383930817612f98d9b0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS0xLTEtMS0zNDQ5MQ_00be7b8b-4289-4648-a272-b2d88417250d"
      unitRef="usd">7022000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if8a59bd234854baab3810f3de2b8b58a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS0zLTEtMS0zNDQ5MQ_614398ea-e957-4927-a5f1-b1b9bb171e9f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8051dc6644dd49ddb271e164ef97c689_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS01LTEtMS0zNDQ5MQ_be27809a-d158-4c6b-96f3-e84581c4c99b"
      unitRef="usd">7022000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i67e3e3a40f3c49c083b2d38b581d7312_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNS03LTEtMS0zNDQ5MQ_b7aec4d0-2e27-47a1-abac-cfbd0950f9db"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i74e633e223e04648a650081651dfab52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy0xLTEtMS0zNDQ5MQ_1402b93e-0d09-489b-a17f-cecff6aa54ac"
      unitRef="usd">5304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib4b58e6d555145f0bdc3410179ee3f96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy0zLTEtMS0zNDQ5MQ_faf11c7e-1a84-4617-9945-30842938f560"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8d88606f5f10482f94f0ee9f6cf00522_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy01LTEtMS0zNDQ5MQ_a6e1f559-f3ca-41cb-a1b2-2d57d5f62d90"
      unitRef="usd">5304000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i80ad9ee3c9d74b2db9e200ae3966bdea_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfNy03LTEtMS0zNDQ5MQ_f68f267f-b764-491f-b2ec-3c48ce808094"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6cf5489a8dfe42c2b6bbf447a6a435a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS0xLTEtMS0zNDQ5MQ_50356a7a-29ef-487d-828e-ffbcf9c91f50"
      unitRef="usd">115436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6bca70cbb1754fb0bb05cb61bb3092c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS0zLTEtMS0zNDQ5MQ_0721f0ed-3307-4dc1-b8a9-50da9a56d341"
      unitRef="usd">71175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i65da5e485ec14c3284891b7e6b8296a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS01LTEtMS0zNDQ5MQ_ab3d6650-f07f-4848-ae73-f42bee13f64b"
      unitRef="usd">44261000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id077c7e922dd4a4482ae82df90440e4a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfOS03LTEtMS0zNDQ5MQ_ce824730-f12b-4acd-8f19-2fdb4736ce20"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8d869a99367f4854a7b935212b14932c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItMS0xLTEtMzQ0OTE_88e788eb-227d-4b86-82a2-888ea39564bc"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifd39e9f5df1041638177826f6d98c2c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItMy0xLTEtMzQ0OTE_8b58cf03-7b48-40a1-b743-21637772ac27"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iae239e1a1fb44ff689e8fe9e2e2b5049_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItNS0xLTEtMzQ0OTE_23a5edbb-a1d3-4b28-ba31-b6e72e17843a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib86f2f199f92428483fdae875ebaf628_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTItNy0xLTEtMzQ0OTE_d01f08a2-3f21-4da2-99d9-a3db2ab8d5d0"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6cf5489a8dfe42c2b6bbf447a6a435a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtMS0xLTEtMzQ0OTE_d5db5cbd-71da-43d3-a03d-48eedbbe3d44"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6bca70cbb1754fb0bb05cb61bb3092c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtMy0xLTEtMzQ0OTE_4958a12c-8c81-4220-a4a1-747c84cdb301"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i65da5e485ec14c3284891b7e6b8296a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtNS0xLTEtMzQ0OTE_d0f80eb0-618d-4f49-8c68-2839680f7b92"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id077c7e922dd4a4482ae82df90440e4a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80MC9mcmFnOjczMDkwZDA3OTU0ZTQyNTRiZWMzZGE0ZWJmMGE0OTY3L3RhYmxlOmRjMWMzZTU2MTkzMTRhNzJiZGIxZWUyYmVkYTY2ZDg2L3RhYmxlcmFuZ2U6ZGMxYzNlNTYxOTMxNGE3MmJkYjFlZTJiZWRhNjZkODZfMTMtNy0xLTEtMzQ0OTE_557f911a-a04c-4853-970c-8f634f979681"
      unitRef="usd">698000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMjc4_734ae970-94b3-4857-a904-d644a3eee324">INVENTORY&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid commercial manufacturing of $17.8&#160;million and $9.4&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, consist of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months. Prepayments for commercial manufacturing of $3.8&#160;million as of June&#160;30, 2022 that are expected to be converted into inventory after 12 months are included in other assets on our Condensed Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMjc5_2e604996-669c-4157-a11f-4bd1cac6aa3c">Inventory consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfMS0yLTEtMS0zNDQ5MQ_c9f073c7-5db0-46cb-a235-dd20428641a2"
      unitRef="usd">460000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfMi0yLTEtMS0zNDQ5MQ_4888f3b5-0b8c-4cc5-b884-d73e1e14cf98"
      unitRef="usd">3606000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfMy0yLTEtMS0zNDQ5MQ_64e3d1bb-c6ad-499b-85e1-3756262984e6"
      unitRef="usd">463000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RhYmxlOjNlOTUwNWZiZmMyNjRlYjdiMDhkODljOGM3MDYzMzVlL3RhYmxlcmFuZ2U6M2U5NTA1ZmJmYzI2NGViN2IwOGQ4OWM4YzcwNjMzNWVfNC0yLTEtMS0zNDQ5MQ_362402d5-f58f-47dc-8ce7-12c816feb343"
      unitRef="usd">4529000</us-gaap:InventoryNet>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMTA5OTUxMTYzMDA4Mw_a4a989dd-511e-4378-93d9-f12ed8569d25"
      unitRef="usd">17800000</ardx:PrepaidCommercialManufacturingCurrent>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMTY0OTI2NzQ0MjkyNA_88167b85-925f-41ef-a933-699158e0164e"
      unitRef="usd">9400000</ardx:PrepaidCommercialManufacturingCurrent>
    <ardx:PrepaidCommercialManufacturingExpenseNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80My9mcmFnOjU2MTU3YTE2ZDg0NjQ1NDRhNzg0YzU3MTdjMWMwMGJiL3RleHRyZWdpb246NTYxNTdhMTZkODQ2NDU0NGE3ODRjNTcxN2MxYzAwYmJfMTA5OTUxMTYzMDU3OA_a8cbd08f-b11c-4592-8e7e-ec517c63d67d"
      unitRef="usd">3800000</ardx:PrepaidCommercialManufacturingExpenseNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNzYw_b55dc1a3-1f7e-49db-8afd-e7be129b6031">PRODUCT REVENUE, NET&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received approval from the FDA in September 2019 to market IBSRELA, the first and only NHE3 inhibitor for the treatment of IBS-C in adults, in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $1.6&#160;million and $2.0&#160;million during the three and six months ended June&#160;30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales to AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation made up 40.2%, 22.7%, and 24.6% of our gross product revenue during the three months ended June&#160;30, 2022 and 35.1%, 21.7%, and 22.5% during the six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Fees, Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to 2022 sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/deductions issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no product sales or gross-to-net accruals during the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59ec18a7958d427e9d6cbc9e707fe8c3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMzU5_5c2d9ace-1f6f-4f41-93cf-5f3b949cf88f"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8db22a3a4424d38be4990606ba05153_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODY0NQ_f7c82f36-a88d-4e95-b534-6fcf3385a715"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i030bed782c004d8dba6df6de0d87f2b1_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTY0OTI2NzQ0MjYxOA_e75d7a6e-55c6-449c-a3df-e0e0cf18d3b6"
      unitRef="number">0.402</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icff93d49e06345b38b9bdf4a97525d38_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNDI1_bc308992-5ed0-4979-9b8e-e42642cd44b1"
      unitRef="number">0.227</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id4db73df4aa148be8f8d748314b92bc9_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNDM3_c53da9bc-67a7-4bd0-91b8-694afb1cd157"
      unitRef="number">0.246</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic8bf0daa5741459ebc9bbfb5ddfba604_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODY5Mg_351a0621-eda2-4c25-8460-1a978f374d50"
      unitRef="number">0.351</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icfd33242ba7c449e8338b810a873ad59_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODY5Nw_6283898a-08a1-427d-a5e0-c7679a9cd72e"
      unitRef="number">0.217</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9c98f044f4c64f13aed0711c37e6a610_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfMTA5OTUxMTYyODcwNg_82fbdfa0-4c21-43b0-83b9-729e31464052"
      unitRef="number">0.225</us-gaap:ConcentrationRiskPercentage1>
    <ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNzU5_fcd8cd60-6e84-4653-911c-36c722329a53">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Fees, Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Activity related to 2022 sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/deductions issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i57c496b3e28c4d63ab0345238346321c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS0xLTEtMS0zNDQ5MQ_f8158f2f-69e1-4a26-a6f7-6e189e1bf2a9"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ie399179e3b854e06a2b3d719ffa81575_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS0zLTEtMS0zNDQ5MQ_42a97fa8-64fe-498f-8010-cec31591c4c4"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i7f73fe9f5f3e400faaf0dbba30e2b6c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS01LTEtMS0zNDQ5MQ_b87ccc63-48d6-45cf-a61a-a38a208f6f8d"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMS03LTEtMS0zNDQ5MQ_d836d6e5-a727-4afb-8bd3-1f53117b2191"
      unitRef="usd">0</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="if76af73ff9024e19aceae555eb94a4ca_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi0xLTEtMS0zNDQ5MQ_abee6988-6da9-4191-80f8-69952d2c907f"
      unitRef="usd">84000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="ibdac1bc1d6634022aa3677dde7c770f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi0zLTEtMS0zNDQ5MQ_a1e40895-e276-4d9a-bd65-b7181301eee6"
      unitRef="usd">329000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="ia1bab5938a824507be1fe347458f5a16_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi01LTEtMS0zNDQ5MQ_57a9aa19-6619-4433-b0e6-1a7ef369a24a"
      unitRef="usd">322000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMi03LTEtMS0zNDQ5MQ_f292348e-e787-484e-9c07-e4e24db5a85c"
      unitRef="usd">735000</ardx:ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="if76af73ff9024e19aceae555eb94a4ca_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy0xLTEtMS0zNDQ5MQ_c5c2c3ab-e1e3-45b6-8da8-2bf0b2bb8902"
      unitRef="usd">-41000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="ibdac1bc1d6634022aa3677dde7c770f1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy0zLTEtMS0zNDQ5MQ_bb17d2f5-ac1d-44b4-b117-ded871c133f0"
      unitRef="usd">-15000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="ia1bab5938a824507be1fe347458f5a16_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy01LTEtMS0zNDQ5MQ_298fac97-0d92-4ec8-8d99-ccc667e47e85"
      unitRef="usd">-133000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfMy03LTEtMS0zNDQ5MQ_6adb4ea8-586e-4ab3-8b9c-1cc116d140db"
      unitRef="usd">-189000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="id3f92aef188e44c9ba3e6c4cf63228e7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC0xLTEtMS0zNDQ5MQ_11cb3cd8-0299-49d6-8feb-0cbfa1457fe7"
      unitRef="usd">43000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i2352e72adbd040919db7f1c7395453a2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC0zLTEtMS0zNDQ5MQ_bf0c63bc-a932-4a17-adac-3b347f01e007"
      unitRef="usd">314000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ib616618f955a41fb961d25698786e446_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC01LTEtMS0zNDQ5MQ_2047b171-c7a1-442b-b5e0-71239c8e6f1e"
      unitRef="usd">189000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RhYmxlOjg3OGYyNmIxMjY3NTQ3YWM5ZDk3YjUxM2MzN2M2OTQxL3RhYmxlcmFuZ2U6ODc4ZjI2YjEyNjc1NDdhYzlkOTdiNTEzYzM3YzY5NDFfNC03LTEtMS0zNDQ5MQ_f0101ef6-5d60-4b4b-8b45-86dd3d28959c"
      unitRef="usd">546000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee6cf208bb934fc49b584ea377c5e697_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_509656b1-9165-4b43-b868-420adc71b1b3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:ContractWithCustomerProductSalesGrossToNetAccruals
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_7b4f2ebf-fa57-4632-ba1c-f76c41f71c87"
      unitRef="usd">0</ardx:ContractWithCustomerProductSalesGrossToNetAccruals>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17ad1002e42841d9bab8e33e821c520d_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_83a20da2-5614-4625-909a-9e4d19dc5bfe"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:ContractWithCustomerProductSalesGrossToNetAccruals
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80Ni9mcmFnOjU5NWI0YzdkMTBlYzQ3MTg5ZTgzZjBjOTY3YTkyNDM0L3RleHRyZWdpb246NTk1YjRjN2QxMGVjNDcxODllODNmMGM5NjdhOTI0MzRfNjg4_d47efc00-1c76-4da3-b063-1fe0006f2371"
      unitRef="usd">0</ardx:ContractWithCustomerProductSalesGrossToNetAccruals>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzE0NjgyNTU5MTU4Mg_f974e78c-ee3d-47df-b0b5-0800be92d330">COLLABORATION AND LICENSING AGREEMENTS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kyowa Kirin Co., Ltd. (&#x201c;KKC&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we entered into a research collaboration and option agreement with KKC (the &#x201c;2019 KKC Agreement&#x201d;) for research associated with identifying two preclinical compounds that are ready for designation as development compounds (&#x201c;DCs&#x201d;), with one compound inhibiting the first undisclosed target (&#x201c;Program 1&#x201d;), and a second inhibiting the second undisclosed target (&#x201c;Program 2&#x201d;). Pursuant to the 2019 KKC Agreement, upon completion of the research and designation by the research steering committee of one or more DCs, KKC has the right to execute one or more separate collaborative agreements relating to the development and commercialization of one or both DCs in certain specified territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the terms of the 2019 KKC Agreement, KKC paid us a non-refundable, non-creditable upfront fee of $10.0&#160;million in two installments as follows: the first installment of $5.0&#160;million within 30 days of November 11, 2019 (the &#x201c;Effective Date&#x201d;), and the second installment of $5.0&#160;million on the first anniversary of the Effective Date. The original term of the 2019 KKC Agreement commenced on the Effective Date and was to end on the earliest of: (i) 2 years following the Effective Date, (ii) the nomination of a program DC for both programs, (iii) the nomination of one program DC and the decision by the parties to cease research for the other program, or (iv) the decision by the parties to cease research for both programs. We entered into three amendments to the 2019 KKC Agreement, which have resulted in the extension of the original term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the third amendment to the 2019 KKC Agreement entered into on June 28, 2022, the current term will end on February 28, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have no material future obligations under the 2019 KKC Agreement and recorded no revenue under the 2019 KKC Agreement during the three and six months ended June&#160;30, 2022. During the three and six months ended June&#160;30, 2021, we recognized $1.3&#160;million and $2.8&#160;million, respectively, as collaborative development revenue under the 2019 KKC Agreement in the accompanying condensed statement of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 KKC Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, we entered into an exclusive license agreement with KKC (the &#x201c;2017 KKC Agreement&#x201d;), for the development, commercialization, and distribution of tenapanor in Japan for cardiorenal indications. We granted KKC an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 KKC Agreement, KKC is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for KKC&#x2019;s use in development and commercialization throughout the term of the 2017 KKC Agreement, provided that KKC may exercise an option to manufacture the tenapanor drug substance under certain conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606) and related amendments (&#x201c;ASC 606&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and concluded that the contract counterparty, KKC, is a customer. Under the terms of the 2017 KKC Agreement, we received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30.0&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 KKC Agreement, and as such, each of the performance obligations is distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2017 KKC Agreement, KKC paid us an up-front license fee of $30.0&#160;million. We may be entitled to receive up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$55.0&#160;million in total development and regulatory milestones, of which $10.0&#160;million has been received and recognized as revenue as of June&#160;30, 2022. We may also be eligible to receive approximately &#xa5;8.5&#160;billion for commercialization milestones, or approximately $62.3&#160;million at the currency exchange rate on June&#160;30, 2022, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Deferred Royalty Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the future royalties and commercial milestone payments we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 11, 2022, we entered into a second amendment (the "Amendment") to the 2017 KKC Agreement. Under the terms of the Amendment, we and KKC have agreed to a reduction in the royalty rate payable to us by KKC upon net sales of tenapanor in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Deferred Royalty Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the future commercial milestones and royalties we may receive under the 2017 KKC Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, KKC has agreed to pay us up to an additional $40.0&#160;million payable in two tranches, with the first payment due following KKC's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following KKC&#x2019;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. The variable consideration related to the reduction in the royalty rate has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022 we recognized no licensing revenue upon the achievement of development milestones. During the three and six months ended June&#160;30, 2021, we recognized zero and $5.0&#160;million respectively, as licensing revenue upon the initiation of phase 3 clinical studies by KKC in Japan to evaluate tenapanor for hyperphosphatemia. During the three and six months ended June&#160;30, 2022, we recognized $952&#160;thousand and $966&#160;thousand, respectively, as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;product supply revenue related to the manufacturing supply of tenapanor and other materials to KKC pursuant to the 2017 KKC Agreement. During the three and six months ended June&#160;30, 2021,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we recognized zero and $126&#160;thousand, respectively, as product supply revenue pursuant to the 2017 KKC Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As detailed below under the heading &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we have received prepayments from KKC for the manufacturing of tenapanor drug substance that will be used to satisfy KKC needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#x201c;Fosun Pharma&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we entered into an exclusive license agreement with Fosun&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Fosun Agreement&#x201d;),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IBS-C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Fosun Agreement, Fosun paid us a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.0 million upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license fee. We may be entitled to receive development and commercialization milestones of up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$113.0 million, of which $3.0 million has been received and recognized as revenue as of June&#160;30, 2022, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as these were fully constrained at June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recorded no&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue during the three and six months ended June&#160;30, 2022 or 2021 related&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the Fosun&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Knight Therapeutics, Inc. (&#x201c;Knight&#x201c;) &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, we entered into an exclusive license agreement with Knight (the &#x201c;Knight Agreement&#x201d;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. Under the terms of the Knight Agreement, Knight paid us a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million upfront payment. We may also be eligible to receive approximately CAD22.2&#160;million for development and commercialization milestones, or approximately $17.2 million at the currency exchange rate on June&#160;30, 2022, of which $0.7 million has been received and recognized as revenue as of June&#160;30, 2022. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB (&#x201c;AstraZeneca&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2015, we entered into a termination agreement with AstraZeneca (the &#x201c;AstraZeneca Termination Agreement&#x201d;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a licensee of tenapanor or another NHE3 inhibitor, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of June&#160;30, 2022, to date in aggregate, we have recognized $11.9 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $11.6 million. During the three and six months ended June&#160;30, 2022 we recognized and recorded as cost of revenue $0.2 million and $0.3 million, respectively, related to the AstraZeneca Termination Agreement. During the three and six months ended June&#160;30, 2021 we recognized zero and $1.0 million, respectively, as cost of revenue related to the AstraZeneca Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The June&#160;30, 2022 and 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances are attributable entirely to the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to cash received during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ardx:NumberOfSeparateCollaborativeAgreements
      contextRef="i074ffa4e105544b6beba06ccf79db768_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNjYw_f696305e-36c6-4c73-a45a-663a7d2ad647"
      unitRef="item">1</ardx:NumberOfSeparateCollaborativeAgreements>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTEx_520f04d7-7fd9-44d1-afbb-9fa36605dfb4"
      unitRef="usd">10000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment
      contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTcx_c06eb2f7-f90c-4592-a1f0-7a7846b0e34f"
      unitRef="usd">5000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment>
    <ardx:TermOfPaymentOfLicenseFeeFirstInstallment
      contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTgx_e1556b52-518b-41b2-8f9c-c9448e7d6406">P30D</ardx:TermOfPaymentOfLicenseFeeFirstInstallment>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment
      contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA1OQ_a102a389-3b9b-4c27-bce5-50aab553dc88"
      unitRef="usd">5000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment>
    <ardx:TermOfAgreement
      contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTIxMA_1a3a81df-ec6d-4f08-a291-c0e0f5effbfc">P2Y</ardx:TermOfAgreement>
    <ardx:CollaborationAndLicensingAgreementsNumberOfAmendments
      contextRef="i95cd52616ff5466da36d2f2aa223f06b_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMjc0ODc3OTA4ODEwMA_d5dc4f41-0f07-4ab5-9aa9-f6d9f4a5f5ea"
      unitRef="segment">3</ardx:CollaborationAndLicensingAgreementsNumberOfAmendments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i061c308d6b1a43f0968b363555e92226_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTU2NQ_c68cf941-35db-4d93-a824-b9f1a0e548ad"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fb105e15b8b47d9b8839aab9ebd811a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTU2NQ_e6d9fb46-f8db-4aa8-88fc-c0bbfa47b8eb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f5bff24d8fb4ded926a6a65685e29e5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY4MQ_96f0b135-24e7-4216-a0a4-1efb9a0be097"
      unitRef="usd">1300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3db2f9f0408b4c3b8bc1d23c42421c54_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODU5MQ_c333b033-88bf-40fd-85eb-5d6d64428bd4"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i41b83b1385d64bb0b4fcdd8478229082_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzE2NQ_a60cb498-2826-4fdf-9953-a9e57656cc53"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i41b83b1385d64bb0b4fcdd8478229082_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzU2MQ_a60cb498-2826-4fdf-9953-a9e57656cc53"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="i08c9f146a507443cbf42d1ec3614ba5a_I20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzYwMQ_07814917-cb4e-4ae9-ba5b-1d541db251ec"
      unitRef="usd">55000000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i014594d7c2e34a5ba34aa3612a1cf0fe_D20171101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMzY0Ng_7b09af32-e6eb-4279-8dca-1808809366ff"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="i9b05c8d90cf241fe9da5a7dfc1eabd4c_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTY0MDA4Mw_ac8322b2-52cd-4835-a040-2ad6b46b4a2f"
      unitRef="jpy">8500000000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="i9b05c8d90cf241fe9da5a7dfc1eabd4c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTY0MDA5MA_e0c6c251-d5d4-4e3b-a038-a704dc42348f"
      unitRef="usd">62300000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate
      contextRef="i1d511f2c209a4a5aaff9671b49116eb3_I20220411"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODU1MQ_9ee346f1-4a37-4b24-afc8-a0a1a02b80c7"
      unitRef="usd">40000000</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches
      contextRef="i1d511f2c209a4a5aaff9671b49116eb3_I20220411"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNDc3MQ_4a07a5ab-b217-41c4-8961-6d8fc9bd553e"
      unitRef="payment_tranche">2</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i241a969a3e094d03b3d8dd8e7e25cf1e_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTEyMg_69211798-2195-4d4e-a8c4-bb610e4284c9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82f5715e2fbb4db4a6cd85a32f3fc2f6_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTEyMg_f85bb2b9-cf1b-44e8-9ea3-c748ce7f3f03"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8b1212609cc42c18f655b93c0a406eb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTIzNg_cd7ce893-bec2-420a-a447-e61505753512"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2edefef1531b4386b1099d09c2a70ee0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODYxNA_6896b028-923a-4b80-b13c-9e4b8a649e45"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f7b4102a4754a8cbae7529a244bf3f5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTQxMQ_edc3b628-729f-415f-abc6-80ad91421357"
      unitRef="usd">952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4597c87af79d4327bdff63f69b57b1ae_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODY0Mg_d5f91051-8325-414e-a764-6e08d38a28bb"
      unitRef="usd">966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i109c5f1c267e4db584222bf588b29f9b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNTU5Nw_ffaadb40-1edf-4c0f-bb54-05b9e91ab33d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7671d7833f84b738c08011e9527d6a6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODcwMw_e339e873-1f67-471b-bf14-d695d43d7de6"
      unitRef="usd">126000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i0bc59163e21d45b0a82ec6a938f3e4fb_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNjc1OA_5cef2042-3843-40c5-95b2-de9b4ef5c2c5"
      unitRef="usd">12000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="i9bfae235b525451e977ec2988b5262e7_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ1Nzk2NQ_7d8a45d1-cf02-4734-952b-3aedf3d6d195"
      unitRef="usd">113000000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="i0e3965d572ee4aceaf968a9429112520_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ1Nzk5Mw_7e2ce9d1-1f74-418c-b10f-b96fbf3fe055"
      unitRef="usd">3000000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <ardx:ThresholdPercentageOfSalesForTieredRoyalties
      contextRef="i9bfae235b525451e977ec2988b5262e7_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ1ODIxMA_e74f097d-b1cc-4dc4-8b14-6ac992674936"
      unitRef="number">0.20</ardx:ThresholdPercentageOfSalesForTieredRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifad96d6d72d2427c850a8f4187189002_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_0d7c4472-8de8-4bb6-a767-f5e995bd1f1e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie17162477fe2411892bc4d952ca4b3c7_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_45d8ac7f-7290-4c8f-bf17-7bc151fdcff5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39c1eb48ebc84ec3b3bdd61a6ce8578c_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_4f7c427b-0623-402f-9528-2a8d700cb872"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1177146d35a4e4da142927eaed0ecc9_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfNzUzMg_d8635df6-6960-46da-9cf7-e32be47faa15"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i52011fdfd0334a89bcd53e3d6de2b37f_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfODI4Mw_16ead127-30a2-4e57-a288-ba0a2467b0d7"
      unitRef="usd">2300000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="if3b2a409542f4bc1a83f80b78e672650_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ2MDIwNw_75e816c7-f50e-44da-b341-038780bf741b"
      unitRef="cad">22200000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="if3b2a409542f4bc1a83f80b78e672650_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ2MDIzMQ_e713366b-d2be-4651-99c8-0d918391a0eb"
      unitRef="usd">17200000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="i17126d287de74e979cfde5127eb1da69_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTY0OTI2NzQ2MDA1NQ_414b29be-201c-43f0-8946-8e05906dff2c"
      unitRef="usd">700000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfODk4Mw_65c02c32-51f0-41fb-8c66-1d39a68e8daa"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="i3fa9c0a733e94e138c49c87fb16e296f_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTA2OA_396b92d0-6711-461c-85b2-03dbfe12e4c6"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i2766bdc22382498f96100a7aaec65cb8_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTE3OA_479d9d34-948e-4dd2-b07f-c75bf04b38dc"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:CostOfRevenueAggregateAmountRecognized
      contextRef="i9df8422a3ac54491960b7f51d8d389ad_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTI2Mw_756f0715-7559-4b6c-a29d-d85fd17477b2"
      unitRef="usd">11900000</ardx:CostOfRevenueAggregateAmountRecognized>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i2766bdc22382498f96100a7aaec65cb8_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTI3Mw_479d9d34-948e-4dd2-b07f-c75bf04b38dc"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid
      contextRef="i9df8422a3ac54491960b7f51d8d389ad_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTM0Nw_059b0805-f65a-45cb-9296-156b23680406"
      unitRef="usd">11600000</ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid>
    <us-gaap:CostOfRevenue
      contextRef="i4411ff34351946ec9efc6813633c673b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc1Mw_82e0218a-5c28-418d-9756-ec1ae5e6ab68"
      unitRef="usd">200000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i97f3b674467b417ab75287cabe20b889_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc2Ng_ee0dedff-fd48-4419-a928-42bad9a2e514"
      unitRef="usd">300000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i2de17a790f144efcb20e85eca270e9b7_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc4MQ_769b79ae-95b3-4c1e-877a-16071f91c4ab"
      unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="if2354099a5be4c5f9e83fee570934ba6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfMTA5OTUxMTYzODc5NA_74f5b344-46d9-4894-9cef-ee30200535cd"
      unitRef="usd">1000000</us-gaap:CostOfRevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RleHRyZWdpb246YmFkZGMyYjNmOTAxNDE1N2I0NjU2ZDBlYzUwODllNTRfOTk1Ng_8cc9279c-6e17-40ae-90f9-f99277bf3b81">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period. The June&#160;30, 2022 and 2021 current deferred revenue balance is attributable entirely to the 2019 KKC Agreement and the non-current deferred revenue balances are attributable entirely to the 2017 KKC Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to revenue recognized in the period for which cash has been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to cash received during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2325fcd766374f64b728734271bdcb7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfMS0xLTEtMS0zNDQ5MQ_21341a94-049a-4fd2-896b-79f18ce41571"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3cc77e1d71d74d1a9a74f5ec6a36efde_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfMS0zLTEtMS0zNDQ5MQ_27817b38-6d3f-4b95-8057-bd5bd96dceb2"
      unitRef="usd">4177000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="i061c308d6b1a43f0968b363555e92226_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNC0xLTEtMS0zNDQ5MQ_6de04b5a-bb17-47d2-81f9-acab3d4571c6"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived
      contextRef="i3db2f9f0408b4c3b8bc1d23c42421c54_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNC0zLTEtMS0zNDQ5MQ_c6930833-3c54-4f79-a348-c1337c12687f"
      unitRef="usd">2765000</ardx:ContractWithCustomerLiabilityRevenueRecognizedCashReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0f865d48364e43feb2428abb54224a8d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNi0xLTEtMS0zNDQ5MQ_452a90f5-0c6f-41b4-b77a-9deae2d7f6c2"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie657c8dfb1514308ada6df2d9ee8bf1e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmFiODQ4NjI5NTc0YjQzNjlhNDMyNmI4MDFkNGQyYzU2L3RhYmxlcmFuZ2U6YWI4NDg2Mjk1NzRiNDM2OWE0MzI2YjgwMWQ0ZDJjNTZfNi0zLTEtMS0zNDQ5MQ_156e9165-75e4-40b2-87ba-c0d7b5744cdc"
      unitRef="usd">1412000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6c552aa84944403c8a3fb465c4b3bc03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMS0xLTEtMS0zNDQ5MQ_e0974372-bfb4-4a63-80c2-9e53db51b8d2"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ieee60570c43f40948f1db4079104e9e0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMS0zLTEtMS0zNDQ5MQ_904718a5-881c-4a95-a032-25e5e828ffc6"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:ContractWithCustomerLiabilityIncreaseForCashReceived
      contextRef="i531d15c78ece4f9a9905d6f96710a74c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMi0xLTEtMS0zNDQ5MQ_f77ae66f-5a15-499e-b1e4-f43f1564de90"
      unitRef="usd">3829000</ardx:ContractWithCustomerLiabilityIncreaseForCashReceived>
    <ardx:ContractWithCustomerLiabilityIncreaseForCashReceived
      contextRef="i84c7c1add2584109ba82c720ff846b37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMi0zLTEtMS0zNDQ5MQ_e9173eb0-7087-4038-9528-a6197b986717"
      unitRef="usd">2947000</ardx:ContractWithCustomerLiabilityIncreaseForCashReceived>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="i531d15c78ece4f9a9905d6f96710a74c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMy0xLTEtMS0zNDQ5MQ_f27b62b8-99ce-41eb-a7c6-36cd195f457c"
      unitRef="usd">3865000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="i84c7c1add2584109ba82c720ff846b37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfMy0zLTEtMS0zNDQ5MQ_d7d3e1dd-c8aa-4ff5-874e-ce0e35c763ac"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i865d6c576ab546bcbf3614308dda7939_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfNi0xLTEtMS0zNDQ5MQ_d46b886c-87c1-4b26-9698-292aa110f41d"
      unitRef="usd">12421000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i87b20fa0c635463cae3c68920d3544be_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV80OS9mcmFnOmJhZGRjMmIzZjkwMTQxNTdiNDY1NmQwZWM1MDg5ZTU0L3RhYmxlOmZjMzkxZmM0ZGQ0MzQ5YWI5ZTMzM2U3OTVmMzVmYWNjL3RhYmxlcmFuZ2U6ZmMzOTFmYzRkZDQzNDlhYjllMzMzZTc5NWYzNWZhY2NfNi0zLTEtMS0zNDQ5MQ_7ade92b9-8e2c-4228-b605-2876e72181ae"
      unitRef="usd">2947000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AssetRetirementObligationDisclosureTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF83MTQ2ODI1NTg4NzU5_e96847ac-5884-4c51-a409-23e4bddf1927">DEFERRED ROYALTY OBLIGATION&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 28, 2022, we and HealthCare Royalty Partners IV, L.P. (&#x201c;HCR&#x201d;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (the &#x201c;HCR Agreement&#x201d;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#x201c;Royalty Interest Payments&#x201d;) that we may receive under our 2017 License Agreement with KKC based upon KKC's net sales of tenapanor in Japan. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $10.0 million upfront payment, and we are eligible to receive a $5.0 million payment following KKC's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $5.0 million payment in the event net sales by KKC in Japan exceed a certain annual target level by the end of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 KKC Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 KKC Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 KKC Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 KKC Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 KKC Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.&lt;/span&gt;&lt;/div&gt;We received the $10.0&#160;million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation on our condensed balance sheet. As part of the sale, we incurred approximately $0.4 million in transaction costs, which, along with the deferred royalty obligation, will be amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by KKC, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. To determine the amortization of the deferred royalty obligation, we are required to estimate the total amount of future royalty payments to be received from KKC for sales of tenapanor in Japan. There are a number of factors that could materially affect the amount and timing of royalty payments from KKC, most of which are not within our control. We will periodically assess the estimated royalty payments from KKC and, to the extent that the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation. As of June&#160;30, 2022, our effective interest rate used to amortize the liability is 34.4%. During the three and six months ended June&#160;30, 2022, we did not recognize a material amount of non-cash interest expense for the amortization of the deferred royalty obligation.</us-gaap:AssetRetirementObligationDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i2776e4b43d244212bb36a96e1f7f6bf0_D20220628-20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MTAw_23400831-122f-4198-9c37-bbac842d0d29"
      unitRef="usd">20000000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic5599d31da844dc09d6e245bda588015_I20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MDA4_2828db50-19f9-4165-9739-6890f5045a81"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic5599d31da844dc09d6e245bda588015_I20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MDI2_7c56c88a-ec20-4720-9e05-e284cd11187f"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic5599d31da844dc09d6e245bda588015_I20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MTA4_6f4b29d2-4b6a-4d64-b431-3a7f1aafd554"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ide6b9c3554974336b19c0254e81adba0_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8yNzQ4Nzc5MDc4MjQ5_f7b5771f-02ce-4d56-a3e0-d169bbdf24d0"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <ardx:ContractWithCustomerLiabilityTransactionCosts
      contextRef="ide6b9c3554974336b19c0254e81adba0_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xNjQ5MjY3NDQ3MDY4_6b30411d-d17c-4722-8bf1-f55c1d37a1a1"
      unitRef="usd">400000</ardx:ContractWithCustomerLiabilityTransactionCosts>
    <ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent
      contextRef="ibe07abdbf5b343909ddaf5fb16e06caf_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV8xMTY0L2ZyYWc6ZDRkMjZkNGYzNWQ0NDg3MDlhNWZkOGZiMTgyMjg4YzAvdGV4dHJlZ2lvbjpkNGQyNmQ0ZjM1ZDQ0ODcwOWE1ZmQ4ZmIxODIyODhjMF8xMDk5NTExNjM2MjAz_1fc29994-4386-4704-a078-b5865b551605"
      unitRef="number">0.344</ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNzE4MA_8698ce73-40ee-4b55-9a33-ad66843a6db7">BORROWING &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solar Capital and Western Alliance Bank Loan Agreement&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#x201c;2018 Lenders&#x201d;). The 2018 Loan Agreement provided for a $50.0 million loan facility with a maturity date of November&#160;1, 2022 (the &#x201c;2018 Loan&#x201d;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Derivative Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SLR Investment Corp. Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022 (the &#x201c;Closing Date&#x201d;), we entered into a loan and security agreement (the &#x201c;2022 Loan Agreement&#x201d;) with SLR Investment Corp. as collateral agent (the &#x201c;Agent&#x201d;), and the lenders listed in the 2022 Loan Agreement (collectively the &#x201c;2022 Lenders&#x201d;). The 2022 Loan Agreement provides for a senior secured loan facility, with $27.5 million (the &#x201c;Term A Loan&#x201d;) funded on the Closing Date and an additional $22.5 million that we may borrow on or prior to July 25, 2023; provided that (i) we have received approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (the &#x201c;Term B Loan&#x201d;, and collectively, the Term A Loan and the Term B Loan, the &#x201c;2022 Loan&#x201d;). On August 1, 2022, we entered into an amendment to the 2022 Loan Agreement with SLR Investment Corp. that extends the date by which we must receive approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis in order to borrow the additional $22.5 million from December 31, 2022 to March 31, 2023. The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Loan bear interest at a floating per annum rate equal to 7.95% plus the greater of (i) one tenth percent (0.10%) and (ii) the one-month rate published by the Intercontinental Exchange Benchmark Administration Ltd or its successor. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024. Accordingly, beginning on April 1, 2024, we will be required to make monthly payments of interest plus repay the 2022 Loan in consecutive equal monthly installments of principal over 36 months. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (the &#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0&#160;million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of June&#160;30, 2022 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1. Organization and Basis of Presentation: Liquidity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i332a0792bd1f4c0e92d7f1b5cbe65a8e_I20180516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzc3_652912d8-16f9-4040-8263-0e977956cd3f"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i332a0792bd1f4c0e92d7f1b5cbe65a8e_I20180516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNjA0NzMxMzk1OTk2NA_332d9e08-f422-4366-8ec1-2d7619e7f488"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i45fff355f00f45b192078e143fe5bd5a_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNzc3_22be1f59-7c06-4c5a-9112-06da625be773"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="ibb409ddee548471bb71a3d72714cd69d_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMTM0NQ_834f2467-e7f4-4e49-8327-5b790b602b8c"
      unitRef="usd">27500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <ardx:RemainingFundingBasedOnConditionalMilestoneAchievement
      contextRef="id7b0db6f01a842ee9808c8aadcd299ed_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMTQxMw_01e7ca67-ada7-4c67-9d8d-c1bd1cd70047"
      unitRef="usd">22500000</ardx:RemainingFundingBasedOnConditionalMilestoneAchievement>
    <ardx:RemainingFundingBasedOnConditionalMilestoneAchievement
      contextRef="id7b0db6f01a842ee9808c8aadcd299ed_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMTA5OTUxMTYzNTM3Mg_01e7ca67-ada7-4c67-9d8d-c1bd1cd70047"
      unitRef="usd">22500000</ardx:RemainingFundingBasedOnConditionalMilestoneAchievement>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5ca4f47844fc4780baff69e8911b29c0_D20220223-20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjA1NA_05df2df4-72db-422b-a0a2-1bb58ba5cf2c"
      unitRef="number">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ardx:DebtInstrumentVariableRateBaseOption
      contextRef="i5ca4f47844fc4780baff69e8911b29c0_D20220223-20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjEwMA_0a685888-9501-4e48-b3af-ec218eacba37"
      unitRef="number">0.0010</ardx:DebtInstrumentVariableRateBaseOption>
    <us-gaap:DebtInstrumentTerm
      contextRef="ibb409ddee548471bb71a3d72714cd69d_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjc0ODc3OTA3NzA1NQ_c9dc2232-5214-4d2f-a50e-d1c37aaba1b6">P36M</us-gaap:DebtInstrumentTerm>
    <ardx:DebtInstrumentClosingFeeAmount
      contextRef="i53d431115a854c79807d5f03cee9dc62_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjUxNQ_640798b8-23d0-4a9d-9eb8-a81535b01953"
      unitRef="usd">200000</ardx:DebtInstrumentClosingFeeAmount>
    <ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents
      contextRef="id7b0db6f01a842ee9808c8aadcd299ed_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjU4NA_8be6a5bd-d957-4c69-827d-696401c5bd89"
      unitRef="usd">100000</ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents>
    <ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage
      contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMjgyOQ_1040532c-b795-4cbb-88e1-8c0d768437e7"
      unitRef="number">0.0495</ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i63aef503641b4c29a348a0255e9218d2_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzE2Mw_1c15a7e6-5777-4b5a-bea4-c16eea301947"
      unitRef="number">0.03</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="idf01893ad4c84865891f7430b162cae9_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzI5Mw_9c5c35c5-30ce-4d26-ada4-e8ada37db053"
      unitRef="number">0.02</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i5e0099257ff746c4ba0bf0a5c60285a1_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzQ4Mw_85744885-f679-4df6-9e7e-53f85c873658"
      unitRef="number">0.01</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:ExitFeePercentage
      contextRef="i62823de538114437863d701d8f2af1f0_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfMzg5OA_6d32f082-4a97-455c-b797-25f3399206a5"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNDA4NA_c2e0c691-7a5a-4902-9572-906981dc6270"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <ardx:LoanAgreementExitFeeTerm
      contextRef="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNDI1OQ_eca47477-ade4-42f6-a0da-b2b8661b2b9c">P10Y</ardx:LoanAgreementExitFeeTerm>
    <ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNTEwMw_93e200f0-7e38-47a0-ad21-23cecbbf204e"
      unitRef="number">0.80</ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod
      contextRef="i445b8ba0bc314f23b2c6d8f35b42ac79_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNTI1MA_0c98da53-c75f-4519-9bed-f78cdc3b480c">P6M</ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod>
    <ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNTMxNA_f490374f-e414-4f43-8386-211eecc10a30"
      unitRef="number">0.60</ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:DebtInstrumentInterestRateOnDefaultPercentage
      contextRef="i9fc61d7b192f49609b11da252ff3673e_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNjQ0Mg_8b565812-6967-4fd7-a907-60b56a5a9be4"
      unitRef="number">0.04</ardx:DebtInstrumentInterestRateOnDefaultPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RleHRyZWdpb246MDAzMzQ2YmJjOTY3NDEwNjg3NTU1MTBhOTAzMTM4MDhfNzE3OQ_874e9aa1-cf7e-41f3-8abc-96effcd25b51">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMC0xLTEtMS0zNDQ5MQ_037884e4-1a01-476c-873b-28098afc9dda"
      unitRef="usd">28862000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMS0xLTEtMS0zNDQ5MQ_83967937-9abd-4bf4-aa9c-ec3e438a863b"
      unitRef="usd">1259000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMi0xLTEtMS0zNDQ5MQ_7aab12ea-da28-4e63-af2d-f0eeb09bb098"
      unitRef="usd">1230000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebt
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfMy0xLTEtMS0zNDQ5MQ_23cfde7b-f6e4-4c57-b3b9-3f9689e30beb"
      unitRef="usd">26373000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfNC0xLTEtMS0zNDQ5MQ_8365688b-eb52-47ae-95c9-37b834813743"
      unitRef="usd">26373000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81Mi9mcmFnOjAwMzM0NmJiYzk2NzQxMDY4NzU1NTEwYTkwMzEzODA4L3RhYmxlOmVmNGFhOWVmNTMyYTQzZGU4NzcyOTBkNTY0YTE5MjI2L3RhYmxlcmFuZ2U6ZWY0YWE5ZWY1MzJhNDNkZTg3NzI5MGQ1NjRhMTkyMjZfNS0xLTEtMS0zNDQ5MQ_f0218d4a-2cb7-4785-99d2-8afb316e73dc"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfNDM3Nw_7c262c21-fb6e-4cc4-b56c-1df788203518">DERIVATIVE LIABILITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash (the &#x201c;2018 Exit Fee&#x201d;) upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis and (ii) FDA approval of tenapanor for the treatment of patients with IBS-C, which was obtained on September 12, 2019 when the FDA approved IBSRELA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (tenapanor), a 50 milligram, twice daily oral pill for the treatment of IBS-C in adults (the &#x201c;2018 Exit Fee Agreement&#x201d;). Notwithstanding the February 2022 prepayment of the 2018 Loan our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of both June&#160;30, 2022 and December&#160;31, 2021, the estimated fair value of the 2018 Exit Fee was $0.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2018 derivative liability include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to the 2018 Lenders as a result of the FDA approvals and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR (or a comparable successor rate if LIBOR no longer exists). Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of  2% of the 2022 Loan funded (the &#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis (the "Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of June&#160;30, 2022, the estimated fair value of the 2022 Exit Fee is $0.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in chronic kidney disease patients on dialysis by December 31, 2022, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10.0% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i45fff355f00f45b192078e143fe5bd5a_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTg1_22be1f59-7c06-4c5a-9112-06da625be773"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic904ee852e2546278f6d6a2a871ab36c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTA5OTUxMTYzMjI0Ng_7e26980b-9f1a-46fc-a30d-42aaade052e1"
      unitRef="usd">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idb141ea05dc14bd488bc51b17742bb1b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTA5OTUxMTYzMjI0Ng_a9136754-8e7e-48fd-b219-e5475fa97aeb"
      unitRef="usd">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i45fff355f00f45b192078e143fe5bd5a_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTU2Nw_22be1f59-7c06-4c5a-9112-06da625be773"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="i9edf9296a4894494938a6948e6255770_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTk5NA_20942b27-af9d-4969-a504-6d653111dee7"
      unitRef="number">0.100</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation
      contextRef="i9edf9296a4894494938a6948e6255770_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMjEyOA_11870450-85a7-48da-aef1-626d2a3b201d"
      unitRef="usd">100000</ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation>
    <ardx:ExitFeePercentage
      contextRef="i62823de538114437863d701d8f2af1f0_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMjMxMQ_4ffa2813-ab0a-440f-93df-bc90f6158f47"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="i1931e8f63bf74b1c9180e0fbbe595f64_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMjQ5Nw_8ca61a5d-83c1-4cc8-a483-50e8697ffab8"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6999cc41a5f44cf0a5b525b6303dd7ea_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMTA5OTUxMTYzMjMzOA_d4cd58e2-32c0-4af5-bf78-45589a9b9f43"
      unitRef="usd">400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="i628699ac92bb4cc4aec87c7221cb6c0e_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfMzk5Mg_5d633696-2f93-42b7-8979-cbb31d1649f9"
      unitRef="number">0.100</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RleHRyZWdpb246MzgwOWVmYTc4OTJkNDJjZDkxYzRjMTA3YTQ2ZjgzYjRfNDM3OA_2d21b4f8-f000-46e3-af48-9aa54fce4eae">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our exit fee derivative liabilities recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our statements of operations and were as follows for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0ef0d267ad3d436b9af9981688d023fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMi0xLTEtMS0zNDQ5MQ_75a4e003-f723-44e3-b3c8-e2adf51f2614"
      unitRef="usd">698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if76ea5067c204fabaac4ade032cb88b0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMi0zLTEtMS0zNDQ5MQ_3840295f-5a6d-415f-bdb3-b75402062829"
      unitRef="usd">1376000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i01f7c79b7bcf4056b7704b95788cba3b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMy0xLTEtMS0zNDQ5MQ_af155d71-9d20-435d-ab28-5f8c8e826349"
      unitRef="usd">375000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i3004be0bc24d40129c1b7ba07661f272_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfMy0zLTEtMS0zNDQ5MQ_5729befb-3b2f-441a-9dd5-0af9f3411375"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i02ce57c9f03945a8810129f2967308c3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0xLTEtMS0zNjE3MA_5fa80f47-bf71-4a77-a1c4-79c8d2ac7e8a"
      unitRef="usd">-29000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i016dc6bfae9845e092f75be5637f0b18_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0zLTEtMS0zNjE3MA_58eaf5fc-688d-474e-8596-03ecaa1c6475"
      unitRef="usd">-713000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="idd618c73d00048398fb1fc314aaf0e8a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNi0xLTEtMS0zNjE3MA_83dd38c5-4eed-4284-9ae1-79ef2fd862f7"
      unitRef="usd">47000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i65431a25e35a45e890530a699eb3a862_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNi0zLTEtMS0zNjE3MA_5021ca0d-b331-4532-9044-ed9c6afa61b3"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8a970c46b2e64b9a887463a2644c5079_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0xLTEtMS0zNDQ5MQ_3fdb731f-c2b6-4c8f-b2b6-4a3300a5b3c3"
      unitRef="usd">1091000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1b9eadd78ecf4cbaa95a089d4e6dde72_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81NS9mcmFnOjM4MDllZmE3ODkyZDQyY2Q5MWM0YzEwN2E0NmY4M2I0L3RhYmxlOjI5OWVkZTViOTI5MzRlNzM5M2ZlNTk2YTEyYWI2NDg0L3RhYmxlcmFuZ2U6Mjk5ZWRlNWI5MjkzNGU3MzkzZmU1OTZhMTJhYjY0ODRfNS0zLTEtMS0zNDQ5MQ_c31e9543-f1e6-42bc-91b4-6eac4ddce917"
      unitRef="usd">663000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzgx_f17521e3-288b-4ce6-afac-95a9a380244f">LEASES&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,752&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,748&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzgy_4993259c-6d9e-43b9-9da0-cf41369eef0f">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,054&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,752&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,691&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,857&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,748&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMS0xLTEtMS0zNDQ5MQ_65cbe5f9-485a-44a0-b41b-82ac1cf2e0a2"
      unitRef="usd">11054000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMS0zLTEtMS0zNDQ5MQ_e17c056b-22fb-4198-8f31-c00d3e60a861"
      unitRef="usd">12752000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMy0xLTEtMS0zNDQ5MQ_6a1d6c0b-ba8f-45f8-b0bf-d14a06a116f3"
      unitRef="usd">3691000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfMy0zLTEtMS0zNDQ5MQ_3bd78acb-4575-4b13-b8a7-fc85fcb4e0f5"
      unitRef="usd">3492000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNC0xLTEtMS0zNDQ5MQ_83ee9a81-a145-4023-a602-247bd03866ce"
      unitRef="usd">7857000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNC0zLTEtMS0zNDQ5MQ_5bf54bb2-a5de-4dbb-a603-109a4051586f"
      unitRef="usd">9748000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNS0xLTEtMS0zNDQ5MQ_b4d7ff0b-1bf7-4d34-8ac2-409c2c1cb09e"
      unitRef="usd">11548000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNS0zLTEtMS0zNDQ5MQ_97b0885b-2be3-43c1-9803-0cb1d3bf873b"
      unitRef="usd">13240000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNy0xLTEtMS0zNDQ5MQ_6dd69424-204b-4819-907c-57166b471ef1">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfNy0zLTEtMS0zNDQ5MQ_29a9d930-74c5-4a26-b0fa-0b7b59d38e19">P3Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfOC0xLTEtMS0zNDQ5MQ_973a5877-3a57-41a4-b172-e8f153d8d86e"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZlYzhiZjgwYzBkNTQyZGY5NGI0MDc0YzZmZTU4NWU0L3RhYmxlcmFuZ2U6ZmVjOGJmODBjMGQ1NDJkZjk0YjQwNzRjNmZlNTg1ZTRfOC0zLTEtMS0zNDQ5MQ_3e39c003-a30a-4e36-acb8-452b0a9590ca"
      unitRef="number">0.069</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzgz_5d3b7243-522c-41e1-a77c-59eb472158ee">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs, which are included in operating expenses in our statements of operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi0xLTEtMS0zNDQ5MQ_273db59d-59fa-4470-bdd0-dbe22919b267"
      unitRef="usd">1064000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi0zLTEtMS0zNDQ5MQ_3aee965e-05e6-478b-af9b-f7bb90bab4a2"
      unitRef="usd">837000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi01LTEtMS0zNDQ5MQ_329820ef-509c-48dc-b0db-bf3212293717"
      unitRef="usd">2128000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMi03LTEtMS0zNDQ5MQ_c37347c6-d8d2-46fc-bdbb-d8115021abb5"
      unitRef="usd">1510000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy0xLTEtMS0zNDQ5MQ_fcd38801-1823-490d-b8fb-ef90abbc4a9e"
      unitRef="usd">1064000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy0zLTEtMS0zNDQ5MQ_e331849c-e6c1-4b9b-a4d7-fea0183e65bc"
      unitRef="usd">766000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy01LTEtMS0zNDQ5MQ_798d90e6-2fcf-414d-ac49-29f5d9d9ea30"
      unitRef="usd">2122000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOmZmZmQyYzkzYWFjNDQyY2JhYmRjNjM5NjQ1MDkzMWJjL3RhYmxlcmFuZ2U6ZmZmZDJjOTNhYWM0NDJjYmFiZGM2Mzk2NDUwOTMxYmNfMy03LTEtMS0zNDQ5MQ_e103e958-c144-4892-9001-d0b3d6abc03b"
      unitRef="usd">1554000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RleHRyZWdpb246YmY2NDE5MjdmZDljNGE2Nzg0NTcxOTM2MDUxYjhkMzBfNzg0_de2de67f-41df-4d81-98e5-6d9a615f0ba9">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of June&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMC0xLTEtMS0zNDQ5MQ_d35dd614-c8b0-4c18-af99-008b838b1888"
      unitRef="usd">2170000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMS0xLTEtMS0zNDQ5MQ_aea5b90d-732a-4a15-9bb0-4c728ce0b470"
      unitRef="usd">4440000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMi0xLTEtMS0zNDQ5MQ_512b4a0b-213d-4d09-9195-2fadf236d8e7"
      unitRef="usd">4589000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMy0xLTEtMS0zNDQ5MQ_17872a95-358e-400f-afe4-694f04bc27a4"
      unitRef="usd">1321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfNC0xLTEtMS0zNDQ5MQ_f57fe767-8e78-485c-8935-daa7be14be53"
      unitRef="usd">252000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfNi0xLTEtMS0zNDQ5MQ_659be724-1181-4c9e-9a8a-b0eb0d3066af"
      unitRef="usd">12772000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfNy0xLTEtMS0zNDQ5MQ_e3566ab8-a472-440d-8fa0-1104a2b981c3"
      unitRef="usd">1224000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfOC0xLTEtMS0zNDQ5MQ_79400488-c840-47ae-be57-c7e0fd8230b9"
      unitRef="usd">11548000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfOS0xLTEtMS0zNDQ5MQ_64493c55-eaee-45d9-9215-7e57d6086a26"
      unitRef="usd">3691000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV81OC9mcmFnOmJmNjQxOTI3ZmQ5YzRhNjc4NDU3MTkzNjA1MWI4ZDMwL3RhYmxlOjcxYjVlN2FiODRkOTRjNGI4ZmU3MmEyMDI5MGMzZjNmL3RhYmxlcmFuZ2U6NzFiNWU3YWI4NGQ5NGM0YjhmZTcyYTIwMjkwYzNmM2ZfMTAtMS0xLTEtMzQ0OTE_ca5b0941-19b1-40e2-8c62-822f586b4cdf"
      unitRef="usd">7857000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMjM5Nw_96e2ae9a-6161-48fd-b1f5-270a15a8417d">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At the Market Offerings Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, we filed a Form S-3 registration statement, which became effective in August 2020 ("Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $100.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#x201c;at the market offerings&#x201d; (the "2020 Open Market Sales Agreement"). The 2020 Open Market Sales Agreement was fully utilized as of December 31, 2021. During the six months ended June&#160;30, 2021 we sold 9.0 million shares and received gross proceeds of $63.8 million at a weighted average sales price of approximately $7.10 per share under the 2020 Open Market Sales Agreement.&lt;/span&gt;&lt;/div&gt;In August 2021, we filed an additional prospectus supplement under the Registration Statement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under an additional sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. We are not required to sell shares under the 2021 Open Market Sales Agreement. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, receives a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the six months ended June&#160;30, 2022 we sold 20.5 million shares and received gross proceeds of $18.9 million at a weighted average sales price of approximately $0.92 per share under the 2021 Open Market Sales Agreement.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="id37f41791c3a4469a79f174900a9480a_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMzE1_0c236f96-7169-4f39-89b2-50cbf06e8437"
      unitRef="usd">250000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i3134b5534dfe4e7488897f77ce075b19_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfNTYy_c77362da-da24-415b-9545-569a11c3501d"
      unitRef="usd">100000000</ardx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfODkx_fbda8abb-6b25-49e7-8d4c-47100a4ddf31"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfOTMy_2c809821-e1a5-4842-8526-ed7959ce4ad0"
      unitRef="usd">63800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="i6a3036e50c6248bfb591a3c4deb13553_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfOTg2_ac6339b0-0c53-433c-908c-e910bc2e4a2a"
      unitRef="usdPerShare">7.10</ardx:SaleOfStockWeightedAveragePricePerShare>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i7723c20c25bd40d6a71d48a503fa8f2f_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTIyNg_c8b3f561-1813-446c-89f9-5b1516a03ef2"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i7723c20c25bd40d6a71d48a503fa8f2f_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTQ2Mg_c8b3f561-1813-446c-89f9-5b1516a03ef2"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTcwNQ_5ed60d78-2b80-44c7-902b-d686e3a64a20"
      unitRef="number">0.03</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTg0Nw_e66d3080-e7cd-4214-87d7-32eb2e2eda53"
      unitRef="shares">20500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTg4OA_615143f9-89b4-4f58-b881-c95c7d5bdb58"
      unitRef="usd">18900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="if628f9bb121445238321e4a4cf89b71f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82MS9mcmFnOjI1MjI2ODI2MWRkODQ3MTVhMTcxNzQzZDQ4NjFhOTA5L3RleHRyZWdpb246MjUyMjY4MjYxZGQ4NDcxNWExNzE3NDNkNDg2MWE5MDlfMTk0Mg_5c515e83-06b8-41db-85ef-611c4601c25c"
      unitRef="usdPerShare">0.92</ardx:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5NA_2c2e3bab-f082-4428-b95b-80e9c923f5a1">EQUITY INCENTIVE PLANS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the balance of inventory included in our condensed balance sheet includes $0.2 million stock-based compensation. During the three and six months ending June&#160;30, 2022, the amount of stock-based compensation released from inventory into cost of revenue was not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option grants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, we sold approximately 0.1 million shares of our common stock under the ESPP. The shares were purchased by employees at a purchase price of $0.65 per share resulting in proceeds to us of approximately $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuance of Common Stock for Services&lt;/span&gt;&lt;/div&gt;Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the six months ended June&#160;30, 2022, we issued no shares of our common stock to members of the board of directors in accordance with the program.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5NQ_c6524160-cf47-472a-88e5-0acbdf729311">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), performance-based restricted stock units ("PRSUs") and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94e0bb25c3c34a6a85f20fb41dddf6e0_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy0xLTEtMS0zNDQ5MQ_34bc3cc0-5953-4f8c-aab9-43a924e1fec5"
      unitRef="usd">2220000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib634f3437de24f219bf6e52991431efe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy0zLTEtMS0zNDQ5MQ_7e18315c-a4b6-45e6-bef4-6bc834b20bce"
      unitRef="usd">2132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic965a8cbb9a44f0fae1e69681ba94b33_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy01LTEtMS0zNDQ5MQ_77333ee2-8551-433d-9a08-68ec8e281232"
      unitRef="usd">4728000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i40f8bd2473da4add99b5d428ef128fec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfMy03LTEtMS0zNDQ5MQ_117f8b26-5eb3-4d0a-bb19-5327e10237ec"
      unitRef="usd">4127000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03ab1c8385364a98838fa5f372f40780_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0xLTEtMS0zODc4OQ_d7bd6ea6-d7bf-4d34-928b-1fe46049bfc9"
      unitRef="usd">973000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7bcb071485841a8932ec94f8a5df8bf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0zLTEtMS0zODc4OQ_2465b76b-7b9a-4b9d-81e8-4d0e16097a61"
      unitRef="usd">1087000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i376a6465db724ab699369fb13e61e824_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC01LTEtMS0zODc4OQ_ec9a5e7e-5ccd-4908-9d8d-82f8d54092a8"
      unitRef="usd">2096000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc375ebed1e748e3906510f688eb4df4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC03LTEtMS0zODc4OQ_3361badb-a173-4100-91b3-b0be7d248a59"
      unitRef="usd">2179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0xLTEtMS0zNDQ5MQ_d4dda598-ef16-4470-917a-d3e0ef8c9547"
      unitRef="usd">3193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC0zLTEtMS0zNDQ5MQ_70be32af-47c3-4fe2-a983-1e8122d76bb0"
      unitRef="usd">3219000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC01LTEtMS0zNDQ5MQ_fbb0deee-4dce-410e-ae3a-94e1ff2d6394"
      unitRef="usd">6824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOmM5N2FjMzA3NjQzYjRhYjliOTI4NTM0OWNiYTQwNjUxL3RhYmxlcmFuZ2U6Yzk3YWMzMDc2NDNiNGFiOWI5Mjg1MzQ5Y2JhNDA2NTFfNC03LTEtMS0zNDQ5MQ_0ad98574-471a-4fba-be62-95d1915667a1"
      unitRef="usd">6306000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTA5OTUxMTYyOTUyNw_1726d3a7-4dee-46d6-be1f-b0f43e46870d"
      unitRef="usd">200000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5Ng_0a7dfb19-5c96-4736-b94d-98f55ed2660a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option grants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id51d0832aa5449abae8f15be39293d79_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMS0xLTEtMS0zNDQ5MQ_5ce10b7d-d4aa-4515-9c5e-a1c8ce3b405c"
      unitRef="usd">13096000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1a90b663e53f4f6cb5da4185a20aab45_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMS0zLTEtMS0zNDQ5MQ_c9781161-6dcc-4783-bd36-982cfa830909">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1e7d4677dbca464bb097b04e809bdcfc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMi0xLTEtMS0zNDQ5MQ_2ffbceb0-adcd-4823-90db-755a58d8cdbe"
      unitRef="usd">3524000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMi0zLTEtMS0zNDQ5MQ_fd39db99-c376-40e4-b0b6-c9951a7b5e70">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i69584cc6d6d54ac49447a7432d983409_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMy0xLTEtMS0zNDQ5MQ_673f1b0f-b1f7-4615-baee-9a46daf3b98e"
      unitRef="usd">21000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id3ca526cfc424a98962ab7e989aefbac_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjgyNzYyY2I0ZjQ0YTQ5NjNhYjljNWQ0ZTM3MTQ1ZjkxL3RhYmxlcmFuZ2U6ODI3NjJjYjRmNDRhNDk2M2FiOWM1ZDRlMzcxNDVmOTFfMy0zLTEtMS0zNDQ5MQ_a56ea81d-6004-40b4-9862-044dea8e431d">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5Nw_0ae29372-454c-4b2a-a697-8f11816adc72">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMS0xLTEtMS0zNDQ5MQ_aa4465c0-7f3d-4d7b-8568-6151c684c66b"
      unitRef="shares">10417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i925bda1ddc9b4f2ca467776b876445bb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMS0zLTEtMS0zNDQ5MQ_7375e786-8f5b-4a7a-82e6-fa183f5b1891"
      unitRef="usdPerShare">7.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMi0xLTEtMS0zNDQ5MQ_f6f36b53-4418-4c22-8e79-f7fd46e3baab"
      unitRef="shares">4773000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMi0zLTEtMS0zNDQ5MQ_cd09c15b-7e96-48bb-8efb-4f709ac0e969"
      unitRef="usdPerShare">0.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMy0xLTEtMS0zNDQ5MQ_3a729423-33f9-4595-839d-f32180e1ded7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfMy0zLTEtMS0zNDQ5MQ_33595250-5c50-4b45-9f88-738b4f727bc4"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNC0xLTEtMS0zNDQ5MQ_b4313133-6d93-493e-bea2-3efbcdad9c73"
      unitRef="shares">1190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNC0zLTEtMS0zNDQ5MQ_67874e3d-420e-41e3-b65e-32678ae9929b"
      unitRef="usdPerShare">7.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNS0xLTEtMS0zNDQ5MQ_0fbcfa8f-6462-4302-a7a9-f74598b596d0"
      unitRef="shares">14000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNS0zLTEtMS0zNDQ5MQ_6ee021d1-e231-4e15-85da-bac6897a2ac6"
      unitRef="usdPerShare">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNi0xLTEtMS0zNDQ5MQ_e84cc4f1-8352-40b4-906c-b0055ab4c06a"
      unitRef="shares">7085000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjFkZmEyMzVmMWQ5MzQ0Zjg4ZDFhZWNmZGMyMjYzZDY5L3RhYmxlcmFuZ2U6MWRmYTIzNWYxZDkzNDRmODhkMWFlY2ZkYzIyNjNkNjlfNi0zLTEtMS0zNDQ5MQ_1c276839-d08b-408b-8169-647c1199cea3"
      unitRef="usdPerShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTQ5OA_6577af74-948f-487c-90d0-c05fd4ccbf41">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the six months ended June&#160;30, 2022 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMS0xLTEtMS0zNDQ5MQ_7f02e6c2-80b0-4441-9676-7b1a830ea272"
      unitRef="shares">3529000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMS0zLTEtMS0zNDQ5MQ_2a6d68c1-3698-4e53-84a0-a25730db356f"
      unitRef="usdPerShare">2.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMi0xLTEtMS0zNDQ5MQ_960a3854-ccd2-4737-8410-8a55b2a76c5a"
      unitRef="shares">1980000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMi0zLTEtMS0zNDQ5MQ_fd7ae230-ce39-47e1-9539-c3eae5252a30"
      unitRef="usdPerShare">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMy0xLTEtMS0zNDQ5MQ_2dcbea63-588a-45b6-9e33-c5cbc831bd4b"
      unitRef="shares">3714000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfMy0zLTEtMS0zNDQ5MQ_b3ec6a24-9187-435f-b01a-762d1a0a56aa"
      unitRef="usdPerShare">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNC0xLTEtMS0zNDQ5MQ_d9901184-f848-4e33-9a54-bacfb3c6165e"
      unitRef="shares">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNC0zLTEtMS0zNDQ5MQ_c9ae105d-f5da-4d15-8f14-b3c5df50969d"
      unitRef="usdPerShare">2.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1e7d4677dbca464bb097b04e809bdcfc_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNS0xLTEtMS0zNDQ5MQ_e9e3b847-4bd6-4391-a7c9-68f2b60c40ee"
      unitRef="shares">1674000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1e7d4677dbca464bb097b04e809bdcfc_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RhYmxlOjlkMDg0MzNlNzlmYzQ2MzY5NmFlMzlhODZjYmNmNTI3L3RhYmxlcmFuZ2U6OWQwODQzM2U3OWZjNDYzNjk2YWUzOWE4NmNiY2Y1MjdfNS0zLTEtMS0zNDQ5MQ_d9fa2ae2-75bb-45d0-afca-941994fe58ec"
      unitRef="usdPerShare">2.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfOTY5_f914c7b2-f2d2-4633-88fb-f14f4aefe4e2"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare
      contextRef="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTA3Nw_97d2382c-cda8-48c4-93ff-b8a53127385c"
      unitRef="usdPerShare">0.65</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare>
    <us-gaap:ProceedsFromStockPlans
      contextRef="iefab7a26d5d64d71889dc8c6ff561ed3_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTEzNQ_1997335e-3129-4ad7-8930-5edab9209c37"
      unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i8a7e1558c9254a6f8b2556d7cf1b84b3_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV82NC9mcmFnOmMyMmY5NGU0NGIwMjQ2YjRiMGRjNGJkOGZlOGVlY2QzL3RleHRyZWdpb246YzIyZjk0ZTQ0YjAyNDZiNGIwZGM0YmQ4ZmU4ZWVjZDNfMTM5Ng_d9044a34-4b76-4478-8297-720270dafcea"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RleHRyZWdpb246ODMwNDAxNTg0YzRkNGU4N2EwZjc3ZTVjMTc5MjRmMWFfMTI1NA_fa9e2f7c-b28f-4227-8bf3-c255aa36f153">NET LOSS PER SHAREBasic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the six months ended June&#160;30, 2022 and 2021, all potential common shares were determined to be anti-dilutive. &lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods presented, all common stock equivalents are excluded from the computation of diluted loss per share, as the result would be anti-dilutive, including the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,099&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,182&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,211&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,819&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,802&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,406&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RleHRyZWdpb246ODMwNDAxNTg0YzRkNGU4N2EwZjc3ZTVjMTc5MjRmMWFfMTI1Ng_d7484624-f8d8-42ec-bdf0-286f835e9307">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,009)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi0xLTEtMS0zNDQ5MQ_3d0e22ad-85ca-4c26-96ec-8b8a227b510e"
      unitRef="usd">-26938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi0zLTEtMS0zNDQ5MQ_d1352238-99c1-41e8-b39b-aae8105df0ea"
      unitRef="usd">-45189000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi01LTEtMS0zNDQ5MQ_4e3b3493-e94f-4152-a685-4d743ff70325"
      unitRef="usd">-55009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfMi03LTEtMS0zNDQ5MQ_169bd6b3-9d8f-473c-b6fa-dd49c1359405"
      unitRef="usd">-78344000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0xLTEtMS0zNDQ5MQ_0d99dd72-6d62-4348-a07c-6a075229bdd8"
      unitRef="shares">145544000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0xLTEtMS0zNDQ5MQ_40e5a1e1-c28d-43c5-a4e2-fb03743e8b2a"
      unitRef="shares">145544000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0zLTEtMS0zNDQ5MQ_4c6fa988-6cc3-4b1e-b6d8-5a991d835975"
      unitRef="shares">100040000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC0zLTEtMS0zNDQ5MQ_ef2f6ea4-e9e3-40c8-8484-9a1295d458da"
      unitRef="shares">100040000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC01LTEtMS0zNDQ5MQ_80b67e29-8264-429f-b626-c286c90b74ed"
      unitRef="shares">138280000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC01LTEtMS0zNDQ5MQ_8ce142bf-f2e1-49f5-9d0b-81def61b8b18"
      unitRef="shares">138280000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC03LTEtMS0zNDQ5MQ_63cc04fe-0685-4baf-8534-c6166ad7d342"
      unitRef="shares">98618000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNC03LTEtMS0zNDQ5MQ_ff6dc99a-e3b1-4a57-a333-2879f29a0762"
      unitRef="shares">98618000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0xLTEtMS0zNDQ5MQ_8f54097e-2e64-4f3d-8fce-765f0dee5c15"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0xLTEtMS0zNDQ5MQ_9fbd2188-7a48-4408-8c7a-405c053194b9"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0zLTEtMS0zNDQ5MQ_2aea7436-174b-4d92-a9b0-e0a7c2c920f3"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS0zLTEtMS0zNDQ5MQ_9a888292-5c71-44fe-9057-7fc0c0f7913f"
      unitRef="usdPerShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS01LTEtMS0zNDQ5MQ_03403fe8-d13d-477e-9a74-33f97cd2cf18"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS01LTEtMS0zNDQ5MQ_140b50a3-3233-4aff-8c72-854ccecf7a3d"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS03LTEtMS0zNDQ5MQ_76d206b6-9f9d-41e4-b0f5-1debbd191d32"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOmJhOTZlY2JiY2M0OTQwOTg5ZGJhNTQ0NWUxMjQ0NDM0L3RhYmxlcmFuZ2U6YmE5NmVjYmJjYzQ5NDA5ODlkYmE1NDQ1ZTEyNDQ0MzRfNS03LTEtMS0zNDQ5MQ_dc4eebed-767b-4eb4-b910-c50fe204518c"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RleHRyZWdpb246ODMwNDAxNTg0YzRkNGU4N2EwZjc3ZTVjMTc5MjRmMWFfMTA5OTUxMTYyNzk3NTc_89cbedfc-c8e4-4c99-a8f3-36dbe2161f32">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods presented, all common stock equivalents are excluded from the computation of diluted loss per share, as the result would be anti-dilutive, including the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,099&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,447&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,182&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,211&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,520&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,963&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,819&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,802&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,321&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,406&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7dc07daee1204d6c8c91b07672cc6eb4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMi0xLTEtMS0zNjkyMw_a90488a9-1618-4a26-989c-e540da94d941"
      unitRef="shares">13099000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id703e5f35ca0467cbd70c6dc2f683e5e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMi0zLTEtMS0zNjkyMw_7ec3882f-fb92-482d-9196-d1d845f05d38"
      unitRef="shares">12447000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a90b663e53f4f6cb5da4185a20aab45_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMS0xLTEtMS0zNTEyNw_c44b023b-c8bb-4d89-ae56-6ddd82fe090f"
      unitRef="shares">13182000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i44792157aa014c89a7a354b1be5cd930_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMS0zLTEtMS0zNTEyNw_1e157f27-8117-4cc1-a8aa-d1b9ddff4553"
      unitRef="shares">12211000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idca1e42204a84d5baa052102db6344f5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNC0xLTEtMS0zNjkyMw_53c8887e-a518-4efb-808b-64be687c4b83"
      unitRef="shares">3520000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i587c8cafb989442c848613b09b327f6e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNC0zLTEtMS0zNjkyMw_3603bc95-c072-4e04-81d5-22c3365b105b"
      unitRef="shares">1125000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i93fb2b6b0a44445abf4ee9b873f38392_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMy0xLTEtMS0zNTEyNw_755a12a9-048e-4e17-8008-4f8d456ef7a1"
      unitRef="shares">3963000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3a3791c5deb445cbbe81a4916add381d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfMy0zLTEtMS0zNTEyNw_92f263e1-1902-44d1-83cb-32fa13b5d545"
      unitRef="shares">1006000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i64cb03795f754f9e866d8829eb6f1a18_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0xLTEtMS0zNjkyMw_af98e432-c2a3-455c-bb1b-88a89d60dfe7"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i477ce922c8374f6e9d0c3d4093c4654b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0zLTEtMS0zNjkyMw_dba84975-bb5f-426c-a75a-661b3baa611a"
      unitRef="shares">230000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib25fb22c28764b7fa0ee953c024cf888_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNS0xLTEtMS0zNTEyNw_aa311bb6-092c-4733-b606-332444c36a64"
      unitRef="shares">176000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i217bb17f2bb2437bb698a25f2f589406_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNS0zLTEtMS0zNTEyNw_b5a5884e-ce2b-44b5-bad2-c295d72b02c4"
      unitRef="shares">188000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNy0xLTEtMS0zNjkyMw_a50a4c45-1c0c-45c4-9bea-023dfd7d8f3c"
      unitRef="shares">16819000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib2291f07e25a44999a22885c21de57cd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNy0zLTEtMS0zNjkyMw_986aad68-b794-40b8-a548-f2d87ea71573"
      unitRef="shares">13802000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0xLTEtMS0zNTEyNw_f2693972-d517-42ed-b0b4-55c2a1c35305"
      unitRef="shares">17321000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa192ba2d7904b0aa6c0838f64e748d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83MC9mcmFnOjgzMDQwMTU4NGM0ZDRlODdhMGY3N2U1YzE3OTI0ZjFhL3RhYmxlOjEwZDVmYTJlZTU4NDRkODZiNGM3MDJkMjQwYWY1NDcwL3RhYmxlcmFuZ2U6MTBkNWZhMmVlNTg0NGQ4NmI0YzcwMmQyNDBhZjU0NzBfNi0zLTEtMS0zNTEyNw_72901e82-6490-43b2-9263-770c2fde018e"
      unitRef="shares">13406000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i285f507425f845998ab1cc87f33146fa_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83Ni9mcmFnOmYyYjU2ZTIzMDFkNDRhNjI5ZmYzM2YzYzdkNmI4MzQ1L3RleHRyZWdpb246ZjJiNTZlMjMwMWQ0NGE2MjlmZjMzZjNjN2Q2YjgzNDVfNDA1_2897cfee-d892-424b-af59-38cf15a933ed">CONTINGENCIESFrom time to time we may be involved in claims arising in connection with our business. Based on information currently available, management believes that the amount, or range, of reasonably possible losses in connection with any pending actions against us will not be material to our financial condition or cash flows, and no contingent liabilities were accrued as of June&#160;30, 2022 or 2021.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="if62c57c8d0834b5693f69a9e3e0744b3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83Ni9mcmFnOmYyYjU2ZTIzMDFkNDRhNjI5ZmYzM2YzYzdkNmI4MzQ1L3RleHRyZWdpb246ZjJiNTZlMjMwMWQ0NGE2MjlmZjMzZjNjN2Q2YjgzNDVfMzUy_513d57bc-c4b0-4b54-9b6b-08eacefa5105"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i642f45e96f164e29bc7beb0165e50cab_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTQzMGY2YmI3NDQ3Njg4Njg0MzVlMjhjMzI5OTE1L3NlYzozYTE0MzBmNmJiNzQ0NzY4ODY4NDM1ZTI4YzMyOTkxNV83Ni9mcmFnOmYyYjU2ZTIzMDFkNDRhNjI5ZmYzM2YzYzdkNmI4MzQ1L3RleHRyZWdpb246ZjJiNTZlMjMwMWQ0NGE2MjlmZjMzZjNjN2Q2YjgzNDVfMzUy_8ab81fba-861f-432c-8543-16abd1312301"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M=7LOX&Y\\++,"E;*C)=(L-75X!J?SWQ?#Z@M_LK8@SRZ1CJ4!>??],V'Y=7
MTXA8SE*E75#XLV,SEN?:$^#XOG<Z.+Q3#SR^?O+^>QT\!+.@DLUX_G>V5)NK
MP62 EFQ%JUQ]Y@_OV3Z@4/M+>2[K_]'#WM8;H+22BA?[P8"@R,KF+_VQ3\31
M !ST#"#[ >2E _S]@#ISXP99'=8-571Z*?@#$MH:O.F+.C?U:(@F*_4TSI6
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M+S7-C>+;^F/'@BO%B_IRPRB UP;P^XH#[^]O]/>3P_>RZ;]02P,$%     @
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M+R);5 <YGS,ALJ3Z..?AC.<E 'Y_R3*Q^5).L#UM//P/4$L#!!0    ( '*
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M0'2QO8["272WY;Q4RZ'E)+J.<FZBZRAX@.B2CF<0/\_HM;[=V61^@[X]GS@
M!@E1@ADQE[B#&G-0-0&EIJ?:,0SB9QA/KG-W)VD3A 1'YHPS)HZU#<3,QI:*
M4\:H,4:XH]PP1C@E)M%U%8P.=/X.(!#\$XDN >4%H&H34#4.JB:@U/1.L/=(
MR(E8X?M7O?N=>_<(FR\@'*/0/.Z NG)0-0&EIF?=X05R(EXX;?'[UFU_)DQ,
MR.O?HM[CV(8,IB,'=110:GIB'6$@ISZ3<N+]%F(C@=",#)1!@*IQ4#4!I::'
MV[$*<NJS*"  W^_>>_JU+_YQFD:(8G/^!248H&H"2DT/O&,=Y,3G64Y&^'[#
MWAF['FFA*0XMA@_JRT'5!)2:'G)'4LB)3[;T8OC$L6XDL9\M<Q2SQJ,#IB@E
M<U6O?Z]Z9_ CT ?IT ?QHX\^8)[86"%*S>89^PU['Q2/\>2@G@)*37^RNB,M
MU$]:8,$\M3G)$(7FR:=_DWH_-0T*7$#5Q%/MH8?6@13J!RD^.$\=2(*QT,1V
M8[]%[Q @U?B1^R"@7/48.E!#_2L]CH?SV)D4*)FA]DH.Q$C[N!TQ5W. &G-0
M-0&EID?:81?JQRY^..^.T08@C(3F^?>8.M[78;)CAU2"46B^1H4[R@WC*$Z)
M-4 <!?<)OMY*>^_C\ .+7@NNW8T&20/&U.8/B$2$A"0R,12H,0=5$U!J>JH=
MU*!^J/'DBFMWDC:YB"A*37JQ+:9U?VM>LJ62D&'S#3/<46X84Q2&R.S^CH+)
M@8>=:,<':/03^3P%Q0&@:A-0-0ZJ)J#4]$[0,0/Z/>_ ^&Y(Y'?OW2L< "%)
M<!2;-\A ;3FHFH!2TP/O^ &%Y@=/9@RZ.(,Z> )E"4W,67$"ZLM!U024FAYR
M!RCHB>_6Z 6)J&.Y!F8FK!M3QVH-,RJWDDDD_'O5.X,?02181R28GTCT@43,
MOKXFF)DK:OV&?0^*1WER4$\!I:9'TO$&YN<-L)"(.:[NL;E\T[]%O3,#Q1.@
M:N*)YM CZ]@$\[,)'R)B-BH8XB@E)L7V6_3. )0Z'+D/ LI5CZ'C":P73^B+
MB/SJ?4\1F&.IQ@%$!&K,0=4$E)H>:0<_F!]^G("(F+TBPX6(',4L1.0HXT1$
MCG)N1.0J:".BT=[+J=N7E;_-JKMV_B_DK:H6OHA5IZH>W__]^*4I5YOW57\J
MFZ9<;#[.9::NC=L"ZO?;LFR^?6E?@;U["_O%'U!+ P04    " !R@ 15:E##
M&YD(  #S)@  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+5:VW+CN!']
M%9:RE4JJ5B,2 "]R;%5Y;,_NI'8\KM%L]IFB((L9DM"2H"_Y^C1 BI"(B^R4
M\F+KTFB=;G3W:31Q^<SJ'\V64NZ]E$757$VVG.\N9K,FV](R;3ZP':W@FPVK
MRY3#V_IQUNQJFJ[EHK*8(=^/9F6:5Y/%I?SLH5Y<LI87>44?:J]IRS*M7S_2
M@CU?38+)_H-O^>.6BP]FB\M=^DB7E/^^>ZCAW6S0LLY+6C4YJ[R:;JXFU\'%
M#4G$ BGQKYP^-P>O/6'*BK$?XLWG]=7$%XAH03,N5*3P[XG>T*(0F@#'G[W2
MR?";8N'AZ[WV3])X,&:5-O2&%7_D:[Z]FB03;TTW:5OP;^SY5]H;% I]&2L:
M^==[[F7]B9>U#6=EOQ@0E'G5_4]?>D<<+  ]Y@6H7X#&"XAE >X78&EHATR:
M=9OR='%9LV>O%M*@3;R0OI&KP9J\$MNXY#5\F\,ZOKCY>G][=[^\N_66WZ^_
MWWVYN_^^]+Y^\FZNE[]ZGW[[^L?2FWJ_+V^]O_WT=^\G+Z^\[UO6-FFU;BYG
M'  (-;.L_[&/W8\ARX]%WA=6\6WCW55KNCY>/P/@ WJT1_\1.17^LZT^>-C_
MV4,^0@8\-V]?'CC@X,&96.K#%GU?=[1.>5X]=M&9\YP:O=1I(68M(G$OFEV:
MT:L)9&9#ZR<Z6?SU+T'D_\-DXIF4'1E,!H.)2_OB'NI,P1JCD=W*2*X4Q>1I
M,0U#WY]?SIX.X1O$X@03,H@= 0L'8*%S)Z[7_X;<@7+#&X\SJ#<9J[*\H%[5
M(Q:?BM=9VFR]MJ%K$=K,L'\7)MO"<V[@F90=^2D:_!0Y-_"6@M(L3V5)I2]
M#@TU&=QI"0]VB?CQ:"=UF3B)S=L8#_!B)[SKDM4\_T\'CVU$?:9U#9NUR:L4
M-A1V*F,--\9?K,%!*!I!UF5P$)DA)P/DY'^#G+%2N+?[ OC7$WN99^8*D6C
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M*8C)H09]R;H'5&)3NQD76Q7YH\P]\\ZZAM:]S88.@N#8<H@@JC4@)V;;!\W
MP=,TP4&LJOH;3?+1RF';4$#;ZIJ']C]Z>'<":V1J$!KW=+.#ZT,EK1_EK:K&
MDP/9[B[.\.EP<^M:WE<:??XQN+CI[E\I-=UUL"]I#0S5P$9M0*7_(087U]T-
MJ^X-9SMY26G%.&>E?+FE*?A*",#W&\;X_HWX@>&>V^*_4$L#!!0    ( '*
M!%7Z&FK,<18  !)!   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULQ5QM
M<QLWDOXK*&UNRZFBJ!<G3M:Q727+=M9[B>VRG$U=KNX#R %)Q,,! \R(8G[]
M/=V-MZ%H6;Z[K?L2B_/2Z/=^NH')DZWS'\/*F%[=K-LN/#U:]?WF\<E)F*_,
M6H>IVY@.=Q;.KW6/GWYY$C;>Z(9?6K<GYZ>GCT[6VG9'SY[PM7?^V1,W]*WM
MS#NOPK!>:[][;EJW?7IT=I0NO+?+54\73IX]V>BEN3+]+YMW'K].,I7&KDT7
MK.N4-XNG1Q=GCY]_0\_S _^T9ANJOQ5),G/N(_UXW3P].B6&3&OF/5'0^.?:
M7)JV)4)@XX](\R@O22_6?R?JKUAVR#+3P5RZ]E?;]*NG1]\?J<8L]-#V[]WV
M[R;*\RW1F[LV\'_5-CY[>J3F0^C=.KX,#M:VDW_U3=3#?5XXCR^<,]^R$'/Y
M0O?ZV1/OMLK3TZ!&?["H_#:8LQT9Y:KWN&OQ7O_LK5_JSOZI145=HY[K8(-R
M"_7.FV"ZGN\\.>FQ%KUQ,H]TGPO=\T_0?:1^=EV_"NIEUYAF_/X)>,R,GB=&
MGY_?2? ?0S=5#T\GZOST_/P.>@^SX ^9WL-["#Y1EZX+KK5-T4,M/JGCE>UT
M-[>Z55>X:."7?5#_>3$+O8=G_=<A#0D#WQQF@*+M<=CHN7EZM*&U_+4Y>O;7
MOYP].OWA#O&^R>)]<Q?U_X5=/T/W_8\7;U[_=O'A]=LWZN+-"_7\XNKUE7K[
M2KU[__+JY9L/\8YO3+N[F:C7W7RJ'O0KH_[ZE^_/ST]_N'3KC>YV$_YY]D.Z
MO#7[5X:0+CB?KKG!QXM?*TBCU<RZS4HC.N=FZ.T<UID+?;5P WD>PJE?X<&U
M#9Q'>J<:&^;NVO@)HO<:66G#^L%[:^/)P/9/HVS7N6M-"4,MK _]L>V.YZT.
M0:U-8^=02E#]2O?XB<09[+*S"RS?]6KHUJ:7I\!-9TP3INI7HY!&/?P&E)7K
MC)H-@8@$%<R2?&FBMBL[7Y%4I*S(&=VYQ5UVR=O";[QKACFR]&%SJP\K_  Q
M:*8+4,XB.W4H3KW2D'IF3 =R9J,]GK.4/N?.-WC:1)7B]]#UMEOB,0LBFQ8Z
M69H.8K;MCNZ;32_ODD2_=)9^<? P8Q<0"$RK!]&VOTROINK'BXMWV<(D^&;P
M82"]PG!$QIL_!NLCIZ!"UZ[,?/"VMZ!+K[R\F:]TMS0(ZG4R>UKDZN5E)H^*
M!N9Z<+$&V8WS),Q4700%4ZUM3^R2#WDLXJ V/[1Q!6^60\L:#1,U-[Y'\0,Y
MUW>.A?/*@2]?J==V4C_9!<EOH%;5T272512J4;.=RFJH[% ,1J2%M>G_V)A.
M#!+TVE!!HS@"SX-7:Q=Z\#(7I^L&4#I($RJ8)+.ZC>VB.ZYUAS(NSHS22G57
M03REF]]1Q_C5[.7=O!T:O-U!>E$#+3QX3_Y4O8  FB-* !?( 3;BRVJAK<>+
MQ'-A<.."E62.IU"3V3TDZJ*AV"L"<8ZR.O^X<BV,RUGF[+L?%-F@WTTDW'18
MJ04 2V O(4&3IX"@=4U(O$1#<#APXB$!/F,3<2$XT.B!VD7"R@TMW('\77,(
M@>3O0R=(AN./>-)#8_N[5I&(D97$-\DO#509+<"T28\78N_W' ?D(H1YU-GI
M\;]G#>R,]LIP4GT!JZQG\/"'9UR0ST0)2?'IC7[EC6%&@KV!>S$@$ HHYR:7
M\Q@-?;:VA75M1RF44S ,F4B#=6C%W&S@721Y7 D2(X RBV2$?1[/)Q0]] *5
M!PG0L5'Y_M /D=!4_1)X[9>AMVM.6R2DQ%%.P@=U+P8C>\*EQ%XEKF.TARI@
M2*RU_@@Y\E*DM=^'9BD$)6<L%A13;/DU)=\0\U;)LI_TA)%_CEQAJMX20H#-
MEXYN<DJ8U,R9:]T.S)0%M<SB)#H1O10S9'0U2(-H=BB*24L>]:P;#((0@()+
M5>^)2[#EX7<4G? .0E*T\+# 'X/D@OP BX? 5\0-VP7EV$3Q6JMGMN4:P&PY
MY+9>WT0]<K@?$WCG2HJ&)K#]INKG(B7=WI.0XF!E\;9GELGKO#54 HDJ;E[#
M5=T0HC>AJ_EH^N, WR0TD.(<ZJ.$&M#W;#@51>10+6U:"P4E[T;,!]?I66MR
M_4&>MWX^K&%5+(_Z?@$%<=*4L)ASOB"F2:V(GL;"6>#.WJVC<;)44_63A0<V
MY)H7G"5'P8@<;5 V8A(D&6P'WOI<<O4&,..&:6&AK[X_FYX"7K4M*_17(R4'
M-D VIVHC&1BF;%T@#0/WS/F^V61P2AD(EA[6@S@0VBJ K)X+TQY[A)"^^N[1
M=]._E47?XG5>#KIL"3G16P?9URV!+Y"@;!.&!2V3XH^0'#&R:757<EAG;G![
M:UH(%3/8PK4H#>+V1(P RMQ$-!(.!V$JU^39SB-PM<6O,,S(HCT]V[AA1N5W
MJ3V'%.N$G9IK'\6'10B13K224,4UH(].DEI.8@L&F)P*H_GOSR3,1^+3@KII
M/ %4XJ,8,5?&,1+C%.<J,QS2_D2N"D;D[$WL!=T*('S]_.K]RY\N)F($I"C1
M"P$2N^G9\W %0)/?A?%!UQ$09S*\. RC9RXF9V3I'BN%>Q+<Z)W(DLG]0R-A
M"L8Z0+>*S6"HXB,IH_2D=$X$?K)S@@'J8HDZ*,!HSZJ$DH- _KG>V![L218!
MUS TW*ZE?U%(W;"4HF_70-KKNC5EK<8>4I=9AR!BSL5H"@Q5-\056*8&")D?
M#Q*N0KKB@LD>BM(GM9CSE>=D(^F*&#<+>)H4X1PM]W -R# C7V=9%T,[5:\7
MGW666OP2E5^T<D(5XSA?P&X5K*2D#OFIZDNQ*/1GK5T*>)0(H^2B0_]_F1;$
M(=J4CR?50^12-F?(W"\B]U*!J11;97U!"*4Y^(*68#^GQ,X 2S>.M9@P.Z&G
M&J''QBPA$H;/U"ES0YQ<]'"I3H5P1V(4DT0L0Y"AET>V%!X=N27R]]+XN[+A
M5%W)@)'6O:HZ\XO2L;YS+3E$X,I1=^]U5YN>(3=J#$+&S@1HO4$J46<IR.\$
MX:F*+!!RN',7A)Y\ 2:?WHOQ+X?A;:@Z WHUTZ*<,00"4#,C@9:A7EPZ2&*]
M)MPRX4CN4.EVDX3]XAPC]!4>9!;+;"/-+Z0FH!JE1L?<)+3 T41PAC!L9&8B
M4+9R[,[EJ*C;/G<?:W-K=TVPCF%4F .W?%&?= ];3Y,S!E!*2BO7BB()JF2,
MWQDI6I1F)#/3DLCD@X_]K5^:F9Y_C%$8$37QRS.O00 <2H 83E(PC9A1)<6E
M$DA,HY6\%B_%$ 4)O)@<[ FLYC25.H5L*!!8,I:1?%_D(CSD=6-J46>Z%:DH
MX+:>IAQ$!@(OM>UBWBT,;5>X#8QH.2?.F 0G"VEZ,UE.DY3 9E+(4X)TJH&@
M$>U>4XCW-/;IV/.IV^KN(ST13N.;Z2$XG;#M+<M&<8D(]23>LAH7ZJMOIF<)
MVAZ"-H0>R;Q?G4V_'3]7!5)E5N'IE@M^EJ^MWF?L='_!6XRALJ>X5^^ 1GT9
MV_'$C*YS^P _(9*-'Y8YZ!&2#4W@J87;5AT$5^A0Y;/2(9I;1-ATT@UEQ-=R
M?='7VK;B)0Z08,,!S,"KJ*W50S=?)7<MT]1?*:\L!1='G"93XB0LY37*'<&!
M3I_&SA'1JD9Z64X.((P[?PP D; &5I+<S]Y,B])(0H#*>"*=:)%9$*40Q(85
M%B)7V$8A8+9F-)](&CLH8L;;,I,CPBFFZ._]>) A6!*8&D1= B^.30@'NS5:
MWQDP_L+VM3_ S[DP-BH20VR)!J0HE.0CF0Y=, V[B;IT_*Q2?K9BK8#P-*>/
M?[B!IO"H%4W-A-@I09E^97US3'A^]XGYPV3TS :Y51(:06V >WCJPO/&WT1Q
M%,0%2.] I^CB.T.3O6L'G)B'-.,)!W1(P&<2 7"#3 (N:(-B1;,_)BB-F8=V
M>#0V!!HX<F*7]6A7(^DD&CST$<+)F#LJ0.9TZ=F<J6'W. \;*RI!S,H6AZ97
M5"_--J5\Q*N-_M>D87_R7AY"5>4'S!F@=[)YK/EH#:)HT@@5'"R%H240O-#7
MR#@QXQ..=;_+/'"V&XVAJ8J8X\9M.^:BB!<Q9\K<.0;*V)5V.\A70\8L2T=S
MW^#:;,@RY\V0;SQT3GLWB,D5;61?&YZ"3)$<)5U=D= 3]09R_FI2.F:326X]
MC(PF'" '-F4^N V"[]'I(W4,8!$A%F7JR^C=L5._3.5!L6=)]B=I4V[.@P,>
M6[Z"Y"S*"TJU%PU<Q]*^9U]OK;QZ<5'VYCIU1;L_7''.3\_^)@-.MF=..SEH
MXS0-CAU<8X>U6NT:[Y9(129NY:!LY77>_/WEPVJAE9W9/@YV&>S"5_MD">OA
M %+5D&R S'<=**]S+@&JH.Z?Q3@"8\>71\R\;FBJEC<YQGM7#XY(*4=?5V4A
MH%&E6$YNGMXCY>'OG[6'<Q$:X'<:4IZ=#7W)ZG$+C6M5:O8U6J4U+]P-K$@.
M5 ?[PP<B".!9HVXI-\E.X(X\Y=K2QH9Z$.$.3-ONI-,\RI8G_@GQ%5>@813B
M :HC2U#KG;BCK1<AG_;82&DR,;J2:L,K;'D0+W-U] 7>D^VJ 1'G4IZ?Y.8O
M<LOF6U+2Z^CY8P1Q([6"%O. )K3"<6>6KI<"ZX%T&2KLP]X,=:?C$!A%D.!J
M'E'_2=4Z55]$+N_"<.->]?^4>6AF'!:V9 L;"V91H9OQ5B#7$M?NX0AQ\SE0
M35##AK*C:6$:2LKO9?]?DO4_D>399^E0 EE2'#0*$PY)0^R5E)4F%.DN] =Q
M'B!@NZ!E"XDO?;VW'3>:?"]XN,U\S&L^ZJE_MD'6^21Y!E[:(,?2'$!FUL3Q
MTNMU+'2EUB=)8A^31A?53H@WI<FH1PUHL#K9$Y6Y^;S5=ATWA5)_&O5#TSEO
M\F!"$CO/Q<2^E-X],O-!1&P7U;+<;^A= I)N%$(\A\V3:)L&?7<1T$JPA6PA
M<#G3F2+2A<SD*"_#9MRP]'?I)\V7PP"[:H(Z#6BAXB&<-.NA*KFI2U"S@?>%
M)+)Y#$IV1"1W<4)U<!=D4@9X5:LI&RZZ'[C0U@.YB<I;(Q\[U.14$7C0$S<L
M08X.3+R]YF,$2=C*4E"96$HLFS::B<D9=#)VX4KKC#/K> *A6/1EYDF]0M\2
MAJA]C8!2)I7$G)88'=.T833$D7JT%W52Z6)?9&[Z/.0ZU,OJT;R"IB8^\%[Q
MOFBR=4( (XU6ZO266F#./I*TZ/VABX<7^MVMWH7N'\X C.3K6@$TR/@V[TJE
M +VE<U35M&^4,0=!L7JWRE5CB!$>3'M=::M36HYKFO3=?I&+D8PI]P-F#/;B
MIFK)0F581?D%89%7C!LL'%JL&IY6S SO-K)'<[>-A6E@H=:.9E*' Z=X:9[B
M\M-&7Q/ '[E@WNP>>IN/_[#$%7$.[S3*J+?29+N-Z!2L(:)*)TC%A[/XX_1'
M;H]R$2[3H])N_<PGG&S$A/(JP5K*\8!(Z?;1U_D@@ESR5-<HNI=&_:@WMU[Q
MAI!)8H4>S]ZTI;2]Z'._U\E@BZ8#<<B4.G9)K+$)E1TM1AT$L>*)JI(UN1:/
M,EC:KN&$W@+AM0=VN]@C!F"$^7$PE'3+>@F!W:YE4IJ*;+EHV^I03O2S^O"&
MI+SDG"/PDLZ[D H(NI9D66EDY-?L5&F$D*#RH;J584Z=U'A'OA[+N/UF*$V0
M^%2J]*YEKH@@S:Y#S&2O2&JIC!(934!![Z"]M;V9[-68Y)[*2\JH!YFQ%T^O
MLM*7@VVD5Y3K]<F;G)9D;W(?7O/Y@L,!Z7R%SF-U&@%G8;N,H7)IOL7%5%T6
M4/NX_B&;$3D<96>N)/5T%BUYL^$#=$#(@=!)^E/)C*&M\N:HKZ"RD]9@@(:J
M)8.#\ICT1@!L"8"3X>8?Y? B9W,^)S$S_=;$:B/5S]*A$.YS-N0"T- 0R!3]
MB'SVTWT^\EM[ST<*AP1'4HX99#$:,LWWU%I/U0Z&8YXM_PMB\@#NS ?+/)_$
M&_M7S;P-E52Y= C$*L])=$SB]>R?E>7WD7GMWJ3?W<:DFG[;NZ;J179+(O/*
M4$FA4$R(4J 4!V ^)?KPE'AX=(KZM:-,\;GV-NW'I5V,= "'0N<VWJA[E3BQ
M4PMC]A8B ,([7S'VR3[K#2'@715J,8VP))3_V:P1SY(BV$DDUW%Z.$PE'E^3
MQD6ZSBA)='C@60 !1B^-B1-MPCIM6Z$] 33-2-^U?(=:1%[L7^FL;[F!29WL
M8_4NC@C(PP265.,LV\73!:S]I/BY.]YK&IGKQ((-J=S'[%U\@A)M'DG4]6:_
M ]A?(-9J3BEHQY>6,G,B=4<K$+O9>,:K,7*T:U1*,FG.3=6DF=K4D.:^C%RJ
MP_JE6:VQ0=9XZARC&<:5F <,;(;]6F[O4Z<OXZ SC4TN]S9K.;9"7[5#(6HU
MV[6:D>XWQQ,Y;2E#9YIHQN,Y$5-F;QTV&SK)D#&89"7O=IP'HJS%,OGX$!HI
M.J_C/#O %^S21'-6/E]O_D3$>7 #2ZKNI#!39L_Q5''(9S@GJ6&Y?92?=P E
M;<D\9)9-7#4Z^WLKG/83$LD'!TGB)@;CU@9D$FY7HN3>) 7& 4@P/)KDN5GY
MY  54_%Y^+*/*P2J2?[0V7XT0].E%E;[7?<^>[ U-7.;>O/P4WMF=#"$$2IB
MW?S_;)Y-;P5)GJ7E\V3-P(.>"YJ8_P;;S77J0$LWE7.+5O763(X"F:MR+N##
MVS14_U:^JSFZ^$U]J-[)A\V.^!N9/-; >P_LU\F;))ZXG!+<\W'/_^STW^B?
M,CNL ZM\V$ S^!(A,]J14G'/HI4S;PGN/K!8\SQ2==UQBN-J2E'A[4\?XI.#
M/E*HDD_>ZR.9$?<)'U=2Y!V$4 ZOLMH;*2J[VG!H2Z2U7.L;NQ[6O"W^W;?E
M &R>S"R7=)*SE\$VZ3TI(VVX2-BDV43.X&6[*6F(2^!V[QT\A00?-JZ+@UAY
MEC'JTM(DF;;MHP2?<L,#AR#J>.XJ*4C.L[-RYO80H\6;/^614_4&+L"G]5ZS
M/X/ RYC0\=P+.IU(3OX^.LG;/(%G*$Q>R573-"%JA&%#WJPBE^6"E#[)N>7K
M,DY 9OM3[-LE?FSB)Q48FE'L-:"M792#,:6(E" =0DI[AJ=*]MH4PFDS6B9$
M! %KQAA&K&T?3S>5._L?0.EREI1^IAJ>0R*J,,59V<3(DZ;,&T_AN)_*PB81
M=3'9A_V]Y:A 75?+.]:=I %K_LJ)H%:-SWK7ZQK>CLRV*QZ\S=B:*&@ZZE>.
MK.IJERP-P:O#(+<.2=;(D"NM7<<ATOZZ$_DPBG??*&NG8Z6Q"Y"<Q1L^LDW/
MG0 -Y5I&FNE\;Y'O;L&25Y?%PC#[/=X<>8!\B'5@DEPOYRO)& KD56VX_<%
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MN&N#H0GX?*ZUV][0 KL/3;?_ 5!+ P04    " !R@ 15#@@E!J('  ">$P
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MOX-2/6H?6/XA=,F2L"H37<F<&!3&>2'3E2P]:H*I'<!N'\"<)!%U)VK+%WS
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MMG_6\4 UKW>S,+)R+^9"&GH:W#2G#QY45H#.EU*:W<(:V']"#?X&4$L#!!0
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M3 GN:D3O'CE%Z 92^<9U.#QH^<:MZ,&/ZT3O[NH>WM0!GG%4;>_M:&9% =+
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M:J(6D#>$AOQ;+R9BM3&!R!:N(T(+-Z6T%E;*3!HD"'<S&##Q!)5+"_U -?V
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MI&<6=T@AZ5G?$);=Z6>MWK772][1&\$769E"PVV58_Y:OT\^=(XD.T>NDY.
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M,\??"&LG@/.EPK7>+9R!_O]F^@]02P,$%     @ <H $55VP:&;:!0  W0T
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MX0.-Y<HUP'C8@SB,1D-2C,8#5A^.X4Y9\G, O3 >]]PSB<?T'(2CI.^>O6@
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MYH=1$B?O2*!=M3(-8TB&0D_9?4'KPYCZ/#KRWOK;P'83$??#*.(AT^^,8V*
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M:#+\<!*![694MW&F#G-A91Q/F; L>:RC]09\7QCC]AOOH/^CF/\#4$L#!!0
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MHNC%+O(AAN0N*>%)A;7DM5UI.%1&4MVV^L:V0TL+_-O#^_-SE#=-(SDH7M'
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M+)2EQN.'*^KTJ!V ]C.E[&;B C3_CLE_4$L#!!0    ( '* !%7/_!Z7, ,
M  $'   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;(5576_;.@S]*X17
M#"U0U%]IDG9)@*9=T0T;4*SW;@_#'A2;CH7)4B;)2?OO1\J)FSMDN2_6%WG.
M(471DXVQ/UV-Z.&Y4=I-H]K[U74<NZ+&1K@+LT)-)Y6QC?"TM,O8K2R*,C@U
M*LZ29!@W0NIH-@E[CW8V,:U74N.C!=<VC; O<U1F,XW2:+?Q12YKSQOQ;+(2
M2WQ"_^_JT=(J[E%*V:!VTFBP6$VCF_1Z/F#[8/!5XL;MS8$C61CSDQ<?RFF4
ML"!46'A&$#2L\1:58B"2\6N+&?64[+@_WZ'?A]@IEH5P>&O4-UGZ>AJ-(RBQ
M$JWR7\SF ;?Q7#)>890+7]ATMD,R+EKG3;-U)@6-U-THGK=YV',8)W]QR+8.
M6=#=$065=\*+V<2:#5BV)C2>A%"#-XF3FB_ER5LZE>3G9W=HY5IP9N"3% NI
MI'^!TW_$0J$[F\2>*-@P+K9P\PXN^PO<$#X;[6L'[W6)Y7_]8Y+6Z\MV^N;9
M4<"/K;Z /#F'+,FR(WAY'V\>\/+_C_>#=MZV5&#>@= E/&"YE'H)-UPHTDMT
M<"==H8QK+<+WFP694Q'].)25CG1PF)0?UK5;B0*G$;T<AW:-T>SMFW28O#L2
MTJ /:7 ,??9$#[5L%8*IX+86>DG"I89[(2U\%:H-!X?N^5 @1ZD.![+'Z6N$
MBGG7.U[36L!GZ:%"I-?2BU!;$9QEBT5K+:>^0<')[NY$ZD*U5$4,_ G7J"!G
MQ#\X:HE6V*)^ 4&W%%1I3T["@2%3RS"FP7/0U.$(B04Y+_R6A"6N"(%;1%<&
M&R0<\JZ,HH[%HPV<OK84 ELX^0Q-5^;(90Y4I-@7:3"A20JG(2.F=;3CSJZ[
MTW R%TKH@M \?!2ZI6X(Z3F<P/!J3-_T/!\-.^OWG+I[YBU+V;4QOQ]]/KJ$
MMV_&69J]V[][=%Y2QR)IK[;,GXY?$4_@-+LZXV&4YF=_T)W 8$2?'?2^WEVL
MK#.Y2EGU,(=#=1SOM:4&[3(T7P>%:;7O.E2_V_?WFZZMO9IW/X?/PM+;=*"P
M(M?D8G09@>T:;K?P9A6:W,)X:IEA6M,_"BT;T'EEC-\MF*#_Z\U^ U!+ P04
M    " !R@ 15@(H*@SD$  #%"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6R=5FUOVS80_BL'K1T20+%E69;MS#:0I"O6(D6#)%T_#/M 2V>+J"1J
M)!7'^_4]DK+L>(X0[(O,E[N'S]T]/'.V$?*'RA U/!=YJ>9>IG5UV>^K),."
MJ9ZHL*2=E9 %TS25Z[ZJ)++4.A5Y/PR"N%\P7GJ+F5V[DXN9J'7.2[R3H.JB
M8')[C;G8S+V!MUNXY^M,FX7^8E:Q-3Z@_E;=29KU6Y24%U@J+DJ0N)I[5X/+
MZ]C86X,_.6[4P1A,)$LA?IC)IW3N!880YIAH@\#HYPEO,,\-$-'XI\'TVB.-
MX^%XA_[1QDZQ+)G"&Y%_YZG.YM[$@Q17K,[UO=C\@4T\(X.7B%S9+VP:V\"#
MI%9:%(TS,2AXZ7[9<Y.'MSB$C4-H>;N#+,L/3+/%3(H-2&--:&9@0[7>1(Z7
MIB@/6M(N)S^]N$4*2<'9(UOFJ,YG?4V@9JN?- #7#B!\!2"&+Z+4F8+?RQ33
ME_Y](M,R"G>,KL-.P,]UV8-AX$,8A&$'WK"-<&CQAMT1_G6U5%J2"/X^%:.#
MB$Y#F(MQJ2J6X-PCY2N43^@M?OUE$ >_=1",6H)1%_KBP=T'$"NX2E-NQ,IR
M^(":\5R951?!*=K=P(\9PDKD=.]XN09M*@R5%$\\I7RP_5'I_BA12UBQA.=<
M;R%WF;,AEQI3X*4U2 25NE2TL&0Y*Q,$JS]244JG,:F,H<Y$K5B9JO-+^.@0
M.8%1=;&M+@698+%$"<.!71F [0H78G51*P2FE(%]!X.!'XPB,PC]\2B$FUI*
MH@25D/9N$W-+%G+.EKNCAGX\'= WFH;PM4+)M$G#2[NM#R5U/O)/CB#'_F0T
MAJD_CB;P*#2ER=(8T90&0S^, OAN[SRF%^R)X-=(7<KT07L,7R&<;9&R<0YA
M;PK#7O1?^Y2K1-1T*I%#B'L3>$_?*;SOD-6HE=7HK;*R H(;H?1)%77BG!:_
M0TP,H@^;C"<9,(E4]R2OTT8I;<KQN3)R43O]*$W14F/73G+.3I0&":6I>J-:
M$M21D!XSB?BBX>P%]<"?7]FQ4K/JVH^.!=%P-+7U@]A(;3(<TS?T!Z&MN#\:
M!'##5 85XRDQE <1.HR][SB.&]_0^9)X.TH:MR6-WUK2;^5..Q2II77'MB:G
M\'69\[5+J&6YC]05[79_14Z)H9/!:3&<ZC/N3Y[_2U4W):\/Z28NBXZN.*)K
MK(\3>WBKF17-R]H>R^3>7L.4^@J96@M;C'%@)D.(_"BRPXB&H\G4#$=4I:%3
M2 PAM1AWYU_P/J;5A*!L5QJ'\*FH:M<F->E8Z;WPSP9^&$;G#6A7>$V+N46E
M+D^UN==\MW!F^]WY_VAU[YIF=TJA_8.G18%R;1]0"FQ*W"NC76W?:%?N:;(W
M=P^\+TRN.54YQQ6Y!KTQ]1WI'DUNHD5E'RI+H>G98X<9O3-1&@/:7PFA=Q-S
M0/MR7?P$4$L#!!0    ( '* !%7%MIVZ. 4  *H-   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;,U7VV[;.!#]E8%:% F@VKHXEITF!IPVW>T"[1IQ
MTV*QV =:&EM")5$EJ5SVZW>&E!6G==P\[HM(B7,YPSDSI,YNI?JF<T0#=U59
MZW,O-Z8Y'0YUFF,E]$ V6-/*6JI*&'I5FZ%N%(K,*E7E, J"\; 21>W-SNRW
MA9J=R=:418T+!;JM*J'N+["4M^=>Z&T_7!6;W/"'X>RL$1M<HKEN%HK>AKV5
MK*BPUH6L0>'ZW)N'IQ<)RUN!+P7>ZITY<"0K*;_QRX?LW L8$):8&K8@:+C!
MMUB6;(A@?.]L>KU+5MR=;ZV_M[%3+"NA\:TLOQ:9R<^]B0<9KD5;FBMY^SMV
M\9RPO526VC[AMI,-/$A;;635*1."JJC=*.ZZ?7B.0M0I1!:W<V11OA-&S,Z4
MO 7%TF2-)S94JTW@BIJ3LC2*5@O2,[/+[VUA[N%#G6+-^P.+4M0:CCZ+58GZ
M^&QHR F+#M/.X(4S&#UA< P?96UR#9=UAMEC_2&!ZQ%&6X07T4&#?[3U .+
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M8UIRN7F;[;]7*V,UD>._4_GV[O+3[ES#3$S+2IP%U!$&]3,&\Y]_2D;Q+V?
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M-$B]6-.7"VJG0.=KI>Q^X0(<OH7FWP%02P,$%     @ <H $59BT]DAA!0
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M&LC[:TK%TXGJH/Z69/(_4$L#!!0    ( '* !%5"1W!1/08  $PH   9
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MT7@'=[[6FG:*3S!LY/P/4$L#!!0    ( '* !%6.OU:&EP@  "50   9
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MIF5 \?]UDN0_GY1WBCO>&7#Q/U!+ P04    " !R@ 15.&GHM6D"   @!P
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MLGD2I/YN'V RQ"L!Y@/ ?!+@&FN W7BUDCGH483.(-Y#B)(@><(P&>65#/'
M$$\R?&6"X0$MR%;*\9,3/T.8)]$3@LD8KR1(!H)DDN!2&LK'$D^>;Y\X_/0D
M\^>+_NRP+AU_KW[9N^,'55LF-.&P04UP_ 'A55>/NXZ1M2MI-])@@73-$J\P
M4'8!SF^D- \=6R6'2S'[#5!+ P04    " !R@ 15AQ>"+E8"  #P!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6RM5%U/VS 4_2N6AR:0&/FD!99&
M@E;3F+2I@K$]3'MPD]O&PK&S:Z>%?S_;"5$9A6W:7F)?^Y[C<^S<FVT4WNH*
MP)"[6D@]H94QS5D0Z**"FNDCU8"T.TN%-3,VQ%6@&P16>E M@C@,1T'-N*1Y
MYM?FF&>J-8)+F"/1;5TSO+\ H383&M&'A2N^JHQ;"/*L82NX!G/3S-%&P<!2
M\AJDYDH2A.6$GD=GT]3E^X0O'#9Z:TZ<DX52MRZX+"<T=() 0&$< [/#&J8@
MA".R,G[TG'0XT@&WYP_L[[QWZV7!-$R5^,I+4TWH"24E+%DKS)7:O(?>S['C
M*Y30_DLV7>[QF)*BU4;5/=@JJ+GL1G;7W\,6($J? <0](/Y30-(#$F^T4^9M
MS9AA>89J0]!E6S8W\7?CT=8-E^X5KPW:76YQ)K^4:Y!&X3UY0SXQ1.9NE>S/
MP# N](%=O;F>D?V] [)'N"2?*]5J)DN=!<:>[CB"HC_IHCLI?N:D#ZT\(DEX
M2.(PCG? IR_#9U!8>.3AT6-X8#T/QN/!>.SYDM\:GW%="*5;!/+M?*$-VE_K
M^RY_'6&ZF]"5VYEN6 $3:NM) ZZ!YJ]?1:/P[2ZW_XGLD?=D\)Z\Q)[/$1K&
M2U*HN@8L.!/VEY+MTAIOD<O5+O,=X\@SNM:PSJ/Q^#3)@O6VJZ=9IVDX&I(>
MJ4T'M>D_J3TD4LFB1;3ON4MY^D13<A*&OPA_4<+?/D>P58^N%WYDN.)2$P%+
M2Q\>C8\IP:Z_=(%1C2_1A3*VX/VTLBT9T"78_:52YB%P53\T^?PG4$L#!!0
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M4RK7<$_CA]:J>Z%.[,Q)373R9HJ:O %O'#6&&?U_3548@^=%A0^<&O]@656
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M?ED>9,N!%AMW>+P7VAQ%W65J#O\@[03S?"6$W@]L@OK?"?-_ 5!+ P04
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MEE4Q;P?7>S"?YNO_9G^T?Q%; _K#%P98[0#KV0#+>F% OQW0/W3 H!TP.'3
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MR":B;#:H__RV**JG;YH)/A?E[ZNG.?X_4$L#!!0    ( '* !%7%D?,3S@,
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MLG+B#>&"WT0Y3G+=YJ\2K]^.9V+\3JUI!!,+@UB!W( 5_OZ;ZSOOVL1>">Q
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M!%LIS=QFAG.MF5PC'1(+3&8'_8^V0 VV8!(.05]NB!.N+9;F[PY#%[6 <;<
M=TF<F8JEN CH%C"H'S%(_G@QG$9ON[+S/Y$=Y&K<YFK<QY[<M?ONR67$^!2E
MJBQ1IYP).AT"Z;Q0,G817>FHUYCZ-=P5]YC$T3Q\W#?9*^,W34Y:DY->DP]5
MKFG'[RQT.:@))GL.AL\=3'XPN1=RH&O:ZIKVZEK6>L J6-$5@"G2WLNZY$U_
M6'OR3%WO2K^9W]/6QVFOCT]TH@RK2TBJ3/<>Z:7XU2-3DPWCO81$@W'WUYBU
M+F:]+LY+I2W_UU_3)X!YCKX:TEUKD219H+L!3Z"BDW%D$_7R_ZK%FFP8'5@<
MC9^;#/?*%!W:M:_>AC[#1MJZ8K6C[0/AW-?%\'MX_;JX97K-I0&!.4&CP2GM
M>%U7[+IC5>6+WDI9*J&^6= C![4+H/E<*;OKN 7:9U/R'U!+ P04    " !R
M@ 15<3<N)6L(   K2   &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6RU
MG%]OX[@5Q;\*X19%%DAC2[(=9YH82"(&.\7,-ICIM@]%'QB)MH651"]%)1.@
M'WY)23%-1Z9'@]-YF,A_[D_R/>:ESA6MZQ<A?ZLVG"ORK<C+ZF:T46K[83RN
MD@TO6'4AMKS4KZR$+)C2#^5Z7&TE9VD35.3C<#*9CPN6E:/E=?/<HUQ>BUKE
M6<D?):GJHF#R]8[GXN5F%(S>GOB2K3?*/#%>7F_9FG_EZM?MH]2/QCM*FA6\
MK#)1$LE7-Z/;X .=SDQ \XY_9?REVMLFYJ,\"?&;>? QO1E-S!'QG"?*()C^
M\\SO>9X;DCZ.WSOH:+=/$[B__49_:#Z\_C!/K.+W(O]WEJK-S6@Q(BE?L3I7
M7\3+S[S[0,T!)B*OFO_)2_?>R8@D=:5$T07K(RBRLOW+OG6)V L(ID<"PBX@
M/ R8'0F(NH#H," Z$C#M J;?&S#K IJ//FX_>Y.XF"FVO);BA4CS;DTS&TWV
MFVB=KZPT7Y2O2NI7,QVGEG="ZHBL7)._DE^8E,SH1LYBKEB65S_I9W_]&I.S
M/_]T/59Z=R9HG'3H^Q8='D'/R6=1JDU%:)GRU(T?ZYWNCC5\.]:[T M\X$\7
M)(S.23@)P[[C\8?_O2XO2#0Y&A[[PS^S5Q(%)CI8]$33T]'!O"_:246TDRUJ
M<-$17,R?%/E85DK6>M0J\I]/^@WDH^)%]=^>@[MK:=-^FBE&'ZHM2_C-2%>;
MBLMG/EK^Y4_!?/*WOC0C83$21D$P1Y+I3I*IC[Y\E%F99%N6$UV/*\7*5(^J
M/BV\F*%:M+!Y S.3PO,R7"SF>IJ87(^?]_.,W"L%P9P\SW9YGGGS;$80^2>7
M!?DD6$G^9[?[DNUE#4TV$A8C810$<P29[P290VO1'"D)$A8C810$<R2YW$ER
MZ1TCS9#(S?!8Z5T05HBZ5'U:>#%#M4#"8B2,7KZKDK-)^V]7)9T\+W9Y7F!J
MOA<S-,](6(R$T<7[V6CFR_/5+L]7)VI^&'Y_S?>RAB8;"8N1, J".8($$^L;
M)M"JW^% JD!I,91&4317F#U#%WC'RD-6ZGJTXIRD-2?U5KMQ[:=KF:G7<^W+
M$^W1C<L3Y3G1^]^R5R/?.1&2*#VH='!CX,^V7";ZA3[?=]<=@?F@NX$^N9A,
MKV;N2>>]_U 'RX2D413-E2FT,H5>F9I"QM:2\V;X).*9E\P(D;!J0_1,TF[P
MW^OLF>7Z+15A%>E486M.Q&I_TFEG^R>6LS+AYZ93D!5UT2M>>UQ7CG:+0^&\
M!S]8."2-HFBN<-9Y!UX7>2#<.5JYA.5)G;>#4,=D(NT5$6KH3WSB.2F:1DZO
MM%#_CJ*YTEH''_@M_-$Q67*EBZ5(ZT01R?6SNK*"1N.T9S3.#T<CTKS'4!I%
MT5S);#,@\'<#;M,T,V-%3WE=>YADI9[(>*658HKWYGS6D_/)]##I4+</I5$4
MS4VZ-?R!U[QZ3L?UMO9$YEQ"D%4FM0BL++-G+BLF7\T@27)1F0&2'M,&VAV
MTF(HC:)HKH:V0Q!<8L_?H:T"*"V&TBB*Y@IC6PK!J9["VTFY.3\OLKH@9WJN
M8<1[1K[H*VG184F#=@Z@-(JBN5FW#8;@1SL,>OMVI6>4GGJF-E+4ZPVI>"+T
M:=_04@?M4T!I,91&433WJJ%M58385D4(;55 :3&41E$T5QC;J@C]K8H?*G4=
M\Z#4A0>ESK_GP5F'=AY0-#?KMO,0^CL/WU'J>@J:/J%[:R,=K6C^'0\>.- >
M!)1&43170MN#"+&7_T-HNP!*BZ$TBJ*YPM@.0GAJ$<"/5+2^'L D.*QHT"8
ME$91-#?KM@D0GEH2X*EHGS[>_>-+;]JA:P.@M!A*HRB:*X]M%X38!0(AM <
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M'ZAL[TS3/E!BV]QZY4DH)8IF<\-9RJ5Y@WY])81Z>V!VL+L_T/(/4$L#!!0
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M=3$P,LUWN[DTN'?FERL\W8"R$_#Y0DKS.+ ;:'5>"O\ 4$L#!!0    ( '*
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M]APGLC-,<FL^U<_NV'Q*2Y&2'.X8XF6687:X@93N9Y9KO3VX)YNM4 _L^;3
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M[CG'YQI\B5>,/XL"0*)U55(QM@HIZY%MBZR "HM+5@-53^:,5UBJ*5_8HN:
M<P.J2MMSG,BN,*%6$IO8'4]BULB24+CC2#15A?GO"91L-;9<:Q.X)XM"ZH"=
MQ#5>P /(Q_J.JYG=L^2D BH(HXC#?&S=N*-9J/--P@\"*[$U1MK)$V//>O(Y
M'UN.7A"4D$G-@-5M"5,H2TVDEO&KX[1Z20W<'F_8/QKORLL3%C!EY4^2RV)L
M75LHASEN2GG/5I^@\V,6F+%2F"M:M;EA9*&L$9)5'5BMH"*TO>-U5X<M@.(9
M!G@=P-L'!"\ _ [@GZH0=(#@5(6P QCK=NO=%"[%$B<Q9RO$=;9BTP-3?8-6
M]2)4OR</DJNG1.%D\A54E05ZC\P 39F0 IVG(#$IQ86*/SZDZ/SL ITA0M'W
M@C4"TUS$ME3BFL+..J%)*^2](.2C6T9E(=",YI /X-/C^.@(WE:F>^?>QOG$
M.TKXI:&7R'?>(<_QO('U3$^'NT-V_D]]]L_J.\7P^]? -WS^L=< 97KWA[:V
M!0?#8'V4C42-,QA;ZJP2P)=@)6_?N)'S8:BNKTF6OB;9[)7(=G8@Z'<@.,:>
M?*N!8TGH I5F+V"M6H& H=UHB2)#I/O ,G&=*(CMY7:5#Y.N_:O=G/0PQW.]
MZ]VDV8!:Z#I]TH[9L#<;'C4[Q:) -28Y4IT.L5WK0Y;#4RP?)EU%T9[EPQQE
MV=NS/* 6AL&>97OKT*V +TRW$^H;:JAL/[P^VC?4&]-']N(3=S1U!^*I:L!M
MO_Q+WW;O6\P7A I5KKF2<BZOU()YVQ';B62U.?*?F%0-Q P+]1,!7">HYW/&
MY&:B!?K?DN0/4$L#!!0    ( '* !%638F]P50,  !4,   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;*V7;6^;,!2%_XK%IFF3N@+F+>D2I#75M$Z=
M5K7K]MD!)[%F,+--T_[[70.ED!!:1?O2\.)S>,ZU;-_.MD+^41M*-7K(>*[F
MUD;KXLRV5;*A&5&GHJ YO%D)F1$-MW)MJT)2DE:BC-O8<4([(RRWXEGU[%K&
M,U%JSG)Z+9$JLXS(QW/*Q79NN=;3@QNVWFCSP(YG!5G36ZKOBFL)=W;KDK*,
MYHJ)'$FZFEN?W;.%BXV@&O&+T:WJ7",392G$'W-SF<XMQQ!13A-M+ C\W-,%
MY=PX <??QM1JOVF$W>LG]R]5> BS)(HN!/_-4KV96Q,+I71%2JYOQ/8K;0(%
MQB\17%5_T;89ZU@H*94662,&@HSE]2]Y: K1$;C^ 0%N!/BU J\1>%70FJR*
M=4$TB6=2;)$TH\'-7%2UJ=20AN5F&F^UA+<,=#J^HE #A3ZBNSQE*A%EKFF*
M%D1MT#5YA/G2Z,>2LS4Q15?H_075A''UP2AN+]#[MQ_06\1R]',C2D7R5,UL
M#5C&W$X:A/,: 1] ^%;FI\AS3A!V,!Z0+\;E%S0!N5O)W;[<AF*T%<%M17#E
MYQWPZQ4B,84HFD*(YT(,I:QM_6%;LQS/5$$2.K=@O2DJ[ZD5OWOCALZGH<S_
MR:Q7 :^M@#?F'M]0L_Y3*I%8'9J4\]HBK"S,7G$?8S=R9O9]-\7H=XY,X;<I
M_-$4 .X-@=>JH /N^_XN^*CUD>!!"QZ\!.X/@0?[X,%DN@,^:GTD>-B"AR^!
M!T/@X1ZXZYFEV@,?M3X2/&K!HY? PR'P: \<!WB'>]3Y2.Y)RST9Y?XI-.&H
M[&Y8<+Y+V*+R->)F9W_:NP8WK,G^O. HV@TXBG!DP&D;<#H:\#(K2I.*039P
MUX@^0/\"!]90G.E>G(\N-DNI%V?T@T?&<9WGT]9YQ8SM3A)G9,DXTVPX6./9
MFR@W\"<[R9IA87^==;:V/G.G0W!'F:^H4F=H44II#L%"R*K_@J/A4(S'P1#N
M_O1XX71W&Q@<YD_Q@1#/A[H[>F+&/PZQGJ <FF5(D_0##F; >Q6.)D&T&V%_
MU#3JS%:=P.[T;*9A_D[DFD&'Q>D*9,YI!"60=0]:WVA15&W<4FAH"JO+#?3M
M5)H!\'XEA'ZZ,9UA^Y] _ ]02P,$%     @ <H $58CF #!E!0  [B<  !D
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MQ@>X\XW6N'?\!3B\=_E?4$L#!!0    ( '* !%6?.=(J8 ,  ,P5   -
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !R@ 15>NT'A^T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !R@ 15
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( '* !%5I%DX)V 4  *D?   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !R@ 15
M *6-+)$&   [&P  &               @($:#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ <H $50V=^>4# P  6@H  !@
M     ("!X10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M '* !%60D]'B=0<  'DL   8              " @1H8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !R@ 15;,FS%GX*  "170  &
M            @('%'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ <H $56I0PQN9"   \R8  !@              ("!>2H  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( '* !%7Z&FK,<18  !)!
M   8              " @4@S  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !R@ 15UJ5=#E$'  !T$@  &               @('O20
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ <H $50X()0:B
M!P  GA,  !@              ("!=E$  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( '* !%73"IY.H ,  .('   9              "
M@4Y9  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ <H $
M5;>#&?U:!   3@D  !D              ("!)5T  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !R@ 156,I""+\.   ',0  &0
M        @(&V80  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( '* !%5E+Z%J4P8   8/   9              " @:QP  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ <H $5<U.H+$.#0  U2,
M !D              ("!-G<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !R@ 15QT.B+ X(  #G%P  &0              @(%[A
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( '* !%64JCX:
M@00  )H*   9              " @<",  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ <H $551,;<+\ P  ZP@  !D
M ("!>)$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !R
M@ 157;!H9MH%  #=#0  &0              @(&KE0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( '* !%4 "+9(C00  'P*   9
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M970R,RYX;6Q02P$"% ,4    " !R@ 15<<CL4&$"   W!0  &0
M    @('AP   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M '* !%5?7%5J'P,  +,&   9              " @7G#  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ <H $54I#18-. P  &@@  !D
M             ("!S\8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !R@ 15;HC%M=T"  !'!@  &0              @(%4R@  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( '* !%7/_!Z7, ,
M  $'   9              " @6C-  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ <H $58"*"H,Y!   Q0H  !D              ("!
MS]   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !R@ 15
MQ;:=NC@%  "J#0  &0              @($_U0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( '* !%4H6^CBZ0,  !<)   9
M      " @:[:  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ <H $59BT]DAA!0  5R(  !D              ("!SMX  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !R@ 150D=P43T&  !,*
M&0              @(%FY   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( '* !%6P8ALQ>0(  )T%   9              " @=KJ  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ <H $58Z_5H:7
M"   )5   !D              ("!BNT  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !R@ 15.&GHM6D"   @!P  &0
M@(%8]@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( '*
M!%6'%X(N5@(  / %   9              " @?CX  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ <H $5=ZNWGFY!   =!\  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( '* !%5Q-RXE:P@  "M(   9
M  " @3(< 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M<H $56%RN([M @  .PD  !D              ("!U"0! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !R@ 15%:)G(F4$  "Q'   &0
M            @('X)P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( '* !%6JFO [PP,  !(3   9              " @90L 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ <H $5:J."N8D P
M\ D  !D              ("!CC ! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " !R@ 15QI I'K$"  "B"   &0              @('I
M,P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( '* !%63
M8F]P50,  !4,   9              " @=$V 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ <H $58CF #!E!0  [B<  !D
M     ("!73H! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '* !%7]]LFL3 ,  !L+   9              "
M@:!. 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ <H $
M53T!1H:/ P  TPT  !D              ("!(U(! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " !R@ 15('=O P<$  ! %@  &0
M        @('I50$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( '* !%5BR@QB%P(  /L$   9              " @2=: 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ <H $59\YTBI@ P  S!4
M  T              ( !=5P! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !R
M@ 15EXJ[',     3 @  "P              @ $ 8 $ 7W)E;',O+G)E;'-0
M2P$"% ,4    " !R@ 154";)=] $  !C)@  #P              @ 'I8 $
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ <H $51,G[+KO 0  I2(  !H
M             ( !YF4! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ <H $56(CYQC8 0  2"(  !,              ( !#6@! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $( 0@ %$@  %FH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>262</ContextCount>
  <ElementCount>292</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash, Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</Role>
      <ShortName>Cash, Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Product Revenue, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNet</Role>
      <ShortName>Product Revenue, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</Role>
      <ShortName>Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Deferred Royalty Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DeferredRoyaltyObligation</Role>
      <ShortName>Deferred Royalty Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Borrowing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Borrowing</Role>
      <ShortName>Borrowing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2151114 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Product Revenue, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetTables</Role>
      <ShortName>Product Revenue, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/ProductRevenueNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Collaboration and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables</Role>
      <ShortName>Collaboration and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Borrowing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingTables</Role>
      <ShortName>Borrowing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Borrowing</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Derivative Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityTables</Role>
      <ShortName>Derivative Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DerivativeLiability</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2334308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/EquityIncentivePlans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Inventory - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryScheduleDetails</Role>
      <ShortName>Inventory - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Product Revenue, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails</Role>
      <ShortName>Product Revenue, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails</Role>
      <ShortName>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Deferred Royalty Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails</Role>
      <ShortName>Deferred Royalty Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DeferredRoyaltyObligation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Borrowing - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingNarrativeDetails</Role>
      <ShortName>Borrowing - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Borrowing - Future Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails</Role>
      <ShortName>Borrowing - Future Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Derivative Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails</Role>
      <ShortName>Derivative Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Derivative Liability - Changes in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails</Role>
      <ShortName>Derivative Liability - Changes in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435416 - Disclosure - Leases - Additional Details of Facility Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails</Role>
      <ShortName>Leases - Additional Details of Facility Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails</Role>
      <ShortName>Leases - Undiscounted Cash Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/StockholdersEquity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2442420 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2443421 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Equity Incentive Plans - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Net Loss Per Share - Summary of Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ardx-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2452427 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Contingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ardx-20220630.htm">ardx-20220630.htm</File>
    <File>ardx-20220630.xsd</File>
    <File>ardx-20220630_cal.xml</File>
    <File>ardx-20220630_def.xml</File>
    <File>ardx-20220630_lab.xml</File>
    <File>ardx-20220630_pre.xml</File>
    <File>ardx-20220630xex311.htm</File>
    <File>ardx-20220630xex312.htm</File>
    <File>ardx-20220630xex321.htm</File>
    <File>hcr-ardelyxxroyaltyandmile.htm</File>
    <File>secondamendedandrestatedno.htm</File>
    <File>slr-ardelyxxfirstamendment.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="673">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 26,
   "contextCount": 262,
   "dts": {
    "calculationLink": {
     "local": [
      "ardx-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ardx-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ardx-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 487,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 63,
   "keyStandard": 229,
   "memberCustom": 30,
   "memberStandard": 33,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Inventory",
     "role": "http://www.ardelyx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Product Revenue, Net",
     "role": "http://www.ardelyx.com/role/ProductRevenueNet",
     "shortName": "Product Revenue, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Collaboration and Licensing Agreements",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreements",
     "shortName": "Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Deferred Royalty Obligation",
     "role": "http://www.ardelyx.com/role/DeferredRoyaltyObligation",
     "shortName": "Deferred Royalty Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Borrowing",
     "role": "http://www.ardelyx.com/role/Borrowing",
     "shortName": "Borrowing",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Derivative Liability",
     "role": "http://www.ardelyx.com/role/DerivativeLiability",
     "shortName": "Derivative Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Leases",
     "role": "http://www.ardelyx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Stockholders' Equity",
     "role": "http://www.ardelyx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Equity Incentive Plans",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Net Loss Per Share",
     "role": "http://www.ardelyx.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED BALANCE SHEETS",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151114 - Disclosure - Contingencies",
     "role": "http://www.ardelyx.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash, Cash Equivalents and Investments (Tables)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables",
     "shortName": "Cash, Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventory (Tables)",
     "role": "http://www.ardelyx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Product Revenue, Net (Tables)",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetTables",
     "shortName": "Product Revenue, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Collaboration and Licensing Agreements (Tables)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables",
     "shortName": "Collaboration and Licensing Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Borrowing (Tables)",
     "role": "http://www.ardelyx.com/role/BorrowingTables",
     "shortName": "Borrowing (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Derivative Liability (Tables)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityTables",
     "shortName": "Derivative Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334308 - Disclosure - Leases (Tables)",
     "role": "http://www.ardelyx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:CashAndCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:CashAndCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i2ffac70a8f02419f80d424ef9aec9556_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i2ffac70a8f02419f80d424ef9aec9556_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Inventory - Schedule (Details)",
     "role": "http://www.ardelyx.com/role/InventoryScheduleDetails",
     "shortName": "Inventory - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:PrepaidCommercialManufacturingCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Inventory - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/InventoryNarrativeDetails",
     "shortName": "Inventory - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ardx:PrepaidCommercialManufacturingExpenseNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Product Revenue, Net - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
     "shortName": "Product Revenue, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "ib2291f07e25a44999a22885c21de57cd_D20210401-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerProductSalesGrossToNetAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i925bda1ddc9b4f2ca467776b876445bb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
     "shortName": "Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i925bda1ddc9b4f2ca467776b876445bb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
     "shortName": "Collaboration and Licensing Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i3fb105e15b8b47d9b8839aab9ebd811a_D20220401-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i925bda1ddc9b4f2ca467776b876445bb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
     "shortName": "Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i2325fcd766374f64b728734271bdcb7f_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i2776e4b43d244212bb36a96e1f7f6bf0_D20220628-20220628",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInRoyaltiesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Deferred Royalty Obligation (Details)",
     "role": "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails",
     "shortName": "Deferred Royalty Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i2776e4b43d244212bb36a96e1f7f6bf0_D20220628-20220628",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInRoyaltiesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Borrowing - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
     "shortName": "Borrowing - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i332a0792bd1f4c0e92d7f1b5cbe65a8e_I20180516",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Borrowing - Future Payment Obligations (Details)",
     "role": "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
     "shortName": "Borrowing - Future Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i45fff355f00f45b192078e143fe5bd5a_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Derivative Liability - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
     "shortName": "Derivative Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "ic904ee852e2546278f6d6a2a871ab36c_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "idb141ea05dc14bd488bc51b17742bb1b_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Derivative Liability - Changes in Fair Value (Details)",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
     "shortName": "Derivative Liability - Changes in Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i0ef0d267ad3d436b9af9981688d023fa_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435416 - Disclosure - Leases - Additional Details of Facility Leases (Details)",
     "role": "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
     "shortName": "Leases - Additional Details of Facility Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - Leases - Lease Costs (Details)",
     "role": "http://www.ardelyx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)",
     "role": "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails",
     "shortName": "Leases - Undiscounted Cash Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if50bec065c1f4bf58f6a04567d2d85b9_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if50bec065c1f4bf58f6a04567d2d85b9_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.ardelyx.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id37f41791c3a4469a79f174900a9480a_I20200731",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ardx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442420 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443421 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id51d0832aa5449abae8f15be39293d79_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id51d0832aa5449abae8f15be39293d79_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i925bda1ddc9b4f2ca467776b876445bb_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Equity Incentive Plans - Stock Options (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i925bda1ddc9b4f2ca467776b876445bb_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
     "shortName": "Equity Incentive Plans - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "ie37c16e9bd874f9da0f3fa7e2ff52bc4_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Net Loss Per Share - Summary of Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Summary of Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "id2986e2b71e5420e8c52858ab55401ce_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452427 - Disclosure - Contingencies (Details)",
     "role": "http://www.ardelyx.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "if62c57c8d0834b5693f69a9e3e0744b3_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash, Cash Equivalents and Investments",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments",
     "shortName": "Cash, Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Fair Value Measurements",
     "role": "http://www.ardelyx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20220630.htm",
      "contextRef": "i285f507425f845998ab1cc87f33146fa_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "ardx_AccountsReceivableCollaboratorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Collaborator",
        "label": "Accounts Receivable, Collaborator [Member]",
        "terseLabel": "Collaborators"
       }
      }
     },
     "localname": "AccountsReceivableCollaboratorMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AccountsReceivableCommercialCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Commercial Customer",
        "label": "Accounts Receivable, Commercial Customer [Member]",
        "terseLabel": "Commercial customers"
       }
      }
     },
     "localname": "AccountsReceivableCommercialCustomerMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AmerisourceBergenDrugCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Drug Corporation",
        "label": "AmerisourceBergen Drug Corporation [Member]",
        "terseLabel": "AmerisourceBergen Drug Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenDrugCorporationMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstraZenecaTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca Termination Agreement",
        "label": "AstraZeneca Termination Agreement [Member]",
        "terseLabel": "AZ Termination Agreement"
       }
      }
     },
     "localname": "AstraZenecaTerminationAgreementMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AstraZeneca.",
        "label": "Astrazeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstrazenecaMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "label": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "terseLabel": "Short-term available-for-sale securities contractual maturities, maximum"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_CardinalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health",
        "label": "Cardinal Health [Member]",
        "terseLabel": "Cardinal Health"
       }
      }
     },
     "localname": "CardinalHealthMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CashAndCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Amortized Cost",
        "label": "Cash And Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAmortizedCost",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashAndCashEquivalentsGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ardx_CashAndCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Gross Unrealized Gains",
        "label": "Cash And Cash Equivalents, Gross Unrealized Gains",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedGains",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashAndCashEquivalentsGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ardx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents, Gross Unrealized Losses",
        "label": "Cash And Cash Equivalents, Gross Unrealized Losses",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedLosses",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized gains.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Gains",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedGains",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized losses.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Losses",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Current, Rollforward",
        "label": "Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Noncurrent, Rollforward",
        "label": "Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - non-current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Collaboration and Licensing Agreements",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsAbstract",
     "nsuri": "http://www.ardelyx.com/20220630",
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsNumberOfAmendments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Number Of Amendments",
        "label": "Collaboration And Licensing Agreements, Number Of Amendments",
        "terseLabel": "Number of amendments"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsNumberOfAmendments",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees",
        "terseLabel": "Upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFees",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, First Installment",
        "terseLabel": "First installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees, Second Installment",
        "terseLabel": "Second installment of upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFeesSecondInstallment",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "terseLabel": "Fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "terseLabel": "Number of payment tranches for fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_CollaborativeArrangementPotentialCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Commercialization Milestones",
        "label": "Collaborative Arrangement, Potential Commercialization Milestones",
        "terseLabel": "Potential commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of future development and commercialization milestone under collaborative arrangements.",
        "label": "Collaborative Arrangement, Potential Development And Commercialization Milestones",
        "terseLabel": "Potential development and commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Development Milestones",
        "label": "Collaborative Arrangement, Potential Development Milestones",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentMilestones",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "label": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "terseLabel": "Maximum potential payment per agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Development [Member]",
        "label": "Collaborative Development [Member]",
        "terseLabel": "Collaborative development revenue"
       }
      }
     },
     "localname": "CollaborativeDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerDiscountsAndChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Discounts And Chargebacks",
        "label": "Contract With Customer, Discounts And Chargebacks [Member]",
        "terseLabel": "Discounts and Chargebacks"
       }
      }
     },
     "localname": "ContractWithCustomerDiscountsAndChargebacksMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Credits Or Deductions Issued",
        "label": "Contract With Customer, Gross To Credits Or Deductions Issued",
        "terseLabel": "Credits/deductions issued"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToCreditsOrDeductionsIssued",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period",
        "label": "Contract With Customer, Gross To Net Sales, Accrual Activity During Current Period",
        "terseLabel": "Activity related to 2022 sales"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccrualActivityDuringCurrentPeriod",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accrual",
        "label": "Contract With Customer, Gross To Net Sales Accrual [Roll Forward]",
        "terseLabel": "Gross-to-net sales accruals and reserves"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccrualRollForward",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accruals",
        "label": "Contract With Customer, Gross To Net Sales Accruals",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccruals",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent",
        "label": "Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent",
        "terseLabel": "Amortization, effective interest rate, percent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "label": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "terseLabel": "Increases to amounts invoiced, for which cash has not yet been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseForAmountsInvoiced",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseForCashReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase For Cash Received",
        "label": "Contract With Customer, Liability, Increase For Cash Received",
        "terseLabel": "Increases due to cash received during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseForCashReceived",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueRecognizedCashReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received.",
        "label": "Contract With Customer, Liability, Revenue Recognized Cash Received",
        "negatedTerseLabel": "Decreases due to revenue recognized in the period for which cash has been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedCashReceived",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Transaction Costs",
        "label": "Contract With Customer, Liability, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityTransactionCosts",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Other Fees, Copay And Returns",
        "label": "Contract With Customer, Other Fees, Copay And Returns [Member]",
        "terseLabel": "Other Fees, Copay and Returns"
       }
      }
     },
     "localname": "ContractWithCustomerOtherFeesCopayAndReturnsMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerProductSalesGrossToNetAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer Product Sales Gross To Net Accruals",
        "label": "Contract With Customer Product Sales Gross To Net Accruals",
        "terseLabel": "Contract with customer product sales gross to net accruals"
       }
      }
     },
     "localname": "ContractWithCustomerProductSalesGrossToNetAccruals",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Rebates",
        "label": "Contract With Customer, Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ContractWithCustomerRebatesMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CostOfRevenueAggregateAmountRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of revenue, aggregate amount recognized.",
        "label": "Cost Of Revenue, Aggregate Amount Recognized",
        "terseLabel": "Aggregate cost of revenue recognized"
       }
      }
     },
     "localname": "CostOfRevenueAggregateAmountRecognized",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentClosingFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Closing Fee Amount",
        "label": "Debt Instrument, Closing Fee Amount",
        "terseLabel": "Closing fee"
       }
      }
     },
     "localname": "DebtInstrumentClosingFeeAmount",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "label": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "terseLabel": "Final fee due upon maturity, acceleration, prepayment, or termination (percent)"
       }
      }
     },
     "localname": "DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentInterestRateOnDefaultPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional default interest rate on the event of default.",
        "label": "Debt Instrument, Interest Rate On Default, Percentage",
        "terseLabel": "Additional default interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateOnDefaultPercentage",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fee payable on prepayment of debt.",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Prepayment premium (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentVariableRateBaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate, Base Option",
        "label": "Debt Instrument, Variable Rate, Base Option",
        "terseLabel": "Addition to floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentVariableRateBaseOption",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DeferredRoyaltyObligationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalty Obligation, Noncurrent",
        "label": "Deferred Royalty Obligation, Noncurrent",
        "terseLabel": "Deferred royalty obligation"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationNoncurrent",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DerivativeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Issued",
        "label": "Derivative Issued",
        "terseLabel": "Issuance of derivative in connection with issuance of loan payable"
       }
      }
     },
     "localname": "DerivativeIssued",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP shares issuable"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFee2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2018",
        "label": "Exit Fee 2018 [Member]",
        "terseLabel": "2018 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2018Member",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFee2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2022",
        "label": "Exit Fee 2022 [Member]",
        "terseLabel": "2022 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2022Member",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee, Percentage",
        "label": "Exit Fee, Percentage",
        "terseLabel": "Exit fee (percent)"
       }
      }
     },
     "localname": "ExitFeePercentage",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "label": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "terseLabel": "Fair value analysis, percentage change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "label": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "terseLabel": "Fair value analysis, effect on fair value based on 10% change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Axis]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Axis]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationAxis",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Domain]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationDomain",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_HealthCareRoyaltyPartnersIVLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCare Royalty Partners IV, L.P",
        "label": "HealthCare Royalty Partners IV, L.P [Member]",
        "terseLabel": "Healthcare royalty partners IV, L.P"
       }
      }
     },
     "localname": "HealthCareRoyaltyPartnersIVLPMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Prepaid Commercial Manufacturing Expense",
        "label": "Increase (Decrease) In Prepaid Commercial Manufacturing Expense",
        "negatedTerseLabel": "Prepaid commercial manufacturing"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidCommercialManufacturingExpense",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_KnightTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Knight Therapeutics Inc.",
        "label": "Knight Therapeutics Inc [Member]",
        "terseLabel": "Knight"
       }
      }
     },
     "localname": "KnightTherapeuticsIncMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_KyowaKirinCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Kyowa Kirin Co., Ltd.",
        "label": "Kyowa Kirin Co. Ltd [Member]",
        "terseLabel": "KKC"
       }
      }
     },
     "localname": "KyowaKirinCo.LtdMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Canada [Member]",
        "terseLabel": "Knight Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.",
        "label": "License Agreement Development Commercialization Distribution In China [Member]",
        "terseLabel": "Fosun Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInChinaMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Japan [Member]",
        "terseLabel": "2017 KKC Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInJapanMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period",
        "label": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period",
        "terseLabel": "Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period"
       }
      }
     },
     "localname": "LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "label": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "terseLabel": "Exit fee, net product revenue threshold"
       }
      }
     },
     "localname": "LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LoanAgreementExitFeeTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Term",
        "label": "Loan Agreement, Exit Fee, Term",
        "terseLabel": "Exit fee, term (in years)"
       }
      }
     },
     "localname": "LoanAgreementExitFeeTerm",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "label": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "terseLabel": "Future obligation upon loan funding or other events"
       }
      }
     },
     "localname": "LoanAgreementFutureObligationUponFundingOrOtherEvents",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Interest Expense On Deferred Royalty Obligation",
        "label": "Non Cash Interest Expense On Deferred Royalty Obligation [Policy Text Block]",
        "terseLabel": "Non-cash Interest Expense on Deferred Royalty Obligation"
       }
      }
     },
     "localname": "NonCashInterestExpenseOnDeferredRoyaltyObligationPolicyTextBlock",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_NumberOfSeparateCollaborativeAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of separate collaborative agreements.",
        "label": "Number Of Separate Collaborative Agreements",
        "terseLabel": "Number of separate collaborative agreements"
       }
      }
     },
     "localname": "NumberOfSeparateCollaborativeAgreements",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_OpenMarketSalesAgreement2020AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2020, At The Market Offering",
        "label": "Open Market Sales Agreement 2020, At The Market Offering [Member]",
        "terseLabel": "2020 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2020AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2021, At The Market Offering",
        "label": "Open Market Sales Agreement 2021, At The Market Offering [Member]",
        "terseLabel": "2021 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2021AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of uncharged license fees, aggregate amount paid.",
        "label": "Payments Of Uncharged License Fees, Aggregate Amount Paid",
        "terseLabel": "Aggregate amount paid"
       }
      }
     },
     "localname": "PaymentsOfUnchargedLicenseFeesAggregateAmountPaid",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_PercentageOfNonRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of non-royalty revenue.",
        "label": "Percentage Of Non-Royalty Revenue",
        "terseLabel": "Percentage of non-royalty revenue"
       }
      }
     },
     "localname": "PercentageOfNonRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PercentageOfRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of royalty revenue.",
        "label": "Percentage of Royalty Revenue",
        "terseLabel": "Percentage of royalty revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PrepaidCommercialManufacturingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Commercial Manufacturing, Current",
        "label": "Prepaid Commercial Manufacturing, Current",
        "terseLabel": "Prepaid commercial manufacturing"
       }
      }
     },
     "localname": "PrepaidCommercialManufacturingCurrent",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_PrepaidCommercialManufacturingExpenseNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Commercial Manufacturing Expense, Noncurrent",
        "label": "Prepaid Commercial Manufacturing Expense, Noncurrent",
        "terseLabel": "Prepaid commercial manufacturing, noncurrent"
       }
      }
     },
     "localname": "PrepaidCommercialManufacturingExpenseNoncurrent",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Future Royalties, Net Of Issuance Costs",
        "label": "Proceeds From Sale Of Future Royalties, Net Of Issuance Costs",
        "terseLabel": "Proceeds from the sale of future royalties, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfFutureRoyaltiesNetOfIssuanceCosts",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ProductIBSRELAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, IBSRELA",
        "label": "Product, IBSRELA [Member]",
        "terseLabel": "IBSRELA"
       }
      }
     },
     "localname": "ProductIBSRELAMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ProductSupplyRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Supply Revenue",
        "label": "Product Supply Revenue [Member]",
        "terseLabel": "Product Supply Revenue"
       }
      }
     },
     "localname": "ProductSupplyRevenueMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RemainingFundingBasedOnConditionalMilestoneAchievement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Funding Based On Conditional Milestone Achievement",
        "label": "Remaining Funding Based On Conditional Milestone Achievement",
        "terseLabel": "Remaining funding based on milestone achievement"
       }
      }
     },
     "localname": "RemainingFundingBasedOnConditionalMilestoneAchievement",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ResearchCollaborationAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the research collaboration and option agreement for research associated with identifying two pre-clinical compounds. The 2019 KKC AGreement.",
        "label": "Research Collaboration And Option Agreement [Member]",
        "terseLabel": "2019 KKC Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndOptionAgreementMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RevenueGeneralPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, General Payment Terms",
        "label": "Revenue, General Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenueGeneralPaymentTerms",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Weighted-Average Price Per Share",
        "label": "Sale Of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average sales price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of additional details of the leases.",
        "label": "Schedule Of Additional Details Of Leases [Table Text Block]",
        "terseLabel": "Summary of Additional Details of Leases"
       }
      }
     },
     "localname": "ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Gross To Net Sales Accruals",
        "label": "Schedule Of Gross To Net Sales Accruals [Table Text Block]",
        "terseLabel": "Schedule of Chargebacks, Discounts and Reserve Balances"
       }
      }
     },
     "localname": "ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Shanghai Fosun Pharmaceutical Industrial Development.",
        "label": "Shanghai Fosun Pharmaceutical Industrial Development [Member]",
        "terseLabel": "Fosun Pharma"
       }
      }
     },
     "localname": "ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase price per share of shares issued to employees under the plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_StockIssuanceCostCommissionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Cost, Commission, Percent",
        "label": "Stock Issuance Cost, Commission, Percent",
        "terseLabel": "Commission on sale of stock per agreement (percent)"
       }
      }
     },
     "localname": "StockIssuanceCostCommissionPercent",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_TermLoan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2018",
        "label": "Term Loan 2018 [Member]",
        "terseLabel": "2018 Term Loan"
       }
      }
     },
     "localname": "TermLoan2018Member",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022AMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 A",
        "label": "Term Loan 2022 A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoan2022AMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022BMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 B",
        "label": "Term Loan 2022 B [Member]",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoan2022BMember",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022",
        "label": "Term Loan 2022 [Member]",
        "terseLabel": "2022 Term Loan"
       }
      }
     },
     "localname": "TermLoan2022Member",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of agreement.",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_TermOfPaymentOfLicenseFeeFirstInstallment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of payment of first installment fee.",
        "label": "Term Of Payment Of License Fee, First Installment",
        "terseLabel": "Term of payment of license fee, first installment"
       }
      }
     },
     "localname": "TermOfPaymentOfLicenseFeeFirstInstallment",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_ThresholdPercentageOfSalesForTieredRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold percentage of net sales for tiered royalties.",
        "label": "Threshold Percentage of Sales For Tiered Royalties",
        "terseLabel": "Threshold percentage of net sales for tiered royalties"
       }
      }
     },
     "localname": "ThresholdPercentageOfSalesForTieredRoyalties",
     "nsuri": "http://www.ardelyx.com/20220630",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r94",
      "r95",
      "r241",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r162",
      "r317",
      "r322",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r276",
      "r338",
      "r339",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r537",
      "r540",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r276",
      "r338",
      "r339",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r537",
      "r540",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r162",
      "r317",
      "r322",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r160",
      "r219",
      "r220",
      "r317",
      "r320",
      "r504",
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r160",
      "r219",
      "r220",
      "r317",
      "r320",
      "r504",
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r211",
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r276",
      "r329",
      "r338",
      "r339",
      "r370",
      "r371",
      "r372",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r537",
      "r540",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r211",
      "r218",
      "r219",
      "r220",
      "r221",
      "r240",
      "r276",
      "r329",
      "r338",
      "r339",
      "r370",
      "r371",
      "r372",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r501",
      "r537",
      "r540",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r94",
      "r95",
      "r241",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r163",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium on investment securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r44",
      "r45",
      "r46",
      "r525",
      "r545",
      "r546"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r52",
      "r53",
      "r54",
      "r98",
      "r99",
      "r100",
      "r403",
      "r466",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r381",
      "r382",
      "r383",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r341",
      "r385",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Royalties [Abstract]"
       }
      }
     },
     "localname": "AdvanceRoyaltiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r66",
      "r81",
      "r260",
      "r449"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Non-cash interest associated with debt discount accretion"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDeferredCharges": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of deferred charges applied against earnings during the period.",
        "label": "Amortization of Deferred Charges",
        "terseLabel": "Amortization of deferred compensation for services"
       }
      }
     },
     "localname": "AmortizationOfDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r60",
      "r81",
      "r260",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r180",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetRetirementObligationDisclosureTextBlock": {
     "auth_ref": [
      "r208",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.",
        "label": "Asset Retirement Obligation Disclosure [Text Block]",
        "terseLabel": "Deferred Royalty Obligation"
       }
      }
     },
     "localname": "AssetRetirementObligationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r9",
      "r92",
      "r149",
      "r152",
      "r158",
      "r187",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r400",
      "r404",
      "r440",
      "r468",
      "r470",
      "r506",
      "r523"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "verboseLabel": "Right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r29",
      "r92",
      "r187",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r400",
      "r404",
      "r440",
      "r468",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r176",
      "r194"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r173",
      "r177",
      "r194",
      "r510"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r175",
      "r194"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r7",
      "r83"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ardx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]",
        "verboseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r83",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r441"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplementary disclosure of non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r89",
      "r92",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r129",
      "r130",
      "r131",
      "r187",
      "r226",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r274",
      "r275",
      "r279",
      "r283",
      "r290",
      "r440",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r394",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r330",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r511",
      "r529"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r222",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized; 153,797,834 and 130,182,535 shares issued and outstanding as of June\u00a030, 2022 and December\u00a031, 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r58",
      "r514",
      "r532"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r162",
      "r438",
      "r439",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r162",
      "r438",
      "r439",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r162",
      "r438",
      "r439",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r138",
      "r139",
      "r162",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r162",
      "r438",
      "r439",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r297",
      "r298",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r297",
      "r298",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r297",
      "r298",
      "r318"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r330",
      "r337",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r62",
      "r92",
      "r187",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r440"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r136",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r261",
      "r262",
      "r264",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowing"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Borrowing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r91",
      "r96",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r452",
      "r507",
      "r508",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r12",
      "r265",
      "r508",
      "r522"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal outstanding",
        "verboseLabel": "Total repayment obligations"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r237",
      "r268",
      "r269",
      "r450",
      "r452",
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "negatedTerseLabel": "Less: Unaccreted value of final fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36",
      "r91",
      "r96",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to first anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After second anniversary to maturity date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After first anniversary through second anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r91",
      "r96",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r268",
      "r269",
      "r270",
      "r271",
      "r291",
      "r292",
      "r293",
      "r294",
      "r449",
      "r450",
      "r452",
      "r453",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Payment term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r250",
      "r266",
      "r268",
      "r269",
      "r451"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r182",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r204"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Exit Fee derivative liability",
        "verboseLabel": "Derivative liabilities for exit fees"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r42",
      "r414",
      "r415",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r422",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r408",
      "r409",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Agreed amount for exit fee upon change of control or regulatory approval",
        "verboseLabel": "Agreed amount for exit fee upon occurrence of certain conditions"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r343",
      "r344",
      "r376",
      "r377",
      "r379",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r112",
      "r114",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r425",
      "r426",
      "r515",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)",
        "verboseLabel": "Net loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r114",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r425",
      "r426",
      "r515",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)",
        "verboseLabel": "Net loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Share-based compensation benefits"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based Compensation [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Average Remaining Vesting Period (Years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r52",
      "r53",
      "r54",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r128",
      "r188",
      "r290",
      "r295",
      "r381",
      "r382",
      "r383",
      "r390",
      "r391",
      "r424",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r466",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r428",
      "r429",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r428",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r429",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r330",
      "r331",
      "r336",
      "r337",
      "r429",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r330",
      "r331",
      "r336",
      "r337",
      "r429",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r429",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Change in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r432",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "2022 Exit Fee addition at fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilityNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r198",
      "r199",
      "r263",
      "r288",
      "r422",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r81",
      "r203",
      "r206"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Gain on sale of equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedTerseLabel": "Debt refinancing costs"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r505",
      "r512",
      "r517",
      "r534"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r207",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r109",
      "r110",
      "r148",
      "r389",
      "r392",
      "r393",
      "r535"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in derivative liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r80",
      "r458"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.",
        "label": "Increase (Decrease) in Royalties Payable",
        "terseLabel": "Royalty payments and commercial milestone payments"
       }
      }
     },
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r55",
      "r147",
      "r448",
      "r451",
      "r516"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r75",
      "r78",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r28",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r26",
      "r86",
      "r127",
      "r200",
      "r201",
      "r202",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Cash and investments",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Additional details"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest expenses"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r92",
      "r153",
      "r187",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r401",
      "r404",
      "r405",
      "r440",
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r92",
      "r187",
      "r440",
      "r470",
      "r509",
      "r527"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r34",
      "r92",
      "r187",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r401",
      "r404",
      "r405",
      "r440",
      "r468",
      "r469",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License",
        "verboseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r12",
      "r251",
      "r267",
      "r268",
      "r269",
      "r508",
      "r524"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r49",
      "r54",
      "r57",
      "r82",
      "r92",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r117",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r187",
      "r226",
      "r227",
      "r228",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r426",
      "r440",
      "r513",
      "r531"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r457",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "verboseLabel": "Undiscounted cash payment obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: Current portion of operating lease liability",
        "terseLabel": "Current portion of lease liabilities",
        "verboseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r461",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r460",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining life (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofFacilityLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97",
      "r111",
      "r143",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r398",
      "r399",
      "r402"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized (losses) gains on available-for-sale securities",
        "verboseLabel": "Unrealized losses on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June\u00a030, 2022 and December\u00a031, 2021, respectively."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from the sale of future royalties, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in at the market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from 2022 Loan, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r72",
      "r380"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r67",
      "r68",
      "r174"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from maturities and redemptions of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r205",
      "r470",
      "r519",
      "r528"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Repayment of 2018 Loan, net of settlement costs"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r388",
      "r503",
      "r553"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r295",
      "r470",
      "r526",
      "r544",
      "r546"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r188",
      "r381",
      "r382",
      "r383",
      "r390",
      "r391",
      "r424",
      "r541",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r150",
      "r155",
      "r156",
      "r160",
      "r161",
      "r162",
      "r316",
      "r317",
      "r504"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Product Sales, Net and Reserves for Variable Consideration"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r319",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue, Net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Payment to be received"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r459",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Gross product revenue"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Securities Classified as Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r374",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Assets and Liabilities Measured or Disclosed on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r6",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Debt Payment Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r340",
      "r342",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r347",
      "r363",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding balance, ending (in shares)",
        "periodStartLabel": "Outstanding balance, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant\u00a0Date\u00a0Fair Value Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited or canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding balance, ending (in shares)",
        "periodStartLabel": "Options outstanding balance, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of\u00a0Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Options outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise\u00a0Price\u00a0per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareSummaryofAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r89",
      "r92",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r129",
      "r130",
      "r131",
      "r187",
      "r226",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r274",
      "r275",
      "r279",
      "r283",
      "r290",
      "r440",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r52",
      "r53",
      "r54",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r128",
      "r188",
      "r290",
      "r295",
      "r381",
      "r382",
      "r383",
      "r390",
      "r391",
      "r424",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r466",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r128",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r290",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r290",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in at the market offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r14",
      "r15",
      "r290",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r290",
      "r295",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r290",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r290",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in at the market offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r290",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r92",
      "r171",
      "r187",
      "r440",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r275",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r295",
      "r296",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r180",
      "r181",
      "r184",
      "r185",
      "r186",
      "r263",
      "r288",
      "r422",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government-sponsored agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r140",
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r113",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Shares used in computing net loss per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r112",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)",
        "verboseLabel": "Shares used in computing net loss per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7569-110849"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/subtopic&trid=2175671"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r556": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r557": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r558": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r561": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r562": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r563": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r566": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001628280-22-021047-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-021047-xbrl.zip
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MY_@9(C3/(S+I4G+6:  4F5'&R<"E)=0KH#BT)B>R:?5 $CG4I'34&IMF"#)
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MM. L6L,%J8']^J/EVG>J9M_2CW_TD8^X+N3K:C+"(@].,H4J3K#LV%O%G->
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M%3I0JL/SN2/9O9,GZ&(4[8-7I$&K5URWX6753W\O&'5;, 'R5G2/#QM\W[=
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M3S6A7EB&'\9-4(!\%R!/NP,")<(G90OQJB&@(019ZP.*-F!GE/6<YAYEM$E
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MDT3HW%G*7#XS)><_GM[0I /"&NYP&/?:F3@7[M=Y^%<MD%:<Q3S52H2DMY+
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M.Q]R N/<E9H*7IN+U]JM](+7NO Z8Y);X:G*)8U=/FN@B$!:Y;KK'))"I#V
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M&8X(UB$&9J,T-B&X '=U@?N@26IWW)<+JF^%ZNF,-:L]>.QSBII)J&8&D(U
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MM133.DXU?XC5N7)3MW72/^O=ADOO,#L/>&M-!1\:$NVXS0F8/3-P1RU&KE"
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M\7GSRR_-G/C>H*RE?.F7$SLZZ@V:/<_IYTO;5)Y7??S+EUZ8'#\WYAF5)K]
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M0W) Y;2U+737X)NX8Z_%2 _(-?)DD>'VPC0M,MP3,BQK.[D5-V ZTD%I!"*
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M1KDZVL_9[WKN",XZCTPGO5E;MO+&"S<O[-TD RT6BE;%I/D^<^.L>M4JQ/#
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M$+F<UA?SK?H<=^89JV^:(KO:_06G>@'$9QB^5RV]K5>^Q#+Z>K#[^B-7)IC
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M-\ X-P,&&Z\&@?K*V2OKA7V<A7U&M?S]9<&4=3G_._C;J7#!DA"\<3Q14+E
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M:H'&2Q*_G\ BQ5_6BTX<K.?OR^D-8"VS[,J#Z9[$7CF[_I@LII8V#V#C&6#
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M0_<T2PY0DD&YN+T$R<.?(\MR4_I9!K9 _I;D.1A_E96@3IS>BI(J9N=>,D8
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M^;;5J;PB!]UNN!?]\T8 ]B*::RT=P,:;]R[O78U1M\&HLP6,DCRR0)Q#7MJ
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M[-XAR/#:USY1U?]S'&5,Y<B^G'_Q#<17 F(M1=[;[:T,(1_CR: 4YCF)T&1
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MT<0WBLMC=!;XKK+&(HB'\#!SOCC4_E$7_#:F!B=.,[!Q-*BKW#GL>/(A:*Z
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M>$(J%59CYFT,A ;NYI2X9#GIM-$0$88\#Y4KE"O S% @ID0)_AT)TW"Z^/J
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MQU(3S(,.>"$U8O. [\7E4G\9YDVF #3FDB@CD%*)EMAH@0QF%%$11%!4Q;C
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MAEN!7__?WKS!QW"??Z4?\TC1JX/B![>=CAJHU-QEE^J5QP""+H%2W6T$H!.
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M9WAJ?,AYFS07$=Y<M=H\GVN <V/*/_%(QI[OZ.G"PQBT\4PK_T ER\N%WOK
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M6MN\$J8!N@]2&U.16ME?,BS.!<6X4S&"M-C;(F)B%*<A:(55HF;SSE.MPV"
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M9D(4F!6<6.ZH-HPK@ZD004,HX>>X'-?KT4A30*-6&I**A=_1^H\#XL"SDZ%
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MB/JU3*@Y&5!V'=V5"K7@&X72BZ="%1N2W(]A]?K/F.*/LUBQ"-[603,@3JV
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MI(E;X> *!R<I2&01C,"%=!3S:*PQCJ?Z>T:=5<J650#DR7#P.;!3/1.0O)P
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M#D)1>(9!)(-T'G%X,TA)+Q&CP=) @S>YL1=OB%^99UBXI*SR#/<5$KZS>5"
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M20UI!>EA=,,1?#.5F8$I+=,ZY22(WGWF,4Q*0EF2/DL0GLW,!DXW,%6+G]E
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M:E.*/,W&K[+DSP!1)XOJL/%:"<G3? X#/JHUR(:"(BT\T404A30D(2K##]X
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MO;]!AG,C=D,U,!!TQS! Z0>QJ88@J!@SG5BW32'4@")YM(>BQ('/D'$<U A
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ME*]0VD+R5T^JY1^2D@DP#3>O;T;U+D6F)19#RY,1C5S, 48R0E+ LVE6>T.
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MTAMQ5Z&Q ]C<Z^IP:BB-^_*!L"^7&>O7O;6:.8AS&LDECQ)0A(7=<)# "LE
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M"X@C)<P!@46E(<.-82AC0(WJZ@IY$/N3!2/*^+AW+R!?WRH+=!]K+S#S=$\
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MC8"1G/L4X3E+3UH$GN1,9H$I(Z)Z:7SW>C7W0UC846.]Z_.;%[.@ESTBN^T
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MT^^M5PQBM*<H!9'VM4S,Q--4,HF$C2W[?&!N;YY/64>W3ZR@ZNIE16N+:0K
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M-*(=:!N)1!SQ98AXF=:@MY(P4U[;TP143Y^&SSB0Z@!)@8UH(V7?]-HHX/%
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M]:ZNP-[T8(:WH/S+=;>,KHOIZ\,T3W!-WE(_@N2:5UGKF/I8NU'FO&O5+2P
M_3 >+;YEYH#PF<C+-)K+4?\7AYM$__LJ,9ENF5KL!(%K6:[C>8YGF38WO- T
M?%^W_]8U\U5QUU56*9!+K@:PB=]4%L,4W[+>#9ODKWYNLB+PX=3*+UJTA[0T
MB>-'6T4Q#J#7-",F>@O& \_P*A@.VYBQ*,"Z\?^^^L<RVPERARI!@'GVX8U
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M)*<#\?>'+.,1IN6_!A79=<NO&+VY2!22;Y?90EWE$[[]&BL$PG&&#TB''#.
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MM+&X)OA"D $9SW/1#Z#<7EKJ&'-],R2X3$[Z)AE=B6Q?N3?SMD02ZB4?X-.
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MOH=%%*I:D6 M'L5N#%N_/0'R9PA(8C-,.ZR4LR_7THB3 BG$KI0,8DVB%XE
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M\TG<>'3D8__S_XR:O_SG]ES=Z+GJH4WG6<%H)S$AOA2M+O2%SC/=AQ@0^?.
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ME\U_7O")N/0SUOE*5+;J)E;.V:7O^A&,024<5H3F=@2IS5H'FZM>=.+&:B6
MY2G\-_$LJ LC F Q(W$'<$4RGM6*VO-WGG;DZT+9>^X4C-PG7X-UB+*@QDH>
M<VULZGGSBNXT6X!#+1[Z)=LM@L%&0QGY'B@F$-=N1;<D+E!8:OFKYG0#@@HO
M6>VP79 HCQ"L)#I=NW ]1 "GF'4?0%1[YX>[EQNB,57O).)(21TAH7#<L0L1
MX[-"+X%EDK:*"AH/<P_-(QQC+*1-I8QQ"%HK8QYGG1[Y/HRVA(3(%$KKNXL4
M3= 6^?O&.EZ(;/S@>*!.BO9SFYQX"P=[ZJ^Z=M_U!%P?[)G%[3/E7*A)81:W
M-X^TW?U&IAV3&"ZS&M;*LQ8@R92QV=WKE6;B(T"%K"=V V7SPH6ZKZ=D7V#W
M#V%0KHBOV:)9C]2Z-?7LE8Y;=6>KQZY9A'QEQ%#":\95FK:;;+N%VZG7.BT+
MS)$!U TK'&-XV/9.^TX#,+VZ$"8D#4SY(!S7M%+K6''$1I, ];<-^ >";V/L
M?QLROL<HDNT2_V$-%!G;70!%'&L%QG;%VF<H0+1%>-W2PH616EXF]O=T<0*G
M]X*F2/<2F[6_Q69ML5E;.75["H:#)_#\TM ';=O _-.B(\"V+A!?VS7[(_%T
M+@+:)F<%O2ZR"]IL*A:>6]VKF@JN5SJ<3D0 QTNE)E+8>&""D)$8C,*R6 '0
M?+HU/V[->0PH7%+$CZV6<W*654M2GVV:F!W!B+_@1^R>Y4H]!/U=CE!1-EZ%
MZ\\D&$I&'I)'&R^V HYL/VQEQ:TT!FARSE5JC]461>JNMZK2/")0())BVV[]
M=CWZ1<VTH0Q<.*O+,_',06F1G;==L1QLZ>%;EER(J-+P !W6[0+?O04.PRU,
M4CC-&YS:-*D7YL:A;4-3G&G"P;??9 A\CA<.DZ-I%QO=![[@N8YA3<P7PT!#
M*4R?9;27JE,A7%A_#L/[Y#=1&QKI3K.%[=T";"_@<@FZ7@3Z?%F7>6-A0\XX
MQ\ENSPUMF)_O$=7W*2[A=D?.0>TD$6]9-Y?ZOS"K!_A:-_I-CQ5=WN9!0RB7
MB3$VF%&>=!4IWTFA(")^RS\[.N!YL[.L=_2?#,6*02;.+'< "W;#8K!) -1S
MY?QZH92ADURX&O($Z":'!N/K#9G0RS%ZT(4>?0YE#9>>LH]QK=SD!JC&AASE
M>F[RB*O0!1H1#(3[QL@ZKZ54T_#QH0!V(T:#S'# :=PBRZ7K&&DIY%1B5 'A
MHK0<C/%L.1\(]]K#&^YALIW9!3:A"X=+M'X_*O)ZE/5KW! >$LGPO(&1WZ>^
M*;>YD .4(0+>83*G2,8YZ1^6&'+*TG4E1Y%>UXQS)V<;8Q 2_*#OK;0&2/U6
MG_,>_/VEZ[>RWV^O$O%3.6X:7T5X<7'CMQCAT7A<R[L4V\>EAU;/R/PYO:8N
MHHAH*9;=),Z 2&^Y8;*B#WVR(FN<"N4U!TB"=>T4^-,2NBTJ9'0K#\SY:V_#
M5*##VJFG.R<Y!\D^K19Y<N2*28UFZI4\6B]2ENZ0LNL]*7<H9UTC*^FT%>%E
M(^. :U6Q;J_K9@XZL*)==*3$3GPY*!BMP4-NKW[]\N0D?--+6ORYO4I0(KB$
MYV%:C[M6&G-,\CEI$+09<_U=N'@T6V;!0'1?8X=H.E]IC@9G;O-:3<,F;>^#
MKG^/!KL"55R:RON6:9+B>_:?!3<%DU;UF,_P#,]\YM@*K\@"EEZ=5TR[QDD'
M$=])X_P2!C3YOE]>RB*M_;E'. :V*3$0Q/V*3_2E5%$1I&.-NZSV+&(R$Z,5
M7NAQYE>ADG(L5"2/VO$L)^F@M0D#Y%+X','VMM'0(G([*XM6#GX86&1;/3C<
M>\C-?,+.0C7P2T:\=?&(;X+9*F*ULB-T15:KFP#)W1FS+H1 7[.69%UG?0M+
M3^#G3($ENQ]5[6'7S GY-;6BA;VMKIF.JQ,?7:?UY7W#308@]TT;XA)3\6):
MAK@$S[Q50T#IDS=LA=O9 6G<1-00\\-NX15JLWY'%]8XSA'B3>TY6[SI_8L<
MWBV\Z3K(E)9[%E(A7DXK<2_!4P=;\-06/+45F3<*Q"'I!&/' BZY2CL<L,ER
M9M)4"O+#JDZ+H80J')83O(M&BI$X*7>)A1(;)4&]OK,'W$M]>>DV\WMK>^4J
MA>ED>9$CAOQ#D\/-GQ0MES*[>-7'$Q>_^/,5L&]A0M\'3&C+['4[2?XHW^JJ
M\UM.\Z<!XI-I,/*RW)&DO\:I7/S$'6&DJ#,I0NPJA@LRBUM0R$\G6(XWDQ2T
MX ?7YN:<H0B4&:*)HJ<TTNR3[[]CW-LM=JNU9?0.Z*)+$1*!7^9V%_<>RK\P
M4L$8S6((0)6?UK1!M,L4@J^,S6A ,\"*T6/.A9YA[DT<NGA23!DI1?^J6V7%
M:'-R6^&!>HMG6[SV)P,AVT:[-@AYNP]N5I;XH*6O3=7D[+7+4VW1M^6I=V%E
M;PROO+4T[]X"WQA>^9:QR1S1W.ZFVP0G^P37&CCY.J&".YQ&#V'X?^D1CJWS
M[8;<>+"5A?0*$>6V:&12(U>]$:B<8^""E/7LX &YWN;<8!!7_";M[&_Z3/QC
MT^3PW+%C?-$:K)$1ZI2W A >I.=C[E"2BTVW6$(0EME*EJ+L3W3@2D7S_)*D
M8K',-55,MO-BZ;NQKZ6!0R_,>U[VX$&,W4!#P#19CP;]A5TJ'Q"ZV@1>.'^2
M^685'P+?3=D @A2@.<E%-!^A$DH\8'WD21PR#!+2VQ3T=ZH?-APC"#C8"),F
M.U?"OCXXRZ(!O$U[69"MS7C#F0Y.-D#7E^3Y:[:3"1>1)]#"F!"/18(-Z-[M
MDMUFJPC#DZ+#>U-HQW==K&).YKR@CCTV@RUQ/7WH-3+NU*ZW@ZC)H:!9B?;I
MR3U30'"Y]:BH*RG%(5^BGO9A1CR2PC1:QDR6??SO._K[J?SX$?#H/.AZ?/+J
MW4>7-I. MFDCWH\)&(/]X]_ECHWW;R"4%>90Y>_)QI\1IBA('X%+M%N6$M5@
M["DS;$)1(AL6:4LF"B\PR2/!@P,ZHQ'YE(\-!^'UM8LRXRMRFB:$268Y&0^S
M,==?"-ZF<=89I_\4)2TC2*72"]#Y5HV_O)2F[APL VI6[.^$25,C89K*X)E-
MPCZ:)#2&KL9Z$X1U0 G-RMIF#^2R8_K(?!N6N9,2.*ADG I/<E']UE5Z\O5\
MQN=M7)P5S)Y+ZSHO("T62$Y#26^7^,Z82B;*A+-EXE:OHM$P!H7KV- &82XR
MQQ]SE9*CDF1;,JJ_&#/Z>=;P0===5?')WR));NUTCZV;?-MI=&"6LPLO9<;L
M8S9S<\P"!;-=J]O 58B-(W*7U#N2'6WKV>S/\BU3PNV$MIM\T2U%.V)U4 J.
M<OR+XP>W&\H"\A9U[FJKT5G/3VMF8SMCLTY$PX(KY9=DU:47F *IE$9)<;S*
M][#KX$6=I2\+DODF C[0PRC(6L*)0PT82%!AP$H_QC=OA$)>5EHO"$PMM]A<
MG7TO,>*'6XSX%B-^'VH3CUIQJ&DP*T\8P)F.G-LJTHLXQ%WT(ANI](!A%H#0
M5X=?"],J&^?T"PV@<\>A%P'#!-=MA?*-HP'TCE%7E!/SF!E3Q3^$&9>Z.<TJ
M30?<JZK!ZZS5->=1"&Y^]Q)?7G:\F4 DH*#@B"=4K)8Q5E &Y%G_*P]:*L*]
M.BLF]#,IQ"$J'&&_*?-LTJ:2Z%E9(MUYANH)2KR'=#0=&BN5C.-XC,O1ID>(
M(L5]M!PNLUP9$#"C,2%QM)AAAM TI6C1!3*?Z,!BIMAEGLWO$T.*E&^"BHBM
MKR:7Y)_G8^A1BV![<*80,96(>==6)]JBXVPA.?)".QE>#,ITWF*_D"2?W"L"
MHO>^M11F%5O:1TTX)R&A;[C4K1 9P'!53%J5X12MM:F<Y"/ZF6MZI2D]UK*L
ME2&+^;.0,\U.FUR[8S*V>3@/LL@$1UUW2S0DF@A *GB%]'00VQYG-9]F-,0T
M"F6SW,PBRUGA^T;F446UR/=*RX0T) >' =$'&^16 )-=N((L9C^^/4G>N+9A
M9&<UB]WD 19/@VAOT42J<<D&9DO*^DAZN4B>/0F+:#MLP!\?[^WN)30+)><)
M\F8NXYIF8T'(\$AXJ66,($;"OI N0_O\>4^%G81O9 H9;%,GB#Q+TH]TY6/W
MLGI@GARN@%2*>H@_'AP$-^F>UC?XCK5TX%ID@50N<27O@^*A0S0X@@[4#]33
M0>J-Z[,$)((X6S0%+JX]K\[A?O ]#PH:"*/=A2+.1+*VN'31&_-1Z5MIS6O0
MM) _@^:[$\USN#GE9[_%?!_9GF'^FZ/NE Z#+LO0KD.M-&V(N19<;'C6!?N/
MC1"NV)BTQ@:4 YBA+C4-'R-04AL_S[U:Q(A3ZK)9YIZ?V,0TXE&-9HU1Y)F>
M'F\27NSUM:"[9=?J;PYWDW^0650Z2Q#2L9AP_SZWA;UD3#6XL/G4:KZCQ=&B
MEYUEM"_HGV.:$!(KS<H+^3#I&)M0K69+''T8ZM5-1?LVP8)<#O*H*G'#MNID
M+]6MZV/H>"%J!\\B(QBUG;.L.A7\#S=!Q/%Q31;1T["@\<FQY[1B"X F_T5(
MDG1CK>Q!@L5ECI4E#;:54\DWD $A=(> V-2E/%4D#.)-DCVD)5DRB(E)%271
MH"T5XRYZEM'7-I&)M&@,/H\/>A4^-A7 U!@S%1(<1:ML5Y1D!;N)C:8,2A0C
M9@.:3T)M;9!#*XIO[HV.+^+FJ?YF>IQ@QNJ2+:?>3:EH[@GMLH$_!(M -@J-
MF#>+[<E6KSF5/'*X(HJ*S<C>+POI6*U(:/*!%"VE1N,:>EIZA+HMI5*Y'SIS
M)<AM?MEF%:,IO[]6@S$>@N5NJ>;?//N<B]$.,K>Z*E=6SMH:4")6ULM94W>G
M,]\"\)'RR"U<8TZV .<:QR6+OF*(O&<F2_6V67T.,%[Z]8:DV*KK@T0P=]W
M%(C=VEW#DA8\K.M/8+^8'T/O2&%W."0WJ,%.I4\ONTPVN6XNKO3:%[@?\<JQ
M"BSK$&NF^Y6>DH9Y<2#2Q1UG%EQMP;N&5S=305Z>MR]"T\YQ(VJ(P!OFSBQ7
MT8S"29X@6D7^&-7$6=O"S-#443 \>V^9G\KI-T2]3^F.LNHST*?C5?CW%T8N
MU%46#\"&P<NP1431S7*7KIIT.;<-/<_]AJ@< 4QK;(A%,Q$H$#H-!S%\.3;A
MI+#R&.=2VZFQ"#5A#3,3[5;C9!MT</KS2$/K2#P%+%1\ ^K>Z?3YWM7CK)WA
MR4$C9NEL'"@?6!JM.[DX8J+],#8S!%#"X [=^MB5C8ZII[ O^8H-!VR7#"M,
M)#"U;;[I>',L(970&,KER#Z5[M>\T4Q0!_YME2,4!1MGC2WB:HA=& 4]5L[(
M'A<70Q=7:;7*EG35%[P)5(APG;4NHY5DU!*-3^G@F;'+)[X&.LQ( %7A!::2
MA#K<S7)\%7+EW*/6N\/N2C'H\G; 2%$YX<R2!_D7,_X&M:L]/28#SSQ">5'F
MD]/\8:R%T\!LI(.CJ PU% >R5RYFL^[&AQJ\%Z?(7&(0WCXG!+]]A.=>ILP>
M;5-FVY39]Q3L_-0OCKVHL!9HL*Y5D%B?YG 29 /89E"[8S=YK5S[GGHQ !!<
ME_Q?*"<NJAB1"J4U9@+&*"QG4!%1VH+V1,.<.;T[7#9%0SKW)3%QJ&TQE(<A
MO6A=8DJ'3<O"P:11T!XB(/&+DG$HP,S(Q>R8/U"LA9 90+$=>(J4]E\P-'):
M3_'7"C]E0@J^X!+37*O >9L"9RY5J]AC\[H->&,1J?)&7X:\7-#&G:RPC[W6
M$NG:+ R6Y/TQ$*>#*ZWL'_3RJVTKMR-"XM#(U$HEZCLA=Z)=:LZ0%WW4U!E-
MG7K,0VPS8(7H5R!ZWF;$!)D><J78>!% \/E0B2SY2E3K-?23)G9A45?Y%-8S
M>X%:DQQ@Z^4V.0I!(EG05&X_3N+-&")Q4[<G=50<'<RM/8QS?'L$!LS\>L'F
M=_U9S(M)+<'H_1H.17# 25+GS*S [G5J+N4@&JQ-0]I>UP%F,_VM.QR;4&"[
MB9%#NT\BJUE3',HOY Y4[T,E+Q$,:%;  Q,GCHD^ROI<8[FTI6BXA;AS3O\8
MWTS8X 5NF@P>9C,)H\K"786+I=\7?:!MDAI>E!"NXC0\B!CZ^4Z+<5^L/,2,
M<&OK$11OY)S_H^*M^7$IH4TYV18%(\7-G/@DR$<@LKO$?@"N79CO< Z6JX6*
MESDI%,ML2,L \5JEJ(<N_?=LOGBA/Y(4^9@W9P6@'%8L=.QKA5).SI#E,%YY
M+OO>9R0OP3GD^I[^).<>8_ZIHX7RSU=B^L*PVMF$7(*BA9^GOJP;HI;G<AT/
M#8>G9L+A%6$35!?YW.5]ENR)RH0X(<D3J#HK$%X2$+-W[28?8BV*+!+G.[CF
M7D6QKD2\"HNZQ %K_4$4T8@1LV\<J +Z!,3::"<LL>_ W832L:4D/[E7EGP.
M;E9U@F]>B[JM;P1G_5GTJT9(Y3Z>9CI);/I.-IWE*YUCKE3#P4*LZ?-UZ<Y9
M@??T@FU(,=JUMX31IOX^WO]$L\*64I+_M4\N B9^$D%_SRK);._M[Z>\TPI4
MRN.KN7D+3M %/)52PJ?O=78C$I868;Z4/1/O%$=$1-7GG)LVDP H/1FGW:3"
MU[W21>LQ$ YXKX_& J8(&7&<BR35O-6HMPDBDJZTB<J5#R\.?QI0 TTEYQJ)
M6A-/8D:1/= 4TD/)_K*CY8!T/4^%CAA788V66L8](W.P7^()<R],P.L@92>*
MZU"$K4*8+G7N"C4]_^E5R$]=XZ?^E ,I04)9XX2&WNHX(VV[A],Q^X^,"E5B
MQ,R2P,P9(^$I6"(^7[3*7^:R>]PV:>-3#Q[O)D<^MD>O&+5\)+N&][5[I& <
M%/.GH <.(,^SY1(9HA%=6542S>0'IS)C6):=8>+8JTV<U09+9-6!'WBY939U
MLRD1G]=I.L5Z]MO<O9YV:45V:UV=YA*6]U8NEJ/5A#*WEIG0ZV,%EGP@[9N\
MW$U^G8$UIF#]LJS)/,P:L8CI0/YFC7=@T/KNYK0C><Q2];!2MI3*]QAT'LYE
M/J"V$HJ2^NV,XQ>.N@QY*FR6I:?&U1D+U@BG!/%<) ["3(#/V;0H[+V>4(ZD
M,<?6]:@'Q<0@Y&#J'=D"HPQ_+Z8#WHKE'N0P<^:*MSO\#>EBN7(=$PM+QZDS
MM_#\P%@[6/>6>]<'^*R%R'49.9F)V$VG3<VI;<1'M8N0[2O$P4MF3![#AV""
MP1$;:+Q>,\!V1MGX\_U*8;_OEER&/F!]*_)44UYA"0TMC%=20;:#3<T6\BP*
MQ4@O4M7E;>#H:I#.BREU@Y&QS4ONS"G>!9LM7,TTI_W+:KWB/;.#IY(Z4.ZQ
M@NE"ST3IO.J0FB&=2D[[)$M)DM+\TH]DI6?!('@WL*)"II5?#XECE%0L($CZ
MH6Z=R^(U)!'2EG8M=P0=Y#M-.>&"?3[4ZJAH?2LQ&C);J&Y ;)/,A0!!?^5\
MHK'('Z/HC4*QP8J<T3D1BH5@">@NY$2+=LYI-QQ==LYLJ34T(38)>A'VYDE\
M;,'D*Y_1M/BBQ[T^KVQ\'&'# *4F7(=(NH>F<U[38M6-RDH9EJ+\5<J@Q6"0
M<:W)"#VM^GO)07@DR<OK;BL3:#]7<<9PEA#A:/C\L%^0R ('>;/8TAB ":"?
MPN:'"&$5E>[DEH$5&XZ3("3[AG3P@@!P#/$Y\02FKJU@[%@&#85AN(?A#!?,
M]GJ(S;FLK45/&&Y1PJ0ZW]N<X+?("3[>Y@2W.<'OR 1X1Z*U9MA8J&BU*FDH
MK3)@\0T&OGP@GZ5JMA"?A&W#(*@NMI^G*V0E&(777=A:L@51;(*!6T82/!@%
M'(HX2N(F"UTI\3EHE*T++_.+%)RJ#3:MX7G@K(3)H*O2,XK#.B%E>9XUD\BX
M6)L9FENUMM* 4@FX0J'26;"*TU G)UA($HP-^C6AQX8VEW?>4^WPR5@N^E!A
M:ZW:O.=C^EU![^1P^RAKR!#0C-HHY_W2"/)$_19Z?K,R=A$7YKU/546_0L=*
M;@1DB_AG7?70<,*@;_W3AJQ'3OPPYB[&Y865?4$%WX8BOS3T#KFS=9C] 'V>
MP8GHTJ"D,J;IZA-4N1BMA6\:91(]+]IPK.$G!J_])\I>'"$F6KAJ6[=4/<+-
MI6M7S+M&I -XYK3C0815=B;GXCH2M:H"D!4RA#=3%W=7U,*OD$\B!L6#+R7^
MD2:8(?K3>>YHR!3RGZJ[%F;U&21HA8DK5\Y8KC;L_M1(WQ##DY#MH TN 8F0
MDY9$GO;IC1_,^%7D/;B[8*&.2=>Z\FX [[JQJ[BLT')848V\K5Q+[&4W8;<,
MLCL(71K-J6Q;;7\8-T:\<$BKOM=&UOQ":='#_L'O^_V]M&!C$Z%>@&'L3Q[Y
MG98'5HEM ^\8;QY6M^#PC$KESN,>CT+\9_&LP4\F'5(B;'@Z\^(K>$486V:A
M1!LJ-3\L$)F"&>#PS<:7\1=KKEJ[!=/]!:<QG.>T43)^KN"Q GVJ<:J_U?4D
M>1<]_0/>"+\SFAC+!X[_]NY#ZS."[/6&:ZV5;9E$_'79.?$U5LT\+32('A59
MWR=A\RG:P_D%U?:V!G%NFI76LM!^OE9P$R3O@Q55:L1-SZ_)':M03H/X !<'
M!6J.ZZ2<R/'!2I8)@C0CK3<7$U)CX/$3M+3#13G%QL.H5T5>HFI?NZ':^0X3
M(<BC1JU87;L;WT75LP^00FN%TH#-PADI.G16P;V>40#E^>C"4$:DD/TC-,TG
M8H R05RBS5<Y(A-$[SS#M"?AI]'4XX+3"?PD:_NCDH^NY/")X6H\-N0"::IZ
M*;!4W+S'=D!/2I#4TW).09D4.*E?BGDW9Z7CH#+Q7=!>XZ@BO!]M8>,E>*O8
M,;O)ZT)*;,+N,_&7U%+3AFM\K"N^Q.WW+-KQOD)72P@FUH=A_62P38^3VNO6
MRU&Q*K?R ;:*Y$F6]N35]!'W8-\N\_&L*O[9J0AS'*Z&@P_Z%\I,>X69]MXL
M,[I0Z#J<QEXSS VLAK1QI*PGH+#(R3/!A1P[M3G5X%MHY\;%#UQ7=/3AS7I(
MCN."8\N",BV6TYR>GER,:L0%JY4G="=K&44V6@V[[(,;'2(_'EB?'2N8<__
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MN!<&QP'+K*NTFV3@L-KN8J=Y4TX<%AE&CTB-XJG,F^4ALSL>PH:\,ZXR0$&
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M0G0^LU--ZL4RC_HO;/1]^VJ'Q#JTF;,G-,8CQ.%+A#(U;5&9G..&M8,:S+=
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MI]"X$KYEK9HYIRRQC6RSM17M]1MEH("C"A9I\?V\6FYTM6 /(R-^.:+1#D7
M.LW3<:/385D]UD,0 1R@=6,^#<>+$A]C[S761E3%T'I)@IM"AQ7AZ]=P.^?E
M<+/+ 9V:VC'CMC&3?AJ7+?D:H,I[3EI<A/>!RB-9=LZ.'IRX>PD8^7H&C,R
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MB/KTTHBH!J7&@@OWQ ^)/W'+/-6UG-!56>EZL:JU7KZN4V4B"F172"9&THX
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M:+[C7, G<9R$&5_4S*JEGK0B*1X-G*:KCX,4G@D!X'H^EF/:V"N$<TD<PB;
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M4PK9S(M*8V,?$SKN( R*U6^E.@!=BZ):^IVX<4!SK?+P@BS,L;.(NJO,QMK
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MHX_^[#<X@EF$&I'^_JR#D]^_TR\E^N?>6"Q>5?4%M&:^6+D"S9'_OY]SM]J
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MX+.@4C(TU#I.XH G*2;M^=.WUL/3[@%!I8>>#H7DQ9!TX?_Z"6C$=M[T[#;
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M#0 )'NZ$$)(D L@X[ A8K[6F#%B%Z<+RTI78M9'^/A1B=[9<S B^B%6)6;T
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MJSJ'^*R@",]E&#QMTLS?)3R(D^[62I[(/K &/AP[+2Y2('/RX^='_8!MOI?
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M[XH$><;HAH\7/P2N)3,W6[^L"M!7)BT_J.A$-R7^*HZ>C3* J$,@6LY]L+I
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M&_,M_Z"W_'T=+G_CFT_!X4Y\Z)U\A)!]_?V-^5D'74[,7-QPQNS!;<^8'7Y
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M'8:/KAL90H[T.@?E7QY\.Q^4M^"K\T$Y?_7V?_6/<E ^?'#;S\E/^OKO4/%
MN-+'""L3HC1O6;7T!?8D^^.F=6630S?S#R*\2@R,<)V?T_*L U'W+_[QP]N?
MO_PK4F0$.LD?T@)YN4\W#GGJD; *P*',;/2 B1S@!!-Z!_Y(F<B1#"-<,O!2
MPK5>QURY4 JLW08>^!Q@-DVC_!(D_XX,H_D'D 9O-Z @FS%:=>2!]/8'[O\$
MI#F>^T'][3<BXH_S+Q=*R_E+F789,G\?)N@\GH_I^9@>'M-_ (O]]2VPV)_C
MS8$>V?ON8%BQ=8 DM!9/TS9=0'/7N*D&$\RZ$JC?0A]*DZL__XX_S7#.7QTZ
M3%\AE\=_!:J0*ZD.\/7Z\G.?5VONX2/1FOMZDB+EFAS13_P&6];Y;WND)T*\
M!;X(> !"%<T1/C%G+0$O6[N,U-@MISF2<G_[X.$7RR^_>/C@2_CY6W?6L33,
MZ=%_'R]._*3OA/M_4;'6K]X012N6H!Y5EWFS\1\UW4XD-0K2I<(H.W!SPO9\
M]F&U :T3<%>V>0-*+(MNAVSDJ%X_S6)U]?7Q<0OMUND<(FO/?]R254<40L1*
MYM_.OU=*@C5H<,%($P^]_MG_JZS*(U$A5(W"Q4H@:U6]7^R\CWP[B,M&F9MN
M#9O9GW\?-K/O_O1?GY[-[$X3EWWV9[EQ+O3/L,C'"<I.7_SXZN3='X2VU>:>
M200*1; T>.X=C7HL<A;ZX5\>?TW*:V^1'QZT#/V9WBPRX.A$=:Z,#OR:%"&
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M,S!?8V%L+GAM;.5=6W-;.8Y^[U_AS;XN.KQ?NJ9[*A>G)U7I..4DT[-/*E[
M6-NRY)7D)-Y?O^"QG/@:RQ*/?9*9FG+:MGS.1^ C"( @^+>_?SZ<['S$^6(\
MF_[ZB/_,'NW@-,WR>/KAUT?OW[T ]^COO_WTT]_^ ^!?3_=?[3R?I>-#G"YW
MGLTQ+#'O?!HO#W;^S+CX:Z?,9X<[?\[F?XT_!H#?NC]Z-CLZF8\_'"QW!!/B
M\F_GOVAET3IC(?N00$7+($0M0$FC!(_)FF3^Z\,O'CUF$3,PS^B7)1=PD2&P
MH(4HD1?DI7OH9#S]ZY?Z)88%[M#@IHONVU\?'2R71[\\?OSITZ>?/\?YY.?9
M_,-CP9A\?/;I1ZN/?[[R^4^R^S3WWC_N?OOEHXOQ=1^DQ_+'__KCU=MT@(<!
MQM/%,DQ3?<%B_,NB^^&K60K+3N:WXMJY\1/U.SC[&-0? 1<@^<^?%_G1;S_M
M[)R*8SZ;X#Z6G?KO^_V7%UX9YADG)Y]_3K/#Q_7WCY_MO7Z^^_KM[O.G3UX]
M>?UL]^T_=G??O27HW:.6)T?XZZ/%^/!H@F<_.YAC^?41/>@S5!TS(UD%\)\W
M/.GQ5V I3-+QI)/#*_I^];P*8WN,^'F)TXRG<CA[X626+GQH4K4PFY_]Y21$
MG'0_'1TOX$,(1Z,GBP4N%Z/DK7'6&&"6A*S0>**I<2 P1;08G9#IHCPJ_@4-
MH--8"8O8J6WUV,=54(]QLER<_:0372>VBV\^%=>V^)\=S^<T:4?>^6(\S1OA
M"@/%$D(0T0(S)NAL [=&]C*,%8"+HSFG_B?SM#,C-<_)!CW:^8358JS,T2F:
M,$]7>'%Q,JP^\7AQ?'C8/1/&2SP\^_MJF[;6['+62KBGZB/(V^IW;WF \U,<
MKV?3M(*"PD0IM0)G728H.H,76H-/493D5:+?-];SM4#6T;?X?O2]O;#;Z?T(
MYS3JZ8=72+9_O\IOK[Q?8(=N)$-4)M%**4LVH(05$*.68)TT.BM9BK*M]?\M
M0.OP0'Y'/&@F_&9\>#.?$:CER9M)F"Z?3//N_QZ/CZJC]IH0N2"U,TJ1/7(:
ME#8)@N,*F$B%0%J?>&NS_RT\Z[!!?3]L:";Z9F1X-0YQ/!DOQ[@8R20X:D0H
M,5:W.ACP,B)D*RTOY'5GWWHI./?Z;4?R;#9=SD-:_DE1QK/CQ7)VB/.SQY^<
ML\&,XHA4; $L/((*SH-SBH'P67K%F2F2-Q[EFM"&Y/)LRHO+C.]#*SVMC-?!
M2L9Z*]! =!B UN< GL"!,:A4YJZ@"+VNCAO2Y+X\I58T::N)K0E2(]31<RQ(
M[\[[LY,P69[LQ<GX0R>3<ZBT2R6QK*%81@NX=>3:*2(P4UR9$K7)2=P6_*[[
MLB%Y1MOJO1<!][$HGD5LA3F>K2*K9(T%53!#U-J##IE[8SDMTJR_M?$.,?%]
M>4.M9OZ6LNY3YW7129(5L$$0]W1(%*TI7D/UH+G@O#3WA6_3^0;CFDT_O,/Y
MX7.,RR\"YCZES$BVT2A0F906E.4@$ZE1>]3,N-8#NPICH.[.)MJ_0NHMA=Z,
MU4]2FA]C/C<\BCJZW,3Y^9N]-DX(!)X,(R-K"G@C.8U7ZN)%B(YA8SZL!6R@
MGDX+AK173#/.[!X>368GB/LXJ=LVUPQ<,[+)43NPGB=0@DPUC9B!2X%%'HJ3
M037FRZV@!NH=M>!*6X6TM"VSX^ER\2:<A#C!+R-5)C!7"C"9"RCGR66W&D&I
M6-#[$(3LP9A<@V2@WE(CZ[&MZ/L.HL\PQ218\FA!%$&82K'@(QFSDK0,T<1@
M\9XBZ#O00G^?M&BHBF;T>+N<I;\.9A.2ZZ*F.Y<G(R19*:\2.%^SWI9,ED>A
MH!AA8XHJ*]G:_;R*8OLL^BIZ[1[]SS YQI'Q2;HB)00F1<U1T')=I"-;;+6,
MS-F4=?/D^1480_*KM]3^U?SY=D)OQNIGL\/#V?0<"L]LECXRX)IS4,8*<$IP
M8$X;682A>=9:]9<Q#,E;;JSWK<3=SN')>5S''B9OPCB_G#X+1^-EF)P#-]*9
M2250@A!)4I 7-'A.([7=T!-+T34O_K@5U9!<X\;$:*R29E39QV483S'OAOF4
MUN,%.6S'A\>=^_X<RSB-ER/4Q06# 9)2@5PT7>T6+?2",-EBLI&R-*;*[:B&
MY#,WIDICE;0,H\YP=/$_<?=HC@<X78P_XLMIFAWBJ]EB\1J7>^5=^#PR+'#,
M2H PG&3 "\F $TC/@X_*T@*9>HBO[@)Q2!YV:WO3H[+:,>I"K9E(7F69 X24
MNHVS!#%G"^@02S8<;3+W5\BWD:-]1+9]]_,121G/LF07Q\@T12\FU6HJSLC&
M(T*0AJR]5B69F&K-1GO'^S980W+$-^?$-3YX4WTTST?MTYP:?ZQY$9J&9X@4
M*PI5+A R0U!"<G!<,= ^*:XC9[%YS/DM/$/RU=M1HYD&VG'B8QA/*I 7L_G;
M,,&WF([G7;ZE;LU\_>X,9"XE2L$XQ(@45^B<":358%!*70AYSJU+H.X(<4C.
M?$/F]*BG9F1Z.?U([Y[-3VJU'I/%!I<B!&X3*&0&'-)";X5$I47VL7EET/GW
M#\E1;T>#C27<IN)GM;35Z!'G:1PF?X3I<0EI2>R;?O@R0(>!91DA2:U!26D@
M&DD!I34%O71<Q$NIGAMJ?M9ZW9"<Z>T5W9.8V^7UPN* 7)KZ3XT6/I(IHO7L
MR?)9F,]/"-QI]LEZF2*]'YS*OIY$(X<> ZUL0GKZCRAT\JV3?>L 6X<KYKOA
M2G\ZZ:-HB!!>$VO2<(U4)H*7G%#Y3*AR$%!8T3HYKXUOO5-^&Z:6%>.E'JD,
M+H!+GM2*E@::$H=BM32\*.=DZ\,C=RP/>8 "HNV9\(T:N3N)O.EVQWAYV,T[
MFHFS:=UDQ&GJ (F08HD.L(Y.67+*0N86K/0BJY30^M:1U3?@#"FPZI43K532
MYT9O2A3A*>; TD).7,4,/K "!9.TF7MN7.MHZC9[-YC"H/:,V%(!EXCPM\>7
MY?6*OM_VI/C;=T_>[?ZQ^_K=V[T7>V]V]Y^\>[GW^NV3U\^?[?WQ9G_W'_2A
ME__<?;7W=KMCY'=X3<LSYIN.KM$!]*_YYQ?$O%.3<$Q68546,ILNGF*9S5=Y
MZG?A,RYV/R_G@2;!>!KF)R^)N]UIU7IF9S:AUWQX.5WB'!?+472*9?0<I"$?
M2RE:@#S' MP$$1CR$)KO.O0XG&8U3U\QCG3D/CF,(()2M5;3DHNK HTK*&TQ
M%>M[*W3Z"F-(/M%0^'ACF=2&VFN84#H=S2J7/HHL<6-* .YB+>,D!\_%0O^E
M5'&*EG3C<_-)=@'"'=TG^+?DSS9J:\8=&M?L(H_/X!"#;:C%P+56L#; <>"\
M3R!$L$D&C,ZV#LIN!#,DYVNH=&JCR8:QWJ(+*58@R#0:E.0PDE64/-,7'<$Q
M:<&C84X:SY5K??3M,H868]HK^_@1I\<T7S$450P'5NI\Y:Y B'7S('JFO7#H
M=1\#^@)@2&OT5MJ^&I-N*N:&A5<+I,?4A.%SPC&9=>T5SB:43R&@$ ("CS4>
M\C0NJUD]7,J$\:X(VSH@_2:@(64KFC*AG1K:Y2>P,]F_XY1L[82 /<F'X^EX
ML:R6]^,7FVL=EXQ7'U @1>":S&U4-E<2LTQVO7#?.K>_'K(A+:5-N=*#8MH?
M;CD7*I18/%KF0.14:*W/"9Q)]?"S,$%['8IN'0K?&NAM8B@[*WWF"EWNT;'[
M.4V.:VO'NH]#_\^UFBV6$HJW C):!%43T*%FIR)WP6@=5&F^F[$!S"$MK]OR
MYZI=[5=K_7F1629-PV000R)?5B8#/CM"(4Q$Z9+PZGZ]R <.;ELS8RN!MXM*
M<7EN/-$%;<D)I+>7NB>K#:T*=4>"@AA#JX7/HO76T 4 V^=G^HL8)3J!SBDP
MSCI0.7OP22BPF7%B@7'T]7M-J#ZLS=V<@U<3/</0?\.$XPKHRDH\)9^KC)<C
M8X)-65E(R9"0&-?@:O?DE'GP2FNGFD_4&Z ,RD:W9M)V@F^YFW_YT,*7 PO%
MRVB52,!9+2\HR=5$E@=3F"SDRFL66[MXWX#3=CDR.4IM% -NZVZH<4@1A(^@
M/0M,J<"D:CVV;RQ'#YWW:<.!*\G,C27>ML_Q->/[4F-,)GMQH<;X2?X?<J!7
M?3@[&;R9S3O%+)?S<3Q>UK]Z-WL3NEHV&SBWD2QWH7>#LBC)GU8(/CC/8Y%"
MZ-8']WH>TK#24/T0<TBLN/=2BV=/WO[CQ:N]/]M557Q]8E\%%#=@;E0K40^F
MA,7!F_GLXYB>]O3D/47++Z<OR&^;IAI I^7XXVG%G:W9JYP#6!D-K?82P6DL
M((4A)X[+@KSUKNSZZ!HT@TZ(N7-P7RX6Q_7RB;UR_OQTM$9&H01D+LE135R=
M1I2U3[W XH./K0.56T$-:27MB4G7M(YNJ*B&^RU'X:2K0MPKG>FLIZDCA3>6
M,?)M#:"O6Y<F) A)&N <+0DA"-L\C7X#E*%%%/=!EA9::=EO_AKFOCV@=7/Q
MGDSYG!9B@DHK<JV)K#]^&D@J=:VFA;J3:NV7OJ"/G28W.[KO'74!^*CHJ'@6
M!BP+NK9CKT,J#H1W+AE5A..M0]=>!S2D;9X'-6T/09"^.7]N*CH6F2&#3?XB
MR4IQE\%9;R&[X*6)B7'3N@W]K:"&=*CP8;FWH:):'4/\BJD>AMTK+XZ7A.>T
M3S:-N(M'SM!VB?]1D9@B#Q*8$Q0:F1@I\O 4'S%IO$_"\B1O<_0W??F0CBCV
M3)M[T4_+W9CKA/%EZ^F<,%(T*AJ?08E,5K(&LBZ%",*4*'U,(OO6VW/KHVN0
M]I[7CHC/\?3?E]-+#31'2D;R@YR#Z'EM4T%?0@HD \9T5M9Z%UOW[;H5U'<0
MY&S+I&O2Y T5U6P>_1[&TT5-:.)B;[J/B^7\>'58>:]T:X16,19$!HR1<ZT8
MMQ BC=XF$K:S+K1W0F_#]#V$/:WITU1/+3?=+I'ZK,U!U^+;&BV*L""PNA=>
M"G#12"@L"Y%%SCRW[R/Q#4!WC#]^"-ZTTU"[QC6'-=?\?YV0R+\X<U].G0DK
MK5-9\-H90Y SD2PXI2BD"0*3MD$;;%WA_RT\WT'8T)HQS=33HY6YVHV)8AF-
M3I'I<]X7HC*/$%B]C2($X61$+F7K&TW6P77' .('M3E;ZJNG&JXL;+W>,$(.
M.54("F(DAPLM)A-"<K)YGN+.F^;WU=/DGJBQN0+ZM2:7+BP9U8.15M>F+HZ^
MJ,@91$T4]=$4GSP+I7FSXW5PK<,8^V,QIKFZFA'I.1[-,8T[68UL\2R&[M94
M[D 5+R#:4*!HPPW]+W'6NDWG^?>O0PSW8Q%C8_'WY,B>7?GW["#,/]#8A$C<
MNGKML90<5'8&8F&Z7GEA/,O6B= Z^ODFH'4HXG\LBK134(^KSW.<DTM4MX#.
M6S2.P3"+M9%HB:"<*V31'(><$R_2AYR;]Y=9$]I:N3OV8Q&I#ZWU2*E5%\(S
MPE_;SWB4LC>!*0E9QWKR3!1PHN:/2([%!5M*\^96FR%=BW#\AX^AFBNUZ4V,
MV"GDHKT=+TZC/L)(X _'QX>+FGPZ+3PDIRU:Z16!XTG7 G%:LUV(G+ JIC)Z
MXYKORVR&="T"_F@)YWM0:D_WM.U7+>P5$DLW*<[C_]+6I-!JCRE"JDT&5=(4
M+W#+(3#/F.=9.=Z:>G?%N!;I'KA:IC7G>M5CKR[<ZK;O57N(%-#HF T-NMYM
M6M#1)) 4G=H<I<K,:MXZL70KJ+7X](.ELMMJJK>X,2[/K.K*HH[09JXMBV"]
M2*"TID%+ED$(KE(RT7/;^CC/K:#6(M #U\+T'4!NIZD>+= -UV..C'52,<&
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MTT(E:RZ(JY_7+Y'>]=M/_P]02P,$%     @ <H $52E!(Q//4P  -J8# !4
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M")CX 7R&>#E&,L'D)/V?R\FTZ'RAFH^C<<.RZ73<#Y?3\K>^C#[BLAY.>]P
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M[-XL6<!Y#A;)3J+O(*AC!5H!MLA;;P'M4';(-:P'8X+LIL+[J+&G_ ]A>-R
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M5%UF#SUO4UEF&WD?NF1(&VP_*\MLK<5M:H?LHH*#T\1+ZZ14),42[R8!UX8
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M9'@M,C R,C V,S!?9S$N:G!G[+P'6)/=UC;X("J*!4&0)D0%I DH10&!B+R
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M.QCAIJ1ULC?]78<\T,Z@Q/FW%\$R!:MEVPX&>T7BBR3XQ4ZG[)@=CDL2V3'
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M M0.R3T(RQ7P7N-.FW2?S!ADKN?4]>88B?<'_AE2MQ$Q*=SP@/"0H#_=&,0
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M942JM*;4,L!5/YUBW%!55EYCN]GK+9&@W%'P^!Q'.]J(QJQ!I_*M/"(6G-%
ME:WYHH/@O;J;U7U("_STQ_WJO@Z=PV@X>":NYF+NVA/V0O7435BB%<8VS1SQ
M_ILR5/Z':_ E='*:?R6D."MVP+]/85GN+%6S3X.?#+,UA0ZN;K_3 #4JM:P=
MW)=8_AX,'-5XO0GN8"9[^/X:>)J>L8S!U;V %WLQ@ L+RZ\W_5NA,1KGR%4S
MAX?4=(OL7+#Q7YTSYE["?4\], Y-8;'@H6ZU"<L_5A[MZ\*6Y4T&8K+Z]FQ1
M\^ /7Z!-#?6'7$:*2$/7W0]M3D"OBU,_81/H(JZ8TU78P0;-PHEE;"\#D)$5
ME?D<)+%8M/J>PZ4M.X;J5^7R^O&R67)*5DF-'\T:_#!'YYV$U-/L')YL/4NQ
MV5?,[/N6F8*Y@?\9<B^UQN376(>BO-[QOLM/GSXLCE,YR/E-9#@G^P5NB!6K
M$PHBB-#9C? <D6@#1#0OG:M'[')]7FA:GUQEP\9.2YC1;D0HDJ!%RB9XKK$\
M$M0<.KW659\[4%IV8LRVMQ/YAF/C/-/CNP12N_;=KZY?CPW,K?D2$=XAZF:&
M?_ S3.5@4 Q-*U(-TK-9;]**\=1[FKR;M)F*FEVOMZ!BHJD270KZ0RUR#\QV
M8G:MMQ)BYXLI8[2,;#0+#<ETH4]H$8*T5AZYGU_-(+>4=\TY O,B-, 2/F7A
M24+<IIA.@]LGCU$]?L(KU92*K)<Y\X7=;JQEC67UZ\ <J#HGE46?0/LR%3I4
M# ,%'TA9Y5GHZ\EI#P5^HJ["58C76!^/G$7%Y@6%B@L]I$%U9_LW:X>8EB&Q
M=43\66+T3Q6(&#$<CXB$'0KPKI+C<C&V;/^Z=XHC:V8IBM >GJJNLJC0R9K>
MPA.3$YDK18Z6:%:M'D_:<5MLGG9]Z-(>*2QKFAHMYC>9I&MM=Y2B"V^Z$2).
M^&/,N<Y>/+I!6_CNJ/5MC5ZWR>UAX\1$VE#GMZ;18;0M+1<\]9XN0>XCQ<MI
MR9-=6WP<CGNA9=<'\C8>";$(&0?,AEFA0U!?O]2WNT*/O4+).3-!]&,;W8=)
M68.0:*^H\&MS;8Z]/::Q3&;_$2/!-*WMR2V\_YK8S :.S9RB^])7/&GXJLRA
M%Z#ZRFH&X*O0R0"<HSV#IIB9CJ7=WINOKI<S)B-SKMYCC;:P\4OM#.BH]@/"
MY[LO_/0LY;XP4]R<:M@_*\7]?TEE@PA>QOJKZK;JI]A\.^>@B%K:&*F?;RPH
M+N']+EOX1(5349[)T]D\@\KA@A(!V)V8E&D361XNY\6!(:5Y1#7&$4R6.GBM
M_83TC.@Q=[DC=6T?=;L] [.A=7"<H0JE\+#K2N,QNS*B1O(A>D:@*]S^Z8?I
M+S4I>F>+EOF\7(F%C:Q3T+4K,Y,C*Y"M[1.:Z Z1R"\#ZPIB);U#"DW,5;SE
M&41#O0BQ;YM6\1KI\GU0HTK&HO3DZNP\[8F&LH0GQV+1XA==4AA (I5CH!@Z
M"1*KW6_2#JA9':%X!9B2PA,$SR0^!7-=;G'&RA\W'*>F3>G1-TY@XXYC*[';
M'I",^UN75-ONNT@V[4"3K?-F5WL7+@U(MCM\B8KH,/5*7V0 BB37'ENFZ]I%
M+_SK@^?_)B*7M2^U2N5WBE<]P7##+I'A4]B(Q\-JVODM>2,=S1XJ2?[M-W4:
M+1'O]S,!@Q 6B@E] GV>O"'6GISSE@J>-N\2#)CDY>T>V/T!?L$ >I7V F>K
M65"Q,^NJW>7L<$S(D%7_,7\F47P=B$ERQ'DA#LQ;TJ!CLE9Z*]?*-Z'?J6D]
M.8MRN& ZNV9.B I%)WX*5;&RCYM7D=,;MW\\KBQ"<^6XX8<P[<(VT]7(X24A
MAL1+^^V-!;8NZ1%->_-O*YZ/W'MJ)O3Z!NOGXB#I/=.8@ &%WL*MAW-.,N\K
M8_9\89YVPU:@H1"9IL#'6OII1P5[J*9!G=1].3&'B8V[3-XQBRCYEW.)_Q0A
M[I+C,8O?2S_*EV>>TO6&FM*_@PDFH9"O&,>^!E]2_)-;-J)!,51L=0X-L[><
M,[D@7/(5]3H?]>3\S*46\=901Q;CMAWK ME^:R5R:;Q"2^\7?[D?EQF ><>
MB:WP#[D&NR4Z1Z$3+8[@&%^)? D[6S.TK7YSU'3  _O4].MHRG[X&.?/\#".
M@^R#J$[X<TSEM1BP8R\7W"D MI<38Z(QX"!K-[QZ\D<6.NYR2Z:P(?PFYK'G
MJ'@+N#(T;+09KT?D=JX+E0UDL5_NNR;\D :(?#E[FJ;7!+MX7Z'R\]":/B>U
M9$F.@*%5K>!(M=2:]BQ^_*8.45$.PD'M= 41Y6BUSA/8LI5!8VW8&]AC;F-M
MX%\OM];+1!0NFQDGZ7T]\.Q, X242ZMJ4*>H6';:\Z85DS_]\=WJJ>?FZ.PC
MM56-J<6;M'G\^^M1R70LG&"<O^U71YAL&7VY4,<?LV)EH^CM)^TYDD%/?PIJ
MR>(+,0J%:Q0$*_4,#MC8V*@D63KX;(B<3OIN))K<>1%S H\Y4S"M\IE?VJ2@
MHJ#!?DXX"09GWUJBI!T(T#?E[4;\2(Y7'U+/E2/ZQFR2D6EVB)F%=D_.$"^B
M37K'RYVC<AZ"%R3HJU?SX6&*BT7[61^3DVVJN"%;=B*G(9SF9BN=72;^[O75
MU%%P[N5?+A9!QA]N2EV.*?_-S9A9I-C@7Y9*_I[D#2A=?R=X-W+]QXRK=9$_
ME[:BH<FM-S[\%CY'=G@.<>,OOAN>23$U#P:YTSN1!!.)G:M5A(U6O9S(Z3(A
M=,VSLLY%66#:B*9X%AYPTH(6=7#)]X">8''BMP^)@W,6PIIL7Y3(+79[E(NP
M<0'LUV-OGL9;]PXWB/:$>U@K6#@6W33RF.-@J^[7 S<0Y&*3/W0_ZQ5,N6IV
MS94:BMVML?6LHPHF-(A$>+C!=%(<Z_/*X5.K#*"^8LD=N23&$TN@S C'$XV:
MJ^N&P^$G<SZ-<R19]-Y4+6+M^KQ^\DA)(3TAQXKG?F&_BW%2G?.X(LEY1W<K
MWD5)TJ"_,//1NW27'J6^]TRDTKK\K^M1SM.E0ZQ^PHX%J.)MB"<V1T8TFQ&-
MHNM!HJY#;_9/9B8_.UKLS1=S3[*KREFB76JMYE'2\D@UB,.\T:(OAU=2;T2T
M=#242RG$>.;=]2:K0\,%17;62_NA2?SB7]Z2/KJ ?P!GD[_.8\!@-XY1K EY
M5*PCBBJ/%8"\:.%.W"K'WQ-&C=NK)V/,Z8LS&!<YW"24ENM+->QW1@M5)?MF
MO4ERN+>]):KFF8P2C^ADY1?=4X++D9_/O+;I[);KRH@XD5G-3.YF()E):QF.
M90X.JDQN:OX\?Z$IJBZ!&+4XMU >;+O,#'>8/.S[OQYQ_M_%?[*" :R!9HQ&
M>MNT[O9YJ'5;O@FM,'J3[!F00VFI./E=11A_CIX(ZT561D7!G3:.,@ GIPJ^
MTBG ;FF+DQ1[32.'G#(U'<7V*XQMEN81HDI&E(1($-U+:]Y##?*6S^1)7Q 6
M"NA27NSR[LHZ 4O\BK[P<%,@)L)ZL*6F.*CCAQ#2MV(S")E!Q$8%W-G/0-T>
M)!YUEDW:1,+%Z[:L0)]3(+', *PVC*7H.74[7GN=2RX<5L>:'T);/FMW>(%L
M0!?MIJ%U^"C:<"L'RVI>^19=_K#T3+$*:/(J]MZ.[J:=:\K,YMB=SP&_E VO
MY^WE#6G$.S7'2*!N;/W3&CA_5Z1_P)W!..A-6D8(WWYDSH5Q%W]V\Q8#W0.N
M-3L,X/$5JJ$.FV;2#;4 *@QT*"I5FD>)3]NV9F!_L<;S#[_[E_GB/"XHVUPZ
MFR?^* VZ4C0B8_D$O[%V:)H!C$PV^;C@!J<_O9(?L<CAT-C71+S6??^M6Y@;
M9,.ZET?<)843V=8X\7I*[BX^G]LMW8IS[&<MVN$1NCY>\AVI(C\!!9A<R$,L
M6IG<C[<E'IJNJT^;B^=VC\&I)8G$PR-T8!]GD_1$-W>HR1T3YV>>+*,X;A):
MM)>$RVMP:8O5=IZF^Z//0M1:'BFF7FC,BTX:MA6!5X"&UJFIS[6Y(?-Y2W_-
M?C3/XN01S*,-8:K[YFR?HN"'!^)@SWH&H%O5D>]'80 $H -7?UD%)LYO=K?9
M-&5V7_LJ V!%"+UY\/GINQ#;6\W2Q>GZ1+7Y&(KK=!Z5RZ7_8((G+SG=-5I9
MQO5CNX@F W!_=#"1 0"F&W9+4YZ_*J81+802QVFAJ\L.35N^AZX5&Z$V] 'X
M^ &,05>(8&^9GA%GMS8\< +ZU)-<"7-,)W>^FK:.!*57T)?+*7.>30J;NSH$
MTH<9:82X45D#.@.1-''F=>U2<YAK]4^F'M$PD5&2)RLY4<O^\$Q/R>#"V7F#
MG+,[2]#"?8\TUQR<3..[AC.?Y<83^%J=,#>4"U;6O6 'IQ]B<&4^:>2'.7NU
MH&.QQ%'N28HLUQ4&P)V)$3N])6+  ,*"0VP&;]90+V2/\X'2W76&O'>$'V_T
M5\F I]*1/!YW*Y;J;&O9!!\-VHLR@$D55+^J]$C>5*H6*"87P@ \=;>?X^\1
M:S326@R3&$"-PWX/,@,+(AB 8E[=_%XM<.>[Z@47R2_T %")(Q3>=%U#UC+?
M@?#]VEFND!)#[%P'I9]C0&G?05LUZ^@L%\X7\C%GORD&&?^6ZA\AOL(/2]:=
M,ZRB"(7<_6F6#C_HVN^^0G+2&-A@ )>Z(9PSH$.N&IS)CTL^+@=9.PIZK-F=
M1I)/\5 $[V1-7,^W4K'7$_&.-+?M:AF#(&((TH?$Z#TQ*? V'KGN%-)E]'7[
MAPP YU661GZ$WRL Q=V#+$\FP!^A(AD IUE"WA0-U .[,UP6FF02JM]Z+WGG
M8H/T#)3*!=<>Y-)K$)^17KOJ<:MZ\*[-S=#P?'/C=:UT<MQH4]S6\4Q"J5+:
MHSV'W=O=Z\D:DY)$I$AKU7&3U[SCI4XT8CUE!A'IA#(BMU"$0VZ019.,BIQ\
MQI;*?#Q7.7#N7W<>'IX57B^R>P!-PY>/F;,7?8C+D_)9$QV@!@4B\Z>>7)*]
MFH0*+Q!(W#B33E7=8Y90-KKW_V2#BN7)#>Q&B$R)U;*5^^ P9-CDZ/NL,SBB
M\NPIUVUQTA5:;3%=!:?%Q TN/<\',XMW#_K\X>WR%<YU\D#G<CC*#'\>KEJH
MKU];+)N3=50T,L!&[VQBF7G\\V_G$C39,F/VZ1SX2YX<,XTE;#V&4&[A?NC'
M--W=<:>0*#XOCV,O+Z.[ZN8*0)'.KKS[;3M0WZR\U3F>S8U538J?>-L#SVDP
M[Y@V1S3WP?)&MPLNSSCJQE],&H*J.=B6I>@MWY3#V3+OX^._=A&#2\M"36T%
MJ/X0 P7R%GB:^M@@+O68H*">V[[>4^<=(\+(2-'O"KAOYG]>:PF22>^'5V9%
M4:X&G*^2T8OXD>/#KTA3!W'9W0)O<_,+9M34GA.^XP?F"&OIYHE)BKM0.KI$
M>VI=DSVX\G7*FV_L#Z\O%BJ&AIVR&"RDW*H<LP:F&"UB*HS"3\Q-6_<\)%H^
M75.QYO!J(6=0RE!^U,-ZJ.^3T9.GJU!QP@H-V*J5]H9!.<'DO@O&N_;:=&Z[
MEKTD ]!IM+@KE$_-,1#EBHT/S+>[)I[]1\YZ>RQ5HC%J2S1]887, !#*6YRM
M? FW[)0#,'[J#*!1=J,<)ZT]A%D]R3JE!N:8WEMP?BC:N.1'7PU)@S1DH;*U
MN8VA2-#[/[^T9CUL-]!$PPK/O*7J-%XL-D$D;.+(]Z3;'9]9D\WXNDR,8^J#
M+SA(M,N:^.G[F:+N_>Y1VO?RPWX.7,*YOQG8MIG>T?]I7[/RS5!!Q'=:AV59
M.U22(@MO4EP-44[%+;2*Q1H/*B>I"UDH5=4NJ\V#5OC@3T.RZIOP*_K6%JON
M.9%\^$B^E L7),RTSP+ %,L2M,X+'OZZ3$JY8:W.>]P4>IH!G*9H('EAYC#>
M=N$K?2TJ#WS^*-1W-*9*4Z77@JCJM8DS<%;X?3D6JN MCU*WCNBJ-X3V+>,X
M1:>6!J_-V-YS[[Z#&^TF"CEOYK,77@;6]+7A-QT"-8[)Y*Q>5GRM3-*'0^IA
M[M5P]?FW[=?D2]:(0PXFMJ.C?6YI27J_'3AQ_F^M,@L_SS1&F '<-V*ENNB5
MKKFGM:CBY] C#TY9S'GN.W.P3WR,+S8R1_ED-XP-B#<]OF<'$M*[AWA<O67T
ME#IP9[N\ 2^8.FP1=P)B:#LPV5F2ONF<LYF'WUW-FV'2!>Q=!A ]E(93K!5T
M$WA7^J@J39U%N>L:Y1++%%XD?<N*]F9H.]86?B>K:W]X8O/'TO$GFFH/;\V9
M#LIG'=&(1$O0BAG 5$;_8N)X0.STF(*M5:G#ESX?.Z<HD_OJ-O#/,$^#,18J
MOAU]"ONUW>)[UHYDB<VUS%#P6_AL=Z\Y7-<+$CMXI3^!0[E*%:&M_D$..@??
MD][L X&,;R_V79>6-#<-.])T. ES&NSVIUL@!S>M[R3IK)U-_.S@H.P@\DIS
MAV?7<U6:XBN7D#30A):O/U:2S^F,BRMYGG\R3)*#NK/MB5_:1>\V<^>OG2Z2
MYG%0.7CVE.L2&1)#?'ORRL//I<2@VW+.LKT5J[MV:4;SRD41EP-))Z:];_=;
MM>L'H%?JUJMAU:XD6,R>(XF;]B6'G.SL.#5Y9OP2[$+$07/>\AJ![.?/$HRH
MU:P8(C,2L<LN]*YI^KFF!65EO)=)@]U*,=2BJ@_5X9L#C@\(CR*^O2IO<<G-
M7:QB2:PO;PC<XEC(5*NQHO6?WS\J]9^I:5,'3?4^1X5HEHZ%9K7W!)U\]*YW
M/)Z-J" <OFP(B-J_;#7]<-NL2$_GBD'UMI[,Z-66Z65(D8#BPSE)Q22KZHE.
M?C"(KNZ$J>AX)JO4\]"@_VR'@U-)M.?C]IMR[]>MLQ,"E=FVV/#B[4*>>&3"
M>H,FRB80"P&)>K]O-2\[X-<>7AZ']-$3%TVV E=>ZZ YDF+(X1I5A5<B#WWW
MNWI[MLV!UT&X.*@"SKG-Q_H"-0OF5-XO#8TF\?GA(\-WS<=Z]W+W96-[*O:W
M6M LN:^F&]'G)1\^;ES 2-$MZ*BBS5L2V3'409K$G]]@KZ'S416'->0"<!TM
M^T)%MBZ\O1%"9Y3.5M32>8P[P=^GS"LE!DM,%)VUNTR<1:O<&Y/D47;O!'Q*
MS&]?B7&OR=;S&!4E0P@YMN0^O'0H6PO)(##4>TO8K^, 1Z-(C;9Q%GKJ>!(+
M3826!G\$Y:#W6)UR,E.2X[3Y--IH>(O0"N]5[K@N0EK^U:D.#-(RP(][.$AN
MA)M+=2ZQ[W1FI9<%PC^)-KR"+TK(^Z$\??0TXJ'#PL)D3ZV+>6<]5"0?0GNT
M.N'!#6A]_1HJ<H8W6FDK/:GIOG4"?T@F=7(W6'=^I_QW1BA"IOQ74!^D",.!
M/D<@VX^YHDX'F/"YA9@)O+U88R.J6JT>? D=WX<X09O>V\M?VA70I@[7W.UQ
M]W47T;XD_T$W>G"JB/7;.8(F:J1PKX8T1XNY3^[+M0E MI@O<<26B'S__(G'
M]Q%TVF/"">1;CW=>A1 FN1H4$N3E>WS>X J'O:">]3%TCY4U>"Q\K$&)*&^A
MHBO5DQ=D=,N EM!EM!<,KJ +8=2<\L:L.YV]14W:B=V"W$]]<=]:PHZLZN;*
M8][Z]2$'(.C\/^L02?WKKL?R%\+TSF?Q<NF*NIGEW/<YP@2?A0N8FY@'T%%M
MC:O.WF3[UC1VM&Q%W)Y)8I7OK930Z=$>UHV3\AH/J#=@ 4/Q(I"ZGTKZP2N"
MT25R,J*6#]+%)44-\\ZG)&@>1M>'?\'PO+(WOX!H/.JL_#2))EJGD16?,QO0
M\>)R@V980-#$*KY8?%ANQZAP93D9_%@"Q4&+Q;C60W'7FY$/!K,$/7F=O1'5
M-P'M>L.P@(X\@Z^AP^K/K7;9Z=^[%-QD'5]$7F.3==)SGAO7Z''KHSIFS"D7
M5_"JG9%7JXC%]E;8#HQ?_F<?G].Y'V/YTLPXR<@%R)TQXK(@@V\T#"GIY[M5
M4HZD!T?/*5LDZNB!IU24]I(IMO1!+ .HK$F@?J.N0$\L%9L:5-B')VQ^D]=]
M,YD4QS*6-4G:IWVVQLN]?$1 19563-O*0B<-^/'WWAE-] 8,TOI^)M8CTT!7
M(9N3,7;GX,YF@890N3%M2D]HK1RM2KV^T>\6_2.AIH4!K"[K7_TN0ME#^8++
M>)GUD1+&X=,:,X5#8Y&5?P7-/*/8*(^W'BQ979U*75Y?UX[DLS?IE2YKSF<M
M$'T>0U.@Q3$ !U?H2/U7Z_6<!$_NY6^H IL#@IU"?QR!US5^H_3TWG@?,$D]
M#2;9GAG.F;E:ZTD9J='.UKI :YNSPPM3"RD>ZH/8$26:TC2(M5B&YQW>GM*)
M&L\C/:1CBU/'<U;RMN1B,[V(9EEZ86GK4PP@ (M+HF@D!N^F?<IEJED+BOSO
MT$*0$+Q)F\GIB 76MB%_$'I0^W](S[OZE2%V\E7'\ND$$%SHQOC@%3 79'6[
MK+BO7+5(Y$!QL?P1]7B8.WT"5-Y+E0"]9+W7?]^!4-HHHIYOO/FK9^B]^$"1
M.$7E[-I%3$:(S9195'+O9<Y=9C4;D*9#QVUZSFQABVJVTUZ$/"5R6@IKV&U#
MUD>7TW[!G%U!,JK29!FF&F'(QC]K*0$Z*W&X@##0-JPZ'^LKEI6;=ULL4AN<
MGCA^ZS>&7<#<!3LP"U(M?=I'NE!'H=5J]9",7UO!B&.&I?=@4,[]UQIOV5ZY
M;F;7&SV#GZU"C.S.R*!>*J9.SM'7UX?>%/M_3M[2F?PN[/55V#N&=KIE0KGH
ME;V*5#5A"[:_1IN;KRLM,NBO68"=]U*_Q #8>F]W<QH$(S"[T.3%?74_#P90
MD@*Y3BB:24@D)G]-%3[?)ZM&$9S]P;'_S<:K[\MJ5X (D?^@P&(1Y1C'RSR[
M3%?CI)1'R09N R,YY%W.J(*;Q?G#L7'9..?U]/^(=?M3_XPP1[UB,LD<<-4D
M5:1:@:I!&,=2[\@F"_0,NC, X3Y.YM,R'-V2NFW")I8P:4&K8  NTO"1END^
MBDB;7'25KU/E+T&D=(4AGE*0Q4:\RG8G<>]UP;*_P'".=Z"_8AHOQ$2Q0E_$
M(] VP3)Z74\%U4*UPF,*^@-E#T,;TW=QE"MPQV%]6-^. 6QZ6NY J$_ACS(B
M;1#T!<GT>>AT[&A#HX"7L38/M1UN^)?4D$'0522!'8X3P1]*2###WJYF /J#
M\W9J];XB4AR/?6XB#$863P3FPM["FI!,9:D2DV&I6W8W1; -.F?V*2+ST;=H
M@^*T(161BNL) 2@T82$"7J/@-%"(>6(T@4Q? E$"EY;\?Y)!G%^**!R2KV\;
M[0ZI_PK4*&<"E3FZVM;(<4!Q-)37H*:B,O)ZL/6M5+Z'FA'1W$ AVWN /2M&
MFG+UBIZE&YS_MD%]8W.,Q*=S_QU;EMKC0<WQ"GC'EG?Z+4',/YGCPCDM=BRM
M^I5/$HIR^Y<&-;Q)::#/8N;R=AEW[LW*P!S1 :/'6?&"#X@\7COV=K'>*5;.
M)0-6GV#JU-ODX((02>)PWO2:'4C\;O_\Y6]LX]Y#MD:^#N>?;U_XO+(!)4NB
M5A<8P%%$N AQ..VPK\PAM1+MNT_4/P7 GPB>90!UWXW&>0AF<"YBWO'!;Q5Z
M4Q.?R>\I;6M;UF"E7W3<%/IB7M:<5[O,Q<:1TGYK:M9*YV\4OQCZI[LO:] R
MZ)J9-T4E8+<3G62I)EVL^NG#D>[0=W7'7H FH#.L&W)G7WVA71ZH$@R%&H6M
M#SNMRWCD6'Y(O3J6E'.\2/+L*<V# E0'U.??1=9D%9)D-@;F4-/VI<=Z=5#.
MS)@S@'L+R1YZJV,IVRIV4QQC#6)X3*&9Y455:'TR;13^V&AU7V\-9U<'$YS!
M'@CU2/Y!N$*;A6QP48RAKL/2,.(V=@TGD8WYA)B_^U>'<S%'#(CK*>:%W<'!
M!NWBGME?SF7\@J @\\7\G'J%4^^#LEK2)U$_H&0)CC4]!G"LOF/REX!ZD^?Q
M@"#S>PY@F9UO7943RRKW2&/P6$0\/DLF]Y4#ZM3J<O<MW89ZC,0Z7=\/43[E
M<;H(.6_<LES08=E=&2RGXH;V?-0K3IXF(LS(&\0+#* UJ )&6JK6/**B?TOS
M^@7H?8X9/76]4IT8:7(-3TQ1=,DE[4 50X/JB;7&$5IN1'-_BW&"\(M[#[B3
M]!^E?F/RMP75OZ+AS_&8%J%Q&-4^B;@JZ<_Q-L?IG MDQ*;X^9%-O#K:L5W7
MEV,)FF<VA2088L(8 *%(@\7:!7)E=4C- F+\)G'KDG+K4080PL4 +&^MV>U"
M?TWP$F:ZRF\99E?=GJ#6CU"E9^N>NB,[-"2\!7N>U#9G-*IJS ;;AA@MR#::
M:&IS0Q8[%L[_ WWV@]=(EY=3%:S&VLZ2=CDK3=I7:A_I\$GI>FFV2V_FD3Z1
MA:ZMTH@9]W[Z=3V=]ZQR+L=0JZI]_)Z,%1PZNJ,%+7J]A:%RAT\9465 X6QV
MY5&PLFDAK);37FZ5\E8:_0  OQ^?4+47%3,F1RM*4=,6H^!XD];QI)Q=:91B
MFNDV V /R*%(7[,(0NV:K?&.Z*]V;_C!#-!1"^K,\/RFN[/X9X_OF;[/TG=.
MNC6>DW3U>''>\8\^1S2R,[0!6"JL!50E!?L)Y]!H*?B.(;QVDBB;"//R%%FL
M 8*WW9YZ!!S/;NS'G*>?#+$<TC@:\L= @]Y'O=@B?GGBE3U9>S4U(WKW2?4O
M(J^D=ZRG(:WC<GB.9XJ3G$Z;>ZE6*9K-2,RQ!(&KVP[W-?>#(#L=$6/NM(JP
M_2PIZ!IW:N.<4$JC>?]6Q3)<A)S3!/[U:[+T@3V]UVP))S_>T;<!DBZ-TF::
M=#EJ[N_>WO3?WT[Y3GU(+OE$Y28_*2 GFWMNVVK(=)]2#H[F."K )-/?;Y!F
MLUA^;\,&!)F@+#?;)9GUO(SU[Q)_1JH]@F_KMH%HZEHCE]HU.OL5BA&\N9@
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MU.*6N;]PN>'E68KL$$G=M47.<V%P/2OX[:<OZ5JI2;JRWT,[YS]D8UY5V&R
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M-ZPUF]8A!9#W(IT[RG -??B+W0UN^O$/M&/58U?&<)E6^(1B3/JHI B1X\M
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M(T"%99H]XQ'YZ)ID=H9^C5O%8<4=6M\ =59ON2;TXT5 ?<D(P&*6\F#MMO@
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MAG@>[.[9E?BQ/CO*I^VAZS$FZAPJ+N/0*X"HSSV G\-M76Z;/^X?IU$ZC5E
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MA[5[;1HYVI_]Z5(+26ZN6K@C:ZZ?J00*=:5Y$[:CY7SS@8[5<P?;SDE03JQ
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M!2-A9C\8@.(-\KMS-:WCY"T$-_WVA\T_)EY>I/;^-HNPF<Y:0TAX;@,DEI;
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MUOI1R#0ZDBJ (.PTDN-#<Z[=[U6H"BU+Y-B)FQ+J,[SC_Y(=(>Y36P^\T\X
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MV]L+8?;(]\RQBW5Y@H?YOT+] T86<=1#=H^8*\!GKO ?73-<9#VFO)LAY3,
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M%KIGQTV7^%_7O@O]]>)Q"I=17+K(Q2K%KW(1=MP\DEG?R#,$23P=11R8]$K
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M.;?91*)^"9XD#@A9G-&P!$^6,WF,T!9%P\_SYJY*V$7TG#SY'YK4]C_9)!=
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MT+;]C+0O$_X3=5QJ4QW\9$#_#7J-=<6_Y?4,,BTJK";TF_!.KQ%TZ#T_%YO
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MG4I4PC[,Y WS:%,3B2_? ??WZ6DA'A*PQ^X77>*MFSQ3U6KHJ['65C04L,(
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M9H0DKMUO&^ZY=:>653-!X!.(7$A6):()F65<K@?G*CV""8KX< M.((J(9%C
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M/_/3TD@%?//*7E9L[3[[[^2+"]8VIE>LQA'/Q,:S8^XK!I&N^3ZWBMO;2IC
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M0FP#[RDX$+_^'=9K-5KDK<D^X3DU@!4$_CY/.B0!5 B[6A]2U<@15Z6I@UR
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MFC_!CKY '_O!CJ)NQ#/"Z-K1U+1CYIG4[$;"Y0CJ3'WCX3D248X@T*2T.AZ
MSTEXQ):'4;9I=Z4_GZ>/LKYF>L-'>;W 6+-OB#$,D-#[LEAR2&,>0R'T=BU
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MXRC$(6,0Z8V2,5Z$)EU0!C4#TI P$2"$'*)UQI)K;KNKC09 ;%5HKCGY<R7
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MXYC9E4:S[G%N5+ 6;WT)ZLH&YP"V98818?/.$JV,X(>UM#\:5\L-D)_. #F
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M:XOSISV<&\F!%AVTLH//OC%VR>3I">N)+E\_RWO=7)LQY%;J_X9\ZJ.E!AV
M97_>4)<&)TPJ.D#/_8RC0QJX,&G(3D$-DW+M()J\V@\GK_:#SS=VN:8M<W8F
M*(VH7E&H@E@D&21$A##D@LE(BB!2Z:!$(6-*.;=U:'WM)8 RZ26:,I8#4X&,
M.I@J4V$<D@"FC'>&$(J0@"22,D !3:)0NN=#??$A_;O)GNIG5 FGD<*,0I2&
M>HKR#$$:! H2B424()'%$7;-M3J3,9UW9E8_PVEWVGWQ ?*\Q=SFY;G:K1#5
M)H'=51*T6H)]-:_ 1D_0*+J3+[9MUD-*'Q]#,78:GU%E?)G4/3Y@/IFNQTMG
M(P6Y;/>4P4(04S&.QC#FIGYXD"20)DQ!P;$@6:)BE3F%./=U-K?MUGYD1FDB
M,WYPBT>T@MB.F,<"SC._'D:S6(4=7A[(<@0.7T$LNUV]; #+$:7/!J\<>V>
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M';JO3]$,JR#"D =AJN<M93 3E$ 5!2J-68QP9I6+^ (9YC:W&^E!*[[#=<+
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M1Z66GE-JQ?:5C[5JN]A0K=SH5G.:?4:VWFB3TVA6=)W! @)^88(+,=*8\U]
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M4FKI=<G)V]KK&SHGQP./H*^ G;=[*\,.?0K_%C9UY^4: /Q0#%TA11N7JVL
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M6D%#+FLNHA%J>7-^H'&7.1<5/EKN7+[C*G; )+EIEN$Q8PE/\P(2H@3$VDE
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M"I+H14/*!8,8J0Q23 F,49IED@F<,S1_K#H\?MO2S=9N)3&2]"Y?U6L=AOO
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M=MJIA?,U"QWB95;YG")B#HAYEMBL]!JRC&<0B9P*0KE0+/-+^-(9L7$2N@3
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M!YL(YICD$%$IJ:9"I\HIZWX@>:9&3I_-EF<#34]/AY5+/!V3^XZ1(T>-A_S
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M8DD-B^0I8NYI6RYT,#62*.N95>8UC^O<2\@YW)CWQ&-@)MA#8>4#/]^>_F[
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MSPB*!$<L@5&.*,2QK<T6"P()9H1SE"&11\YA1YU$F!J5E +#S0HNU0845F;
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M!)-8)EX>5PY]3FT#VHA<3B&Y%]JW?-5ML-TX*C"$ Y/3$7H'\C;73P,4M?0
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M<')E+GAM;-R]:9>;.8XF^GU^1=ZZ7R\JN2]]IGN.TTN5IYT.C^WJFIDO.EQ
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MU_G=;(4TZ>!T.='&%,>5 .."!Z5MAN@(X3)H)9AB 4-L$!#<O_IVT.@^_]A
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M,GKKHM&O\V,2^K(:P-79I6@"2237;"376E/\5SP$J2P(5U06T>GH'FL1L0M
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M/GOF D89L/6]S(/$_#-<Q3P'87?.[R9:ZN"@OM8FEH17_>I)\#88P^O8>BM
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M@L[;H@T(9Y&B458@\)@A%N>=93XDT_I2[-.4C%]+/R!T]A3XB8?_DPU&VB8
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M:Z(C+4GA:DU@+3..NE:+20'2&5F[\$J+K=/;@S#22XC0!KSCZWKLG,6M!/[
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MA'T4.!](FB,B8[FXG'R>7E9+^WZ6I]^G^2I<K%9)$#(G40J8DFD'9RQ"5$6
M#$Y8[G- ME42D-YPSUK0_]U9BF=?WDNV9(S-IXU&>H/4?TTOOZY<QUHW]W7Z
MU^?Y6PK"+G^LEV%6F((V"7*5D2J9!*4L0O:L.%>D-6HK9V=7L+U,UCB6JA$
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MNO/LEUP(7"PM!1D:/UG$0Q8"8S%LT9OO-,8X6@SB?]_[HVGI1$<T#==LPJ?
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M>/M<\-;?.[S=/@C.RQ<GW?CXU-:(JDL"H@B=91(?#^RAC]PUXP8\1C#F,E%
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M*K>I\IG+2?5GN"KE+VV=_1=02P,$%     @ <X $53C[UG)"!0  !1D  !<
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M1M*E_N:T3@ ]77 Q \<VWD+,A7:988 \ II&:AB^FJ?TZ9%S:K<\[ PU :M
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M:^Y-+A/0G#=RJ7FCC_B@OD0,BBRIRL5+[E%;]8(>9I@]LX;9.#>KF8J1W!N
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M\G*BGHK ;@GT^R\@9$ZNUDDG87 EDP18CQD+&1H4,?P>B2DXS@DQ)U#"I A
M5VN%+PN,^$;X>1$48Y$DH-UO)+'L1(J4 !>G>78#RI<NZ2FC7EZ?G[X'8;]6
M>3Z023;;I9W_YSR;B>"?"MRLX#0#J?F^C/>#'32\8,WSX'.:S5*4\_S%7\3G
MSUG[Z[LLUB=3D<[OE*__$/"5D ^NH4?(O(JT#;C@/89!+%",L[:YR&[D9 !W
M/GJ)&N<0_ITI,.1R64QE!&991L_4WB8NK<PK4!QP'#E^CF^-BTTDR/DHF\[Q
MIK.QBL8A7#N21(IT1R0R80<@A$%13>$J_0L\#C4%.[%@^#$)3[+8CD(E\S&7
M91:B A5E*= U"OAO^#+])%%;Y;]>7?+\]?)PHI>XCY6XTRHO*G):F#LZ>*RH
M!G\X_,,"F)DEC143="'+ $0#\ :1MDJM++>N%EZ1RPDP<H$\KDK,+,$]L>!#
M:8%MC#9";P<^XDYEN-*?^)^M8V>J&&-14P9GER0@#:GK!*5A>B/94D=OMABB
MJ,Z"GZJYS-G(IA^=ZT44R2D[P85(I+D5$P_?3J21MM#M/8=Y-C%KR88A^]"X
M4)<F4-#:XB'0 $:4:Y.\32YA4$TSIK2'$"U3*CG#-0$SR6T'O5U\_#T,KI'H
M?OYX>1:NUU6D4$T!5EAN4\UDHU5E)1+X[$:F@A2HJ&/ N9S"N<*/6F_B 8+K
MA5$6)5VI8X0.*7APZO!3N@^JTV&6@%F#(*:OOE1UK,@%Z3[&%=N&G7T5C<CR
MZ_V71-,8!8+_O3O[^?R"PA*/\H6:P>JC%YVLM*8M-SWTV%FQWY=M/WK.^_Y.
M#E7*,NQ+7>K>Q=^DYE)*]Z"P1C7";I[A[99S5W_?N'E?P^ ]VY!^!Y6B?U>*
M,R$]""O1\1>+OA[;%JP21+UB#D/.@T\R+S*@*M!+(L!"XT2R<2(B4QC%'TGL
M%4)M17DB&;O?@L?"!]1ZA?D6,'QD2=\U1A9ZCZ3WP-[%VC2D8+@S6"?@)%(N
M %QI^B-KP_8=PF!G8&Y>!HD4!?BIP43\D>681==7_9:5R =7919]=IX.#\*"
M2GU[_B,EV%Z^+?230K:Y=+!ED.@F(-2\IHC.\9GQCN0D2!$;3R$.,"^9 7G0
M7DJ!+RS @YB-V6.&:S"-HM*;++G!&\+Z93[B3W!KLD3%;!+0$185W(&=9CZC
M+9%Q_6;IF(UBL,1:Q7YKYVQMT]&B@D05)8?Q;+?L'9XK$C7QNKY:%45%%$@F
M/UYD4>ZIS4!'%+$B,L<\^SR(L*(6+YEBK0JR'#H\<$NBTM:JLH>LRE/S"JAY
M.%2)<OI&UDG$;+8@*3MZ1P<V,RJQ+2@.J'])*&$=DOXI=*@TRB83G>J&;^@8
M9-J0D0&6%&$T9YH54N>L,!=N3<70)*KT73J6A_T(F@-(@L--3$Y.<L@&-&$8
MQ(K"I:0@S<\SFT4;!E91-9+N1E<5K*1R?#!H:[3GC):Q[O]-5J)]QRPJ$VV+
MPPWX<5E>,&]C]TAKP6F6[MVQZ/N+0P[V#U\\C>J0PT?5AOBZD8VM&^EW#<B:
M%-@7BB\)C@18 4I''%D6XP?3;,:14GU/BFV)5(SJ.L<I6+J1=B;(?N@65OL;
M%WW<1!.A1X41)%:<?'4PPK%+1K--@5TG _!..3_H[<<5$(?)[087%6>4#?LO
M12I;OYOTB$4W\^8GH&V2X/"0R[3"=IV6#B90\J:^F?1TN (Z_+36<I F?0GV
MDZ=@MD]$)"M"T@0A!405*R(JCG9A24-29-II2>9@X0S!G^9D+U!<G%<C$P"+
MI'9<*/9UDZD8_T:6?E8-X):P ]I#42EV TCRH:9Y1G=!:\[3X0KH4+>$-BVB
MW@6*D$Q,2(;LZ^9ZT3!7Z0V:65R#L_ -M/X6XYIHA3M_MO5#9-,W;S#L_"K>
MH"-:BN%9M7B/CNNU)?"SDDD,#'/G<008 *=2(PPM<P\-;/@9_V![>3W;K(YM
MEG=2KYUGL$ C23@$FLQ#A_1XH>$]Q(96P3\R\(;J"]PD0&C"H+!):)DTHJ98
M0MTJTUB,EGI?:'5T>I4E"!JI):0^I]Z0JA/)K\/RM&00DZ-<3()_IMEL[Y=L
M1OY\'!3P&8A ,&?K?)@"NK/184^LFTBL"^C(/0GN4Y.JTKE6 63IEE:R::SI
MD"]Z6,%=*VOK9&M-"(H*X^AJ7=]<Y=%8H P_T2E>?GAC;;R$@6QEHK6A,=1(
MLOVD (NSO4X"\+R^@I.^I^>[#P*@5DV%G J*XTX:J^5BU.D4ZSSJ^$M'<$5P
M?@\N;-U!-TYPVH(3@@UQ0L4MF$JCD#:HJUB7Y=*?R85&OP1T/([7H RVA8BN
M6S$^+*SZBE==]^KC7=Y),!2S*?[.E;)4>ZLFZ-=,9!YAPD-?^%Z6)6O=SCO5
M%U"IUT3,41Y16X6,W9X*_$TW5<2VH6*F0/-R4P7_-9?31$3P,Q46EW#6)!#A
MO][560VG J,N>+G]\73(_4<^C6H'G!+HY5@K[V55310HP 0]&IV<%L2OV_
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M4YBM_T)*<H+H:Z FLF$Y$[G<#<TL8?T0',DQP-$D^B([W8I_Q0R$V5H3Y]1
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M5:(6S=RC7!>-ZQD/12U*[--JU"6+I6R^+_]=P>/T8;3QF"AY"!]@73A0(</
M43&0@07N$%P.B>S<,L#:<G)R^ZW3D.N2W.;]A14Q5B3E0.>,.*HCAV:0L(F1
MX3QA,G?1X4)-;88+Z^"5F2Q,QPBGZOHG/J_OY/6/?5[?Y_57G==_B'>R)E^D
MM\$+.];A=JUC XB0^[E#H#+6NC.ZQ'*G7=D@@UZGOTYAN2BE>M&3IPM@.RPA
M,T59UF%.\+LZQQ"1I3%4B6XRK?TL:^'A=!2VGVW%L?MANYIZ^6UF8QR^8"W9
M78N9 !N2:BM]8?@T27?,NM4CM+.<)S^#S-<HO9@IP\?3U8MFF-4GE0D]9Q%-
MJ'!@&=I-8Z$;-+2AY@+1+FC&!I<]$UZP:[J!]2,%J;>B]MEINRWE\'9R%%"Z
M,4#NK7;6086C?#^C:M&&%@48QH-D3A".\'[M^1@.M#25FN()[=I::;) BRX3
MM%AB>3I+-\W#-S(OVRX#/L;V=3>\A;!]&^OCF?H 7A20;V(>+ R>;UW/6N/Z
MVODGA)= 'I^!*^8N$$XMF$$^.OI>. X*WYSQ%9SB[[DM_MX95#B[BQO-VR#2
MN%NYTC&(U/$YT6+A2AAL0&D.;'J]]^S@14C_><G_>85/QQ]>FV6!*5Z7WIAI
M>'78.W!_X1PPUR G\@;M(9=Q GT;O7>U YF(F5M;WX)AQNJ?77X.CO><ZBEC
MW)&/X:8M3$T>]2XUN13$>XL#VU&? MMT"F>6D^NVG@=G;YK)R:Z$( LIN+*?
MMHX33WRVWGCB0C27- %K 3>U1T/SVE&6\.$!><XF-$IV]*PONNMR9/W%B8UW
M0.]L,0O'?6)ASDU1/ )'].8W,J:@Q)=KL-[OO^S3_I,(==F3<3X66 LO7@:#
M7[,8(VFTQZ>6XSRK1N-."_YQ3;\;8JKTKXK*GE#M#FPO@PW[PV#/]@^.<2.N
MNHR*UB#Z.IYOX*%<OL395"8?YC#8"0^EQ:RIRF6=3 -659.)C-'Y1JR?&Z$2
MTG[#"K/-8"IQ.6O#+06O93)%9*QVS1:Z63I?16-?N#T;>Q53R6'WG<-=6"Y\
M&R&OW@EK:[F"8(M);M0?DF.=>I?->$[SX,G^-7)A,\N #@]>]9PN5'_HXMG^
MB]>X$3]G24*5&$T6;P32'E(4.9!PF[;'U'LGZ7AGL+NCU#K/!9VEB?@L=?C-
MG :(TCT"(;,C*7>PBQL=GGZ'VQ?%21_"[K6E\Y?OG[_Z"G_B\-DS(V3Z(%%.
M>B-1#E_O\T90P)Z"_3>"JG-$D,+CXKP:+6 LW('O-\SRQM=U3/YGA?%F79;[
MZ<.[DZ9=1)PD;,V(4[ V#/[W\Q"V _]GRS"VA0Q^Z@T9'!UH)_[>0\#&)P,I
M:4NW[#3N0-YB04RS-L'2C)VK-<<JS*,#<&Q\U8M3]?)L83=\U8NO>EEEU8LW
MQK_ &+\FK(>V_61G2_>W\VC!I-Y=JV5BIST/%HH^;51C,8QAHABE3$T4XZ 9
MQBB<6HR88YF:U3M.[;1VDZ@['I/0'5^C! @)GHDLPS\G=+,?N$F7@B.W)#.U
M%?4^BSX/LMO@A#L!: _N2I6HV-'B%-9UAVB0YZ)RN$2/N<1%@U)^T2A5ME>
M&Z/DC7$Y:XT_L8..-Z#7KH/BUVF$??<C0LRCY1UK%!G3&JYKIIMF,I.,BSJ#
M.'U84F &W]?'O82\2ZP,0N8RT<*-F7'>FR,S F>(*96=YVU9TP"E3'4; ML5
MW 9TE]"I[1D0*_OP5<Z$DYRS<\SYZ V&>Z=@("C%HL(98$H;\T0>R/*5G3YN
MJ6UQ28\E/"ZC&118)X6M)?RM8OD2+:6&&IB>O$;*5\U$'A=+)2\'R\, 6Z$2
M[G ;C;#=H:Q'O1=96_IQRT'MQ@#?G2]]>3,?!KR4M!%;7^[(F/U"//O[=VNQ
MYZ$>'5_+@B52W[11;'7(M4=FWJ&.D"S4/]3X'W D/"/-E'_.E\A>A_&HUS K
ML'@:2*!*2.$Z+=#6N4;O@'OMN )MBCGVM+2%B\ NZ*S,-T'_UH@A:VYV7R*G
M=<WATBU6.+$BEJ;B+\I ,J/VW*"M_VVM&]_17T^N?C_WK&5[K-E0;%@#3DD6
M1D^Q[Q=Q98.AP#V-I5O=S#//RG;%E1Y0R572FAVT?"K-[/H[Y%G31 !]"1K$
M::RKRZ<E+@?\G] \9" *5=C.:BOH: 0E%4778RH;:^Q:H/'^Q@IKBG>.P?>+
M5^#R=1Z'Z0]0!7MP8: ;QMN5^XU-((."7EU;%_H5.596YCA+J^"6#5W%#P^8
M8D5[7>Q3@$5"QJ6^.4@O!7=+I(@9@[C=+LI0R106U6%ZAWIVM#!<N(E](&4=
MP1\<!F=<I0E;\Y$GSK::PN_Y)O?6ATN/<;F4-IM S:[@<N?V[2=HVG7N0HAD
MVJZ>5[G[[G*(<AP+]+&QV-0:TE;=R.:3]9JYX;.Y<.R34%FL#ZTV#2G101=H
MP@8Z^MD<^TVF8C._,LZJ 7#8CMAM,8F\122^PG93U(W""SQ#&--HQR9JHLK6
M?:SA0AZ@= O8;:PBEQC!D-19@;7LF9D7U\#6WPB0'2/)7ZVYQ)9CSP/;5<T!
MGH*Z6.I&?F0SB;/G75+A,FC3ST&-[?5E(:%1:"A(>Z^!Y+-WP"?Z?3RH:-=Z
M/$V&( :8+Y _,"W&?,%*1%;A 14YM4'IH!IVTSO259ON1FYP;SZU;+G'2^RZ
M6+F)XK^NR=3H3/0X#:.@W%8EW>:D$R<X(ZW".<][4W B94D-56:0!'548<>7
M*JSK00NJ00L:HR$$>)/@#\\++4."H2310/U=,:=:!A+ED1;\=<&H1I/0>]%^
MR*[/ KI9P.<^"^BS@.O- OJB[ <795]DV-123:9;A(O<;C$E;"K;&;D #]GL
M?^R"^:<82JY,3DF7(P)WY7,/]_2(BD.--E9H:$63C)OJ_BKN/*X;XW <#?75
M=J$FZ18LW==;3<Q!G]U2HS 6=XD!6#<\F@:^_'$ M,JSIL  .@'CXR%?K7U&
M-G4URA*-S*(A.YGS7?QSXMP+F\"3N>-1MF>GWUGS?'AP='#4SYKGW@K8_C7H
MMM,?V]M_T#\ 81?F-PQ,5SS&5+04KV-K($H*=8LAD!<F=C/L+E(GQ').#(J.
MZ2DZ)FQS9\+DSKJ":"WB0-A8%YG8P#VH>A)+T2AJV.D]#DK7$)E>E&9WS79<
M7HRB0XK.0=2*05%5\<2T(:#9$4D7?:. 72EPE@7F44WZ<Y?]8XQLD4.Y_-E+
M:>6Z@3>AD2#NNA/FU2FQS"G>9.ZFL1N4QPNK$?)H=&)=UU'7$("Y#W[+SF%7
M'<$_TVQ&8)VN!AR:)%4DU=1F$AD+!FN+MKA!JX> O'<GA6VPU@W5X(>%L8 X
MOFIZV!M6M8V\A!9>A8)Y=D@+DJ"1KFUAB31O,3GYX5S\@=5GWZRPH/<4U#_D
MBX;4( I*LYJ 3!9/=AZ8(8MF9)\5-+I;(-8,&@_W3O13Q9E"V;4&?ONY-6A:
MK=?E[*8Q@_%DG/FQ2%E+)5DD&G%>C5H-%H"MAZ:_VR\J*X]^32E3<84X9@AM
MO<@:M7#E@#AVVN$2]']!5X.]H(HQ9I#E-!$12](NOFE]I24_PY[2@V>5WK**
MK1U:1E/L^)BRS:6N3QO@S[VC9:8:^0RT!6&]!8067^?*A^Z%.LOL(D O3'BA
M=!>8"U(#0#N>48M_M L0FH];[VG D-'":7ZC?EYSJ!@]M_.%6T\.%_D47FOA
M[J&&D&9$]-N2X/O 7'J<;=R_*5N]&;-UL'_\RAVS=7GVZ?+LZNSB^N3Z_./%
M57!R\2[X_>3R\N3B^OSL"D=O79V]?W]VN1WA<:V7- *HK19DFUZ7"CIHYS:E
M5,=#FA6&[%<B[KY&$V'H?:=(L8'$0T]9B(7@W(B%V];K02^#%E+SN BNHK&,
M*P3N<F+PG)/6GQ DZ(3'V!%4Y3063;B1':U,HVPZ=[H7X!(3^.=K'+^]57S9
M57/IK)R*+@<27Y]*+^EJ:@?WX=<5A%\_YB.1;M?8SX[1)>B87U6#0L5*Y)3%
MR+$'#7,/_/Z:_F_@A6+XJ[Q516G !DWQG,V7U9!TB9@5QO'7U7 J-XR+ZKL)
MP O?M)GP[ADK"PNU2'Q@$TW1+)+!-)OA)$T#0ZO171%U3X,5LW@(C16OOZI[
M_PL_B<"MQGCAJS%\-<:JJS%Z,W= &\Y4BQ:!/IYC$J@IS 8F:BTPF3PCG*&*
M&ELY&XV5 ^AUQ+K/J_Z\":!M\S[W#-"2G14&=D6+** A@5),2T1%SS5@CU!)
ME4N]HB(S,C*N9226SN78&9NH(;:EC87.E:-EDE5)3+\Y20JLW+N=<DLOW)?E
M<O#!T/=)C&7<,F"DVP<*=^0W5$+U,K#3*'/VG)/X"QH(Q\036FX#IUJY[8C.
M'L &\!,(\9TS,LW[\1MSGQ+U<-SQ8L8\I@UKO$\8.(/-V&1-5%'VND7>&,+'
M^P>'ZX_$T<DUL<<=D\'L9MW[D((E3J#BPI3-V_-XW,CI#;&?CWMG/Y\T;"X.
MPY^9@6)8Y_(5Y]#[=$MO*QI0.%'7DAUUT3*?67GQV964YJW+%L+.D1*M[%US
MG.X=*BLST^?=/)U;%,5*2G^)M2 84JC+]/P&?E+C5QH&6%23B4D=+5>JRV[D
M#"#H.KQO75QU@8@2=R/!UT$(,UFD:Y=Y)(;>OM900IT\_X)-YYX=_5MH.K?L
MIN,*ECWF[J,8S.V]!_.0FP*T%48WP3X["M""J1)Q)KA&;<MM8@:OI5&$-DJ4
M#>DO0VY8H/8OMJFM]<5!X+]CPP'5#Z)RMQQ@9X-\ FV/3]5&%:MQ,M2U*PHV
M43S7#L! >P\<UYHJCCVS$5+WT]G,4#TMG 87TE(+ATF= 30\\B5"9^ >RW"+
MY6L/"R(^TDANV"W)W6]+1!_1=4T!9.76IK>5L+'+\8VX(_6PH%7366],MZ?>
M.V>V*:Z& CAT\4"Q:5MSO3M=Z)Z9GPLMS*VP#F%#V[ JYR,R<U-3FVO*/Q@!
MPPZ&"9T!HCCF*',B<.!UHY*"7:JH7;10<*XBYSB3X*00O!.P18RH$[951Q>=
MC&2*4X$HK&5^X9XF#;)D!M%XVW EI:VJU*2W%9'5A_I1Z^WPH^)W[E8E^8&1
MJ'>Z,V\JM4S([:S@CAH\E&ND=TBS-86#+E!O>KT<UTI1B<^-,;!$S7ZC%60X
MRA=7L?R>G?6U=<K*&?1H)N&&],OBWG4MSE3<\E+FC]^.NV[*!@6!#M"1XH>F
MD;J?806[F^O&L.[G]JP7_Z??XT37CWNN@&4YZ >&A$$:0:-M-I;D(J!E!09]
M92P-7=]E<;HP\\3QQ"^,GFZA=?*L=]8)8GHGJC9RWX.-N15VBHT"+<W\\L#,
M.CEUH[+$N CLF^I*W3J!!33,WR*?91ZZ<R!AY\+@CRH><3H"7 =4X5BA&P+_
M@+$.'#%%+J)Z"3.-TY2+#>9W:4A8S-V6@GD?CELHPK4Q#D]7#T=[W8VW)6?-
MT<284:C[.@=4"9J/9*SC"91-@"M&X!.EMB19AS!8\X?=N]RQE 8L*;4TYAEA
MKF7+QK\%V*&(00IPOVS.YC%BRF?"G4SX2Y\)]YGP)YP)_S););RWS$@KFSMT
MS+H4RST6R7"X%@LX7#= T.:JVGLT[#;:U<][:%>G0]CTK4Y,]*_/[D)#,3XT
MG^@D[+HS&*DV.]W,HD[ V13@O1D_G>=S8+:ZFSW)+JV!/6QM^9)AKKL+^4MW
M98T\"F9*>+@662(,RP(BA)QT)E0M8=SJ'X-)G+?4EI-M$;"Q0X%7U#E2A"V!
MAYJDM+MU-@<XH 0([;\UB;3<+)I(-+80/-@YV64\992B&HWFT6KQSDBD75,D
M"MG0P5HAM(^ *STPV/G3;O-E>(LI*U27J$79!)9C2N:Y3=X<-:=+3?:IH$%9
M>3GG)Y"EJ'.Q!I[<Y'B9.'X]/=T[)%"Z-"+0.>RO8QJVY7UU8GLGV["A (=K
M!N;=#1?R\T,S_0RS]/HPK)8V&7JV\N8ZGXZ?+#'$=&Y=EQ]VI==#I__"Y-:+
M):EU2S5 -F@K!#GVIVN#Q$*(.NC!0)O(H(GA<H>+'4-"7YEWIE.; %'ZA86&
M^.^ZDD<E%,MXRWC\2X$::N93-[N.X*(:#;2H])NHB?'"+2*[PGU-O^RQP#QU
M?2,7*"#&@[C)'*S;+=;Z/1Q*WRA&+8,1.L[(,*B]2?P29XQR+>U<AJR/4M>D
MX#6$OTI:FWM PIIJ]+U=,Z*;CO:#X,(IC)W3ZK[ERK*TQ@BI']N$ B[<0?%+
M*7R+B5?VB7@UM&#:="_A#!VJ28U4'2[6GV#-O<RY=\[I[5MJ%Z%H8\OHGH0L
MJY?[TC</*13?7DKJX>AZX_UHP91V% EH<*.<JUUYNL5C#%4T/AN6:DV>G8\"
MXM!>1 ]HJK_QB_XAGGZ<I8RFOR7)P(]N3XHTVM#8:P$-1EXH[KW7L]?69G?L
MH ;5ML$'?<,3Z^2'CL='PPPR<#;'64+5Q\.P.^45Z%$>3BEY&_@3/!(4\U21
MF^#X*A,*U.VB;+>ZEJRQ(SJMV4:_#\T68X.>AC=2)3U*$WHK706<WLAED*1=
M_5YN57V[NZBT(%<YFDZP17&HGT!>46$*44WU\@R='<1AIX8T71)=6UOF;G K
MB8B'?"MSH^[;F/V;9KE+&8M'H[V'A;=V=_H!&Z#'!6JR:4>";-VL2TAIYC.9
M;B;SE<]D^DSFD\UD+O$B79RM.J+C.(6=H0\SG[>&/.@JP_@"F;4(_L72O2'P
MC:AW@*\7ND@6;Q2C7T7ML8C!.=+VIW+"H1P]I^_5WCRU0"/):U@74&N1CONQ
MMFW-[6-# @/'9L@C*6<7[EJ/WM!A-=NUV8![N6-G;9/90W7\XW0[SUIVW$=&
MD,SIZD84?JF:AK\F<D0%-@AK(TL=TC8-=%_8-$<V&84SZE3.8.X41S>;N>I
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M*@)3]+RE)3+%Y),E@WYP;QHUH!C\\-\4J<$_WH!M!8=#P$2H@#!4V/:0>;:
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M_ZSRN CCR:X'UAYZ:-M:U>B6I2I4^Q*G(;P4HU U3I"V0:X37K5OZ'[H4C6
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ML"-=L4*"F_=*MR!6:TTH:;FK,'CS?64'L2^R3B"ONPN#H&IWP>V>A#4OP+2
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M7K7WP,'#H&8Y*BI@?<R:I:MH/ 5E\)V]%TEW-)T752FKTBCU6EG?6+KD--*
M?X Z]Z0_NTQ%+)V=1/2DE@\?*',<$X)!$7/%5-TCCZ=J[1PF%V,!']#Z&@\?
M!#$"^>U@ ?QQ<-P5*4 ;/'Q$ /C %U(@[NX\%>I HOQ[C(P/2W;Y;)YDR\AU
M]0NC"VS61E(AT]CV%V+9EF;8LPA<C8/'."_M)@ESXBT>X,P00[*;_>0:#7*W
MN84TINPB3JN@115QW[X)CHE+(?CI*I4XKW*PYRFL*NZZ;NH@N<.N$,(.0@_
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M;DD.7B]N6BS]%4HGK#2'/<O75.."*,#7I*_WGNP_ZLD:3$C[/K!:6"UL@I=
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M]FH/;=M#V_;0-KUE7-RZ:F* ;@XM%I=LZ8PF;0,.WH44<%[4Z(34=UAHA]%
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MU/@%%2U-NWP:?:/OF)KHKY/SNG=.#N6LYMA,FOJ#[T;T[M-#Q+5+$F)#"X6
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MG!DL.4''6EVF<Z2J[%PG+%$)JQQG 8K+4FZDB5M9KT!/V9%4LEDLUBEIP.2
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M2DN9FU\/>7JZ/-N&('T(8G#[4ICG4_@;Y6J'7/H/LCB_HT=LNT1_8TSA^SF
MI]MW /_Y0%.[;Z>87X:;Q#NV.M)+\,S2PJ+S_HK(SC]>N&/S:]O$VNB<JJD_
M/CH\?:'<S?-L!KITB;70QR NO6&*]:_>3405T%G*'8V.CW[Z;PVVF\8%J%)O
M&0580HM%JV]@U\_&4>Z='OO>R='Q*PK/6,\[]KJ>ASPR]I->PX/@"0F'D(;S
M/$Z\8[KKR8E\KIE:;L')1LY0P3V,OC"W*56Y(NM7EAZNS1'^W4*D+X');CGV
M'^,L7,+_/)2SY/_\/U!+ P04    " !S@ 15GQ8H9WT.  #;8P  '@   '-E
M8V]N9&%M96YD961A;F1R97-T871E9&YO+FAT;>U=_U/C-A;__?X*E;W;PDU"
MX@#+%NC.4$A[>[,+#-#V^M.-;"M$7=OR23(A]]??>_J2V(X#A&$/A[;=84DL
MRT]/G_?]R7OTS>GYR?5O%T,RUFE"+G[^X=/'$[+1[?5^W3GI]4ZO3\D_KC]_
M(KO;_8!<2YHIKKG(:-+K#<\VR,98Z_R@UYM,)MN3G6TA;WK7ESV<:K>7"*'8
M=JSCC0]'^ W\9#3^\)>C;[I=<BJB(F69)I%D5+.8%(IG-^37F*DOI-MUHTY$
M/I7\9JS)H#\8D%^%_,)OJ;VNN4[8!S_/4<]^/NJ9AQR%(IY^.(KY+>'Q]QL\
MV._3H/^.T??[\6Y_L$NC[\+^=S2@T5X4T'[T[P"([,%P>X_2TX1]OY'RK#MF
M^/R#_4&N#R<\UN.#H-__VT9EG&9WNDL3?I,=&&KAZDC VMSE2"1"'KSIF_\.
M\4IW1%.>3 ^^O>8I4^2,3<BE2&GV;4<!A[N*23ZR Q7_+SL( GBX^3AQU, \
M"<^8I\Z2-+P;\Y!K$O2W=XYZ.-ZO:6%E)8HCX!Z3+T3R\>7I\--O_^J0CV<G
MVU6:6TCMU?#D_.R4''\>GIT.X6_X_7)X=7U\/3QM/>UGYV?=X>>+3^>_#8?D
M]./E\.3Z_)*<G'^^&)Y='5]_/#\C%Y?G/UT>?UYY*2!M\L-C[OJ]4)J/IH^Z
M+:7R!L0O%%J+]"! \5N<R7[%LQC(.=AYEW]]R=MM9J[(NBS-$S%EC*0L#9E4
M1(R('C,2"BIC_!!SR2(MX,HF?O_VS?O!H'_H&?"5R#8S'G -;(L>@9(?D-BO
M3-*]G#1<"0ZWD&'',F;)] Z40Q9MMYAI)R+-:39M!=O4F"8)"1EA("<\3!C1
M@@#N&+]E)*)J3&@6$_:?@NLIB8!PEBF*%IU011339"2D'A.> 78YD ? 'GI@
MGSH DY/R?1=2W$B:XO[ #:W<($=B&S:H0R9C'HW)!-A-:"QR]'WR0JJ" E&P
M5XAR(X5X1[!_J&#WE$@*Y#7HE(Q\IE,RV.F 1Q3L=LQN4G" XM6GD4"&G6>_
MXS[BC/#YN]GG #\/ O.8?Q89(\&>^6:P3<CU^ %$@2\721X"91Y.'BLSE.:4
M@VZ4^&M*8]9!%-(\AVVE@%WX6(#VA]DB&#\U#YIP/18%X+0 G#)):&2>Y92M
M67('&< HT&]5<>4B\%\0("43&N8C,ZWMQCA91IKPKYQ*=%+ADRI"Q6-.Y;0^
M=!,?!:2V$_N-$MP&23 ;D0*8ER@K5< &&GP!]QO@U2%%EC"E[,!F116S" E0
M9K_,Q+G&[7MH;A).R41RK5F&0.$1\S+E-MW ?P'0DJ44H Y_V&@$% "%FB<$
M7'*.\G?+%3-H!U&,N!%9>,X]0*X_Q7'+R7N'I"+F(V[G!'<,PA432L&D<[A3
M;8"L80N1,*Z!80(X'7,03H:/=**,$R@C8I'(8NX4Q:A)<%61@X/#8F9E1')X
MOM<$;]_L[A\NX2J5$$#>,(S7%!H:,#CR%IF+4M\HK"'3$\:RBKP9E9<9,<35
M-.Z\:MZ@D $]S.T.@DS8J6/@FW]PE @3BKJ// -6T 24:P@"!]^. /;VLB<(
MYDQA(J5%]*7%;LIPMNI36&X;5,#RB*_!^\]I' /CNR;"-LY^BP."8/OMF^!=
M_W#QY\OQW?(&5**01AP/"F"3Q%'@PJ+TEMVZEX0'R.XSAH68N7DA%&S2K?6"
MP7&6%:#K+ID&.P8J_H51,*1++?N]<0[X==2N1+J5H+K^Z^Y>!TBN&!ZG_[VU
M?26P"]<-=G'LLLJD90C\"$ARQ*&'?Q\6/?@03R.1)&*";D(-A^KMF[WWA\\(
MLZ#__N5PQM<,9R=CRB7,7_$Q7QAAQ\M A1H* :1((]DUU-$Y4 %N3=IOIS_7
M?AC^.!6XD@_6:C"N&QJ/"]@O=+I2##1?U"$''#X:B!CZS>/4VB)61N5@"2H?
M14\]9JP3LRE,9*W'U$60<_JW5J8T>/7RLVX"5$E#MT6.GB9&S4M9':-[SRA-
M2VAZ5J':[^R]9IFZY5MDO63J3)@LHG5=8]AVF>,H1GX2MTQF-(M8:T3MB;*V
MTA*?S4P\2017(_59)7.))EF]S/__3RXVR]NRGYO1FIF]"SHUG5.P2VT)D[%^
M4(]TJ^6_*Q;9BD*P2;<,F(/-<*O%V?(V)2(6J_NF;NKJ/+X, 5RF!$L7B:O+
M)D6:@_2FA*<IBSGHC61:2DW@O=6:@-F76DG$U%'=WJ:,Z5)IQ#UX5F$V!9"Q
M2&+<?3K21A?5GV&3*O@]NT44+TNJ<.5++T T2^!+6^>B>2YXAA_*56YSQ11B
MK"I$1<B,S.!ZJ%M-53WZ%<ZSA2NLKV,#CAI([+X 8??4)&NU[QJW$^;*@+.5
MHJQW2"Z-XH]MFG.$P\R-6>'M10HP&BNR*45A2HM%[CF4@2[!:BO@P@S:<H5*
M7*JM4,Y&K<Z()UB$^QN_?,/ESO;N+I9]A.TX/9 LH8BBI5V8SBGLSV^AH6EY
M6'[+UV_.&SRN7+3 C?LX]>S7RC_'TB\^IS>L&TI&OW2-,!_09$*G:F.E%MD'
MGODJ'(AXW9S\H=<RH" NG4=X9:K78$,^<5:8ZC:8D)=U*XYG)F3$I=*@,&>.
MSX+BO<^L=9;T"#A5/*8N:T]#GF#/ G8/604K*EG]A8>BQ84_$]?@J3P+$\="
M8X7+75G8<.1Y#ZYUBFK]EL=LP9;/_&ZX.\<V^F5+2$%43)-%PIS]CED"!%N^
M51]6;6$AF2"@4;U%#/; "$V5Z^8H6XXGV(2:C8<'+#?T*?W"5(4SS\'VCK>L
M3S'M,, 8:D8F' !2;4(#RWTCJ?5 <%US"PQPDLSTS(P*''G+%(YJ;!.!N:(B
M\>TZH 9Y[,%+;VXDNS'N6 JV7,^RFW4^.,S\"%$>]NM]89K\0I," D&*WO<(
M1KG6.Y (VXYSD0#GRI=#!F*S9=IMJ5W TLZ6FJMBF- AWMV(Q22;PP89X7T.
M,ZL+$NQ,9NO4W!/R_+0.&X)X=DD5X>].%'6E2<E(CIHW*2WN*39(^G5_S-"^
M(Z*.#6P,'UR/GW4+YUV'L]6[%B8^NS=/K.N8==%],MNP(+GMC6A*$&A#,%-7
M$L83-]R&/>4@.5DTK?1_E2&,""@WIG5*Z&CN68-9M13)L[NK:W5.8;!F;4EN
MRUO4F'2O)U$Q#<SK#Z?MYND0HW-]UJ3QXG.KQKKH+$Q?FXO=L:BP+9MSC\)T
M7%JK2\%"V3;.#@IL4ACC1;6FT1AF8_8@FKEH&J<U/,5&\K8[ BG-L2%6% K[
MNG,DN=:YBAE3-+YSO5P2[]J28,S4TEZ2>[!RW)OB^<D&3 SPS#7.P_R& VKN
M1XC<YJEP')"#!M$S!_T.DT-5.7Q45<8ODM4V!;=6FFIIL+5N+74?7?^P\3M>
M.D][3T.=.Q:Q2LYM68KOWN:\3MV/-&&.[[)>FO]"=RWWT0$$1=&8*D:^#CL?
ME[.9>_M-SF?%<\8S*^!>&U5CUSU"G_W6..NV-\=4C3HD++0?G=([GA9I8WPQ
ML./=-R\)JL>L?YFI\Z>"7&V #+ T,,..9",FI<4<;>G!LA8)MW.KT4-Y*/'L
MC7XJ)+/!O\@8J:SEOE[8-30:Z]80>P4^$WB/Z#6T %K+2]=H-#;Y%@%E#, "
M-\;7LLM]U2:9135)&%5 /+_SI0HZTY[S4LST.6M-QHO"QD";QT$/B6>%L49(
MJ#MWM*3^U%@S,\;*D=:92U0U0^3DJ]G259?WV@U;L+>:80O6S; ]UK*%:V;9
MVJ6!9L;M1V'EG-X*'IOV%WRQ@BA"O;P]WSNR(U$N)I@#D55W5C^M%.PV5F0@
M^J7^FHH]142 ^LD<'HPD&'7@'=Y.*2['H\GSB::DOA>->L43#(":L"19S8"W
MS%X_9*S7_'C.NC4<7;NCQ>YX\I4_.S4BBYFP%W94/E??O3(_\8]Y''_6OV[;
M5CGLCW.IF3QBULF?N\9A?'ZRS(AXT['EQSP%Q[K#Y!5/RK@Q5?50TS/E:F,E
MKJ*AP. ;[? LR:=GQ3GX;'-=IA@RX6H>NW?L4Y=%\\[W*D%D)$7Z+&SH+&@^
MXS,V]959"VO6^'J.\<5KJ">,;+F]^LGGPI=$I.IUIRJ71J,0CZQ9P\B%CTLN
M) AU"YI-<R9=M9K=,1FAOLJE,TJF8]'%5#=S"-Y_>A.T#$V>5$ZOU\Z7ULSQ
M%T<6A :.LNWG5%9K)03K=MKH%Z;0P6Y#!K]J\BV L=G$&%?_CA,K%Z9P9HRP
M*UNA* 3F)2T[[^!;9W%=!%XK U:? [BU+U7"[(UY&U.&94%5,MRUWI#:=,WR
MY[(R&+OPK/%@/OPF17$SMH\WT<ZMW8SEPO-'["(=_-E%^CBE^4(Z,K;M[T:$
M%V+ZITIQ,'A(BIO2!RL*LGUGG1<ZVQ0712QAYC 2B"U6V2LIT^=H(RSE=2OT
MU *8(G.-=C:?;/1#;-H^O[[^<5OZLWT3&1(PBY]PG^S;N7S+029(+J0/HQ="
M-Z!E8:LLX\%=F"T21A59&18V>K/Y+..)-"YSQF!=#>8;UUMY699G+K[DK_18
M<\+";)!KU'C$LZOE,C/E0H37F;_?R_3E5;LR8/7V:]M;TPTIOE+-Y5]%H;'3
M)/;'Y<8LF;64-!+6*4O=@R@6451("%HCQ^>3,;[,#.\[$:;UXB%'L5,#;H5>
M;8&%V_AJCK^NWY%R#&%;$-Z@D,Y"F;($/#Z@"7&6C&P&_2TR911;Y#$O\\>(
M1G;6K,_QDO$T+*2R/74M *#/UOE3PXX\"\AFV)DJKQE,E<CLZUMC]W9^4PPM
M=%>,NCF &2)K+>DM2^R!0Z/00_P' -"(LCOL]638BF3TK5'A]YRG<XHV9Q+[
M"GU-"*MO<!%GC@O-V:Q;KWQ:,H*]L%6D>IIR9K)*[8>.L#DWS&&47,!USF:=
MEQ&+"W3"J"J]!]2*GJ\XH8I_JJ"]:(#Q=^+^_S/L*BN;]H1=/?O/7IA_@./#
M_P!02P,$%     @ <X $515<#$XH$@  )'$  !X   !S;'(M87)D96QY>'AF
M:7)S=&%M96YD;65N="YH=&WM75E3XT@2?M]?44O']M(1PA?W,4086X!GC4W8
MIEF>-LI2V:Y!EK0Z<+M__69FE63YZJ&[:2S8F9AAL"55965E?GF6./M[O5WK
M/=R:;!2-'79[=]%LU-C63K%XOULK%NN].KONW3397J%49KV NZ&,I.=RIU@T
M6UML:Q1%_DFQ.)E,"I/=@A<,B[U.$8?:*SJ>%XJ"'=E;YV?X#?P4W#[_V]G?
M=W98W;/BL7 C9@6"1\)F<2C=(;NW1?C(=G;T737/GP9R.(I8I52IL'LO>)1/
M7%V/9.2(\V2<LZ+Z?%:D2<[ZGCT]/[/E$Y/V;UNRO[LG=@='%=L^$GL'E=VC
MX[UC?GA8$J6#@\'@J/2?,A!9A-O5,V$T=<1O6V/I[HP$SG]R6/&CTXFTH]%)
MN53ZQ];<?9'X$NUP1P[=$Z(6K@X\6)N^;'F.%YQ\*-$_IWAE9\#'TIF>_+,G
MQR)D+3%A'6_,W7\:(7!X)Q2!'*@;0_E5G)3+,#E]G&AJ8!Q'NB*A3I%D?AG)
MOHQ8N52HG!7Q_F1-RROCP1 6U_>BR!N?E'%QF458P% 1O/@J2L]:Q66CT^VQ
MZHW9JL-_/=9KLV:[VF+55IUUS=I=I]%[8-6KCFGBY?EU/GN%?\1A) =3]95T
M;5CPR>Z!__([M[CFO95K[ETWNNS[%LZVHY$,V<</1Y5*Z31APR8VK KZ9RL=
M? TB5G.0^% ^_<2 )R2] "G2C3S&0^8-6#4>PHZSLD% 8K#^E''79GSL >AT
MFQW6:'TVNSUB;*W=N2T8C+,;'DP=O,WR M\+. (?F\AH!,_"H -I">9X%L$7
MC]A^J<1N>?#(JD_"C87!=G\)0PX*^\_@R*GO*:0^"80#E#^)T\CS3W9VZ>DG
M$432XH[6ACX/!0ZP=1[8F]Q$=@DV(S!HN ? >OCM = ,H7\[!X(.<I('$3=0
MIF%2V%81<(?Q(=K1;>FR,+9&S.(^MV0T-5CD#44T$H&261F%>(,EPM +0B7^
M80C;'QIY0)':;$'584[ !%@X$JP)\": 8XX,4=,! S9'FS)8MK T')W$2)O2
MW:XU$G;LB(\?R@>ETW*AO%%51L$3@+]>P#S\?2)# 9CJ\R":IA<'@3=F$<P+
MLJK^+UW+B6VI41ED&L4V$6D4?*[W@VT+#M+.\R"[BJ(<2"Q3ULIQA(60[TR5
M!.>&16$.>(3X"5RJ=NIF\^'?!EC^&EG[.MC)"0_$LK57IC[,VGJ8@5W* 5Q,
MC'TWEI%@E7+)8/?<B49\;+";*BM5]O;+Z*OE8A<NO"#P)KD0U4^%]^&Z5PL*
M;Y=_+EHT@R7L)P%,S,J(/XEYEQ6$!^)B<-$XX%_3 V<3[^\**PX0!*O#0 B*
MG6TECN3A7HI^$(/#RBJ[RLEEVXB6Z)L+VP#+[_L./84F+(O)8\^6 PG?+H%Q
M?L #>9 N.P_"R_PX"&,.! "O)B,)EFAN/_W >Y+ >+R<[GJRI0XL)T3;QBW
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M44RZ&,D"II8+>PFNSB\)$[X)-"EG%Y.[8%T=;F$:0:'D .Y \PL<J0-DCOL
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MX>(" &%R9'@M,C R,C V,S N>'-D4$L! A0#%     @ <H $5<[)TV#L&@
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M<F1X+3(P,C(P-C,P>&5X,S(Q+FAT;5!+ 0(4 Q0    ( '. !%7)01&;]=0
M !>3"  >              "  >O)!0!H8W(M87)D96QY>'AR;WEA;'1Y86YD
M;6EL92YH=&U02P$"% ,4    " !S@ 15GQ8H9WT.  #;8P  '@
M    @ $<GP8 <V5C;VYD86UE;F1E9&%N9')E<W1A=&5D;F\N:'1M4$L! A0#
M%     @ <X $515<#$XH$@  )'$  !X              ( !U:T& '-L<BUA
M<F1E;'EX>&9I<G-T86UE;F1M96YT+FAT;5!+!08     #0 - '\#   YP 8
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
